Uuringus osaleja informeeri mise leht ja teadliku nõusoleku vorm Käesolev dokument sisaldab teavet uuringu "Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus” kohta, et aidata Teil otsustada, kas soovite selles osaleda. Uuringusse kutsutakse geenidoonor eid , et täiendada g eenivaramus olemasolevaid andmeid ning soovi korral anda kog utud andmete põhjal tagasisidet personaalsete terviseriskide kohta. Käesoleval vormil on kaks osa: Informatsioon uuringu kohta Teadliku n õusoleku vorm allkirjastamiseks , kui soovite uuringus osaleda Uuringu viivad läbi Tartu Ülikooli Eesti geenivaramu, Lausanne´i Ülikooli Integreeritud Genoomika Keskuse ja Genfis asuva Health 2030 Genoomika Keskuse teadlased. Teie kontaktandmed on saadud Tartu Ülikooli E esti g eenivaramu (edaspidi g eenivaramu ) andmebaasis hoitavate andmete depseudonüümimise ehk tagasikodeerimise teel. Tagasikodeerimise käigus järgiti andmekaitse nõudeid, mis on sätestatud i nimgeeniuuringute seaduse ja isikuandmete kaitse seadusega . Inimgeeniuuringute seaduse §24 lõige (2) punkt 4 kohaselt on vastutaval töötlejal lubatud tagasikodeerimist läbi viia vastutava töötleja ettepanekul ja eetikakomitee nõusolekul geenidoonori tuvastamiseks, temaga ühenduse võtmiseks ning tema kirjalikul nõusolekul terviseseisundi kirjelduse uuendamiseks, täiendamiseks või kontrollimiseks. Geenivaramu vastutav töötleja on Tartu Ülikool. Tagasikodeerimise teostasid g eenivaramu töötajad, kellele on vastavad volitused andnud g eenivaramu direktor . Allkirjastatud nõusoleku vormi säilitatakse g eenivaramus. Teile antakse allkirjastatud nõusoleku vormi koopia. Küsimuste tekkimise korral saate ühendust võtta uuringu juhiga. Neeme Tõnisson, meditsiinigeneetika vanemteadur 56684694;
[email protected] Informatsioon uuringu kohta Lühikokkuvõte uuringust I nimgeeniuuringute seaduse kohaselt on Eesti g eenivaramu eesmärk edendada geeniuuringute arengut, koguda teavet Eesti rahvastiku tervise ja pärilikkuse informatsiooni kohta ja rakendada saadud geeniuuringute tulemused rahva tervise parandamiseks. Käesoleva uuringu põhiline eesmärk on uurida inimese pärilikkust ning selle seost teatud füüsiliste tunnuste (näiteks kehakaal , lihastugevus jt. ) ja tervislike seisunditega (näiteks probleemid südame või neerudega, närvi- ja lihaskonnahaigused, meeleoluhäired jt. ) , mille kohta võib leiduda olulist teavet juba varase ea terviseandmetes. Sellepärast soovime täiendada n eid andmeid, mis on Teie kohta g eenivaramus olemas. Uuringu käigus toimub kaks uuringuvisiiti. Esimene visiit kestab 3 kuni 5 tundi ja teine 2-3 tundi . Uuringu olemusega seotud küsimusi ja geeniuuringutega seotud informatsiooni selgita vad Teile vastava nõustamiskogemusega spetsialist ja kliinilise geneetika spetsialist . Kogu uuring viiakse läbi juhindudes g eenivaramu andmekogumise protseduurijuhenditest, kehtivast heast kliinilisest tavast ja isikuandmete kaitse seadusest. Esimese v astuvõt u käigus tutvustatakse uuringut lähemalt ning kirjaliku nõusoleku andnud uuring us osalejaga on plaanis täiendada tema tervise andmeid ning koguda lapseea arengut ja igapäevaelu käsitlevaid andmeid , mida varem ei ole küsitud . Selleks on koostatud üksikasjalik ud küsimustik ud , mis täidetakse koos nõustamiskogemusega spetsialistiga . Lisaks võetakse esimesel vastuvõtul osalejalt vereproov (kuni 4 0 ml veeniverd) ja tehakse täiendavad pikkuse, kehakaalu jms objektiivsed mõõtmised. T erviseandmete uuendamine ja vereproovi võtmine on vajalik selleks, et geenivaramu andmebaasi tekiks Teie kohta uus ajapunkt ja et saaks ime teha DNA-põhise kontrolltuvastamise, kinnitav a geeniana lüüs i ning kliinilise vere analüüs i . Samuti palutakse luba teha Teist foto d , kasutades geenivaramu fotoaparaati. Tehakse kolm fotot Teie näost: otse- ja kaks külgvaadet. Koos suure hulga teiste fotodega kasutatakse Teie fotot isikustamata kujul lisauuringutes, mis p õhinevad arvutuslike seoste leidmisel teatud geenivariantide ja näojoonte vahel . Teie foto t hoitakse koos t eiste tundlike isikuandmetega isikustatud kujul geenivaramu kodeerimis keskuses . Fotot ei avaldata foto kujul mitte mingis vormis. Teadustööna avaldada on neid võimalik vaid arvutuslike seoste põhjal nii, et neid ei ole võimalik seostada Teie isikuga . Teise vastuvõt u käigus on Teil soovi korral võimalus saada kliinilise geneetika spetsialistilt geneetilist nõustamist, soovitusi ja kirjalik kokkuvõte uuringu tulemustest, milles kirjeldatakse Teie terviseriske ja personaalseid geneetilisi eripärasid. Et uurida, kuidas on muutunud geenidoonorite le osutatav terviseabi peale geneetilis e omapära kohta saadud tagasiside t tehakse päringuid raviasutuste ja e - tervise infosüsteemidesse . N ende käigus kogutud andmeid kasutatakse isikustamata kujul . Teine visiit toimub vaid juhul, kui olete nõus olemasolevaid andmeid uuendama ja vereproovi loovutama. Kogutud andmeid rakendatakse teadustöös . Uuringu tulemused võivad kaasa aidata geneetilistest muutustest tingitud haiguste avastamis ele - ja ravivõimaluste väljatöötamisele. Uuringus osalemine on vabatahtlik. Ainult Teie otsust ate , kas soovite uuringus osaleda . Kui Te soovite uuringus osaleda, tagatakse Teile soovi korral võimalus saada geneetilist nõustamist , kui olete täiendava vereproovi esimesel vastuvõtul andnud . Geneetiline nõustamine põhineb läbiviidud uuringu tulemustel , Teie isiklike terviseriskide hindamisel ja vajadusel võimalikul mõjul perekonnale. Mida uuringus osalemine Teie jaoks tähendab? Uuringus järgitakse Eesti Vabariigi ( i nimgeeniuuringute seadus, i sikuandmete kaitse seadus) ja Euroopa Liidu (isikuandmete kaitse üldmäärus ) seadus aktidest tulenevaid nõudeid. Pärast nõusoleku vormi allkirjastamist toimub vestlus, andmete täiendamine, täidetakse küsimustik ud ja m õõ detakse Teie pikkust, kaalu , pea - ja vöö ümbermõõtu , käte haardetugevust , vererõhku ja südame löögisagedust . On oluline r õ hutada, et Teil on õ igus jätta vastamata küsimustele, mis tunduvad Teile ebamugavad v õ i Te ei soovi neile muul p õ hjusel vastata. Kogutud andmeid hoitakse koos Teiste tundlike isikuandmetega geenivaramu kodeerimis keskuses , neid kasutatakse uuringus ja avaldatakse nii, et neid ei ole v õ imalik seostada Teie isikuga. Nõusoleku vormi ja terviseandmeid hoitakse geenivaramus tähtajatult. Uuringus palutakse teha Teie näost kolm fotot: otse- ja kaks külgvaadet , kasutades g eenivaramu fotoaparaati. Fotot ei avaldata foto kujul mitte mingis vormis. Teadustöö tulemused avalda takse vaid numbriliste väärtustena, mis on saadud arvutuslike seoste põhjal . N eid ei ole võimalik seostada Teie isikuga. Lisaks võetakse vereproov (kuni 4 0ml veeniverd), milleks kasutatakse ühekordseid vahendeid. Sellise verekoguse loovutamine v õ ib tekitada kerget ebamugavustunnet, kuid ei kujuta Teie tervisele ohtu. Uuringu s osalejana on Teil võimalik saada uuringu tulemuste kohta tagasisidet . Seda tehakse juhul, kui Te olete andnud täiendava vereproovi ja avaldate soovi tagasiside saamiseks . Lisaks edastame Teile soovi korral Tartu Ülikooli Kliinikumi ühendlaboris tehtud kliinilise vereanalüüsi tulemused . Mis on võimalik kasu Teie jaoks selles uuringus? Projekti käigus tekkiv informatsioon annab Teile ülevaate oma tervise näitajatest (kliinil ise vereanalüüsi tulemused ) ja ge neetilisel infol põhinevatest hinnangulistest riskides t tulevikus. Ehkki t agas iside r aportis sisalduv teave võib olla Teie jaoks ootamatu ja murettekitav , on u uring ke skendunud Teie tervisekäitumise suunamisele ja elu jooksul pigem hiljem avalduvate tüsistuste vältimisele . Võimalik kasu geneetilise info teadmisest, kaalub üles võimalikud ebameeldivused, näiteks ajakulu, vereanalüüsi võtmine, psühholoogiline ja sotsiaalne mõju . Millised riskid võivad olla seotud uuringus osalemisega ? Kvalifitseeritud medits iiniõde võtab vereproovi (kuni 4 0ml veeniverd), milleks kasutatakse ühekordseid vahendeid. Sellise verekoguse loovutamine ei kujuta Teie tervisele mingit ohtu. Vereproovi võtmine võib mõningatel juhtudel põhjustada verevalumi teket ja jätta jälje, mis kaob lühikese aja möödudes. Kui Te peaks vereproovi võtmise jooksul või pärast tundma kerget pearinglust või ebamugavust, saate jääda andmekogumiskabinetti puhkama, kuni tunnete, et olete valmis lahkuma. Teie andmed hoiustatakse Eesti geenivaramus ja kasutatakse uuringus kujul , mis ei võimalda nende seostamist Teie isikuga . Kõik Teiega seonduvad andmed on salajased ja teadlastele väljastatakse ainult isikustamata andmeid . Uuringu käigus analüüsitakse põhjalikult vaid teatud geene ja piirkondi pärilikkusaines. Seetõttu ei saa me garanteerida, et tuvastatakse kõik Teile meditsiiniliselt olulised geneetilised omapärad . Juhime tähelepanu asjaolule, et kuna geneetiline informatsioon on elu jooksul praktiliselt muutumatu, siis võib uuringus osalemisel ja saadud tagasisidel olla Teile pikaaegne mõju. Uuringuga seotud kulu de kompenseerimine Uuringu vastuvõtud toimuvad Tartus Riia 23b geenivaramu andmekogumiskabinetis . S õiduga seotud transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel , kuni 50 eur ot visiidi kohta . Samuti pakume vastuvõtu päeval sooja lõunat. Tagasiside mõju hindamine Projekti käigus palutakse Teil täita kaks küsimustikku saadud geneetilise tagasiside arusaadavuse ja isikliku mõju kohta . Esimene küsimustik antakse vahetult pärast tagasiside visiiti ning teine küsimustik kuus kuud peale teist visiiti . Küsimustik vahetu tagasiside kohta on võimalik täita paberkandjal ning küsimustik kuus kuud hiljem kas paber il või elektroonsel kujul. Mõlema küsimustiku täitmine võtab eeldatavalt aega alla 20 minuti küsimustiku kohta . Kogutud andmeid kasutatakse isikustamata kujul teadustöös, mille tulemused annavad ülevaate inimeste meelsus es t , huvist ja muredest peale personaalset geneetilist tagasisidet. Teie vastused on abiks sarnase uuringumetoodika arendamisel ja rakendamisel edaspidi. Teie õigused uuringus osalemisel Uuringus osalemine on vabatahtlik. Kõik Teiega seonduvad andmed on konfidentsiaalsed ja teadlastele väljastatakse ainult isikustamata andmeid. Teil on võimalus ise otsustada, kas Te soovite teada saada uuringu tulemusi ja geneetilist nõustamist või mitte. Geneetiline nõustamine põhineb läbiviidud uuringu tulemustel, personaalsetel geneetilistel eripäradel , Teie isiklike terviseriskide hindamisel ja vajadusel võimalikul mõjul perekonnale . Kliinilise geneetika spetsialisti poolt antud s oovitused võivad abiks olla T eie terviseseisundi jäl gimisel . Teil on õigus keelduda oma andmete uuendamisest , sh vereproovi loovutamisest. Peate arvestama, et vereproovi loovutamine on eelduseks geneetilise tagasiside saamisele, et teha DNA-põhine kontroll ja geneetilise omapära kinnitamine. U uringus tehakse teist foto ainult juhul , kui Te ise selleks allpool vastava kirjaliku märkega loa annate. Uuringu käigus on Teil õigus jätta vastamata küsimustele, mis tunduvad Teile ebamugavad või millele Te ei soovi vastata. Teil on õigus igal ajahetkel uuringust loobuda. Geenivaramu hävitab selleks ajaks kogutud andmed (sh vereproov) , kui olete nii soovinud, välja arvatud juhul, kui see tehniliselt võimalik ei ole. Uuringust loobumisel ei ole Teie jaoks negatiivseid tagajärgi. Uuringuga seonduvate korralduslike ja uuringu ülesehitust puudutavate küsimuste korral saate täiendavat informatsiooni: telefon : 7374030; 5206959 e-mail:
[email protected] Geenivaramu koduleht www.genoomika.ut.ee Teadliku nõusoleku vorm Uuringu nimetus: "Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus” Mina ,………………………………………………………………………………………… ………….. , olen lugenud või mulle on ette loetud „ U uringus osaleja informeerimise leht ja teadlik u nõusoleku vorm “ k uupäevaga …………… ………….. …………. ja ma olen informeeritud uuringust "Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus” . Mul on olnud võimalus küsida küsimusi ja olen saanud rahul dava vastus e oma küsimustele. O len teadlik läbiviidava uurimistöö eesmärgist, uuringu metoodikast ja kinnitan oma nõusolekut selles osalemiseks allkirjaga. Tean, et uuringute käigus tekkivate lisa küsimuste ja võimalike tervisehäirete kohta saan mulle vajalikku täiendavat informatsiooni uuringu juhilt: Neeme Tõnisson, meditsiinigeneetika vanemteadur 56684694;
[email protected] Olen teadlik, et vereproovi loovutamine on eelduseks teisele visiidile, kus nõusoleku korral on võimalik saada personaalset geneetilist tagasisidet ning kliinilise vereanalüüsi tulemused. Uuringu läbiviijad on teadlikud ja kinnitavad , et minu identiteeti ega isiklikke andmeid ei kasutata isikustatud kujul, kui projekt i tulemus ed avaldatakse teadusartiklitena . Olen nõus uute andmete kogumisega Jah □ Ei □ Olen nõus foto tegemisega Jah □ Ei □ Mul on õigus teada/mitte teada käesolevast uuringust tulenevaid personaalselt minu kohta käivaid tulemusi ja tulemustega koos saada meditsiinigeneetiku nõustamist : □ Soovin teada tulemusi ja saada geneetilist nõustamist □ Ei soovi teada tulemusi Minu kontaktandmed: e-posti aadress……………………………………………………………………………… … Postiaadress ………………………………………………………………………………… … Telefoni number……………………………………………………………………………… Kuupäev, kuu, aasta………………………………………………………………………... A llkiri…………………………………………………………………………………. Uuringus osalejale i nformatsiooni andnud isik: Olen andnud uuringus osalejale ülevaate selle uuringu olemusest, võimalikest riskidest ja osaleja õigustest. Kinnitan , et uuringus osaleja on seletustest aru saanud ja nõusoleku andmiseks teovõimeline . N imi…………………………………………………………………………………………………………. Kuupäev ………………………………………………………………………… ……… ………………. Nõustaja a llkiri………………………………………………………………………………………… .
Vastused Eesti Bioeetika ja Inimuuringu te Nõukogu küsimustele ja kommentaaridele P rojekt : „Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus“ Vastutav uurija: Katrin Männik , PhD Health2030 Genome Center , Campus Biotech Head of Data Strategy Campus Biotech , 9 chemin des Mines CH-1202 Geneva , Switzerland Nõukogu esitas taotlusele järgmised küsimused : Palun põhjendage, mis eesmärgil võrreldakse näojooni geneetilise infoga. Kuna taotluses on põhjendus esitamata, on nõukogul küsimus, kas sellise uuringu läbiviimine on proportsionaalne geenidoonoritele põhjustatud ebamugavustega. Vastus: Selgitus antud küsimuse kohta on toodud allpool koos vastusega järgnevale küsimusele. Infolehel on info: Tehakse kolm fotot Teie näost: otse- ja kaks külgvaadet. Koos suure hulga teiste fotodega kasutatakse Teie fotot isikustamata kujul lisauuringutes, mis põhinevad arvutuslike seoste leidmisel teatud geenivariantide ja näojoonte vahel. Palun põhjendage, kuidas kasutate fotot isikustamata kujul? Kuidas toimub fotode umbisikustamine ? Kas sama infot ei ole võimalik koguda ilma uuritavate fotosid kogumata ja salvestamata? Vastus: Tehisintellektil p õ hinev patsientide n äofotod e analüüs, nn. digitaalne düsmorfoloogia (ingl. k. digital facial dysmorphology ) , on viimaste aastate jooksul kujunenud äärmiselt oluliseks töövahendiks kliinilise geneetika tavapraktikas . V õ rreldes traditsioonilise, individuaalse meditsiinigeneetiku hinnagul p õ hineva, düsmorfoloogiaga v õ imaldab digitaalne düsmorfoloogia s õ ltumatut ning oluliselt täpsemat diagnoosimist. Näiteks kasutab kommertsiaalset digitaalse düsmorfoloogia lahendust Face2Gene enam kui 2000 medit s iinigeneetika keskust üle maailma (täpsem info platvormi ning selle GDPR ja HIPAA n õ uetele vastavuse kohta on saadaval https://www.face2gene.com ). Sarnaselt kliinilisele praktikale on suuremahuliste sama geneetilise leiuga patsien dihulkade pildianalüüs oluline metoodika teadusprojektides, mille eesmärgiks on leida geneetiliste le haiguste le vastavaid mitteinvasiivseid biomarkereid ning parandada haiguste täpset ja varajast diagnoosimist. Näiteks on selliseks teadusprojektiks Oxfordi ülikooli poolt juhitav algatus Minerva & Me ( https://www.minervaandme.com ). Käesolevas projektis taotleti fotode kogumist eesmärgil, et CNV leiuga geenidoonorite kohta oleks Eesti Geenivaramu kodeerimiskeskuses olemas lisainfo, mida vajadusel saab isikustamata numbrilisel kujul (ingl. k . de- identified mathematical facial descriptors ) ning rangelt andmekaitse reegleid järgides kasutada digitaalsel düsmorfoloogial põhinevates koostööprojektides. Kuna fotoandmete kasutamine ei kuulu antud projekti esmaste eesmärkide hulka, eelistasime peale N õ ukogu kommentaaride analüüsimist eemaldada luba fotode kogumiseks käesolevast taotlusest ning liikuda edasi N õ ukogu l oa saamiseks projekti p õ hi tegevuste täitmiseks. Tänasel päeval puudub Eestis tugev teaduspraktika digitaalse düsmorfoloogia vallas . Selleks, et seda uuenduslikku metoodikat Eesti Geenivaramu kontekstis diagnoosimata patsientide hüvanguks kasutada , jätk ame läbirääkimisi digitaalsele pilditöötlusele spetsialiseerunud välispartnerite ga. Peale täpsust atud riskianalüüsi ja protokolli optimeerimist viisi l, et kogutud andme id maksimaalselt kasu tada, esitame vajadusel N õ ukogule jätkutaotluse geenidoonorite pildiandmete kogumiseks. Fotode kogumist puudutav informatsioon on eemaldatud uuendatud taotluses ja infolehel. Muudatused on sisse viidud dokumendi Mannik_MainApplication_Revised_2 7 0320.docx lehekülgedel 17 ja 20, ning dokumendi Mannik_Appendix2_Revised_260320.docx lehekülgedel 2, 3, 5 ja 6. Infolehel on info: Võimalik kasu geneetilise info teadmisest, kaalub üles võimalikud ebameeldivused, näiteks ajakulu, vereanalüüsi võtmine, psühholoogiline ja sotsiaalne mõju. Mille alusel on selline väide esitatud? Antud väide näib uuritavate mõjutamisena ja soovitame kaaluda sõnastuse muutmist. Vastus: Täname Nõukogu tähelepanu juhtimise eest, et antud väide v õ ib m õ jutada uuritavate s õ ltumatut otsust uuringus osalemise v õ i mitteosalemise kohta! V õ imaliku uuritavate kallutamisohu t õ ttu otsustasime antud lause infolehelt eemaldada. Geneetilise info kasu uuritavale kirjeldavad objektiivselt sama l õ igu eelnevad laused . Parandatud versioon l õ igust on järgnev: „ Projekti käigus tekkiv informatsioon annab Teile ülevaate oma tervisenäitajatest (kliinilise vereanalüüsi tulemused) ja geneetilisel infol põhinevatest hinnangulistest riskidest tulevikus. Ehkki tagasiside raportis sisalduv teave võib olla Teie jaoks ootamatu ja murettekitav, on uuring keskendunud Teie tervisekäitumise suunamisele ja elu jooksul pigem hiljem avalduvate tüsistuste vältimisele. “ Parandus ed on sisse viidud dokumendi Mannik_Appendix2_Revised_260320.docx lehekül gedel 3 ja 4. Katrin Männik /allkirjastatud digitaalselt/ 2 7 .0 3 .2020
Application to the Estonian Committee on Bioethics and Human Research for project appoval RESEARCH DATA Project Title: " The impact of clinically relevant CNVs in the general population – the health consequences and personalized management of undiagnosed adult CNV carriers" “ Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus ” List of Collaborating Countries : Estonia, Switzerland Main purpose of the study: The proposed project focuses on the Estonian biobank voluntary participants who are carriers of DNA copy-number variants ( CNVs ) with confirmed high clinical relevance. We aim to apply genotype-driven phenotyping to gather a comprehensive collection of health information in a clinically unbiased adult cohort and to investigat e h ow these variants affect health in the general population . In addition, we are willing to disclose the identified genetic finding to the consenting CNV carriers , and through evaluation of at-risk individuals ’ expectations and experience to set up a n evidence-based model for the identification and counselling of previously undiagnosed biobank participants at high genetic risk for complex disorders . Uurimistöö peamine eesmärk : Taotletav projekt keskendub Eesti geenivaramu vabatahtlik use alusel ühinenud geenidoonoritele , ke llel on leitud kliiniliselt oluli ne struktuurne geenivariant ehk DN A koopia-arvu variatsioon (CNV). Uuringu eesmärgiks on rakendada nö . genotüübil p õ hinevat terviseandmete kogumist , et uurida CNV- dega inimeste tervise tulemeid täiskasvanud üldpopulatsioonis . Lisaks soovivad uuringu läbiviijad anda CNV kandjatele personaalse kokkuvõtte ja tagada geneetiline nõustamine nende senituvastamata geneetilise leiu kohta . K ogutud andmete alusel on kavas välja töötada t õ endus-p õ hine protokoll geneetilise tagasiside andmiseks k õ rge komplekshaiguste riskiga geenidoonoritele . RESEARCH INVESTIGATORS AND INSTITUTIONS 2.1. Principal i nvestigator s Katrin Männik , PhD Health2030 Genome Center , Campus Biotech Head of Data Strateg y Campus Biotech , 9 chemin des Mines CH-1202 Geneva , Switzerland +41 787 45 42 75
[email protected] / signed digitally / Neeme Tõnisson , MD, PhD Estonian Biobank, Institute of Genomics, University of Tartu Dep artment of Clinical Genetics in Tallinn, Tartu University Hospital Senior Research Fellow and Clinical Geneticist 23b Riia St Tartu 51010, Estonia +372 5668 4694
[email protected] / signed digitally / Alexandre Reymond , PhD Center for Integrative Genomics, University of Lausanne Director, Professor Center for Integrative Genomics , University of Lausanne , Genopode building CH-1015 Lausanne, Switzerland +41 21 692 3960
[email protected] /Signature please see in attachment Appendix 7- Signatures_1 / 2.2. Sub-investigators Eleonora Porcu , PhD Center for Integrative Genomics, University of Lausanne Post-doctoral Research Fellow Center for Integrative Genomics , University of Lausanne , Genopode building CH-1015 Lausanne, Switzerland +41 21 692 3960
[email protected] /Signature please see in attachment Appendix 7- Signatures_1 / Marili Palover, MSc Estonian Biobank, Institute of Genomics, University of Tartu PhD student and biomedical specialist 23b Riia St., Tartu 51010, Estonia +372 5124 795
[email protected] / signed digitally / Ioannis Xenarios , PhD Health2030 Genome Center , Campus Biotech Chief Data Analyst Campus Biotech, 9 chemin des Mines , CH-1202 Geneva, Switzerland +41 58 201 02 41
[email protected] /Signature please see in attachment Appendix 8- Signatures_2 / Olivier Menzel, PhD Health2030 Genome Center , Campus Biotech Head of Strategic Partnerships Campus Biotech, 9 chemin des Mines , CH-1202 Geneva , Switzerland +41 58 201 02 41
[email protected] /Signature please see in attachment Appendix 8- Signatures_2 / Helene Alavere , MD, MScHs Estonian Biobank, Institute of Genomics, University of Tartu Head of Data Collection Department, Project Manager 23b Riia St., Tartu 51010, Estonia +372 737 4038
[email protected] / signed digitally / Liis Leitsalu , PhD Estonian Biobank, Institute of Genomics, University of Tartu G enetic counselor and researcher Riia 23b, Tartu 51010 Estonia +372 53 088 075
[email protected] / signed digitally / Triinu Temberg , MSc Estonian Biobank, Institute of Genomics, University of Tartu Recruitment specialist 23b Riia St, Tartu 51010 + 372 737 4031
[email protected] / signed digitally / Esta Pintsaar Estonian Biobank, Institute of Genomics, University of Tartu Recruitment specialist 23b Riia St, Tartu 51010 + 372 737 4030
[email protected] / signed digitally / Margit Nõukas , MSc Institute of Molecular and Cell Biology and Estonian Biobank, Institute of Genomics, University of Tartu PhD student/ specialist 23b Riia St., Tartu 51010, Estonia + 372 5112 755
[email protected] / signed digitally / Anu Reigo , MD Lead Specialist of Medical Genomics Estonian Biobank, Institute of Genomics, University of Tartu 23b Riia St., Tartu 51010, Estonia +372 737 4040
[email protected] / signed digitally / Maarja Lepamets , MSc Specialist Estonian Biobank, Institute of Genomics, University of Tartu 23b Riia St., Tartu 51010, Estonia +372 737 4035
[email protected] / signed digitally / 2.3. Director of the institution or head of the structural unit of the principal i nvestigator Mait Metspalu , PhD Institute of Genomics, University of Tartu Director Riia 23b, 51010 Tartu , Estonia +372 737 5052
[email protected] /Signature please see in attachment Appendix 9- Signatures_3 / Emmanouil T. Dermitzakis, PhD Health2030 Genome Center , Campus Biotech Director , Professor Campus Biotech, 9 chemin des Mines , CH-1202 Geneva , Switzerland +41 58 201 02 41
[email protected] /Signature please see in attachment Appen dix 9- Signatures_3 / Alexandre Reymond , PhD Center for Integrative Genomics, University of Lausanne Director, Professor Center for Integrative Genomics , University of Lausanne , Genopode building CH-1015 Lausanne, Switzerland +41 21 692 3960
[email protected] /Signature please see in attachment Appendix 9- Signatures_3 / SOURCE OF FINANCE The total budget of the study is expected to be 200 00 0 EUR . C ost s of the project will be covered by the Jacobs Foundation Research Fellowship to Katrin Männik ( grant #2016 1217 09) , by the Swiss National Science Foundation grant to Alexandre Reymond (grant #31003A_182632) and by the Estonian Research Council grant to Neeme T õ nisson (grant # PRG555 ) . These funds will be used for recruiting , evaluating and counselling research subjects , performing validation experiments, adapting existing secure computational resources in the Institute of Genom ics at the University of Tartu for data collection and storage for the current study . Additionally , the funds will be used for salaries of two researchers of the Institute of Genomics who are responsible for the recruitment and counselling of study participants . These salaries will be defined according to the hours worked for the project and to the salary requirements established by the University of Tartu . Each participating research institute covers the research costs of their part of the project and salaries of their other employees involved in the project . T ransportation to the Estonian Biobank ( EstBB ) at the Institute of Genomics in Tartu, Estonia will be organized and the costs will be reimbursed (maximum cost of 50 euros per visit) to the research participants. Costs for justified daily allowances (e.g. lunch, coffee, tea and refreshments) will be covered . The participants will not receive compensation for participating in the study . The study does not include interventions or medical procedures that pose health risks to the participants, no specific insurance or damage compensation will be required. BRIEF OVERVIEW OF LITERATURE AND RESEARCH CONDUCTED ON THE SAME TOPIC EARLIER Each year, mental disorders cost 298 billion euros to the European healthcare system. In contrast to other key groups, indirect costs in human capital and economic growth through loss of productivity and income are exceptionally high in mental disorders PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HdXN0YXZzc29uPC9BdXRob3I+PFllYXI+MjAxMTwvWWVh cj48UmVjTnVtPjkyNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMSwgMl08L0Rpc3BsYXlUZXh0Pjxy ZWNvcmQ+PHJlYy1udW1iZXI+OTI0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9 IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3Rh bXA9IjE1ODI3Mzk0NTAiPjkyNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo b3I+R3VzdGF2c3NvbiwgQS48L2F1dGhvcj48YXV0aG9yPlN2ZW5zc29uLCBNLjwvYXV0aG9yPjxh dXRob3I+SmFjb2JpLCBGLjwvYXV0aG9yPjxhdXRob3I+QWxsZ3VsYW5kZXIsIEMuPC9hdXRob3I+ PGF1dGhvcj5BbG9uc28sIEouPC9hdXRob3I+PGF1dGhvcj5CZWdoaSwgRS48L2F1dGhvcj48YXV0 aG9yPkRvZGVsLCBSLjwvYXV0aG9yPjxhdXRob3I+RWttYW4sIE0uPC9hdXRob3I+PGF1dGhvcj5G YXJhdmVsbGksIEMuPC9hdXRob3I+PGF1dGhvcj5GcmF0aWdsaW9uaSwgTC48L2F1dGhvcj48YXV0 aG9yPkdhbm5vbiwgQi48L2F1dGhvcj48YXV0aG9yPkpvbmVzLCBELiBILjwvYXV0aG9yPjxhdXRo b3I+SmVubnVtLCBQLjwvYXV0aG9yPjxhdXRob3I+Sm9yZGFub3ZhLCBBLjwvYXV0aG9yPjxhdXRo b3I+Sm9uc3NvbiwgTC48L2F1dGhvcj48YXV0aG9yPkthcmFtcGFtcGEsIEsuPC9hdXRob3I+PGF1 dGhvcj5LbmFwcCwgTS48L2F1dGhvcj48YXV0aG9yPktvYmVsdCwgRy48L2F1dGhvcj48YXV0aG9y Pkt1cnRoLCBULjwvYXV0aG9yPjxhdXRob3I+TGllYiwgUi48L2F1dGhvcj48YXV0aG9yPkxpbmRl LCBNLjwvYXV0aG9yPjxhdXRob3I+TGp1bmdjcmFudHosIEMuPC9hdXRob3I+PGF1dGhvcj5NYWVy Y2tlciwgQS48L2F1dGhvcj48YXV0aG9yPk1lbGluLCBCLjwvYXV0aG9yPjxhdXRob3I+TW9zY2Fy ZWxsaSwgTS48L2F1dGhvcj48YXV0aG9yPk11c2F5ZXYsIEEuPC9hdXRob3I+PGF1dGhvcj5Ob3J3 b29kLCBGLjwvYXV0aG9yPjxhdXRob3I+UHJlaXNpZywgTS48L2F1dGhvcj48YXV0aG9yPlB1Z2xp YXR0aSwgTS48L2F1dGhvcj48YXV0aG9yPlJlaG0sIEouPC9hdXRob3I+PGF1dGhvcj5TYWx2YWRv ci1DYXJ1bGxhLCBMLjwvYXV0aG9yPjxhdXRob3I+U2NobGVob2ZlciwgQi48L2F1dGhvcj48YXV0 aG9yPlNpbW9uLCBSLjwvYXV0aG9yPjxhdXRob3I+U3RlaW5oYXVzZW4sIEguIEMuPC9hdXRob3I+ PGF1dGhvcj5TdG92bmVyLCBMLiBKLjwvYXV0aG9yPjxhdXRob3I+VmFsbGF0LCBKLiBNLjwvYXV0 aG9yPjxhdXRob3I+VmFuIGRlbiBCZXJnaCwgUC48L2F1dGhvcj48YXV0aG9yPnZhbiBPcywgSi48 L2F1dGhvcj48YXV0aG9yPlZvcywgUC48L2F1dGhvcj48YXV0aG9yPlh1LCBXLjwvYXV0aG9yPjxh dXRob3I+V2l0dGNoZW4sIEguIFUuPC9hdXRob3I+PGF1dGhvcj5Kb25zc29uLCBCLjwvYXV0aG9y PjxhdXRob3I+T2xlc2VuLCBKLjwvYXV0aG9yPjxhdXRob3I+Qy4gREJFU3R1ZHkgR3JvdXA8L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5PcHR1bUluc2lnaHQs IFN0b2NraG9sbSwgU3dlZGVuLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNvc3Qgb2Yg ZGlzb3JkZXJzIG9mIHRoZSBicmFpbiBpbiBFdXJvcGUgMjAxMDwvdGl0bGU+PHNlY29uZGFyeS10 aXRsZT5FdXIgTmV1cm9wc3ljaG9waGFybWFjb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5FdXIgTmV1cm9wc3ljaG9waGFybWFjb2w8L2Z1bGwtdGl0 bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz43MTgtNzk8L3BhZ2VzPjx2b2x1bWU+MjE8L3ZvbHVtZT48 bnVtYmVyPjEwPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+ PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5B Z2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD5CcmFpbiBEaXNlYXNlcy8qZWNvbm9t aWNzL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29y ZD5DaGlsZCwgUHJlc2Nob29sPC9rZXl3b3JkPjxrZXl3b3JkPipDb3N0IG9mIElsbG5lc3M8L2tl eXdvcmQ+PGtleXdvcmQ+RXVyb3BlL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5GZW1h bGU8L2tleXdvcmQ+PGtleXdvcmQ+KkhlYWx0aCBDYXJlIENvc3RzPC9rZXl3b3JkPjxrZXl3b3Jk PkhlYWx0aCBFeHBlbmRpdHVyZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxr ZXl3b3JkPkluZmFudDwva2V5d29yZD48a2V5d29yZD5JbmZhbnQsIE5ld2Jvcm48L2tleXdvcmQ+ PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlzb3JkZXJzLyplY29ub21p Y3MvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxr ZXl3b3JkPlByZXZhbGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+UHVibGljIEhlYWx0aC8qZWNvbm9t aWNzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PHB1Yi1kYXRl cz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xODczLTc4NjIgKEVs ZWN0cm9uaWMpJiN4RDswOTI0LTk3N1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIx OTI0NTg5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMTkyNDU4OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmV1cm9uZXVyby4yMDExLjA4 LjAwODwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRo b3I+VHJhdXRtYW5uPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjkyMzwvUmVjTnVt PjxyZWNvcmQ+PHJlYy1udW1iZXI+OTIzPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh cHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1l c3RhbXA9IjE1ODI3MzkzODkiPjkyMzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh dXRob3I+VHJhdXRtYW5uLCBTLjwvYXV0aG9yPjxhdXRob3I+UmVobSwgSi48L2F1dGhvcj48YXV0 aG9yPldpdHRjaGVuLCBILiBVLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0 aC1hZGRyZXNzPkluc3RpdHV0ZSBvZiBDbGluaWNhbCBQc3ljaG9sb2d5IGFuZCBQc3ljaG90aGVy YXB5LCBUZWNobmlzY2hlIFVuaXZlcnNpdGF0IERyZXNkZW4sIERyZXNkZW4sIEdlcm1hbnkuJiN4 RDtJbnN0aXR1dGUgb2YgQ2xpbmljYWwgUHN5Y2hvbG9neSBhbmQgUHN5Y2hvdGhlcmFweSwgVGVj aG5pc2NoZSBVbml2ZXJzaXRhdCBEcmVzZGVuLCBEcmVzZGVuLCBHZXJtYW55IENlbnRyZSBmb3Ig QWRkaWN0aW9uIGFuZCBNZW50YWwgSGVhbHRoLCBUb3JvbnRvLCBPTiwgQ2FuYWRhLjwvYXV0aC1h ZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBlY29ub21pYyBjb3N0cyBvZiBtZW50YWwgZGlzb3Jk ZXJzOiBEbyBvdXIgc29jaWV0aWVzIHJlYWN0IGFwcHJvcHJpYXRlbHkgdG8gdGhlIGJ1cmRlbiBv ZiBtZW50YWwgZGlzb3JkZXJzPzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5FTUJPIFJlcDwvc2Vj b25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkVNQk8gUmVwPC9m dWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTI0NS05PC9wYWdlcz48dm9sdW1lPjE3PC92 b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPipDb3N0IG9mIElsbG5l c3M8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1lbnRhbCBEaXNv cmRlcnMvKmVjb25vbWljczwva2V5d29yZD48a2V5d29yZD4qU29jaWV0aWVzPC9rZXl3b3JkPjxr ZXl3b3JkPlN0YXRpc3RpY3MgYXMgVG9waWM8L2tleXdvcmQ+PGtleXdvcmQ+VW5pdGVkIFN0YXRl czwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+ PGRhdGU+U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ2OS0zMTc4IChFbGVj dHJvbmljKSYjeEQ7MTQ2OS0yMjFYIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNzQ5 MTcyMzwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cu bmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjc0OTE3MjM8L3VybD48L3JlbGF0ZWQtdXJscz48L3Vy bHM+PGN1c3RvbTI+UE1DNTAwNzU2NTwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+ MTAuMTUyNTIvZW1ici4yMDE2NDI5NTE8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3Jk PjwvQ2l0ZT48L0VuZE5vdGU+AG== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HdXN0YXZzc29uPC9BdXRob3I+PFllYXI+MjAxMTwvWWVh cj48UmVjTnVtPjkyNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMSwgMl08L0Rpc3BsYXlUZXh0Pjxy ZWNvcmQ+PHJlYy1udW1iZXI+OTI0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9 IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3Rh bXA9IjE1ODI3Mzk0NTAiPjkyNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo b3I+R3VzdGF2c3NvbiwgQS48L2F1dGhvcj48YXV0aG9yPlN2ZW5zc29uLCBNLjwvYXV0aG9yPjxh dXRob3I+SmFjb2JpLCBGLjwvYXV0aG9yPjxhdXRob3I+QWxsZ3VsYW5kZXIsIEMuPC9hdXRob3I+ PGF1dGhvcj5BbG9uc28sIEouPC9hdXRob3I+PGF1dGhvcj5CZWdoaSwgRS48L2F1dGhvcj48YXV0 aG9yPkRvZGVsLCBSLjwvYXV0aG9yPjxhdXRob3I+RWttYW4sIE0uPC9hdXRob3I+PGF1dGhvcj5G YXJhdmVsbGksIEMuPC9hdXRob3I+PGF1dGhvcj5GcmF0aWdsaW9uaSwgTC48L2F1dGhvcj48YXV0 aG9yPkdhbm5vbiwgQi48L2F1dGhvcj48YXV0aG9yPkpvbmVzLCBELiBILjwvYXV0aG9yPjxhdXRo b3I+SmVubnVtLCBQLjwvYXV0aG9yPjxhdXRob3I+Sm9yZGFub3ZhLCBBLjwvYXV0aG9yPjxhdXRo b3I+Sm9uc3NvbiwgTC48L2F1dGhvcj48YXV0aG9yPkthcmFtcGFtcGEsIEsuPC9hdXRob3I+PGF1 dGhvcj5LbmFwcCwgTS48L2F1dGhvcj48YXV0aG9yPktvYmVsdCwgRy48L2F1dGhvcj48YXV0aG9y Pkt1cnRoLCBULjwvYXV0aG9yPjxhdXRob3I+TGllYiwgUi48L2F1dGhvcj48YXV0aG9yPkxpbmRl LCBNLjwvYXV0aG9yPjxhdXRob3I+TGp1bmdjcmFudHosIEMuPC9hdXRob3I+PGF1dGhvcj5NYWVy Y2tlciwgQS48L2F1dGhvcj48YXV0aG9yPk1lbGluLCBCLjwvYXV0aG9yPjxhdXRob3I+TW9zY2Fy ZWxsaSwgTS48L2F1dGhvcj48YXV0aG9yPk11c2F5ZXYsIEEuPC9hdXRob3I+PGF1dGhvcj5Ob3J3 b29kLCBGLjwvYXV0aG9yPjxhdXRob3I+UHJlaXNpZywgTS48L2F1dGhvcj48YXV0aG9yPlB1Z2xp YXR0aSwgTS48L2F1dGhvcj48YXV0aG9yPlJlaG0sIEouPC9hdXRob3I+PGF1dGhvcj5TYWx2YWRv ci1DYXJ1bGxhLCBMLjwvYXV0aG9yPjxhdXRob3I+U2NobGVob2ZlciwgQi48L2F1dGhvcj48YXV0 aG9yPlNpbW9uLCBSLjwvYXV0aG9yPjxhdXRob3I+U3RlaW5oYXVzZW4sIEguIEMuPC9hdXRob3I+ PGF1dGhvcj5TdG92bmVyLCBMLiBKLjwvYXV0aG9yPjxhdXRob3I+VmFsbGF0LCBKLiBNLjwvYXV0 aG9yPjxhdXRob3I+VmFuIGRlbiBCZXJnaCwgUC48L2F1dGhvcj48YXV0aG9yPnZhbiBPcywgSi48 L2F1dGhvcj48YXV0aG9yPlZvcywgUC48L2F1dGhvcj48YXV0aG9yPlh1LCBXLjwvYXV0aG9yPjxh dXRob3I+V2l0dGNoZW4sIEguIFUuPC9hdXRob3I+PGF1dGhvcj5Kb25zc29uLCBCLjwvYXV0aG9y PjxhdXRob3I+T2xlc2VuLCBKLjwvYXV0aG9yPjxhdXRob3I+Qy4gREJFU3R1ZHkgR3JvdXA8L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5PcHR1bUluc2lnaHQs IFN0b2NraG9sbSwgU3dlZGVuLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNvc3Qgb2Yg ZGlzb3JkZXJzIG9mIHRoZSBicmFpbiBpbiBFdXJvcGUgMjAxMDwvdGl0bGU+PHNlY29uZGFyeS10 aXRsZT5FdXIgTmV1cm9wc3ljaG9waGFybWFjb2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5FdXIgTmV1cm9wc3ljaG9waGFybWFjb2w8L2Z1bGwtdGl0 bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz43MTgtNzk8L3BhZ2VzPjx2b2x1bWU+MjE8L3ZvbHVtZT48 bnVtYmVyPjEwPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+ PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5B Z2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD5CcmFpbiBEaXNlYXNlcy8qZWNvbm9t aWNzL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29y ZD5DaGlsZCwgUHJlc2Nob29sPC9rZXl3b3JkPjxrZXl3b3JkPipDb3N0IG9mIElsbG5lc3M8L2tl eXdvcmQ+PGtleXdvcmQ+RXVyb3BlL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5GZW1h bGU8L2tleXdvcmQ+PGtleXdvcmQ+KkhlYWx0aCBDYXJlIENvc3RzPC9rZXl3b3JkPjxrZXl3b3Jk PkhlYWx0aCBFeHBlbmRpdHVyZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxr ZXl3b3JkPkluZmFudDwva2V5d29yZD48a2V5d29yZD5JbmZhbnQsIE5ld2Jvcm48L2tleXdvcmQ+ PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlzb3JkZXJzLyplY29ub21p Y3MvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxr ZXl3b3JkPlByZXZhbGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+UHVibGljIEhlYWx0aC8qZWNvbm9t aWNzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PHB1Yi1kYXRl cz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xODczLTc4NjIgKEVs ZWN0cm9uaWMpJiN4RDswOTI0LTk3N1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIx OTI0NTg5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMTkyNDU4OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9qLmV1cm9uZXVyby4yMDExLjA4 LjAwODwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRo b3I+VHJhdXRtYW5uPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjkyMzwvUmVjTnVt PjxyZWNvcmQ+PHJlYy1udW1iZXI+OTIzPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh cHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1l c3RhbXA9IjE1ODI3MzkzODkiPjkyMzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh dXRob3I+VHJhdXRtYW5uLCBTLjwvYXV0aG9yPjxhdXRob3I+UmVobSwgSi48L2F1dGhvcj48YXV0 aG9yPldpdHRjaGVuLCBILiBVLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0 aC1hZGRyZXNzPkluc3RpdHV0ZSBvZiBDbGluaWNhbCBQc3ljaG9sb2d5IGFuZCBQc3ljaG90aGVy YXB5LCBUZWNobmlzY2hlIFVuaXZlcnNpdGF0IERyZXNkZW4sIERyZXNkZW4sIEdlcm1hbnkuJiN4 RDtJbnN0aXR1dGUgb2YgQ2xpbmljYWwgUHN5Y2hvbG9neSBhbmQgUHN5Y2hvdGhlcmFweSwgVGVj aG5pc2NoZSBVbml2ZXJzaXRhdCBEcmVzZGVuLCBEcmVzZGVuLCBHZXJtYW55IENlbnRyZSBmb3Ig QWRkaWN0aW9uIGFuZCBNZW50YWwgSGVhbHRoLCBUb3JvbnRvLCBPTiwgQ2FuYWRhLjwvYXV0aC1h ZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBlY29ub21pYyBjb3N0cyBvZiBtZW50YWwgZGlzb3Jk ZXJzOiBEbyBvdXIgc29jaWV0aWVzIHJlYWN0IGFwcHJvcHJpYXRlbHkgdG8gdGhlIGJ1cmRlbiBv ZiBtZW50YWwgZGlzb3JkZXJzPzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5FTUJPIFJlcDwvc2Vj b25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkVNQk8gUmVwPC9m dWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTI0NS05PC9wYWdlcz48dm9sdW1lPjE3PC92 b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPipDb3N0IG9mIElsbG5l c3M8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1lbnRhbCBEaXNv cmRlcnMvKmVjb25vbWljczwva2V5d29yZD48a2V5d29yZD4qU29jaWV0aWVzPC9rZXl3b3JkPjxr ZXl3b3JkPlN0YXRpc3RpY3MgYXMgVG9waWM8L2tleXdvcmQ+PGtleXdvcmQ+VW5pdGVkIFN0YXRl czwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+ PGRhdGU+U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ2OS0zMTc4IChFbGVj dHJvbmljKSYjeEQ7MTQ2OS0yMjFYIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNzQ5 MTcyMzwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cu bmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjc0OTE3MjM8L3VybD48L3JlbGF0ZWQtdXJscz48L3Vy bHM+PGN1c3RvbTI+UE1DNTAwNzU2NTwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+ MTAuMTUyNTIvZW1ici4yMDE2NDI5NTE8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3Jk PjwvQ2l0ZT48L0VuZE5vdGU+AG== ADDIN EN.CITE.DATA [1, 2] . Most mental disorders are considered neurodevelopmental. Neurodevelopmental disorders (ND D s) affect approximately 1 in 25 individuals in Europe and, due to their life-long consequences, have a major impact on families, healthcare systems and society ( HYPERLINK "https://www.nimh.nih.gov/health/statistics/index.shtml" NIH_MentalHealth ) . N D Ds are caused by alterations in development and function of the brain. Increasing evidence suggests that ND D s and other medical conditions , including cardiovascular, endocrine and respiratory diseases , are associated . The co-morbidity between mental and physical health disturbances in ND D s is predictable, given that the underlying genetic factors might be the same and the genes associated with brain development are often also expressed in peripheral organs. This biological relatedness between co-occurring medical traits suggests that studies of NDDs could open a new vista for understanding causative mechanisms of complex diseases and have a broad set of clinical implications for diagnosis and health management over patient's lifetime PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QbHVtbWVyPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48 UmVjTnVtPjkyNTwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMywgNF08L0Rpc3BsYXlUZXh0PjxyZWNv cmQ+PHJlYy1udW1iZXI+OTI1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE1ODI3Mzk4MjEiPjkyNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ UGx1bW1lciwgSi4gVC48L2F1dGhvcj48YXV0aG9yPkdvcmRvbiwgQS4gSi48L2F1dGhvcj48YXV0 aG9yPkxldml0dCwgUC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5JbnN0aXR1dGUgZm9yIHRoZSBEZXZlbG9waW5nIE1pbmQsIFRoZSBTYWJhbiBSZXNlYXJj aCBJbnN0aXR1dGUsIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBMb3MgQW5nZWxlcyAsIExvcyBB bmdlbGVzLCBDQSAsIFVTQS4mI3hEO0tlY2sgU2Nob29sIG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5 IG9mIFNvdXRoZXJuIENhbGlmb3JuaWEgLCBMb3MgQW5nZWxlcywgQ0EgLCBVU0EuJiN4RDtJbnN0 aXR1dGUgZm9yIHRoZSBEZXZlbG9waW5nIE1pbmQsIFRoZSBTYWJhbiBSZXNlYXJjaCBJbnN0aXR1 dGUsIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBMb3MgQW5nZWxlcywgTG9zIEFuZ2VsZXMsIENB LCBVU0E7IERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgS2VjayBTY2hvb2wgb2YgTWVkaWNpbmUs IFVuaXZlcnNpdHkgb2YgU291dGhlcm4gQ2FsaWZvcm5pYSwgTG9zIEFuZ2VsZXMsIENBLCBVU0Eu PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+VGhlIEdlbmV0aWMgSW50ZXJzZWN0aW9uIG9m IE5ldXJvZGV2ZWxvcG1lbnRhbCBEaXNvcmRlcnMgYW5kIFNoYXJlZCBNZWRpY2FsIENvbW9yYmlk aXRpZXMgLSBSZWxhdGlvbnMgdGhhdCBUcmFuc2xhdGUgZnJvbSBCZW5jaCB0byBCZWRzaWRlPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkZyb250IFBzeWNoaWF0cnk8L3NlY29uZGFyeS10aXRsZT48 L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Gcm9udCBQc3ljaGlhdHJ5PC9mdWxsLXRp dGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTQyPC9wYWdlcz48dm9sdW1lPjc8L3ZvbHVtZT48a2V5 d29yZHM+PGtleXdvcmQ+YXV0aXNtPC9rZXl3b3JkPjxrZXl3b3JkPmJyYWluIGRldmVsb3BtZW50 PC9rZXl3b3JkPjxrZXl3b3JkPm1lbnRhbCBpbGxuZXNzPC9rZXl3b3JkPjxrZXl3b3JkPm5ldXJv Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+c2NoaXpvcGhyZW5pYTwva2V5d29yZD48L2tleXdv cmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTY2NC0wNjQwIChQcmlu dCkmI3hEOzE2NjQtMDY0MCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjc1OTc4MzI8 L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmku bmxtLm5paC5nb3YvcHVibWVkLzI3NTk3ODMyPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxj dXN0b20yPlBNQzQ5OTI2ODY8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjMz ODkvZnBzeXQuMjAxNi4wMDE0MjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D aXRlPjxDaXRlPjxBdXRob3I+SGFwcGVsbDwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051 bT45MjY8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjkyNjwvcmVjLW51bWJlcj48Zm9yZWln bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJm NTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzM5OTMwIj45MjY8L2tleT48L2ZvcmVpZ24ta2V5cz48 cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9y cz48YXV0aG9ycz48YXV0aG9yPkhhcHBlbGwsIEIuPC9hdXRob3I+PGF1dGhvcj5HYWxsZXRseSwg Qy48L2F1dGhvcj48YXV0aG9yPkNhc3RsZSwgRC48L2F1dGhvcj48YXV0aG9yPlBsYXRhbmlhLVBo dW5nLCBDLjwvYXV0aG9yPjxhdXRob3I+U3RhbnRvbiwgUi48L2F1dGhvcj48YXV0aG9yPlNjb3R0 LCBELjwvYXV0aG9yPjxhdXRob3I+TWNLZW5uYSwgQi48L2F1dGhvcj48YXV0aG9yPk1pbGxhciwg Ri48L2F1dGhvcj48YXV0aG9yPkxpdSwgRC48L2F1dGhvcj48YXV0aG9yPkJyb3duZSwgTS48L2F1 dGhvcj48YXV0aG9yPkZ1cm5lc3MsIFQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz PjxhdXRoLWFkZHJlc3M+U3luZXJneSwgTnVyc2luZyBhbmQgTWlkd2lmZXJ5IFJlc2VhcmNoIENl bnRyZSwgVW5pdmVyc2l0eSBvZiBDYW5iZXJyYSBhbmQgQUNUIEhlYWx0aCwgQ2FuYmVycmEgSG9z cGl0YWwsIEFDVCwgQ2FuYmVycmEsIEF1c3RyYWxpYS4mI3hEO1RoZSBBZGVsYWlkZSBDbGluaWMs IEFkZWxhaWRlLCBTb3V0aCBBdXN0cmFsaWEsIEF1c3RyYWxpYS4mI3hEO1NjaG9vbCBvZiBNZWRp Y2luZSwgVW5pdmVyc2l0eSBvZiBBZGVsYWlkZSwgQWRlbGFpZGUsIFNvdXRoIEF1c3RyYWxpYSwg QXVzdHJhbGlhLiYjeEQ7U3QgVmluY2VudCZhcG9zO3MgSG9zcGl0YWwsIE1lbGJvdXJuZSwgVmlj dG9yaWEsIEF1c3RyYWxpYS4mI3hEO1NjaG9vbCBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBN ZWxib3VybmUsIE1lbGJvdXJuZSwgVmljdG9yaWEsIEF1c3RyYWxpYS4mI3hEO0NlbnRyYWwgUXVl ZW5zbGFuZCBVbml2ZXJzaXR5LCBDZW50cmFsIFF1ZWVuc2xhbmQgVW5pdmVyc2l0eSwgU2Nob29s IG9mIEh1bWFuIEhlYWx0aCBhbmQgU29jaWFsIFNjaWVuY2VzLCBCdW5kYWJlcmcsIFF1ZWVuc2xh bmQsIEF1c3RyYWxpYS4mI3hEO0NlbnRyYWwgUXVlZW5zbGFuZCBVbml2ZXJzaXR5LCBTY2hvb2wg b2YgTWVkaWNhbCBhbmQgQXBwbGllZCBTY2llbmNlcywgTWVsYm91cm5lLCBWaWN0b3JpYSwgQXVz dHJhbGlhLiYjeEQ7U2Nob29sIG9mIE51cnNpbmcsIE1pZHdpZmVyeSBhbmQgUGFyYW1lZGljaW5l LCBBdXN0cmFsaWFuIENhdGhvbGljIFVuaXZlcnNpdHksIE1lbGJvdXJuZSwgVmljdG9yaWEsIEF1 c3RyYWxpYS4mI3hEO05vcnRoV2VzdGVybiBNZW50YWwgSGVhbHRoLCBNZWxib3VybmUsIFZpY3Rv cmlhLCBBdXN0cmFsaWEuJiN4RDtFYXN0ZXJuIEhlYWx0aCwgTWVsYm91cm5lLCBWaWN0b3JpYSwg QXVzdHJhbGlhLiYjeEQ7Tm9ydGhlcm4gTWVudGFsIEhlYWx0aCBTZXJ2aWNlLCBTYWxpc2J1cnks IFNvdXRoIEF1c3RyYWxpYSwgQXVzdHJhbGlhLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl PlNjb3BpbmcgcmV2aWV3IG9mIHJlc2VhcmNoIGluIEF1c3RyYWxpYSBvbiB0aGUgY28tb2NjdXJy ZW5jZSBvZiBwaHlzaWNhbCBhbmQgc2VyaW91cyBtZW50YWwgaWxsbmVzcyBhbmQgaW50ZWdyYXRl ZCBjYXJlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkludCBKIE1lbnQgSGVhbHRoIE51cnM8L3Nl Y29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBNZW50 IEhlYWx0aCBOdXJzPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NDIxLTM4PC9wYWdl cz48dm9sdW1lPjI0PC92b2x1bWU+PG51bWJlcj41PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk PkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QmlvbWVkaWNhbCBSZXNl YXJjaDwva2V5d29yZD48a2V5d29yZD4qRGVsaXZlcnkgb2YgSGVhbHRoIENhcmUsIEludGVncmF0 ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+SGVhbHRoIFN0YXR1czwva2V5d29yZD48a2V5d29yZD5IdW1h bnM8L2tleXdvcmQ+PGtleXdvcmQ+TWVudGFsIERpc29yZGVycy8qY29tcGxpY2F0aW9ucy9lcGlk ZW1pb2xvZ3kvdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5jb21vcmJpZGl0eTwva2V5d29yZD48 a2V5d29yZD5tZW50YWwgaGVhbHRoIG51cnNpbmc8L2tleXdvcmQ+PGtleXdvcmQ+cGh5c2ljYWwg aWxsbmVzczwva2V5d29yZD48a2V5d29yZD5wc3ljaG9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+cmV2 aWV3PC9rZXl3b3JkPjxrZXl3b3JkPnNjaGl6b3BocmVuaWE8L2tleXdvcmQ+PC9rZXl3b3Jkcz48 ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPk9jdDwvZGF0ZT48L3B1Yi1k YXRlcz48L2RhdGVzPjxpc2JuPjE0NDctMDM0OSAoRWxlY3Ryb25pYykmI3hEOzE0NDUtODMzMCAo TGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjYyMjAxNTE8L2FjY2Vzc2lvbi1udW0+PHVy bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk LzI2MjIwMTUxPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNl LW51bT4xMC4xMTExL2lubS4xMjE0MjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+ PC9DaXRlPjwvRW5kTm90ZT4A ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QbHVtbWVyPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48 UmVjTnVtPjkyNTwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMywgNF08L0Rpc3BsYXlUZXh0PjxyZWNv cmQ+PHJlYy1udW1iZXI+OTI1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE1ODI3Mzk4MjEiPjkyNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ UGx1bW1lciwgSi4gVC48L2F1dGhvcj48YXV0aG9yPkdvcmRvbiwgQS4gSi48L2F1dGhvcj48YXV0 aG9yPkxldml0dCwgUC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5JbnN0aXR1dGUgZm9yIHRoZSBEZXZlbG9waW5nIE1pbmQsIFRoZSBTYWJhbiBSZXNlYXJj aCBJbnN0aXR1dGUsIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBMb3MgQW5nZWxlcyAsIExvcyBB bmdlbGVzLCBDQSAsIFVTQS4mI3hEO0tlY2sgU2Nob29sIG9mIE1lZGljaW5lLCBVbml2ZXJzaXR5 IG9mIFNvdXRoZXJuIENhbGlmb3JuaWEgLCBMb3MgQW5nZWxlcywgQ0EgLCBVU0EuJiN4RDtJbnN0 aXR1dGUgZm9yIHRoZSBEZXZlbG9waW5nIE1pbmQsIFRoZSBTYWJhbiBSZXNlYXJjaCBJbnN0aXR1 dGUsIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCBMb3MgQW5nZWxlcywgTG9zIEFuZ2VsZXMsIENB LCBVU0E7IERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgS2VjayBTY2hvb2wgb2YgTWVkaWNpbmUs IFVuaXZlcnNpdHkgb2YgU291dGhlcm4gQ2FsaWZvcm5pYSwgTG9zIEFuZ2VsZXMsIENBLCBVU0Eu PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+VGhlIEdlbmV0aWMgSW50ZXJzZWN0aW9uIG9m IE5ldXJvZGV2ZWxvcG1lbnRhbCBEaXNvcmRlcnMgYW5kIFNoYXJlZCBNZWRpY2FsIENvbW9yYmlk aXRpZXMgLSBSZWxhdGlvbnMgdGhhdCBUcmFuc2xhdGUgZnJvbSBCZW5jaCB0byBCZWRzaWRlPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkZyb250IFBzeWNoaWF0cnk8L3NlY29uZGFyeS10aXRsZT48 L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Gcm9udCBQc3ljaGlhdHJ5PC9mdWxsLXRp dGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTQyPC9wYWdlcz48dm9sdW1lPjc8L3ZvbHVtZT48a2V5 d29yZHM+PGtleXdvcmQ+YXV0aXNtPC9rZXl3b3JkPjxrZXl3b3JkPmJyYWluIGRldmVsb3BtZW50 PC9rZXl3b3JkPjxrZXl3b3JkPm1lbnRhbCBpbGxuZXNzPC9rZXl3b3JkPjxrZXl3b3JkPm5ldXJv Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+c2NoaXpvcGhyZW5pYTwva2V5d29yZD48L2tleXdv cmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTY2NC0wNjQwIChQcmlu dCkmI3hEOzE2NjQtMDY0MCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjc1OTc4MzI8 L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmku bmxtLm5paC5nb3YvcHVibWVkLzI3NTk3ODMyPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxj dXN0b20yPlBNQzQ5OTI2ODY8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjMz ODkvZnBzeXQuMjAxNi4wMDE0MjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D aXRlPjxDaXRlPjxBdXRob3I+SGFwcGVsbDwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051 bT45MjY8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjkyNjwvcmVjLW51bWJlcj48Zm9yZWln bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJm NTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzM5OTMwIj45MjY8L2tleT48L2ZvcmVpZ24ta2V5cz48 cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9y cz48YXV0aG9ycz48YXV0aG9yPkhhcHBlbGwsIEIuPC9hdXRob3I+PGF1dGhvcj5HYWxsZXRseSwg Qy48L2F1dGhvcj48YXV0aG9yPkNhc3RsZSwgRC48L2F1dGhvcj48YXV0aG9yPlBsYXRhbmlhLVBo dW5nLCBDLjwvYXV0aG9yPjxhdXRob3I+U3RhbnRvbiwgUi48L2F1dGhvcj48YXV0aG9yPlNjb3R0 LCBELjwvYXV0aG9yPjxhdXRob3I+TWNLZW5uYSwgQi48L2F1dGhvcj48YXV0aG9yPk1pbGxhciwg Ri48L2F1dGhvcj48YXV0aG9yPkxpdSwgRC48L2F1dGhvcj48YXV0aG9yPkJyb3duZSwgTS48L2F1 dGhvcj48YXV0aG9yPkZ1cm5lc3MsIFQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz PjxhdXRoLWFkZHJlc3M+U3luZXJneSwgTnVyc2luZyBhbmQgTWlkd2lmZXJ5IFJlc2VhcmNoIENl bnRyZSwgVW5pdmVyc2l0eSBvZiBDYW5iZXJyYSBhbmQgQUNUIEhlYWx0aCwgQ2FuYmVycmEgSG9z cGl0YWwsIEFDVCwgQ2FuYmVycmEsIEF1c3RyYWxpYS4mI3hEO1RoZSBBZGVsYWlkZSBDbGluaWMs IEFkZWxhaWRlLCBTb3V0aCBBdXN0cmFsaWEsIEF1c3RyYWxpYS4mI3hEO1NjaG9vbCBvZiBNZWRp Y2luZSwgVW5pdmVyc2l0eSBvZiBBZGVsYWlkZSwgQWRlbGFpZGUsIFNvdXRoIEF1c3RyYWxpYSwg QXVzdHJhbGlhLiYjeEQ7U3QgVmluY2VudCZhcG9zO3MgSG9zcGl0YWwsIE1lbGJvdXJuZSwgVmlj dG9yaWEsIEF1c3RyYWxpYS4mI3hEO1NjaG9vbCBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBN ZWxib3VybmUsIE1lbGJvdXJuZSwgVmljdG9yaWEsIEF1c3RyYWxpYS4mI3hEO0NlbnRyYWwgUXVl ZW5zbGFuZCBVbml2ZXJzaXR5LCBDZW50cmFsIFF1ZWVuc2xhbmQgVW5pdmVyc2l0eSwgU2Nob29s IG9mIEh1bWFuIEhlYWx0aCBhbmQgU29jaWFsIFNjaWVuY2VzLCBCdW5kYWJlcmcsIFF1ZWVuc2xh bmQsIEF1c3RyYWxpYS4mI3hEO0NlbnRyYWwgUXVlZW5zbGFuZCBVbml2ZXJzaXR5LCBTY2hvb2wg b2YgTWVkaWNhbCBhbmQgQXBwbGllZCBTY2llbmNlcywgTWVsYm91cm5lLCBWaWN0b3JpYSwgQXVz dHJhbGlhLiYjeEQ7U2Nob29sIG9mIE51cnNpbmcsIE1pZHdpZmVyeSBhbmQgUGFyYW1lZGljaW5l LCBBdXN0cmFsaWFuIENhdGhvbGljIFVuaXZlcnNpdHksIE1lbGJvdXJuZSwgVmljdG9yaWEsIEF1 c3RyYWxpYS4mI3hEO05vcnRoV2VzdGVybiBNZW50YWwgSGVhbHRoLCBNZWxib3VybmUsIFZpY3Rv cmlhLCBBdXN0cmFsaWEuJiN4RDtFYXN0ZXJuIEhlYWx0aCwgTWVsYm91cm5lLCBWaWN0b3JpYSwg QXVzdHJhbGlhLiYjeEQ7Tm9ydGhlcm4gTWVudGFsIEhlYWx0aCBTZXJ2aWNlLCBTYWxpc2J1cnks IFNvdXRoIEF1c3RyYWxpYSwgQXVzdHJhbGlhLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl PlNjb3BpbmcgcmV2aWV3IG9mIHJlc2VhcmNoIGluIEF1c3RyYWxpYSBvbiB0aGUgY28tb2NjdXJy ZW5jZSBvZiBwaHlzaWNhbCBhbmQgc2VyaW91cyBtZW50YWwgaWxsbmVzcyBhbmQgaW50ZWdyYXRl ZCBjYXJlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkludCBKIE1lbnQgSGVhbHRoIE51cnM8L3Nl Y29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBNZW50 IEhlYWx0aCBOdXJzPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NDIxLTM4PC9wYWdl cz48dm9sdW1lPjI0PC92b2x1bWU+PG51bWJlcj41PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk PkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QmlvbWVkaWNhbCBSZXNl YXJjaDwva2V5d29yZD48a2V5d29yZD4qRGVsaXZlcnkgb2YgSGVhbHRoIENhcmUsIEludGVncmF0 ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+SGVhbHRoIFN0YXR1czwva2V5d29yZD48a2V5d29yZD5IdW1h bnM8L2tleXdvcmQ+PGtleXdvcmQ+TWVudGFsIERpc29yZGVycy8qY29tcGxpY2F0aW9ucy9lcGlk ZW1pb2xvZ3kvdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5jb21vcmJpZGl0eTwva2V5d29yZD48 a2V5d29yZD5tZW50YWwgaGVhbHRoIG51cnNpbmc8L2tleXdvcmQ+PGtleXdvcmQ+cGh5c2ljYWwg aWxsbmVzczwva2V5d29yZD48a2V5d29yZD5wc3ljaG9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+cmV2 aWV3PC9rZXl3b3JkPjxrZXl3b3JkPnNjaGl6b3BocmVuaWE8L2tleXdvcmQ+PC9rZXl3b3Jkcz48 ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRhdGVzPjxkYXRlPk9jdDwvZGF0ZT48L3B1Yi1k YXRlcz48L2RhdGVzPjxpc2JuPjE0NDctMDM0OSAoRWxlY3Ryb25pYykmI3hEOzE0NDUtODMzMCAo TGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjYyMjAxNTE8L2FjY2Vzc2lvbi1udW0+PHVy bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk LzI2MjIwMTUxPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNl LW51bT4xMC4xMTExL2lubS4xMjE0MjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+ PC9DaXRlPjwvRW5kTm90ZT4A ADDIN EN.CITE.DATA [3, 4] . Extensive genome-wide screening in clinical cohorts has revealed that approximately 20% of children with ND D s are carriers of pathogenic DNA copy number variants (CNVs) ADDIN EN.CITE <EndNote><Cite><Author>Hochstenbach</Author><Year>2011</Year><RecNum>927</RecNum><DisplayText>[5]</DisplayText><record><rec-number>927</rec-number><foreign-keys><key app="EN" db-id="t90dxwwvnpsrrtexe9opzw9vw9r2f500f9rf" timestamp="1582740059">927</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hochstenbach, R.</author><author>Buizer-Voskamp, J. E.</author><author>Vorstman, J. A.</author><author>Ophoff, R. A.</author></authors></contributors><auth-address>Division of Biomedical Genetics, Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands.
[email protected]</auth-address><titles><title>Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research</title><secondary-title>Cytogenet Genome Res</secondary-title></titles><periodical><full-title>Cytogenet Genome Res</full-title></periodical><pages>174-202</pages><volume>135</volume><number>3-4</number><keywords><keyword>Animals</keyword><keyword>Congenital Abnormalities/genetics</keyword><keyword>*DNA Copy Number Variations</keyword><keyword>Epilepsy/diagnosis/*genetics</keyword><keyword>Gene Dosage</keyword><keyword>Genetic Pleiotropy</keyword><keyword>Genetic Predisposition to Disease</keyword><keyword>Genome, Human</keyword><keyword>*Genome-Wide Association Study</keyword><keyword>Humans</keyword><keyword>Mental Disorders/diagnosis/*genetics</keyword><keyword>Mice</keyword><keyword>Oligonucleotide Array Sequence Analysis</keyword><keyword>Penetrance</keyword></keywords><dates><year>2011</year></dates><isbn>1424-859X (Electronic)&#xD;1424-8581 (Linking)</isbn><accession-num>22056632</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/22056632</url></related-urls></urls><electronic-resource-num>10.1159/000332928</electronic-resource-num></record></Cite></EndNote> [5] . Akin to ND D s in general, besides their effect on brain development and risk for mental disorders , CNVs are linked to other co-occurring complex health conditions. To date, the relevance of CNVs has almost exclusively been investigated in clinically ascertained children with severe ND D s , such as intellectual disability and autism spectrum disorder . Th us , the perception of CNV effect has suffered from an ascertainment bias towards phenotypes presenting with early onset and posing the greatest medical management challenges . A systematic understanding on how CNVs affect health and life quality in the general population has remained largely unknown . No conclusions are currently available about CNV-associated disease traits in adulthood and age-related trajectories of health problems. Recent studies have shown that cumulatively CNVs could also be a common health problem in the adult population. Approximately 1% of participants in general population biobanks carry a known neurodevelopmental CNV (ND-CNV) , and an additional 10% of the population carries a rare CNV that has yet remained clinically uncharacterized PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2XTwvRGlzcGxheVRleHQ+PHJlY29yZD48 cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi LWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4 MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYW5u aWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwgQS48 L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwuPC9h dXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4g TS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBBLjwv YXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48L2F1 dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEuIE0u PC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEuPC9h dXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRob3I+ PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhvcj48 YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRo b3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1 dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48L2F1 dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9yIElu dGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dp dHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0 dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBMYXVz YW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1h dGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5 IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGljYWwg U2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kgTGFi b3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVuaXZl cnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9sIEdl bmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQgQ29t bXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRlZCBL aW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNvY2lh bCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2ws IFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBVbml2 ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9mIE5l dXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYywg VGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2YgTW9s ZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3Rv bmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21tdW5p dHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2FsZCwg R2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2Yg TWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGljYWwg VGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFuLCBJ dGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5uZXNv dGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNzLCBM YXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3Ms IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0dXRl IG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0eSBI b3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3IgSW50 ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0 emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJpYXRp b25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25zPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIg VmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdvcmQ+ PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwva2V5 d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNzb2Np YXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48a2V5 d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlz b3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9rZXl3 b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9r ZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48ZGF0 ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVsZWN0 cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2MDEw NjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5u Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs cz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4x MC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48 L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2XTwvRGlzcGxheVRleHQ+PHJlY29yZD48 cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi LWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4 MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYW5u aWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwgQS48 L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwuPC9h dXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4g TS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBBLjwv YXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48L2F1 dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEuIE0u PC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEuPC9h dXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRob3I+ PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhvcj48 YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRo b3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1 dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48L2F1 dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9yIElu dGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dp dHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0 dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBMYXVz YW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1h dGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5 IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGljYWwg U2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kgTGFi b3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVuaXZl cnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9sIEdl bmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQgQ29t bXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRlZCBL aW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNvY2lh bCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2ws IFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBVbml2 ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9mIE5l dXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYywg VGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2YgTW9s ZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3Rv bmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21tdW5p dHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2FsZCwg R2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2Yg TWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGljYWwg VGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFuLCBJ dGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5uZXNv dGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNzLCBM YXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3Ms IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0dXRl IG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0eSBI b3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3IgSW50 ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0 emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJpYXRp b25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25zPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIg VmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdvcmQ+ PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwva2V5 d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNzb2Np YXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48a2V5 d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlz b3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9rZXl3 b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9r ZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48ZGF0 ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVsZWN0 cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2MDEw NjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5u Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs cz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4x MC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48 L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE.DATA [6] . Preliminary data indicate that CNVs explain a substantial portion of population variance in education attainment , are associated with lower socio-economic status and a complex set of clinical outcomes PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2LTExXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTQ4MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5N YW5uaWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwg QS48L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwu PC9hdXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwg QS4gTS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBB LjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48 L2F1dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEu IE0uPC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEu PC9hdXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRo b3I+PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhv cj48YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9h dXRob3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48 L2F1dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48 L2F1dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48 L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9y IEludGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwg U3dpdHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwg VGFydHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBU YXJ0dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0 b3J5IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGlj YWwgU2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kg TGFib3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVu aXZlcnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9s IEdlbmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQg Q29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRl ZCBLaW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNv Y2lhbCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0 b2wsIFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBV bml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3Rvbmlh biBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9m IE5ldXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5p YywgVGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3Rvbmlh biBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2Yg TW9sZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBF c3RvbmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9p bmZvcm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21t dW5pdHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2Fs ZCwgR2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkg b2YgTWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMs IFVuaXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGlj YWwgVGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFu LCBJdGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5u ZXNvdGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNz LCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRp Y3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJ bnN0aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0 dXRlIG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0 eSBIb3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3Ig SW50ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBT d2l0emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJp YXRpb25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25z PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn ZXM+MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+ PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tl eXdvcmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1i ZXIgVmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdv cmQ+PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwv a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNz b2NpYXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48 a2V5d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48 a2V5d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdv cmQ+SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwg RGlzb3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVz PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48 ZGF0ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVs ZWN0cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2 MDEwNjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51 bT4xMC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y ZD48L0NpdGU+PENpdGU+PEF1dGhvcj5LZW5kYWxsPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48 UmVjTnVtPjUwNzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NTA3PC9yZWMtbnVtYmVyPjxm b3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2 dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE0OTE4MTQ3NjEiPjUwNzwva2V5PjwvZm9yZWlnbi1r ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2VuZGFsbCwgSy4gTS48L2F1dGhvcj48YXV0aG9yPlJl ZXMsIEUuPC9hdXRob3I+PGF1dGhvcj5Fc2NvdHQtUHJpY2UsIFYuPC9hdXRob3I+PGF1dGhvcj5F aW5vbiwgTS48L2F1dGhvcj48YXV0aG9yPlRob21hcywgUi48L2F1dGhvcj48YXV0aG9yPkhld2l0 dCwgSi48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0aG9yPjxhdXRo b3I+T3dlbiwgTS4gSi48L2F1dGhvcj48YXV0aG9yPldhbHRlcnMsIEouIFQuPC9hdXRob3I+PGF1 dGhvcj5LaXJvdiwgRy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5NUkMgQ2VudHJlIGZvciBOZXVyb3BzeWNoaWF0cmljIEdlbmV0aWNzICZhbXA7IEdlbm9t aWNzLCBEaXZpc2lvbiBvZiBQc3ljaG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVy b3NjaWVuY2UsIENhcmRpZmYgVW5pdmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUsIENhcmRpZmYu JiN4RDtEZXBhcnRtZW50IG9mIEdlcmlhdHJpYyBNZWRpY2luZSwgRGl2aXNpb24gb2YgUG9wdWxh dGlvbiBNZWRpY2luZSwgTGxhbmRvdWdoIEhvc3BpdGFsLCBQZW5hcnRoLCBVbml0ZWQgS2luZ2Rv bS4mI3hEO01SQyBDZW50cmUgZm9yIE5ldXJvcHN5Y2hpYXRyaWMgR2VuZXRpY3MgJmFtcDsgR2Vu b21pY3MsIERpdmlzaW9uIG9mIFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5pY2FsIE5l dXJvc2NpZW5jZSwgQ2FyZGlmZiBVbml2ZXJzaXR5IFNjaG9vbCBvZiBNZWRpY2luZSwgQ2FyZGlm Zi4gRWxlY3Ryb25pYyBhZGRyZXNzOiBraXJvdkBjYXJkaWZmLmFjLnVrLjwvYXV0aC1hZGRyZXNz Pjx0aXRsZXM+PHRpdGxlPkNvZ25pdGl2ZSBQZXJmb3JtYW5jZSBBbW9uZyBDYXJyaWVycyBvZiBQ YXRob2dlbmljIENvcHkgTnVtYmVyIFZhcmlhbnRzOiBBbmFseXNpcyBvZiAxNTIsMDAwIFVLIEJp b2JhbmsgU3ViamVjdHM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QmlvbCBQc3ljaGlhdHJ5PC9z ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QmlvbCBQc3lj aGlhdHJ5PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48a2V5d29yZHM+PGtleXdvcmQ+QWZmeW1l dHJpeDwva2V5d29yZD48a2V5d29yZD5DbnY8L2tleXdvcmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9r ZXl3b3JkPjxrZXl3b3JkPk5ldXJvZGV2ZWxvcG1lbnRhbDwva2V5d29yZD48a2V5d29yZD5TY2hp em9waHJlbmlhPC9rZXl3b3JkPjxrZXl3b3JkPlVLIEJpb2Jhbms8L2tleXdvcmQ+PC9rZXl3b3Jk cz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkF1ZyAxODwvZGF0ZT48 L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE4NzMtMjQwMiAoRWxlY3Ryb25pYykmI3hEOzAwMDYt MzIyMyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjc3NzMzNTQ8L2FjY2Vzc2lvbi1u dW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3Yv cHVibWVkLzI3NzczMzU0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJl c291cmNlLW51bT4xMC4xMDE2L2ouYmlvcHN5Y2guMjAxNi4wOC4wMTQ8L2VsZWN0cm9uaWMtcmVz b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkd1eWF0dDwvQXV0aG9yPjxZ ZWFyPjIwMTg8L1llYXI+PFJlY051bT45Mjk8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjky OTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2 bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzQwNTg4Ij45Mjk8 L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwv cmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkd1eWF0dCwgQS4gTC48L2F1 dGhvcj48YXV0aG9yPlN0ZXJnaWFrb3VsaSwgRS48L2F1dGhvcj48YXV0aG9yPk1hcnRpbiwgSi48 L2F1dGhvcj48YXV0aG9yPldhbHRlcnMsIEouPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7RG9ub3Zh biwgTS48L2F1dGhvcj48YXV0aG9yPk93ZW4sIE0uPC9hdXRob3I+PGF1dGhvcj5UaGFwYXIsIEEu PC9hdXRob3I+PGF1dGhvcj5LaXJvdiwgRy48L2F1dGhvcj48YXV0aG9yPlJvZHJpZ3VleiwgUy48 L2F1dGhvcj48YXV0aG9yPlJhaSwgRC48L2F1dGhvcj48YXV0aG9yPlphbW1pdCwgUy48L2F1dGhv cj48YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48 YXV0aC1hZGRyZXNzPk1SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgUG9wdWxhdGlv biBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVk IEtpbmdkb20uJiN4RDtDZW50cmUgZm9yIEFjYWRlbWljIE1lbnRhbCBIZWFsdGgsIFBvcHVsYXRp b24gSGVhbHRoIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRl ZCBLaW5nZG9tLiYjeEQ7TVJDIENlbnRyZSBmb3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyBh bmQgR2Vub21pY3MsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgVW5pdGVkIEtpbmdkb20u JiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgRXBpZGVtaW9sb2d5ICZhbXA7IEJpb3N0YXRpc3Rp Y3MsIEthcm9saW5za2EgSW5zdGl0dXRldCwgU3RvY2tob2xtLCBTd2VkZW4uPC9hdXRoLWFkZHJl c3M+PHRpdGxlcz48dGl0bGU+QXNzb2NpYXRpb24gb2YgY29weSBudW1iZXIgdmFyaWF0aW9uIGFj cm9zcyB0aGUgZ2Vub21lIHdpdGggbmV1cm9wc3ljaGlhdHJpYyB0cmFpdHMgaW4gdGhlIGdlbmVy YWwgcG9wdWxhdGlvbjwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5BbSBKIE1lZCBHZW5ldCBCIE5l dXJvcHN5Y2hpYXRyIEdlbmV0PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+ PGZ1bGwtdGl0bGU+QW0gSiBNZWQgR2VuZXQgQiBOZXVyb3BzeWNoaWF0ciBHZW5ldDwvZnVsbC10 aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQ4OS01MDI8L3BhZ2VzPjx2b2x1bWU+MTc3PC92b2x1 bWU+PG51bWJlcj41PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdv cmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW54aWV0eS9nZW5ldGljczwva2V5 d29yZD48a2V5d29yZD5BdHRlbnRpb24gRGVmaWNpdCBEaXNvcmRlciB3aXRoIEh5cGVyYWN0aXZp dHkvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+QXV0aXNtIFNwZWN0cnVtIERpc29yZGVyL2dl bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkROQSBDb3B5 IE51bWJlciBWYXJpYXRpb25zLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5EZXByZXNzaW9u L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HZW5l dGljIFByZWRpc3Bvc2l0aW9uIHRvIERpc2Vhc2UvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk Pkdlbm9tZS1XaWRlIEFzc29jaWF0aW9uIFN0dWR5L21ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+ SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkludGVsbGlnZW5jZS9nZW5ldGljczwva2V5d29yZD48 a2V5d29yZD5Mb25naXR1ZGluYWwgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3 b3JkPjxrZXl3b3JkPk1lbnRhbCBEaXNvcmRlcnMvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk PlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Qb2x5bW9ycGhpc20sIFNpbmdsZSBOdWNsZW90 aWRlL2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvZ2VuZXRpY3M8L2tl eXdvcmQ+PGtleXdvcmQ+KkFsc3BhYzwva2V5d29yZD48a2V5d29yZD4qY2hpbGRob29kPC9rZXl3 b3JkPjxrZXl3b3JkPipnZW5ldGljIGVwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD4qc3Ry dWN0dXJhbCB2YXJpYXRpb248L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxODwv eWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju PjE1NTItNDg1WCAoRWxlY3Ryb25pYykmI3hEOzE1NTItNDg0MSAoTGlua2luZyk8L2lzYm4+PGFj Y2Vzc2lvbi1udW0+Mjk2ODc5NDQ8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48 dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI5Njg3OTQ0PC91cmw+PC9y ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzYwOTkzNzU8L2N1c3RvbTI+PGVsZWN0cm9u aWMtcmVzb3VyY2UtbnVtPjEwLjEwMDIvYWptZy5iLjMyNjM3PC9lbGVjdHJvbmljLXJlc291cmNl LW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5Pd2VuPC9BdXRob3I+PFllYXI+MjAx ODwvWWVhcj48UmVjTnVtPjkyODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+OTI4PC9yZWMt bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRl eGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE1ODI3NDA1NTAiPjkyODwva2V5Pjwv Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+T3dlbiwgRC48L2F1dGhvcj48YXV0aG9y PkJyYWNoZXItU21pdGgsIE0uPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBLLiBNLjwvYXV0aG9y PjxhdXRob3I+UmVlcywgRS48L2F1dGhvcj48YXV0aG9yPkVpbm9uLCBNLjwvYXV0aG9yPjxhdXRo b3I+RXNjb3R0LVByaWNlLCBWLjwvYXV0aG9yPjxhdXRob3I+T3dlbiwgTS4gSi48L2F1dGhvcj48 YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0aG9yPjxhdXRob3I+S2lyb3YsIEcuPC9h dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+TVJDIENlbnRyZSBm b3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyAmYW1wOyBHZW5vbWljcywgSW5zdGl0dXRlIG9m IFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5pY2FsIE5ldXJvc2NpZW5jZXMsIENhcmRp ZmYgVW5pdmVyc2l0eSwgU2Nob29sIG9mIE1lZGljaW5lLCBIYWR5biBFbGxpcyBCdWlsZGluZywg TWFpbmR5IFJvYWQsIENhcmRpZmYsIENGMjQgNEhRLCBVSy4mI3hEO01SQyBDZW50cmUgZm9yIE5l dXJvcHN5Y2hpYXRyaWMgR2VuZXRpY3MgJmFtcDsgR2Vub21pY3MsIEluc3RpdHV0ZSBvZiBQc3lj aG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVyb3NjaWVuY2VzLCBDYXJkaWZmIFVu aXZlcnNpdHksIFNjaG9vbCBvZiBNZWRpY2luZSwgSGFkeW4gRWxsaXMgQnVpbGRpbmcsIE1haW5k eSBSb2FkLCBDYXJkaWZmLCBDRjI0IDRIUSwgVUsuIGtpcm92QGNhcmRpZmYuYWMudWsuPC9hdXRo LWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RWZmZWN0cyBvZiBwYXRob2dlbmljIENOVnMgb24gcGh5 c2ljYWwgdHJhaXRzIGluIHBhcnRpY2lwYW50cyBvZiB0aGUgVUsgQmlvYmFuazwvdGl0bGU+PHNl Y29uZGFyeS10aXRsZT5CTUMgR2Vub21pY3M8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5CTUMgR2Vub21pY3M8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2Fs PjxwYWdlcz44Njc8L3BhZ2VzPjx2b2x1bWU+MTk8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48 a2V5d29yZHM+PGtleXdvcmQ+QmlvbG9naWNhbCBTcGVjaW1lbiBCYW5rczwva2V5d29yZD48a2V5 d29yZD5Cb2R5IFdlaWdodC9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5DZWxsIEFkaGVzaW9u IE1vbGVjdWxlcywgTmV1cm9uYWwvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29t ZSBEZWxldGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTYv Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDIyL2dl bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIgVmFyaWF0aW9uczwva2V5 d29yZD48a2V5d29yZD5FdXJvcGVhbiBDb250aW5lbnRhbCBBbmNlc3RyeSBHcm91cC8qZ2VuZXRp Y3M8L2tleXdvcmQ+PGtleXdvcmQ+R2VuZSBEdXBsaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5I dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TmVydmUgVGlzc3VlIFByb3RlaW5zL2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgS2luZ2Rv bTwva2V5d29yZD48a2V5d29yZD5XYWlzdC1IaXAgUmF0aW88L2tleXdvcmQ+PGtleXdvcmQ+QW50 aHJvcG9tZXRyaWM8L2tleXdvcmQ+PGtleXdvcmQ+Qm1pPC9rZXl3b3JkPjxrZXl3b3JkPkNudjwv a2V5d29yZD48a2V5d29yZD5IZWlnaHQ8L2tleXdvcmQ+PGtleXdvcmQ+T2Jlc2l0eTwva2V5d29y ZD48a2V5d29yZD5QdWxzZTwva2V5d29yZD48a2V5d29yZD5VSyBCaW9iYW5rPC9rZXl3b3JkPjxr ZXl3b3JkPldhaXN0PC9rZXl3b3JkPjxrZXl3b3JkPldlaWdodDwva2V5d29yZD48L2tleXdvcmRz PjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+RGVjIDQ8L2RhdGU+PC9w dWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDcxLTIxNjQgKEVsZWN0cm9uaWMpJiN4RDsxNDcxLTIx NjQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwNTA5MTcwPC9hY2Nlc3Npb24tbnVt Pjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1 Ym1lZC8zMDUwOTE3MDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM2Mjc4 MDQyPC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTg2L3MxMjg2NC0wMTgt NTI5Mi03PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1 dGhvcj5DcmF3Zm9yZDwvQXV0aG9yPjxZZWFyPjIwMTk8L1llYXI+PFJlY051bT44NjY8L1JlY051 bT48cmVjb3JkPjxyZWMtbnVtYmVyPjg2NjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkg YXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGlt ZXN0YW1wPSIxNTcwMDQwOTk4Ij44NjY8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFt ZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48 YXV0aG9yPkNyYXdmb3JkLCBLLjwvYXV0aG9yPjxhdXRob3I+QnJhY2hlci1TbWl0aCwgTS48L2F1 dGhvcj48YXV0aG9yPk93ZW4sIEQuPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBLLiBNLjwvYXV0 aG9yPjxhdXRob3I+UmVlcywgRS48L2F1dGhvcj48YXV0aG9yPlBhcmRpbmFzLCBBLiBGLjwvYXV0 aG9yPjxhdXRob3I+RWlub24sIE0uPC9hdXRob3I+PGF1dGhvcj5Fc2NvdHQtUHJpY2UsIFYuPC9h dXRob3I+PGF1dGhvcj5XYWx0ZXJzLCBKLiBULiBSLjwvYXV0aG9yPjxhdXRob3I+TyZhcG9zO0Rv bm92YW4sIE0uIEMuPC9hdXRob3I+PGF1dGhvcj5Pd2VuLCBNLiBKLjwvYXV0aG9yPjxhdXRob3I+ S2lyb3YsIEcuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+ TVJDIENlbnRyZSBmb3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyBhbmQgR2Vub21pY3MsIElu c3RpdHV0ZSBvZiBQc3ljaG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVyb3NjaWVu Y2VzLCBTY2hvb2wgb2YgTWVkaWNpbmUsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgVUsu PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+TWVkaWNhbCBjb25zZXF1ZW5jZXMgb2YgcGF0 aG9nZW5pYyBDTlZzIGluIGFkdWx0czogYW5hbHlzaXMgb2YgdGhlIFVLIEJpb2Jhbms8L3RpdGxl PjxzZWNvbmRhcnktdGl0bGU+SiBNZWQgR2VuZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIE1lZCBHZW5ldDwvZnVsbC10aXRsZT48L3BlcmlvZGlj YWw+PHBhZ2VzPjEzMS0xMzg8L3BhZ2VzPjx2b2x1bWU+NTY8L3ZvbHVtZT48bnVtYmVyPjM8L251 bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+VUsgYmlvYmFuazwva2V5d29yZD48a2V5d29yZD5jbnY8 L2tleXdvcmQ+PGtleXdvcmQ+bWVkaWNhbDwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh cj4yMDE5PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+TWFyPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0 ZXM+PGlzYm4+MTQ2OC02MjQ0IChFbGVjdHJvbmljKSYjeEQ7MDAyMi0yNTkzIChMaW5raW5nKTwv aXNibj48YWNjZXNzaW9uLW51bT4zMDM0MzI3NTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRl ZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzAzNDMyNzU8 L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEx MzYvam1lZGdlbmV0LTIwMTgtMTA1NDc3PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y ZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CdXJnaGVsPC9BdXRob3I+PFllYXI+MjAyMDwvWWVhcj48 UmVjTnVtPjkzMDwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+OTMwPC9yZWMtbnVtYmVyPjxm b3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2 dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE1ODI3NDA5MjgiPjkzMDwva2V5PjwvZm9yZWlnbi1r ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QnVyZ2hlbCwgRy4gSi48L2F1dGhvcj48YXV0aG9yPkto YW4sIFUuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFcuIFkuPC9hdXRob3I+PGF1dGhvcj5XaGl0dGFr ZXIsIFcuPC9hdXRob3I+PGF1dGhvcj5CYW5rYSwgUy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250 cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5NYW5jaGVzdGVyIENlbnRyZSBmb3IgR2Vub21pYyBNZWRp Y2luZSwgU3QgTWFyeSZhcG9zO3MgSG9zcGl0YWwsIE1hbmNoZXN0ZXIgVW5pdmVyc2l0eSBOSFMg Rm91bmRhdGlvbiBUcnVzdCwgTWFuY2hlc3RlciwgVUsuJiN4RDtTY2hvb2wgb2YgSGVhbHRoIFNj aWVuY2UsIEZhY3VsdHkgb2YgQmlvbG9neSwgTWVkaWNpbmUgYW5kIEhlYWx0aCwgVW5pdmVyc2l0 eSBvZiBNYW5jaGVzdGVyLCBNYW5jaGVzdGVyLCBVSy4mI3hEO05vcnRoZXJuIEluc3RpdHV0ZSBm b3IgQ2FuY2VyIFJlc2VhcmNoLCBNZWRpY2FsIFNjaG9vbCwgTmV3Y2FzdGxlIFVuaXZlcnNpdHks IE5ld2Nhc3RsZSB1cG9uIFR5bmUsIFR5bmUsIFVLLiYjeEQ7RGl2aXNpb24gb2YgUG9wdWxhdGlv biBIZWFsdGgsIEhlYWx0aCBTZXJ2aWNlcyBSZXNlYXJjaCAmYW1wOyBQcmltYXJ5IENhcmUsIFVu aXZlcnNpdHkgb2YgTWFuY2hlc3RlciwgTWFuY2hlc3RlciwgVUsuJiN4RDtNYW5jaGVzdGVyIENl bnRyZSBmb3IgR2Vub21pYyBNZWRpY2luZSwgU3QgTWFyeSZhcG9zO3MgSG9zcGl0YWwsIE1hbmNo ZXN0ZXIgVW5pdmVyc2l0eSBOSFMgRm91bmRhdGlvbiBUcnVzdCwgTWFuY2hlc3RlciwgVUsgU2lk ZGhhcnRoLkJhbmthQG1hbmNoZXN0ZXIuYWMudWsuJiN4RDtEaXZpc2lvbiBvZiBFdm9sdXRpb24g YW5kIEdlbm9taWNzLCBTY2hvb2wgb2YgQmlvbG9naWNhbCBTY2llbmNlcywgRmFjdWx0eSBvZiBC aW9sb2d5LCBNZWRpY2luZSBhbmQgSGVhbHRoLCBVbml2ZXJzaXR5IG9mIE1hbmNoZXN0ZXIsIE1h bmNoZXN0ZXIsIFVLLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlByZXNlbmNlIG9mIHBh dGhvZ2VuaWMgY29weSBudW1iZXIgdmFyaWFudHMgKENOVnMpIGlzIGNvcnJlbGF0ZWQgd2l0aCBz b2Npb2Vjb25vbWljIHN0YXR1czwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIE1lZCBHZW5ldDwv c2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogTWVkIEdl bmV0PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NzAtNzI8L3BhZ2VzPjx2b2x1bWU+ NTc8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+Q252PC9rZXl3 b3JkPjxrZXl3b3JkPnNvY2lvZWNvbm9taWMgc3RhdHVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRh dGVzPjx5ZWFyPjIwMjA8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KYW48L2RhdGU+PC9wdWItZGF0 ZXM+PC9kYXRlcz48aXNibj4xNDY4LTYyNDQgKEVsZWN0cm9uaWMpJiN4RDswMDIyLTI1OTMgKExp bmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMxNTQ4MjE0PC9hY2Nlc3Npb24tbnVtPjx1cmxz PjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8z MTU0ODIxNDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u dW0+MTAuMTEzNi9qbWVkZ2VuZXQtMjAxOS0xMDYyOTI8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVt PjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2LTExXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTQ4MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5N YW5uaWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwg QS48L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwu PC9hdXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwg QS4gTS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBB LjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48 L2F1dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEu IE0uPC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEu PC9hdXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRo b3I+PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhv cj48YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9h dXRob3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48 L2F1dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48 L2F1dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48 L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9y IEludGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwg U3dpdHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwg VGFydHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBU YXJ0dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0 b3J5IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGlj YWwgU2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kg TGFib3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVu aXZlcnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9s IEdlbmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQg Q29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRl ZCBLaW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNv Y2lhbCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0 b2wsIFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBV bml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3Rvbmlh biBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9m IE5ldXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5p YywgVGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3Rvbmlh biBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2Yg TW9sZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBF c3RvbmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9p bmZvcm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21t dW5pdHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2Fs ZCwgR2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkg b2YgTWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMs IFVuaXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGlj YWwgVGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFu LCBJdGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5u ZXNvdGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNz LCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRp Y3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJ bnN0aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0 dXRlIG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0 eSBIb3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3Ig SW50ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBT d2l0emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJp YXRpb25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25z PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn ZXM+MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+ PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tl eXdvcmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1i ZXIgVmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdv cmQ+PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwv a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNz b2NpYXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48 a2V5d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48 a2V5d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdv cmQ+SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwg RGlzb3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVz PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48 ZGF0ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVs ZWN0cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2 MDEwNjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51 bT4xMC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y ZD48L0NpdGU+PENpdGU+PEF1dGhvcj5LZW5kYWxsPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48 UmVjTnVtPjUwNzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NTA3PC9yZWMtbnVtYmVyPjxm b3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2 dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE0OTE4MTQ3NjEiPjUwNzwva2V5PjwvZm9yZWlnbi1r ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2VuZGFsbCwgSy4gTS48L2F1dGhvcj48YXV0aG9yPlJl ZXMsIEUuPC9hdXRob3I+PGF1dGhvcj5Fc2NvdHQtUHJpY2UsIFYuPC9hdXRob3I+PGF1dGhvcj5F aW5vbiwgTS48L2F1dGhvcj48YXV0aG9yPlRob21hcywgUi48L2F1dGhvcj48YXV0aG9yPkhld2l0 dCwgSi48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0aG9yPjxhdXRo b3I+T3dlbiwgTS4gSi48L2F1dGhvcj48YXV0aG9yPldhbHRlcnMsIEouIFQuPC9hdXRob3I+PGF1 dGhvcj5LaXJvdiwgRy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5NUkMgQ2VudHJlIGZvciBOZXVyb3BzeWNoaWF0cmljIEdlbmV0aWNzICZhbXA7IEdlbm9t aWNzLCBEaXZpc2lvbiBvZiBQc3ljaG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVy b3NjaWVuY2UsIENhcmRpZmYgVW5pdmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUsIENhcmRpZmYu JiN4RDtEZXBhcnRtZW50IG9mIEdlcmlhdHJpYyBNZWRpY2luZSwgRGl2aXNpb24gb2YgUG9wdWxh dGlvbiBNZWRpY2luZSwgTGxhbmRvdWdoIEhvc3BpdGFsLCBQZW5hcnRoLCBVbml0ZWQgS2luZ2Rv bS4mI3hEO01SQyBDZW50cmUgZm9yIE5ldXJvcHN5Y2hpYXRyaWMgR2VuZXRpY3MgJmFtcDsgR2Vu b21pY3MsIERpdmlzaW9uIG9mIFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5pY2FsIE5l dXJvc2NpZW5jZSwgQ2FyZGlmZiBVbml2ZXJzaXR5IFNjaG9vbCBvZiBNZWRpY2luZSwgQ2FyZGlm Zi4gRWxlY3Ryb25pYyBhZGRyZXNzOiBraXJvdkBjYXJkaWZmLmFjLnVrLjwvYXV0aC1hZGRyZXNz Pjx0aXRsZXM+PHRpdGxlPkNvZ25pdGl2ZSBQZXJmb3JtYW5jZSBBbW9uZyBDYXJyaWVycyBvZiBQ YXRob2dlbmljIENvcHkgTnVtYmVyIFZhcmlhbnRzOiBBbmFseXNpcyBvZiAxNTIsMDAwIFVLIEJp b2JhbmsgU3ViamVjdHM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QmlvbCBQc3ljaGlhdHJ5PC9z ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QmlvbCBQc3lj aGlhdHJ5PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48a2V5d29yZHM+PGtleXdvcmQ+QWZmeW1l dHJpeDwva2V5d29yZD48a2V5d29yZD5DbnY8L2tleXdvcmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9r ZXl3b3JkPjxrZXl3b3JkPk5ldXJvZGV2ZWxvcG1lbnRhbDwva2V5d29yZD48a2V5d29yZD5TY2hp em9waHJlbmlhPC9rZXl3b3JkPjxrZXl3b3JkPlVLIEJpb2Jhbms8L2tleXdvcmQ+PC9rZXl3b3Jk cz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkF1ZyAxODwvZGF0ZT48 L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE4NzMtMjQwMiAoRWxlY3Ryb25pYykmI3hEOzAwMDYt MzIyMyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjc3NzMzNTQ8L2FjY2Vzc2lvbi1u dW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3Yv cHVibWVkLzI3NzczMzU0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJl c291cmNlLW51bT4xMC4xMDE2L2ouYmlvcHN5Y2guMjAxNi4wOC4wMTQ8L2VsZWN0cm9uaWMtcmVz b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkd1eWF0dDwvQXV0aG9yPjxZ ZWFyPjIwMTg8L1llYXI+PFJlY051bT45Mjk8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjky OTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2 bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzQwNTg4Ij45Mjk8 L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwv cmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkd1eWF0dCwgQS4gTC48L2F1 dGhvcj48YXV0aG9yPlN0ZXJnaWFrb3VsaSwgRS48L2F1dGhvcj48YXV0aG9yPk1hcnRpbiwgSi48 L2F1dGhvcj48YXV0aG9yPldhbHRlcnMsIEouPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7RG9ub3Zh biwgTS48L2F1dGhvcj48YXV0aG9yPk93ZW4sIE0uPC9hdXRob3I+PGF1dGhvcj5UaGFwYXIsIEEu PC9hdXRob3I+PGF1dGhvcj5LaXJvdiwgRy48L2F1dGhvcj48YXV0aG9yPlJvZHJpZ3VleiwgUy48 L2F1dGhvcj48YXV0aG9yPlJhaSwgRC48L2F1dGhvcj48YXV0aG9yPlphbW1pdCwgUy48L2F1dGhv cj48YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48 YXV0aC1hZGRyZXNzPk1SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgUG9wdWxhdGlv biBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVk IEtpbmdkb20uJiN4RDtDZW50cmUgZm9yIEFjYWRlbWljIE1lbnRhbCBIZWFsdGgsIFBvcHVsYXRp b24gSGVhbHRoIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRl ZCBLaW5nZG9tLiYjeEQ7TVJDIENlbnRyZSBmb3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyBh bmQgR2Vub21pY3MsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgVW5pdGVkIEtpbmdkb20u JiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgRXBpZGVtaW9sb2d5ICZhbXA7IEJpb3N0YXRpc3Rp Y3MsIEthcm9saW5za2EgSW5zdGl0dXRldCwgU3RvY2tob2xtLCBTd2VkZW4uPC9hdXRoLWFkZHJl c3M+PHRpdGxlcz48dGl0bGU+QXNzb2NpYXRpb24gb2YgY29weSBudW1iZXIgdmFyaWF0aW9uIGFj cm9zcyB0aGUgZ2Vub21lIHdpdGggbmV1cm9wc3ljaGlhdHJpYyB0cmFpdHMgaW4gdGhlIGdlbmVy YWwgcG9wdWxhdGlvbjwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5BbSBKIE1lZCBHZW5ldCBCIE5l dXJvcHN5Y2hpYXRyIEdlbmV0PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+ PGZ1bGwtdGl0bGU+QW0gSiBNZWQgR2VuZXQgQiBOZXVyb3BzeWNoaWF0ciBHZW5ldDwvZnVsbC10 aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQ4OS01MDI8L3BhZ2VzPjx2b2x1bWU+MTc3PC92b2x1 bWU+PG51bWJlcj41PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdv cmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW54aWV0eS9nZW5ldGljczwva2V5 d29yZD48a2V5d29yZD5BdHRlbnRpb24gRGVmaWNpdCBEaXNvcmRlciB3aXRoIEh5cGVyYWN0aXZp dHkvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+QXV0aXNtIFNwZWN0cnVtIERpc29yZGVyL2dl bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkROQSBDb3B5 IE51bWJlciBWYXJpYXRpb25zLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5EZXByZXNzaW9u L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HZW5l dGljIFByZWRpc3Bvc2l0aW9uIHRvIERpc2Vhc2UvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk Pkdlbm9tZS1XaWRlIEFzc29jaWF0aW9uIFN0dWR5L21ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+ SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkludGVsbGlnZW5jZS9nZW5ldGljczwva2V5d29yZD48 a2V5d29yZD5Mb25naXR1ZGluYWwgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3 b3JkPjxrZXl3b3JkPk1lbnRhbCBEaXNvcmRlcnMvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk PlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Qb2x5bW9ycGhpc20sIFNpbmdsZSBOdWNsZW90 aWRlL2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvZ2VuZXRpY3M8L2tl eXdvcmQ+PGtleXdvcmQ+KkFsc3BhYzwva2V5d29yZD48a2V5d29yZD4qY2hpbGRob29kPC9rZXl3 b3JkPjxrZXl3b3JkPipnZW5ldGljIGVwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD4qc3Ry dWN0dXJhbCB2YXJpYXRpb248L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxODwv eWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju PjE1NTItNDg1WCAoRWxlY3Ryb25pYykmI3hEOzE1NTItNDg0MSAoTGlua2luZyk8L2lzYm4+PGFj Y2Vzc2lvbi1udW0+Mjk2ODc5NDQ8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48 dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI5Njg3OTQ0PC91cmw+PC9y ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzYwOTkzNzU8L2N1c3RvbTI+PGVsZWN0cm9u aWMtcmVzb3VyY2UtbnVtPjEwLjEwMDIvYWptZy5iLjMyNjM3PC9lbGVjdHJvbmljLXJlc291cmNl LW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5Pd2VuPC9BdXRob3I+PFllYXI+MjAx ODwvWWVhcj48UmVjTnVtPjkyODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+OTI4PC9yZWMt bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRl eGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE1ODI3NDA1NTAiPjkyODwva2V5Pjwv Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+T3dlbiwgRC48L2F1dGhvcj48YXV0aG9y PkJyYWNoZXItU21pdGgsIE0uPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBLLiBNLjwvYXV0aG9y PjxhdXRob3I+UmVlcywgRS48L2F1dGhvcj48YXV0aG9yPkVpbm9uLCBNLjwvYXV0aG9yPjxhdXRo b3I+RXNjb3R0LVByaWNlLCBWLjwvYXV0aG9yPjxhdXRob3I+T3dlbiwgTS4gSi48L2F1dGhvcj48 YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0aG9yPjxhdXRob3I+S2lyb3YsIEcuPC9h dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+TVJDIENlbnRyZSBm b3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyAmYW1wOyBHZW5vbWljcywgSW5zdGl0dXRlIG9m IFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5pY2FsIE5ldXJvc2NpZW5jZXMsIENhcmRp ZmYgVW5pdmVyc2l0eSwgU2Nob29sIG9mIE1lZGljaW5lLCBIYWR5biBFbGxpcyBCdWlsZGluZywg TWFpbmR5IFJvYWQsIENhcmRpZmYsIENGMjQgNEhRLCBVSy4mI3hEO01SQyBDZW50cmUgZm9yIE5l dXJvcHN5Y2hpYXRyaWMgR2VuZXRpY3MgJmFtcDsgR2Vub21pY3MsIEluc3RpdHV0ZSBvZiBQc3lj aG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVyb3NjaWVuY2VzLCBDYXJkaWZmIFVu aXZlcnNpdHksIFNjaG9vbCBvZiBNZWRpY2luZSwgSGFkeW4gRWxsaXMgQnVpbGRpbmcsIE1haW5k eSBSb2FkLCBDYXJkaWZmLCBDRjI0IDRIUSwgVUsuIGtpcm92QGNhcmRpZmYuYWMudWsuPC9hdXRo LWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RWZmZWN0cyBvZiBwYXRob2dlbmljIENOVnMgb24gcGh5 c2ljYWwgdHJhaXRzIGluIHBhcnRpY2lwYW50cyBvZiB0aGUgVUsgQmlvYmFuazwvdGl0bGU+PHNl Y29uZGFyeS10aXRsZT5CTUMgR2Vub21pY3M8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5CTUMgR2Vub21pY3M8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2Fs PjxwYWdlcz44Njc8L3BhZ2VzPjx2b2x1bWU+MTk8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48 a2V5d29yZHM+PGtleXdvcmQ+QmlvbG9naWNhbCBTcGVjaW1lbiBCYW5rczwva2V5d29yZD48a2V5 d29yZD5Cb2R5IFdlaWdodC9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5DZWxsIEFkaGVzaW9u IE1vbGVjdWxlcywgTmV1cm9uYWwvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29t ZSBEZWxldGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTYv Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDIyL2dl bmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIgVmFyaWF0aW9uczwva2V5 d29yZD48a2V5d29yZD5FdXJvcGVhbiBDb250aW5lbnRhbCBBbmNlc3RyeSBHcm91cC8qZ2VuZXRp Y3M8L2tleXdvcmQ+PGtleXdvcmQ+R2VuZSBEdXBsaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5I dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TmVydmUgVGlzc3VlIFByb3RlaW5zL2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgS2luZ2Rv bTwva2V5d29yZD48a2V5d29yZD5XYWlzdC1IaXAgUmF0aW88L2tleXdvcmQ+PGtleXdvcmQ+QW50 aHJvcG9tZXRyaWM8L2tleXdvcmQ+PGtleXdvcmQ+Qm1pPC9rZXl3b3JkPjxrZXl3b3JkPkNudjwv a2V5d29yZD48a2V5d29yZD5IZWlnaHQ8L2tleXdvcmQ+PGtleXdvcmQ+T2Jlc2l0eTwva2V5d29y ZD48a2V5d29yZD5QdWxzZTwva2V5d29yZD48a2V5d29yZD5VSyBCaW9iYW5rPC9rZXl3b3JkPjxr ZXl3b3JkPldhaXN0PC9rZXl3b3JkPjxrZXl3b3JkPldlaWdodDwva2V5d29yZD48L2tleXdvcmRz PjxkYXRlcz48eWVhcj4yMDE4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+RGVjIDQ8L2RhdGU+PC9w dWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDcxLTIxNjQgKEVsZWN0cm9uaWMpJiN4RDsxNDcxLTIx NjQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwNTA5MTcwPC9hY2Nlc3Npb24tbnVt Pjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1 Ym1lZC8zMDUwOTE3MDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM2Mjc4 MDQyPC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTg2L3MxMjg2NC0wMTgt NTI5Mi03PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1 dGhvcj5DcmF3Zm9yZDwvQXV0aG9yPjxZZWFyPjIwMTk8L1llYXI+PFJlY051bT44NjY8L1JlY051 bT48cmVjb3JkPjxyZWMtbnVtYmVyPjg2NjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkg YXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGlt ZXN0YW1wPSIxNTcwMDQwOTk4Ij44NjY8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFt ZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48 YXV0aG9yPkNyYXdmb3JkLCBLLjwvYXV0aG9yPjxhdXRob3I+QnJhY2hlci1TbWl0aCwgTS48L2F1 dGhvcj48YXV0aG9yPk93ZW4sIEQuPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBLLiBNLjwvYXV0 aG9yPjxhdXRob3I+UmVlcywgRS48L2F1dGhvcj48YXV0aG9yPlBhcmRpbmFzLCBBLiBGLjwvYXV0 aG9yPjxhdXRob3I+RWlub24sIE0uPC9hdXRob3I+PGF1dGhvcj5Fc2NvdHQtUHJpY2UsIFYuPC9h dXRob3I+PGF1dGhvcj5XYWx0ZXJzLCBKLiBULiBSLjwvYXV0aG9yPjxhdXRob3I+TyZhcG9zO0Rv bm92YW4sIE0uIEMuPC9hdXRob3I+PGF1dGhvcj5Pd2VuLCBNLiBKLjwvYXV0aG9yPjxhdXRob3I+ S2lyb3YsIEcuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+ TVJDIENlbnRyZSBmb3IgTmV1cm9wc3ljaGlhdHJpYyBHZW5ldGljcyBhbmQgR2Vub21pY3MsIElu c3RpdHV0ZSBvZiBQc3ljaG9sb2dpY2FsIE1lZGljaW5lIGFuZCBDbGluaWNhbCBOZXVyb3NjaWVu Y2VzLCBTY2hvb2wgb2YgTWVkaWNpbmUsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgVUsu PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+TWVkaWNhbCBjb25zZXF1ZW5jZXMgb2YgcGF0 aG9nZW5pYyBDTlZzIGluIGFkdWx0czogYW5hbHlzaXMgb2YgdGhlIFVLIEJpb2Jhbms8L3RpdGxl PjxzZWNvbmRhcnktdGl0bGU+SiBNZWQgR2VuZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48 cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIE1lZCBHZW5ldDwvZnVsbC10aXRsZT48L3BlcmlvZGlj YWw+PHBhZ2VzPjEzMS0xMzg8L3BhZ2VzPjx2b2x1bWU+NTY8L3ZvbHVtZT48bnVtYmVyPjM8L251 bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+VUsgYmlvYmFuazwva2V5d29yZD48a2V5d29yZD5jbnY8 L2tleXdvcmQ+PGtleXdvcmQ+bWVkaWNhbDwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh cj4yMDE5PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+TWFyPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0 ZXM+PGlzYm4+MTQ2OC02MjQ0IChFbGVjdHJvbmljKSYjeEQ7MDAyMi0yNTkzIChMaW5raW5nKTwv aXNibj48YWNjZXNzaW9uLW51bT4zMDM0MzI3NTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRl ZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzAzNDMyNzU8 L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEx MzYvam1lZGdlbmV0LTIwMTgtMTA1NDc3PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y ZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CdXJnaGVsPC9BdXRob3I+PFllYXI+MjAyMDwvWWVhcj48 UmVjTnVtPjkzMDwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+OTMwPC9yZWMtbnVtYmVyPjxm b3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2 dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE1ODI3NDA5MjgiPjkzMDwva2V5PjwvZm9yZWlnbi1r ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QnVyZ2hlbCwgRy4gSi48L2F1dGhvcj48YXV0aG9yPkto YW4sIFUuPC9hdXRob3I+PGF1dGhvcj5MaW4sIFcuIFkuPC9hdXRob3I+PGF1dGhvcj5XaGl0dGFr ZXIsIFcuPC9hdXRob3I+PGF1dGhvcj5CYW5rYSwgUy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250 cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5NYW5jaGVzdGVyIENlbnRyZSBmb3IgR2Vub21pYyBNZWRp Y2luZSwgU3QgTWFyeSZhcG9zO3MgSG9zcGl0YWwsIE1hbmNoZXN0ZXIgVW5pdmVyc2l0eSBOSFMg Rm91bmRhdGlvbiBUcnVzdCwgTWFuY2hlc3RlciwgVUsuJiN4RDtTY2hvb2wgb2YgSGVhbHRoIFNj aWVuY2UsIEZhY3VsdHkgb2YgQmlvbG9neSwgTWVkaWNpbmUgYW5kIEhlYWx0aCwgVW5pdmVyc2l0 eSBvZiBNYW5jaGVzdGVyLCBNYW5jaGVzdGVyLCBVSy4mI3hEO05vcnRoZXJuIEluc3RpdHV0ZSBm b3IgQ2FuY2VyIFJlc2VhcmNoLCBNZWRpY2FsIFNjaG9vbCwgTmV3Y2FzdGxlIFVuaXZlcnNpdHks IE5ld2Nhc3RsZSB1cG9uIFR5bmUsIFR5bmUsIFVLLiYjeEQ7RGl2aXNpb24gb2YgUG9wdWxhdGlv biBIZWFsdGgsIEhlYWx0aCBTZXJ2aWNlcyBSZXNlYXJjaCAmYW1wOyBQcmltYXJ5IENhcmUsIFVu aXZlcnNpdHkgb2YgTWFuY2hlc3RlciwgTWFuY2hlc3RlciwgVUsuJiN4RDtNYW5jaGVzdGVyIENl bnRyZSBmb3IgR2Vub21pYyBNZWRpY2luZSwgU3QgTWFyeSZhcG9zO3MgSG9zcGl0YWwsIE1hbmNo ZXN0ZXIgVW5pdmVyc2l0eSBOSFMgRm91bmRhdGlvbiBUcnVzdCwgTWFuY2hlc3RlciwgVUsgU2lk ZGhhcnRoLkJhbmthQG1hbmNoZXN0ZXIuYWMudWsuJiN4RDtEaXZpc2lvbiBvZiBFdm9sdXRpb24g YW5kIEdlbm9taWNzLCBTY2hvb2wgb2YgQmlvbG9naWNhbCBTY2llbmNlcywgRmFjdWx0eSBvZiBC aW9sb2d5LCBNZWRpY2luZSBhbmQgSGVhbHRoLCBVbml2ZXJzaXR5IG9mIE1hbmNoZXN0ZXIsIE1h bmNoZXN0ZXIsIFVLLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlByZXNlbmNlIG9mIHBh dGhvZ2VuaWMgY29weSBudW1iZXIgdmFyaWFudHMgKENOVnMpIGlzIGNvcnJlbGF0ZWQgd2l0aCBz b2Npb2Vjb25vbWljIHN0YXR1czwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIE1lZCBHZW5ldDwv c2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogTWVkIEdl bmV0PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NzAtNzI8L3BhZ2VzPjx2b2x1bWU+ NTc8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+Q252PC9rZXl3 b3JkPjxrZXl3b3JkPnNvY2lvZWNvbm9taWMgc3RhdHVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRh dGVzPjx5ZWFyPjIwMjA8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KYW48L2RhdGU+PC9wdWItZGF0 ZXM+PC9kYXRlcz48aXNibj4xNDY4LTYyNDQgKEVsZWN0cm9uaWMpJiN4RDswMDIyLTI1OTMgKExp bmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMxNTQ4MjE0PC9hY2Nlc3Npb24tbnVtPjx1cmxz PjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8z MTU0ODIxNDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u dW0+MTAuMTEzNi9qbWVkZ2VuZXQtMjAxOS0xMDYyOTI8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVt PjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG== ADDIN EN.CITE.DATA [6-11] . Our study in the clinically unselected Estonian Biobank ( EstBB ; in Estonian: Geenivaramu ) indicated that 49% of ND-CNV carriers reach only basic education. A notable 70% of carriers suffer from major diseases (e.g. mental disorders, obesity, epilepsy, cardiac, renal and/or endocrine diseases), but had no prior awareness of their genetic disorder PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2XTwvRGlzcGxheVRleHQ+PHJlY29yZD48 cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi LWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4 MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYW5u aWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwgQS48 L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwuPC9h dXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4g TS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBBLjwv YXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48L2F1 dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEuIE0u PC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEuPC9h dXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRob3I+ PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhvcj48 YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRo b3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1 dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48L2F1 dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9yIElu dGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dp dHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0 dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBMYXVz YW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1h dGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5 IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGljYWwg U2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kgTGFi b3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVuaXZl cnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9sIEdl bmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQgQ29t bXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRlZCBL aW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNvY2lh bCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2ws IFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBVbml2 ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9mIE5l dXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYywg VGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2YgTW9s ZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3Rv bmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21tdW5p dHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2FsZCwg R2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2Yg TWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGljYWwg VGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFuLCBJ dGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5uZXNv dGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNzLCBM YXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3Ms IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0dXRl IG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0eSBI b3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3IgSW50 ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0 emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJpYXRp b25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25zPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIg VmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdvcmQ+ PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwva2V5 d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNzb2Np YXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48a2V5 d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlz b3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9rZXl3 b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9r ZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48ZGF0 ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVsZWN0 cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2MDEw NjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5u Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs cz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4x MC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48 L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYW5uaWs8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxS ZWNOdW0+NDc3PC9SZWNOdW0+PERpc3BsYXlUZXh0Pls2XTwvRGlzcGxheVRleHQ+PHJlY29yZD48 cmVjLW51bWJlcj40Nzc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi LWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4 MDAwMjk4NyI+NDc3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYW5u aWssIEsuPC9hdXRob3I+PGF1dGhvcj5NYWdpLCBSLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwgQS48 L2F1dGhvcj48YXV0aG9yPkNvbGUsIEIuPC9hdXRob3I+PGF1dGhvcj5HdXlhdHQsIEEuIEwuPC9h dXRob3I+PGF1dGhvcj5TaGloYWIsIEguIEEuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4g TS48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5Lb2xrLCBBLjwv YXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5NaWhhaWxvdiwgRS48L2F1 dGhvcj48YXV0aG9yPkxlaXRzYWx1LCBMLjwvYXV0aG9yPjxhdXRob3I+RmVycmVpcmEsIEEuIE0u PC9hdXRob3I+PGF1dGhvcj5Ob3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5UZXVtZXIsIEEuPC9h dXRob3I+PGF1dGhvcj5TYWx2aSwgRS48L2F1dGhvcj48YXV0aG9yPkN1c2ksIEQuPC9hdXRob3I+ PGF1dGhvcj5NY0d1ZSwgTS48L2F1dGhvcj48YXV0aG9yPklhY29ubywgVy4gRy48L2F1dGhvcj48 YXV0aG9yPkdhdW50LCBULiBSLjwvYXV0aG9yPjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRo b3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1 dGhvcj48YXV0aG9yPlBhbmtyYXR6LCBOLjwvYXV0aG9yPjxhdXRob3I+VGltcHNvbiwgTi48L2F1 dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1 dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5DZW50ZXIgZm9yIElu dGVncmF0aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dp dHplcmxhbmQyRXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUuJiN4RDtFc3RvbmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0 dS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBvZiBMYXVz YW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1h dGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5 IE1lZGljaW5lIGFuZCBQYXRob2xvZ3ksIFVuaXZlcnNpdHkgb2YgTWlubmVzb3RhIE1lZGljYWwg U2Nob29sLCBNaW5uZWFwb2xpcy4mI3hEO0JyaXN0b2wgR2VuZXRpYyBFcGlkZW1pb2xvZ3kgTGFi b3JhdG9yaWVzLCBTY2hvb2wgb2YgU29jaWFsIGFuZCBDb21tdW5pdHkgTWVkaWNpbmUsIFVuaXZl cnNpdHkgb2YgQnJpc3RvbCwgQnJpc3RvbCwgVW5pdGVkIEtpbmdkb20uJiN4RDtCcmlzdG9sIEdl bmV0aWMgRXBpZGVtaW9sb2d5IExhYm9yYXRvcmllcywgU2Nob29sIG9mIFNvY2lhbCBhbmQgQ29t bXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2wsIFVuaXRlZCBL aW5nZG9tN01SQyBJbnRlZ3JhdGl2ZSBFcGlkZW1pb2xvZ3kgVW5pdCwgU2Nob29sIG9mIFNvY2lh bCBhbmQgQ29tbXVuaXR5IE1lZGljaW5lLCBVbml2ZXJzaXR5IG9mIEJyaXN0b2wsIEJyaXN0b2ws IFVuaXRlZCBLaW5nZG9tLiYjeEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBVbml2 ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dThEZXBhcnRtZW50IG9mIE5l dXJvbG9neSBhbmQgTmV1cm9yZWhhYmlsaXRhdGlvbiwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYywg VGFydHUgVW5pdmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtFc3RvbmlhbiBH ZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dTlJbnN0aXR1dGUgb2YgTW9s ZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3Rv bmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBM YXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kNFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZv cm1hdGljcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7SW5zdGl0dXRlIGZvciBDb21tdW5p dHkgTWVkaWNpbmUsIFVuaXZlcnNpdHkgTWVkaWNpbmUgR3JlaWZzd2FsZCwgR3JlaWZzd2FsZCwg R2VybWFueS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2Yg TWlsYW4sIE1pbGFuLCBJdGFseS4mI3hEO0RlcGFybWVudCBvZiBIZWFsdGggU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgTWlsYW4sIE1pbGFuLCBJdGFseTEySW5zdGl0dXRlIG9mIEJpb21lZGljYWwg VGVjaG5vbG9naWVzLCBJdGFsaWFuIE5hdGlvbmFsIFJlc2VhcmNoIENvdW5jaWwsIE1pbGFuLCBJ dGFseS4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hvbG9neSwgVW5pdmVyc2l0eSBvZiBNaW5uZXNv dGEsIE1pbm5lYXBvbGlzLiYjeEQ7U3dpc3MgSW5zdGl0dXRlIG9mIEJpb2luZm9ybWF0aWNzLCBM YXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3Ms IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDRTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIExhdXNhbm5lLCBTd2l0emVybGFuZDE0SW5zdGl0dXRl IG9mIFNvY2lhbCBhbmQgUHJldmVudGl2ZSBNZWRpY2luZSwgTGF1c2FubmUgVW5pdmVyc2l0eSBI b3NwaXRhbCAoQ0hVViksIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3IgSW50 ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0 emVybGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db3B5IG51bWJlciB2YXJpYXRp b25zIGFuZCBjb2duaXRpdmUgcGhlbm90eXBlcyBpbiB1bnNlbGVjdGVkIHBvcHVsYXRpb25zPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpBTUE8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy aW9kaWNhbD48ZnVsbC10aXRsZT5KQU1BPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ MjA0NC01NDwvcGFnZXM+PHZvbHVtZT4zMTM8L3ZvbHVtZT48bnVtYmVyPjIwPC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+Q29nbml0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPipETkEgQ29weSBOdW1iZXIg VmFyaWF0aW9uczwva2V5d29yZD48a2V5d29yZD5FZHVjYXRpb25hbCBTdGF0dXM8L2tleXdvcmQ+ PGtleXdvcmQ+RXBpbGVwc3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RXN0b25pYTwva2V5 d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21lLVdpZGUgQXNzb2Np YXRpb24gU3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+R3JlYXQgQnJpdGFpbjwva2V5d29yZD48a2V5 d29yZD4qSGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ SXRhbHk8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NZW50YWwgRGlz b3JkZXJzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2dlbmV0aWNzPC9rZXl3 b3JkPjxrZXl3b3JkPlBoZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9r ZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTU8L3llYXI+PHB1Yi1kYXRlcz48ZGF0 ZT5NYXkgMjY8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM4LTM1OTggKEVsZWN0 cm9uaWMpJiN4RDswMDk4LTc0ODQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI2MDEw NjMzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5u Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNjAxMDYzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs cz48Y3VzdG9tMj5QTUM0Njg0MjY5PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4x MC4xMDAxL2phbWEuMjAxNS40ODQ1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48 L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE.DATA [6] . This suggests that despite negative effect on health, this vulnerable group has escaped the attention of the medical genetic system and not received proper evaluation and support, although genotype-tailored healthcare could significantly improve their quality of life . In a recent pilot study, we aimed to evaluate the response of EstBB participants to the disclosure of this type of incidental genetic findings by using the ND- CNVs in the human 16p11.2 chromosome locus as a paradigm . The 16p11.2 CNVs are among the most frequent known genetic causes of NDDs PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XZWlzczwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl Y051bT40MDI8L1JlY051bT48RGlzcGxheVRleHQ+WzEyLTE1XTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj40MDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTQ3MDMwMDQxOSI+NDAyPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5X ZWlzcywgTC4gQS48L2F1dGhvcj48YXV0aG9yPlNoZW4sIFkuPC9hdXRob3I+PGF1dGhvcj5Lb3Ju LCBKLiBNLjwvYXV0aG9yPjxhdXRob3I+QXJraW5nLCBELiBFLjwvYXV0aG9yPjxhdXRob3I+TWls bGVyLCBELiBULjwvYXV0aG9yPjxhdXRob3I+Rm9zc2RhbCwgUi48L2F1dGhvcj48YXV0aG9yPlNh ZW11bmRzZW4sIEUuPC9hdXRob3I+PGF1dGhvcj5TdGVmYW5zc29uLCBILjwvYXV0aG9yPjxhdXRo b3I+RmVycmVpcmEsIE0uIEEuPC9hdXRob3I+PGF1dGhvcj5HcmVlbiwgVC48L2F1dGhvcj48YXV0 aG9yPlBsYXR0LCBPLiBTLjwvYXV0aG9yPjxhdXRob3I+UnVkZXJmZXIsIEQuIE0uPC9hdXRob3I+ PGF1dGhvcj5XYWxzaCwgQy4gQS48L2F1dGhvcj48YXV0aG9yPkFsdHNodWxlciwgRC48L2F1dGhv cj48YXV0aG9yPkNoYWtyYXZhcnRpLCBBLjwvYXV0aG9yPjxhdXRob3I+VGFuemksIFIuIEUuPC9h dXRob3I+PGF1dGhvcj5TdGVmYW5zc29uLCBLLjwvYXV0aG9yPjxhdXRob3I+U2FudGFuZ2Vsbywg Uy4gTC48L2F1dGhvcj48YXV0aG9yPkd1c2VsbGEsIEouIEYuPC9hdXRob3I+PGF1dGhvcj5Ta2xh ciwgUC48L2F1dGhvcj48YXV0aG9yPld1LCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+RGFseSwgTS4g Si48L2F1dGhvcj48YXV0aG9yPkF1dGlzbSwgQ29uc29ydGl1bTwvYXV0aG9yPjwvYXV0aG9ycz48 L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkF1dGlzbSBDb25zb3J0aXVtICwgQm9zdG9uLCBV U0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QXNzb2NpYXRpb24gYmV0d2VlbiBtaWNy b2RlbGV0aW9uIGFuZCBtaWNyb2R1cGxpY2F0aW9uIGF0IDE2cDExLjIgYW5kIGF1dGlzbTwvdGl0 bGU+PHNlY29uZGFyeS10aXRsZT5OIEVuZ2wgSiBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxl cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OIEVuZ2wgSiBNZWQ8L2Z1bGwtdGl0bGU+PC9wZXJp b2RpY2FsPjxwYWdlcz42NjctNzU8L3BhZ2VzPjx2b2x1bWU+MzU4PC92b2x1bWU+PG51bWJlcj43 PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkF1dGlzdGljIERpc29yZGVyLypnZW5ldGljczwv a2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBBYmVy cmF0aW9uczwva2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBEZWxldGlvbjwva2V5d29yZD48 a2V5d29yZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTUvZ2VuZXRpY3M8L2tleXdvcmQ+PGtl eXdvcmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5d29yZD48a2V5 d29yZD5ETkEgTXV0YXRpb25hbCBBbmFseXNpczwva2V5d29yZD48a2V5d29yZD5EZXZlbG9wbWVu dGFsIERpc2FiaWxpdGllcy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdv cmQ+PGtleXdvcmQ+KkdlbmV0aWMgUHJlZGlzcG9zaXRpb24gdG8gRGlzZWFzZTwva2V5d29yZD48 a2V5d29yZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdv cmQ+SW50ZWxsZWN0dWFsIERpc2FiaWxpdHkvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+TWFs ZTwva2V5d29yZD48a2V5d29yZD5QaGVub3R5cGU8L2tleXdvcmQ+PGtleXdvcmQ+U2VxdWVuY2Ug QW5hbHlzaXMsIEROQS9tZXRob2RzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw MDg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTQ8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl cz48aXNibj4xNTMzLTQ0MDYgKEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9p c2JuPjxhY2Nlc3Npb24tbnVtPjE4MTg0OTUyPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE4MTg0OTUyPC91 cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDU2 L05FSk1vYTA3NTk3NDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxD aXRlPjxBdXRob3I+WnVmZmVyZXk8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxSZWNOdW0+NDg2 PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj40ODY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5 cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5 cmYiIHRpbWVzdGFtcD0iMTQ4MDAwMjk4NyI+NDg2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10 eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1 dGhvcnM+PGF1dGhvcj5adWZmZXJleSwgRi48L2F1dGhvcj48YXV0aG9yPlNoZXJyLCBFLiBILjwv YXV0aG9yPjxhdXRob3I+QmVja21hbm4sIE4uIEQuPC9hdXRob3I+PGF1dGhvcj5IYW5zb24sIEUu PC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4gTS48L2F1dGhvcj48YXV0aG9yPkhpcHBvbHl0 ZSwgTC48L2F1dGhvcj48YXV0aG9yPk1hY2UsIEEuPC9hdXRob3I+PGF1dGhvcj5GZXJyYXJpLCBD LjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1dGhvcj48YXV0aG9yPkFuZHJpZXV4LCBK LjwvYXV0aG9yPjxhdXRob3I+QXlsd2FyZCwgRS48L2F1dGhvcj48YXV0aG9yPkJhcmtlciwgTS48 L2F1dGhvcj48YXV0aG9yPkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1dGhvcj5Cb3VxdWlsbG9uLCBT LjwvYXV0aG9yPjxhdXRob3I+Q29udXMsIFAuPC9hdXRob3I+PGF1dGhvcj5EZWxvYmVsLCBCLjwv YXV0aG9yPjxhdXRob3I+RmF1Y2V0dCwgVy4gQS48L2F1dGhvcj48YXV0aG9yPkdvaW4tS29jaGVs LCBSLiBQLjwvYXV0aG9yPjxhdXRob3I+R3JhbnQsIEUuPC9hdXRob3I+PGF1dGhvcj5IYXJld29v ZCwgTC48L2F1dGhvcj48YXV0aG9yPkh1bnRlciwgSi4gVi48L2F1dGhvcj48YXV0aG9yPkxlYm9u LCBTLjwvYXV0aG9yPjxhdXRob3I+TGVkYmV0dGVyLCBELiBILjwvYXV0aG9yPjxhdXRob3I+TWFy dGluLCBDLiBMLjwvYXV0aG9yPjxhdXRob3I+TWFubmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TWFy dGluZXQsIEQuPC9hdXRob3I+PGF1dGhvcj5NdWtoZXJqZWUsIFAuPC9hdXRob3I+PGF1dGhvcj5S YW1vY2tpLCBNLiBCLjwvYXV0aG9yPjxhdXRob3I+U3BlbmNlLCBTLiBKLjwvYXV0aG9yPjxhdXRo b3I+U3RlaW5tYW4sIEsuIEouPC9hdXRob3I+PGF1dGhvcj5UamVybmFnZWwsIEouPC9hdXRob3I+ PGF1dGhvcj5TcGlybywgSi4gRS48L2F1dGhvcj48YXV0aG9yPlJleW1vbmQsIEEuPC9hdXRob3I+ PGF1dGhvcj5CZWNrbWFubiwgSi4gUy48L2F1dGhvcj48YXV0aG9yPkNodW5nLCBXLiBLLjwvYXV0 aG9yPjxhdXRob3I+SmFjcXVlbW9udCwgUy48L2F1dGhvcj48YXV0aG9yPlNpbW9ucywgVi4gSS4g UC4gQ29uc29ydGl1bTwvYXV0aG9yPjxhdXRob3I+cDExLjIgRXVyb3BlYW4sIENvbnNvcnRpdW08 L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5TZXJ2aWNlIGRl IEdlbmV0aXF1ZSBNZWRpY2FsZSwgQ2VudHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgVmF1 ZG9pcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl PkEgNjAwIGtiIGRlbGV0aW9uIHN5bmRyb21lIGF0IDE2cDExLjIgbGVhZHMgdG8gZW5lcmd5IGlt YmFsYW5jZSBhbmQgbmV1cm9wc3ljaGlhdHJpYyBkaXNvcmRlcnM8L3RpdGxlPjxzZWNvbmRhcnkt dGl0bGU+SiBNZWQgR2VuZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48 ZnVsbC10aXRsZT5KIE1lZCBHZW5ldDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjY2 MC04PC9wYWdlcz48dm9sdW1lPjQ5PC92b2x1bWU+PG51bWJlcj4xMDwvbnVtYmVyPjxrZXl3b3Jk cz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxr ZXl3b3JkPkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48 a2V5d29yZD5DaGlsZCBEZXZlbG9wbWVudCBEaXNvcmRlcnMsIFBlcnZhc2l2ZS9kaWFnbm9zaXMv KmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPipDaHJvbW9zb21lIERlbGV0aW9uPC9rZXl3b3Jk PjxrZXl3b3JkPipDaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTY8L2tleXdvcmQ+PGtleXdvcmQ+ RGV2ZWxvcG1lbnRhbCBEaXNhYmlsaXRpZXMvZGlhZ25vc2lzLypnZW5ldGljczwva2V5d29yZD48 a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2VuZSBPcmRlcjwva2V5d29yZD48a2V5 d29yZD5IZXRlcm96eWdvdGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3 b3JkPkludGVsbGlnZW5jZSBUZXN0czwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxr ZXl3b3JkPipQaGVub3R5cGU8L2tleXdvcmQ+PGtleXdvcmQ+U3luZHJvbWU8L2tleXdvcmQ+PGtl eXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMjwv eWVhcj48cHViLWRhdGVzPjxkYXRlPk9jdDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju PjE0NjgtNjI0NCAoRWxlY3Ryb25pYykmI3hEOzAwMjItMjU5MyAoTGlua2luZyk8L2lzYm4+PGFj Y2Vzc2lvbi1udW0+MjMwNTQyNDg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48 dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIzMDU0MjQ4PC91cmw+PC9y ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzM0OTQwMTE8L2N1c3RvbTI+PGVsZWN0cm9u aWMtcmVzb3VyY2UtbnVtPjEwLjExMzYvam1lZGdlbmV0LTIwMTItMTAxMjAzPC9lbGVjdHJvbmlj LXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5NY0NhcnRoeTwvQXV0 aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJlY051bT4yNDA8L1JlY051bT48cmVjb3JkPjxyZWMtbnVt YmVyPjI0MDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5 MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNDcwMzAwNDE5 Ij4yNDA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xl Ij4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk1jQ2FydGh5LCBT LiBFLjwvYXV0aG9yPjxhdXRob3I+TWFrYXJvdiwgVi48L2F1dGhvcj48YXV0aG9yPktpcm92LCBH LjwvYXV0aG9yPjxhdXRob3I+QWRkaW5ndG9uLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+TWNDbGVs bGFuLCBKLjwvYXV0aG9yPjxhdXRob3I+WW9vbiwgUy48L2F1dGhvcj48YXV0aG9yPlBlcmtpbnMs IEQuIE8uPC9hdXRob3I+PGF1dGhvcj5EaWNrZWwsIEQuIEUuPC9hdXRob3I+PGF1dGhvcj5LdXNl bmRhLCBNLjwvYXV0aG9yPjxhdXRob3I+S3Jhc3Rvc2hldnNreSwgTy48L2F1dGhvcj48YXV0aG9y PktyYXVzZSwgVi48L2F1dGhvcj48YXV0aG9yPkt1bWFyLCBSLiBBLjwvYXV0aG9yPjxhdXRob3I+ R3JvemV2YSwgRC48L2F1dGhvcj48YXV0aG9yPk1hbGhvdHJhLCBELjwvYXV0aG9yPjxhdXRob3I+ V2Fsc2gsIFQuPC9hdXRob3I+PGF1dGhvcj5aYWNrYWksIEUuIEguPC9hdXRob3I+PGF1dGhvcj5L YXBsYW4sIFAuPC9hdXRob3I+PGF1dGhvcj5HYW5lc2gsIEouPC9hdXRob3I+PGF1dGhvcj5LcmFu dHosIEkuIEQuPC9hdXRob3I+PGF1dGhvcj5TcGlubmVyLCBOLiBCLjwvYXV0aG9yPjxhdXRob3I+ Um9jY2Fub3ZhLCBQLjwvYXV0aG9yPjxhdXRob3I+QmhhbmRhcmksIEEuPC9hdXRob3I+PGF1dGhv cj5QYXZvbiwgSy48L2F1dGhvcj48YXV0aG9yPkxha3NobWksIEIuPC9hdXRob3I+PGF1dGhvcj5M ZW90dGEsIEEuPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBKLjwvYXV0aG9yPjxhdXRob3I+TGVl LCBZLiBILjwvYXV0aG9yPjxhdXRob3I+VmFjaWMsIFYuPC9hdXRob3I+PGF1dGhvcj5HYXJ5LCBT LjwvYXV0aG9yPjxhdXRob3I+SWFrb3VjaGV2YSwgTC4gTS48L2F1dGhvcj48YXV0aG9yPkNyb3cs IFQuIEouPC9hdXRob3I+PGF1dGhvcj5DaHJpc3RpYW4sIFMuIEwuPC9hdXRob3I+PGF1dGhvcj5M aWViZXJtYW4sIEouIEEuPC9hdXRob3I+PGF1dGhvcj5TdHJvdXAsIFQuIFMuPC9hdXRob3I+PGF1 dGhvcj5MZWh0aW1ha2ksIFQuPC9hdXRob3I+PGF1dGhvcj5QdXVyYSwgSy48L2F1dGhvcj48YXV0 aG9yPkhhbGRlbWFuLUVuZ2xlcnQsIEMuPC9hdXRob3I+PGF1dGhvcj5QZWFybCwgSi48L2F1dGhv cj48YXV0aG9yPkdvb2RlbGwsIE0uPC9hdXRob3I+PGF1dGhvcj5XaWxsb3VyLCBWLiBMLjwvYXV0 aG9yPjxhdXRob3I+RGVyb3NzZSwgUC48L2F1dGhvcj48YXV0aG9yPlN0ZWVsZSwgSi48L2F1dGhv cj48YXV0aG9yPkthc3NlbSwgTC48L2F1dGhvcj48YXV0aG9yPldvbGZmLCBKLjwvYXV0aG9yPjxh dXRob3I+Q2hpdGthcmEsIE4uPC9hdXRob3I+PGF1dGhvcj5NY01haG9uLCBGLiBKLjwvYXV0aG9y PjxhdXRob3I+TWFsaG90cmEsIEEuIEsuPC9hdXRob3I+PGF1dGhvcj5Qb3Rhc2gsIEouIEIuPC9h dXRob3I+PGF1dGhvcj5TY2h1bHplLCBULiBHLjwvYXV0aG9yPjxhdXRob3I+Tm90aGVuLCBNLiBN LjwvYXV0aG9yPjxhdXRob3I+Q2ljaG9uLCBTLjwvYXV0aG9yPjxhdXRob3I+UmlldHNjaGVsLCBN LjwvYXV0aG9yPjxhdXRob3I+TGVpYmVubHVmdCwgRS48L2F1dGhvcj48YXV0aG9yPkt1c3Rhbm92 aWNoLCBWLjwvYXV0aG9yPjxhdXRob3I+TGFqb25jaGVyZSwgQy4gTS48L2F1dGhvcj48YXV0aG9y PlN1dGNsaWZmZSwgSi4gUy48L2F1dGhvcj48YXV0aG9yPlNrdXNlLCBELjwvYXV0aG9yPjxhdXRo b3I+R2lsbCwgTS48L2F1dGhvcj48YXV0aG9yPkdhbGxhZ2hlciwgTC48L2F1dGhvcj48YXV0aG9y Pk1lbmRlbGwsIE4uIFIuPC9hdXRob3I+PGF1dGhvcj5XZWxsY29tZSBUcnVzdCBDYXNlIENvbnRy b2wsIENvbnNvcnRpdW08L2F1dGhvcj48YXV0aG9yPkNyYWRkb2NrLCBOLjwvYXV0aG9yPjxhdXRo b3I+T3dlbiwgTS4gSi48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0 aG9yPjxhdXRob3I+U2hhaWtoLCBULiBILjwvYXV0aG9yPjxhdXRob3I+U3Vzc2VyLCBFLjwvYXV0 aG9yPjxhdXRob3I+RGVsaXNpLCBMLiBFLjwvYXV0aG9yPjxhdXRob3I+U3VsbGl2YW4sIFAuIEYu PC9hdXRob3I+PGF1dGhvcj5EZXV0c2NoLCBDLiBLLjwvYXV0aG9yPjxhdXRob3I+UmFwb3BvcnQs IEouPC9hdXRob3I+PGF1dGhvcj5MZXZ5LCBELiBMLjwvYXV0aG9yPjxhdXRob3I+S2luZywgTS4g Qy48L2F1dGhvcj48YXV0aG9yPlNlYmF0LCBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1 dG9ycz48dGl0bGVzPjx0aXRsZT5NaWNyb2R1cGxpY2F0aW9ucyBvZiAxNnAxMS4yIGFyZSBhc3Nv Y2lhdGVkIHdpdGggc2NoaXpvcGhyZW5pYTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgR2Vu ZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQg R2VuZXQ8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMjIzLTc8L3BhZ2VzPjx2b2x1 bWU+NDE8L3ZvbHVtZT48bnVtYmVyPjExPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPipDaHJv bW9zb21lcywgSHVtYW4sIFBhaXIgMTY8L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmUgRHVwbGljYXRp b248L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmV0aWMgUHJlZGlzcG9zaXRpb24gdG8gRGlzZWFzZTwv a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9r ZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvKmdlbmV0aWNzPC9rZXl3b3JkPjwva2V5d29y ZHM+PGRhdGVzPjx5ZWFyPjIwMDk8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2RhdGU+PC9w dWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTQ2LTE3MTggKEVsZWN0cm9uaWMpJiN4RDsxMDYxLTQw MzYgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE5ODU1MzkyPC9hY2Nlc3Npb24tbnVt Pjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzE5ODU1MzkyPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI5NTEx ODA8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMzgvbmcuNDc0PC9lbGVj dHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5EJmFwb3M7 QW5nZWxvPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjQ3NTwvUmVjTnVtPjxyZWNv cmQ+PHJlYy1udW1iZXI+NDc1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE0ODAwMDI5ODciPjQ3NTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ RCZhcG9zO0FuZ2VsbywgRC48L2F1dGhvcj48YXV0aG9yPkxlYm9uLCBTLjwvYXV0aG9yPjxhdXRo b3I+Q2hlbiwgUS48L2F1dGhvcj48YXV0aG9yPk1hcnRpbi1CcmV2ZXQsIFMuPC9hdXRob3I+PGF1 dGhvcj5TbnlkZXIsIEwuIEcuPC9hdXRob3I+PGF1dGhvcj5IaXBwb2x5dGUsIEwuPC9hdXRob3I+ PGF1dGhvcj5IYW5zb24sIEUuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4gTS48L2F1dGhv cj48YXV0aG9yPkZhdWNldHQsIFcuIEEuPC9hdXRob3I+PGF1dGhvcj5NYWNlLCBBLjwvYXV0aG9y PjxhdXRob3I+UGFpbiwgQS48L2F1dGhvcj48YXV0aG9yPkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1 dGhvcj5DaGF3bmVyLCBTLiBKLjwvYXV0aG9yPjxhdXRob3I+RGF2aWQsIEEuPC9hdXRob3I+PGF1 dGhvcj5BbmRyaWV1eCwgSi48L2F1dGhvcj48YXV0aG9yPkF5bHdhcmQsIEUuPC9hdXRob3I+PGF1 dGhvcj5CYXVqYXQsIEcuPC9hdXRob3I+PGF1dGhvcj5DYWxkZWlyYSwgSS48L2F1dGhvcj48YXV0 aG9yPkNvbnVzLCBQLjwvYXV0aG9yPjxhdXRob3I+RmVycmFyaSwgQy48L2F1dGhvcj48YXV0aG9y PkZvcnphbm8sIEYuPC9hdXRob3I+PGF1dGhvcj5HZXJhcmQsIE0uPC9hdXRob3I+PGF1dGhvcj5H b2luLUtvY2hlbCwgUi4gUC48L2F1dGhvcj48YXV0aG9yPkdyYW50LCBFLjwvYXV0aG9yPjxhdXRo b3I+SHVudGVyLCBKLiBWLjwvYXV0aG9yPjxhdXRob3I+SXNpZG9yLCBCLjwvYXV0aG9yPjxhdXRo b3I+SmFjcXVldHRlLCBBLjwvYXV0aG9yPjxhdXRob3I+Sm9uY2gsIEEuIEUuPC9hdXRob3I+PGF1 dGhvcj5LZXJlbiwgQi48L2F1dGhvcj48YXV0aG9yPkxhY29tYmUsIEQuPC9hdXRob3I+PGF1dGhv cj5MZSBDYWlnbmVjLCBDLjwvYXV0aG9yPjxhdXRob3I+TWFydGluLCBDLiBMLjwvYXV0aG9yPjxh dXRob3I+TWFubmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TWV0c3BhbHUsIEEuPC9hdXRob3I+PGF1 dGhvcj5NaWdub3QsIEMuPC9hdXRob3I+PGF1dGhvcj5NdWtoZXJqZWUsIFAuPC9hdXRob3I+PGF1 dGhvcj5Pd2VuLCBNLiBKLjwvYXV0aG9yPjxhdXRob3I+UGFzc2VnZ2VyaSwgTS48L2F1dGhvcj48 YXV0aG9yPlJvb3J5Y2stVGhhbWJvLCBDLjwvYXV0aG9yPjxhdXRob3I+Um9zZW5mZWxkLCBKLiBB LjwvYXV0aG9yPjxhdXRob3I+U3BlbmNlLCBTLiBKLjwvYXV0aG9yPjxhdXRob3I+U3RlaW5tYW4s IEsuIEouPC9hdXRob3I+PGF1dGhvcj5UamVybmFnZWwsIEouPC9hdXRob3I+PGF1dGhvcj5WYW4g SGFlbHN0LCBNLjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgWS48L2F1dGhvcj48YXV0aG9yPkRyYWdh bnNraSwgQi48L2F1dGhvcj48YXV0aG9yPlNoZXJyLCBFLiBILjwvYXV0aG9yPjxhdXRob3I+TGVk YmV0dGVyLCBELiBILjwvYXV0aG9yPjxhdXRob3I+dmFuIGRlbiBCcmVlLCBNLiBCLjwvYXV0aG9y PjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRob3I+PGF1dGhvcj5TcGlybywgSi4gRS48L2F1 dGhvcj48YXV0aG9yPlJleW1vbmQsIEEuPC9hdXRob3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwv YXV0aG9yPjxhdXRob3I+Q2h1bmcsIFcuIEsuPC9hdXRob3I+PGF1dGhvcj5DYXJkaWZmIFVuaXZl cnNpdHkgRXhwZXJpZW5jZXMgb2YgQ2hpbGRyZW4gV2l0aCBDb3B5IE51bWJlciBWYXJpYW50cywg U3R1ZHk8L2F1dGhvcj48YXV0aG9yPnAxMS4yIEV1cm9wZWFuLCBDb25zb3J0aXVtPC9hdXRob3I+ PGF1dGhvcj5TaW1vbnMgVmFyaWF0aW9uIGluIEluZGl2aWR1YWxzIFByb2plY3QsIENvbnNvcnRp dW08L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRt ZW50IG9mIEJpb3N0YXRpc3RpY3MsIE1haWxtYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIENv bHVtYmlhIFVuaXZlcnNpdHksIE5ldyBZb3JrLCBOZXcgWW9yay4mI3hEO1BlZGlhdHJpYyBOZXVy b2xvZ3kgVW5pdCwgRGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBMYXVzYW5uZSBVbml2ZXJzaXR5 IEhvc3BpdGFsLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGlj YWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkg b2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NsaW5pY2FsIFJlc2VhcmNo IEFzc29jaWF0ZXMsIE5ldyBZb3JrLCBOZXcgWW9yay4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hp YXRyeSwgQm9zdG9uIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNj aG9vbCwgQm9zdG9uLCBNYXNzYWNodXNldHRzLiYjeEQ7R2Vub21pYyBNZWRpY2luZSBJbnN0aXR1 dGUsIEdlaXNpbmdlciBDbGluaWMsIERhbnZpbGxlLCBQZW5uc3lsdmFuaWEuJiN4RDtEZXBhcnRt ZW50IG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwgYW5k IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDdTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5l LCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSBhbmQgQmVoYXZpb3Jh bCBTY2llbmNlLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0bGUuJiN4RDtNZWRpY2Fs IFJlc2VhcmNoIENvdW5jaWwgQ2VudHJlIGZvciBOZXVyb3BzeWNoaWF0cmljIEdlbmV0aWNzIGFu ZCBHZW5vbWljcywgSW5zdGl0dXRlIG9mIFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5p Y2FsIE5ldXJvc2NpZW5jZXMsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgV2FsZXMuJiN4 RDtTZXJ2aWNlIGRlIEdlbmV0aXF1ZSBNZWRpY2FsZSwgRmFjdWx0ZSBkZSBNZWRlY2luZSwgQ2Vu dHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgKENIVSkgTmFudGVzLCBJbnN0aXR1dCBOYXRp b25hbCBkZSBsYSBTYW50ZSBldCBkZSBsYSBSZWNoZXJjaGUgTWVkaWNhbGUgKElOU0VSTSkgVW5p dGVzIE1peHRlcyBkZSBSZWNoZXJjaGUgOTU3LCBOYW50ZXMsIEZyYW5jZS4mI3hEO0luc3RpdHV0 IGRlIEdlbmV0aXF1ZSBNZWRpY2FsZSwgSG9zcGl0YWwgSmVhbm5lIGRlIEZsYW5kcmUsIENlbnRy ZSBIb3NwaXRhbGllciBSZWdpb25hbCBVbml2ZXJzaXRhaXJlIChDSFJVKSBkZSBMaWxsZSwgTGls bGUsIEZyYW5jZS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgQnJhaW4gUmVzZWFyY2gsIENo aWxkcmVuJmFwb3M7cyBSZXNlYXJjaCBJbnN0aXR1dGUsIFNlYXR0bGUsIFdhc2hpbmd0b24uJiN4 RDtEZXBhcnRlbWVudCBkZSBHZW5ldGlxdWUsIEhvcGl0YWwgTmVja2VyLUVuZmFudHMgTWFsYWRl cywgQXNzaXN0YW5jZSBQdWJsaXF1ZS1Ib3BpdGF1eCBkZSBQYXJpcyAoQVAtSFApLCBQYXJpcywg RnJhbmNlIDE0SU5TRVJNIFUxMTYzLCBIb3BpdGFsIE5lY2tlci1FbmZhbnRzIE1hbGFkZXMsIFBh cmlzLCBGcmFuY2UxNUluc3RpdHV0IEltYWdpbmUsIFVuaXZlcnNpdGUgUGFyaXMgRGVzY2FydGVz LVNvcmJvbm5lIFBhcmlzIENpdGUsIFBhcmlzLiYjeEQ7RGVwYXJ0bWVudCBvZiBQc3ljaGlhdHJ5 LCBDZXJ5IEhvc3BpdGFsLCBDSFUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwg TGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGl2aXNpb24gb2YgTWVkaWNhbCBHZW5ldGljcywg R2FsbGllcmEgSG9zcGl0YWwsIEdlbm92YSwgSXRhbHkuJiN4RDtEZXBhcnRlbWVudCBkZSBHZW5l dGlxdWUsIEFQLUhQLCBIb3BpdGFsIFJvYmVydCBEZWJyZSwgVW5pdmVyc2l0ZSBQYXJpcyBWSUkt UGFyaXMgRGlkZXJvdCwgUGFyaXMsIEZyYW5jZS4mI3hEO1NlY3Rpb24gb2YgUHN5Y2hvbG9neSwg RGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBCYXlsb3IgQ29sbGVnZSBvZiBNZWRpY2luZSwgSG91 c3RvbiwgVGV4YXMuJiN4RDtEZXBhcnRtZW50IG9mIFJhZGlvbG9neSwgQm9zdG9uIENoaWxkcmVu JmFwb3M7cyBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwgQm9zdG9uLCBNYXNzYWNo dXNldHRzLiYjeEQ7RGVwYXJ0bWVudCBvZiBSYWRpb2xvZ3ksIEJheWxvciBDb2xsZWdlIG9mIE1l ZGljaW5lLCBIb3VzdG9uLCBUZXhhcy4mI3hEO0RlcGFydGVtZW50IGRlIEdlbmV0aXF1ZSBldCBk ZSBDeXRvZ2VuZXRpcXVlLCBVbml0ZSBmb25jdGlvbm5lbGxlIGRlIEdlbmV0aXF1ZSBDbGluaXF1 ZSwgQVAtSFAsIEhvcGl0YWwgUGl0aWUtU2FscGV0cmllcmUsIFBhcmlzLCBGcmFuY2UyM0NlbnRy ZSBkZSBSZWZlcmVuY2UgRGVmaWNpZW5jZXMgSW50ZWxsZWN0dWVsbGVzIGRlIENhdXNlcyBSYXJl cywgUGFyaXMsIEZyYW5jZTI0R3JvdXBlIGRlIFJlY2hlcmNoZSBDbGluaXF1ZSwgRGVmaWNpZS4m I3hEO0RlcGFydG1lbnQgb2YgR2VuZXRpY3MgYW5kIEN5dG9nZW5ldGljcywgR3JvdXBlIEhvc3Bp dGFsaWVyIFBpdGllIFNhbHBldHJpZXJlLCBBUC1IUCwgUGFyaXMsIEZyYW5jZS4mI3hEO1NlcnZp Y2UgZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBGYWN1bHRlIGRlIE1lZGVjaW5lLCBDZW50cmUgSG9z cGl0YWxpZXIgVW5pdmVyc2l0YWlyZSAoQ0hVKSBOYW50ZXMsIEluc3RpdHV0IE5hdGlvbmFsIGRl IGxhIFNhbnRlIGV0IGRlIGxhIFJlY2hlcmNoZSBNZWRpY2FsZSAoSU5TRVJNKSBVbml0ZXMgTWl4 dGVzIGRlIFJlY2hlcmNoZSA5NTcsIE5hbnRlcywgRnJhbmNlMjZTZXJ2aWNlIGRlIEdlbmV0aXF1 ZSBNZWRpY2FsZSwgQ0hVIGRlIEJvci4mI3hEO0F1dGlzbSBhbmQgRGV2ZWxvcG1lbnRhbCBNZWRp Y2luZSBJbnN0aXR1dGUsIEdlaXNpbmdlciBIZWFsdGggU3lzdGVtLCBEYW52aWxsZSwgUGVubnN5 bHZhbmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kMjlFc3RvbmlhbiBHZW5vbWUgQ2VudGVy LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgRXN0b25pYS4mI3hEO0VzdG9uaWFuIEdlbm9t ZSBDZW50ZXIsIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3RvbmlhMzBJbnN0aXR1dGUg b2YgTW9sZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1 LCBFc3RvbmlhLiYjeEQ7RGVwYXJ0bWVudCBvZiBSYWRpb2xvZ3kgYW5kIEJpb21lZGljYWwgSW1h Z2luZywgVW5pdmVyc2l0eSBvZiBDYWxpZm9ybmlhLCBTYW4gRnJhbmNpc2NvLiYjeEQ7U2Vydmlj ZSBkZSBHZW5ldGlxdWUgTWVkaWNhbGUsIENIVSBkZSBCb3JkZWF1eCwgQm9yZGVhdXgsIEZyYW5j ZTMyTGFib3JhdG9pcmUgTWFsYWRpZXMgUmFyZXM6IEdlbmV0aXF1ZSBldCBNZXRhYm9saXNtZSwg VW5pdmVyc2l0ZSBkZSBCb3JkZWF1eCwgQm9yZGVhdXgsIEZyYW5jZS4mI3hEO1NpZ25hdHVyZSBH ZW5vbWljIExhYm9yYXRvcmllcywgTExDLCBQZXJraW5FbG1lciwgSW5jLCBTcG9rYW5lLiYjeEQ7 RGVwYXJ0bWVudCBvZiBOZXVyb2xvZ3ksIEJvc3RvbiBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWws IEhhcnZhcmQgTWVkaWNhbCBTY2hvb2wsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cy4mI3hEO0RlcGFy dG1lbnQgb2YgTmV1cm9sb2d5LCBTZWF0dGxlIENoaWxkcmVuJmFwb3M7cyBSZXNlYXJjaCBJbnN0 aXR1dGUgYW5kIFVuaXZlcnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZS4mI3hEO0RlcGFydG1l bnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBNZWRpY2FsIENlbnRyZSBVdHJlY2h0 LCBVdHJlY2h0LCB0aGUgTmV0aGVybGFuZHMuJiN4RDtHZW5ldGljIERpYWdub3N0aWMgTGFib3Jh dG9yeSwgRGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5IE1lZGljaW5lLCBDaGlsZHJlbiZhcG9zO3Mg SG9zcGl0YWwsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cy4mI3hEO0xhYm9yYXRvaXJlIGRlIFJlY2hl cmNoZSBlbiBOZXVyb2ltYWdlcmllLCBEZXBhcnRtZW50IGZvciBDbGluaWNhbCBOZXVyb3NjaWVu Y2VzLCBDZW50cmUgSG9zcGl0YWxvLVVuaXZlcnNpdGFpcmUgVmF1ZG9pcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBOZXVy b2xvZ3ksIFVuaXZlcnNpdHkgb2YgQ2FsaWZvcm5pYSwgU2FuIEZyYW5jaXNjby4mI3hEO1NpbW9u cyBGb3VuZGF0aW9uLCBOZXcgWW9yaywgTmV3IFlvcmsuJiN4RDtDZW50ZXIgZm9yIEludGVncmF0 aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxh bmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNp dHkgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVy bGFuZDQxQ0hVIFNhaW50ZS1KdXN0aW5lIFJlc2VhcmNoIENlbnRlciwgTW9udHJlYWwsIENhbmFk YTQyRGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBVbml2ZXJzaXRlIGRlIE1vbnRyZWFsLCBNb250 cmVhbCwgUXVlYmVjLCBDYW5hZGEuJiN4RDtEaXZpc2lvbiBvZiBNb2xlY3VsYXIgR2VuZXRpY3Ms IERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgQ29sdW1iaWEgVW5pdmVyc2l0eSwgTmV3IFlvcmss IE5ldyBZb3JrNDREZXBhcnRtZW50IG9mIE1lZGljaW5lLCBDb2x1bWJpYSBVbml2ZXJzaXR5LCBO ZXcgWW9yaywgTmV3IFlvcmsuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RGVmaW5pbmcg dGhlIEVmZmVjdCBvZiB0aGUgMTZwMTEuMiBEdXBsaWNhdGlvbiBvbiBDb2duaXRpb24sIEJlaGF2 aW9yLCBhbmQgTWVkaWNhbCBDb21vcmJpZGl0aWVzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpB TUEgUHN5Y2hpYXRyeTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs LXRpdGxlPkpBTUEgUHN5Y2hpYXRyeTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjIw LTMwPC9wYWdlcz48dm9sdW1lPjczPC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+PGtleXdvcmRz PjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtl eXdvcmQ+QXV0aXNtIFNwZWN0cnVtIERpc29yZGVyL2VwaWRlbWlvbG9neS9nZW5ldGljcy8qcHN5 Y2hvbG9neTwva2V5d29yZD48a2V5d29yZD5BdXRpc3RpYyBEaXNvcmRlci9lcGlkZW1pb2xvZ3kv Z2VuZXRpY3MvKnBzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FzZS1Db250cm9sIFN0dWRp ZXM8L2tleXdvcmQ+PGtleXdvcmQ+Q2VyZWJlbGx1bS9hYm5vcm1hbGl0aWVzPC9rZXl3b3JkPjxr ZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+ PGtleXdvcmQ+Q2hyb21vc29tZSBEZWxldGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21l IERpc29yZGVycy9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3MvKnBzeWNob2xvZ3k8L2tleXdvcmQ+PGtl eXdvcmQ+KkNocm9tb3NvbWUgRHVwbGljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29t ZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD4qQ29nbml0aW9u PC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkNvbW9y YmlkaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkROQSBDb3B5IE51bWJlciBWYXJpYXRpb25zPC9rZXl3 b3JkPjxrZXl3b3JkPkRldmVsb3BtZW50YWwgRGlzYWJpbGl0aWVzL2VwaWRlbWlvbG9neS9nZW5l dGljczwva2V5d29yZD48a2V5d29yZD5FcGlsZXBzeS9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3M8L2tl eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48 a2V5d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3MvKnBz eWNob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWNyb2Nl cGhhbHkvZXBpZGVtaW9sb2d5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2Vk PC9rZXl3b3JkPjxrZXl3b3JkPk5lcnZvdXMgU3lzdGVtIE1hbGZvcm1hdGlvbnMvZXBpZGVtaW9s b2d5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvZXBpZGVtaW9sb2d5 LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5TY2hpem9waHJlbmljIFBzeWNob2xvZ3k8L2tl eXdvcmQ+PGtleXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll YXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh dGVzPjxpc2JuPjIxNjgtNjIzOCAoRWxlY3Ryb25pYykmI3hEOzIxNjgtNjIyWCAoTGlua2luZyk8 L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjY2Mjk2NDA8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0 ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI2NjI5NjQw PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4x MDAxL2phbWFwc3ljaGlhdHJ5LjIwMTUuMjEyMzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9y ZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XZWlzczwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl Y051bT40MDI8L1JlY051bT48RGlzcGxheVRleHQ+WzEyLTE1XTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj40MDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTQ3MDMwMDQxOSI+NDAyPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5X ZWlzcywgTC4gQS48L2F1dGhvcj48YXV0aG9yPlNoZW4sIFkuPC9hdXRob3I+PGF1dGhvcj5Lb3Ju LCBKLiBNLjwvYXV0aG9yPjxhdXRob3I+QXJraW5nLCBELiBFLjwvYXV0aG9yPjxhdXRob3I+TWls bGVyLCBELiBULjwvYXV0aG9yPjxhdXRob3I+Rm9zc2RhbCwgUi48L2F1dGhvcj48YXV0aG9yPlNh ZW11bmRzZW4sIEUuPC9hdXRob3I+PGF1dGhvcj5TdGVmYW5zc29uLCBILjwvYXV0aG9yPjxhdXRo b3I+RmVycmVpcmEsIE0uIEEuPC9hdXRob3I+PGF1dGhvcj5HcmVlbiwgVC48L2F1dGhvcj48YXV0 aG9yPlBsYXR0LCBPLiBTLjwvYXV0aG9yPjxhdXRob3I+UnVkZXJmZXIsIEQuIE0uPC9hdXRob3I+ PGF1dGhvcj5XYWxzaCwgQy4gQS48L2F1dGhvcj48YXV0aG9yPkFsdHNodWxlciwgRC48L2F1dGhv cj48YXV0aG9yPkNoYWtyYXZhcnRpLCBBLjwvYXV0aG9yPjxhdXRob3I+VGFuemksIFIuIEUuPC9h dXRob3I+PGF1dGhvcj5TdGVmYW5zc29uLCBLLjwvYXV0aG9yPjxhdXRob3I+U2FudGFuZ2Vsbywg Uy4gTC48L2F1dGhvcj48YXV0aG9yPkd1c2VsbGEsIEouIEYuPC9hdXRob3I+PGF1dGhvcj5Ta2xh ciwgUC48L2F1dGhvcj48YXV0aG9yPld1LCBCLiBMLjwvYXV0aG9yPjxhdXRob3I+RGFseSwgTS4g Si48L2F1dGhvcj48YXV0aG9yPkF1dGlzbSwgQ29uc29ydGl1bTwvYXV0aG9yPjwvYXV0aG9ycz48 L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkF1dGlzbSBDb25zb3J0aXVtICwgQm9zdG9uLCBV U0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QXNzb2NpYXRpb24gYmV0d2VlbiBtaWNy b2RlbGV0aW9uIGFuZCBtaWNyb2R1cGxpY2F0aW9uIGF0IDE2cDExLjIgYW5kIGF1dGlzbTwvdGl0 bGU+PHNlY29uZGFyeS10aXRsZT5OIEVuZ2wgSiBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxl cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OIEVuZ2wgSiBNZWQ8L2Z1bGwtdGl0bGU+PC9wZXJp b2RpY2FsPjxwYWdlcz42NjctNzU8L3BhZ2VzPjx2b2x1bWU+MzU4PC92b2x1bWU+PG51bWJlcj43 PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkF1dGlzdGljIERpc29yZGVyLypnZW5ldGljczwv a2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBBYmVy cmF0aW9uczwva2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBEZWxldGlvbjwva2V5d29yZD48 a2V5d29yZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTUvZ2VuZXRpY3M8L2tleXdvcmQ+PGtl eXdvcmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5d29yZD48a2V5 d29yZD5ETkEgTXV0YXRpb25hbCBBbmFseXNpczwva2V5d29yZD48a2V5d29yZD5EZXZlbG9wbWVu dGFsIERpc2FiaWxpdGllcy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdv cmQ+PGtleXdvcmQ+KkdlbmV0aWMgUHJlZGlzcG9zaXRpb24gdG8gRGlzZWFzZTwva2V5d29yZD48 a2V5d29yZD5HZW5vdHlwZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdv cmQ+SW50ZWxsZWN0dWFsIERpc2FiaWxpdHkvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+TWFs ZTwva2V5d29yZD48a2V5d29yZD5QaGVub3R5cGU8L2tleXdvcmQ+PGtleXdvcmQ+U2VxdWVuY2Ug QW5hbHlzaXMsIEROQS9tZXRob2RzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw MDg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTQ8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl cz48aXNibj4xNTMzLTQ0MDYgKEVsZWN0cm9uaWMpJiN4RDswMDI4LTQ3OTMgKExpbmtpbmcpPC9p c2JuPjxhY2Nlc3Npb24tbnVtPjE4MTg0OTUyPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE4MTg0OTUyPC91 cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDU2 L05FSk1vYTA3NTk3NDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxD aXRlPjxBdXRob3I+WnVmZmVyZXk8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFyPjxSZWNOdW0+NDg2 PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj40ODY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5 cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5 cmYiIHRpbWVzdGFtcD0iMTQ4MDAwMjk4NyI+NDg2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10 eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1 dGhvcnM+PGF1dGhvcj5adWZmZXJleSwgRi48L2F1dGhvcj48YXV0aG9yPlNoZXJyLCBFLiBILjwv YXV0aG9yPjxhdXRob3I+QmVja21hbm4sIE4uIEQuPC9hdXRob3I+PGF1dGhvcj5IYW5zb24sIEUu PC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4gTS48L2F1dGhvcj48YXV0aG9yPkhpcHBvbHl0 ZSwgTC48L2F1dGhvcj48YXV0aG9yPk1hY2UsIEEuPC9hdXRob3I+PGF1dGhvcj5GZXJyYXJpLCBD LjwvYXV0aG9yPjxhdXRob3I+S3V0YWxpaywgWi48L2F1dGhvcj48YXV0aG9yPkFuZHJpZXV4LCBK LjwvYXV0aG9yPjxhdXRob3I+QXlsd2FyZCwgRS48L2F1dGhvcj48YXV0aG9yPkJhcmtlciwgTS48 L2F1dGhvcj48YXV0aG9yPkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1dGhvcj5Cb3VxdWlsbG9uLCBT LjwvYXV0aG9yPjxhdXRob3I+Q29udXMsIFAuPC9hdXRob3I+PGF1dGhvcj5EZWxvYmVsLCBCLjwv YXV0aG9yPjxhdXRob3I+RmF1Y2V0dCwgVy4gQS48L2F1dGhvcj48YXV0aG9yPkdvaW4tS29jaGVs LCBSLiBQLjwvYXV0aG9yPjxhdXRob3I+R3JhbnQsIEUuPC9hdXRob3I+PGF1dGhvcj5IYXJld29v ZCwgTC48L2F1dGhvcj48YXV0aG9yPkh1bnRlciwgSi4gVi48L2F1dGhvcj48YXV0aG9yPkxlYm9u LCBTLjwvYXV0aG9yPjxhdXRob3I+TGVkYmV0dGVyLCBELiBILjwvYXV0aG9yPjxhdXRob3I+TWFy dGluLCBDLiBMLjwvYXV0aG9yPjxhdXRob3I+TWFubmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TWFy dGluZXQsIEQuPC9hdXRob3I+PGF1dGhvcj5NdWtoZXJqZWUsIFAuPC9hdXRob3I+PGF1dGhvcj5S YW1vY2tpLCBNLiBCLjwvYXV0aG9yPjxhdXRob3I+U3BlbmNlLCBTLiBKLjwvYXV0aG9yPjxhdXRo b3I+U3RlaW5tYW4sIEsuIEouPC9hdXRob3I+PGF1dGhvcj5UamVybmFnZWwsIEouPC9hdXRob3I+ PGF1dGhvcj5TcGlybywgSi4gRS48L2F1dGhvcj48YXV0aG9yPlJleW1vbmQsIEEuPC9hdXRob3I+ PGF1dGhvcj5CZWNrbWFubiwgSi4gUy48L2F1dGhvcj48YXV0aG9yPkNodW5nLCBXLiBLLjwvYXV0 aG9yPjxhdXRob3I+SmFjcXVlbW9udCwgUy48L2F1dGhvcj48YXV0aG9yPlNpbW9ucywgVi4gSS4g UC4gQ29uc29ydGl1bTwvYXV0aG9yPjxhdXRob3I+cDExLjIgRXVyb3BlYW4sIENvbnNvcnRpdW08 L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5TZXJ2aWNlIGRl IEdlbmV0aXF1ZSBNZWRpY2FsZSwgQ2VudHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgVmF1 ZG9pcywgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl PkEgNjAwIGtiIGRlbGV0aW9uIHN5bmRyb21lIGF0IDE2cDExLjIgbGVhZHMgdG8gZW5lcmd5IGlt YmFsYW5jZSBhbmQgbmV1cm9wc3ljaGlhdHJpYyBkaXNvcmRlcnM8L3RpdGxlPjxzZWNvbmRhcnkt dGl0bGU+SiBNZWQgR2VuZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48 ZnVsbC10aXRsZT5KIE1lZCBHZW5ldDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjY2 MC04PC9wYWdlcz48dm9sdW1lPjQ5PC92b2x1bWU+PG51bWJlcj4xMDwvbnVtYmVyPjxrZXl3b3Jk cz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxr ZXl3b3JkPkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48 a2V5d29yZD5DaGlsZCBEZXZlbG9wbWVudCBEaXNvcmRlcnMsIFBlcnZhc2l2ZS9kaWFnbm9zaXMv KmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPipDaHJvbW9zb21lIERlbGV0aW9uPC9rZXl3b3Jk PjxrZXl3b3JkPipDaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTY8L2tleXdvcmQ+PGtleXdvcmQ+ RGV2ZWxvcG1lbnRhbCBEaXNhYmlsaXRpZXMvZGlhZ25vc2lzLypnZW5ldGljczwva2V5d29yZD48 a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2VuZSBPcmRlcjwva2V5d29yZD48a2V5 d29yZD5IZXRlcm96eWdvdGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3 b3JkPkludGVsbGlnZW5jZSBUZXN0czwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxr ZXl3b3JkPipQaGVub3R5cGU8L2tleXdvcmQ+PGtleXdvcmQ+U3luZHJvbWU8L2tleXdvcmQ+PGtl eXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMjwv eWVhcj48cHViLWRhdGVzPjxkYXRlPk9jdDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju PjE0NjgtNjI0NCAoRWxlY3Ryb25pYykmI3hEOzAwMjItMjU5MyAoTGlua2luZyk8L2lzYm4+PGFj Y2Vzc2lvbi1udW0+MjMwNTQyNDg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48 dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIzMDU0MjQ4PC91cmw+PC9y ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzM0OTQwMTE8L2N1c3RvbTI+PGVsZWN0cm9u aWMtcmVzb3VyY2UtbnVtPjEwLjExMzYvam1lZGdlbmV0LTIwMTItMTAxMjAzPC9lbGVjdHJvbmlj LXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5NY0NhcnRoeTwvQXV0 aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJlY051bT4yNDA8L1JlY051bT48cmVjb3JkPjxyZWMtbnVt YmVyPjI0MDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5 MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNDcwMzAwNDE5 Ij4yNDA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xl Ij4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk1jQ2FydGh5LCBT LiBFLjwvYXV0aG9yPjxhdXRob3I+TWFrYXJvdiwgVi48L2F1dGhvcj48YXV0aG9yPktpcm92LCBH LjwvYXV0aG9yPjxhdXRob3I+QWRkaW5ndG9uLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+TWNDbGVs bGFuLCBKLjwvYXV0aG9yPjxhdXRob3I+WW9vbiwgUy48L2F1dGhvcj48YXV0aG9yPlBlcmtpbnMs IEQuIE8uPC9hdXRob3I+PGF1dGhvcj5EaWNrZWwsIEQuIEUuPC9hdXRob3I+PGF1dGhvcj5LdXNl bmRhLCBNLjwvYXV0aG9yPjxhdXRob3I+S3Jhc3Rvc2hldnNreSwgTy48L2F1dGhvcj48YXV0aG9y PktyYXVzZSwgVi48L2F1dGhvcj48YXV0aG9yPkt1bWFyLCBSLiBBLjwvYXV0aG9yPjxhdXRob3I+ R3JvemV2YSwgRC48L2F1dGhvcj48YXV0aG9yPk1hbGhvdHJhLCBELjwvYXV0aG9yPjxhdXRob3I+ V2Fsc2gsIFQuPC9hdXRob3I+PGF1dGhvcj5aYWNrYWksIEUuIEguPC9hdXRob3I+PGF1dGhvcj5L YXBsYW4sIFAuPC9hdXRob3I+PGF1dGhvcj5HYW5lc2gsIEouPC9hdXRob3I+PGF1dGhvcj5LcmFu dHosIEkuIEQuPC9hdXRob3I+PGF1dGhvcj5TcGlubmVyLCBOLiBCLjwvYXV0aG9yPjxhdXRob3I+ Um9jY2Fub3ZhLCBQLjwvYXV0aG9yPjxhdXRob3I+QmhhbmRhcmksIEEuPC9hdXRob3I+PGF1dGhv cj5QYXZvbiwgSy48L2F1dGhvcj48YXV0aG9yPkxha3NobWksIEIuPC9hdXRob3I+PGF1dGhvcj5M ZW90dGEsIEEuPC9hdXRob3I+PGF1dGhvcj5LZW5kYWxsLCBKLjwvYXV0aG9yPjxhdXRob3I+TGVl LCBZLiBILjwvYXV0aG9yPjxhdXRob3I+VmFjaWMsIFYuPC9hdXRob3I+PGF1dGhvcj5HYXJ5LCBT LjwvYXV0aG9yPjxhdXRob3I+SWFrb3VjaGV2YSwgTC4gTS48L2F1dGhvcj48YXV0aG9yPkNyb3cs IFQuIEouPC9hdXRob3I+PGF1dGhvcj5DaHJpc3RpYW4sIFMuIEwuPC9hdXRob3I+PGF1dGhvcj5M aWViZXJtYW4sIEouIEEuPC9hdXRob3I+PGF1dGhvcj5TdHJvdXAsIFQuIFMuPC9hdXRob3I+PGF1 dGhvcj5MZWh0aW1ha2ksIFQuPC9hdXRob3I+PGF1dGhvcj5QdXVyYSwgSy48L2F1dGhvcj48YXV0 aG9yPkhhbGRlbWFuLUVuZ2xlcnQsIEMuPC9hdXRob3I+PGF1dGhvcj5QZWFybCwgSi48L2F1dGhv cj48YXV0aG9yPkdvb2RlbGwsIE0uPC9hdXRob3I+PGF1dGhvcj5XaWxsb3VyLCBWLiBMLjwvYXV0 aG9yPjxhdXRob3I+RGVyb3NzZSwgUC48L2F1dGhvcj48YXV0aG9yPlN0ZWVsZSwgSi48L2F1dGhv cj48YXV0aG9yPkthc3NlbSwgTC48L2F1dGhvcj48YXV0aG9yPldvbGZmLCBKLjwvYXV0aG9yPjxh dXRob3I+Q2hpdGthcmEsIE4uPC9hdXRob3I+PGF1dGhvcj5NY01haG9uLCBGLiBKLjwvYXV0aG9y PjxhdXRob3I+TWFsaG90cmEsIEEuIEsuPC9hdXRob3I+PGF1dGhvcj5Qb3Rhc2gsIEouIEIuPC9h dXRob3I+PGF1dGhvcj5TY2h1bHplLCBULiBHLjwvYXV0aG9yPjxhdXRob3I+Tm90aGVuLCBNLiBN LjwvYXV0aG9yPjxhdXRob3I+Q2ljaG9uLCBTLjwvYXV0aG9yPjxhdXRob3I+UmlldHNjaGVsLCBN LjwvYXV0aG9yPjxhdXRob3I+TGVpYmVubHVmdCwgRS48L2F1dGhvcj48YXV0aG9yPkt1c3Rhbm92 aWNoLCBWLjwvYXV0aG9yPjxhdXRob3I+TGFqb25jaGVyZSwgQy4gTS48L2F1dGhvcj48YXV0aG9y PlN1dGNsaWZmZSwgSi4gUy48L2F1dGhvcj48YXV0aG9yPlNrdXNlLCBELjwvYXV0aG9yPjxhdXRo b3I+R2lsbCwgTS48L2F1dGhvcj48YXV0aG9yPkdhbGxhZ2hlciwgTC48L2F1dGhvcj48YXV0aG9y Pk1lbmRlbGwsIE4uIFIuPC9hdXRob3I+PGF1dGhvcj5XZWxsY29tZSBUcnVzdCBDYXNlIENvbnRy b2wsIENvbnNvcnRpdW08L2F1dGhvcj48YXV0aG9yPkNyYWRkb2NrLCBOLjwvYXV0aG9yPjxhdXRo b3I+T3dlbiwgTS4gSi48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztEb25vdmFuLCBNLiBDLjwvYXV0 aG9yPjxhdXRob3I+U2hhaWtoLCBULiBILjwvYXV0aG9yPjxhdXRob3I+U3Vzc2VyLCBFLjwvYXV0 aG9yPjxhdXRob3I+RGVsaXNpLCBMLiBFLjwvYXV0aG9yPjxhdXRob3I+U3VsbGl2YW4sIFAuIEYu PC9hdXRob3I+PGF1dGhvcj5EZXV0c2NoLCBDLiBLLjwvYXV0aG9yPjxhdXRob3I+UmFwb3BvcnQs IEouPC9hdXRob3I+PGF1dGhvcj5MZXZ5LCBELiBMLjwvYXV0aG9yPjxhdXRob3I+S2luZywgTS4g Qy48L2F1dGhvcj48YXV0aG9yPlNlYmF0LCBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1 dG9ycz48dGl0bGVzPjx0aXRsZT5NaWNyb2R1cGxpY2F0aW9ucyBvZiAxNnAxMS4yIGFyZSBhc3Nv Y2lhdGVkIHdpdGggc2NoaXpvcGhyZW5pYTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5OYXQgR2Vu ZXQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OYXQg R2VuZXQ8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMjIzLTc8L3BhZ2VzPjx2b2x1 bWU+NDE8L3ZvbHVtZT48bnVtYmVyPjExPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPipDaHJv bW9zb21lcywgSHVtYW4sIFBhaXIgMTY8L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmUgRHVwbGljYXRp b248L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmV0aWMgUHJlZGlzcG9zaXRpb24gdG8gRGlzZWFzZTwv a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9r ZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvKmdlbmV0aWNzPC9rZXl3b3JkPjwva2V5d29y ZHM+PGRhdGVzPjx5ZWFyPjIwMDk8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2RhdGU+PC9w dWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTQ2LTE3MTggKEVsZWN0cm9uaWMpJiN4RDsxMDYxLTQw MzYgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE5ODU1MzkyPC9hY2Nlc3Npb24tbnVt Pjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzE5ODU1MzkyPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI5NTEx ODA8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMzgvbmcuNDc0PC9lbGVj dHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5EJmFwb3M7 QW5nZWxvPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjQ3NTwvUmVjTnVtPjxyZWNv cmQ+PHJlYy1udW1iZXI+NDc1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE0ODAwMDI5ODciPjQ3NTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ RCZhcG9zO0FuZ2VsbywgRC48L2F1dGhvcj48YXV0aG9yPkxlYm9uLCBTLjwvYXV0aG9yPjxhdXRo b3I+Q2hlbiwgUS48L2F1dGhvcj48YXV0aG9yPk1hcnRpbi1CcmV2ZXQsIFMuPC9hdXRob3I+PGF1 dGhvcj5TbnlkZXIsIEwuIEcuPC9hdXRob3I+PGF1dGhvcj5IaXBwb2x5dGUsIEwuPC9hdXRob3I+ PGF1dGhvcj5IYW5zb24sIEUuPC9hdXRob3I+PGF1dGhvcj5NYWlsbGFyZCwgQS4gTS48L2F1dGhv cj48YXV0aG9yPkZhdWNldHQsIFcuIEEuPC9hdXRob3I+PGF1dGhvcj5NYWNlLCBBLjwvYXV0aG9y PjxhdXRob3I+UGFpbiwgQS48L2F1dGhvcj48YXV0aG9yPkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1 dGhvcj5DaGF3bmVyLCBTLiBKLjwvYXV0aG9yPjxhdXRob3I+RGF2aWQsIEEuPC9hdXRob3I+PGF1 dGhvcj5BbmRyaWV1eCwgSi48L2F1dGhvcj48YXV0aG9yPkF5bHdhcmQsIEUuPC9hdXRob3I+PGF1 dGhvcj5CYXVqYXQsIEcuPC9hdXRob3I+PGF1dGhvcj5DYWxkZWlyYSwgSS48L2F1dGhvcj48YXV0 aG9yPkNvbnVzLCBQLjwvYXV0aG9yPjxhdXRob3I+RmVycmFyaSwgQy48L2F1dGhvcj48YXV0aG9y PkZvcnphbm8sIEYuPC9hdXRob3I+PGF1dGhvcj5HZXJhcmQsIE0uPC9hdXRob3I+PGF1dGhvcj5H b2luLUtvY2hlbCwgUi4gUC48L2F1dGhvcj48YXV0aG9yPkdyYW50LCBFLjwvYXV0aG9yPjxhdXRo b3I+SHVudGVyLCBKLiBWLjwvYXV0aG9yPjxhdXRob3I+SXNpZG9yLCBCLjwvYXV0aG9yPjxhdXRo b3I+SmFjcXVldHRlLCBBLjwvYXV0aG9yPjxhdXRob3I+Sm9uY2gsIEEuIEUuPC9hdXRob3I+PGF1 dGhvcj5LZXJlbiwgQi48L2F1dGhvcj48YXV0aG9yPkxhY29tYmUsIEQuPC9hdXRob3I+PGF1dGhv cj5MZSBDYWlnbmVjLCBDLjwvYXV0aG9yPjxhdXRob3I+TWFydGluLCBDLiBMLjwvYXV0aG9yPjxh dXRob3I+TWFubmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TWV0c3BhbHUsIEEuPC9hdXRob3I+PGF1 dGhvcj5NaWdub3QsIEMuPC9hdXRob3I+PGF1dGhvcj5NdWtoZXJqZWUsIFAuPC9hdXRob3I+PGF1 dGhvcj5Pd2VuLCBNLiBKLjwvYXV0aG9yPjxhdXRob3I+UGFzc2VnZ2VyaSwgTS48L2F1dGhvcj48 YXV0aG9yPlJvb3J5Y2stVGhhbWJvLCBDLjwvYXV0aG9yPjxhdXRob3I+Um9zZW5mZWxkLCBKLiBB LjwvYXV0aG9yPjxhdXRob3I+U3BlbmNlLCBTLiBKLjwvYXV0aG9yPjxhdXRob3I+U3RlaW5tYW4s IEsuIEouPC9hdXRob3I+PGF1dGhvcj5UamVybmFnZWwsIEouPC9hdXRob3I+PGF1dGhvcj5WYW4g SGFlbHN0LCBNLjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgWS48L2F1dGhvcj48YXV0aG9yPkRyYWdh bnNraSwgQi48L2F1dGhvcj48YXV0aG9yPlNoZXJyLCBFLiBILjwvYXV0aG9yPjxhdXRob3I+TGVk YmV0dGVyLCBELiBILjwvYXV0aG9yPjxhdXRob3I+dmFuIGRlbiBCcmVlLCBNLiBCLjwvYXV0aG9y PjxhdXRob3I+QmVja21hbm4sIEouIFMuPC9hdXRob3I+PGF1dGhvcj5TcGlybywgSi4gRS48L2F1 dGhvcj48YXV0aG9yPlJleW1vbmQsIEEuPC9hdXRob3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwv YXV0aG9yPjxhdXRob3I+Q2h1bmcsIFcuIEsuPC9hdXRob3I+PGF1dGhvcj5DYXJkaWZmIFVuaXZl cnNpdHkgRXhwZXJpZW5jZXMgb2YgQ2hpbGRyZW4gV2l0aCBDb3B5IE51bWJlciBWYXJpYW50cywg U3R1ZHk8L2F1dGhvcj48YXV0aG9yPnAxMS4yIEV1cm9wZWFuLCBDb25zb3J0aXVtPC9hdXRob3I+ PGF1dGhvcj5TaW1vbnMgVmFyaWF0aW9uIGluIEluZGl2aWR1YWxzIFByb2plY3QsIENvbnNvcnRp dW08L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRt ZW50IG9mIEJpb3N0YXRpc3RpY3MsIE1haWxtYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIENv bHVtYmlhIFVuaXZlcnNpdHksIE5ldyBZb3JrLCBOZXcgWW9yay4mI3hEO1BlZGlhdHJpYyBOZXVy b2xvZ3kgVW5pdCwgRGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBMYXVzYW5uZSBVbml2ZXJzaXR5 IEhvc3BpdGFsLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGlj YWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkg b2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NsaW5pY2FsIFJlc2VhcmNo IEFzc29jaWF0ZXMsIE5ldyBZb3JrLCBOZXcgWW9yay4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hp YXRyeSwgQm9zdG9uIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNj aG9vbCwgQm9zdG9uLCBNYXNzYWNodXNldHRzLiYjeEQ7R2Vub21pYyBNZWRpY2luZSBJbnN0aXR1 dGUsIEdlaXNpbmdlciBDbGluaWMsIERhbnZpbGxlLCBQZW5uc3lsdmFuaWEuJiN4RDtEZXBhcnRt ZW50IG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwgYW5k IFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZDdTd2lzcyBJbnN0 aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5l LCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSBhbmQgQmVoYXZpb3Jh bCBTY2llbmNlLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0bGUuJiN4RDtNZWRpY2Fs IFJlc2VhcmNoIENvdW5jaWwgQ2VudHJlIGZvciBOZXVyb3BzeWNoaWF0cmljIEdlbmV0aWNzIGFu ZCBHZW5vbWljcywgSW5zdGl0dXRlIG9mIFBzeWNob2xvZ2ljYWwgTWVkaWNpbmUgYW5kIENsaW5p Y2FsIE5ldXJvc2NpZW5jZXMsIENhcmRpZmYgVW5pdmVyc2l0eSwgQ2FyZGlmZiwgV2FsZXMuJiN4 RDtTZXJ2aWNlIGRlIEdlbmV0aXF1ZSBNZWRpY2FsZSwgRmFjdWx0ZSBkZSBNZWRlY2luZSwgQ2Vu dHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgKENIVSkgTmFudGVzLCBJbnN0aXR1dCBOYXRp b25hbCBkZSBsYSBTYW50ZSBldCBkZSBsYSBSZWNoZXJjaGUgTWVkaWNhbGUgKElOU0VSTSkgVW5p dGVzIE1peHRlcyBkZSBSZWNoZXJjaGUgOTU3LCBOYW50ZXMsIEZyYW5jZS4mI3hEO0luc3RpdHV0 IGRlIEdlbmV0aXF1ZSBNZWRpY2FsZSwgSG9zcGl0YWwgSmVhbm5lIGRlIEZsYW5kcmUsIENlbnRy ZSBIb3NwaXRhbGllciBSZWdpb25hbCBVbml2ZXJzaXRhaXJlIChDSFJVKSBkZSBMaWxsZSwgTGls bGUsIEZyYW5jZS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgQnJhaW4gUmVzZWFyY2gsIENo aWxkcmVuJmFwb3M7cyBSZXNlYXJjaCBJbnN0aXR1dGUsIFNlYXR0bGUsIFdhc2hpbmd0b24uJiN4 RDtEZXBhcnRlbWVudCBkZSBHZW5ldGlxdWUsIEhvcGl0YWwgTmVja2VyLUVuZmFudHMgTWFsYWRl cywgQXNzaXN0YW5jZSBQdWJsaXF1ZS1Ib3BpdGF1eCBkZSBQYXJpcyAoQVAtSFApLCBQYXJpcywg RnJhbmNlIDE0SU5TRVJNIFUxMTYzLCBIb3BpdGFsIE5lY2tlci1FbmZhbnRzIE1hbGFkZXMsIFBh cmlzLCBGcmFuY2UxNUluc3RpdHV0IEltYWdpbmUsIFVuaXZlcnNpdGUgUGFyaXMgRGVzY2FydGVz LVNvcmJvbm5lIFBhcmlzIENpdGUsIFBhcmlzLiYjeEQ7RGVwYXJ0bWVudCBvZiBQc3ljaGlhdHJ5 LCBDZXJ5IEhvc3BpdGFsLCBDSFUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwg TGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGl2aXNpb24gb2YgTWVkaWNhbCBHZW5ldGljcywg R2FsbGllcmEgSG9zcGl0YWwsIEdlbm92YSwgSXRhbHkuJiN4RDtEZXBhcnRlbWVudCBkZSBHZW5l dGlxdWUsIEFQLUhQLCBIb3BpdGFsIFJvYmVydCBEZWJyZSwgVW5pdmVyc2l0ZSBQYXJpcyBWSUkt UGFyaXMgRGlkZXJvdCwgUGFyaXMsIEZyYW5jZS4mI3hEO1NlY3Rpb24gb2YgUHN5Y2hvbG9neSwg RGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBCYXlsb3IgQ29sbGVnZSBvZiBNZWRpY2luZSwgSG91 c3RvbiwgVGV4YXMuJiN4RDtEZXBhcnRtZW50IG9mIFJhZGlvbG9neSwgQm9zdG9uIENoaWxkcmVu JmFwb3M7cyBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwgQm9zdG9uLCBNYXNzYWNo dXNldHRzLiYjeEQ7RGVwYXJ0bWVudCBvZiBSYWRpb2xvZ3ksIEJheWxvciBDb2xsZWdlIG9mIE1l ZGljaW5lLCBIb3VzdG9uLCBUZXhhcy4mI3hEO0RlcGFydGVtZW50IGRlIEdlbmV0aXF1ZSBldCBk ZSBDeXRvZ2VuZXRpcXVlLCBVbml0ZSBmb25jdGlvbm5lbGxlIGRlIEdlbmV0aXF1ZSBDbGluaXF1 ZSwgQVAtSFAsIEhvcGl0YWwgUGl0aWUtU2FscGV0cmllcmUsIFBhcmlzLCBGcmFuY2UyM0NlbnRy ZSBkZSBSZWZlcmVuY2UgRGVmaWNpZW5jZXMgSW50ZWxsZWN0dWVsbGVzIGRlIENhdXNlcyBSYXJl cywgUGFyaXMsIEZyYW5jZTI0R3JvdXBlIGRlIFJlY2hlcmNoZSBDbGluaXF1ZSwgRGVmaWNpZS4m I3hEO0RlcGFydG1lbnQgb2YgR2VuZXRpY3MgYW5kIEN5dG9nZW5ldGljcywgR3JvdXBlIEhvc3Bp dGFsaWVyIFBpdGllIFNhbHBldHJpZXJlLCBBUC1IUCwgUGFyaXMsIEZyYW5jZS4mI3hEO1NlcnZp Y2UgZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBGYWN1bHRlIGRlIE1lZGVjaW5lLCBDZW50cmUgSG9z cGl0YWxpZXIgVW5pdmVyc2l0YWlyZSAoQ0hVKSBOYW50ZXMsIEluc3RpdHV0IE5hdGlvbmFsIGRl IGxhIFNhbnRlIGV0IGRlIGxhIFJlY2hlcmNoZSBNZWRpY2FsZSAoSU5TRVJNKSBVbml0ZXMgTWl4 dGVzIGRlIFJlY2hlcmNoZSA5NTcsIE5hbnRlcywgRnJhbmNlMjZTZXJ2aWNlIGRlIEdlbmV0aXF1 ZSBNZWRpY2FsZSwgQ0hVIGRlIEJvci4mI3hEO0F1dGlzbSBhbmQgRGV2ZWxvcG1lbnRhbCBNZWRp Y2luZSBJbnN0aXR1dGUsIEdlaXNpbmdlciBIZWFsdGggU3lzdGVtLCBEYW52aWxsZSwgUGVubnN5 bHZhbmlhLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kMjlFc3RvbmlhbiBHZW5vbWUgQ2VudGVy LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgRXN0b25pYS4mI3hEO0VzdG9uaWFuIEdlbm9t ZSBDZW50ZXIsIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3RvbmlhMzBJbnN0aXR1dGUg b2YgTW9sZWN1bGFyIGFuZCBDZWxsIEJpb2xvZ3ksIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1 LCBFc3RvbmlhLiYjeEQ7RGVwYXJ0bWVudCBvZiBSYWRpb2xvZ3kgYW5kIEJpb21lZGljYWwgSW1h Z2luZywgVW5pdmVyc2l0eSBvZiBDYWxpZm9ybmlhLCBTYW4gRnJhbmNpc2NvLiYjeEQ7U2Vydmlj ZSBkZSBHZW5ldGlxdWUgTWVkaWNhbGUsIENIVSBkZSBCb3JkZWF1eCwgQm9yZGVhdXgsIEZyYW5j ZTMyTGFib3JhdG9pcmUgTWFsYWRpZXMgUmFyZXM6IEdlbmV0aXF1ZSBldCBNZXRhYm9saXNtZSwg VW5pdmVyc2l0ZSBkZSBCb3JkZWF1eCwgQm9yZGVhdXgsIEZyYW5jZS4mI3hEO1NpZ25hdHVyZSBH ZW5vbWljIExhYm9yYXRvcmllcywgTExDLCBQZXJraW5FbG1lciwgSW5jLCBTcG9rYW5lLiYjeEQ7 RGVwYXJ0bWVudCBvZiBOZXVyb2xvZ3ksIEJvc3RvbiBDaGlsZHJlbiZhcG9zO3MgSG9zcGl0YWws IEhhcnZhcmQgTWVkaWNhbCBTY2hvb2wsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cy4mI3hEO0RlcGFy dG1lbnQgb2YgTmV1cm9sb2d5LCBTZWF0dGxlIENoaWxkcmVuJmFwb3M7cyBSZXNlYXJjaCBJbnN0 aXR1dGUgYW5kIFVuaXZlcnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZS4mI3hEO0RlcGFydG1l bnQgb2YgTWVkaWNhbCBHZW5ldGljcywgVW5pdmVyc2l0eSBNZWRpY2FsIENlbnRyZSBVdHJlY2h0 LCBVdHJlY2h0LCB0aGUgTmV0aGVybGFuZHMuJiN4RDtHZW5ldGljIERpYWdub3N0aWMgTGFib3Jh dG9yeSwgRGVwYXJ0bWVudCBvZiBMYWJvcmF0b3J5IE1lZGljaW5lLCBDaGlsZHJlbiZhcG9zO3Mg SG9zcGl0YWwsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cy4mI3hEO0xhYm9yYXRvaXJlIGRlIFJlY2hl cmNoZSBlbiBOZXVyb2ltYWdlcmllLCBEZXBhcnRtZW50IGZvciBDbGluaWNhbCBOZXVyb3NjaWVu Y2VzLCBDZW50cmUgSG9zcGl0YWxvLVVuaXZlcnNpdGFpcmUgVmF1ZG9pcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBOZXVy b2xvZ3ksIFVuaXZlcnNpdHkgb2YgQ2FsaWZvcm5pYSwgU2FuIEZyYW5jaXNjby4mI3hEO1NpbW9u cyBGb3VuZGF0aW9uLCBOZXcgWW9yaywgTmV3IFlvcmsuJiN4RDtDZW50ZXIgZm9yIEludGVncmF0 aXZlIEdlbm9taWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxh bmQuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNp dHkgSG9zcGl0YWwgYW5kIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVy bGFuZDQxQ0hVIFNhaW50ZS1KdXN0aW5lIFJlc2VhcmNoIENlbnRlciwgTW9udHJlYWwsIENhbmFk YTQyRGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBVbml2ZXJzaXRlIGRlIE1vbnRyZWFsLCBNb250 cmVhbCwgUXVlYmVjLCBDYW5hZGEuJiN4RDtEaXZpc2lvbiBvZiBNb2xlY3VsYXIgR2VuZXRpY3Ms IERlcGFydG1lbnQgb2YgUGVkaWF0cmljcywgQ29sdW1iaWEgVW5pdmVyc2l0eSwgTmV3IFlvcmss IE5ldyBZb3JrNDREZXBhcnRtZW50IG9mIE1lZGljaW5lLCBDb2x1bWJpYSBVbml2ZXJzaXR5LCBO ZXcgWW9yaywgTmV3IFlvcmsuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RGVmaW5pbmcg dGhlIEVmZmVjdCBvZiB0aGUgMTZwMTEuMiBEdXBsaWNhdGlvbiBvbiBDb2duaXRpb24sIEJlaGF2 aW9yLCBhbmQgTWVkaWNhbCBDb21vcmJpZGl0aWVzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkpB TUEgUHN5Y2hpYXRyeTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs LXRpdGxlPkpBTUEgUHN5Y2hpYXRyeTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjIw LTMwPC9wYWdlcz48dm9sdW1lPjczPC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+PGtleXdvcmRz PjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtl eXdvcmQ+QXV0aXNtIFNwZWN0cnVtIERpc29yZGVyL2VwaWRlbWlvbG9neS9nZW5ldGljcy8qcHN5 Y2hvbG9neTwva2V5d29yZD48a2V5d29yZD5BdXRpc3RpYyBEaXNvcmRlci9lcGlkZW1pb2xvZ3kv Z2VuZXRpY3MvKnBzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FzZS1Db250cm9sIFN0dWRp ZXM8L2tleXdvcmQ+PGtleXdvcmQ+Q2VyZWJlbGx1bS9hYm5vcm1hbGl0aWVzPC9rZXl3b3JkPjxr ZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+ PGtleXdvcmQ+Q2hyb21vc29tZSBEZWxldGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21l IERpc29yZGVycy9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3MvKnBzeWNob2xvZ3k8L2tleXdvcmQ+PGtl eXdvcmQ+KkNocm9tb3NvbWUgRHVwbGljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29t ZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD4qQ29nbml0aW9u PC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkNvbW9y YmlkaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkROQSBDb3B5IE51bWJlciBWYXJpYXRpb25zPC9rZXl3 b3JkPjxrZXl3b3JkPkRldmVsb3BtZW50YWwgRGlzYWJpbGl0aWVzL2VwaWRlbWlvbG9neS9nZW5l dGljczwva2V5d29yZD48a2V5d29yZD5FcGlsZXBzeS9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3M8L2tl eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48 a2V5d29yZD5JbnRlbGxlY3R1YWwgRGlzYWJpbGl0eS9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3MvKnBz eWNob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWNyb2Nl cGhhbHkvZXBpZGVtaW9sb2d5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2Vk PC9rZXl3b3JkPjxrZXl3b3JkPk5lcnZvdXMgU3lzdGVtIE1hbGZvcm1hdGlvbnMvZXBpZGVtaW9s b2d5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvZXBpZGVtaW9sb2d5 LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5TY2hpem9waHJlbmljIFBzeWNob2xvZ3k8L2tl eXdvcmQ+PGtleXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll YXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh dGVzPjxpc2JuPjIxNjgtNjIzOCAoRWxlY3Ryb25pYykmI3hEOzIxNjgtNjIyWCAoTGlua2luZyk8 L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjY2Mjk2NDA8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0 ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI2NjI5NjQw PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4x MDAxL2phbWFwc3ljaGlhdHJ5LjIwMTUuMjEyMzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9y ZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A ADDIN EN.CITE.DATA [12-15] . They impact carriers’ appetite control , BMI, pubertal onset, and are significantly associated with diverse health outcomes (e.g. obesity, scoliosis, congenital heart disease , epilepsy, speech and language deficit, mood or psychotic disorders, etc.) eXdvcmQ+PGtleXdvcmQ+SGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5 d29yZD48a2V5d29yZD5JbnRlbGxpZ2VuY2UgVGVzdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwv a2V5d29yZD48a2V5d29yZD4qUGhlbm90eXBlPC9rZXl3b3JkPjxrZXl3b3JkPlN5bmRyb21lPC9r ZXl3b3JkPjxrZXl3b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5 ZWFyPjIwMTI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9k YXRlcz48aXNibj4xNDY4LTYyNDQgKEVsZWN0cm9uaWMpJiN4RDswMDIyLTI1OTMgKExpbmtpbmcp PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzMDU0MjQ4PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh dGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMzA1NDI0 ODwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUMzNDk0MDExPC9jdXN0b20y PjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2L2ptZWRnZW5ldC0yMDEyLTEwMTIwMzwv ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5= ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EJmFwb3M7QW5nZWxvPC9BdXRob3I+PFllYXI+MjAxNjwv WWVhcj48UmVjTnVtPjQ3NTwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTMsIDE1LTE5XTwvRGlzcGxh eVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj40NzU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48 a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYi IHRpbWVzdGFtcD0iMTQ4MDAwMjk4NyI+NDc1PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBl IG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhv cnM+PGF1dGhvcj5EJmFwb3M7QW5nZWxvLCBELjwvYXV0aG9yPjxhdXRob3I+TGVib24sIFMuPC9h dXRob3I+PGF1dGhvcj5DaGVuLCBRLjwvYXV0aG9yPjxhdXRob3I+TWFydGluLUJyZXZldCwgUy48 L2F1dGhvcj48YXV0aG9yPlNueWRlciwgTC4gRy48L2F1dGhvcj48YXV0aG9yPkhpcHBvbHl0ZSwg TC48L2F1dGhvcj48YXV0aG9yPkhhbnNvbiwgRS48L2F1dGhvcj48YXV0aG9yPk1haWxsYXJkLCBB LiBNLjwvYXV0aG9yPjxhdXRob3I+RmF1Y2V0dCwgVy4gQS48L2F1dGhvcj48YXV0aG9yPk1hY2Us IEEuPC9hdXRob3I+PGF1dGhvcj5QYWluLCBBLjwvYXV0aG9yPjxhdXRob3I+QmVybmllciwgUi48 L2F1dGhvcj48YXV0aG9yPkNoYXduZXIsIFMuIEouPC9hdXRob3I+PGF1dGhvcj5EYXZpZCwgQS48 L2F1dGhvcj48YXV0aG9yPkFuZHJpZXV4LCBKLjwvYXV0aG9yPjxhdXRob3I+QXlsd2FyZCwgRS48 L2F1dGhvcj48YXV0aG9yPkJhdWphdCwgRy48L2F1dGhvcj48YXV0aG9yPkNhbGRlaXJhLCBJLjwv YXV0aG9yPjxhdXRob3I+Q29udXMsIFAuPC9hdXRob3I+PGF1dGhvcj5GZXJyYXJpLCBDLjwvYXV0 aG9yPjxhdXRob3I+Rm9yemFubywgRi48L2F1dGhvcj48YXV0aG9yPkdlcmFyZCwgTS48L2F1dGhv cj48YXV0aG9yPkdvaW4tS29jaGVsLCBSLiBQLjwvYXV0aG9yPjxhdXRob3I+R3JhbnQsIEUuPC9h dXRob3I+PGF1dGhvcj5IdW50ZXIsIEouIFYuPC9hdXRob3I+PGF1dGhvcj5Jc2lkb3IsIEIuPC9h dXRob3I+PGF1dGhvcj5KYWNxdWV0dGUsIEEuPC9hdXRob3I+PGF1dGhvcj5Kb25jaCwgQS4gRS48 L2F1dGhvcj48YXV0aG9yPktlcmVuLCBCLjwvYXV0aG9yPjxhdXRob3I+TGFjb21iZSwgRC48L2F1 dGhvcj48YXV0aG9yPkxlIENhaWduZWMsIEMuPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW4sIEMuIEwu PC9hdXRob3I+PGF1dGhvcj5NYW5uaWssIEsuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFsdSwgQS48 L2F1dGhvcj48YXV0aG9yPk1pZ25vdCwgQy48L2F1dGhvcj48YXV0aG9yPk11a2hlcmplZSwgUC48 L2F1dGhvcj48YXV0aG9yPk93ZW4sIE0uIEouPC9hdXRob3I+PGF1dGhvcj5QYXNzZWdnZXJpLCBN LjwvYXV0aG9yPjxhdXRob3I+Um9vcnljay1UaGFtYm8sIEMuPC9hdXRob3I+PGF1dGhvcj5Sb3Nl bmZlbGQsIEouIEEuPC9hdXRob3I+PGF1dGhvcj5TcGVuY2UsIFMuIEouPC9hdXRob3I+PGF1dGhv cj5TdGVpbm1hbiwgSy4gSi48L2F1dGhvcj48YXV0aG9yPlRqZXJuYWdlbCwgSi48L2F1dGhvcj48 YXV0aG9yPlZhbiBIYWVsc3QsIE0uPC9hdXRob3I+PGF1dGhvcj5TaGVuLCBZLjwvYXV0aG9yPjxh dXRob3I+RHJhZ2Fuc2tpLCBCLjwvYXV0aG9yPjxhdXRob3I+U2hlcnIsIEUuIEguPC9hdXRob3I+ PGF1dGhvcj5MZWRiZXR0ZXIsIEQuIEguPC9hdXRob3I+PGF1dGhvcj52YW4gZGVuIEJyZWUsIE0u IEIuPC9hdXRob3I+PGF1dGhvcj5CZWNrbWFubiwgSi4gUy48L2F1dGhvcj48YXV0aG9yPlNwaXJv LCBKLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1dGhvcj48YXV0aG9yPkphY3F1 ZW1vbnQsIFMuPC9hdXRob3I+PGF1dGhvcj5DaHVuZywgVy4gSy48L2F1dGhvcj48YXV0aG9yPkNh cmRpZmYgVW5pdmVyc2l0eSBFeHBlcmllbmNlcyBvZiBDaGlsZHJlbiBXaXRoIENvcHkgTnVtYmVy IFZhcmlhbnRzLCBTdHVkeTwvYXV0aG9yPjxhdXRob3I+cDExLjIgRXVyb3BlYW4sIENvbnNvcnRp dW08L2F1dGhvcj48YXV0aG9yPlNpbW9ucyBWYXJpYXRpb24gaW4gSW5kaXZpZHVhbHMgUHJvamVj dCwgQ29uc29ydGl1bTwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRy ZXNzPkRlcGFydG1lbnQgb2YgQmlvc3RhdGlzdGljcywgTWFpbG1hbiBTY2hvb2wgb2YgUHVibGlj IEhlYWx0aCwgQ29sdW1iaWEgVW5pdmVyc2l0eSwgTmV3IFlvcmssIE5ldyBZb3JrLiYjeEQ7UGVk aWF0cmljIE5ldXJvbG9neSBVbml0LCBEZXBhcnRtZW50IG9mIFBlZGlhdHJpY3MsIExhdXNhbm5l IFVuaXZlcnNpdHkgSG9zcGl0YWwsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1l bnQgb2YgTWVkaWNhbCBHZW5ldGljcywgTGF1c2FubmUgVW5pdmVyc2l0eSBIb3NwaXRhbCBhbmQg VW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7Q2xpbmlj YWwgUmVzZWFyY2ggQXNzb2NpYXRlcywgTmV3IFlvcmssIE5ldyBZb3JrLiYjeEQ7RGVwYXJ0bWVu dCBvZiBQc3ljaGlhdHJ5LCBCb3N0b24gQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCBIYXJ2YXJk IE1lZGljYWwgU2Nob29sLCBCb3N0b24sIE1hc3NhY2h1c2V0dHMuJiN4RDtHZW5vbWljIE1lZGlj aW5lIEluc3RpdHV0ZSwgR2Vpc2luZ2VyIENsaW5pYywgRGFudmlsbGUsIFBlbm5zeWx2YW5pYS4m I3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgTGF1c2FubmUgVW5pdmVyc2l0eSBI b3NwaXRhbCBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5k N1N3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1hdGljcywgVW5pdmVyc2l0eSBvZiBMYXVzYW5u ZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7RGVwYXJ0bWVudCBvZiBQc3ljaGlhdHJ5IGFu ZCBCZWhhdmlvcmFsIFNjaWVuY2UsIFVuaXZlcnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZS4m I3hEO01lZGljYWwgUmVzZWFyY2ggQ291bmNpbCBDZW50cmUgZm9yIE5ldXJvcHN5Y2hpYXRyaWMg R2VuZXRpY3MgYW5kIEdlbm9taWNzLCBJbnN0aXR1dGUgb2YgUHN5Y2hvbG9naWNhbCBNZWRpY2lu ZSBhbmQgQ2xpbmljYWwgTmV1cm9zY2llbmNlcywgQ2FyZGlmZiBVbml2ZXJzaXR5LCBDYXJkaWZm LCBXYWxlcy4mI3hEO1NlcnZpY2UgZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBGYWN1bHRlIGRlIE1l ZGVjaW5lLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0YWlyZSAoQ0hVKSBOYW50ZXMsIElu c3RpdHV0IE5hdGlvbmFsIGRlIGxhIFNhbnRlIGV0IGRlIGxhIFJlY2hlcmNoZSBNZWRpY2FsZSAo SU5TRVJNKSBVbml0ZXMgTWl4dGVzIGRlIFJlY2hlcmNoZSA5NTcsIE5hbnRlcywgRnJhbmNlLiYj eEQ7SW5zdGl0dXQgZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBIb3NwaXRhbCBKZWFubmUgZGUgRmxh bmRyZSwgQ2VudHJlIEhvc3BpdGFsaWVyIFJlZ2lvbmFsIFVuaXZlcnNpdGFpcmUgKENIUlUpIGRl IExpbGxlLCBMaWxsZSwgRnJhbmNlLiYjeEQ7Q2VudGVyIGZvciBJbnRlZ3JhdGl2ZSBCcmFpbiBS ZXNlYXJjaCwgQ2hpbGRyZW4mYXBvcztzIFJlc2VhcmNoIEluc3RpdHV0ZSwgU2VhdHRsZSwgV2Fz aGluZ3Rvbi4mI3hEO0RlcGFydGVtZW50IGRlIEdlbmV0aXF1ZSwgSG9waXRhbCBOZWNrZXItRW5m YW50cyBNYWxhZGVzLCBBc3Npc3RhbmNlIFB1YmxpcXVlLUhvcGl0YXV4IGRlIFBhcmlzIChBUC1I UCksIFBhcmlzLCBGcmFuY2UgMTRJTlNFUk0gVTExNjMsIEhvcGl0YWwgTmVja2VyLUVuZmFudHMg TWFsYWRlcywgUGFyaXMsIEZyYW5jZTE1SW5zdGl0dXQgSW1hZ2luZSwgVW5pdmVyc2l0ZSBQYXJp cyBEZXNjYXJ0ZXMtU29yYm9ubmUgUGFyaXMgQ2l0ZSwgUGFyaXMuJiN4RDtEZXBhcnRtZW50IG9m IFBzeWNoaWF0cnksIENlcnkgSG9zcGl0YWwsIENIVSBWYXVkb2lzIGFuZCBVbml2ZXJzaXR5IG9m IExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEaXZpc2lvbiBvZiBNZWRpY2Fs IEdlbmV0aWNzLCBHYWxsaWVyYSBIb3NwaXRhbCwgR2Vub3ZhLCBJdGFseS4mI3hEO0RlcGFydGVt ZW50IGRlIEdlbmV0aXF1ZSwgQVAtSFAsIEhvcGl0YWwgUm9iZXJ0IERlYnJlLCBVbml2ZXJzaXRl IFBhcmlzIFZJSS1QYXJpcyBEaWRlcm90LCBQYXJpcywgRnJhbmNlLiYjeEQ7U2VjdGlvbiBvZiBQ c3ljaG9sb2d5LCBEZXBhcnRtZW50IG9mIFBlZGlhdHJpY3MsIEJheWxvciBDb2xsZWdlIG9mIE1l ZGljaW5lLCBIb3VzdG9uLCBUZXhhcy4mI3hEO0RlcGFydG1lbnQgb2YgUmFkaW9sb2d5LCBCb3N0 b24gQ2hpbGRyZW4mYXBvcztzIEhvc3BpdGFsLCBIYXJ2YXJkIE1lZGljYWwgU2Nob29sLCBCb3N0 b24sIE1hc3NhY2h1c2V0dHMuJiN4RDtEZXBhcnRtZW50IG9mIFJhZGlvbG9neSwgQmF5bG9yIENv bGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLiYjeEQ7RGVwYXJ0ZW1lbnQgZGUgR2Vu ZXRpcXVlIGV0IGRlIEN5dG9nZW5ldGlxdWUsIFVuaXRlIGZvbmN0aW9ubmVsbGUgZGUgR2VuZXRp cXVlIENsaW5pcXVlLCBBUC1IUCwgSG9waXRhbCBQaXRpZS1TYWxwZXRyaWVyZSwgUGFyaXMsIEZy YW5jZTIzQ2VudHJlIGRlIFJlZmVyZW5jZSBEZWZpY2llbmNlcyBJbnRlbGxlY3R1ZWxsZXMgZGUg Q2F1c2VzIFJhcmVzLCBQYXJpcywgRnJhbmNlMjRHcm91cGUgZGUgUmVjaGVyY2hlIENsaW5pcXVl LCBEZWZpY2llLiYjeEQ7RGVwYXJ0bWVudCBvZiBHZW5ldGljcyBhbmQgQ3l0b2dlbmV0aWNzLCBH cm91cGUgSG9zcGl0YWxpZXIgUGl0aWUgU2FscGV0cmllcmUsIEFQLUhQLCBQYXJpcywgRnJhbmNl LiYjeEQ7U2VydmljZSBkZSBHZW5ldGlxdWUgTWVkaWNhbGUsIEZhY3VsdGUgZGUgTWVkZWNpbmUs IENlbnRyZSBIb3NwaXRhbGllciBVbml2ZXJzaXRhaXJlIChDSFUpIE5hbnRlcywgSW5zdGl0dXQg TmF0aW9uYWwgZGUgbGEgU2FudGUgZXQgZGUgbGEgUmVjaGVyY2hlIE1lZGljYWxlIChJTlNFUk0p IFVuaXRlcyBNaXh0ZXMgZGUgUmVjaGVyY2hlIDk1NywgTmFudGVzLCBGcmFuY2UyNlNlcnZpY2Ug ZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBDSFUgZGUgQm9yLiYjeEQ7QXV0aXNtIGFuZCBEZXZlbG9w bWVudGFsIE1lZGljaW5lIEluc3RpdHV0ZSwgR2Vpc2luZ2VyIEhlYWx0aCBTeXN0ZW0sIERhbnZp bGxlLCBQZW5uc3lsdmFuaWEuJiN4RDtDZW50ZXIgZm9yIEludGVncmF0aXZlIEdlbm9taWNzLCBV bml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQyOUVzdG9uaWFuIEdl bm9tZSBDZW50ZXIsIFVuaXZlcnNpdHkgb2YgVGFydHUsIFRhcnR1LCBFc3RvbmlhLiYjeEQ7RXN0 b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIEVzdG9uaWEz MEluc3RpdHV0ZSBvZiBNb2xlY3VsYXIgYW5kIENlbGwgQmlvbG9neSwgVW5pdmVyc2l0eSBvZiBU YXJ0dSwgVGFydHUsIEVzdG9uaWEuJiN4RDtEZXBhcnRtZW50IG9mIFJhZGlvbG9neSBhbmQgQmlv bWVkaWNhbCBJbWFnaW5nLCBVbml2ZXJzaXR5IG9mIENhbGlmb3JuaWEsIFNhbiBGcmFuY2lzY28u JiN4RDtTZXJ2aWNlIGRlIEdlbmV0aXF1ZSBNZWRpY2FsZSwgQ0hVIGRlIEJvcmRlYXV4LCBCb3Jk ZWF1eCwgRnJhbmNlMzJMYWJvcmF0b2lyZSBNYWxhZGllcyBSYXJlczogR2VuZXRpcXVlIGV0IE1l dGFib2xpc21lLCBVbml2ZXJzaXRlIGRlIEJvcmRlYXV4LCBCb3JkZWF1eCwgRnJhbmNlLiYjeEQ7 U2lnbmF0dXJlIEdlbm9taWMgTGFib3JhdG9yaWVzLCBMTEMsIFBlcmtpbkVsbWVyLCBJbmMsIFNw b2thbmUuJiN4RDtEZXBhcnRtZW50IG9mIE5ldXJvbG9neSwgQm9zdG9uIENoaWxkcmVuJmFwb3M7 cyBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwgQm9zdG9uLCBNYXNzYWNodXNldHRz LiYjeEQ7RGVwYXJ0bWVudCBvZiBOZXVyb2xvZ3ksIFNlYXR0bGUgQ2hpbGRyZW4mYXBvcztzIFJl c2VhcmNoIEluc3RpdHV0ZSBhbmQgVW5pdmVyc2l0eSBvZiBXYXNoaW5ndG9uLCBTZWF0dGxlLiYj eEQ7RGVwYXJ0bWVudCBvZiBNZWRpY2FsIEdlbmV0aWNzLCBVbml2ZXJzaXR5IE1lZGljYWwgQ2Vu dHJlIFV0cmVjaHQsIFV0cmVjaHQsIHRoZSBOZXRoZXJsYW5kcy4mI3hEO0dlbmV0aWMgRGlhZ25v c3RpYyBMYWJvcmF0b3J5LCBEZXBhcnRtZW50IG9mIExhYm9yYXRvcnkgTWVkaWNpbmUsIENoaWxk cmVuJmFwb3M7cyBIb3NwaXRhbCwgQm9zdG9uLCBNYXNzYWNodXNldHRzLiYjeEQ7TGFib3JhdG9p cmUgZGUgUmVjaGVyY2hlIGVuIE5ldXJvaW1hZ2VyaWUsIERlcGFydG1lbnQgZm9yIENsaW5pY2Fs IE5ldXJvc2NpZW5jZXMsIENlbnRyZSBIb3NwaXRhbG8tVW5pdmVyc2l0YWlyZSBWYXVkb2lzLCBV bml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRt ZW50IG9mIE5ldXJvbG9neSwgVW5pdmVyc2l0eSBvZiBDYWxpZm9ybmlhLCBTYW4gRnJhbmNpc2Nv LiYjeEQ7U2ltb25zIEZvdW5kYXRpb24sIE5ldyBZb3JrLCBOZXcgWW9yay4mI3hEO0NlbnRlciBm b3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5l LCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBHZW5ldGljcywgTGF1c2Fu bmUgVW5pdmVyc2l0eSBIb3NwaXRhbCBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwgTGF1c2Fu bmUsIFN3aXR6ZXJsYW5kNDFDSFUgU2FpbnRlLUp1c3RpbmUgUmVzZWFyY2ggQ2VudGVyLCBNb250 cmVhbCwgQ2FuYWRhNDJEZXBhcnRtZW50IG9mIFBlZGlhdHJpY3MsIFVuaXZlcnNpdGUgZGUgTW9u dHJlYWwsIE1vbnRyZWFsLCBRdWViZWMsIENhbmFkYS4mI3hEO0RpdmlzaW9uIG9mIE1vbGVjdWxh ciBHZW5ldGljcywgRGVwYXJ0bWVudCBvZiBQZWRpYXRyaWNzLCBDb2x1bWJpYSBVbml2ZXJzaXR5 LCBOZXcgWW9yaywgTmV3IFlvcms0NERlcGFydG1lbnQgb2YgTWVkaWNpbmUsIENvbHVtYmlhIFVu aXZlcnNpdHksIE5ldyBZb3JrLCBOZXcgWW9yay48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRs ZT5EZWZpbmluZyB0aGUgRWZmZWN0IG9mIHRoZSAxNnAxMS4yIER1cGxpY2F0aW9uIG9uIENvZ25p dGlvbiwgQmVoYXZpb3IsIGFuZCBNZWRpY2FsIENvbW9yYmlkaXRpZXM8L3RpdGxlPjxzZWNvbmRh cnktdGl0bGU+SkFNQSBQc3ljaGlhdHJ5PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlv ZGljYWw+PGZ1bGwtdGl0bGU+SkFNQSBQc3ljaGlhdHJ5PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNh bD48cGFnZXM+MjAtMzA8L3BhZ2VzPjx2b2x1bWU+NzM8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJl cj48a2V5d29yZHM+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29yZD48a2V5d29yZD5BZHVsdDwv a2V5d29yZD48a2V5d29yZD5BdXRpc20gU3BlY3RydW0gRGlzb3JkZXIvZXBpZGVtaW9sb2d5L2dl bmV0aWNzLypwc3ljaG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkF1dGlzdGljIERpc29yZGVyL2Vw aWRlbWlvbG9neS9nZW5ldGljcy8qcHN5Y2hvbG9neTwva2V5d29yZD48a2V5d29yZD5DYXNlLUNv bnRyb2wgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5DZXJlYmVsbHVtL2Fibm9ybWFsaXRpZXM8 L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQsIFByZXNjaG9v bDwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21lIERlbGV0aW9uPC9rZXl3b3JkPjxrZXl3b3Jk PkNocm9tb3NvbWUgRGlzb3JkZXJzL2VwaWRlbWlvbG9neS9nZW5ldGljcy8qcHN5Y2hvbG9neTwv a2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBEdXBsaWNhdGlvbjwva2V5d29yZD48a2V5d29y ZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTYvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3Jk PipDb2duaXRpb248L2tleXdvcmQ+PGtleXdvcmQ+Q29ob3J0IFN0dWRpZXM8L2tleXdvcmQ+PGtl eXdvcmQ+Q29tb3JiaWRpdHk8L2tleXdvcmQ+PGtleXdvcmQ+RE5BIENvcHkgTnVtYmVyIFZhcmlh dGlvbnM8L2tleXdvcmQ+PGtleXdvcmQ+RGV2ZWxvcG1lbnRhbCBEaXNhYmlsaXRpZXMvZXBpZGVt aW9sb2d5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkVwaWxlcHN5L2VwaWRlbWlvbG9neS9n ZW5ldGljczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5z PC9rZXl3b3JkPjxrZXl3b3JkPkludGVsbGVjdHVhbCBEaXNhYmlsaXR5L2VwaWRlbWlvbG9neS9n ZW5ldGljcy8qcHN5Y2hvbG9neTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3 b3JkPk1pY3JvY2VwaGFseS9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+TmVydm91cyBTeXN0ZW0gTWFsZm9ybWF0aW9u cy9lcGlkZW1pb2xvZ3kvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+U2NoaXpvcGhyZW5pYS9l cGlkZW1pb2xvZ3kvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWMgUHN5 Y2hvbG9neTwva2V5d29yZD48a2V5d29yZD5Zb3VuZyBBZHVsdDwva2V5d29yZD48L2tleXdvcmRz PjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuPC9kYXRlPjwvcHVi LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MjE2OC02MjM4IChFbGVjdHJvbmljKSYjeEQ7MjE2OC02MjJY IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNjYyOTY0MDwvYWNjZXNzaW9uLW51bT48 dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt ZWQvMjY2Mjk2NDA8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3Vy Y2UtbnVtPjEwLjEwMDEvamFtYXBzeWNoaWF0cnkuMjAxNS4yMTIzPC9lbGVjdHJvbmljLXJlc291 cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5KYWNxdWVtb250PC9BdXRob3I+ PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjE2ODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+ MTY4PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0idDkwZHh3 d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9IjE0NzAzMDA0MTkiPjE2 ODwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3 PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SmFjcXVlbW9udCwgUy48 L2F1dGhvcj48YXV0aG9yPlJleW1vbmQsIEEuPC9hdXRob3I+PGF1dGhvcj5adWZmZXJleSwgRi48 L2F1dGhvcj48YXV0aG9yPkhhcmV3b29kLCBMLjwvYXV0aG9yPjxhdXRob3I+V2FsdGVycywgUi4g Ry48L2F1dGhvcj48YXV0aG9yPkt1dGFsaWssIFouPC9hdXRob3I+PGF1dGhvcj5NYXJ0aW5ldCwg RC48L2F1dGhvcj48YXV0aG9yPlNoZW4sIFkuPC9hdXRob3I+PGF1dGhvcj5WYWxzZXNpYSwgQS48 L2F1dGhvcj48YXV0aG9yPkJlY2ttYW5uLCBOLiBELjwvYXV0aG9yPjxhdXRob3I+VGhvcmxlaWZz c29uLCBHLjwvYXV0aG9yPjxhdXRob3I+QmVsZmlvcmUsIE0uPC9hdXRob3I+PGF1dGhvcj5Cb3Vx dWlsbG9uLCBTLjwvYXV0aG9yPjxhdXRob3I+Q2FtcGlvbiwgRC48L2F1dGhvcj48YXV0aG9yPmRl IExlZXV3LCBOLjwvYXV0aG9yPjxhdXRob3I+ZGUgVnJpZXMsIEIuIEIuPC9hdXRob3I+PGF1dGhv cj5Fc2tvLCBULjwvYXV0aG9yPjxhdXRob3I+RmVybmFuZGV6LCBCLiBBLjwvYXV0aG9yPjxhdXRo b3I+RmVybmFuZGV6LUFyYW5kYSwgRi48L2F1dGhvcj48YXV0aG9yPkZlcm5hbmRlei1SZWFsLCBK LiBNLjwvYXV0aG9yPjxhdXRob3I+R3JhdGFjb3MsIE0uPC9hdXRob3I+PGF1dGhvcj5HdWlsbWF0 cmUsIEEuPC9hdXRob3I+PGF1dGhvcj5Ib3llciwgSi48L2F1dGhvcj48YXV0aG9yPkphcnZlbGlu LCBNLiBSLjwvYXV0aG9yPjxhdXRob3I+S29veSwgUi4gRi48L2F1dGhvcj48YXV0aG9yPkt1cmcs IEEuPC9hdXRob3I+PGF1dGhvcj5MZSBDYWlnbmVjLCBDLjwvYXV0aG9yPjxhdXRob3I+TWFubmlr LCBLLjwvYXV0aG9yPjxhdXRob3I+UGxhdHQsIE8uIFMuPC9hdXRob3I+PGF1dGhvcj5TYW5sYXZp bGxlLCBELjwvYXV0aG9yPjxhdXRob3I+VmFuIEhhZWxzdCwgTS4gTS48L2F1dGhvcj48YXV0aG9y PlZpbGxhdG9ybyBHb21leiwgUy48L2F1dGhvcj48YXV0aG9yPldhbGhhLCBGLjwvYXV0aG9yPjxh dXRob3I+V3UsIEIuIEwuPC9hdXRob3I+PGF1dGhvcj5ZdSwgWS48L2F1dGhvcj48YXV0aG9yPkFi b3VyYSwgQS48L2F1dGhvcj48YXV0aG9yPkFkZG9yLCBNLiBDLjwvYXV0aG9yPjxhdXRob3I+QWxl bWJpaywgWS48L2F1dGhvcj48YXV0aG9yPkFudG9uYXJha2lzLCBTLiBFLjwvYXV0aG9yPjxhdXRo b3I+QXJ2ZWlsZXIsIEIuPC9hdXRob3I+PGF1dGhvcj5CYXJ0aCwgTS48L2F1dGhvcj48YXV0aG9y PkJlZG5hcmVrLCBOLjwvYXV0aG9yPjxhdXRob3I+QmVuYSwgRi48L2F1dGhvcj48YXV0aG9yPkJl cmdtYW5uLCBTLjwvYXV0aG9yPjxhdXRob3I+QmVyaSwgTS48L2F1dGhvcj48YXV0aG9yPkJlcm5h cmRpbmksIEwuPC9hdXRob3I+PGF1dGhvcj5CbGF1bWVpc2VyLCBCLjwvYXV0aG9yPjxhdXRob3I+ Qm9ubmVhdSwgRC48L2F1dGhvcj48YXV0aG9yPkJvdHRhbmksIEEuPC9hdXRob3I+PGF1dGhvcj5C b3V0ZSwgTy48L2F1dGhvcj48YXV0aG9yPkJydW5uZXIsIEguIEcuPC9hdXRob3I+PGF1dGhvcj5D YWlsbGV5LCBELjwvYXV0aG9yPjxhdXRob3I+Q2FsbGllciwgUC48L2F1dGhvcj48YXV0aG9yPkNo aWVzYSwgSi48L2F1dGhvcj48YXV0aG9yPkNocmFzdCwgSi48L2F1dGhvcj48YXV0aG9yPkNvaW4s IEwuPC9hdXRob3I+PGF1dGhvcj5Db3V0dG9uLCBDLjwvYXV0aG9yPjxhdXRob3I+Q3Vpc3NldCwg Si4gTS48L2F1dGhvcj48YXV0aG9yPkN1dmVsbGllciwgSi4gQy48L2F1dGhvcj48YXV0aG9yPkRh dmlkLCBBLjwvYXV0aG9yPjxhdXRob3I+ZGUgRnJlbWludmlsbGUsIEIuPC9hdXRob3I+PGF1dGhv cj5EZWxvYmVsLCBCLjwvYXV0aG9yPjxhdXRob3I+RGVscnVlLCBNLiBBLjwvYXV0aG9yPjxhdXRo b3I+RGVtZWVyLCBCLjwvYXV0aG9yPjxhdXRob3I+RGVzY2FtcHMsIEQuPC9hdXRob3I+PGF1dGhv cj5EaWRlbG90LCBHLjwvYXV0aG9yPjxhdXRob3I+RGlldGVyaWNoLCBLLjwvYXV0aG9yPjxhdXRo b3I+RGlzY2lnbGlvLCBWLjwvYXV0aG9yPjxhdXRob3I+RG9jby1GZW56eSwgTS48L2F1dGhvcj48 YXV0aG9yPkRydW5hdCwgUy48L2F1dGhvcj48YXV0aG9yPkR1YmFuLUJlZHUsIEIuPC9hdXRob3I+ PGF1dGhvcj5EdWJvdXJnLCBDLjwvYXV0aG9yPjxhdXRob3I+RWwtU2F5ZWQgTW91c3RhZmEsIEou IFMuPC9hdXRob3I+PGF1dGhvcj5FbGxpb3R0LCBQLjwvYXV0aG9yPjxhdXRob3I+RmFhcywgQi4g SC48L2F1dGhvcj48YXV0aG9yPkZhaXZyZSwgTC48L2F1dGhvcj48YXV0aG9yPkZhdWRldCwgQS48 L2F1dGhvcj48YXV0aG9yPkZlbGxtYW5uLCBGLjwvYXV0aG9yPjxhdXRob3I+RmVycmFyaW5pLCBB LjwvYXV0aG9yPjxhdXRob3I+RmlzaGVyLCBSLjwvYXV0aG9yPjxhdXRob3I+RmxvcmksIEUuPC9h dXRob3I+PGF1dGhvcj5Gb3JlciwgTC48L2F1dGhvcj48YXV0aG9yPkdhaWxsYXJkLCBELjwvYXV0 aG9yPjxhdXRob3I+R2VyYXJkLCBNLjwvYXV0aG9yPjxhdXRob3I+R2llZ2VyLCBDLjwvYXV0aG9y PjxhdXRob3I+R2ltZWxsaSwgUy48L2F1dGhvcj48YXV0aG9yPkdpbWVsbGksIEcuPC9hdXRob3I+ PGF1dGhvcj5HcmFiZSwgSC4gSi48L2F1dGhvcj48YXV0aG9yPkd1aWNoZXQsIEEuPC9hdXRob3I+ PGF1dGhvcj5HdWlsbGluLCBPLjwvYXV0aG9yPjxhdXRob3I+SGFydGlrYWluZW4sIEEuIEwuPC9h dXRob3I+PGF1dGhvcj5IZXJvbiwgRC48L2F1dGhvcj48YXV0aG9yPkhpcHBvbHl0ZSwgTC48L2F1 dGhvcj48YXV0aG9yPkhvbGRlciwgTS48L2F1dGhvcj48YXV0aG9yPkhvbXV0aCwgRy48L2F1dGhv cj48YXV0aG9yPklzaWRvciwgQi48L2F1dGhvcj48YXV0aG9yPkphaWxsYXJkLCBTLjwvYXV0aG9y PjxhdXRob3I+SmFyb3MsIFouPC9hdXRob3I+PGF1dGhvcj5KaW1lbmV6LU11cmNpYSwgUy48L2F1 dGhvcj48YXV0aG9yPkhlbGFzLCBHLiBKLjwvYXV0aG9yPjxhdXRob3I+Sm9udmVhdXgsIFAuPC9h dXRob3I+PGF1dGhvcj5LYWtzb25lbiwgUy48L2F1dGhvcj48YXV0aG9yPktlcmVuLCBCLjwvYXV0 aG9yPjxhdXRob3I+S2xvc3MtQnJhbmRzdGF0dGVyLCBBLjwvYXV0aG9yPjxhdXRob3I+S25vZXJz LCBOLiBWLjwvYXV0aG9yPjxhdXRob3I+S29vbGVuLCBELiBBLjwvYXV0aG9yPjxhdXRob3I+S3Jv aXNlbCwgUC4gTS48L2F1dGhvcj48YXV0aG9yPktyb25lbmJlcmcsIEYuPC9hdXRob3I+PGF1dGhv cj5MYWJhbG1lLCBBLjwvYXV0aG9yPjxhdXRob3I+TGFuZGFpcywgRS48L2F1dGhvcj48YXV0aG9y PkxhcGksIEUuPC9hdXRob3I+PGF1dGhvcj5MYXlldCwgVi48L2F1dGhvcj48YXV0aG9yPkxlZ2Fs bGljLCBTLjwvYXV0aG9yPjxhdXRob3I+TGVoZXVwLCBCLjwvYXV0aG9yPjxhdXRob3I+TGV1YmUs IEIuPC9hdXRob3I+PGF1dGhvcj5MZXdpcywgUy48L2F1dGhvcj48YXV0aG9yPkx1Y2FzLCBKLjwv YXV0aG9yPjxhdXRob3I+TWFjRGVybW90LCBLLiBELjwvYXV0aG9yPjxhdXRob3I+TWFnbnVzc29u LCBQLjwvYXV0aG9yPjxhdXRob3I+TWFyc2hhbGwsIEMuPC9hdXRob3I+PGF1dGhvcj5NYXRoaWV1 LURyYW1hcmQsIE0uPC9hdXRob3I+PGF1dGhvcj5NY0NhcnRoeSwgTS4gSS48L2F1dGhvcj48YXV0 aG9yPk1laXRpbmdlciwgVC48L2F1dGhvcj48YXV0aG9yPk1lbmNhcmVsbGksIE0uIEEuPC9hdXRo b3I+PGF1dGhvcj5NZXJsYSwgRy48L2F1dGhvcj48YXV0aG9yPk1vZXJtYW4sIEEuPC9hdXRob3I+ PGF1dGhvcj5Nb29zZXIsIFYuPC9hdXRob3I+PGF1dGhvcj5Nb3JpY2UtUGljYXJkLCBGLjwvYXV0 aG9yPjxhdXRob3I+TXVjY2lvbG8sIE0uPC9hdXRob3I+PGF1dGhvcj5OYXVjaywgTS48L2F1dGhv cj48YXV0aG9yPk5kaWF5ZSwgTi4gQy48L2F1dGhvcj48YXV0aG9yPk5vcmRncmVuLCBBLjwvYXV0 aG9yPjxhdXRob3I+UGFzcXVpZXIsIEwuPC9hdXRob3I+PGF1dGhvcj5QZXRpdCwgRi48L2F1dGhv cj48YXV0aG9yPlBmdW5kdCwgUi48L2F1dGhvcj48YXV0aG9yPlBsZXNzaXMsIEcuPC9hdXRob3I+ PGF1dGhvcj5SYWpjYW4tU2VwYXJvdmljLCBFLjwvYXV0aG9yPjxhdXRob3I+UmFtZWxsaSwgRy4g UC48L2F1dGhvcj48YXV0aG9yPlJhdWNoLCBBLjwvYXV0aG9yPjxhdXRob3I+UmF2YXp6b2xvLCBS LjwvYXV0aG9yPjxhdXRob3I+UmVpcywgQS48L2F1dGhvcj48YXV0aG9yPlJlbmllcmksIEEuPC9h dXRob3I+PGF1dGhvcj5SaWNoYXJ0LCBDLjwvYXV0aG9yPjxhdXRob3I+UmllZCwgSi4gUy48L2F1 dGhvcj48YXV0aG9yPlJpZXVibGFuZCwgQy48L2F1dGhvcj48YXV0aG9yPlJvYmVydHMsIFcuPC9h dXRob3I+PGF1dGhvcj5Sb2V0emVyLCBLLiBNLjwvYXV0aG9yPjxhdXRob3I+Um9vcnljaywgQy48 L2F1dGhvcj48YXV0aG9yPlJvc3NpLCBNLjwvYXV0aG9yPjxhdXRob3I+U2FlbXVuZHNlbiwgRS48 L2F1dGhvcj48YXV0aG9yPlNhdHJlLCBWLjwvYXV0aG9yPjxhdXRob3I+U2NodXJtYW5uLCBDLjwv YXV0aG9yPjxhdXRob3I+U2lndXJkc3NvbiwgRS48L2F1dGhvcj48YXV0aG9yPlN0YXZyb3BvdWxv cywgRC4gSi48L2F1dGhvcj48YXV0aG9yPlN0ZWZhbnNzb24sIEguPC9hdXRob3I+PGF1dGhvcj5U ZW5nc3Ryb20sIEMuPC9hdXRob3I+PGF1dGhvcj5UaG9yc3RlaW5zZG90dGlyLCBVLjwvYXV0aG9y PjxhdXRob3I+VGluYWhvbmVzLCBGLiBKLjwvYXV0aG9yPjxhdXRob3I+VG91cmFpbmUsIFIuPC9h dXRob3I+PGF1dGhvcj5WYWxsZWUsIEwuPC9hdXRob3I+PGF1dGhvcj52YW4gQmluc2Jlcmdlbiwg RS48L2F1dGhvcj48YXV0aG9yPlZhbiBkZXIgQWEsIE4uPC9hdXRob3I+PGF1dGhvcj5WaW5jZW50 LURlbG9ybWUsIEMuPC9hdXRob3I+PGF1dGhvcj5WaXN2aWtpcy1TaWVzdCwgUy48L2F1dGhvcj48 YXV0aG9yPlZvbGxlbndlaWRlciwgUC48L2F1dGhvcj48YXV0aG9yPlZvbHprZSwgSC48L2F1dGhv cj48YXV0aG9yPlZ1bHRvLXZhbiBTaWxmaG91dCwgQS4gVC48L2F1dGhvcj48YXV0aG9yPldhZWJl ciwgRy48L2F1dGhvcj48YXV0aG9yPldhbGxncmVuLVBldHRlcnNzb24sIEMuPC9hdXRob3I+PGF1 dGhvcj5XaXR3aWNraSwgUi4gTS48L2F1dGhvcj48YXV0aG9yPlp3b2xpbmtzaSwgUy48L2F1dGhv cj48YXV0aG9yPkFuZHJpZXV4LCBKLjwvYXV0aG9yPjxhdXRob3I+RXN0aXZpbGwsIFguPC9hdXRo b3I+PGF1dGhvcj5HdXNlbGxhLCBKLiBGLjwvYXV0aG9yPjxhdXRob3I+R3VzdGFmc3NvbiwgTy48 L2F1dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxhdXRob3I+U2NoZXJlciwgUy4g Vy48L2F1dGhvcj48YXV0aG9yPlN0ZWZhbnNzb24sIEsuPC9hdXRob3I+PGF1dGhvcj5CbGFrZW1v cmUsIEEuIEkuPC9hdXRob3I+PGF1dGhvcj5CZWNrbWFubiwgSi4gUy48L2F1dGhvcj48YXV0aG9y PkZyb2d1ZWwsIFAuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJl c3M+U2VydmljZSBvZiBNZWRpY2FsIEdlbmV0aWNzLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVy c2l0YWlyZSBWYXVkb2lzLCAxMDExIExhdXNhbm5lLCBTd2l0emVybGFuZC48L2F1dGgtYWRkcmVz cz48dGl0bGVzPjx0aXRsZT5NaXJyb3IgZXh0cmVtZSBCTUkgcGhlbm90eXBlcyBhc3NvY2lhdGVk IHdpdGggZ2VuZSBkb3NhZ2UgYXQgdGhlIGNocm9tb3NvbWUgMTZwMTEuMiBsb2N1czwvdGl0bGU+ PHNlY29uZGFyeS10aXRsZT5OYXR1cmU8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9k aWNhbD48ZnVsbC10aXRsZT5OYXR1cmU8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz45 Ny0xMDI8L3BhZ2VzPjx2b2x1bWU+NDc4PC92b2x1bWU+PG51bWJlcj43MzY3PC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5BZ2luZzwva2V5d29yZD48a2V5d29y ZD5Cb2R5IEhlaWdodC9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD4qQm9keSBNYXNzIEluZGV4 PC9rZXl3b3JkPjxrZXl3b3JkPkNhc2UtQ29udHJvbCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3Jk PkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdv cmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5d29yZD48a2V5d29y ZD5Db2hvcnQgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5Db21wYXJhdGl2ZSBHZW5vbWljIEh5 YnJpZGl6YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+RGV2ZWxvcG1lbnRhbCBEaXNhYmlsaXRpZXMv Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+RW5lcmd5IE1ldGFib2xpc20vZ2VuZXRpY3M8L2tl eXdvcmQ+PGtleXdvcmQ+RXVyb3BlPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48 a2V5d29yZD5HZW5lIERvc2FnZS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+R2VuZSBEdXBs aWNhdGlvbi9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5HZW5lIEV4cHJlc3Npb24gUHJvZmls aW5nPC9rZXl3b3JkPjxrZXl3b3JkPkdlbmV0aWMgUHJlZGlzcG9zaXRpb24gdG8gRGlzZWFzZS9n ZW5ldGljczwva2V5d29yZD48a2V5d29yZD5HZW5vbWUtV2lkZSBBc3NvY2lhdGlvbiBTdHVkeTwv a2V5d29yZD48a2V5d29yZD5IZWFkL2FuYXRvbXkgJmFtcDsgaGlzdG9sb2d5PC9rZXl3b3JkPjxr ZXl3b3JkPkhldGVyb3p5Z290ZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl eXdvcmQ+SW5mYW50PC9rZXl3b3JkPjxrZXl3b3JkPkluZmFudCwgTmV3Ym9ybjwva2V5d29yZD48 a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1lbnRhbCBEaXNvcmRlcnMvZ2VuZXRpY3M8 L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+TXV0YXRpb24v Z2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Tm9ydGggQW1lcmljYTwva2V5d29yZD48a2V5d29y ZD5PYmVzaXR5LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD4qUGhlbm90eXBlPC9rZXl3b3Jk PjxrZXl3b3JkPlJOQSwgTWVzc2VuZ2VyL2FuYWx5c2lzL2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3 b3JkPlNlcXVlbmNlIERlbGV0aW9uL2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPlRoaW5uZXNz LypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5UcmFuc2NyaXB0aW9uLCBHZW5ldGljPC9rZXl3 b3JkPjxrZXl3b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy PjIwMTE8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3QgNjwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh dGVzPjxpc2JuPjE0NzYtNDY4NyAoRWxlY3Ryb25pYykmI3hEOzAwMjgtMDgzNiAoTGlua2luZyk8 L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjE4ODE1NTk8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0 ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjE4ODE1NTk8 L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DMzYzNzE3NTwvY3VzdG9tMj48 ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9uYXR1cmUxMDQwNjwvZWxlY3Ryb25pYy1y ZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TWFpbGxhcmQ8L0F1dGhv cj48WWVhcj4yMDE1PC9ZZWFyPjxSZWNOdW0+NDc5PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJl cj40Nzk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBk eHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4MDAwMjk4NyI+ NDc5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+ MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYWlsbGFyZCwgQS4g TS48L2F1dGhvcj48YXV0aG9yPlJ1ZWYsIEEuPC9hdXRob3I+PGF1dGhvcj5QaXp6YWdhbGxpLCBG LjwvYXV0aG9yPjxhdXRob3I+TWlnbGlhdmFjY2EsIEUuPC9hdXRob3I+PGF1dGhvcj5IaXBwb2x5 dGUsIEwuPC9hdXRob3I+PGF1dGhvcj5BZGFzemV3c2tpLCBTLjwvYXV0aG9yPjxhdXRob3I+RHVr YXJ0LCBKLjwvYXV0aG9yPjxhdXRob3I+RmVycmFyaSwgQy48L2F1dGhvcj48YXV0aG9yPkNvbnVz LCBQLjwvYXV0aG9yPjxhdXRob3I+TWFubmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+WmF6aHl0c2th LCBNLjwvYXV0aG9yPjxhdXRob3I+U2lmZnJlZGksIFYuPC9hdXRob3I+PGF1dGhvcj5NYWVkZXIs IFAuPC9hdXRob3I+PGF1dGhvcj5LdXRhbGlrLCBaLjwvYXV0aG9yPjxhdXRob3I+S2hlcmlmLCBG LjwvYXV0aG9yPjxhdXRob3I+SGFkamlraGFuaSwgTi48L2F1dGhvcj48YXV0aG9yPkJlY2ttYW5u LCBKLiBTLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1dGhvcj48YXV0aG9yPkRyYWdh bnNraSwgQi48L2F1dGhvcj48YXV0aG9yPkphY3F1ZW1vbnQsIFMuPC9hdXRob3I+PGF1dGhvcj5w MTEuMiBFdXJvcGVhbiwgQ29uc29ydGl1bTwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y cz48YXV0aC1hZGRyZXNzPlNlcnZpY2Ugb2YgTWVkaWNhbCBHZW5ldGljcywgQ2VudHJlIEhvc3Bp dGFsaWVyIFVuaXZlcnNpdGFpcmUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwg TGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7TFJFTi1EZXBhcnRlbWVudCBkZXMgbmV1cm9zY2ll bmNlcyBjbGluaXF1ZXMsIENlbnRyZSBIb3NwaXRhbGllciBVbml2ZXJzaXRhaXJlIFZhdWRvaXMg YW5kIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEOzFd IFNlcnZpY2Ugb2YgTWVkaWNhbCBHZW5ldGljcywgQ2VudHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNp dGFpcmUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6 ZXJsYW5kIFsyXSBMUkVOLURlcGFydGVtZW50IGRlcyBuZXVyb3NjaWVuY2VzIGNsaW5pcXVlcywg Q2VudHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7MV0gQ2VudGVyIGZvciBJbnRl Z3JhdGl2ZSBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6 ZXJsYW5kIFsyXSBTd2lzcyBJbnN0aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIFVuaXZlcnNpdHkg b2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEOzFdIExSRU4tRGVwYXJ0ZW1l bnQgZGVzIG5ldXJvc2NpZW5jZXMgY2xpbmlxdWVzLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVy c2l0YWlyZSBWYXVkb2lzIGFuZCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dp dHplcmxhbmQgWzJdIERlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBNYXgtUGxhbmNrIEluc3RpdHV0 ZSBmb3IgSHVtYW4gQ29nbml0aXZlIGFuZCBCcmFpbiBTY2llbmNlLCBMZWlwemlnLCBHZXJtYW55 LiYjeEQ7RGVwYXJ0bWVudCBvZiBQc3ljaGlhdHJ5LCBDRVJZIEhvc3BpdGFsIENlbnRyZSBIb3Nw aXRhbGllciBVbml2ZXJzaXRhaXJlIFZhdWRvaXMgYW5kIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUs IExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21p Y3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZC4mI3hEO0Rl cGFydG1lbnQgb2YgUmFkaW9sb2d5LCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0YWlyZSBW YXVkb2lzIGFuZCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQu JiN4RDsxXSBTd2lzcyBJbnN0aXR1dGUgb2YgQmlvaW5mb3JtYXRpY3MsIFVuaXZlcnNpdHkgb2Yg TGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFuZCBbMl0gRGVwYXJ0bWVudCBvZiBNZWRpY2Fs IEdlbmV0aWNzLCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQg WzNdIEluc3RpdHV0ZSBvZiBTb2NpYWwgYW5kIFByZXZlbnRpdmUgTWVkaWNpbmUgKElVTVNQKSwg Q2VudHJlIEhvc3BpdGFsaWVyIFVuaXZlcnNpdGFpcmUgVmF1ZG9pcyBhbmQgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kLiYjeEQ7MV0gQnJhaW4gTWluZCBJbnN0 aXR1dGUsIFNjaG9vbCBvZiBMaWZlIFNjaWVuY2VzLCBFY29sZSBQb2x5dGVjaG5pcXVlIEZlZGVy YWxlIGRlIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQgWzJdIEF0aGlub3VsYSBBLiBN YXJ0aW5vcyBDZW50ZXIgZm9yIEJpb21lZGljYWwgSW1hZ2luZywgTWFzc2FjaHVzc2V0dHMgR2Vu ZXJhbCBIb3NwaXRhbCwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwgQ2hhcmxlc3Rvd24sIE1BLCBV U0EgWzNdIEdpbGxiZXJnIE5ldXJvcHN5Y2hpYXRyeSBDZW50cmUsIFNhaGxncmVuc2thIEFjYWRl bXksIFVuaXZlcnNpdHkgb2YgR290aGVuYnVyZywgR290aGVuYnVyZywgU3dlZGVuLiYjeEQ7MV0g U2VydmljZSBvZiBNZWRpY2FsIEdlbmV0aWNzLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0 YWlyZSBWYXVkb2lzIGFuZCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgU3dpdHpl cmxhbmQgWzJdIFN3aXNzIEluc3RpdHV0ZSBvZiBCaW9pbmZvcm1hdGljcywgVW5pdmVyc2l0eSBv ZiBMYXVzYW5uZSwgTGF1c2FubmUsIFN3aXR6ZXJsYW5kIFszXSBEZXBhcnRtZW50IG9mIE1lZGlj YWwgR2VuZXRpY3MsIFVuaXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCBTd2l0emVybGFu ZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5UaGUgMTZwMTEuMiBsb2N1cyBtb2R1bGF0 ZXMgYnJhaW4gc3RydWN0dXJlcyBjb21tb24gdG8gYXV0aXNtLCBzY2hpem9waHJlbmlhIGFuZCBv YmVzaXR5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk1vbCBQc3ljaGlhdHJ5PC9zZWNvbmRhcnkt dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TW9sIFBzeWNoaWF0cnk8L2Z1 bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xNDAtNzwvcGFnZXM+PHZvbHVtZT4yMDwvdm9s dW1lPjxudW1iZXI+MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3 b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFudGhyb3BvbWV0cnk8L2tleXdv cmQ+PGtleXdvcmQ+QXJhYmlkb3BzaXMgUHJvdGVpbnMvbWV0YWJvbGlzbTwva2V5d29yZD48a2V5 d29yZD5BdXRpc3RpYyBEaXNvcmRlci8qZ2VuZXRpY3MvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3 b3JkPkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5CcmFpbi8qcGF0aG9sb2d5PC9r ZXl3b3JkPjxrZXl3b3JkPkJyYWluIE1hcHBpbmc8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tl eXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29tZXMsIEh1bWFuLCBQYWlyIDE2LypnZW5ldGljczwva2V5 d29yZD48a2V5d29yZD5ETkEgQ29weSBOdW1iZXIgVmFyaWF0aW9ucy8qZ2VuZXRpY3M8L2tleXdv cmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdlbmUgRG9zYWdlPC9rZXl3b3Jk PjxrZXl3b3JkPkdlbmV0aWMgQXNzb2NpYXRpb24gU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5I dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW50cmFtb2xlY3VsYXIgVHJhbnNmZXJhc2VzL21ldGFi b2xpc208L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdl ZDwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5LypnZW5ldGljcy9wYXRob2xvZ3k8L2tleXdvcmQ+ PGtleXdvcmQ+UGhlbm90eXBlPC9rZXl3b3JkPjxrZXl3b3JkPlBzeWNoaWF0cmljIFN0YXR1cyBS YXRpbmcgU2NhbGVzPC9rZXl3b3JkPjxrZXl3b3JkPlNjaGl6b3BocmVuaWEvKmdlbmV0aWNzL3Bh dGhvbG9neTwva2V5d29yZD48a2V5d29yZD5Zb3VuZyBBZHVsdDwva2V5d29yZD48L2tleXdvcmRz PjxkYXRlcz48eWVhcj4yMDE1PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+RmViPC9kYXRlPjwvcHVi LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3Ni01NTc4IChFbGVjdHJvbmljKSYjeEQ7MTM1OS00MTg0 IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNTQyMTQwMjwvYWNjZXNzaW9uLW51bT48 dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt ZWQvMjU0MjE0MDI8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNDMyMDI4 NjwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAzOC9tcC4yMDE0LjE0NTwv ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+U2hp bmF3aTwvQXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+PFJlY051bT4zMzA8L1JlY051bT48cmVjb3Jk PjxyZWMtbnVtYmVyPjMzMDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg ZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIx NDcwMzAwNDE5Ij4zMzA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlNo aW5hd2ksIE0uPC9hdXRob3I+PGF1dGhvcj5MaXUsIFAuPC9hdXRob3I+PGF1dGhvcj5LYW5nLCBT LiBILjwvYXV0aG9yPjxhdXRob3I+U2hlbiwgSi48L2F1dGhvcj48YXV0aG9yPkJlbG1vbnQsIEou IFcuPC9hdXRob3I+PGF1dGhvcj5TY290dCwgRC4gQS48L2F1dGhvcj48YXV0aG9yPlByb2JzdCwg Ri4gSi48L2F1dGhvcj48YXV0aG9yPkNyYWlnZW4sIFcuIEouPC9hdXRob3I+PGF1dGhvcj5HcmFo YW0sIEIuIEguPC9hdXRob3I+PGF1dGhvcj5QdXJzbGV5LCBBLjwvYXV0aG9yPjxhdXRob3I+Q2xh cmssIEcuPC9hdXRob3I+PGF1dGhvcj5MZWUsIEouPC9hdXRob3I+PGF1dGhvcj5Qcm91ZCwgTS48 L2F1dGhvcj48YXV0aG9yPlN0b2NjbywgQS48L2F1dGhvcj48YXV0aG9yPlJvZHJpZ3VleiwgRC4g TC48L2F1dGhvcj48YXV0aG9yPktvemVsLCBCLiBBLjwvYXV0aG9yPjxhdXRob3I+U3BhcmFnYW5h LCBTLjwvYXV0aG9yPjxhdXRob3I+Um9lZGVyLCBFLiBSLjwvYXV0aG9yPjxhdXRob3I+TWNHcmV3 LCBTLiBHLjwvYXV0aG9yPjxhdXRob3I+S3VyY3p5bnNraSwgVC4gVy48L2F1dGhvcj48YXV0aG9y PkFsbGlzb24sIEwuIEouPC9hdXRob3I+PGF1dGhvcj5BbWF0bywgUy48L2F1dGhvcj48YXV0aG9y PlNhdmFnZSwgUy48L2F1dGhvcj48YXV0aG9yPlBhdGVsLCBBLjwvYXV0aG9yPjxhdXRob3I+U3Rh bmtpZXdpY3osIFAuPC9hdXRob3I+PGF1dGhvcj5CZWF1ZGV0LCBBLiBMLjwvYXV0aG9yPjxhdXRo b3I+Q2hldW5nLCBTLiBXLjwvYXV0aG9yPjxhdXRob3I+THVwc2tpLCBKLiBSLjwvYXV0aG9yPjwv YXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgTW9sZWN1 bGFyIGFuZCBIdW1hbiBHZW5ldGljcywgQmF5bG9yIENvbGxlZ2Ugb2YgTWVkaWNpbmUsIE9uZSBC YXlsb3IgUGxhemEsIE5BQiAyMDE1LCBIb3VzdG9uLCBUZXhhcyA3NzAzMCwgVVNBOyBzY2hldW5n QGJjbS50bWMuZWR1LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlY3VycmVudCByZWNp cHJvY2FsIDE2cDExLjIgcmVhcnJhbmdlbWVudHMgYXNzb2NpYXRlZCB3aXRoIGdsb2JhbCBkZXZl bG9wbWVudGFsIGRlbGF5LCBiZWhhdmlvdXJhbCBwcm9ibGVtcywgZHlzbW9ycGhpc20sIGVwaWxl cHN5LCBhbmQgYWJub3JtYWwgaGVhZCBzaXplPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogTWVk IEdlbmV0PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+ SiBNZWQgR2VuZXQ8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4zMzItNDE8L3BhZ2Vz Pjx2b2x1bWU+NDc8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+ QWJub3JtYWxpdGllcywgTXVsdGlwbGUvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkFkb2xl c2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QXR0ZW50aW9uIERlZmljaXQgRGlzb3JkZXIgd2l0aCBI eXBlcmFjdGl2aXR5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkF1dGlzdGljIERpc29yZGVy L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxk LCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdvcmQ+KkNocm9tb3NvbWUgQWJlcnJhdGlvbnM8L2tl eXdvcmQ+PGtleXdvcmQ+Q2hyb21vc29tZSBEZWxldGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJv bW9zb21lcywgSHVtYW4sIFBhaXIgMTYvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkNvbXBh cmF0aXZlIEdlbm9taWMgSHlicmlkaXphdGlvbjwva2V5d29yZD48a2V5d29yZD5DcmFuaW9mYWNp YWwgQWJub3JtYWxpdGllcy9nZW5ldGljcy9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RGV2 ZWxvcG1lbnRhbCBEaXNhYmlsaXRpZXMvKmdlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkVwaWxl cHN5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5I dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5mYW50PC9rZXl3b3JkPjxrZXl3b3JkPkludGVsbGVj dHVhbCBEaXNhYmlsaXR5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkxhbmd1YWdlIERldmVs b3BtZW50IERpc29yZGVycy9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3Jk PjxrZXl3b3JkPk1pY3JvY2VwaGFseS9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PbGlnb251 Y2xlb3RpZGUgQXJyYXkgU2VxdWVuY2UgQW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+UGhlbm90 eXBlPC9rZXl3b3JkPjxrZXl3b3JkPlNlZ21lbnRhbCBEdXBsaWNhdGlvbnMsIEdlbm9taWM8L2tl eXdvcmQ+PGtleXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll YXI+MjAxMDwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heTwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh dGVzPjxpc2JuPjE0NjgtNjI0NCAoRWxlY3Ryb25pYykmI3hEOzAwMjItMjU5MyAoTGlua2luZyk8 L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTk5MTQ5MDY8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0 ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMTk5MTQ5MDY8 L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DMzE1ODU2NjwvY3VzdG9tMj48 ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTEzNi9qbWcuMjAwOS4wNzMwMTU8L2VsZWN0cm9u aWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPldhbHRlcnM8L0F1 dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNOdW0+NDkxPC9SZWNOdW0+PHJlY29yZD48cmVjLW51 bWJlcj40OTE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0 OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTQ4MDAwMjk4 NyI+NDkxPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNs ZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5XYWx0ZXJzLCBS LiBHLjwvYXV0aG9yPjxhdXRob3I+SmFjcXVlbW9udCwgUy48L2F1dGhvcj48YXV0aG9yPlZhbHNl c2lhLCBBLjwvYXV0aG9yPjxhdXRob3I+ZGUgU21pdGgsIEEuIEouPC9hdXRob3I+PGF1dGhvcj5N YXJ0aW5ldCwgRC48L2F1dGhvcj48YXV0aG9yPkFuZGVyc3NvbiwgSi48L2F1dGhvcj48YXV0aG9y PkZhbGNoaSwgTS48L2F1dGhvcj48YXV0aG9yPkNoZW4sIEYuPC9hdXRob3I+PGF1dGhvcj5BbmRy aWV1eCwgSi48L2F1dGhvcj48YXV0aG9yPkxvYmJlbnMsIFMuPC9hdXRob3I+PGF1dGhvcj5EZWxv YmVsLCBCLjwvYXV0aG9yPjxhdXRob3I+U3R1dHptYW5uLCBGLjwvYXV0aG9yPjxhdXRob3I+RWwt U2F5ZWQgTW91c3RhZmEsIEouIFMuPC9hdXRob3I+PGF1dGhvcj5DaGV2cmUsIEouIEMuPC9hdXRo b3I+PGF1dGhvcj5MZWNvZXVyLCBDLjwvYXV0aG9yPjxhdXRob3I+VmF0aW4sIFYuPC9hdXRob3I+ PGF1dGhvcj5Cb3VxdWlsbG9uLCBTLjwvYXV0aG9yPjxhdXRob3I+QnV4dG9uLCBKLiBMLjwvYXV0 aG9yPjxhdXRob3I+Qm91dGUsIE8uPC9hdXRob3I+PGF1dGhvcj5Ib2xkZXItRXNwaW5hc3NlLCBN LjwvYXV0aG9yPjxhdXRob3I+Q3Vpc3NldCwgSi4gTS48L2F1dGhvcj48YXV0aG9yPkxlbWFpdHJl LCBNLiBQLjwvYXV0aG9yPjxhdXRob3I+QW1icmVzaW4sIEEuIEUuPC9hdXRob3I+PGF1dGhvcj5C cmlvc2NoaSwgQS48L2F1dGhvcj48YXV0aG9yPkdhaWxsYXJkLCBNLjwvYXV0aG9yPjxhdXRob3I+ R2l1c3RpLCBWLjwvYXV0aG9yPjxhdXRob3I+RmVsbG1hbm4sIEYuPC9hdXRob3I+PGF1dGhvcj5G ZXJyYXJpbmksIEEuPC9hdXRob3I+PGF1dGhvcj5IYWRqaWtoYW5pLCBOLjwvYXV0aG9yPjxhdXRo b3I+Q2FtcGlvbiwgRC48L2F1dGhvcj48YXV0aG9yPkd1aWxtYXRyZSwgQS48L2F1dGhvcj48YXV0 aG9yPkdvbGRlbmJlcmcsIEEuPC9hdXRob3I+PGF1dGhvcj5DYWxtZWxzLCBOLjwvYXV0aG9yPjxh dXRob3I+TWFuZGVsLCBKLiBMLjwvYXV0aG9yPjxhdXRob3I+TGUgQ2FpZ25lYywgQy48L2F1dGhv cj48YXV0aG9yPkRhdmlkLCBBLjwvYXV0aG9yPjxhdXRob3I+SXNpZG9yLCBCLjwvYXV0aG9yPjxh dXRob3I+Q29yZGllciwgTS4gUC48L2F1dGhvcj48YXV0aG9yPkR1cHVpcy1HaXJvZCwgUy48L2F1 dGhvcj48YXV0aG9yPkxhYmFsbWUsIEEuPC9hdXRob3I+PGF1dGhvcj5TYW5sYXZpbGxlLCBELjwv YXV0aG9yPjxhdXRob3I+QmVyaS1EZXhoZWltZXIsIE0uPC9hdXRob3I+PGF1dGhvcj5Kb252ZWF1 eCwgUC48L2F1dGhvcj48YXV0aG9yPkxlaGV1cCwgQi48L2F1dGhvcj48YXV0aG9yPk91bmFwLCBL LjwvYXV0aG9yPjxhdXRob3I+Qm9jaHVrb3ZhLCBFLiBHLjwvYXV0aG9yPjxhdXRob3I+SGVubmlu ZywgRS48L2F1dGhvcj48YXV0aG9yPktlb2doLCBKLjwvYXV0aG9yPjxhdXRob3I+RWxsaXMsIFIu IEouPC9hdXRob3I+PGF1dGhvcj5NYWNkZXJtb3QsIEsuIEQuPC9hdXRob3I+PGF1dGhvcj52YW4g SGFlbHN0LCBNLiBNLjwvYXV0aG9yPjxhdXRob3I+VmluY2VudC1EZWxvcm1lLCBDLjwvYXV0aG9y PjxhdXRob3I+UGxlc3NpcywgRy48L2F1dGhvcj48YXV0aG9yPlRvdXJhaW5lLCBSLjwvYXV0aG9y PjxhdXRob3I+UGhpbGlwcGUsIEEuPC9hdXRob3I+PGF1dGhvcj5NYWxhbiwgVi48L2F1dGhvcj48 YXV0aG9yPk1hdGhpZXUtRHJhbWFyZCwgTS48L2F1dGhvcj48YXV0aG9yPkNoaWVzYSwgSi48L2F1 dGhvcj48YXV0aG9yPkJsYXVtZWlzZXIsIEIuPC9hdXRob3I+PGF1dGhvcj5Lb295LCBSLiBGLjwv YXV0aG9yPjxhdXRob3I+Q2FpYXp6bywgUi48L2F1dGhvcj48YXV0aG9yPlBpZ2V5cmUsIE0uPC9h dXRob3I+PGF1dGhvcj5CYWxrYXUsIEIuPC9hdXRob3I+PGF1dGhvcj5TbGFkZWssIFIuPC9hdXRo b3I+PGF1dGhvcj5CZXJnbWFubiwgUy48L2F1dGhvcj48YXV0aG9yPk1vb3NlciwgVi48L2F1dGhv cj48YXV0aG9yPldhdGVyd29ydGgsIEQuPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0 aG9yPjxhdXRob3I+Vm9sbGVud2VpZGVyLCBQLjwvYXV0aG9yPjxhdXRob3I+V2FlYmVyLCBHLjwv YXV0aG9yPjxhdXRob3I+S3VyZywgQS48L2F1dGhvcj48YXV0aG9yPlBhbHRhLCBQLjwvYXV0aG9y PjxhdXRob3I+RXNrbywgVC48L2F1dGhvcj48YXV0aG9yPk1ldHNwYWx1LCBBLjwvYXV0aG9yPjxh dXRob3I+TmVsaXMsIE0uPC9hdXRob3I+PGF1dGhvcj5FbGxpb3R0LCBQLjwvYXV0aG9yPjxhdXRo b3I+SGFydGlrYWluZW4sIEEuIEwuPC9hdXRob3I+PGF1dGhvcj5NY0NhcnRoeSwgTS4gSS48L2F1 dGhvcj48YXV0aG9yPlBlbHRvbmVuLCBMLjwvYXV0aG9yPjxhdXRob3I+Q2FybHNzb24sIEwuPC9h dXRob3I+PGF1dGhvcj5KYWNvYnNvbiwgUC48L2F1dGhvcj48YXV0aG9yPlNqb3N0cm9tLCBMLjwv YXV0aG9yPjxhdXRob3I+SHVhbmcsIE4uPC9hdXRob3I+PGF1dGhvcj5IdXJsZXMsIE0uIEUuPC9h dXRob3I+PGF1dGhvcj5PJmFwb3M7UmFoaWxseSwgUy48L2F1dGhvcj48YXV0aG9yPkZhcm9vcWks IEkuIFMuPC9hdXRob3I+PGF1dGhvcj5NYW5uaWssIEsuPC9hdXRob3I+PGF1dGhvcj5KYXJ2ZWxp biwgTS4gUi48L2F1dGhvcj48YXV0aG9yPlBhdHRvdSwgRi48L2F1dGhvcj48YXV0aG9yPk1leXJl LCBELjwvYXV0aG9yPjxhdXRob3I+V2FsbGV5LCBBLiBKLjwvYXV0aG9yPjxhdXRob3I+Q29pbiwg TC4gSi48L2F1dGhvcj48YXV0aG9yPkJsYWtlbW9yZSwgQS4gSS48L2F1dGhvcj48YXV0aG9yPkZy b2d1ZWwsIFAuPC9hdXRob3I+PGF1dGhvcj5CZWNrbWFubiwgSi4gUy48L2F1dGhvcj48L2F1dGhv cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5TZWN0aW9uIG9mIEdlbm9taWMgTWVkaWNp bmUsIEltcGVyaWFsIENvbGxlZ2UgTG9uZG9uLCBMb25kb24gVzEyIDBOTiwgVUsuPC9hdXRoLWFk ZHJlc3M+PHRpdGxlcz48dGl0bGU+QSBuZXcgaGlnaGx5IHBlbmV0cmFudCBmb3JtIG9mIG9iZXNp dHkgZHVlIHRvIGRlbGV0aW9ucyBvbiBjaHJvbW9zb21lIDE2cDExLjI8L3RpdGxlPjxzZWNvbmRh cnktdGl0bGU+TmF0dXJlPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1 bGwtdGl0bGU+TmF0dXJlPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NjcxLTU8L3Bh Z2VzPjx2b2x1bWU+NDYzPC92b2x1bWU+PG51bWJlcj43MjgxPC9udW1iZXI+PGtleXdvcmRzPjxr ZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdv cmQ+QWdlIG9mIE9uc2V0PC9rZXl3b3JkPjxrZXl3b3JkPkFnaW5nPC9rZXl3b3JkPjxrZXl3b3Jk PkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5DYXNlLUNvbnRyb2wgU3R1ZGllczwv a2V5d29yZD48a2V5d29yZD5DaGlsZDwva2V5d29yZD48a2V5d29yZD4qQ2hyb21vc29tZSBEZWxl dGlvbjwva2V5d29yZD48a2V5d29yZD5DaHJvbW9zb21lcywgSHVtYW4sIFBhaXIgMTYvKmdlbmV0 aWNzPC9rZXl3b3JkPjxrZXl3b3JkPkNvZ25pdGlvbiBEaXNvcmRlcnMvY29tcGxpY2F0aW9ucy9n ZW5ldGljczwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGllczwva2V5d29yZD48a2V5d29y ZD5FdXJvcGU8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdlbm9t ZS1XaWRlIEFzc29jaWF0aW9uIFN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPkhldGVyb3p5Z290ZTwv a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5oZXJpdGFuY2UgUGF0 dGVybnMvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5N dXRhdGlvbi9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5PYmVzaXR5L2NvbXBsaWNhdGlvbnMv KmdlbmV0aWNzLypwaHlzaW9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KlBlbmV0cmFuY2U8 L2tleXdvcmQ+PGtleXdvcmQ+UmVwcm9kdWNpYmlsaXR5IG9mIFJlc3VsdHM8L2tleXdvcmQ+PGtl eXdvcmQ+U2V4IENoYXJhY3RlcmlzdGljczwva2V5d29yZD48a2V5d29yZD5Zb3VuZyBBZHVsdDwv a2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEwPC95ZWFyPjxwdWItZGF0ZXM+PGRh dGU+RmViIDQ8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDc2LTQ2ODcgKEVsZWN0 cm9uaWMpJiN4RDswMDI4LTA4MzYgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIwMTMw NjQ5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5u Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMDEzMDY0OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs cz48Y3VzdG9tMj5QTUMyODgwNDQ4PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4x MC4xMDM4L25hdHVyZTA4NzI3PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0Np dGU+PENpdGU+PEF1dGhvcj5adWZmZXJleTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051 bT40ODY8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ4NjwvcmVjLW51bWJlcj48Zm9yZWln bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJm NTAwZjlyZiIgdGltZXN0YW1wPSIxNDgwMDAyOTg3Ij40ODY8L2tleT48L2ZvcmVpZ24ta2V5cz48 cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9y cz48YXV0aG9ycz48YXV0aG9yPlp1ZmZlcmV5LCBGLjwvYXV0aG9yPjxhdXRob3I+U2hlcnIsIEUu IEguPC9hdXRob3I+PGF1dGhvcj5CZWNrbWFubiwgTi4gRC48L2F1dGhvcj48YXV0aG9yPkhhbnNv biwgRS48L2F1dGhvcj48YXV0aG9yPk1haWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+SGlw cG9seXRlLCBMLjwvYXV0aG9yPjxhdXRob3I+TWFjZSwgQS48L2F1dGhvcj48YXV0aG9yPkZlcnJh cmksIEMuPC9hdXRob3I+PGF1dGhvcj5LdXRhbGlrLCBaLjwvYXV0aG9yPjxhdXRob3I+QW5kcmll dXgsIEouPC9hdXRob3I+PGF1dGhvcj5BeWx3YXJkLCBFLjwvYXV0aG9yPjxhdXRob3I+QmFya2Vy LCBNLjwvYXV0aG9yPjxhdXRob3I+QmVybmllciwgUi48L2F1dGhvcj48YXV0aG9yPkJvdXF1aWxs b24sIFMuPC9hdXRob3I+PGF1dGhvcj5Db251cywgUC48L2F1dGhvcj48YXV0aG9yPkRlbG9iZWws IEIuPC9hdXRob3I+PGF1dGhvcj5GYXVjZXR0LCBXLiBBLjwvYXV0aG9yPjxhdXRob3I+R29pbi1L b2NoZWwsIFIuIFAuPC9hdXRob3I+PGF1dGhvcj5HcmFudCwgRS48L2F1dGhvcj48YXV0aG9yPkhh cmV3b29kLCBMLjwvYXV0aG9yPjxhdXRob3I+SHVudGVyLCBKLiBWLjwvYXV0aG9yPjxhdXRob3I+ TGVib24sIFMuPC9hdXRob3I+PGF1dGhvcj5MZWRiZXR0ZXIsIEQuIEguPC9hdXRob3I+PGF1dGhv cj5NYXJ0aW4sIEMuIEwuPC9hdXRob3I+PGF1dGhvcj5NYW5uaWssIEsuPC9hdXRob3I+PGF1dGhv cj5NYXJ0aW5ldCwgRC48L2F1dGhvcj48YXV0aG9yPk11a2hlcmplZSwgUC48L2F1dGhvcj48YXV0 aG9yPlJhbW9ja2ksIE0uIEIuPC9hdXRob3I+PGF1dGhvcj5TcGVuY2UsIFMuIEouPC9hdXRob3I+ PGF1dGhvcj5TdGVpbm1hbiwgSy4gSi48L2F1dGhvcj48YXV0aG9yPlRqZXJuYWdlbCwgSi48L2F1 dGhvcj48YXV0aG9yPlNwaXJvLCBKLiBFLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1 dGhvcj48YXV0aG9yPkJlY2ttYW5uLCBKLiBTLjwvYXV0aG9yPjxhdXRob3I+Q2h1bmcsIFcuIEsu PC9hdXRob3I+PGF1dGhvcj5KYWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+U2ltb25zLCBW LiBJLiBQLiBDb25zb3J0aXVtPC9hdXRob3I+PGF1dGhvcj5wMTEuMiBFdXJvcGVhbiwgQ29uc29y dGl1bTwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlNlcnZp Y2UgZGUgR2VuZXRpcXVlIE1lZGljYWxlLCBDZW50cmUgSG9zcGl0YWxpZXIgVW5pdmVyc2l0YWly ZSBWYXVkb2lzLCBMYXVzYW5uZSwgU3dpdHplcmxhbmQuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48 dGl0bGU+QSA2MDAga2IgZGVsZXRpb24gc3luZHJvbWUgYXQgMTZwMTEuMiBsZWFkcyB0byBlbmVy Z3kgaW1iYWxhbmNlIGFuZCBuZXVyb3BzeWNoaWF0cmljIGRpc29yZGVyczwvdGl0bGU+PHNlY29u ZGFyeS10aXRsZT5KIE1lZCBHZW5ldDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp Y2FsPjxmdWxsLXRpdGxlPkogTWVkIEdlbmV0PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFn ZXM+NjYwLTg8L3BhZ2VzPjx2b2x1bWU+NDk8L3ZvbHVtZT48bnVtYmVyPjEwPC9udW1iZXI+PGtl eXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdv cmQ+PGtleXdvcmQ+Qm9keSBNYXNzIEluZGV4PC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3 b3JkPjxrZXl3b3JkPkNoaWxkIERldmVsb3BtZW50IERpc29yZGVycywgUGVydmFzaXZlL2RpYWdu b3Npcy8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+KkNocm9tb3NvbWUgRGVsZXRpb248L2tl eXdvcmQ+PGtleXdvcmQ+KkNocm9tb3NvbWVzLCBIdW1hbiwgUGFpciAxNjwva2V5d29yZD48a2V5 d29yZD5EZXZlbG9wbWVudGFsIERpc2FiaWxpdGllcy9kaWFnbm9zaXMvKmdlbmV0aWNzPC9rZXl3 b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HZW5lIE9yZGVyPC9rZS== ADDIN EN.CITE.DATA eXdvcmQ+PGtleXdvcmQ+SGV0ZXJvenlnb3RlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5 d29yZD48a2V5d29yZD5JbnRlbGxpZ2VuY2UgVGVzdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwv a2V5d29yZD48a2V5d29yZD4qUGhlbm90eXBlPC9rZXl3b3JkPjxrZXl3b3JkPlN5bmRyb21lPC9r ZXl3b3JkPjxrZXl3b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5 ZWFyPjIwMTI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9k YXRlcz48aXNibj4xNDY4LTYyNDQgKEVsZWN0cm9uaWMpJiN4RDswMDIyLTI1OTMgKExpbmtpbmcp PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzMDU0MjQ4PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh dGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMzA1NDI0 ODwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUMzNDk0MDExPC9jdXN0b20y PjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTM2L2ptZWRnZW5ldC0yMDEyLTEwMTIwMzwv ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5= ADDIN EN.CITE.DATA [13, 15-19] . Among the 11 individuals identified in the E st BB pilot dataset as carriers of the 16p11.2 CNV , no one were previously diagnosed with genetic disease . E ight out of 11 carriers (72.7%) consented for disclosure of incidental genetic finding . All eight participants were further evaluated, counsell ed regarding their carrier status and surveyed 11–17 months later. Six out of eight 16p11.2 CNV carriers (87.5%) suffer ed from major clinical problems pr esumably linked to the found genetic alteration and were provided personalized suggestions for their health management . Although the sample size was small for firm conclusions, all participants in the pilot study demonstrated preference for disclosure and rated received information favourably (evaluated one year after receiving the information) . Notably, most respondents wished they would have learned earlier about the genetic finding , one participant reported modifications in treatment and three felt that their treatment had since improved PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE.DATA [20] . REASON FOR RESEARCH PLANNED Pioneering nation-wide initiatives of genome-based medicine have reached clinical practice in a limited number of European countries, such as Finland, Estonia and Switzerland , with the field just burgeoning. These initiatives have so far been focusing on individual risk predictions for familial cancers, rare monogenic (e.g. familial hypercholesterolemia) and common diseases (e.g. type 2 diabetes) . The complex nature of interrelated and co-occurring clinical conditions and delicate subject of neurodevelopmental genetics have so far hampered application of precision medicine to citizens who have incidentally identified as at high genetic risk for NDDs . The proposed project focuses on subgroup of NDDs – the individuals who are affected by ND- CNVs in the human genome . There are estimated 4.6 million carriers of ND- CNVs in the European Union. Due to non-specific combinations of developmental and common traits, not all ND- CNV carriers are currently routinely detected by medical personnel, especially at adulthood. Those who have remained undiagnosed until adulthood often live autonomously but belong to a vulnerable fraction of the society. R ecent array- and sequencing-based variant screening s in large-scale biobanks have confirmed that citizens at high genetic risk for NDDs will undoubtedly be uncovered in population initi atives of precision medicine ADDIN EN.CITE <EndNote><Cite><Author>Kostick</Author><Year>2020</Year><RecNum>931</RecNum><DisplayText>[21]</DisplayText><record><rec-number>931</rec-number><foreign-keys><key app="EN" db-id="t90dxwwvnpsrrtexe9opzw9vw9r2f500f9rf" timestamp="1582744059">931</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kostick, K.</author><author>Pereira, S.</author><author>Brannan, C.</author><author>Torgerson, L.</author><author>Lazaro-Munoz, G.</author></authors></contributors><auth-address>Center for Medical Ethics &amp; Health Policy, Baylor College of Medicine, Houston, TX, USA.&#xD;Center for Medical Ethics &amp; Health Policy, Baylor College of Medicine, Houston, TX, USA.
[email protected].</auth-address><titles><title>Psychiatric genomics researchers&apos; perspectives on best practices for returning results to individual participants</title><secondary-title>Genet Med</secondary-title></titles><periodical><full-title>Genet Med</full-title></periodical><pages>345-352</pages><volume>22</volume><number>2</number><keywords><keyword>Elsi</keyword><keyword>ethics</keyword><keyword>genetic</keyword><keyword>neuroethics</keyword><keyword>qualitative</keyword></keywords><dates><year>2020</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1530-0366 (Electronic)&#xD;1098-3600 (Linking)</isbn><accession-num>31477844</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/31477844</url></related-urls></urls><custom2>PMC7000323</custom2><electronic-resource-num>10.1038/s41436-019-0642-7</electronic-resource-num></record></Cite></EndNote> [21] . There is currently no standard in reporting incidental genetic findings with strong complex effect to biobank volunteer participants. Moreover, t he current reference model in genom ic medicine ( e.g. common risk scores, automated decision support systems and active engagement of people in their health management) is hardly applicable to citizens who are not fully capable of proactive actions and self-management. In order to equalize their access to the benefits of genome-based medicine, these individuals need an approach that is tailored to their skills and resources. To avoid exclusion of a significant sub-population of individuals and diminish inequality in risk areas where vulnerability may be increased by current practices in precision medicine , t he research community must come up with a precise plan how to meet these needs and deal with incidental NDD findings . In parallel, t he international recommendations to address needs of undiagnosed rare disease patients urge all stakeholders to recognise undiagnosed patients as a distinct population with unmet need s and stress the demand for national sustainable programmes to enable rapid and equitable access to diagnosis enabling personalized health and social support for undiagnosed patients. T he document distinguishes a group of ‘ not yet diagnosed’ refer ring to the individuals living with an undiagnosed condition who ha ve not been referred to the appropriate clinician due to common, misleading or unusual clinical presentation of a known rare condition . T h e recommendations to ameliorate the outcomes for the ‘not yet diagnosed’ group call for enabling better accessibility to extensive genomic data and paving the way for improved quality of diagnostic tools ( UDNI.pdf ) . The goals of the proposed project align directly with t hese needs by addressing the following aspects : To exploit previously generated genotype data in the E st BB cohort to systematic ally identif y undiagnosed carriers of clinically significant CNVs . To apply genotype- driven deep-phenotyping to gather a comprehensive collection of ND- CNV-associated developmental and health information in a clinically unbiased adult cohort . To use th e collected resource for investigat ing h ow these variants affect health in the general population and h ow the disease traits evolve during ND- CNV carriers' life-course . To disclose the incidentally identified genetic finding to the consenting ND- CNV carriers and to provide them counse l ling tailored to the ir individual needs and presented health conditions . To utilize the ND-CNV carriers as representatives for collect ing data on at-risk individuals ’ expectations , experience and the impact of adult-age genetic finding on their health and social support. T o carefully evaluate how to deliver incidental genetic findings to previously undiagnosed biobank participants in a manner that produces maximal benefits and fully respects the ir rights for autonomy, dignity and other critical socio-ethical aspects . T o set up a model framework for the identification and assistance of citizens at high genetic risk for complex disorders in the population-based initiatives of genomic medicine. TIME OF CONDUCTING THE STUDY Start of the project: April 2020 End of the project: March 2025 STUDY GROUP AND DESCRIPTION OF RECRUITMENT 7.1. Selection and number of research participants To identify undiagnosed carriers of ND- CNVs in the Estonian population biobank, w e will screen the E st BB cohort of > 2 0 0,000 individuals for CNVs with confirmed high clinical relevance . Th e total number of individuals who carry a ND- CNV is expected to be a pproximately 1,8 00. We will re-contact up to 400 individuals re-grouped by their ND-CNV carrier status (see Section 8.1 for details) . The re-contact group needs to meet the following inclusion criteria: The high clinical value of the presented CNV is confirmed , accepted and well characterized by the medical genetic s community (see Section 8.1. for details) The CNV is recurrently present in the population ( for analytical power; ≥5 carriers in the E st BB cohort) The CNV carrier is a living permanent resident of Estonia The CNV carrier status of an individual is experimentally validated before sending the invitation letter (See Section 8.2 for details). The re-contacted CNV carrier will become a research participant after respond ing positively to the invitation letter and consent ing for participating in the project . 7. 2 . Request of de-pseudonymization We request the ECBHR approval to de-pseudonymi ze the personal data of up to 400 EstBB participants. The de-pseudonymization process is required to obtain the contact details necessary for re-contacting the EstBB participants. T he data transferred to the EstBB database from the Estonian Population Register will be used for collecting the confirmed personal postal address, e-mail address and pho ne number of potential study participant s. Registry access to retrieve and update data for participants who has not prohibited the supplementation, renewal or verification of the description of their state of health, will be performed under the auspice of the Estonian Human Genes Research Act (HGRA) §24 (2) clause 3. Re-contact with the EstBB participants will be executed under the auspice of t he HGRA §24 (2) clause 4, that allows de-pseudonymization on the proposal of the chief processor of the EstBB , the Institute of Genomics at the University of Tartu, and with the consent of the Ethics Committee in order to identify and contact a biobank participant for updating , supplementing or verifying a description of their state of health with their written consent. 7. 3 . Description of recruitment All participants have volunt a r i ly joined the biobank and signed the broad consent form ( HYPERLINK "https://www.riigiteataja.ee/akt/117042019016" EstBB_Consent ) , allowing E st BB to follow up their data (if not stated otherwise in the consent ). Upon approval by the ECBHR, selected CNV carriers ( potential study participants ) will be invited by a personally addressed letter (Appendix 1 ) and will be offered to receive genetic counselling and personal report of the genetic results . T he research title in the letter is simplified (in Estonian “ Inimese pärilikkusmaterjali omapärade seos erinevate terviseriskidega ” ). This is important regarding neutrality and not revealing exact details about the research to the gene donors before formal informing procedure . Invitation letter will be marked by the potential participant’s name and with the note “ P ersonal”. According to the Estonian Postal Act §33 ( 1 ) the p ostal secrecy means confidentiality of all information pertaining to the contents of a postal item and concerning the postal traffic of a specific person. The obligation to maintain postal secrecy by all postal service providers during and after the provision of the postal service is stated by the §33 (2) of the Act , prohibition of collecting information concerning the content of postal items or specific circumstances of postal traffic for purposes other than the provision of postal services by the §33 (3). The invitation package contain s an invitation letter addressed to the potential study participant , a response card and a pre -paid envelope to send their response to the E st BB (Appendix 1 ). The potential participants will be informed about T he ir right to decide whether to take or not to take part of the study, and the possibility to inform the research team about their decision by using the enclosed contact details Th eir right to decline t he participat ion without any negative consequences and any further attempt to contact them by filling and returning the pre-paid re sponse card to the E st BB Th e possibility that if they do not respond during 10 days after the date the invitation letter is expected to arrive , a recruitment specialist will follow-up with a participant by phone to clarify their willingness to participate. No response to t he phone calls during three weeks will be recorded as refusal to participate . For the individuals who demonstrated their interest to participate, a recruitment specialist will , by phone or e-mail, schedule a suitable date for the first visit. During the first visit a trained specialist in genomic medicine or a genetic counsellor will provide comprehensive information about the project that allows the potential study participant to decide whether or not to give their consent. E ach participant who chooses to join the study will read the information sheet and confirms their decision by signing an informed consent form (Appendix 2 ). The investigators ensure that a ll recruitment procedures are conducted under the E st BB data collection instructions and by following international standards and guidelines for good clinical practice. DESCRIPTION OF RESEARCH METHOLOGY 8.1 . Selection of ND-CNVs and the ‘genotype-first’ approach The selection of ND-CNVs is based on the expert-reviewed clinical syndromes listed in the DECIPHER database ( HYPERLINK "https://decipher.sanger.ac.uk/disorders" \l "syndromes/overview" DECIPHER_Syndromes ) and is in compliance with the standard for the interpretation and reporting of CNVs in routine diagnostics (published by the American College of Human Genetics and Genomics, November 6 th , 2019; ACMG_TechnicalStandard_2019 ). In the first stage of the study, w e will use the ‘ genotype-first ’ approach to fetch a comprehensive set of health data from the E st BB database and linked electronic registries ( E-health, Estonian Health Insurance Fund , Estonian Causes of Death Register ), and to map each ND-CNV with their co-occurring disease traits . The ‘ genotype-first ’ strategy uses genetic testing prior to phenotype evaluation and systematically re-groups patients by their shared genetic etiology . This method i s oppos ite to the traditional ‘ phenotype-first ’ where the selection of cases and controls is guided by the presence of a disease trait . T he ‘ genotype-first ’ strategy has advantages in studying complex conditions and a strong potential to advance precision health care . It reduces the costs on exhaustive phenotyping, increases analytical power to detect valid biomarkers and probability to identify shared biological mechanisms in genetically homogeneous groups of individuals PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Bcm5ldHQ8L0F1dGhvcj48WWVhcj4yMDE5PC9ZZWFyPjxS ZWNOdW0+OTMzPC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyMiwgMjNdPC9EaXNwbGF5VGV4dD48cmVj b3JkPjxyZWMtbnVtYmVyPjkzMzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF TiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1w PSIxNTgyNzQ0Mjg5Ij45MzM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91 cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y PkFybmV0dCwgQS4gQi48L2F1dGhvcj48YXV0aG9yPlRyaW5oLCBTLjwvYXV0aG9yPjxhdXRob3I+ QmVybmllciwgUi4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5Vbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIERlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSAm YW1wOyBCZWhhdmlvcmFsIFNjaWVuY2VzLCBDZW50ZXIgb24gSHVtYW4gRGV2ZWxvcG1lbnQgYW5k IERpc2FiaWxpdHksIEJveCAzNTc5MjAsIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0EuJiN4RDtVbml2 ZXJzaXR5IG9mIFdhc2hpbmd0b24sIERlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSAmYW1wOyBCZWhh dmlvcmFsIFNjaWVuY2VzLCBDZW50ZXIgb24gSHVtYW4gRGV2ZWxvcG1lbnQgYW5kIERpc2FiaWxp dHksIEJveCAzNTc5MjAsIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0EuIEVsZWN0cm9uaWMgYWRkcmVz czogUmFiMkB1dy5lZHUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+VGhlIHN0YXRlIG9m IHJlc2VhcmNoIG9uIHRoZSBnZW5ldGljcyBvZiBhdXRpc20gc3BlY3RydW0gZGlzb3JkZXI6IG1l dGhvZG9sb2dpY2FsLCBjbGluaWNhbCBhbmQgY29uY2VwdHVhbCBwcm9ncmVzczwvdGl0bGU+PHNl Y29uZGFyeS10aXRsZT5DdXJyIE9waW4gUHN5Y2hvbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVz PjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkN1cnIgT3BpbiBQc3ljaG9sPC9mdWxsLXRpdGxlPjwv cGVyaW9kaWNhbD48cGFnZXM+MS01PC9wYWdlcz48dm9sdW1lPjI3PC92b2x1bWU+PGRhdGVzPjx5 ZWFyPjIwMTk8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9k YXRlcz48aXNibj4yMzUyLTI1MTggKEVsZWN0cm9uaWMpJiN4RDsyMzUyLTI1MFggKExpbmtpbmcp PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMDU5ODcxPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh dGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8zMDA1OTg3 MTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAu MTAxNi9qLmNvcHN5Yy4yMDE4LjA3LjAwNDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+U3Rlc3NtYW48L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFy PjxSZWNOdW0+OTMyPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj45MzI8L3JlYy1udW1iZXI+ PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3 OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTU4Mjc0NDI0NSI+OTMyPC9rZXk+PC9mb3JlaWdu LWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250 cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TdGVzc21hbiwgSC4gQS48L2F1dGhvcj48YXV0aG9y PkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1dGhvcj5FaWNobGVyLCBFLiBFLjwvYXV0aG9yPjwvYXV0 aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgR2Vub21lIFNj aWVuY2VzLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0Eu JiN4RDtEZXBhcnRtZW50IG9mIFBzeWNoaWF0cnkgYW5kIEJlaGF2aW9yYWwgU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZSwgV0EgOTgxOTUsIFVTQS4mI3hEO0RlcGFy dG1lbnQgb2YgR2Vub21lIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0 bGUsIFdBIDk4MTk1LCBVU0E7IEhvd2FyZCBIdWdoZXMgTWVkaWNhbCBJbnN0aXR1dGUsIFVuaXZl cnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZSwgV0EgOTgxOTUsIFVTQS4gRWxlY3Ryb25pYyBh ZGRyZXNzOiBlZWVAZ3Mud2FzaGluZ3Rvbi5lZHUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0 bGU+QSBnZW5vdHlwZS1maXJzdCBhcHByb2FjaCB0byBkZWZpbmluZyB0aGUgc3VidHlwZXMgb2Yg YSBjb21wbGV4IGRpc2Vhc2U8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Q2VsbDwvc2Vjb25kYXJ5 LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNlbGw8L2Z1bGwtdGl0bGU+ PC9wZXJpb2RpY2FsPjxwYWdlcz44NzItNzwvcGFnZXM+PHZvbHVtZT4xNTY8L3ZvbHVtZT48bnVt YmVyPjU8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QXV0aXN0aWMgRGlzb3JkZXIvY2xhc3Np ZmljYXRpb24vZGlhZ25vc2lzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5Db21tdW5pdHkg TmV0d29ya3M8L2tleXdvcmQ+PGtleXdvcmQ+RXhvbWU8L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmV0 aWMgSGV0ZXJvZ2VuZWl0eTwva2V5d29yZD48a2V5d29yZD4qR2Vub3R5cGU8L2tleXdvcmQ+PGtl eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk11dGF0aW9uPC9rZXl3b3JkPjxrZXl3b3Jk PlBoZW5vdHlwZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxw dWItZGF0ZXM+PGRhdGU+RmViIDI3PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTA5 Ny00MTcyIChFbGVjdHJvbmljKSYjeEQ7MDA5Mi04Njc0IChMaW5raW5nKTwvaXNibj48YWNjZXNz aW9uLW51bT4yNDU4MTQ4ODwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+ aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjQ1ODE0ODg8L3VybD48L3JlbGF0 ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNDA3NjE2NjwvY3VzdG9tMj48ZWxlY3Ryb25pYy1y ZXNvdXJjZS1udW0+MTAuMTAxNi9qLmNlbGwuMjAxNC4wMi4wMDI8L2VsZWN0cm9uaWMtcmVzb3Vy Y2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Bcm5ldHQ8L0F1dGhvcj48WWVhcj4yMDE5PC9ZZWFyPjxS ZWNOdW0+OTMzPC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyMiwgMjNdPC9EaXNwbGF5VGV4dD48cmVj b3JkPjxyZWMtbnVtYmVyPjkzMzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF TiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1w PSIxNTgyNzQ0Mjg5Ij45MzM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91 cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y PkFybmV0dCwgQS4gQi48L2F1dGhvcj48YXV0aG9yPlRyaW5oLCBTLjwvYXV0aG9yPjxhdXRob3I+ QmVybmllciwgUi4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRk cmVzcz5Vbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIERlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSAm YW1wOyBCZWhhdmlvcmFsIFNjaWVuY2VzLCBDZW50ZXIgb24gSHVtYW4gRGV2ZWxvcG1lbnQgYW5k IERpc2FiaWxpdHksIEJveCAzNTc5MjAsIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0EuJiN4RDtVbml2 ZXJzaXR5IG9mIFdhc2hpbmd0b24sIERlcGFydG1lbnQgb2YgUHN5Y2hpYXRyeSAmYW1wOyBCZWhh dmlvcmFsIFNjaWVuY2VzLCBDZW50ZXIgb24gSHVtYW4gRGV2ZWxvcG1lbnQgYW5kIERpc2FiaWxp dHksIEJveCAzNTc5MjAsIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0EuIEVsZWN0cm9uaWMgYWRkcmVz czogUmFiMkB1dy5lZHUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+VGhlIHN0YXRlIG9m IHJlc2VhcmNoIG9uIHRoZSBnZW5ldGljcyBvZiBhdXRpc20gc3BlY3RydW0gZGlzb3JkZXI6IG1l dGhvZG9sb2dpY2FsLCBjbGluaWNhbCBhbmQgY29uY2VwdHVhbCBwcm9ncmVzczwvdGl0bGU+PHNl Y29uZGFyeS10aXRsZT5DdXJyIE9waW4gUHN5Y2hvbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVz PjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkN1cnIgT3BpbiBQc3ljaG9sPC9mdWxsLXRpdGxlPjwv cGVyaW9kaWNhbD48cGFnZXM+MS01PC9wYWdlcz48dm9sdW1lPjI3PC92b2x1bWU+PGRhdGVzPjx5 ZWFyPjIwMTk8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9k YXRlcz48aXNibj4yMzUyLTI1MTggKEVsZWN0cm9uaWMpJiN4RDsyMzUyLTI1MFggKExpbmtpbmcp PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMDU5ODcxPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh dGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8zMDA1OTg3 MTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAu MTAxNi9qLmNvcHN5Yy4yMDE4LjA3LjAwNDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNv cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+U3Rlc3NtYW48L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFy PjxSZWNOdW0+OTMyPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj45MzI8L3JlYy1udW1iZXI+ PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3 OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0iMTU4Mjc0NDI0NSI+OTMyPC9rZXk+PC9mb3JlaWdu LWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250 cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TdGVzc21hbiwgSC4gQS48L2F1dGhvcj48YXV0aG9y PkJlcm5pZXIsIFIuPC9hdXRob3I+PGF1dGhvcj5FaWNobGVyLCBFLiBFLjwvYXV0aG9yPjwvYXV0 aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgR2Vub21lIFNj aWVuY2VzLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0bGUsIFdBIDk4MTk1LCBVU0Eu JiN4RDtEZXBhcnRtZW50IG9mIFBzeWNoaWF0cnkgYW5kIEJlaGF2aW9yYWwgU2NpZW5jZXMsIFVu aXZlcnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZSwgV0EgOTgxOTUsIFVTQS4mI3hEO0RlcGFy dG1lbnQgb2YgR2Vub21lIFNjaWVuY2VzLCBVbml2ZXJzaXR5IG9mIFdhc2hpbmd0b24sIFNlYXR0 bGUsIFdBIDk4MTk1LCBVU0E7IEhvd2FyZCBIdWdoZXMgTWVkaWNhbCBJbnN0aXR1dGUsIFVuaXZl cnNpdHkgb2YgV2FzaGluZ3RvbiwgU2VhdHRsZSwgV0EgOTgxOTUsIFVTQS4gRWxlY3Ryb25pYyBh ZGRyZXNzOiBlZWVAZ3Mud2FzaGluZ3Rvbi5lZHUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0 bGU+QSBnZW5vdHlwZS1maXJzdCBhcHByb2FjaCB0byBkZWZpbmluZyB0aGUgc3VidHlwZXMgb2Yg YSBjb21wbGV4IGRpc2Vhc2U8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+Q2VsbDwvc2Vjb25kYXJ5 LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNlbGw8L2Z1bGwtdGl0bGU+ PC9wZXJpb2RpY2FsPjxwYWdlcz44NzItNzwvcGFnZXM+PHZvbHVtZT4xNTY8L3ZvbHVtZT48bnVt YmVyPjU8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QXV0aXN0aWMgRGlzb3JkZXIvY2xhc3Np ZmljYXRpb24vZGlhZ25vc2lzLypnZW5ldGljczwva2V5d29yZD48a2V5d29yZD5Db21tdW5pdHkg TmV0d29ya3M8L2tleXdvcmQ+PGtleXdvcmQ+RXhvbWU8L2tleXdvcmQ+PGtleXdvcmQ+KkdlbmV0 aWMgSGV0ZXJvZ2VuZWl0eTwva2V5d29yZD48a2V5d29yZD4qR2Vub3R5cGU8L2tleXdvcmQ+PGtl eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk11dGF0aW9uPC9rZXl3b3JkPjxrZXl3b3Jk PlBoZW5vdHlwZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxw dWItZGF0ZXM+PGRhdGU+RmViIDI3PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTA5 Ny00MTcyIChFbGVjdHJvbmljKSYjeEQ7MDA5Mi04Njc0IChMaW5raW5nKTwvaXNibj48YWNjZXNz aW9uLW51bT4yNDU4MTQ4ODwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+ aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjQ1ODE0ODg8L3VybD48L3JlbGF0 ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNDA3NjE2NjwvY3VzdG9tMj48ZWxlY3Ryb25pYy1y ZXNvdXJjZS1udW0+MTAuMTAxNi9qLmNlbGwuMjAxNC4wMi4wMDI8L2VsZWN0cm9uaWMtcmVzb3Vy Y2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE.DATA [22, 23] . In the second stage of the study , w e will select a representative set of 10 ND- CNV s as a paradigm for further evaluation of health consequences in adult CNV carriers, genetic data return and analysis of at-risk individuals ’ experience and the impact of disclosed genetic finding on their health support. 8.2. Validation of ND-CNV carrier status and de-pseudonymi z ation of participant data Before disclosing the incidentally identified genetic finding to the participant during the second visit, the clinically relevant ND-CNV will be validated twice according to the previously published protocol PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE.DATA [20] : First ly , prior to de-pseudonymi zation of personal data , by using the DNA sample stored in the E st BB and the Illumina high-resolution SNP genotyping platform, for example the Illumina Infinium Human OmniExpress assay that allows seamless and confident detection of all selected ND-CNVs Secondly , after the first visit and consent for disclosure of genetic finding, by using the DNA extracted from the blood sample taken on the first visit and real-time quantitative polymerase chain reaction (real-time quantitative PCR) targeted to the specific CNV locus The first confirmation will be followed by de-pseudonymi zat ion of validated CNV carriers’ data , obtain of contact information and invitation to participate in the study according to the E st BB procedur al guidelines (see Section 7 for recruitment description) . 8.3. First appointment , consent and data collection The estimated duration of the first appointment is 3- 5 hours . T he visit take s place in the EstBB recruitment office in Tartu. During the appointmen t , a genetic counsellor or a trained specialist in genomic medicine give s additional information about the study and obtains the informed consent. The participant will be informed about the possibility to receive personali z ed feedback based on their individual genetic and health risks. At this stage no details about any potential genetic risk s will be disclosed to the participant. The p articipant will be notified that during the first visit: A dditional data about participants health and development will be collected by using ad hoc interviews for health and developmental aspects (Appendix 3 ) and validated published tests for social and adaptive behaviour (ASEBA Adult Self-Report; Adaptive Behavior Assessment System™, 2 nd Edition , Adult Form) B lood sample (up to 4 0 ml venous blood) will be drawn by a certified medical nurse Their o bjective measures (height, weight, head circumference , waist and hip circumference, blood pressure, heart rate, grip strength ) will be re corded Their family pedigree will be recorded Their photograph s (three facial photos of different head orientation) will be taken for digitalization and group-based analyses To ensure participant’s anonymity, all collected samples , data and documents will be pseudonymized by using unique project code s before any research usage (see Section 10.1 for details about the data release) . The pseudonymized blood samples will be transported by a recruitment assistant to the Institute of Genomics Core Facility and the United Laboratories of Tartu University Hospital . A fraction of the blood sample will be used in the Institute of Genomics Core Facility to confirm the individual based on common genetic markers and to validate potential clinically relevant genetic findings. Another fraction of the blood sample will be sent to the United Laboratories of Tartu University Hospital for hematological ( according to the selected services listed at TYK_Hematology ) and clinical biochemistry analyses ( according to the selected services listed at TY K _Biochemistry ). Both facilities operate according to their best practices. The photos will be taken with the professional camera of the EstBB and stored digital ly in the EstBB secure coding center (see Section 10.2 for details). All files in the memory card of the camera will be permanently deleted at the end of each visit day. The photos will be used only in large groups for computational analys e s to identify combinations of subtle facial changes that might be indicators of a specific genetic variant . Individual photos will not be used or published in any research work to ensure the anonymity of the participant. After completion of the procedures of the first visit , the research team will perform the second validation of the ND-CNV. If confirmed, t his will be followed by prepar ation of a personalized feedback report and scheduling of t he second appointment for disclosing genetic risk information and genetic counselling . 8. 4 . Second appointment, return of genetic risk information and counselling Only participants who consented for receiv ing genetic information and provided a blood sample for ND- CNV validation will be invited to the second visit. The estimated duration of the second appointment is 2-3 hours. The visit takes place in the EstBB recruitment office in Tartu. The procedures d uring the visit are following: A medical specialist will return to the participant their results of hematological and clinical blood biochemistry analyses tested by the United Laboratories of Tartu University Hospital A certified clinical geneticist will introduce a detailed written summary report based on the participant’s personal genetic variation The c ounselling of incidentally identified ND-CNV is customized according to the collected information about each participant’s existing health conditions. The participant will receive recommendations for health and social management tailored to their genetic finding, individual needs and presented health conditions. The procedure follows previously published protocol PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwXTwvRGlzcGxheVRleHQ+PHJlY29y ZD48cmVjLW51bWJlcj45MTk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i IGRiLWlkPSJ0OTBkeHd3dm5wc3JydGV4ZTlvcHp3OXZ3OXIyZjUwMGY5cmYiIHRpbWVzdGFtcD0i MTU3MDQ0MzA1OSI+OTE5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5M ZWl0c2FsdSwgTC48L2F1dGhvcj48YXV0aG9yPkFsYXZlcmUsIEguPC9hdXRob3I+PGF1dGhvcj5K YWNxdWVtb250LCBTLjwvYXV0aG9yPjxhdXRob3I+S29saywgQS48L2F1dGhvcj48YXV0aG9yPk1h aWxsYXJkLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmVpZ28sIEEuPC9hdXRob3I+PGF1dGhvcj5O b3VrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5SZXltb25kLCBBLjwvYXV0aG9yPjxhdXRob3I+TWFu bmlrLCBLLjwvYXV0aG9yPjxhdXRob3I+TmcsIFAuIEMuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFs dSwgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Fc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBVbml2ZXJzaXR5IG9mIFRhcnR1IChFR0NVVCksIFRhcnR1LCA1 MTAxMCwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNb2xlY3VsYXIgJmFtcDsgQ2VsbCBCaW9s b2d5LCBVbml2ZXJzaXR5IG9mIFRhcnR1LCBUYXJ0dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtTZXJ2 aWNlIG9mIE1lZGljYWwgR2VuZXRpY3MsIExhdXNhbm5lIFVuaXZlcnNpdHkgSG9zcGl0YWwsIExh dXNhbm5lLCAxMDExLCBTd2l0emVybGFuZC4mI3hEO0RlcGFydG1lbnQgb2YgTmV1cm9sb2d5LCBD aGlsZHJlbiZhcG9zO3MgQ2xpbmljIG9mIFRhcnR1IFVuaXZlcnNpdHkgSG9zcGl0YWwsIFRhcnR1 LCA1MDQwNiwgRXN0b25pYS4mI3hEO0NlbnRlciBmb3IgSW50ZWdyYXRpdmUgR2Vub21pY3MsIFVu aXZlcnNpdHkgb2YgTGF1c2FubmUsIExhdXNhbm5lLCAxMDE1LCBTd2l0emVybGFuZC4mI3hEO0dl bm9tZSBJbnN0aXR1dGUgb2YgU2luZ2Fwb3JlLCBTaW5nYXBvcmUsIDEzODY3MiwgU2luZ2Fwb3Jl LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlJlcG9ydGluZyBpbmNpZGVudGFsIGZpbmRp bmdzIG9mIGdlbm9taWMgZGlzb3JkZXItYXNzb2NpYXRlZCBjb3B5IG51bWJlciB2YXJpYW50cyB0 byB1bnNlbGVjdGVkIGJpb2JhbmsgcGFydGljaXBhbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl PlBlciBNZWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs ZT5QZXIgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzAzLTMxNDwvcGFnZXM+ PHZvbHVtZT4xMzwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD4x NnAxMS4yIENOVjwva2V5d29yZD48a2V5d29yZD5nZW5vbWljIGRpc29yZGVyczwva2V5d29yZD48 a2V5d29yZD5pbmNpZGVudGFsIGZpbmRpbmdzPC9rZXl3b3JkPjxrZXl3b3JkPnBvcHVsYXRpb24g YmlvYmFuazwva2V5d29yZD48a2V5d29yZD5yZXR1cm4gb2YgcmVzdWx0czwva2V5d29yZD48L2tl eXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRl PjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTc0MS0wNTQxIChQcmludCkmI3hEOzE3NDEtMDU0 MSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjk3NDk4MTM8L2FjY2Vzc2lvbi1udW0+ PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVi bWVkLzI5NzQ5ODEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291 cmNlLW51bT4xMC4yMjE3L3BtZS0yMDE2LTAwMDk8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+ ADDIN EN.CITE.DATA [20] . Unless diagnosed for the participant or specifically asked, the participant will not be counselled about specific disease risks that based on peer-reviewed literature are significantly associated with a given ND-CNV but have demonstrated variable expressivity and incomplete penetrance (i.e. a fraction of CNV carriers have the disease and severity of its outcome varies broadly between individuals ) or are medically not actionable in terms of prevention, therapy or modifications in lifestyle. This holds particularly true for developmental disorders and mental conditions not diagnosed for the participant . I n addition to the personal report and recommendations, each consenting participant will receive an information sheet about the relevant ND-CNV written in non-technical Estonian language (see Appendix 4 for an example sheet for the 16p11.2 deletion). In the end of the visit, a time slot is dedicated for reflection and participant’s questions to the clinical geneticist. Considering the positive feedback from the EstBB gene donors who participated in the project “Feedback to the gene donors” (in Estonian: “ Tagasiside geenidoonorile ” ; approval of the Research Ethics Committee of the University of Tartu, protocol 271/T-22, valid through 1.06.2022) , the interested participants will be given a possibility to opt-in for additional genetic feedback in the frames of the EstBB current projects approved by the Ethics Committee (see Section 11 for details about the projects). As this information may have an added value on the estimation of participant’s health risks, the investigators want to respect the partici p ants’ right to know and not to exclude this possibility. The participants who choose for this option, will be asked to sign an informed consent for the respective project and will be handled according to the respective protocol . 8.5. Evaluation of the impact of genetic information Searching for gene variants reliably associated with risks for different health conditions continues to receive considerable attention by the personalized health community . To date, the research has been less focused on the evaluat ion of how disclosure of genetic risk information impacts the psycho-social outcome , e.g. how the participants understand and cop e with the information. One of the goals of the proposed project is to gather information on the psycho-social impact of return of personali z ed genetic results to the population carriers of ND-CNVs . To that end , we will use two questionnaires previously designed to evaluate participants’ experience in the EstBB feedback projects PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwLCAyNF08L0Rpc3BsYXlUZXh0Pjxy ZWNvcmQ+PHJlYy1udW1iZXI+OTE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9 IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3Rh bXA9IjE1NzA0NDMwNTkiPjkxOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo b3I+TGVpdHNhbHUsIEwuPC9hdXRob3I+PGF1dGhvcj5BbGF2ZXJlLCBILjwvYXV0aG9yPjxhdXRo b3I+SmFjcXVlbW9udCwgUy48L2F1dGhvcj48YXV0aG9yPktvbGssIEEuPC9hdXRob3I+PGF1dGhv cj5NYWlsbGFyZCwgQS4gTS48L2F1dGhvcj48YXV0aG9yPlJlaWdvLCBBLjwvYXV0aG9yPjxhdXRo b3I+Tm91a2FzLCBNLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1dGhvcj48YXV0aG9y Pk1hbm5paywgSy48L2F1dGhvcj48YXV0aG9yPk5nLCBQLiBDLjwvYXV0aG9yPjxhdXRob3I+TWV0 c3BhbHUsIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+ RXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSAoRUdDVVQpLCBUYXJ0 dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtJbnN0aXR1dGUgb2YgTW9sZWN1bGFyICZhbXA7IENlbGwg QmlvbG9neSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIDUxMDEwLCBFc3RvbmlhLiYjeEQ7 U2VydmljZSBvZiBNZWRpY2FsIEdlbmV0aWNzLCBMYXVzYW5uZSBVbml2ZXJzaXR5IEhvc3BpdGFs LCBMYXVzYW5uZSwgMTAxMSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE5ldXJvbG9n eSwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYyBvZiBUYXJ0dSBVbml2ZXJzaXR5IEhvc3BpdGFsLCBU YXJ0dSwgNTA0MDYsIEVzdG9uaWEuJiN4RDtDZW50ZXIgZm9yIEludGVncmF0aXZlIEdlbm9taWNz LCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgMTAxNSwgU3dpdHplcmxhbmQuJiN4 RDtHZW5vbWUgSW5zdGl0dXRlIG9mIFNpbmdhcG9yZSwgU2luZ2Fwb3JlLCAxMzg2NzIsIFNpbmdh cG9yZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZXBvcnRpbmcgaW5jaWRlbnRhbCBm aW5kaW5ncyBvZiBnZW5vbWljIGRpc29yZGVyLWFzc29jaWF0ZWQgY29weSBudW1iZXIgdmFyaWFu dHMgdG8gdW5zZWxlY3RlZCBiaW9iYW5rIHBhcnRpY2lwYW50czwvdGl0bGU+PHNlY29uZGFyeS10 aXRsZT5QZXIgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt dGl0bGU+UGVyIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjMwMy0zMTQ8L3Bh Z2VzPjx2b2x1bWU+MTM8L3ZvbHVtZT48bnVtYmVyPjQ8L251bWJlcj48a2V5d29yZHM+PGtleXdv cmQ+MTZwMTEuMiBDTlY8L2tleXdvcmQ+PGtleXdvcmQ+Z2Vub21pYyBkaXNvcmRlcnM8L2tleXdv cmQ+PGtleXdvcmQ+aW5jaWRlbnRhbCBmaW5kaW5nczwva2V5d29yZD48a2V5d29yZD5wb3B1bGF0 aW9uIGJpb2Jhbms8L2tleXdvcmQ+PGtleXdvcmQ+cmV0dXJuIG9mIHJlc3VsdHM8L2tleXdvcmQ+ PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwv ZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE3NDEtMDU0MSAoUHJpbnQpJiN4RDsxNzQx LTA1NDEgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI5NzQ5ODEzPC9hY2Nlc3Npb24t bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292 L3B1Ym1lZC8yOTc0OTgxMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1y ZXNvdXJjZS1udW0+MTAuMjIxNy9wbWUtMjAxNi0wMDA5PC9lbGVjdHJvbmljLXJlc291cmNlLW51 bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5BbHZlcjwvQXV0aG9yPjxZZWFyPjIwMTk8 L1llYXI+PFJlY051bT45MzQ8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjkzNDwvcmVjLW51 bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhl OW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzQ0NDk0Ij45MzQ8L2tleT48L2Zv cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+ PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkFsdmVyLCBNLjwvYXV0aG9yPjxhdXRob3I+ UGFsb3ZlciwgTS48L2F1dGhvcj48YXV0aG9yPlNhYXIsIEEuPC9hdXRob3I+PGF1dGhvcj5MYWxs LCBLLjwvYXV0aG9yPjxhdXRob3I+WmVrYXZhdCwgUy4gTS48L2F1dGhvcj48YXV0aG9yPlRvbmlz c29uLCBOLjwvYXV0aG9yPjxhdXRob3I+TGVpdHNhbHUsIEwuPC9hdXRob3I+PGF1dGhvcj5SZWln bywgQS48L2F1dGhvcj48YXV0aG9yPk5pa29wZW5zaXVzLCBULjwvYXV0aG9yPjxhdXRob3I+QWlu bGEsIFQuPC9hdXRob3I+PGF1dGhvcj5LYWxzLCBNLjwvYXV0aG9yPjxhdXRob3I+TWFnaSwgUi48 L2F1dGhvcj48YXV0aG9yPkdhYnJpZWwsIFMuIEIuPC9hdXRob3I+PGF1dGhvcj5FaGEsIEouPC9h dXRob3I+PGF1dGhvcj5MYW5kZXIsIEUuIFMuPC9hdXRob3I+PGF1dGhvcj5JcnMsIEEuPC9hdXRo b3I+PGF1dGhvcj5QaGlsaXBwYWtpcywgQS48L2F1dGhvcj48YXV0aG9yPk1hcmFuZGksIFQuPC9h dXRob3I+PGF1dGhvcj5OYXRhcmFqYW4sIFAuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFsdSwgQS48 L2F1dGhvcj48YXV0aG9yPkthdGhpcmVzYW4sIFMuPC9hdXRob3I+PGF1dGhvcj5Fc2tvLCBULjwv YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkVzdG9uaWFuIEdl bm9tZSBDZW50ZXIsIEluc3RpdHV0ZSBvZiBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBUYXJ0dSwg VGFydHUsIEVzdG9uaWEuJiN4RDtEZXBhcnRtZW50IG9mIEJpb3RlY2hub2xvZ3ksIEluc3RpdHV0 ZSBvZiBNb2xlY3VsYXIgYW5kIENlbGwgQmlvbG9neSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUsIEVzdG9uaWEuJiN4RDtEZXBhcnRtZW50IG9mIENhcmRpb2xvZ3ksIEluc3RpdHV0ZSBvZiBD bGluaWNhbCBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIEVzdG9uaWEuJiN4 RDtDYXJkaW9sb2d5IENlbnRyZSwgTm9ydGggRXN0b25pYSBNZWRpY2FsIENlbnRyZSwgVGFsbGlu biwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNYXRoZW1hdGljcyBhbmQgU3RhdGlzdGljcywg VW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIEVzdG9uaWEuJiN4RDtCcm9hZCBJbnN0aXR1dGUg b2YgSGFydmFyZCBhbmQgTUlULCBDYW1icmlkZ2UsIE1BLCBVU0EuJiN4RDtZYWxlIFNjaG9vbCBv ZiBNZWRpY2luZSwgTmV3IEhhdmVuLCBDVCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBDbGluaWNh bCBHZW5ldGljcyBpbiBUYWxsaW5uLCBVbml0ZWQgTGFib3JhdG9yaWVzLCBUYXJ0dSBVbml2ZXJz aXR5IEhvc3BpdGFsLCBUYXJ0dSwgRXN0b25pYS4mI3hEO0hlYXJ0IENsaW5pYywgVGFydHUgVW5p dmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtDYXJkaW92YXNjdWxhciBSZXNl YXJjaCBDZW50ZXIgYW5kIENlbnRlciBmb3IgR2Vub21pYyBNZWRpY2luZSwgTWFzc2FjaHVzZXR0 cyBHZW5lcmFsIEhvc3BpdGFsLCBCb3N0b24sIE1BLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIE1l ZGljaW5lLCBIYXJ2YXJkIE1lZGljYWwgU2Nob29sLCBCb3N0b24sIE1BLCBVU0EuJiN4RDtFc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBJbnN0aXR1dGUgb2YgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2Yg VGFydHUsIFRhcnR1LCBFc3RvbmlhLiB0ZXNrb0Bicm9hZGluc3RpdHV0ZS5vcmcuJiN4RDtCcm9h ZCBJbnN0aXR1dGUgb2YgSGFydmFyZCBhbmQgTUlULCBDYW1icmlkZ2UsIE1BLCBVU0EuIHRlc2tv QGJyb2FkaW5zdGl0dXRlLm9yZy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZWNhbGwg YnkgZ2Vub3R5cGUgYW5kIGNhc2NhZGUgc2NyZWVuaW5nIGZvciBmYW1pbGlhbCBoeXBlcmNob2xl c3Rlcm9sZW1pYSBpbiBhIHBvcHVsYXRpb24tYmFzZWQgYmlvYmFuayBmcm9tIEVzdG9uaWE8L3Rp dGxlPjxzZWNvbmRhcnktdGl0bGU+R2VuZXQgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+ PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R2VuZXQgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNh bD48cGFnZXM+MTE3My0xMTgwPC9wYWdlcz48dm9sdW1lPjIxPC92b2x1bWU+PG51bWJlcj41PC9u dW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFwb2xpcG9wcm90ZWluIEItMTAwL2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPkJpb2xvZ2ljYWwgU3BlY2ltZW4gQmFua3M8L2tleXdvcmQ+PGtleXdv cmQ+RXN0b25pYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3Jk PjxrZXl3b3JkPkdlbm90eXBlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5IeXBlcmxpcG9wcm90ZWluZW1pYSBUeXBlIElJLypkaWFnbm9zaXMvKmVwaWRlbWlvbG9n eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NYXNz IFNjcmVlbmluZy8qbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5NdXRhdGlvbjwva2V5d29yZD48 a2V5d29yZD5Qcm9wcm90ZWluIENvbnZlcnRhc2UgOS9nZW5ldGljczwva2V5d29yZD48a2V5d29y ZD5SZWNlcHRvcnMsIExETC9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5TZXF1ZW5jZSBBbmFs eXNpcywgRE5BPC9rZXl3b3JkPjxrZXl3b3JkPipjYXNjYWRlIHNjcmVlbmluZzwva2V5d29yZD48 a2V5d29yZD4qZmFtaWxpYWwgaHlwZXJjaG9sZXN0ZXJvbGVtaWE8L2tleXdvcmQ+PGtleXdvcmQ+ Kmdlbm9taWNzLWd1aWRlZCBkaXNlYXNlIG1hbmFnZW1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+KnBv cHVsYXRpb24tYmFzZWQgYmlvYmFuazwva2V5d29yZD48a2V5d29yZD4qcmVjYWxsIGJ5IGdlbm90 eXBlPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTk8L3llYXI+PHB1Yi1kYXRl cz48ZGF0ZT5NYXk8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMwLTAzNjYgKEVs ZWN0cm9uaWMpJiN4RDsxMDk4LTM2MDAgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMw MjcwMzU5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8zMDI3MDM1OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48Y3VzdG9tMj5QTUM2NDQzNDg1PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51 bT4xMC4xMDM4L3M0MTQzNi0wMTgtMDMxMS0yPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3Jl Y29yZD48L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZWl0c2FsdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+ PFJlY051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+WzIwLCAyNF08L0Rpc3BsYXlUZXh0Pjxy ZWNvcmQ+PHJlYy1udW1iZXI+OTE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9 IkVOIiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3Rh bXA9IjE1NzA0NDMwNTkiPjkxOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo b3I+TGVpdHNhbHUsIEwuPC9hdXRob3I+PGF1dGhvcj5BbGF2ZXJlLCBILjwvYXV0aG9yPjxhdXRo b3I+SmFjcXVlbW9udCwgUy48L2F1dGhvcj48YXV0aG9yPktvbGssIEEuPC9hdXRob3I+PGF1dGhv cj5NYWlsbGFyZCwgQS4gTS48L2F1dGhvcj48YXV0aG9yPlJlaWdvLCBBLjwvYXV0aG9yPjxhdXRo b3I+Tm91a2FzLCBNLjwvYXV0aG9yPjxhdXRob3I+UmV5bW9uZCwgQS48L2F1dGhvcj48YXV0aG9y Pk1hbm5paywgSy48L2F1dGhvcj48YXV0aG9yPk5nLCBQLiBDLjwvYXV0aG9yPjxhdXRob3I+TWV0 c3BhbHUsIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+ RXN0b25pYW4gR2Vub21lIENlbnRlciwgVW5pdmVyc2l0eSBvZiBUYXJ0dSAoRUdDVVQpLCBUYXJ0 dSwgNTEwMTAsIEVzdG9uaWEuJiN4RDtJbnN0aXR1dGUgb2YgTW9sZWN1bGFyICZhbXA7IENlbGwg QmlvbG9neSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIDUxMDEwLCBFc3RvbmlhLiYjeEQ7 U2VydmljZSBvZiBNZWRpY2FsIEdlbmV0aWNzLCBMYXVzYW5uZSBVbml2ZXJzaXR5IEhvc3BpdGFs LCBMYXVzYW5uZSwgMTAxMSwgU3dpdHplcmxhbmQuJiN4RDtEZXBhcnRtZW50IG9mIE5ldXJvbG9n eSwgQ2hpbGRyZW4mYXBvcztzIENsaW5pYyBvZiBUYXJ0dSBVbml2ZXJzaXR5IEhvc3BpdGFsLCBU YXJ0dSwgNTA0MDYsIEVzdG9uaWEuJiN4RDtDZW50ZXIgZm9yIEludGVncmF0aXZlIEdlbm9taWNz LCBVbml2ZXJzaXR5IG9mIExhdXNhbm5lLCBMYXVzYW5uZSwgMTAxNSwgU3dpdHplcmxhbmQuJiN4 RDtHZW5vbWUgSW5zdGl0dXRlIG9mIFNpbmdhcG9yZSwgU2luZ2Fwb3JlLCAxMzg2NzIsIFNpbmdh cG9yZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZXBvcnRpbmcgaW5jaWRlbnRhbCBm aW5kaW5ncyBvZiBnZW5vbWljIGRpc29yZGVyLWFzc29jaWF0ZWQgY29weSBudW1iZXIgdmFyaWFu dHMgdG8gdW5zZWxlY3RlZCBiaW9iYW5rIHBhcnRpY2lwYW50czwvdGl0bGU+PHNlY29uZGFyeS10 aXRsZT5QZXIgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt dGl0bGU+UGVyIE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjMwMy0zMTQ8L3Bh Z2VzPjx2b2x1bWU+MTM8L3ZvbHVtZT48bnVtYmVyPjQ8L251bWJlcj48a2V5d29yZHM+PGtleXdv cmQ+MTZwMTEuMiBDTlY8L2tleXdvcmQ+PGtleXdvcmQ+Z2Vub21pYyBkaXNvcmRlcnM8L2tleXdv cmQ+PGtleXdvcmQ+aW5jaWRlbnRhbCBmaW5kaW5nczwva2V5d29yZD48a2V5d29yZD5wb3B1bGF0 aW9uIGJpb2Jhbms8L2tleXdvcmQ+PGtleXdvcmQ+cmV0dXJuIG9mIHJlc3VsdHM8L2tleXdvcmQ+ PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwv ZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE3NDEtMDU0MSAoUHJpbnQpJiN4RDsxNzQx LTA1NDEgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI5NzQ5ODEzPC9hY2Nlc3Npb24t bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292 L3B1Ym1lZC8yOTc0OTgxMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1y ZXNvdXJjZS1udW0+MTAuMjIxNy9wbWUtMjAxNi0wMDA5PC9lbGVjdHJvbmljLXJlc291cmNlLW51 bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5BbHZlcjwvQXV0aG9yPjxZZWFyPjIwMTk8 L1llYXI+PFJlY051bT45MzQ8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjkzNDwvcmVjLW51 bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhl OW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0YW1wPSIxNTgyNzQ0NDk0Ij45MzQ8L2tleT48L2Zv cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+ PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkFsdmVyLCBNLjwvYXV0aG9yPjxhdXRob3I+ UGFsb3ZlciwgTS48L2F1dGhvcj48YXV0aG9yPlNhYXIsIEEuPC9hdXRob3I+PGF1dGhvcj5MYWxs LCBLLjwvYXV0aG9yPjxhdXRob3I+WmVrYXZhdCwgUy4gTS48L2F1dGhvcj48YXV0aG9yPlRvbmlz c29uLCBOLjwvYXV0aG9yPjxhdXRob3I+TGVpdHNhbHUsIEwuPC9hdXRob3I+PGF1dGhvcj5SZWln bywgQS48L2F1dGhvcj48YXV0aG9yPk5pa29wZW5zaXVzLCBULjwvYXV0aG9yPjxhdXRob3I+QWlu bGEsIFQuPC9hdXRob3I+PGF1dGhvcj5LYWxzLCBNLjwvYXV0aG9yPjxhdXRob3I+TWFnaSwgUi48 L2F1dGhvcj48YXV0aG9yPkdhYnJpZWwsIFMuIEIuPC9hdXRob3I+PGF1dGhvcj5FaGEsIEouPC9h dXRob3I+PGF1dGhvcj5MYW5kZXIsIEUuIFMuPC9hdXRob3I+PGF1dGhvcj5JcnMsIEEuPC9hdXRo b3I+PGF1dGhvcj5QaGlsaXBwYWtpcywgQS48L2F1dGhvcj48YXV0aG9yPk1hcmFuZGksIFQuPC9h dXRob3I+PGF1dGhvcj5OYXRhcmFqYW4sIFAuPC9hdXRob3I+PGF1dGhvcj5NZXRzcGFsdSwgQS48 L2F1dGhvcj48YXV0aG9yPkthdGhpcmVzYW4sIFMuPC9hdXRob3I+PGF1dGhvcj5Fc2tvLCBULjwv YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkVzdG9uaWFuIEdl bm9tZSBDZW50ZXIsIEluc3RpdHV0ZSBvZiBHZW5vbWljcywgVW5pdmVyc2l0eSBvZiBUYXJ0dSwg VGFydHUsIEVzdG9uaWEuJiN4RDtEZXBhcnRtZW50IG9mIEJpb3RlY2hub2xvZ3ksIEluc3RpdHV0 ZSBvZiBNb2xlY3VsYXIgYW5kIENlbGwgQmlvbG9neSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFy dHUsIEVzdG9uaWEuJiN4RDtEZXBhcnRtZW50IG9mIENhcmRpb2xvZ3ksIEluc3RpdHV0ZSBvZiBD bGluaWNhbCBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIEVzdG9uaWEuJiN4 RDtDYXJkaW9sb2d5IENlbnRyZSwgTm9ydGggRXN0b25pYSBNZWRpY2FsIENlbnRyZSwgVGFsbGlu biwgRXN0b25pYS4mI3hEO0luc3RpdHV0ZSBvZiBNYXRoZW1hdGljcyBhbmQgU3RhdGlzdGljcywg VW5pdmVyc2l0eSBvZiBUYXJ0dSwgVGFydHUsIEVzdG9uaWEuJiN4RDtCcm9hZCBJbnN0aXR1dGUg b2YgSGFydmFyZCBhbmQgTUlULCBDYW1icmlkZ2UsIE1BLCBVU0EuJiN4RDtZYWxlIFNjaG9vbCBv ZiBNZWRpY2luZSwgTmV3IEhhdmVuLCBDVCwgVVNBLiYjeEQ7RGVwYXJ0bWVudCBvZiBDbGluaWNh bCBHZW5ldGljcyBpbiBUYWxsaW5uLCBVbml0ZWQgTGFib3JhdG9yaWVzLCBUYXJ0dSBVbml2ZXJz aXR5IEhvc3BpdGFsLCBUYXJ0dSwgRXN0b25pYS4mI3hEO0hlYXJ0IENsaW5pYywgVGFydHUgVW5p dmVyc2l0eSBIb3NwaXRhbCwgVGFydHUsIEVzdG9uaWEuJiN4RDtDYXJkaW92YXNjdWxhciBSZXNl YXJjaCBDZW50ZXIgYW5kIENlbnRlciBmb3IgR2Vub21pYyBNZWRpY2luZSwgTWFzc2FjaHVzZXR0 cyBHZW5lcmFsIEhvc3BpdGFsLCBCb3N0b24sIE1BLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIE1l ZGljaW5lLCBIYXJ2YXJkIE1lZGljYWwgU2Nob29sLCBCb3N0b24sIE1BLCBVU0EuJiN4RDtFc3Rv bmlhbiBHZW5vbWUgQ2VudGVyLCBJbnN0aXR1dGUgb2YgR2Vub21pY3MsIFVuaXZlcnNpdHkgb2Yg VGFydHUsIFRhcnR1LCBFc3RvbmlhLiB0ZXNrb0Bicm9hZGluc3RpdHV0ZS5vcmcuJiN4RDtCcm9h ZCBJbnN0aXR1dGUgb2YgSGFydmFyZCBhbmQgTUlULCBDYW1icmlkZ2UsIE1BLCBVU0EuIHRlc2tv QGJyb2FkaW5zdGl0dXRlLm9yZy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZWNhbGwg YnkgZ2Vub3R5cGUgYW5kIGNhc2NhZGUgc2NyZWVuaW5nIGZvciBmYW1pbGlhbCBoeXBlcmNob2xl c3Rlcm9sZW1pYSBpbiBhIHBvcHVsYXRpb24tYmFzZWQgYmlvYmFuayBmcm9tIEVzdG9uaWE8L3Rp dGxlPjxzZWNvbmRhcnktdGl0bGU+R2VuZXQgTWVkPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+ PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R2VuZXQgTWVkPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNh bD48cGFnZXM+MTE3My0xMTgwPC9wYWdlcz48dm9sdW1lPjIxPC92b2x1bWU+PG51bWJlcj41PC9u dW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFwb2xpcG9wcm90ZWluIEItMTAwL2dlbmV0aWNzPC9r ZXl3b3JkPjxrZXl3b3JkPkJpb2xvZ2ljYWwgU3BlY2ltZW4gQmFua3M8L2tleXdvcmQ+PGtleXdv cmQ+RXN0b25pYS9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3Jk PjxrZXl3b3JkPkdlbm90eXBlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5 d29yZD5IeXBlcmxpcG9wcm90ZWluZW1pYSBUeXBlIElJLypkaWFnbm9zaXMvKmVwaWRlbWlvbG9n eS8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NYXNz IFNjcmVlbmluZy8qbWV0aG9kczwva2V5d29yZD48a2V5d29yZD5NdXRhdGlvbjwva2V5d29yZD48 a2V5d29yZD5Qcm9wcm90ZWluIENvbnZlcnRhc2UgOS9nZW5ldGljczwva2V5d29yZD48a2V5d29y ZD5SZWNlcHRvcnMsIExETC9nZW5ldGljczwva2V5d29yZD48a2V5d29yZD5TZXF1ZW5jZSBBbmFs eXNpcywgRE5BPC9rZXl3b3JkPjxrZXl3b3JkPipjYXNjYWRlIHNjcmVlbmluZzwva2V5d29yZD48 a2V5d29yZD4qZmFtaWxpYWwgaHlwZXJjaG9sZXN0ZXJvbGVtaWE8L2tleXdvcmQ+PGtleXdvcmQ+ Kmdlbm9taWNzLWd1aWRlZCBkaXNlYXNlIG1hbmFnZW1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+KnBv cHVsYXRpb24tYmFzZWQgYmlvYmFuazwva2V5d29yZD48a2V5d29yZD4qcmVjYWxsIGJ5IGdlbm90 eXBlPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTk8L3llYXI+PHB1Yi1kYXRl cz48ZGF0ZT5NYXk8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMwLTAzNjYgKEVs ZWN0cm9uaWMpJiN4RDsxMDk4LTM2MDAgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMw MjcwMzU5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwczovL3d3 dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8zMDI3MDM1OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwv dXJscz48Y3VzdG9tMj5QTUM2NDQzNDg1PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51 bT4xMC4xMDM4L3M0MTQzNi0wMTgtMDMxMS0yPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3Jl Y29yZD48L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE.DATA [20, 24] . The s election of questions was based on previously conducted analogous studies PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNwYXJpYW48L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFy PjxSZWNOdW0+OTM1PC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyNSwgMjZdPC9EaXNwbGF5VGV4dD48 cmVjb3JkPjxyZWMtbnVtYmVyPjkzNTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw PSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0 YW1wPSIxNTgyNzQ0Njg2Ij45MzU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0 aG9yPkthc3BhcmlhbiwgTi4gQS48L2F1dGhvcj48YXV0aG9yPldha2VmaWVsZCwgQy4gRS48L2F1 dGhvcj48YXV0aG9yPk1laXNlciwgQi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+ PGF1dGgtYWRkcmVzcz5Qc3ljaG9zb2NpYWwgUmVzZWFyY2ggR3JvdXAsIERlcGFydG1lbnQgb2Yg TWVkaWNhbCBPbmNvbG9neSwgUHJpbmNlIG9mIFdhbGVzIEhvc3BpdGFsLCBMZXZlbCAzIERpY2tp bnNvbiBCdWlsZGluZywgMjAzMSwgUmFuZHdpY2ssIEF1c3RyYWxpYS4gTi5LYXNwYXJpYW5AdW5z dy5lZHUuYXU8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Bc3Nlc3NtZW50IG9mIHBzeWNo b3NvY2lhbCBvdXRjb21lcyBpbiBnZW5ldGljIGNvdW5zZWxpbmcgcmVzZWFyY2g6IGFuIG92ZXJ2 aWV3IG9mIGF2YWlsYWJsZSBtZWFzdXJlbWVudCBzY2FsZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0 bGU+SiBHZW5ldCBDb3Vuczwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm dWxsLXRpdGxlPkogR2VuZXQgQ291bnM8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz42 OTMtNzEyPC9wYWdlcz48dm9sdW1lPjE2PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdv cmRzPjxrZXl3b3JkPkJyZWFzdCBOZW9wbGFzbXMvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPipHZW5ldGljIENvdW5zZWxpbmc8L2tleXdvcmQ+PGtl eXdvcmQ+R2VuZXRpYyBEaXNlYXNlcywgSW5ib3JuL3BzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdv cmQ+SGVhbHRoIEtub3dsZWRnZSwgQXR0aXR1ZGVzLCBQcmFjdGljZTwva2V5d29yZD48a2V5d29y ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc21zL2VwaWRlbWlvbG9neS9nZW5ldGlj czwva2V5d29yZD48a2V5d29yZD4qUGF0aWVudCBTYXRpc2ZhY3Rpb248L2tleXdvcmQ+PGtleXdv cmQ+UGVyY2VwdGlvbjwva2V5d29yZD48a2V5d29yZD5Tb2NpYWwgU3VwcG9ydDwva2V5d29yZD48 a2V5d29yZD5TdXJ2ZXlzIGFuZCBRdWVzdGlvbm5haXJlczwva2V5d29yZD48a2V5d29yZD5UcmVh dG1lbnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA3PC95ZWFy PjxwdWItZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTA1 OS03NzAwIChQcmludCkmI3hEOzEwNTktNzcwMCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1u dW0+MTc2OTQzOTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBz Oi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE3Njk0Mzk3PC91cmw+PC9yZWxhdGVkLXVy bHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDA3L3MxMDg5Ny0wMDctOTEx MS02PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhv cj5HcmF5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVjTnVtPjkzNjwvUmVjTnVtPjxyZWNv cmQ+PHJlYy1udW1iZXI+OTM2PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE1ODI3NDQ3MTQiPjkzNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ R3JheSwgUy4gVy48L2F1dGhvcj48YXV0aG9yPk1hcnRpbnMsIFkuPC9hdXRob3I+PGF1dGhvcj5G ZXVlcm1hbiwgTC4gWi48L2F1dGhvcj48YXV0aG9yPkJlcm5oYXJkdCwgQi4gQS48L2F1dGhvcj48 YXV0aG9yPkJpZXNlY2tlciwgQi4gQi48L2F1dGhvcj48YXV0aG9yPkNocmlzdGVuc2VuLCBLLiBE LjwvYXV0aG9yPjxhdXRob3I+Sm9mZmUsIFMuPC9hdXRob3I+PGF1dGhvcj5SaW5pLCBDLjwvYXV0 aG9yPjxhdXRob3I+VmVlbnN0cmEsIEQuPC9hdXRob3I+PGF1dGhvcj5NY0d1aXJlLCBBLiBMLjwv YXV0aG9yPjxhdXRob3I+Q3NlciBDb25zb3J0aXVtIE91dGNvbWVzPC9hdXRob3I+PGF1dGhvcj5N ZWFzdXJlcyBXb3JraW5nLCBHcm91cDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48 YXV0aC1hZGRyZXNzPjFdIERlcGFydG1lbnQgb2YgTWVkaWNhbCBPbmNvbG9neSwgRGFuYS1GYXJi ZXIgQ2FuY2VyIEluc3RpdHV0ZSwgQm9zdG9uLCBNYXNzYWNodXNldHRzLCBVU0EgWzJdIEhhcnZh cmQgTWVkaWNhbCBTY2hvb2wsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cywgVVNBIFszXSBEZXBhcnRt ZW50IG9mIE1lZGljaW5lLCBCcmlnaGFtICZhbXA7IFdvbWVuJmFwb3M7cyBIb3NwaXRhbCwgQm9z dG9uLCBNYXNzYWNodXNldHRzLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgT25jb2xv Z3ksIERhbmEtRmFyYmVyIENhbmNlciBJbnN0aXR1dGUsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cywg VVNBLiYjeEQ7Q2VudGVyIGZvciBNZWRpY2FsIEV0aGljcyBhbmQgSGVhbHRoIFBvbGljeSwgQmF5 bG9yIENvbGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLCBVU0EuJiN4RDsxXSBEZXBh cnRtZW50IG9mIE1lZGljaW5lLCBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFVuaXZlcnNp dHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBlbm5zeWx2YW5pYSwgVVNBIFsyXSBQ ZW5uIENlbnRlciBmb3IgdGhlIEludGVncmF0aW9uIG9mIEdlbmV0aWMgSGVhbHRoY2FyZSBUZWNo bm9sb2dpZXMsIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBlbm5z eWx2YW5pYSwgVVNBLiYjeEQ7U29jaWFsIGFuZCBCZWhhdmlvcmFsIFJlc2VhcmNoIEJyYW5jaCwg TmF0aW9uYWwgSHVtYW4gR2Vub21lIFJlc2VhcmNoIEluc3RpdHV0ZSwgTmF0aW9uYWwgSW5zdGl0 dXRlcyBvZiBIZWFsdGgsIEJldGhlc2RhLCBNYXJ5bGFuZCwgVVNBLiYjeEQ7MV0gSGFydmFyZCBN ZWRpY2FsIFNjaG9vbCwgQm9zdG9uLCBNYXNzYWNodXNldHRzLCBVU0EgWzJdIERlcGFydG1lbnQg b2YgTWVkaWNpbmUsIEJyaWdoYW0gJmFtcDsgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBCb3N0b24s IE1hc3NhY2h1c2V0dHMsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBFdGhpY3MgYW5k IEhlYWx0aCBQb2xpY3ksIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEs IFBlbm5zeWx2YW5pYSwgVVNBLiYjeEQ7MV0gVW5pdmVyc2l0eSBvZiBOb3J0aCBDYXJvbGluYSBh dCBDaGFwZWwgSGlsbCwgQ2hhcGVsIEhpbGwsIE5vcnRoIENhcm9saW5hLCBVU0EgWzJdIFVOQyBM aW5lYmVyZ2VyIENvbXByZWhlbnNpdmUgQ2FuY2VyIENlbnRlciwgQ2hhcGVsIEhpbGwsIE5vcnRo IENhcm9saW5hLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIFBoYXJtYWN5LCBQaGFybWFjZXV0aWNh bCBPdXRjb21lcyBSZXNlYXJjaCBhbmQgUG9saWN5IFByb2dyYW0sIFVuaXZlcnNpdHkgb2YgV2Fz aGluZ3RvbiwgU2VhdHRsZSwgV2FzaGluZ3RvbiwgVVNBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+ PHRpdGxlPlNvY2lhbCBhbmQgYmVoYXZpb3JhbCByZXNlYXJjaCBpbiBnZW5vbWljIHNlcXVlbmNp bmc6IGFwcHJvYWNoZXMgZnJvbSB0aGUgQ2xpbmljYWwgU2VxdWVuY2luZyBFeHBsb3JhdG9yeSBS ZXNlYXJjaCBDb25zb3J0aXVtIE91dGNvbWVzIGFuZCBNZWFzdXJlcyBXb3JraW5nIEdyb3VwPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkdlbmV0IE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVz PjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkdlbmV0IE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGlj YWw+PHBhZ2VzPjcyNy0zNTwvcGFnZXM+PHZvbHVtZT4xNjwvdm9sdW1lPjxudW1iZXI+MTA8L251 bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QmVoYXZpb3JhbCBSZXNlYXJjaC8qbWV0aG9kczwva2V5 d29yZD48a2V5d29yZD5EZWNpc2lvbiBNYWtpbmc8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21pY3Mv Km1ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk5hdGlv bmFsIEh1bWFuIEdlbm9tZSBSZXNlYXJjaCBJbnN0aXR1dGUgKFUuUy4pPC9rZXl3b3JkPjxrZXl3 b3JkPk91dGNvbWUgQXNzZXNzbWVudCwgSGVhbHRoIENhcmUvbWV0aG9kczwva2V5d29yZD48a2V5 d29yZD5TZXF1ZW5jZSBBbmFseXNpcywgRE5BLyptZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPipT b2NpYWwgQmVoYXZpb3I8L2tleXdvcmQ+PGtleXdvcmQ+VHJ1dGggRGlzY2xvc3VyZTwva2V5d29y ZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy PjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl cz48aXNibj4xNTMwLTAzNjYgKEVsZWN0cm9uaWMpJiN4RDsxMDk4LTM2MDAgKExpbmtpbmcpPC9p c2JuPjxhY2Nlc3Npb24tbnVtPjI0NjI1NDQ2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk LXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNDYyNTQ0Njwv dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM0MTYzMTIwPC9jdXN0b20yPjxl bGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDM4L2dpbS4yMDE0LjI2PC9lbGVjdHJvbmljLXJl c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNwYXJpYW48L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFy PjxSZWNOdW0+OTM1PC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyNSwgMjZdPC9EaXNwbGF5VGV4dD48 cmVjb3JkPjxyZWMtbnVtYmVyPjkzNTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw PSJFTiIgZGItaWQ9InQ5MGR4d3d2bnBzcnJ0ZXhlOW9wenc5dnc5cjJmNTAwZjlyZiIgdGltZXN0 YW1wPSIxNTgyNzQ0Njg2Ij45MzU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0 aG9yPkthc3BhcmlhbiwgTi4gQS48L2F1dGhvcj48YXV0aG9yPldha2VmaWVsZCwgQy4gRS48L2F1 dGhvcj48YXV0aG9yPk1laXNlciwgQi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+ PGF1dGgtYWRkcmVzcz5Qc3ljaG9zb2NpYWwgUmVzZWFyY2ggR3JvdXAsIERlcGFydG1lbnQgb2Yg TWVkaWNhbCBPbmNvbG9neSwgUHJpbmNlIG9mIFdhbGVzIEhvc3BpdGFsLCBMZXZlbCAzIERpY2tp bnNvbiBCdWlsZGluZywgMjAzMSwgUmFuZHdpY2ssIEF1c3RyYWxpYS4gTi5LYXNwYXJpYW5AdW5z dy5lZHUuYXU8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Bc3Nlc3NtZW50IG9mIHBzeWNo b3NvY2lhbCBvdXRjb21lcyBpbiBnZW5ldGljIGNvdW5zZWxpbmcgcmVzZWFyY2g6IGFuIG92ZXJ2 aWV3IG9mIGF2YWlsYWJsZSBtZWFzdXJlbWVudCBzY2FsZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0 bGU+SiBHZW5ldCBDb3Vuczwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm dWxsLXRpdGxlPkogR2VuZXQgQ291bnM8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz42 OTMtNzEyPC9wYWdlcz48dm9sdW1lPjE2PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdv cmRzPjxrZXl3b3JkPkJyZWFzdCBOZW9wbGFzbXMvZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+ RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPipHZW5ldGljIENvdW5zZWxpbmc8L2tleXdvcmQ+PGtl eXdvcmQ+R2VuZXRpYyBEaXNlYXNlcywgSW5ib3JuL3BzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdv cmQ+SGVhbHRoIEtub3dsZWRnZSwgQXR0aXR1ZGVzLCBQcmFjdGljZTwva2V5d29yZD48a2V5d29y ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc21zL2VwaWRlbWlvbG9neS9nZW5ldGlj czwva2V5d29yZD48a2V5d29yZD4qUGF0aWVudCBTYXRpc2ZhY3Rpb248L2tleXdvcmQ+PGtleXdv cmQ+UGVyY2VwdGlvbjwva2V5d29yZD48a2V5d29yZD5Tb2NpYWwgU3VwcG9ydDwva2V5d29yZD48 a2V5d29yZD5TdXJ2ZXlzIGFuZCBRdWVzdGlvbm5haXJlczwva2V5d29yZD48a2V5d29yZD5UcmVh dG1lbnQgT3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA3PC95ZWFy PjxwdWItZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTA1 OS03NzAwIChQcmludCkmI3hEOzEwNTktNzcwMCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1u dW0+MTc2OTQzOTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBz Oi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE3Njk0Mzk3PC91cmw+PC9yZWxhdGVkLXVy bHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDA3L3MxMDg5Ny0wMDctOTEx MS02PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhv cj5HcmF5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVjTnVtPjkzNjwvUmVjTnVtPjxyZWNv cmQ+PHJlYy1udW1iZXI+OTM2PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO IiBkYi1pZD0idDkwZHh3d3ZucHNycnRleGU5b3B6dzl2dzlyMmY1MDBmOXJmIiB0aW1lc3RhbXA9 IjE1ODI3NDQ3MTQiPjkzNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+ R3JheSwgUy4gVy48L2F1dGhvcj48YXV0aG9yPk1hcnRpbnMsIFkuPC9hdXRob3I+PGF1dGhvcj5G ZXVlcm1hbiwgTC4gWi48L2F1dGhvcj48YXV0aG9yPkJlcm5oYXJkdCwgQi4gQS48L2F1dGhvcj48 YXV0aG9yPkJpZXNlY2tlciwgQi4gQi48L2F1dGhvcj48YXV0aG9yPkNocmlzdGVuc2VuLCBLLiBE LjwvYXV0aG9yPjxhdXRob3I+Sm9mZmUsIFMuPC9hdXRob3I+PGF1dGhvcj5SaW5pLCBDLjwvYXV0 aG9yPjxhdXRob3I+VmVlbnN0cmEsIEQuPC9hdXRob3I+PGF1dGhvcj5NY0d1aXJlLCBBLiBMLjwv YXV0aG9yPjxhdXRob3I+Q3NlciBDb25zb3J0aXVtIE91dGNvbWVzPC9hdXRob3I+PGF1dGhvcj5N ZWFzdXJlcyBXb3JraW5nLCBHcm91cDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48 YXV0aC1hZGRyZXNzPjFdIERlcGFydG1lbnQgb2YgTWVkaWNhbCBPbmNvbG9neSwgRGFuYS1GYXJi ZXIgQ2FuY2VyIEluc3RpdHV0ZSwgQm9zdG9uLCBNYXNzYWNodXNldHRzLCBVU0EgWzJdIEhhcnZh cmQgTWVkaWNhbCBTY2hvb2wsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cywgVVNBIFszXSBEZXBhcnRt ZW50IG9mIE1lZGljaW5lLCBCcmlnaGFtICZhbXA7IFdvbWVuJmFwb3M7cyBIb3NwaXRhbCwgQm9z dG9uLCBNYXNzYWNodXNldHRzLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIE1lZGljYWwgT25jb2xv Z3ksIERhbmEtRmFyYmVyIENhbmNlciBJbnN0aXR1dGUsIEJvc3RvbiwgTWFzc2FjaHVzZXR0cywg VVNBLiYjeEQ7Q2VudGVyIGZvciBNZWRpY2FsIEV0aGljcyBhbmQgSGVhbHRoIFBvbGljeSwgQmF5 bG9yIENvbGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLCBVU0EuJiN4RDsxXSBEZXBh cnRtZW50IG9mIE1lZGljaW5lLCBQZXJlbG1hbiBTY2hvb2wgb2YgTWVkaWNpbmUsIFVuaXZlcnNp dHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBlbm5zeWx2YW5pYSwgVVNBIFsyXSBQ ZW5uIENlbnRlciBmb3IgdGhlIEludGVncmF0aW9uIG9mIEdlbmV0aWMgSGVhbHRoY2FyZSBUZWNo bm9sb2dpZXMsIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEsIFBlbm5z eWx2YW5pYSwgVVNBLiYjeEQ7U29jaWFsIGFuZCBCZWhhdmlvcmFsIFJlc2VhcmNoIEJyYW5jaCwg TmF0aW9uYWwgSHVtYW4gR2Vub21lIFJlc2VhcmNoIEluc3RpdHV0ZSwgTmF0aW9uYWwgSW5zdGl0 dXRlcyBvZiBIZWFsdGgsIEJldGhlc2RhLCBNYXJ5bGFuZCwgVVNBLiYjeEQ7MV0gSGFydmFyZCBN ZWRpY2FsIFNjaG9vbCwgQm9zdG9uLCBNYXNzYWNodXNldHRzLCBVU0EgWzJdIERlcGFydG1lbnQg b2YgTWVkaWNpbmUsIEJyaWdoYW0gJmFtcDsgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBCb3N0b24s IE1hc3NhY2h1c2V0dHMsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBFdGhpY3MgYW5k IEhlYWx0aCBQb2xpY3ksIFVuaXZlcnNpdHkgb2YgUGVubnN5bHZhbmlhLCBQaGlsYWRlbHBoaWEs IFBlbm5zeWx2YW5pYSwgVVNBLiYjeEQ7MV0gVW5pdmVyc2l0eSBvZiBOb3J0aCBDYXJvbGluYSBh dCBDaGFwZWwgSGlsbCwgQ2hhcGVsIEhpbGwsIE5vcnRoIENhcm9saW5hLCBVU0EgWzJdIFVOQyBM aW5lYmVyZ2VyIENvbXByZWhlbnNpdmUgQ2FuY2VyIENlbnRlciwgQ2hhcGVsIEhpbGwsIE5vcnRo IENhcm9saW5hLCBVU0EuJiN4RDtEZXBhcnRtZW50IG9mIFBoYXJtYWN5LCBQaGFybWFjZXV0aWNh bCBPdXRjb21lcyBSZXNlYXJjaCBhbmQgUG9saWN5IFByb2dyYW0sIFVuaXZlcnNpdHkgb2YgV2Fz aGluZ3RvbiwgU2VhdHRsZSwgV2FzaGluZ3RvbiwgVVNBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+ PHRpdGxlPlNvY2lhbCBhbmQgYmVoYXZpb3JhbCByZXNlYXJjaCBpbiBnZW5vbWljIHNlcXVlbmNp bmc6IGFwcHJvYWNoZXMgZnJvbSB0aGUgQ2xpbmljYWwgU2VxdWVuY2luZyBFeHBsb3JhdG9yeSBS ZXNlYXJjaCBDb25zb3J0aXVtIE91dGNvbWVzIGFuZCBNZWFzdXJlcyBXb3JraW5nIEdyb3VwPC90 aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkdlbmV0IE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVz PjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkdlbmV0IE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGlj YWw+PHBhZ2VzPjcyNy0zNTwvcGFnZXM+PHZvbHVtZT4xNjwvdm9sdW1lPjxudW1iZXI+MTA8L251 bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QmVoYXZpb3JhbCBSZXNlYXJjaC8qbWV0aG9kczwva2V5 d29yZD48a2V5d29yZD5EZWNpc2lvbiBNYWtpbmc8L2tleXdvcmQ+PGtleXdvcmQ+R2Vub21pY3Mv Km1ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk5hdGlv bmFsIEh1bWFuIEdlbm9tZSBSZXNlYXJjaCBJbnN0aXR1dGUgKFUuUy4pPC9rZXl3b3JkPjxrZXl3 b3JkPk91dGNvbWUgQXNzZXNzbWVudCwgSGVhbHRoIENhcmUvbWV0aG9kczwva2V5d29yZD48a2V5 d29yZD5TZXF1ZW5jZSBBbmFseXNpcywgRE5BLyptZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPipT b2NpYWwgQmVoYXZpb3I8L2tleXdvcmQ+PGtleXdvcmQ+VHJ1dGggRGlzY2xvc3VyZTwva2V5d29y ZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy PjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl cz48aXNibj4xNTMwLTAzNjYgKEVsZWN0cm9uaWMpJiN4RDsxMDk4LTM2MDAgKExpbmtpbmcpPC9p c2JuPjxhY2Nlc3Npb24tbnVtPjI0NjI1NDQ2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk LXVybHM+PHVybD5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNDYyNTQ0Njwv dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMj5QTUM0MTYzMTIwPC9jdXN0b20yPjxl bGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDM4L2dpbS4yMDE0LjI2PC9lbGVjdHJvbmljLXJl c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPn== ADDIN EN.CITE.DATA [25, 26] . This allows us to compare the outcome in the broad context of genetic data disclosure and, for example, compare the impact of different types of genetic risk information. The Participant Immediate Feedback Questionnaire (Appendix 5 ) will be filled in , as a printed document, at the end of the second appointment and it will provide insight o n the participant ’s psychological response and satisfaction of receiving genetic information. The Participant 6-month Feedback Questionnaire will be sent to the study participants home address or electronically six month s after the feedback appointment (the second visit) . T his questionnaire aims to gather the long-term impact on the EstBB participants’ reaction and involves , for example, questions on coping with the information , usefulness of the communicated results , regret of the ir decision to consent for receiving genetic risk data, etc ( s ee Appendix 6 for details ). Completion of each questionnaire take s less than 20 minutes and to be filled in by the participants anonymously. The participant can ask for and receive explanation, if any of the questions is not clear. However, the clinical geneticist in charge is not allowed to bias the answer of the participant with their assistance . The participants are expected to express their thoughts with full honest y. 8.6. Governance of collected sensitive data Data collection for the proposed project will be held only by the EstBB authori z ed employees. All de- pseudonymized data (including participant responses, recruitment schedules, signed consent forms, filled interviews, objective measures, photographs , etc. ) before, during and after the study are stored in the EstBB coding center that meets the highest security requirements for handling confidential data. O nly limited number of EstBB authorized employees have access to collect, store and de-pseudonymize the data. The biological samples and data for validation and research usage will be pseudonymized with a unique project code provided for each participant by a recruitment specialist. The keys between the identifying data and project codes will be stored in the EstBB coding center with no internet connection server and controlled access limited to the Institute of Genomics authorized employees . Only members of the research team listed in the application have a right to access the pseudonymized data for research purpose. To minimize the risk of data breach, secure data transfer tools and secondary project codes will be used in any case the data will be used outside of the EstBB information infrastructure. The results of the project will be published in peer-reviewed scientific and medical journals and presented in relevant scientific and medical conferences. T he investigators ensure that only minimal necessary potentially identifying meta data (age, sex) will be revealed during the publication process and no individual-level data (e.g. pseudonymized case reports) will be presented outside of professional context , for example in public outreach events . According to the HGRA § 18 ( 1 ) biological samples, genotype and phenotype data in the EstBB will be preserved in pseudonymi z ed or de- pseudonymized form without a term , unless § 21 ( 1 ) or (2) of the HGRA applies. All materials related to recruitment and organizational aspects of the project (e.g. scheduling tables, reimbursement documents , etc.) will be destroyed five years after the end of the project. See Section 10 for details of data protection aspects. ANALYSIS OF ETHICAL ASPECTS OF THE STUDY 9 .1. Respect for individual autonomy and i nformed consent The proposed project involves adult human beings who have previously consented for joining the Estonian B iobank ( HYPERLINK "https://www.riigiteataja.ee/akt/117042019016" EstBB_Consent ) . The legal framework for human subject’s research in the EstBB is up-to-date and transparent , the biobank is conducted according to the Estonian Human Genes Research Act ( HGRA ). Regulated by the HGRA §9 , the v oluntary nature of gene donation , we have no reason to doubt that all E st BB participants have been properly informed and have been able to voluntarily give their consent at the recruitment . According to the §3 ( 1 ) clause 3 of the HGRA , the E st BB has objective to use the results of genetic research to improve public health. In compliance with this objective, we request the ECBHR approval to de-pseudonymi ze the personal data of up to 400 E st BB participants. These individuals will be invited to the second st age of the project for further evaluation , disclosure of their genetic risk results and genetic counselling (see S ections 7 and 8 for study group description and methodology) . Template of the invitation letter is attached to the application as Appendix 1 . The investigators ensure that all invited individuals are free to decide whether or not they are willing to participate in the study. The individuals who choose to participate will be informed about the aims and procedures of the project prior to recruitment . A supplementary informed consent specifically designed for the project will be obtained from each E st BB participant who agree to participate in the second stage . Template of the participant information sheet and consent form is attached to the application as Appendix 2 . The investigators ensure that all recruited participants have fully understood the information and have not fe lt pressured or coerced into giving consent. A person will not be enrolled in the study if the recruitment specialist suspects that he/she is unable to understand provided information or to give voluntary consent. The proposed project will be conducted in compliance with main applicable international and Estonian legal regulations, such as the European Union General Data Protection Regulation (GDPR) and the Estonian Human Genes Research Act . Data processing and analysis conducted by Swiss members of the research team is conducted under the regulation of the GDPR, the Swiss Federal Act on Research Involving Human Beings and the Swiss Federal Act on Data Protection. 9 .2. The principle of justice, r espect for human dignity and r ights of research participants The investigators are familiar with the general ethical principles defined by main declarations and recommendations , such as the WMA Declaration of Helsinki , the OECD Guidelines on Human Biobanks and Genetic Research Databases, the Ethical Framework for Responsible Data Processing in Personalized Health Research developed by the Swiss Personalized Health Network ( SPHN_ELSI ). The investigators ensure that they will carry out their activities throughout the study in accordance with these principles and guidelines . We ensure respect for people and for human dignity . We acknowledge and respect the participants’ confidentiality, values , interests and r ight to have control over their personal information before (see Section 9 .1. or details) and after enrollment in the study. N o participant will be discriminated against upon joining or for being a participant in the project. All participant s can withdraw their consent at any time without a need to explain . I n case a participant applies for destruction of their data, t he data collected in this project for the person in question will be, unless technically impossible, removed from the project database , the identification key and the human tissue samples collected during this project will be destroyed . Withdrawal from the study will not lead to any negative consequences for the participant. According to the Estonian Human Genes Research Act Chapter 2 § 11 ( 2 ) and § 11 ( 4 ) the E st BB participants have the rights to access their personal genetic information and to receive counselling. This is in agreement with the general ly accepted research participants’ right to receive at least clinically actionable information that may result from the analysis of their personal data and biological material ( see for example SPHN_ELSI ). A ddressing the research participants right to know and to set the ground for equal opportunities in the genomic medicine is a central goal of the proposed project (see Sections 4 and 5 for details). Further, t he principle of e quality and justice can be illustrated by the research subjects of the proposed project. The undiagnosed adult ND-CNV carriers are at high genetic risk to suffer from severe and life-long health conditions (See Section 4 and 5 for details ) . We can hypothesize, that i f these individuals have voluntarily joined the biobank, they might hold a certain hope to receive some insight into their health problems. The current mainstream model in the population-based genomic medicine has focused on returning risks related to common variation o r certain monogenic predispositions while le aving behind citizens at high genetic risk for complex and mental disorders . Some might argue that there is a moral duty not to withhold a major genetic risk event that is presumably linked to the participants existing clinical conditions, medically actionable and can be feasibly and reliably identified by the genome-wide techniques broadly used in the population biobanks. The proposed project aims to contribute to set ting up a n evidence-based model that would respond to the health needs of this group of citizens and guid e towards greater equal ity in distribution of benefits that genomic medicine has to offer. 9 .3. The principle of well-meaning and b enefits of the proposed project We ensure that the proposed project is well-meant and presents fair distribution of benefits and burden . The benefits of the proposed study are three-fold. First, at national level, t he results are necessary for the advanc e ment and broader accessibility of personalized medicine in Estonia (see also Sections 5 and 9.2.) . The research results and developed framework for genetic data return are expected to benefit a considerable fraction of the Est BB participants , as well as Estonian population in general . In parallel with the benefits to t he Estonian society by promot ing the implementation of research findings into health care , the proposed research will raise the value and visibility of the Estonian Biobank both locally and internationally . Second, at individual level, t he outcome s of this project will meet the expectations of the volunt ary EstBB participants who consent for receiving feedback about their genetic risks and health. T he application has a high potential to increase the diagnostic yield among the ‘not yet diagnosed’ individuals with CNV disorders . Identification of the undiagnosed (according to the data retrieved from the health registers) genetic risk variant will provide to the participants an opportunity to seek for specialized medical support and to find explanation to some of the ir existing (often life-long) health conditions. We do not expect that this will significantly increase the at-risk individuals’ health care costs . I mprove d identification of genetically determined preventable (e.g. obesity) and treatable conditions (e.g. obsessive-compulsive disorder) will rather allow optimal admission to certain interventions and will lead to more efficient health care plans . As an example, gastric bypass surgery has been generally shown to be a n effective intervention in severely obese adults. However, it poses unnecessary costs and risks in case of patients who are obese due to dysregulation of satiety response in the brain (e.g. carriers of CNVs in the 16p11.2 chromosome region , population prevalence 1:2,000, i.e. estimated 650 individuals in Estonia ). Similarly , adequate counselling of risk behaviours, occupational or speech therapy can positively impact educational choices and employment, which in turn might help to improve self-management and social outcomes of citizens with multimorbid disorders. F or the CNV carriers at younger adult age, receiving their genetic finding will provide the opportunity for , if they are willing so, timely genetic counselling to assist family planning. Third, the international medical genomic s community will benefit from the data and evidence gathered from the project . The goals of the proposal align with t he international recommendations to enabl e better access to extensive genomic data sets for ameliorat ing the diagnostic perspective of ‘not yet diagnosed’ patients with known diseases (see Section 5 for details). Following the same general line, a recent survey among psychiatric genetic ists highlighted the need to take steps towards best practices in returning genetic results to research participants at risk for psychiatric disorders . In this study, 85% of respondents believed that ‘ medically actionable findings ’ and 54% that ‘ clinically valid but non–medically actionable findings ’ should be returned , underlining participants ‘right to know’ and ‘ duty to inform to try to improve the participants quality of life ’ . Notably, the authors pointed to significant gap between the best and the actual practices and current lack of evidence-based norms ADDIN EN.CITE <EndNote><Cite><Author>Kostick</Author><Year>2020</Year><RecNum>931</RecNum><DisplayText>[21]</DisplayText><record><rec-number>931</rec-number><foreign-keys><key app="EN" db-id="t90dxwwvnpsrrtexe9opzw9vw9r2f500f9rf" timestamp="1582744059">931</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kostick, K.</author><author>Pereira, S.</author><author>Brannan, C.</author><author>Torgerson, L.</author><author>Lazaro-Munoz, G.</author></authors></contributors><auth-address>Center for Medical Ethics &amp; Health Policy, Baylor College of Medicine, Houston, TX, USA.&#xD;Center for Medical Ethics &amp; Health Policy, Baylor College of Medicine, Houston, TX, USA.
[email protected].</auth-address><titles><title>Psychiatric genomics researchers&apos; perspectives on best practices for returning results to individual participants</title><secondary-title>Genet Med</secondary-title></titles><periodical><full-title>Genet Med</full-title></periodical><pages>345-352</pages><volume>22</volume><number>2</number><keywords><keyword>Elsi</keyword><keyword>ethics</keyword><keyword>genetic</keyword><keyword>neuroethics</keyword><keyword>qualitative</keyword></keywords><dates><year>2020</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1530-0366 (Electronic)&#xD;1098-3600 (Linking)</isbn><accession-num>31477844</accession-num><urls><related-urls><url>https://www.ncbi.nlm.nih.gov/pubmed/31477844</url></related-urls></urls><custom2>PMC7000323</custom2><electronic-resource-num>10.1038/s41436-019-0642-7</electronic-resource-num></record></Cite></EndNote> [21] into which the proposed project aims to contribute . 9 .4. The principle of non-harming and m inimization of risks The investigators fully comprehend possible risks that may arise from the delicate subject of neurodevelopmental genetic s, potential vulnerability of some research participants and high levels of security required for handling collected sensitive information . The research team has been selected and the research methodology designed to minimiz e risks and ensure non- harm ing of participants. The core research team is composed of specialist s in clinical genetics, genetic counselling and neurodevelopmental genetics, complemented by experts in data security, human research ethics, statistical genetics and human gen omics . T he risk of genetic discrimination in Estonia is minimized by up-to-date transparent legal framework for human subject’s research (the Estonian Human Genes Research Act) , government-funded and strictly regulated genetic testing program in the EstBB and t he state-run solidarity-based health insurance system (the Estonian Health Insurance Fund) . All steps of the project involving research participants and/or de- pseudo nymized personal data will take place in the EstBB re cruitment office and data coding center and will be conducted by the E st BB authori z ed employees. All employees who participate in phenotype data collection, genetic feedback and counselling , have otherwise direct contact with the participants and /or access to personal ized information have been informed about the rules of processing sensitive data , maintain ing research participants’ privacy and have signed the EstBB confidentiality agreement. Medical specialist or a trained specialist in genomic medicine will ensure that the information about the project and the outcomes will be clear and understandable before signing the consent form and conducting the data collection interviews . To maximize the research impact and minimize the risk s regarding sensitive information about participants’ development and health, specialist from the fields of psychology, research ethics, medical genetics , medicine and data security have been involved in the preparation of the research protocol. Selection of questionnaires was consulted with external experts at the Center for Human Development and Disability, University of Washington Medical Center (Seattle, WA, USA), one of the principal recruitment centers for patients with neurodevelopmental disorders in the USA. To enhance the impact of the collected data , the broad u sability of the questionnaires in the field and seamless link ing of the results with those from the other studies was a prerequisite for the selection . Prior to the interview, the p articipant s will be informed about their right to leave questions unanswered if th ey feel uncomfortable or for any other reasons. All employees who administer the interviews ensure to respect the participant choice to do so. Collected p ersonali z ed data will be stored together with any other sensitive data in the E st BB coding center designed for protection of confidential data (see Section 10.2 for details of confidential data governance). The project will consider only the effect of certain blocks of genes, i.e. CNVs, in the genome that are known to be associated with actionable health risk s . To minimize the risks of unjustified confusion, anxiety or worry the following measures have been taken into account: T he CNV-associated risk results will be based on confirmed clinical significance and actionable information (see also Section 8.1.) G enetic variants or risk estimations with potential, but uncertain medical significance will not be reported back to participants The genetic variation report and counselling is customized according to the collected information about each participant’s existing health conditions Unless relevant to a specific participant , disease risks associated with a given ND-CNV that have demonstrated variable expressivity and incomplete penetrance or are medically not actionable will not be communicated. This holds particularly true for developmental disorders and mental conditions not diagnosed for the participant (see also Section 8.4.) The reporting and counselling of genetic risks will be conducted by a certified clinical geneticist and genetic counsellor with help from a trained specialist in genomic medicine At any point , all members of the research team will provide the best caring attitude towards the participants to make the m feel respect ed and supported. The primary outcome of the project for each participant will be personalized health risk information based on individual genetic variation. This information may at first be unexpected and worrisome for some of the study participant. To avoid unnecessary immediate harm and to reduce the negative feelings projected towards their future, the counsellor will carefully explain the reason to address genetic risk information , the opportunity to provide improved healthcare solutions or suggestions for optimal lifestyle choices for prevention. The individual genetic reports prepared for each participant include recommendations for personali z ed health management, for example suggestions to refer the participant to medical specialist for prevent ing late onset complications . To avoid confusion, a time slot is dedicated in the end of the visit for reflection and participant’s questions to the clinical geneticist . In addition to the psycho - social impact, the data collection procedure may be tiresome and/or blood draw may cause temporary discomfort and anxiety for some participants . The research team will provide their best support to the participants. F or example , a break with warm lunch is scheduled during the first visit, refreshments, coffee and tea are offered to the participants if needed (e.g. after blood draw, prolonged duration of a visit, etc.). I f a participant feel s dizzy after giving a blood sample, they are offered a possibility to lay down , or take a break if they feel tired . After careful evaluation of involved risks, burdens and benefits , we strongly believe that the research team is qualified to identify the potential risk areas, to minimize predictable risks and the benefit s expected to result from this project will clearly outweigh the potential burden to the participants . 9 . 5 . Accountability of proposed research The proposed project will be conducted and supervised by competent individuals with the appropriate ethics and scientific education, specialized training and research qualifications. The involved investigators are internationally recognized experts with strong track record in the fields of medical genetics and human genomics (see also Section 12.1) . Methodology of the proposed research is solid, the scientific questions are novel and meet the current needs of the medical genomics community. E xpected results of the project will have implications for personal risk evaluation and support plans for individuals challenged by genetic events with strong effect . They should advance the understanding of mechanisms contributing to the etiologies of complex disease and provide information pertinent to the clinical and research community . The research team is involved in multiple initiatives that aim to embolden collaboration between researchers, physicians and citizens for the emergence of personalized medicine. In addition, we have a d irect link with international rare disease patient organizations and initiatives (Olivier Menzel through EURORDIS, Rare Disease International; Katrin Männik through COST MINDDS - Maximizing Impact of Research in Neurodevelopmental Disorders). This allows us to reach out to patients and other stakeholders , collect their expectations, disseminate our results and raise awareness of genetic susceptibility in complex neurodevelopmental disorders in the community . ANALYSIS OF DATA PROTECTION ASPECTS OF THE STUDY 10.1. Release of the data in the Estonian biobank There are three data releases within the scope of this project : First, the EstBB genotype data is required for research participant selection. T he investigators will screen the EstBB cohort of >200,000 individuals for CNVs with confirmed high clinical relevance to identify undiagnosed carriers of ND-CNVs . Second, to map each ND-CNV with their co-occurring disease traits, a comprehensive set of existing phenotype data from the EstBB database (general data, objective measures, occupational and educational information, reproductive health, disease diagnoses, drug usage) and linked electronic registries (E-health, Estonian Health Insurance Fund, Estonian Causes of Death Register) will be requested for up to 1,800 identified ND-CNV carriers. Third , all data collected during the proposed project and entered to the EstBB database will be requested for fulfilling the research goals of the project . In all cases , a ccess to the EstBB data is granted after the approval from the ECBHR, and the research will be conducted subsequently. The Director of the Institute of Genomics of the University of Tartu will appoint the responsible employees of the Institute of Genomics for the procedures as well as will give the order to release the data. Additionally, the data transfer and use agreement (DTUA) , as well as the data transfer protocol will be signed by the Principal Investigator and the Director of the Institute of Genomics . The released data is stored and processed in the Research Cloud of Tartu University that has passed the ISKE audit i n December 2017 and meets the ISKE M level requirements (security class T1K1S2). The data access is controlled by the Institute of Genomics and restricted only to individuals involved in the research and listed in the current proposal . Findings of the study will be reported back to the Estonian Biobank and integrated in the database on an individual level. The principal investigator will secure the confidentiality of the data and en sure that all data protection regulations according to the signed contract and general data protection regulations are followed. All investigators are informed about the data processing rules. The data shall be used only in accordance to the goals and scope of the proposed research. The distribution of data to third parties is prohibited without the written consent of the Institute of Genomics . The DTUA will specify the measures to ensure that the data will not be misused after conclusion of the research purpose or u pon the expiry of the DTUA (the date defined in the agreement), for example revocation of access, data destruction etc. 10.2. De-pseudonymization of research participants and governance of confidential data The procedure of de-pseudonymization and re-contact will be executed according to the HGRA §24 (2) clause 4 that allows de-pseudonymization on the proposal of the controller of the EstBB and with the consent of the Ethics Committee in order to identify a biobank participant for contacting them for renewing, supplementing or verifying a description of their state of health with their written consent. According to the HGRA § 22 (3) , o nly persons specifically appointed by the controller of EstBB , the Institute of Genomics, are allowed to perform de-pseudonymization . Data collection will be held only by the authorised employees of the Institute of Genomics . All employees who will work , for example at the steps of phenotype data collection, genetic feedback and counselling, directly with the participants and /or will have access to personal ized information have be en informed about the rules of processing of sensitive data and have signed the EstBB confidentiality agreement. All personalized, confidential and sensitive data collected during the project will be stored in the EstBB coding center designed for protection. The room is not connected to internet, has lighting regime of 24 hours per day and 7 days per week, is accessible for limited number of authorized individuals and is protected with a code and alarm. Hard copy images (e.g. drawings of pedigrees) will be digitalized, originals will be archived securely together with all other documents that can be associated with a particular research participant. Unofficial notes are prohibited to take in any form by the medical specialist or data collectors. The results of their genetic and health risks will be returned personally to each participant who consented for receiving this information. The report will be printed in two cop ies and signed by the participant and the clinical geneticist . The signed hard copy for the EstBB shall be held in a non-transparent binder until its arrival to the coding center shortly after the feedback visit. Each participant is free to decide whether to keep the information and the copy of the report to themselves or share it with the ir general practitioner, other medical specialists or family members. 10.3. Governance and r elease of collected pseudonymized data for research purpose All data collected during the project will be directly entered in a pseudonymized form to the EstBB research database. For scientific research purposes, t he investigators can request the pseudonymized data and upon a uthorization issued by the Principal Investigator the EstBB routine procedure for pseudonymized data release follows (see Section 10.1) . No personalized information will be released to the members of the research team. The results of the project will be published in peer-reviewed scientific and medical journals in a coded form impossible to associate with specific study participant s’ identi ties . All members of the r esearch team are responsible to adequately protect the data and their data access credentials against unauthorized access, misuse or corruption . All incidents potentially affecting data security shall be reported with no delay to the Principal Invest i gator and to the director of the Institute of Genomics at the University of Tartu. This application for ethical approval has been reviewed and approved by persons authorized by the Chief Data Protection Officer of the University of Tartu, Helene Alavere , Head of Data Collection Department and Project Manager of the Estonian Institute of Genomics and Evelin Tali , Analyst of the Estonian Institute of Genomics. INFORMATION ON EARLIER OR SIMULTANEOUS ASSESSMENT OR ON APPROVAL OF THE SAME PROJECT ELSEWHERE The current proposal is a follow-up to long-time collaboration between the E st BB and the University of Lausanne in the field of rare clinically relevant CNVs. By using the same strategy, t he study will scale-up our initial approach that targeted one of the CNV regions in the 16p11.2 genomic locus - Katrin Männik “ Deciphering phenotypic variability of genomic disorders using the 16p11.2 syndromes as a paradigm ” (in Estonian: “16p11.2 sündroomide ja teiste genoomsete haiguste fenotüübilise varieeruvuse uuringud ” ) , approved by the Research Ethics Commitee of the Universit y of Tartu ( REC UT; protocol 252/T-6, valid through 31.12.2020 ) . Related project has been reviewed and approved by The Committee of Huma n Research Ethics of the Canton of Vaud, Switzerland (protocol 131/09). T he REC UT has previously given app roval s to conduct similar project s involving the principal investigators of the currently proposed project. These include: Katrin Männik and Santhosh Girirajan “ Towards understanding the complex genetics of human intellectual disability disorders ” ( in Estonian: “ Uuringud inimese intellektipuude aluseks oleva kompleksgeneetika mõistmiseks ” ; protocol 264/T-19, valid through 31.12.2021). T he study is a sub-project of general studies in the 16p12.1 CNV region reviewed and approved by the Internal Review Board of the Penn sylvania State University, PA, USA (protocol HRP-503f ). Neeme Tõnisson “ Meditsiinilist sekkumist vajavate geenivariantide leidmine ja nende osas tagasiside andmine geenidoonoritele ” ; protocol 258/T-22 valid through 31.12.2025 ). Andres Metspalu “Feedback to the gene donors” (in Estonian: “ Tagasiside geenidoonoritele ” ; protocol 271/T-22, valid through 1.06.2022 ) Tõnu Esko “ Determination of the phenotype of familial hypercholesterolaemia and further clinical management on the basis of the finding obtained in genome-wide study ” ( in Estonian: “ Perekondliku hüperkolesteroleemia fenotüübi täpsustamine ja edasine kliiniline käsitlus ülegenoomsel uuringul tuvastatud leiu alusel ” ; protocol 253/T-14 valid through 31.12.2020, amendment approved by protocol 259/M-20, valid through 31.12.2020 ). Peeter Padrik “Implementation of a model for personalised risk-based breast cancer prevention and screening” ( in Estonian: " Rinnavähi personaliseeritud riskidel põhineva ennetuse ja sõeluuringu rakendamine " ; protocol 282/T-29 , valid through 31.12 .2020 ). SUPPLEMENTARY INFORMATION 1 2 .1. CVs of principal investigators and research collaborators 1 2 .2. Participant information and declaration of consent Appendix 1 - Invitation letter to potential research participants (in Estonian) Appendix 2 - Participant information sheet and consent form (in Estonian) 1 2 .3. Study protocols , data collection and return of research results Appendix 3 - Developmental and Medical History Questionnaire (in Estonian) Appendix 4 - Example of ND-CNV patient information sheet (in Estonian) Appendix 5 - Participant Immediate Feedback Questionnaire (in Estonian) Appendix 6 - Participant 6-month Feedback Questionnaire (in Estonian) 12. 4 . Handwritten signatures of the Swiss collaborators and the directors of participating institutions Appendix 7- Signatures_1 Appendix 8- Signatures_2 Appendix 9- Signatures_3 REFERENCES ADDIN EN.REFLIST 1. Gustavsson, A., et al., Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol, 2011. 21 (10): p. 718-79. 2. Trautmann, S., J. Rehm, and H.U. Wittchen, The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep, 2016. 17 (9): p. 1245-9. 3. Plummer, J.T., A.J. Gordon, and P. Levitt, The Genetic Intersection of Neurodevelopmental Disorders and Shared Medical Comorbidities - Relations that Translate from Bench to Bedside. Front Psychiatry, 2016. 7 : p. 142. 4. Happell, B., et al., Scoping review of research in Australia on the co-occurrence of physical and serious mental illness and integrated care. Int J Ment Health Nurs, 2015. 24 (5): p. 421-38. 5. Hochstenbach, R., et al., Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research. Cytogenet Genome Res, 2011. 135 (3-4): p. 174-202. 6. Mannik, K., et al., Copy number variations and cognitive phenotypes in unselected populations. JAMA, 2015. 313 (20): p. 2044-54. 7. Kendall, K.M., et al., Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. Biol Psychiatry, 2016. 8. Guyatt, A.L., et al., Association of copy number variation across the genome with neuropsychiatric traits in the general population. Am J Med Genet B Neuropsychiatr Genet, 2018. 177 (5): p. 489-502. 9. Owen, D., et al., Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. BMC Genomics, 2018. 19 (1): p. 867. 10. Crawford, K., et al., Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. J Med Genet, 2019. 56 (3): p. 131-138. 11. Burghel, G.J., et al., Presence of pathogenic copy number variants (CNVs) is correlated with socioeconomic status. J Med Genet, 2020. 57 (1): p. 70-72. 12. Weiss, L.A., et al., Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med, 2008. 358 (7): p. 667-75. 13. Zufferey, F., et al., A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. J Med Genet, 2012. 49 (10): p. 660-8. 14. McCarthy, S.E., et al., Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet, 2009. 41 (11): p. 1223-7. 15. D'Angelo, D., et al., Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities. JAMA Psychiatry, 2016. 73 (1): p. 20-30. 16. Jacquemont, S., et al., Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature, 2011. 478 (7367): p. 97-102. 17. Maillard, A.M., et al., The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol Psychiatry, 2015. 20 (1): p. 140-7. 18. Shinawi, M., et al., Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet, 2010. 47 (5): p. 332-41. 19. Walters, R.G., et al., A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature, 2010. 463 (7281): p. 671-5. 20. Leitsalu, L., et al., Reporting incidental findings of genomic disorder-associated copy number variants to unselected biobank participants. Per Med, 2016. 13 (4): p. 303-314. 21. Kostick, K., et al., Psychiatric genomics researchers' perspectives on best practices for returning results to individual participants. Genet Med, 2020. 22 (2): p. 345-352. 22. Arnett, A.B., S. Trinh, and R.A. Bernier, The state of research on the genetics of autism spectrum disorder: methodological, clinical and conceptual progress. Curr Opin Psychol, 2019. 27 : p. 1-5. 23. Stessman, H.A., R. Bernier, and E.E. Eichler, A genotype-first approach to defining the subtypes of a complex disease. Cell, 2014. 156 (5): p. 872-7. 24. Alver, M., et al., Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genet Med, 2019. 21 (5): p. 1173-1180. 25. Kasparian, N.A., C.E. Wakefield, and B. Meiser, Assessment of psychosocial outcomes in genetic counseling research: an overview of available measurement scales. J Genet Couns, 2007. 16 (6): p. 693-712. 26. Gray, S.W., et al., Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genet Med, 2014. 16 (10): p. 727-35.
Application to the Estonian Committee on Bioethics and Human Research for
project appoval
1. RESEARCH DATA
Project Title:
"The impact of clinically relevant CNVs in the general population – the health
consequences and personalized management of undiagnosed adult CNV carriers"
“Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis –
diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja
personaliseeritud käsitlus”
List of Collaborating Countries:
Estonia, Switzerland
Main purpose of the study:
The proposed project focuses on the Estonian biobank voluntary participants who are
carriers of DNA copy-number variants (CNVs) with confirmed high clinical
relevance. We aim to apply genotype-driven phenotyping to gather a comprehensive
collection of health information in a clinically unbiased adult cohort and to investigate
how these variants affect health in the general population. In addition, we are willing
to disclose the identified genetic finding to the consenting CNV carriers, and through
evaluation of at-risk individuals’ expectations and experience to set up an evidence-
based model for the identification and counselling of previously undiagnosed biobank
participants at high genetic risk for complex disorders.
Uurimistöö peamine eesmärk:
Taotletav projekt keskendub Eesti geenivaramu vabatahtlikuse alusel ühinenud
geenidoonoritele, kellel on leitud kliiniliselt oluline struktuurne geenivariant ehk
DNA koopia-arvu variatsioon (CNV). Uuringu eesmärgiks on rakendada nö.
1
genotüübil põhinevat terviseandmete kogumist, et uurida CNV-dega inimeste tervise
tulemeid täiskasvanud üldpopulatsioonis. Lisaks soovivad uuringu läbiviijad anda
CNV kandjatele personaalse kokkuvõtte ja tagada geneetiline nõustamine nende
senituvastamata geneetilise leiu kohta. Kogutud andmete alusel on kavas välja
töötada tõendus-põhine protokoll geneetilise tagasiside andmiseks kõrge
komplekshaiguste riskiga geenidoonoritele.
2. RESEARCH INVESTIGATORS AND INSTITUTIONS
2.1. Principal investigators
Katrin Männik, PhD
Health2030 Genome Center, Campus Biotech
Head of Data Strategy
Campus Biotech, 9 chemin des Mines
CH-1202 Geneva, Switzerland
+41 787 45 42 75
[email protected]
/signed digitally/
Neeme Tõnisson, MD, PhD
Estonian Biobank, Institute of Genomics, University of Tartu
Department of Clinical Genetics in Tallinn, Tartu University Hospital
Senior Research Fellow and Clinical Geneticist
23b Riia St
2
Tartu 51010, Estonia
+372 5668 4694
[email protected]
/signed digitally/
Alexandre Reymond, PhD
Center for Integrative Genomics, University of Lausanne
Director, Professor
Center for Integrative Genomics, University of Lausanne, Genopode building
CH-1015 Lausanne, Switzerland
+41 21 692 3960
[email protected]
/Signature please see in attachment Appendix 7- Signatures_1/
2.2. Sub-investigators
Eleonora Porcu, PhD
Center for Integrative Genomics, University of Lausanne
Post-doctoral Research Fellow
Center for Integrative Genomics, University of Lausanne, Genopode building
CH-1015 Lausanne, Switzerland
+41 21 692 3960
[email protected]
/Signature please see in attachment Appendix 7- Signatures_1/
Marili Palover, MSc
Estonian Biobank, Institute of Genomics, University of Tartu
PhD student and biomedical specialist
3
23b Riia St., Tartu 51010, Estonia
+372 5124 795
[email protected]
/signed digitally/
Ioannis Xenarios, PhD
Health2030 Genome Center, Campus Biotech
Chief Data Analyst
Campus Biotech, 9 chemin des Mines, CH-1202 Geneva, Switzerland
+41 58 201 02 41
[email protected]
/Signature please see in attachment Appendix 8- Signatures_2/
Olivier Menzel, PhD
Health2030 Genome Center, Campus Biotech
Head of Strategic Partnerships
Campus Biotech, 9 chemin des Mines, CH-1202 Geneva, Switzerland
+41 58 201 02 41
[email protected]
/Signature please see in attachment Appendix 8- Signatures_2/
Helene Alavere, MD, MScHs
Estonian Biobank, Institute of Genomics, University of Tartu
Head of Data Collection Department, Project Manager
23b Riia St., Tartu 51010, Estonia
+372 737 4038
[email protected]
/signed digitally/
4
Liis Leitsalu, PhD
Estonian Biobank, Institute of Genomics, University of Tartu
Genetic counselor and researcher
Riia 23b, Tartu 51010 Estonia
+372 53 088 075
[email protected]
/signed digitally/
Triinu Temberg, MSc
Estonian Biobank, Institute of Genomics, University of Tartu
Recruitment specialist
23b Riia St, Tartu 51010
+ 372 737 4031
[email protected]
/signed digitally/
Esta Pintsaar
Estonian Biobank, Institute of Genomics, University of Tartu
Recruitment specialist
23b Riia St, Tartu 51010
+ 372 737 4030
[email protected]
/signed digitally/
Margit Nõukas, MSc
Institute of Molecular and Cell Biology and Estonian Biobank, Institute of Genomics,
University of Tartu
5
PhD student/ specialist
23b Riia St., Tartu 51010, Estonia
+ 372 5112 755
[email protected]
/signed digitally/
Anu Reigo, MD
Lead Specialist of Medical Genomics
Estonian Biobank, Institute of Genomics, University of Tartu
23b Riia St., Tartu 51010, Estonia
+372 737 4040
[email protected]
/signed digitally/
Maarja Lepamets, MSc
Specialist
Estonian Biobank, Institute of Genomics, University of Tartu
23b Riia St., Tartu 51010, Estonia
+372 737 4035
[email protected]
/signed digitally/
6
2.3. Director of the institution or head of the structural unit of the principal
investigator
Mait Metspalu, PhD
Institute of Genomics, University of Tartu
Director
Riia 23b, 51010 Tartu, Estonia
+372 737 5052
[email protected]
/Signature please see in attachment Appendix 9- Signatures_3/
Emmanouil T. Dermitzakis, PhD
Health2030 Genome Center, Campus Biotech
Director, Professor
Campus Biotech, 9 chemin des Mines, CH-1202 Geneva, Switzerland
+41 58 201 02 41
[email protected]
/Signature please see in attachment Appendix 9- Signatures_3/
Alexandre Reymond, PhD
Center for Integrative Genomics, University of Lausanne
Director, Professor
Center for Integrative Genomics, University of Lausanne, Genopode building
CH-1015 Lausanne, Switzerland
+41 21 692 3960
[email protected]
/Signature please see in attachment Appendix 9- Signatures_3/
7
3. SOURCE OF FINANCE
The total budget of the study is expected to be 200 000 EUR. Costs of the project will
be covered by the Jacobs Foundation Research Fellowship to Katrin Männik (grant
#2016 1217 09), by the Swiss National Science Foundation grant to Alexandre
Reymond (grant #31003A_182632) and by the Estonian Research Council grant to
Neeme Tõnisson (grant #PRG555).
These funds will be used for recruiting, evaluating and counselling research subjects,
performing validation experiments, adapting existing secure computational resources
in the Institute of Genomics at the University of Tartu for data collection and storage
for the current study. Additionally, the funds will be used for salaries of two
researchers of the Institute of Genomics who are responsible for the recruitment and
counselling of study participants. These salaries will be defined according to the hours
worked for the project and to the salary requirements established by the University of
Tartu.
Each participating research institute covers the research costs of their part of the
project and salaries of their other employees involved in the project.
Transportation to the Estonian Biobank (EstBB) at the Institute of Genomics in Tartu,
Estonia will be organized and the costs will be reimbursed (maximum cost of 50
euros per visit) to the research participants. Costs for justified daily allowances (e.g.
lunch, coffee, tea and refreshments) will be covered. The participants will not receive
compensation for participating in the study. The study does not include interventions
or medical procedures that pose health risks to the participants, no specific insurance
or damage compensation will be required.
4. BRIEF OVERVIEW OF LITERATURE AND RESEARCH CONDUCTED
ON THE SAME TOPIC EARLIER
Each year, mental disorders cost 298 billion euros to the European healthcare system.
In contrast to other key groups, indirect costs in human capital and economic growth
through loss of productivity and income are exceptionally high in mental disorders [1,
2]. Most mental disorders are considered neurodevelopmental. Neurodevelopmental
disorders (NDDs) affect approximately 1 in 25 individuals in Europe and, due to their
8
life-long consequences, have a major impact on families, healthcare systems and
society (NIH_MentalHealth). NDDs are caused by alterations in development and
function of the brain. Increasing evidence suggests that NDDs and other medical
conditions, including cardiovascular, endocrine and respiratory diseases, are
associated. The co-morbidity between mental and physical health disturbances in
NDDs is predictable, given that the underlying genetic factors might be the same and
the genes associated with brain development are often also expressed in peripheral
organs. This biological relatedness between co-occurring medical traits suggests that
studies of NDDs could open a new vista for understanding causative mechanisms of
complex diseases and have a broad set of clinical implications for diagnosis and
health management over patient's lifetime [3, 4].
Extensive genome-wide screening in clinical cohorts has revealed that approximately
20% of children with NDDs are carriers of pathogenic DNA copy number variants
(CNVs) [5]. Akin to NDDs in general, besides their effect on brain development and
risk for mental disorders, CNVs are linked to other co-occurring complex health
conditions. To date, the relevance of CNVs has almost exclusively been investigated
in clinically ascertained children with severe NDDs, such as intellectual disability and
autism spectrum disorder. Thus, the perception of CNV effect has suffered from an
ascertainment bias towards phenotypes presenting with early onset and posing the
greatest medical management challenges. A systematic understanding on how CNVs
affect health and life quality in the general population has remained largely unknown.
No conclusions are currently available about CNV-associated disease traits in
adulthood and age-related trajectories of health problems.
Recent studies have shown that cumulatively CNVs could also be a common health
problem in the adult population. Approximately 1% of participants in general
population biobanks carry a known neurodevelopmental CNV (ND-CNV), and an
additional 10% of the population carries a rare CNV that has yet remained clinically
uncharacterized [6]. Preliminary data indicate that CNVs explain a substantial portion
of population variance in education attainment, are associated with lower socio-
economic status and a complex set of clinical outcomes [6-11]. Our study in the
clinically unselected Estonian Biobank (EstBB; in Estonian: Geenivaramu) indicated
that 49% of ND-CNV carriers reach only basic education. A notable 70% of carriers
suffer from major diseases (e.g. mental disorders, obesity, epilepsy, cardiac, renal
9
and/or endocrine diseases), but had no prior awareness of their genetic disorder [6].
This suggests that despite negative effect on health, this vulnerable group has escaped
the attention of the medical genetic system and not received proper evaluation and
support, although genotype-tailored healthcare could significantly improve their
quality of life.
In a recent pilot study, we aimed to evaluate the response of EstBB participants to the
disclosure of this type of incidental genetic findings by using the ND-CNVs in the
human 16p11.2 chromosome locus as a paradigm. The 16p11.2 CNVs are among the
most frequent known genetic causes of NDDs [12-15]. They impact carriers’ appetite
control, BMI, pubertal onset, and are significantly associated with diverse health
outcomes (e.g. obesity, scoliosis, congenital heart disease, epilepsy, speech and
language deficit, mood or psychotic disorders, etc.) [13, 15-19]. Among the 11
individuals identified in the EstBB pilot dataset as carriers of the 16p11.2 CNV, no
one were previously diagnosed with genetic disease. Eight out of 11 carriers (72.7%)
consented for disclosure of incidental genetic finding. All eight participants were
further evaluated, counselled regarding their carrier status and surveyed 11–17
months later. Six out of eight 16p11.2 CNV carriers (87.5%) suffered from major
clinical problems presumably linked to the found genetic alteration and were provided
personalized suggestions for their health management. Although the sample size was
small for firm conclusions, all participants in the pilot study demonstrated preference
for disclosure and rated received information favourably (evaluated one year after
receiving the information). Notably, most respondents wished they would have
learned earlier about the genetic finding, one participant reported modifications in
treatment and three felt that their treatment had since improved [20].
5. REASON FOR RESEARCH PLANNED
Pioneering nation-wide initiatives of genome-based medicine have reached clinical
practice in a limited number of European countries, such as Finland, Estonia and
Switzerland, with the field just burgeoning. These initiatives have so far been
focusing on individual risk predictions for familial cancers, rare monogenic (e.g.
familial hypercholesterolemia) and common diseases (e.g. type 2 diabetes). The
complex nature of interrelated and co-occurring clinical conditions and delicate
10
subject of neurodevelopmental genetics have so far hampered application of precision
medicine to citizens who have incidentally identified as at high genetic risk for
NDDs.
The proposed project focuses on subgroup of NDDs – the individuals who are
affected by ND-CNVs in the human genome. There are estimated 4.6 million carriers
of ND-CNVs in the European Union. Due to non-specific combinations of
developmental and common traits, not all ND-CNV carriers are currently routinely
detected by medical personnel, especially at adulthood. Those who have remained
undiagnosed until adulthood often live autonomously but belong to a vulnerable
fraction of the society. Recent array- and sequencing-based variant screenings in
large-scale biobanks have confirmed that citizens at high genetic risk for NDDs will
undoubtedly be uncovered in population initiatives of precision medicine [21].
There is currently no standard in reporting incidental genetic findings with strong
complex effect to biobank volunteer participants. Moreover, the current reference
model in genomic medicine (e.g. common risk scores, automated decision support
systems and active engagement of people in their health management) is hardly
applicable to citizens who are not fully capable of proactive actions and self-
management. In order to equalize their access to the benefits of genome-based
medicine, these individuals need an approach that is tailored to their skills and
resources. To avoid exclusion of a significant sub-population of individuals and
diminish inequality in risk areas where vulnerability may be increased by current
practices in precision medicine, the research community must come up with a precise
plan how to meet these needs and deal with incidental NDD findings.
In parallel, the international recommendations to address needs of undiagnosed rare
disease patients urge all stakeholders to recognise undiagnosed patients as a distinct
population with unmet needs and stress the demand for national sustainable
programmes to enable rapid and equitable access to diagnosis enabling personalized
health and social support for undiagnosed patients. The document distinguishes a
group of ‘not yet diagnosed’ referring to the individuals living with an undiagnosed
condition who have not been referred to the appropriate clinician due to common,
misleading or unusual clinical presentation of a known rare condition. The
recommendations to ameliorate the outcomes for the ‘not yet diagnosed’ group call
11
for enabling better accessibility to extensive genomic data and paving the way for
improved quality of diagnostic tools (UDNI.pdf).
The goals of the proposed project align directly with these needs by addressing the
following aspects:
To exploit previously generated genotype data in the EstBB cohort to
systematically identify undiagnosed carriers of clinically significant CNVs.
To apply genotype-driven deep-phenotyping to gather a comprehensive
collection of ND-CNV-associated developmental and health information in a
clinically unbiased adult cohort.
To use the collected resource for investigating how these variants affect health
in the general population and how the disease traits evolve during ND-CNV
carriers' life-course.
To disclose the incidentally identified genetic finding to the consenting ND-
CNV carriers and to provide them counselling tailored to their individual
needs and presented health conditions.
To utilize the ND-CNV carriers as representatives for collecting data on at-
risk individuals’ expectations, experience and the impact of adult-age genetic
finding on their health and social support.
To carefully evaluate how to deliver incidental genetic findings to previously
undiagnosed biobank participants in a manner that produces maximal benefits
and fully respects their rights for autonomy, dignity and other critical socio-
ethical aspects.
To set up a model framework for the identification and assistance of citizens at
high genetic risk for complex disorders in the population-based initiatives of
genomic medicine.
6. TIME OF CONDUCTING THE STUDY
Start of the project: April 2020
End of the project: March 2025
12
7. STUDY GROUP AND DESCRIPTION OF RECRUITMENT
7.1. Selection and number of research participants
To identify undiagnosed carriers of ND-CNVs in the Estonian population biobank, we
will screen the EstBB cohort of >200,000 individuals for CNVs with confirmed high
clinical relevance. The total number of individuals who carry a ND-CNV is expected
to be approximately 1,800. We will re-contact up to 400 individuals re-grouped by
their ND-CNV carrier status (see Section 8.1 for details). The re-contact group needs
to meet the following inclusion criteria:
The high clinical value of the presented CNV is confirmed, accepted and well
characterized by the medical genetics community (see Section 8.1. for details)
The CNV is recurrently present in the population (for analytical power; ≥5
carriers in the EstBB cohort)
The CNV carrier is a living permanent resident of Estonia
The CNV carrier status of an individual is experimentally validated before sending
the invitation letter (See Section 8.2 for details). The re-contacted CNV carrier will
become a research participant after responding positively to the invitation letter and
consenting for participating in the project.
7.2. Request of de-pseudonymization
We request the ECBHR approval to de-pseudonymize the personal data of up to 400
EstBB participants. The de-pseudonymization process is required to obtain the contact
details necessary for re-contacting the EstBB participants.
The data transferred to the EstBB database from the Estonian Population Register will
be used for collecting the confirmed personal postal address, e-mail address and
phone number of potential study participants. Registry access to retrieve and update
data for participants who has not prohibited the supplementation, renewal or
verification of the description of their state of health, will be performed under the
auspice of the Estonian Human Genes Research Act (HGRA) §24 (2) clause 3.
Re-contact with the EstBB participants will be executed under the auspice of the
HGRA §24 (2) clause 4, that allows de-pseudonymization on the proposal of the chief
13
processor of the EstBB, the Institute of Genomics at the University of Tartu, and with
the consent of the Ethics Committee in order to identify and contact a biobank
participant for updating, supplementing or verifying a description of their state of
health with their written consent.
7.3. Description of recruitment
All participants have voluntarily joined the biobank and signed the broad consent
form (EstBB_Consent), allowing EstBB to follow up their data (if not stated
otherwise in the consent). Upon approval by the ECBHR, selected CNV carriers
(potential study participants) will be invited by a personally addressed letter
(Appendix 1) and will be offered to receive genetic counselling and personal report of
the genetic results. The research title in the letter is simplified (in Estonian “Inimese
pärilikkusmaterjali omapärade seos erinevate terviseriskidega”). This is important
regarding neutrality and not revealing exact details about the research to the gene
donors before formal informing procedure.
Invitation letter will be marked by the potential participant’s name and with the note
“Personal”. According to the Estonian Postal Act §33 (1) the postal secrecy means
confidentiality of all information pertaining to the contents of a postal item and
concerning the postal traffic of a specific person. The obligation to maintain postal
secrecy by all postal service providers during and after the provision of the postal
service is stated by the §33 (2) of the Act, prohibition of collecting information
concerning the content of postal items or specific circumstances of postal traffic for
purposes other than the provision of postal services by the §33 (3).
The invitation package contains an invitation letter addressed to the potential study
participant, a response card and a pre-paid envelope to send their response to the
EstBB (Appendix 1). The potential participants will be informed about
Their right to decide whether to take or not to take part of the study, and the
possibility to inform the research team about their decision by using the
enclosed contact details
Their right to decline the participation without any negative consequences and
any further attempt to contact them by filling and returning the pre-paid
response card to the EstBB
14
The possibility that if they do not respond during 10 days after the date the
invitation letter is expected to arrive, a recruitment specialist will follow-up
with a participant by phone to clarify their willingness to participate. No
response to the phone calls during three weeks will be recorded as refusal to
participate.
For the individuals who demonstrated their interest to participate, a recruitment
specialist will, by phone or e-mail, schedule a suitable date for the first visit. During
the first visit a trained specialist in genomic medicine or a genetic counsellor will
provide comprehensive information about the project that allows the potential study
participant to decide whether or not to give their consent. Each participant who
chooses to join the study will read the information sheet and confirms their decision
by signing an informed consent form (Appendix 2). The investigators ensure that all
recruitment procedures are conducted under the EstBB data collection instructions
and by following international standards and guidelines for good clinical practice.
8. DESCRIPTION OF RESEARCH METHOLOGY
8.1. Selection of ND-CNVs and the ‘genotype-first’ approach
The selection of ND-CNVs is based on the expert-reviewed clinical syndromes listed
in the DECIPHER database (DECIPHER_Syndromes) and is in compliance with the
standard for the interpretation and reporting of CNVs in routine diagnostics
(published by the American College of Human Genetics and Genomics, November
6th, 2019; ACMG_TechnicalStandard_2019).
In the first stage of the study, we will use the ‘genotype-first’ approach to fetch a
comprehensive set of health data from the EstBB database and linked electronic
registries (E-health, Estonian Health Insurance Fund, Estonian Causes of Death
Register), and to map each ND-CNV with their co-occurring disease traits. The
‘genotype-first’ strategy uses genetic testing prior to phenotype evaluation and
systematically re-groups patients by their shared genetic etiology. This method is
opposite to the traditional ‘phenotype-first’ where the selection of cases and controls
is guided by the presence of a disease trait. The ‘genotype-first’ strategy has
advantages in studying complex conditions and a strong potential to advance
15
precision health care. It reduces the costs on exhaustive phenotyping, increases
analytical power to detect valid biomarkers and probability to identify shared
biological mechanisms in genetically homogeneous groups of individuals [22, 23].
In the second stage of the study, we will select a representative set of 10 ND-CNVs as
a paradigm for further evaluation of health consequences in adult CNV carriers,
genetic data return and analysis of at-risk individuals’ experience and the impact of
disclosed genetic finding on their health support.
8.2. Validation of ND-CNV carrier status and de-pseudonymization of
participant data
Before disclosing the incidentally identified genetic finding to the participant during
the second visit, the clinically relevant ND-CNV will be validated twice according to
the previously published protocol [20]:
Firstly, prior to de-pseudonymization of personal data, by using the DNA
sample stored in the EstBB and the Illumina high-resolution SNP genotyping
platform, for example the Illumina Infinium Human OmniExpress assay that
allows seamless and confident detection of all selected ND-CNVs
Secondly, after the first visit and consent for disclosure of genetic finding, by
using the DNA extracted from the blood sample taken on the first visit and
real-time quantitative polymerase chain reaction (real-time quantitative PCR)
targeted to the specific CNV locus
The first confirmation will be followed by de-pseudonymization of validated CNV
carriers’ data, obtain of contact information and invitation to participate in the study
according to the EstBB procedural guidelines (see Section 7 for recruitment
description).
8.3. First appointment, consent and data collection
The estimated duration of the first appointment is 3-5 hours. The visit takes place in
the EstBB recruitment office in Tartu. During the appointment, a genetic counsellor
or a trained specialist in genomic medicine gives additional information about the
study and obtains the informed consent. The participant will be informed about the
16
possibility to receive personalized feedback based on their individual genetic and
health risks. At this stage no details about any potential genetic risks will be disclosed
to the participant. The participant will be notified that during the first visit:
Additional data about participants health and development will be collected by
using ad hoc interviews for health and developmental aspects (Appendix 3)
and validated published tests for social and adaptive behaviour (ASEBA Adult
Self-Report; Adaptive Behavior Assessment System™, 2nd Edition, Adult
Form)
Blood sample (up to 40 ml venous blood) will be drawn by a certified medical
nurse
Their objective measures (height, weight, head circumference, waist and hip
circumference, blood pressure, heart rate, grip strength) will be recorded
Their family pedigree will be recorded
Their photographs (three facial photos of different head orientation) will be
taken for digitalization and group-based analyses
To ensure participant’s anonymity, all collected samples, data and documents will be
pseudonymized by using unique project codes before any research usage (see Section
10.1 for details about the data release).
The pseudonymized blood samples will be transported by a recruitment assistant to
the Institute of Genomics Core Facility and the United Laboratories of Tartu
University Hospital. A fraction of the blood sample will be used in the Institute of
Genomics Core Facility to confirm the individual based on common genetic markers
and to validate potential clinically relevant genetic findings. Another fraction of the
blood sample will be sent to the United Laboratories of Tartu University Hospital for
hematological (according to the selected services listed at TYK_Hematology) and
clinical biochemistry analyses (according to the selected services listed at
TYK_Biochemistry). Both facilities operate according to their best practices.
The photos will be taken with the professional camera of the EstBB and stored
digitally in the EstBB secure coding center (see Section 10.2 for details). All files in
the memory card of the camera will be permanently deleted at the end of each visit
day. The photos will be used only in large groups for computational analyses to
17
identify combinations of subtle facial changes that might be indicators of a specific
genetic variant. Individual photos will not be used or published in any research work
to ensure the anonymity of the participant.
After completion of the procedures of the first visit, the research team will perform
the second validation of the ND-CNV. If confirmed, this will be followed by
preparation of a personalized feedback report and scheduling of the second
appointment for disclosing genetic risk information and genetic counselling.
8.4. Second appointment, return of genetic risk information and counselling
Only participants who consented for receiving genetic information and provided a
blood sample for ND-CNV validation will be invited to the second visit. The
estimated duration of the second appointment is 2-3 hours. The visit takes place in the
EstBB recruitment office in Tartu. The procedures during the visit are following:
A medical specialist will return to the participant their results of
hematological and clinical blood biochemistry analyses tested by the United
Laboratories of Tartu University Hospital
A certified clinical geneticist will introduce a detailed written summary report
based on the participant’s personal genetic variation
The counselling of incidentally identified ND-CNV is customized according to the
collected information about each participant’s existing health conditions. The
participant will receive recommendations for health and social management tailored
to their genetic finding, individual needs and presented health conditions. The
procedure follows previously published protocol [20].
Unless diagnosed for the participant or specifically asked, the participant will not be
counselled about specific disease risks that based on peer-reviewed literature are
significantly associated with a given ND-CNV but have demonstrated variable
expressivity and incomplete penetrance (i.e. a fraction of CNV carriers have the
disease and severity of its outcome varies broadly between individuals) or are
medically not actionable in terms of prevention, therapy or modifications in lifestyle.
This holds particularly true for developmental disorders and mental conditions not
diagnosed for the participant.
18
In addition to the personal report and recommendations, each consenting participant
will receive an information sheet about the relevant ND-CNV written in non-technical
Estonian language (see Appendix 4 for an example sheet for the 16p11.2 deletion).
In the end of the visit, a time slot is dedicated for reflection and participant’s
questions to the clinical geneticist.
Considering the positive feedback from the EstBB gene donors who participated in
the project “Feedback to the gene donors” (in Estonian: “Tagasiside geenidoonorile”;
approval of the Research Ethics Committee of the University of Tartu, protocol
271/T-22, valid through 1.06.2022), the interested participants will be given a
possibility to opt-in for additional genetic feedback in the frames of the EstBB current
projects approved by the Ethics Committee (see Section 11 for details about the
projects). As this information may have an added value on the estimation of
participant’s health risks, the investigators want to respect the participants’ right to
know and not to exclude this possibility. The participants who choose for this option,
will be asked to sign an informed consent for the respective project and will be
handled according to the respective protocol.
8.5. Evaluation of the impact of genetic information
Searching for gene variants reliably associated with risks for different health
conditions continues to receive considerable attention by the personalized health
community. To date, the research has been less focused on the evaluation of how
disclosure of genetic risk information impacts the psycho-social outcome, e.g. how
the participants understand and cope with the information.
One of the goals of the proposed project is to gather information on the psycho-social
impact of return of personalized genetic results to the population carriers of ND-
CNVs. To that end, we will use two questionnaires previously designed to evaluate
participants’ experience in the EstBB feedback projects [20, 24]. The selection of
questions was based on previously conducted analogous studies [25, 26]. This allows
us to compare the outcome in the broad context of genetic data disclosure and, for
example, compare the impact of different types of genetic risk information. The
Participant Immediate Feedback Questionnaire (Appendix 5) will be filled in, as a
printed document, at the end of the second appointment and it will provide insight on
the participant’s psychological response and satisfaction of receiving genetic
19
information. The Participant 6-month Feedback Questionnaire will be sent to the
study participants home address or electronically six months after the feedback
appointment (the second visit). This questionnaire aims to gather the long-term
impact on the EstBB participants’ reaction and involves, for example, questions on
coping with the information, usefulness of the communicated results, regret of their
decision to consent for receiving genetic risk data, etc (see Appendix 6 for details).
Completion of each questionnaire takes less than 20 minutes and to be filled in by the
participants anonymously. The participant can ask for and receive explanation, if any
of the questions is not clear. However, the clinical geneticist in charge is not allowed
to bias the answer of the participant with their assistance. The participants are
expected to express their thoughts with full honesty.
8.6. Governance of collected sensitive data
Data collection for the proposed project will be held only by the EstBB authorized
employees. All de-pseudonymized data (including participant responses, recruitment
schedules, signed consent forms, filled interviews, objective measures, photographs,
etc.) before, during and after the study are stored in the EstBB coding center that
meets the highest security requirements for handling confidential data. Only limited
number of EstBB authorized employees have access to collect, store and de-
pseudonymize the data.
The biological samples and data for validation and research usage will be
pseudonymized with a unique project code provided for each participant by a
recruitment specialist. The keys between the identifying data and project codes will be
stored in the EstBB coding center with no internet connection server and controlled
access limited to the Institute of Genomics authorized employees. Only members of
the research team listed in the application have a right to access the pseudonymized
data for research purpose. To minimize the risk of data breach, secure data transfer
tools and secondary project codes will be used in any case the data will be used
outside of the EstBB information infrastructure.
The results of the project will be published in peer-reviewed scientific and medical
journals and presented in relevant scientific and medical conferences. The
investigators ensure that only minimal necessary potentially identifying metadata
(age, sex) will be revealed during the publication process and no individual-level data
20
(e.g. pseudonymized case reports) will be presented outside of professional context,
for example in public outreach events.
According to the HGRA § 18 (1) biological samples, genotype and phenotype data in
the EstBB will be preserved in pseudonymized or de-pseudonymized form without a
term, unless § 21 (1) or (2) of the HGRA applies. All materials related to recruitment
and organizational aspects of the project (e.g. scheduling tables, reimbursement
documents, etc.) will be destroyed five years after the end of the project. See Section
10 for details of data protection aspects.
9. ANALYSIS OF ETHICAL ASPECTS OF THE STUDY
9.1. Respect for individual autonomy and informed consent
The proposed project involves adult human beings who have previously consented for
joining the Estonian Biobank (EstBB_Consent). The legal framework for human
subject’s research in the EstBB is up-to-date and transparent, the biobank is
conducted according to the Estonian Human Genes Research Act (HGRA). Regulated
by the HGRA §9, the voluntary nature of gene donation, we have no reason to doubt
that all EstBB participants have been properly informed and have been able to
voluntarily give their consent at the recruitment.
According to the §3 (1) clause 3 of the HGRA, the EstBB has objective to use the
results of genetic research to improve public health. In compliance with this objective,
we request the ECBHR approval to de-pseudonymize the personal data of up to 400
EstBB participants. These individuals will be invited to the second stage of the project
for further evaluation, disclosure of their genetic risk results and genetic counselling
(see Sections 7 and 8 for study group description and methodology). Template of the
invitation letter is attached to the application as Appendix 1. The investigators ensure
that all invited individuals are free to decide whether or not they are willing to
participate in the study. The individuals who choose to participate will be informed
about the aims and procedures of the project prior to recruitment. A supplementary
informed consent specifically designed for the project will be obtained from each
EstBB participant who agree to participate in the second stage. Template of the
participant information sheet and consent form is attached to the application as
Appendix 2. The investigators ensure that all recruited participants have fully
21
understood the information and have not felt pressured or coerced into giving consent.
A person will not be enrolled in the study if the recruitment specialist suspects that
he/she is unable to understand provided information or to give voluntary consent.
The proposed project will be conducted in compliance with main applicable
international and Estonian legal regulations, such as the European Union General
Data Protection Regulation (GDPR) and the Estonian Human Genes Research Act.
Data processing and analysis conducted by Swiss members of the research team is
conducted under the regulation of the GDPR, the Swiss Federal Act on Research
Involving Human Beings and the Swiss Federal Act on Data Protection.
9.2. The principle of justice, respect for human dignity and rights of research
participants
The investigators are familiar with the general ethical principles defined by main
declarations and recommendations, such as the WMA Declaration of Helsinki, the
OECD Guidelines on Human Biobanks and Genetic Research Databases, the Ethical
Framework for Responsible Data Processing in Personalized Health Research
developed by the Swiss Personalized Health Network (SPHN_ELSI). The
investigators ensure that they will carry out their activities throughout the study in
accordance with these principles and guidelines. We ensure respect for people and for
human dignity. We acknowledge and respect the participants’ confidentiality, values,
interests and right to have control over their personal information before (see Section
9.1. or details) and after enrollment in the study. No participant will be discriminated
against upon joining or for being a participant in the project. All participants can
withdraw their consent at any time without a need to explain. In case a participant
applies for destruction of their data, the data collected in this project for the person in
question will be, unless technically impossible, removed from the project database,
the identification key and the human tissue samples collected during this project will
be destroyed. Withdrawal from the study will not lead to any negative consequences
for the participant.
According to the Estonian Human Genes Research Act Chapter 2 §11 (2) and §11 (4)
the EstBB participants have the rights to access their personal genetic information and
to receive counselling. This is in agreement with the generally accepted research
participants’ right to receive at least clinically actionable information that may result
22
from the analysis of their personal data and biological material (see for example
SPHN_ELSI). Addressing the research participants right to know and to set the
ground for equal opportunities in the genomic medicine is a central goal of the
proposed project (see Sections 4 and 5 for details). Further, the principle of equality
and justice can be illustrated by the research subjects of the proposed project. The
undiagnosed adult ND-CNV carriers are at high genetic risk to suffer from severe and
life-long health conditions (See Section 4 and 5 for details). We can hypothesize, that
if these individuals have voluntarily joined the biobank, they might hold a certain
hope to receive some insight into their health problems. The current mainstream
model in the population-based genomic medicine has focused on returning risks
related to common variation or certain monogenic predispositions while leaving
behind citizens at high genetic risk for complex and mental disorders. Some might
argue that there is a moral duty not to withhold a major genetic risk event that is
presumably linked to the participants existing clinical conditions, medically
actionable and can be feasibly and reliably identified by the genome-wide techniques
broadly used in the population biobanks. The proposed project aims to contribute to
setting up an evidence-based model that would respond to the health needs of this
group of citizens and guide towards greater equality in distribution of benefits that
genomic medicine has to offer.
9.3. The principle of well-meaning and benefits of the proposed project
We ensure that the proposed project is well-meant and presents fair distribution of
benefits and burden. The benefits of the proposed study are three-fold.
First, at national level, the results are necessary for the advancement and broader
accessibility of personalized medicine in Estonia (see also Sections 5 and 9.2.). The
research results and developed framework for genetic data return are expected to
benefit a considerable fraction of the EstBB participants, as well as Estonian
population in general. In parallel with the benefits to the Estonian society by
promoting the implementation of research findings into health care, the proposed
research will raise the value and visibility of the Estonian Biobank both locally and
internationally.
Second, at individual level, the outcomes of this project will meet the expectations of
the voluntary EstBB participants who consent for receiving feedback about their
23
genetic risks and health. The application has a high potential to increase the
diagnostic yield among the ‘not yet diagnosed’ individuals with CNV disorders.
Identification of the undiagnosed (according to the data retrieved from the health
registers) genetic risk variant will provide to the participants an opportunity to seek
for specialized medical support and to find explanation to some of their existing
(often life-long) health conditions. We do not expect that this will significantly
increase the at-risk individuals’ health care costs. Improved identification of
genetically determined preventable (e.g. obesity) and treatable conditions (e.g.
obsessive-compulsive disorder) will rather allow optimal admission to certain
interventions and will lead to more efficient health care plans. As an example, gastric
bypass surgery has been generally shown to be an effective intervention in severely
obese adults. However, it poses unnecessary costs and risks in case of patients who
are obese due to dysregulation of satiety response in the brain (e.g. carriers of CNVs
in the 16p11.2 chromosome region, population prevalence 1:2,000, i.e. estimated 650
individuals in Estonia). Similarly, adequate counselling of risk behaviours,
occupational or speech therapy can positively impact educational choices and
employment, which in turn might help to improve self-management and social
outcomes of citizens with multimorbid disorders. For the CNV carriers at younger
adult age, receiving their genetic finding will provide the opportunity for, if they are
willing so, timely genetic counselling to assist family planning.
Third, the international medical genomics community will benefit from the data and
evidence gathered from the project. The goals of the proposal align with the
international recommendations to enable better access to extensive genomic data sets
for ameliorating the diagnostic perspective of ‘not yet diagnosed’ patients with known
diseases (see Section 5 for details). Following the same general line, a recent survey
among psychiatric geneticists highlighted the need to take steps towards best practices
in returning genetic results to research participants at risk for psychiatric disorders. In
this study, 85% of respondents believed that ‘medically actionable findings’ and 54%
that ‘clinically valid but non–medically actionable findings’ should be returned,
underlining participants ‘right to know’ and ‘duty to inform to try to improve the
participants quality of life’. Notably, the authors pointed to significant gap between
the best and the actual practices and current lack of evidence-based norms [21] into
which the proposed project aims to contribute.
24
9.4. The principle of non-harming and minimization of risks
The investigators fully comprehend possible risks that may arise from the delicate
subject of neurodevelopmental genetics, potential vulnerability of some research
participants and high levels of security required for handling collected sensitive
information. The research team has been selected and the research methodology
designed to minimize risks and ensure non-harming of participants. The core research
team is composed of specialists in clinical genetics, genetic counselling and
neurodevelopmental genetics, complemented by experts in data security, human
research ethics, statistical genetics and human genomics.
The risk of genetic discrimination in Estonia is minimized by up-to-date transparent
legal framework for human subject’s research (the Estonian Human Genes Research
Act), government-funded and strictly regulated genetic testing program in the EstBB
and the state-run solidarity-based health insurance system (the Estonian Health
Insurance Fund).
All steps of the project involving research participants and/or de-pseudonymized
personal data will take place in the EstBB recruitment office and data coding center
and will be conducted by the EstBB authorized employees. All employees who
participate in phenotype data collection, genetic feedback and counselling, have
otherwise direct contact with the participants and/or access to personalized
information have been informed about the rules of processing sensitive data,
maintaining research participants’ privacy and have signed the EstBB confidentiality
agreement.
Medical specialist or a trained specialist in genomic medicine will ensure that the
information about the project and the outcomes will be clear and understandable
before signing the consent form and conducting the data collection interviews. To
maximize the research impact and minimize the risks regarding sensitive information
about participants’ development and health, specialist from the fields of psychology,
research ethics, medical genetics, medicine and data security have been involved in
the preparation of the research protocol. Selection of questionnaires was consulted
with external experts at the Center for Human Development and Disability,
University of Washington Medical Center (Seattle, WA, USA), one of the principal
recruitment centers for patients with neurodevelopmental disorders in the USA. To
25
enhance the impact of the collected data, the broad usability of the questionnaires in
the field and seamless linking of the results with those from the other studies was a
prerequisite for the selection.
Prior to the interview, the participants will be informed about their right to leave
questions unanswered if they feel uncomfortable or for any other reasons. All
employees who administer the interviews ensure to respect the participant choice to
do so. Collected personalized data will be stored together with any other sensitive
data in the EstBB coding center designed for protection of confidential data (see
Section 10.2 for details of confidential data governance).
The project will consider only the effect of certain blocks of genes, i.e. CNVs, in the
genome that are known to be associated with actionable health risks. To minimize the
risks of unjustified confusion, anxiety or worry the following measures have been
taken into account:
The CNV-associated risk results will be based on confirmed clinical
significance and actionable information (see also Section 8.1.)
Genetic variants or risk estimations with potential, but uncertain medical
significance will not be reported back to participants
The genetic variation report and counselling is customized according to the
collected information about each participant’s existing health conditions
Unless relevant to a specific participant, disease risks associated with a given
ND-CNV that have demonstrated variable expressivity and incomplete
penetrance or are medically not actionable will not be communicated. This
holds particularly true for developmental disorders and mental conditions not
diagnosed for the participant (see also Section 8.4.)
The reporting and counselling of genetic risks will be conducted by a certified
clinical geneticist and genetic counsellor with help from a trained specialist in
genomic medicine
At any point, all members of the research team will provide the best caring attitude
towards the participants to make them feel respected and supported.
The primary outcome of the project for each participant will be personalized health
risk information based on individual genetic variation. This information may at first
26
be unexpected and worrisome for some of the study participant. To avoid unnecessary
immediate harm and to reduce the negative feelings projected towards their future, the
counsellor will carefully explain the reason to address genetic risk information, the
opportunity to provide improved healthcare solutions or suggestions for optimal
lifestyle choices for prevention. The individual genetic reports prepared for each
participant include recommendations for personalized health management, for
example suggestions to refer the participant to medical specialist for preventing late
onset complications. To avoid confusion, a time slot is dedicated in the end of the
visit for reflection and participant’s questions to the clinical geneticist.
In addition to the psycho-social impact, the data collection procedure may be tiresome
and/or blood draw may cause temporary discomfort and anxiety for some participants.
The research team will provide their best support to the participants. For example, a
break with warm lunch is scheduled during the first visit, refreshments, coffee and tea
are offered to the participants if needed (e.g. after blood draw, prolonged duration of a
visit, etc.). If a participant feels dizzy after giving a blood sample, they are offered a
possibility to lay down, or take a break if they feel tired.
After careful evaluation of involved risks, burdens and benefits, we strongly believe
that the research team is qualified to identify the potential risk areas, to minimize
predictable risks and the benefits expected to result from this project will clearly
outweigh the potential burden to the participants.
9.5. Accountability of proposed research
The proposed project will be conducted and supervised by competent individuals with
the appropriate ethics and scientific education, specialized training and research
qualifications. The involved investigators are internationally recognized experts with
strong track record in the fields of medical genetics and human genomics (see also
Section 12.1). Methodology of the proposed research is solid, the scientific questions
are novel and meet the current needs of the medical genomics community. Expected
results of the project will have implications for personal risk evaluation and support
plans for individuals challenged by genetic events with strong effect. They should
advance the understanding of mechanisms contributing to the etiologies of complex
disease and provide information pertinent to the clinical and research community.
27
The research team is involved in multiple initiatives that aim to embolden
collaboration between researchers, physicians and citizens for the emergence of
personalized medicine. In addition, we have a direct link with international rare
disease patient organizations and initiatives (Olivier Menzel through EURORDIS,
Rare Disease International; Katrin Männik through COST MINDDS - Maximizing
Impact of Research in Neurodevelopmental Disorders). This allows us to reach out to
patients and other stakeholders, collect their expectations, disseminate our results and
raise awareness of genetic susceptibility in complex neurodevelopmental disorders in
the community.
10. ANALYSIS OF DATA PROTECTION ASPECTS OF THE STUDY
10.1. Release of the data in the Estonian biobank
There are three data releases within the scope of this project:
First, the EstBB genotype data is required for research participant selection.
The investigators will screen the EstBB cohort of >200,000 individuals for
CNVs with confirmed high clinical relevance to identify undiagnosed carriers
of ND-CNVs.
Second, to map each ND-CNV with their co-occurring disease traits, a
comprehensive set of existing phenotype data from the EstBB database
(general data, objective measures, occupational and educational information,
reproductive health, disease diagnoses, drug usage) and linked electronic
registries (E-health, Estonian Health Insurance Fund, Estonian Causes of
Death Register) will be requested for up to 1,800 identified ND-CNV carriers.
Third, all data collected during the proposed project and entered to the EstBB
database will be requested for fulfilling the research goals of the project.
In all cases, access to the EstBB data is granted after the approval from the ECBHR,
and the research will be conducted subsequently. The Director of the Institute of
Genomics of the University of Tartu will appoint the responsible employees of the
Institute of Genomics for the procedures as well as will give the order to release the
data. Additionally, the data transfer and use agreement (DTUA), as well as the data
28
transfer protocol will be signed by the Principal Investigator and the Director of the
Institute of Genomics.
The released data is stored and processed in the Research Cloud of Tartu University
that has passed the ISKE audit in December 2017 and meets the ISKE M level
requirements (security class T1K1S2). The data access is controlled by the Institute of
Genomics and restricted only to individuals involved in the research and listed in the
current proposal. Findings of the study will be reported back to the Estonian Biobank
and integrated in the database on an individual level.
The principal investigator will secure the confidentiality of the data and ensure that all
data protection regulations according to the signed contract and general data
protection regulations are followed. All investigators are informed about the data
processing rules. The data shall be used only in accordance to the goals and scope of
the proposed research. The distribution of data to third parties is prohibited without
the written consent of the Institute of Genomics. The DTUA will specify the measures
to ensure that the data will not be misused after conclusion of the research purpose or
upon the expiry of the DTUA (the date defined in the agreement), for example
revocation of access, data destruction etc.
10.2. De-pseudonymization of research participants and governance of
confidential data
The procedure of de-pseudonymization and re-contact will be executed according to
the HGRA §24 (2) clause 4 that allows de-pseudonymization on the proposal of the
controller of the EstBB and with the consent of the Ethics Committee in order to
identify a biobank participant for contacting them for renewing, supplementing or
verifying a description of their state of health with their written consent.
According to the HGRA § 22 (3), only persons specifically appointed by the
controller of EstBB, the Institute of Genomics, are allowed to perform de-
pseudonymization. Data collection will be held only by the authorised employees of
the Institute of Genomics. All employees who will work, for example at the steps of
phenotype data collection, genetic feedback and counselling, directly with the
participants and/or will have access to personalized information have been informed
about the rules of processing of sensitive data and have signed the EstBB
confidentiality agreement.
29
All personalized, confidential and sensitive data collected during the project will be
stored in the EstBB coding center designed for protection. The room is not connected
to internet, has lighting regime of 24 hours per day and 7 days per week, is accessible
for limited number of authorized individuals and is protected with a code and alarm.
Hard copy images (e.g. drawings of pedigrees) will be digitalized, originals will be
archived securely together with all other documents that can be associated with a
particular research participant. Unofficial notes are prohibited to take in any form by
the medical specialist or data collectors.
The results of their genetic and health risks will be returned personally to each
participant who consented for receiving this information. The report will be printed in
two copies and signed by the participant and the clinical geneticist. The signed hard
copy for the EstBB shall be held in a non-transparent binder until its arrival to the
coding center shortly after the feedback visit. Each participant is free to decide
whether to keep the information and the copy of the report to themselves or share it
with their general practitioner, other medical specialists or family members.
10.3. Governance and release of collected pseudonymized data for research
purpose
All data collected during the project will be directly entered in a pseudonymized form
to the EstBB research database. For scientific research purposes, the investigators can
request the pseudonymized data and upon authorization issued by the Principal
Investigator the EstBB routine procedure for pseudonymized data release follows (see
Section 10.1). No personalized information will be released to the members of the
research team.
The results of the project will be published in peer-reviewed scientific and medical
journals in a coded form impossible to associate with specific study participants’
identities.
All members of the research team are responsible to adequately protect the data and
their data access credentials against unauthorized access, misuse or corruption. All
incidents potentially affecting data security shall be reported with no delay to the
Principal Investigator and to the director of the Institute of Genomics at the University
of Tartu.
30
This application for ethical approval has been reviewed and approved by persons
authorized by the Chief Data Protection Officer of the University of Tartu, Helene
Alavere, Head of Data Collection Department and Project Manager of the Estonian
Institute of Genomics and Evelin Tali, Analyst of the Estonian Institute of Genomics.
11. INFORMATION ON EARLIER OR SIMULTANEOUS ASSESSMENT OR
ON APPROVAL OF THE SAME PROJECT ELSEWHERE
The current proposal is a follow-up to long-time collaboration between the EstBB and
the University of Lausanne in the field of rare clinically relevant CNVs. By using the
same strategy, the study will scale-up our initial approach that targeted one of the
CNV regions in the 16p11.2 genomic locus - Katrin Männik “Deciphering phenotypic
variability of genomic disorders using the 16p11.2 syndromes as a paradigm” (in
Estonian: “16p11.2 sündroomide ja teiste genoomsete haiguste fenotüübilise
varieeruvuse uuringud”), approved by the Research Ethics Commitee of the
University of Tartu (REC UT; protocol 252/T-6, valid through 31.12.2020). Related
project has been reviewed and approved by The Committee of Human Research
Ethics of the Canton of Vaud, Switzerland (protocol 131/09).
The REC UT has previously given approvals to conduct similar projects involving the
principal investigators of the currently proposed project. These include:
Katrin Männik and Santhosh Girirajan “Towards understanding the complex genetics
of human intellectual disability disorders” (in Estonian: “Uuringud inimese
intellektipuude aluseks oleva kompleksgeneetika mõistmiseks”; protocol 264/T-19,
valid through 31.12.2021). The study is a sub-project of general studies in the 16p12.1
CNV region reviewed and approved by the Internal Review Board of the
Pennsylvania State University, PA, USA (protocol HRP-503f).
Neeme Tõnisson “Meditsiinilist sekkumist vajavate geenivariantide leidmine ja nende
osas tagasiside andmine geenidoonoritele”; protocol 258/T-22 valid through
31.12.2025).
Andres Metspalu “Feedback to the gene donors” (in Estonian: “Tagasiside
geenidoonoritele”; protocol 271/T-22, valid through 1.06.2022)
Tõnu Esko “Determination of the phenotype of familial hypercholesterolaemia and
further clinical management on the basis of the finding obtained in genome-wide
31
study” (in Estonian: “Perekondliku hüperkolesteroleemia fenotüübi täpsustamine ja
edasine kliiniline käsitlus ülegenoomsel uuringul tuvastatud leiu alusel”; protocol
253/T-14 valid through 31.12.2020, amendment approved by protocol 259/M-20,
valid through 31.12.2020).
Peeter Padrik “Implementation of a model for personalised risk-based breast cancer
prevention and screening” (in Estonian: "Rinnavähi personaliseeritud riskidel
põhineva ennetuse ja sõeluuringu rakendamine"; protocol 282/T-29, valid through
31.12.2020).
32
12. SUPPLEMENTARY INFORMATION
12.1. CVs of principal investigators and research collaborators
12.2. Participant information and declaration of consent
Appendix 1 - Invitation letter to potential research participants (in Estonian)
Appendix 2 - Participant information sheet and consent form (in Estonian)
12.3. Study protocols, data collection and return of research results
Appendix 3 - Developmental and Medical History Questionnaire (in Estonian)
Appendix 4 - Example of ND-CNV patient information sheet (in Estonian)
Appendix 5 - Participant Immediate Feedback Questionnaire (in Estonian)
Appendix 6 - Participant 6-month Feedback Questionnaire (in Estonian)
12.4. Handwritten signatures of the Swiss collaborators and the directors of
participating institutions
Appendix 7- Signatures_1
Appendix 8- Signatures_2
Appendix 9- Signatures_3
33
REFERENCES
1. Gustavsson, A., et al., Cost of disorders of the brain in Europe 2010. Eur
Neuropsychopharmacol, 2011. 21(10): p. 718-79.
2. Trautmann, S., J. Rehm, and H.U. Wittchen, The economic costs of mental
disorders: Do our societies react appropriately to the burden of mental
disorders? EMBO Rep, 2016. 17(9): p. 1245-9.
3. Plummer, J.T., A.J. Gordon, and P. Levitt, The Genetic Intersection of
Neurodevelopmental Disorders and Shared Medical Comorbidities - Relations
that Translate from Bench to Bedside. Front Psychiatry, 2016. 7: p. 142.
4. Happell, B., et al., Scoping review of research in Australia on the co-
occurrence of physical and serious mental illness and integrated care. Int J
Ment Health Nurs, 2015. 24(5): p. 421-38.
5. Hochstenbach, R., et al., Genome arrays for the detection of copy number
variations in idiopathic mental retardation, idiopathic generalized epilepsy
and neuropsychiatric disorders: lessons for diagnostic workflow and research.
Cytogenet Genome Res, 2011. 135(3-4): p. 174-202.
6. Mannik, K., et al., Copy number variations and cognitive phenotypes in
unselected populations. JAMA, 2015. 313(20): p. 2044-54.
7. Kendall, K.M., et al., Cognitive Performance Among Carriers of Pathogenic
Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. Biol
Psychiatry, 2016.
8. Guyatt, A.L., et al., Association of copy number variation across the genome
with neuropsychiatric traits in the general population. Am J Med Genet B
Neuropsychiatr Genet, 2018. 177(5): p. 489-502.
9. Owen, D., et al., Effects of pathogenic CNVs on physical traits in participants
of the UK Biobank. BMC Genomics, 2018. 19(1): p. 867.
10. Crawford, K., et al., Medical consequences of pathogenic CNVs in adults:
analysis of the UK Biobank. J Med Genet, 2019. 56(3): p. 131-138.
11. Burghel, G.J., et al., Presence of pathogenic copy number variants (CNVs) is
correlated with socioeconomic status. J Med Genet, 2020. 57(1): p. 70-72.
12. Weiss, L.A., et al., Association between microdeletion and microduplication
at 16p11.2 and autism. N Engl J Med, 2008. 358(7): p. 667-75.
13. Zufferey, F., et al., A 600 kb deletion syndrome at 16p11.2 leads to energy
imbalance and neuropsychiatric disorders. J Med Genet, 2012. 49(10): p.
660-8.
14. McCarthy, S.E., et al., Microduplications of 16p11.2 are associated with
schizophrenia. Nat Genet, 2009. 41(11): p. 1223-7.
15. D'Angelo, D., et al., Defining the Effect of the 16p11.2 Duplication on
Cognition, Behavior, and Medical Comorbidities. JAMA Psychiatry, 2016.
73(1): p. 20-30.
16. Jacquemont, S., et al., Mirror extreme BMI phenotypes associated with gene
dosage at the chromosome 16p11.2 locus. Nature, 2011. 478(7367): p. 97-102.
17. Maillard, A.M., et al., The 16p11.2 locus modulates brain structures common
to autism, schizophrenia and obesity. Mol Psychiatry, 2015. 20(1): p. 140-7.
18. Shinawi, M., et al., Recurrent reciprocal 16p11.2 rearrangements associated
with global developmental delay, behavioural problems, dysmorphism,
epilepsy, and abnormal head size. J Med Genet, 2010. 47(5): p. 332-41.
34
19. Walters, R.G., et al., A new highly penetrant form of obesity due to deletions
on chromosome 16p11.2. Nature, 2010. 463(7281): p. 671-5.
20. Leitsalu, L., et al., Reporting incidental findings of genomic disorder-
associated copy number variants to unselected biobank participants. Per Med,
2016. 13(4): p. 303-314.
21. Kostick, K., et al., Psychiatric genomics researchers' perspectives on best
practices for returning results to individual participants. Genet Med, 2020.
22(2): p. 345-352.
22. Arnett, A.B., S. Trinh, and R.A. Bernier, The state of research on the genetics
of autism spectrum disorder: methodological, clinical and conceptual
progress. Curr Opin Psychol, 2019. 27: p. 1-5.
23. Stessman, H.A., R. Bernier, and E.E. Eichler, A genotype-first approach to
defining the subtypes of a complex disease. Cell, 2014. 156(5): p. 872-7.
24. Alver, M., et al., Recall by genotype and cascade screening for familial
hypercholesterolemia in a population-based biobank from Estonia. Genet
Med, 2019. 21(5): p. 1173-1180.
25. Kasparian, N.A., C.E. Wakefield, and B. Meiser, Assessment of psychosocial
outcomes in genetic counseling research: an overview of available
measurement scales. J Genet Couns, 2007. 16(6): p. 693-712.
26. Gray, S.W., et al., Social and behavioral research in genomic sequencing:
approaches from the Clinical Sequencing Exploratory Research Consortium
Outcomes and Measures Working Group. Genet Med, 2014. 16(10): p. 727-
35.
35
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5154082
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
Austatud Nimi Perenimi!
Olete saanud käesoleva kirja, kuna osalete Tartu Ülikooli Eesti geenivaramu projektis ja olete
geenidoonor.
Oleme alustamas uut teadusuuringut, kuhu kaasatakse väike osa geenidoonoritest, kellel soovime
seni olemasolevaid andmeid täiendada. Soovi korral on Teil võimalik saada ka tagasisidet oma
isiklike terviseriskide kohta.
Kutsume Teid geenivaramu uuringusse „Inimese pärilikkusmaterjali omapärade seos erinevate
terviseriskidega“, mis toimub koostöös kahe Šveitsi teadusasutusega - Lausanne´i Ülikooli
Integreeritud Genoomika Keskusega ja Genfis asuva Health2030 Genoomika Keskusega.
Teadustöö põhiline eesmärk on uurida inimese pärilikkust ning selle seost teatud füüsiliste
tunnuste (näiteks kehakaal, lihastugevus) ja tervislike seisunditega (näiteks probleemid südamega,
närvi- ja lihaskonnahaigused, meeleoluhäired jt.), mille kohta võib leiduda olulist teavet juba
varase ea terviseandmetes. Sellepärast soovime täiendada neid andmeid, mis on Teie kohta
geenivaramus juba varasemast olemas.
Uuringus osalemiseks palume Teil tulla kahele vastuvõtule, mis toimuvad Tartus Riia tn 23b,
geenivaramu andmekogumiskabinetis. Teile hüvitatakse sõiduga seotud transpordikulud esitatud
sõidudokumentide alusel. Transpordi juhised ja kulude hüvitamise detailid saate kokku leppida
geenivaramu töötajaga, kes võtab Teiega telefoni või e-maili teel ühendust pärast seda, kui olete
meile teada andnud oma osalemissoovist.
Esimese vastuvõtu käigus tutvustatakse uuringut lähemalt ning Te saate esitada täiendavaid
küsimusi uuringu kohta. Pärast nõusoleku vormi allkirjastamist küsitakse andmeid Teie tervise,
lapseea arengu ja igapäevaelu kohta. Selleks on koostatud üksikasjalikud küsimustikud, mis
täidetakse koos nõustamiskogemusega spetsialistiga esimesel vastuvõtul intervjuu vormis. Samuti
on plaanis võtta Teilt vereproov (kuni 40 ml veeniverd). See on vajalik selleks, et teha kinnitav
geenianalüüs ja kliinilise vere analüüs ning on eelduseks teise visiidi ehk tagasiside vastuvõtu
toimumisele. Pärast vereproovi võtmist pakutakse Teile sooja lõunasööki, kuna enne vereproovi
andmist on vaja olla vähemalt 6 tundi söömata. Esimesele visiidile kulub koos lõunaga kokku 3 kuni
5 tundi.
Teine vastuvõtt toimub juhul, kui soovite saada kliinilise geneetika spetsialistilt soovitusi ja
kirjalikku kokkuvõtet uuringu tulemustest, milles kirjeldatakse Teie terviseriske ja isiklikke
geneetilisi eripärasid ja vajadusel võimalikku mõju perekonnale. Lisaks edastame Teile soovi korral
Tartu Ülikooli Kliinikumi ühendlaboris tehtud kliinilise vereanalüüsi tulemused. Selleks võtab
Teiega telefoni või emaili teel ühendust geenivaramu andmekoguja ja aitab kolme kuu jooksul
peale esimest visiiti leida aja teiseks vastuvõtuks. Teine visiit kestab 2-3 tundi.
1
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5154082
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
Oma huvist uuringus osaleda palume teada anda 10 päeva jooksul:
Geenivaramu telefonil 7374030 või 5206959, tööpäevadel kell 9-16 (lõuna 12-13) või meiliaadressil
[email protected].
Kui võtate ühendust emaili teel, palume lisada kirjale kontakttelefoni number, et saaksime Teile
tagasi helistades paindlikumalt sobivaid vastuvõtuaegu pakkuda.
Kui Te ei ole uuringus osalemisest huvitatud või ei saa uuringus osaleda, palume täita kutsega
kaasas olev „Ma ei soovi uuringus osaleda“ vastuse leht või helistada ülaltoodud
telefoninumbritele. Kui valite vastuse lehe tagasi saatmise, tehke seda palun 10 päeva jooksul.
Selleks saate kasutada kutsega kaasas olevat makstud vastuse ümbrikut.
Kui Te ei ole 14 päeva jooksul teada andnud oma soovist uuringus osaleda või mitte osaleda,
võtame Teiega ise ühendust telefoni teel, et täpsustada, kas geenivaramu kutse on Teieni jõudnud.
Kui geenivaramu ei saa ühendust kolme nädala jooksul, loeme seda uuringus osalemisest
keeldumiseks.
Teie kontaktandmed oleme saanud Teilt geenivaramuga liitumise ajal või andmete täiendamisel
rahvastikuregistrist.
On oluline teada, et uuringus osalemine on Teile vabatahtlik.
Antud uuring ja selles kasutatud küsimustikud ning muud materjalid on saanud kooskõlastuse Eesti
bioeetika ja inimuuringute nõukogult.
Soovime Teile kõike head ja täname koostöö eest Tartu Ülikooli Eesti geenivaramuga!
Neeme Tõnisson,
Tartu Ülikooli Eesti geenivaramu
meditsiinigeneetika vanemteadur
Lisaküsimuste korral uuringu kohta saab meiega kontakti:
Andmekogujad Esta Pintsaar ja Triinu Temberg
7374030; 5206959
ajad, mil saab helistada: esmaspäevast reedeni 9.00 - 16.00
2
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5154082
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
Neeme Tõnisson
56684694;
[email protected]
meditsiinigeneetika vanemteadur, uuringu juht
3
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5154082
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
Vastus
(Palun täitke allpool olev vastuse leht ainult juhul, kui olete otsustanud uuringus mitte osaleda)
Ma ei soovi uuringus osaleda.
Nimi:_______________________________________________________________
Kuupäev:____________________________________________________________
Allkiri: _____________________________________________
Palun saatke vastusleht tagasi meile XXXX kuupäevaks kutsega kaasas olnud ettemakstud ümbrikut
kasutades.
4
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Uuringus osaleja informeerimise leht ja teadliku nõusoleku vorm
Käesolev dokument sisaldab teavet uuringu "Kliiniliselt oluliste struktuursete geenivariantide mõju
üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise
tulemid ja personaliseeritud käsitlus” kohta, et aidata Teil otsustada, kas soovite selles osaleda.
Uuringusse kutsutakse geenidoonoreid, et täiendada geenivaramus olemasolevaid andmeid ning
soovi korral anda kogutud andmete põhjal tagasisidet personaalsete terviseriskide kohta. Käesoleval
vormil on kaks osa:
1. Informatsioon uuringu kohta
2. Teadliku nõusoleku vorm allkirjastamiseks, kui soovite uuringus osaleda
Uuringu viivad läbi Tartu Ülikooli Eesti geenivaramu, Lausanne´i Ülikooli Integreeritud Genoomika
Keskuse ja Genfis asuva Health 2030 Genoomika Keskuse teadlased.
Teie kontaktandmed on saadud Tartu Ülikooli Eesti geenivaramu (edaspidi geenivaramu) andmebaasis
hoitavate andmete depseudonüümimise ehk tagasikodeerimise teel. Tagasikodeerimise käigus järgiti
andmekaitse nõudeid, mis on sätestatud inimgeeniuuringute seaduse ja isikuandmete kaitse
seadusega. Inimgeeniuuringute seaduse §24 lõige (2) punkt 4 kohaselt on vastutaval töötlejal lubatud
tagasikodeerimist läbi viia vastutava töötleja ettepanekul ja eetikakomitee nõusolekul geenidoonori
tuvastamiseks, temaga ühenduse võtmiseks ning tema kirjalikul nõusolekul terviseseisundi kirjelduse
uuendamiseks, täiendamiseks või kontrollimiseks. Geenivaramu vastutav töötleja on Tartu Ülikool.
Tagasikodeerimise teostasid geenivaramu töötajad, kellele on vastavad volitused andnud
geenivaramu direktor.
Allkirjastatud nõusoleku vormi säilitatakse geenivaramus. Teile antakse allkirjastatud nõusoleku vormi
koopia.
Küsimuste tekkimise korral saate ühendust võtta uuringu juhiga.
Neeme Tõnisson,
meditsiinigeneetika vanemteadur
56684694;
[email protected]
1
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Informatsioon uuringu kohta
Lühikokkuvõte uuringust
Inimgeeniuuringute seaduse kohaselt on Eesti geenivaramu eesmärk edendada geeniuuringute
arengut, koguda teavet Eesti rahvastiku tervise ja pärilikkuse informatsiooni kohta ja rakendada
saadud geeniuuringute tulemused rahva tervise parandamiseks.
Käesoleva uuringu põhiline eesmärk on uurida inimese pärilikkust ning selle seost teatud füüsiliste
tunnuste (näiteks kehakaal, lihastugevus jt.) ja tervislike seisunditega (näiteks probleemid südame või
neerudega, närvi- ja lihaskonnahaigused, meeleoluhäired jt.), mille kohta võib leiduda olulist teavet
juba varase ea terviseandmetes. Sellepärast soovime täiendada neid andmeid, mis on Teie kohta
geenivaramus olemas.
Uuringu käigus toimub kaks uuringuvisiiti. Esimene visiit kestab 3 kuni 5 tundi ja teine 2-3 tundi.
Uuringu olemusega seotud küsimusi ja geeniuuringutega seotud informatsiooni selgitavad Teile
vastava nõustamiskogemusega spetsialist ja kliinilise geneetika spetsialist. Kogu uuring viiakse läbi
juhindudes geenivaramu andmekogumise protseduurijuhenditest, kehtivast heast kliinilisest tavast ja
isikuandmete kaitse seadusest.
Esimese vastuvõtu käigus tutvustatakse uuringut lähemalt ning kirjaliku nõusoleku andnud uuringus
osalejaga on plaanis täiendada tema terviseandmeid ning koguda lapseea arengut ja igapäevaelu
käsitlevaid andmeid, mida varem ei ole küsitud. Selleks on koostatud üksikasjalikud küsimustikud, mis
täidetakse koos nõustamiskogemusega spetsialistiga.
Lisaks võetakse esimesel vastuvõtul osalejalt vereproov (kuni 40 ml veeniverd) ja tehakse täiendavad
pikkuse, kehakaalu jms objektiivsed mõõtmised. Terviseandmete uuendamine ja vereproovi võtmine
on vajalik selleks, et geenivaramu andmebaasi tekiks Teie kohta uus ajapunkt ja et saaksime teha DNA-
põhise kontrolltuvastamise, kinnitava geenianalüüsi ning kliinilise vere analüüsi. Samuti palutakse luba
teha Teist fotod, kasutades geenivaramu fotoaparaati. Tehakse kolm fotot Teie näost: otse- ja kaks
külgvaadet. Koos suure hulga teiste fotodega kasutatakse Teie fotot isikustamata kujul lisauuringutes,
mis põhinevad arvutuslike seoste leidmisel teatud geenivariantide ja näojoonte vahel. Teie fotot
hoitakse koos teiste tundlike isikuandmetega isikustatud kujul geenivaramu kodeerimis keskuses.
Fotot ei avaldata foto kujul mitte mingis vormis. Teadustööna avaldada on neid võimalik vaid
arvutuslike seoste põhjal nii, et neid ei ole võimalik seostada Teie isikuga.
Teise vastuvõtu käigus on Teil soovi korral võimalus saada kliinilise geneetika spetsialistilt geneetilist
nõustamist, soovitusi ja kirjalik kokkuvõte uuringu tulemustest, milles kirjeldatakse Teie terviseriske
ja personaalseid geneetilisi eripärasid. Et uurida, kuidas on muutunud geenidoonoritele osutatav
terviseabi peale geneetilise omapära kohta saadud tagasisidet tehakse päringuid raviasutuste ja e-
2
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
tervise infosüsteemidesse. Nende käigus kogutud andmeid kasutatakse isikustamata kujul. Teine visiit
toimub vaid juhul, kui olete nõus olemasolevaid andmeid uuendama ja vereproovi loovutama.
Kogutud andmeid rakendatakse teadustöös. Uuringu tulemused võivad kaasa aidata geneetilistest
muutustest tingitud haiguste avastamisele- ja ravivõimaluste väljatöötamisele.
Uuringus osalemine on vabatahtlik. Ainult Teie otsustate, kas soovite uuringus osaleda. Kui Te soovite
uuringus osaleda, tagatakse Teile soovi korral võimalus saada geneetilist nõustamist, kui olete
täiendava vereproovi esimesel vastuvõtul andnud. Geneetiline nõustamine põhineb läbiviidud
uuringu tulemustel, Teie isiklike terviseriskide hindamisel ja vajadusel võimalikul mõjul perekonnale.
Mida uuringus osalemine Teie jaoks tähendab?
Uuringus järgitakse Eesti Vabariigi (inimgeeniuuringute seadus, isikuandmete kaitse seadus) ja
Euroopa Liidu (isikuandmete kaitse üldmäärus) seadusaktidest tulenevaid nõudeid. Pärast nõusoleku
vormi allkirjastamist toimub vestlus, andmete täiendamine, täidetakse küsimustikud ja mõõdetakse
Teie pikkust, kaalu, pea- ja vööümbermõõtu, käte haardetugevust, vererõhku ja südame
löögisagedust. On oluline rõhutada, et Teil on õigus jätta vastamata küsimustele, mis tunduvad Teile
ebamugavad või Te ei soovi neile muul põhjusel vastata. Kogutud andmeid hoitakse koos Teiste
tundlike isikuandmetega geenivaramu kodeerimis keskuses, neid kasutatakse uuringus ja avaldatakse
nii, et neid ei ole võimalik seostada Teie isikuga. Nõusoleku vormi ja terviseandmeid hoitakse
geenivaramus tähtajatult.
Uuringus palutakse teha Teie näost kolm fotot: otse- ja kaks külgvaadet, kasutades geenivaramu
fotoaparaati. Fotot ei avaldata foto kujul mitte mingis vormis. Teadustöö tulemused avaldatakse vaid
numbriliste väärtustena, mis on saadud arvutuslike seoste põhjal. Neid ei ole võimalik seostada Teie
isikuga.
Lisaks võetakse vereproov (kuni 40ml veeniverd), milleks kasutatakse ühekordseid vahendeid. Sellise
verekoguse loovutamine võib tekitada kerget ebamugavustunnet, kuid ei kujuta Teie tervisele ohtu.
Uuringus osalejana on Teil võimalik saada uuringu tulemuste kohta tagasisidet. Seda tehakse juhul,
kui Te olete andnud täiendava vereproovi ja avaldate soovi tagasiside saamiseks. Lisaks edastame Teile
soovi korral Tartu Ülikooli Kliinikumi ühendlaboris tehtud kliinilise vereanalüüsi tulemused.
Mis on võimalik kasu Teie jaoks selles uuringus?
Projekti käigus tekkiv informatsioon annab Teile ülevaate oma tervisenäitajatest (kliinilise
vereanalüüsi tulemused) ja geneetilisel infol põhinevatest hinnangulistest riskidest tulevikus.
Tagasiside raportis sisalduv teave võib olla Teie jaoks ootamatu ja murettekitav. Uuring on
keskendunud tervisekäitumise suunamisele ja elu jooksul pigem hiljem avalduvate tüsistuste
3
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
vältimisele. Võimalik kasu geneetilise info teadmisest, kaalub üles võimalikud ebameeldivused, näiteks
ajakulu, vereanalüüsi võtmine, psühholoogiline ja sotsiaalne mõju.
Millised riskid võivad olla seotud uuringus osalemisega?
Kvalifitseeritud meditsiiniõde võtab vereproovi (kuni 40ml veeniverd), milleks kasutatakse
ühekordseid vahendeid. Sellise verekoguse loovutamine ei kujuta Teie tervisele mingit ohtu.
Vereproovi võtmine võib mõningatel juhtudel põhjustada verevalumi teket ja jätta jälje, mis kaob
lühikese aja möödudes. Kui Te peaks vereproovi võtmise jooksul või pärast tundma kerget pearinglust
või ebamugavust, saate jääda andmekogumiskabinetti puhkama, kuni tunnete, et olete valmis
lahkuma.
Teie andmed hoiustatakse Eesti geenivaramus ja kasutatakse uuringus kujul, mis ei võimalda nende
seostamist Teie isikuga. Kõik Teiega seonduvad andmed on salajased ja teadlastele väljastatakse ainult
isikustamata andmeid.
Uuringu käigus analüüsitakse põhjalikult vaid teatud geene ja piirkondi pärilikkusaines. Seetõttu ei saa
me garanteerida, et tuvastatakse kõik Teile meditsiiniliselt olulised geneetilised omapärad.
Juhime tähelepanu asjaolule, et kuna geneetiline informatsioon on elu jooksul praktiliselt muutumatu,
siis võib uuringus osalemisel ja saadud tagasisidel olla Teile pikaaegne mõju.
Uuringuga seotud kulude kompenseerimine
Uuringu vastuvõtud toimuvad Tartus Riia 23b geenivaramu andmekogumiskabinetis. Sõiduga seotud
transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel, kuni 50 eurot visiidi kohta.
Samuti pakume vastuvõtu päeval sooja lõunat.
Tagasiside mõju hindamine
Projekti käigus palutakse Teil täita kaks küsimustikku saadud geneetilise tagasiside arusaadavuse ja
isikliku mõju kohta. Esimene küsimustik antakse vahetult pärast tagasiside visiiti ning teine küsimustik
kuus kuud peale teist visiiti. Küsimustik vahetu tagasiside kohta on võimalik täita paberkandjal ning
küsimustik kuus kuud hiljem kas paberil või elektroonsel kujul. Mõlema küsimustiku täitmine võtab
eeldatavalt aega alla 20 minuti küsimustiku kohta. Kogutud andmeid kasutatakse isikustamata kujul
teadustöös, mille tulemused annavad ülevaate inimeste meelsusest, huvist ja muredest peale
personaalset geneetilist tagasisidet. Teie vastused on abiks sarnase uuringumetoodika arendamisel ja
rakendamisel edaspidi.
4
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Teie õigused uuringus osalemisel
Uuringus osalemine on vabatahtlik. Kõik Teiega seonduvad andmed on konfidentsiaalsed ja
teadlastele väljastatakse ainult isikustamata andmeid. Teil on võimalus ise otsustada, kas Te soovite
teada saada uuringu tulemusi ja geneetilist nõustamist või mitte. Geneetiline nõustamine põhineb
läbiviidud uuringu tulemustel, personaalsetel geneetilistel eripäradel, Teie isiklike terviseriskide
hindamisel ja vajadusel võimalikul mõjul perekonnale. Kliinilise geneetika spetsialisti poolt antud
soovitused võivad abiks olla Teie terviseseisundi jälgimisel.
Teil on õigus keelduda oma andmete uuendamisest, sh vereproovi loovutamisest. Peate arvestama,
et vereproovi loovutamine on eelduseks geneetilise tagasiside saamisele, et teha DNA-põhine kontroll
ja geneetilise omapära kinnitamine.
Uuringus tehakse teist foto ainult juhul, kui Te ise selleks allpool vastava kirjaliku märkega loa annate.
Uuringu käigus on Teil õigus jätta vastamata küsimustele, mis tunduvad Teile ebamugavad või millele
Te ei soovi vastata.
Teil on õigus igal ajahetkel uuringust loobuda. Geenivaramu hävitab selleks ajaks kogutud andmed (sh
vereproov), kui olete nii soovinud, välja arvatud juhul, kui see tehniliselt võimalik ei ole. Uuringust
loobumisel ei ole Teie jaoks negatiivseid tagajärgi.
Uuringuga seonduvate korralduslike ja uuringu ülesehitust puudutavate küsimuste korral saate
täiendavat informatsiooni:
telefon: 7374030; 5206959
e-mail:
[email protected]
Geenivaramu koduleht www.genoomika.ut.ee
5
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Teadliku nõusoleku vorm
Uuringu nimetus: "Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis –
diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja
personaliseeritud käsitlus”
Mina,…………………………………………………………………………………………………….., olen lugenud või mulle on
ette loetud „Uuringus osaleja informeerimise leht ja teadliku nõusoleku vorm “ kuupäevaga
………………………..…………. ja ma olen informeeritud uuringust "Kliiniliselt oluliste struktuursete
geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide
kandjate tervise tulemid ja personaliseeritud käsitlus”. Mul on olnud võimalus küsida küsimusi ja olen
saanud rahuldava vastuse oma küsimustele. Olen teadlik läbiviidava uurimistöö eesmärgist, uuringu
metoodikast ja kinnitan oma nõusolekut selles osalemiseks allkirjaga.
Tean, et uuringute käigus tekkivate lisaküsimuste ja võimalike tervisehäirete kohta saan mulle
vajalikku täiendavat informatsiooni uuringu juhilt:
Neeme Tõnisson,
meditsiinigeneetika vanemteadur
56684694;
[email protected]
Olen teadlik, et vereproovi loovutamine on eelduseks teisele visiidile, kus nõusoleku korral on võimalik
saada personaalset geneetilist tagasisidet ning kliinilise vereanalüüsi tulemused.
Uuringu läbiviijad on teadlikud ja kinnitavad, et minu identiteeti ega isiklikke andmeid ei kasutata
isikustatud kujul, kui projekti tulemused avaldatakse teadusartiklitena.
Olen nõus uute andmete kogumisega
Jah □ Ei □
Olen nõus foto tegemisega
Jah □ Ei □
6
Eesti geenivaramu
Riia 23b, 51010 Tartu, Eesti
Telefon: 7374030; 5206959
E-post:
[email protected]
Veeb: www.genoomika.ut.ee
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud
struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Mul on õigus teada/mitte teada käesolevast uuringust tulenevaid personaalselt minu kohta käivaid
tulemusi ja tulemustega koos saada meditsiinigeneetiku nõustamist:
□ Soovin teada tulemusi ja saada geneetilist nõustamist
□ Ei soovi teada tulemusi
Minu kontaktandmed:
e-posti aadress…………………………………………………………………………………
Postiaadress ……………………………………………………………………………………
Telefoni number………………………………………………………………………………
Kuupäev, kuu, aasta………………………………………………………………………...
Allkiri………………………………………………………………………………….
Uuringus osalejale informatsiooni andnud isik:
Olen andnud uuringus osalejale ülevaate selle uuringu olemusest, võimalikest riskidest ja osaleja
õigustest. Kinnitan, et uuringus osaleja on seletustest aru saanud ja nõusoleku andmiseks
teovõimeline.
Nimi………………………………………………………………………………………………………….
Kuupäev ………………………………………………………………………………………………….
Nõustaja allkiri………………………………………………………………………………………….
7
KLIINILINE KÜSIMUSTIK
Uuritava projektikood: …………………………………………………………………..
Kuupäev: ……………………………………………………………………………………….
Nõustaja: ………………………………………………………………………………………..
Olen teadlik, et mul, on õigus jätta vastamata küsimustele, mis tekitavad minus ebamugavust
Jah
SISUKORD
OBJEKTIIVNE LÄBIVAATUS 1
ARENGULISED ASPEKTID 2
Andmed sünnieelse arengu ja imikuea kohta 2
Motoorne areng 3
Keele ja kõne areng 4
Ravi ja eriõpe 5
HARIDUS 5
TERVISEPROBLEEMID 6
Unehäired 6
Söömise ja toitumiskäitumisega seotud aspektid 8
Seedeelundkonna haigused 9
Autoimmuunhaigused 10
Reproduktiivtervis naistel 10
Reproduktiivtervis meestel 12
Vaimse tervisega seotud aspektid 13
Neuroloogilised aspektid 14
Kardiovaskulaarsed haigused 15
Muud haigused ja häired 16
Kirurgilised operatsioonid 17
Medikamentoosne ravi 17
Toidulisandid 18
OBJEKTIIVNE LÄBIVAAT US
1
Vanus (aastates): ……………..
Kaal (kg):………….
Pikkus (cm):……………
Peaümbermõõt (cm): ……….…
Puusaümbermõõt (cm): …………
Vööümbermõõt (cm): ……….
Vererõhk: ………./…………
Südame löögisagedus: ……….
Haardetugevus: ………..
Prillid: Ei Jah
Kui jah, siis mis ajast prille kasutanud olete? (aastates)......................................................
Kuulmisaparaat: Ei Jah
Kui jah, siis mis ajast kuulmisaparaati kasutanud olete? (aastates)......................................................
ARENGULISED ASPEKTID
ANDMED SÜNNIEELSE AR ENGU JA IMIKUEA KOHTA
Tüsistused ja märkimisväärsed probleemid ema raseduse ajal:
Ei Jah Ei tea
Kui jah, palun täpsustage (olulised nakkused, veritsus, rasedusaegne diabeet jt.)
1. …………………..……………………………………………………………………………………………
2. …………………..……………………………………………………………………………………………
3. …………………..……………………………………………………………………………………………
Ema raseduse ajal tarvitatud ravimid:
………………………………………………………………………………………………………………
Ema raseduse kestus (nädalates): …………………..
Kui osaleja ei tea täpset ema raseduse kestust: Kas teate, kas te sündisite ajalise, enneaegse või ülekantud
lapsena?
Enneaegne Ajaline Ülekantud Ei tea
Kas teate, mil viisil olete sündinud:
Vaginaalne iseeneslik sünnitus > valikud: peaseis, vaagnaotsseis, ei tea
2
Vaginaalne abistatud sünnitus > valikud: tangsünnitus, vaakumekstratsioon
Keisrilõige > valikud: plaaniline, erakorraline, ei tea
Ei tea
Tüsistused ja märkimisväärsed probleemid sünnitusel:
Ei Jah Ei tea
Kui jah, palun täpsustage
1. …………………..……………………………………………………………………………………………
2. …………………..…………………………………………………………………………………………....
3. …………………..…………………………………………………………………………………………....
Osaleja sünnikaal:…………. Pikkus:….………. Peaümbermõõt:………. Apgari skaala skoor: …………..
Märkimisväärsed probleemid neonataalsel perioodil ja imikueas:
JUHIS NÕUSTAJALE: Neonataalne iga ehk vastsündinuiga 28 esimest elupäeva; Imikuiga tavaliselt kuni 1.
eluaasta lõpuni, käesolevas küsimustikus erandjuhtudel kuni 2. eluaasta lõpuni.
Ei Jah Ei tea
Kui jah, palun täpsustage (hüpotoonia (madal lihastoonus), söömisraskused, olulised nakkushaigused,
kirurgilised sekkumised (üldnarkoos) jt.)
1. ...……………………………………………………………………………………………………………
2. ……………………………………………………………………………………………………………...
3. ………………………………………………………………………………………………………………
MOTOORNE ARENG
Istumine ilma toeta (kuudes):……………… Roomamine (kuudes):…………………
Kõndimine ilma toeta (kuudes):......................
Kui osaleja ei tea täpset vanust: enne 18. elukuud peale 18. elukuud
Motoorse arengu probleemid varases lapseeas:
Ei Jah Ei tea
Kui jah, palun täpsustage (tasakaaluhäired, kõnemotoorika, jt.)
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
Kas osalejal on diagnoositud motoorne arenguhäire lapseeas?
Ei Jah Ei tea
Kui jah, palun täpsustage diagnoosi nimetus ja vanus diagnoosimisel
3
………………………………………………………………………………………………………………
Motoorse soorituse probleemid täiskasvanueas:
Ei Jah Ei tea
Kui jah, palun täpsustage probleemi olemust (tasakaal, kõnemotoorika, jt.) ja osaleja vanust avaldumisel
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
Käelisus: Vasak Parem Mõlemakäelisus (ambidekstria)
Kehaline aktiivsus/sport lapseeas:
JUHIS NÕUSTAJALE: Järgnemas sama küsimus ka täiskasvanueas. Uuritavale täpsustavaid küsimusi, juhiseid
andes näiteks, „kui tihti kooli ajal sai sporti tehtud?“
Ei Harv (kord kuus) Sage (kord nädalas) Väga sage Ei tea
Palun täpsustage olulisemad aktiivse tegevuse vormid (kohustuslik kehaline kasvatus, treening, tantsimine,
jalutamine, majapidamistööd jt.)
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
Kehaline aktiivsus/sport täiskasvanueas:
Ei Harv (kord kuus) Sage (kord nädalas) Väga sage Ei tea
Palun täpsustage olulisemad aktiivse tegevuse vormid (majapidamistööd, treening, jalutamine jt.)
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
KEELE JA KÕNE ARENG
Esimesed tähendusega sõnad (vanus kuudes või aastates): ………………………………….
JUHIS NÕUSTAJALE: „Kui vana te olite, kui ütlesite esimesed tähendusega sõnad?“ v.a ema, isa
Kui osaleja ei tea täpset vanust:
enne teist eluaastat peale teist eluaastat Ei tea
Esimesed laused (2-3 sõnalised fraasid) (kuudes või aastates): ..................................
Kui osaleja ei tea täpset vanust:
enne kolmandat eluaastat peale kolmandat eluaastat Ei tea
4
Keele- ja kõnearengu probleemid varases lapseeas:
Ei Jah Ei tea
Kui jah, palun täpsustage (artikulatsiooni probleemid, raskused kõnest arusaamisel, jt.)
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
Kas osalejal on diagnoositud kõne või keele arenguhäire?
Ei Jah Ei tea
Kui jah, palun täpsustage diagnoosi nimetus ja vanus diagnoosimisel
………………………………………………………………………………………………………………
Raskused keele- ja kõnega täiskasvanueas Ei Jah
Kui jah, palun täpsustage probleemi olemust (artikulatsiooni probleemid, raskused kõnest arusaamisel, jt.) ja
osaleja vanust avaldumisel
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
RAVI JA ERIÕPE
Kõne- ja keelearengut toetav ravi või õpe Ei Jah Ei tea
Kui jah, palun täpsustage põhjus ja vanus ravi saamisel
…………………………………………………………………………………………………………….
Töö- ja tegevusteraapia Ei Jah Ei tea
Kui jah, palun täpsustage põhjus ja vanus ravi saamisel
…………………………………………………………………………………………………………….
Liikumisteraapia Ei Jah Ei tea
Kui jah, palun täpsustage põhjus ja vanus ravi saamisel
…………………………………………………………………………………………………………….
Füsioteraapia Ei Jah Ei tea
Kui jah, palun täpsustage põhjus ja vanus ravi saamisel
…………………………………………………………………………………………………………….
HARIDUS
5
Osaleja haridustase (kõrgeim lõpetatud õppevorm):
Teaduskraad (magister, doktor)
Kõrgharidus (ülikool, rakenduskõrgharidus)
Keskharidus (üld- ja kutsekeskharidus)
Põhiharidus
Algharidus
Lõpetamata algharidus
Kas osalejal on kunagi esinenud õpiraskuseid? Ei Jah
Kui jah, palun täpsustage vanus ja õpiraskuste iseloom/põhjus
…………………………………………………………………………………………………………….
Kas osaleja sai üldhariduse tavakoolist? Ei Jah
Kas osaleja sai tugiõpet (abiõpetaja, logopeed)? Ei Jah
Kui jah, palun täpsustage tugiõppe liik ja kestus
…………………………………………………………………………………………………………………………
Kas osaleja käis erivajadustele vastavas koolis? Ei Jah
Kui jah, palun täpsustage erivajaduse iseloom, erihariduse tüüp ja kestus
…………………………………………………………………………………………………………………………
Mis olid lemmik-õppeained koolis?
…………………………………………………………………………………………………………………………
Millistes õppeainetes oli lihtne (teadmised jäid külge kergema vaevaga)?
…………………………………………………………………………………………………………………………
Millistes ainetes oli raske (pidi palju õppima ja aega pühendama, et aru saada ja meelde jätta)?
…………………………………………………………………………………………………………………………
Osaleja amet/töökoht käesoleval ajal
…………………………………………………………………………………………………………………………
TERVISEPROBLEEMID
UNEHÄIRED
Keskmine uneaeg tööpäevadel: ………………………….…………
6
Keskmine uneaeg nädalavahetustel: ……………………………..
Kas osalejal on esinenud või diagnoositud unehäireid?
Ei Jah Ei tea
Näiteks, kas osalejal on esinenud:
Raskusi öösel hingamisega (uneapnoed)
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna) ja kestus
…………………………………………………………………………………………………………………………
Sagedast norskamist (rohkem kui pool uneajast)
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna) ja kestus
…………………………………………………………………………………………………………………………
Unes kõndimist või sagedasi õudusunenägusid
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna) ja kestus
…………………………………………………………………………………………………………………………
Sagedasi ärkamisi või öiseid ülevalolekuid
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna), võimalik põhjus (pinged töö- või
eraelus) ja kestus
…………………………………………………………………………………………………………………………
Sagedasi raskusi uinumisega
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna), võimalik põhjus (pinged töö- või
eraelus) ja kestus
…………………………………………………………………………………………………………………………
Sagedasi raskusi hommikul ärkamisega
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna), võimalik põhjus (pinged töö- või
eraelus) ja kestus
7
…………………………………………………………………………………………………………………………
Ebaharilikku väsimust/unisust päeva jooksul
Ei Jah Ei tea
Kui jah, palun täpsustage mis vanuses (lapseeas, teismelisena, täiskasvanuna), võimalik põhjus (pinged töö- või
eraelus) ja kestus
…………………………………………………………………………………………………………………………
Muid und segavaid häireid
Ei Jah
Kui jah, palun kirjeldage, täpsustage mis vanuses ja kestus
…………………………………………………………………………………………………………………………
SÖÖMISE JA TOITUMISK ÄITUMISEGA SEOTUD ASPEKTID
Kas osalejal esines või diagnoositi lapseeas kasvupeetus (madal kaaluiive ja/või mahajäämus pikkuskasvus)
Ei Jah Ei tea
Kui jah, palun täpsustage vanus ja võimalik põhjus (kui on teada)
…………………….……………………………………………………………………………………………………
Kas osalejal esines või diagnoositi lapseeas ülekaal või liiga kiire kasv
Ei Jah Ei tea
Kui jah, palun täpsustage vanus ja võimalik põhjus (kui on teada)
…………………….……………………………………………………………………………………………………
Kas osalejal on esinenud:
Hüperfaagiat (söögiisu suurenemist) või liigsöömishoogusid:
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage avaldumise vanus, hoogude sagedus ja kestus (lühiajaliselt, aastaid, alati)
…………………………………………………………………………………………………………………………
Valikulist või piiratud toiduainete söömist
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun kirjeldage, täpsustage avaldumise vanus ja kestus (lühiajaliselt, aastaid, alati)
…………………………………………………………………………………………………………………………
Kas osaleja on järginud dieeti:
Ei Jah, lapseeas Jah, täiskasvanuna
8
Kui jah palun täpsustage vanus järgimisel, dieedi põhjus ja kestus
…………………………………………………………………………………………………………………………
Kas osaleja on kasutanud toitumisnõustaja abi:
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah palun täpsustage toitumisalase nõustamise põhjus, vanus nõustamise ajal ja kestus
…………………………………………………………………………………………………………………………
SEEDEELUNDKONNA HAIG USED
Kas osaleja on kunagi gastroenteroloogi vastuvõtul käinud?
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kas osalejal on diagnoositud:
Kõhukinnisus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kõhulahtisus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Ärritatud soole sündroom
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Crohni tõbi
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Haavandiline koliit
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Tsöliaakia
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Maohaavand
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Gastroösofageaalne refluks
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Muu seedeelundkonna haigus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage diagnoos/seisund
9
1. ....................................................................................................................................................................
2. ....................................................................................................................................................................
3. ....................................................................................................................................................................
AUTOIMMUUNHAIGUSED
Kas osalejal on diagnoositud:
Kontaktdermatiit
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Astma
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Psoriaas
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Reumatoidartriit
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Luupus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Tüüp I diabeet
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kilpnäärme alatalitlus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kilpnäärme ületalitlus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
REPRODUKTIIVTERVIS NAISTEL
Vanus esimese menstruatsiooni ajal (aastates)
Ei tea Jah, teab
Kui osaleja teab täpset/täpsemat vanust, siis …………………….. (aastates)
Kui osaleja ei tea täpset vanust:
Eakaaslastest varem Samaaegne Eakaaslastest hiljem Endiselt ei oska pakkuda
Kas osalejal on alanud menopaus?
Ei Jah
10
Kui jah, siis vanus menopausi alguse ajal (aastates) :
Ei tea Jah, teab
Kui osaleja teab täpset/täpsemat vanust, siis …………………….. (aastates)
Kui osaleja ei tea täpset vanust:
Enne 40. eluaastat Peale 45. eluaastat Peale 50. eluaastat
Kui menopaus algas enne 45. eluaastat, palun täpsustage põhjus
…………………………………………………………………………………………………………………………
Kas osalejal on esinenud:
Ebaregulaarne menstruatsioon
Ei Jah, harva Jah, sageli
Kui jah palun täpsustage vanus (teismelisena, täiskasvanuna), sagedus ja põhjus (kui on teada)
…………………………………………………………………………………………………………………………
Menstruatsiooni puudumine (≥3 järjestikusel perioodil)
Ei Jah, harva Jah, sageli
Kui jah palun täpsustage vanus (teismelisena, täiskasvanuna), sagedus ja põhjus (kui on teada)
…………………………………………………………………………………………………………………………
Naiste tervise ja rasestumisega seotud probleeme
Ei Jah
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
5. ………………………………………………………………………………………………………………
Naiste tervisega seotud kirurgilisi protseduure
Ei Jah
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
5. ………………………………………………………………………………………………………………
11
Kas on rasestumiseks kasutatud kunstlikku viljastamist
Ei Jah
Kui jah, siis kas osalejal on kunstliku viljastumise tulemusena sündinud lapsi?
Ei Jah
REPRODUKTIIVTERVIS MEESTEL
Vanus häälemurde alguses (aastates) .................
Kui osaleja ei tea täpset vanust Eakaaslastest varem Samaaegne Eakaaslastest hiljem
Vanus karvakasvu alguses näol (aastates).................
Kui osaleja ei tea täpset vanust Eakaaslastest varem Samaaegne Eakaaslastest hiljem
Vanus kasvuspurdi/kiire kasvu ajal (aastates)……………………….
JUHIS NÕUSTAJALE: „Kas osaleja mäletab, millal ta oli lühem/pikem kui teised poisid tema klassis?“
Kui osaleja ei tea täpset vanust Eakaaslastest varem Samaaegne Eakaaslastest hiljem
Kas osaleja on kunagi käinud meestearsti (androloogi)/viljatusraviarsti juures?
Ei Jah
Kas on olnud vaja reproduktiivteraapiat?
Ei Jah
Kas osalejal on esinenud:
Meeste reproduktiivsüsteemiga seotud terviseprobleeme
Ei Jah
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
5. ………………………………………………………………………………………………………………
Meeste reproduktiivsüsteemiga seotud kirurgilisi protseduure
Ei Jah
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
12
5. ………………………………………………………………………………………………………………
VAIMSE TERVISEGA SEO TUD ASPEKTID
Kas osaleja on kunagi psühhiaatri või psühholoogi juures käinud?
Psühhiaater
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Psühholoog
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kas osalejal on diagnoositud:
Depressioon Ei Jah
Kui jah, palun täpsustage avaldumise vanus ja kestus/sagedus (üks episood, korduv, pikaajaline)
…………………………………………………………………………………………………………………………
Muu meeleoluhäire (bipolaarne, obsessiiv-kompulsiivne, vms häire)
Ei Jah Ei tea
Kui jah, palun täpsustage avaldumise vanus ja kestus/sagedus (üks episood, korduv, pikaajaline)
…………………………………………………………………………………………………………………………
Neurootiline või ärevushäire
Ei Jah Ei tea
Kui jah, palun täpsustage häire tüüp (foobia, somatoformne, kohanemis-, paanika, vms.) avaldumise vanus ja
kestus
…………………………………………………………………………………………………………………………
Sõltuvushäire
Ei Jah Ei tea
Kui jah, palun täpsustage sõltuvuse tüüp (alkohol, ravimid, tubakas, mängurlus, uimastid, vms.), avaldumise
vanus ja kestus …………………………………………………………………………………………………………………………
Isiksus- või käitumishäire
Ei Jah Ei tea
Kui jah, palun täpsustage häire tüüp (raevuhood, tähelepanuhäire, emotsionaalne ebastabiilsus, paranoia,
vms.), avaldumise vanus ja kestus
…………………………………………………………………………………………………………………………
Psühhootiline häire või skisofreenia
13
Ei Jah Ei tea
Kui jah, palun täpsustage avaldumise vanus ja kestus/sagedus (üks episood, korduv, pikaajaline)
…………………………………………………………………………………………………………………………
Vaimse või psühholoogilise arengu häire
Ei Jah Ei tea
Kui jah, palun täpsustage häire tüüp (keele ja kõne areng, spetsiifilised õpiraskused, autismispektri häire,
vaimse arengu mahajäämus, vms) ja avaldumise vanus (vanus diagnoosimisel)
…………………………………………………………………………………………………………………………
Kas osalejal esineb teisi meeleolu ja vaimse tervisega seotud haigusi või probleeme (kurvameelsus,
sundmõtted, põhjendamatu hirm või ärevus, meeleolu kiire muutumine, agressiivsus, jt.)
Ei Jah Ei tea
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
5. ………………………………………………………………………………………………………………
NEUROLOOGILISED ASPEKTID
Kas osaleja on kunagi neuroloogi juures käinud?
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kas osalejal on diagnoositud:
Migreen
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Epilepsia või krambid
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp, avaldumise vanus ja kestus/sagedus (üks episood, korduv, pikaajaline)
…………………………………………………………………………………………………………………………
Neuropaatia
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp, avaldumise vanus ja kestus
…………………………………………………………………………………………………………………………
Parkinsoni tõbi
14
Ei Enne 50. eluaastat Peale 50. eluaastat Ei tea
Düstoonia (lihasspasmid, lihastoonuse häired)
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp, avaldumise vanus ja kestus
…………………………………………………………………………………………………………………………
Ataksia
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp, avaldumise vanus ja kestus
…………………………………………………………………………………………………………………………
Muud liigutushäired
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp (treemor, tahtmatud või sundliigutused, tasakaaluhäired), avaldumise vanus ja
kestus
…………………………………………………………………………………………………………………………
Lihaste kõhetumine (atroofia)
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp ja avaldumise vanus
…………………………………………………………………………………………………………………………
Muu neuroloogiline haigus
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kui jah, palun täpsustage tüüp ja avaldumise vanus
…………………………………………………………………………………………………………………………
KARDIOVASKULAARSED H AIGUSED
Kas osaleja on kunagi käinud kardioloogi juures?
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kas osalejal on esinenud/diagnoositud:
Veenitromboos
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Müokardi infarkt
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Ajuinfarkt/insult
15
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Muud probleemid südame-veresoonkonnaga:
Ei Jah Ei tea
Kui jah, palun täpsustage
1. ………………………………………………………………………………………………………………
2. ………………………………………………………………………………………………………………
3. ………………………………………………………………………………………………………………
4. ………………………………………………………………………………………………………………
5. ………………………………………………………………………………………………………………
Mis on osaleja tüüpiline/keskmine vererõhk:
üldiselt madal kõrge normaalne teab täpsustada Ei tea
Kui oskab täpsustada siis:………………………………………………
MUUD HAIGUSED JA HÄI RED
Kas osalejal on esinenud/diagnoositud:
Probleemid kuulmisega
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Probleemid nägemisega
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Probleemid maitse või lõhna tundmisega
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Ortopeedilised probleemid (nihestused, kõõluste ja liigesesidemete rebendid, üldine sidekoe nõrkus, aga
ülihea painduvus; luumurrud; artroosid ehk liigeste jäikus)
JUHIS NÕUSTAJALE: Sage, varases eas ja ebaharilikes kohtades esinemine viitab sidekoe ja/või luukoe
probleemidele
Ei Jah, lapseeas Jah, täiskasvanuna Ei tea
Kaasasündinud väärarengud
Ei Jah Ei tea
Kui jah, palun täpsustage
16
…………………………………………………………………………………………………………………………
Kaasasündinud haigused
Ei Jah Ei tea
Kui jah, palun täpsustage
…………………………………………………………………………………………………………………………
Geneetilised haigused
Ei Jah Ei tea
Kui jah, palun täpsustage
…………………………………………………………………………………………………………………………
Kas osaleja on kunagi käinud meditsiinigeneetiku konsultatsioonil?
Ei Jah Ei tea
KIRURGILISED OPERATS IOONID
Kas osalejal on olnud kirurgilisi protseduure
Ei Jah Ei tea
Kui jah, palun täpsustage põhjus ja vanus protseduuri toimumise ajal
1. ....................................................................................................................................................................
2. ....................................................................................................................................................................
3. ....................................................................................................................................................................
4. ....................................................................................................................................................................
5. ....................................................................................................................................................................
MEDIKAMENTOOSNE RAVI
Ravi käesoleval hetkel:
JUHIS NÕUSTAJALE: Paneme kirja viimase 2-6 kuu jooksul võetud ravimid. Ravimite kohta küsimisel võib aidata
ka küsimused erinevate haiguste-kirurgiliste operatsioonide kohta. Või küsida ravimite kohta läbi haiguste, mis
meenutab neile võetud ravimeid ehk. Inimesel meenuvad tihti ravimid, kui nad tuletavad meelde kindlat
situatsiooni, mis neil elus on olnud.
Ei Jah Ei tea
Kui jah, palun nimetage ravim, täpsustage põhjus, vanus ja kestus
JUHIS NÕUSTAJALE: „Regulaarselt“ tähendaks siin, et iga päev või mingi kindla tsüklilise skeemi järgi.
1. ....................................................................................................................................................................
17
2. ....................................................................................................................................................................
3. ....................................................................................................................................................................
4. ....................................................................................................................................................................
TOIDULISANDID
Kas osaleja on sageli või pikema aja vältel kasutanud toidulisandeid
Ei Jah Ei tea
Kui jah, palun täpsustage lisandi(te) tüüp (nt. vitamiinid, rauapreparaadid jms.), selle võtmise põhjus (rasedus,
peale verekaotust või haigust, vms.), vanus ja kestus
1. ....................................................................................................................................................................
2. ....................................................................................................................................................................
3. ....................................................................................................................................................................
4. ....................................................................................................................................................................
18
16p11.2
mikrodeletsioonisündroom
Teabeleht
uuritavale
Tartu
Ülikooli
Eesti
Geenivaramu
teadusuuringute
raames
teostatud
kromosoomide
mikrokiibi
analüüsi
tulemusena
leiti
Teie
genoomis
16.
kromosoomi
regioonis
p11.2
mikrodeletsioon.
Mis
on
16p11.2
mikrodeletsioon?
Inimese
keha
koosneb
rakkudest.
Pärilik
materjal,
st
geneetiline
materjal
on
pakitud
kromosoomidesse.
Enamasti
on
igas
rakus
23
kromosoomipaari.
Geenid
paiknevad
kromosoomides
kindlas
järgnevuses.
Terve
inimese
arenguks
on
oluline
kromosoomide
ja
geenide
korrektne
arv.
Tavapäraselt
pärib
inimene
igast
geenist
kaks
koopiat,
ühe
kummaltki
vanemalt.
16p11.2
deletsioon
tähendab,
et
16.
kromosoomi
regioonis
p11.2
on
väike
osa
geneetilist
materjali
kaduma
läinud
ehk
deleteerunud.
See
tähendab,
et
16p11.2
deletsiooni
korral
on
inimesel
kahe
koopia
asemel
vastavas
regioonis
ainult
üks
koopia
geneetilist
materjali.
Deletsiooni
ulatust
mõõdetakse
aluspaarides
–
16p11.2
mikrodeletsiooni
puhul
on
umbes
600
kiloaluspaari
suurune
DNA
lõik
puudu.
Sellised
muutused
geeni
koopiate
arvus
võivad
põhjustada
mitmesuguseid
eripärasid.
Ka
16p11.2
mikrodeletsioon
on
seotud
mitmete
iseloomulike
tunnuste
ja
terviseprobleemide
avaldumisega,
mistõttu
kutsutaksegi
seda
16p11.2
mikrodeletsioonisündroomiks.
16p11.2
mikrodeletsioonisündroomi
sagedus
16p11.2
mikrodeletsiooni
esinemissagedus
Euroopas,
sealhulgas
Eestis,
on
umbes
1:1000
indiviidi
kohta.
See
tähendab,
et
1000
isiku
seas
on
ühel
16p11.2
mikrodeletsioon.
16p11.2
mikrodeletsioonisündroomi
pärandumine
Enamus
16p11.2
mikrodeletsioone
on
tekkinud
sugurakkudes
täiesti
juhuslikult.
Elustiil,
vanemate
vanus
raseduse
ajal,
raseduse
ajal
põetud
haigused
jms
tegurid
ei
põhjusta
deletsioonide
teket.
Kuna
võimalikud
terviseprobleemid
ei
takista
enamusel
16p11.2
mikrodeletsioonisündroomiga
inimestest
tavapärase
elu
elamist
ning
perekonna
loomist,
esineb
ka
geenimuutuse
pärandumist
deletsiooni
kandvalt
vanemalt
tema
lapsele.
Tõenäosus
deletsiooni
tekkimiseks
juhuslikult
või
pärandumiseks
vanematelt
lastele
on
meestel
ja
naistel
ühesugune.
Sellel
leheküljel
leiduva
informatsiooni
kohta
kehtib
üldine
vastutamatusesäte
2
16p11.2
mikrodeletsioonisündroomiga
seotud
haigusriskid
ja
terviseprobleemid
Ehkki
16p11.2
deletsiooni
kandvaid
inimesi
on
elanud
juba
aastasadu,
kirjeldati
sündroomi
alles
2008.a.
Tänu
geeniuuringutele,
mida
tehakse
ka
Eesti
Geenivaramus,
on
erinevates
Euroopa
ja
Ameerika
riikides
leitud,
et
16p11.2
mikrodeletsiooniga
inimestel
(sõltumata
nende
päritolust
ja
elustiilist)
võivad
esineda
sarnased
terviseprobleemid.
Järgneval
pildil
on
kujutatud
kromosoomide
mikrokiibi
analüüsi
tulemus
16.
kromosoomis
ning
punase
kastiga
on
tähistatud
kromosoomiregiooni
p11.2
deletsioon.
Samas
on
oluline
teada,
et
16p11.2
mikrodeletsioonile
on
iseloomulik
haigustunnuste
ja
nende
raskusastme
varieerumine
deletsioonikandjate
hulgas
ja
seda
ka
ühe
pere
liikmete
vahel.
Taolist
sümptomite
avaldumise
mitmekesisust
tingib
asjaolu,
et
deleteerunud
kromosoomialas
võib
seni
teadaolevalt
asuda
kuni
27
erinevat
geeni,
millest
igaühel
on
oma
funktsioonid.
Sageli
annab
geneetilise
muutuse
diagnoosimine
selgituse
inimesel
esinevatele
terviseprobleemidele
ja
julgustab
teda
pöörduma
arsti
poole
abi
saamiseks.
16p11.2
mikrodeletsioonisündroomile
võivad
olla
iseloomulikud
järgmised
tunnused
ja
terviseprobleemid:
o 16p11.2
deletsioon
mõjutab
geene,
mis
kontrollivad
inimese
kehakaalu
ning
seetõttu
on
nad
sageli
ülekaalulised.
Kaalutõus
algab
tavaliselt
varases
koolieas
ning
täiskasvanuna
on
deletsiooniga
inimestel
keskmisest
30
korda
suurem
risk
haigestuda
rasvumistõppe.
o 16p11.2
deletsiooniga
lastel
võib
esineda
õppimisraskusi
ning
võrreldes
deletsiooni
mitte
kandvate
õdede
ja
vendadega
võib
neil
olla
madalam
õppeedukus.
Mõnikord
sobib
neile
paremini
erivajadustele
kohandatud
õpe.
o 16p11.2
deletsioonisündroomiga
lapsed
hakkavad
sageli
hiljem
rääkima,
mõned
võivad
vajada
kõneravi.
Sellel
leheküljel
leiduva
informatsiooni
kohta
kehtib
üldine
vastutamatusesäte
3
o 16p11.2
deletsioon
võib
samuti
põhjustada
kognitiivseid
häireid
või
psühhiaatrilisi
probleeme,
näiteks
tähelepanu-‐,
suhtlemis-‐
ja
käitumisprobleeme,
meeleoluhäireid,
ärevust
jt.
Harva
võib
deletsioonikandjatel
esineda
autismispektri
häireid.
o Ka
neuroloogilised
sümptomid
on
16p11.2
deletsiooniga
inimestel
küllalt
sagedased.
Väikelapsed
võivad
hakata
hiljem
kõndima,
neil
võib
esineda
madal
lihastoonus.
Sageli
esineb
peenmotoorika
häireid
(näiteks
raskused
pliiatsi
hoidmisel,
noa
ja
kahvli
kasutamisel
jne).
Harva
esineb
krambihooge.
Üldised
soovitused
16p11.2
mikrodeletsioonisündroomi
korral
Haigustunnuste
või
häirete
puhul,
mis
võivad
olla
tingitud
16p11.2
mikrodeletsioonist,
on
soovitatav
pidada
nõu
oma
perearstiga,
kes
saab
koostada
ravi-‐
ja
taastusplaani
ning
suunata
vastavate
erialaarstide
vastuvõtule.
Näiteks
ülekaalulisuse
korral
võiks
regulaarselt
mõõta
vererõhku
ning
kontrollida
veresuhkrut
ja
kolesterooli.
Kasulikke
nõuandeid
võib
saada
ka
toitumisspetsialistilt
või
dieetarstilt.
Asjakohane
on
nõustamine
meditsiinigeneetiku
poolt.
Kui
ühel
pereliikmel
on
leitud
deletsioon,
siis
võib
sarnane
muutus
esineda
ka
teistel
selle
pere
liikmetel.
Vanematelt
päritud
deletsioonid
moodustavad
umbes
30%
16p11.2
mikrodeletsioonisündroomi
juhtudest.
Kui
deletsioon
on
päritud
ühelt
vanemalt,
võivad
ka
teised
selle
pere
lapsed
kanda
sama
geneetilist
muutust
50%
tõenäosusega.
16p11.2
mikrodeletsioonisündroomi
varajane
diagnoosimine
ja
vastavate
sümptomite
märkamine
võib
olla
väga
oluline,
et
vajadusel
saaksid
lapsed
õigeaegset
abi.
Üldine
vastutamatusesäte:
Käesolev
teabeleht
ei
ole
mõeldud
meditsiinilise
nõustamise
asendamiseks.
Isikud
peaksid
pöörduma
kliiniliste
otsuste
tegemiseks
ja
tervisealaseks
nõustamiseks
arsti
poole.
Teabeleht
on
koostatud
praegusel
ajal
teadaoleva
informatsiooni
põhjal.
Teabelehe
koostajad:
Katrin
Männik,
PhD
Lausanne´i
Ülikool
[email protected]
Margit
Nõukas,
MSc
Tartu
Ülikooli
Eesti
Geenivaramu
[email protected]
Sellel
leheküljel
leiduva
informatsiooni
kohta
kehtib
üldine
vastutamatusesäte
4
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata
täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Kohese tagasiside mõju hindamise küsimustik
Lugupeetud uuringus osaleja!
Osalesite TÜ Eesti Geenivaramu projektis "Kliiniliselt oluliste struktuursete geenivariantide mõju
üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja
personaliseeritud käsitlus”. Palume Teie hinnangut saadud informatsioonile. Palun vastake järgnevatele
küsimustele, märgistades Teie hinnangul sobivaim vastusevariant.
Kuidas Te ennast praegu tunnete? Lugege tähelepanelikult läbi alljärgnevad väited ja otsustage, kuivõrd nad
Teie puhul kehtivad. Teil on valida nelja vastuse vahel. Kui Te olete oma otsuse teinud, siis märkige sobivaim
vastusevariant. Ärge vastates liiga põhjalikult küsimuse peale mõelge, kuna siin ei saa vastata õigesti ega
valesti. Oluline on, et märgiksite oma praeguse hetke tunde põhjal.
Ma olen rahulik See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma olen pinges See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen ärevust See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen end vabalt See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen rahulolu See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma olen mures See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Saadud informatsioon Teie geneetilise eripära ja sellega kaasnevate võimalike terviseprobleemide kohta…
Tõi selgust Nõustun ☐ Pigem nõustun ☐ Pigem ei nõustu ☐ Ei nõustu ☐ Raske öelda ☐
Pakkus kergendust Nõustun ☐ Pigem nõustun ☐ Pigem ei nõustu ☐ Ei nõustu ☐ Raske öelda ☐
Jättis ükskõikseks Nõustun ☐ Pigem nõustun ☐ Pigem ei nõustu ☐ Ei nõustu ☐ Raske öelda ☐
Tekitas segadust Nõustun ☐ Pigem nõustun ☐ Pigem ei nõustu ☐ Ei nõustu ☐ Raske öelda ☐
Tegi murelikuks Nõustun ☐ Pigem nõustun ☐ Pigem ei nõustu ☐ Ei nõustu ☐ Raske öelda ☐
Muu:_____________________________________________________________________________________
Mul on hea meel, et Geenivaramu minuga leitud geneetilise eripära tõttu ühendust võttis
☐ Ei nõustu ☐ Raske öelda ☐
Kas visiidil antud selgitused olid piisavad?
Jah ☐ Ei ☐ Raske öelda ☐
Millist informatsiooni oleksite veel soovinud?
____________________________________________________________________________________________
____________________________________________________________________________________________
Täname Teid!
1
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata
täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Tagasiside mõju hindamise küsimustik kuue kuu pärast peale tagasiside visiiti
Lugupeetud geenidoonor!
Osalesite TÜ Eesti Geenivaramu projektis "Kliiniliselt oluliste struktuursete geenivariantide mõju
üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja
personaliseeritud käsitlus”. Palume Teie hinnangut saadud informatsioonile. Palun vastake järgnevatele
küsimustele, märgistades Teie hinnangul sobivaim vastusevariant.
Kuidas Te ennast praegu tunnete? Lugege tähelepanelikult läbi alljärgnevad väited ja otsustage, kuivõrd nad
Teie puhul kehtivad. Teil on valida nelja vastuse vahel. Kui Te olete oma otsuse teinud, siis märkige sobivaim
vastusevariant. Ärge vastates liiga põhjalikult küsimuse peale mõelge, kuna siin ei saa vastata õigesti ega
valesti. Oluline on, et märgiksite oma praeguse hetke tunde põhjal.
Ma olen rahulik See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma olen pinges See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen ärevust See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen end vabalt See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma tunnen rahulolu See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Ma olen mures See on täiesti nii ☐ See on peaaegu nii ☐ Vähesel määral ☐ Üldse mitte ☐
Meenutades oma otsust saada personaalset geneetilist tagasisidet, palun märkige kuivõrd Te nõustute
järgnevate väidetega märgistades sobivaim vastusevariant.
See oli õige otsus Nõustun ☐ Pigem nõustun ☐ Raske öelda ☐ Pigem ei nõustu ☐ Ei nõustu ☐
Kahetsen oma valikut Nõustun ☐ Pigem nõustun ☐ Raske öelda ☐ Pigem ei nõustu ☐ Ei nõustu ☐
Teeksin sama valiku kui peaksin Nõustun ☐ Pigem nõustun ☐ Raske öelda ☐ Pigem ei nõustu ☐ Ei nõustu ☐
uuesti otsustama
Valik põhjustas mulle palju kahju Nõustun ☐ Pigem nõustun ☐ Raske öelda ☐ Pigem ei nõustu ☐ Ei nõustu ☐
Langetasin targa otsuse Nõustun ☐ Pigem nõustun ☐ Raske öelda ☐ Pigem ei nõustu ☐ Ei nõustu ☐
Kas Te olete informatsiooni oma geneetilise eripära kohta kellegagi jaganud?
Abikaasa/elukaaslasega Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐ Pole võimalik ☐
Lastega Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐ Pole võimalik ☐
Õdede/vendadega Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐ Pole võimalik ☐
(Küsimus jätkub lehekülje pöördel)
1
"Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata
täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus”
Tagasiside mõju hindamise küsimustik kuue kuu pärast peale tagasiside visiiti
Kas Te olete informatsiooni oma geneetilise eripära kohta kellegagi jaganud?
Vanematega Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐ Pole võimalik ☐
Arstiga Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐ Pole võimalik ☐
Muu ________________ Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐
Kui Te jagasite saadud informatsiooni oma geneetilise eripära kohta, siis milline oli vastukaja?
____________________________________________________________________________________________________
Kui Te ei kavatse saadud informatsiooni oma geneetilise eripära kohta kellegagi jagada, siis mis on peamine
põhjus?
____________________________________________________________________________________________________
Milliseid järgnevatest tegevustest olete peale Geenivaramu teadusprojektis osalemist teinud?
Olen käinud perearsti juures
Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐
Perearst muutis vastavalt minu raviplaani
Jah ☐ Ei ☐ Raske öelda ☐
Olen käinud eriarsti juures
Jah ☐ Veel mitte, kuid kavatsen ☐ Ei ☐
Kui jah, siis palun täpsustage millise eriarsti____________________________________________
Eriarst muutis vastavalt minu raviplaani
Jah ☐ Ei ☐ Raske öelda ☐
Kust olete ise täiendavat informatsiooni otsinud? Palun märgistage kõik sobivad vastused.
Küsisin arstilt ☐ Internetist ☐ Ei ole otsinud ☐ Muu __________________________
Kas Teil on soovitusi või ettepanekuid, mida Geenivaramu võiks tagasisidega seoses paremini teha?
___________________________________________________________________________
Täname Teid!
2
CURRICULUM VITAE
Name and surname: Helene Alavere
Contact: +372 5062542
[email protected]
Education and
Qualifications:
2014-2017 Residency programme of Family Medicine
2008-2011 Faculty of Medicine, University of Tartu, Master of
Science in Health Sciences (Public Health) cum laude.
1987-1988 Internship in psychiatry.
1981-1987 Faculty of Medicine, University of Tartu, Medical
Doctor 1987
Experience:
2003- 2009 Estonian Genome Center, Project Manager
2010- Tartu University, Institute of Genomics, Head of the
EGC Database
LIIS LEITSALU
+372 530 88075 •
[email protected]
EDUCATION
University of Tartu, Tartu, Estonia
Institute of Molecular and Cell Biology
PhD student in Gene Technology (November 2011- Present)
Thesis topic – “Personal Genomic Information – analysis and possibilities for implementation”
Sarah Lawrence College, Bronxville, NY, USA
Joan H. Marks Graduate Program in Human Genetics
Master of Science in Human Genetics (May 2010)
Thesis topic - “Counseling for Complex Diseases - Incorporating predictive genetic testing into
the health care system”
University of Edinburgh, Scotland, UK
School of Biology, Genetics Honours Degree (June 2008)
Honours project: "Identifying the links between transcription and splicing"
Berg High School, Oslo, Norway
International Baccalaureate (2002 - 2004)
RESEARCH EXPERIENCE
Estonian Genome Center of the University of Tartu (EGCUT), Tartu, Estonia
- Project manager at the EGCUT, Translational Genomics Working Group
(September 2010 - Present)
Development of a system for return of results to biobank participants.
Tallinn University of Technology, Tallinn, Estonia
- Intern in the Department of Gene Technology, Professor Tõnis Timmusk’s Laboratory,
Project: "Mammalian homologues of the Drosophila gene neuralized"
(Summer 2007)
Investigated the localization of rats’ dendritic mRNAs in human neurons via in situ hybridization.
Primary tasks included probe preparation – cloning and plasmid purification, PCR and
preparation of the tissue samples, in situ hybridization on fixed cells in culture included
tranfection of primary cell cultures with different neu-constructs.
(Summer 2006)
Described the localization of neuralized protein and mRNA and identifying its interaction
partners. Primary tasks involved mammalian primary cell cultures, histochemistry and western
blot analysis.
CLINICAL INTERNSHIP EXPERIENCE
Sarah Lawrence College, Bronxville, NY (2008 - 2009)
- Clinical rotation at Maimonides Clinical Center, Brooklyn, NY
Genetic counseling in pediatrics and prenatal setting - reviewing patient information, introducing
prenatal testing options, giving group sessions for patients in the perinatal center.
- Clinical rotation at Roosevelt Hospital, New York, NY
Genetic counseling in pediatric and prenatal setting - reviewing patient information, coordinated
prenatal testing, communicating test results, and patient follow up.
- Clinical rotation at Bronx-Lebanon Hospital, Bronx, NY
Genetic counseling in prenatal setting - contracting, taking medical and family histories,
introduced prenatal testing options.
- Disability rotation at Richmond Community Services, Yonkers, NY
Obtained insight into the daily lives of people with disabilities and their care.
- Laboratory rotation at Genzyme Genetics, New York, NY
Observed how genetic samples are handled and results obtained. Received insight into the
opportunities available for biologists and genetic counselors in a corporate setting.
COUNSELING EXPERIENCE
University of Edinburgh, Scotland, UK (September 2007- May 2008)
- Trained volunteer for the Edinburgh support organization called Nightline.
Offered empathic non-directional advice and provided information when needed, advocated for
the importance of the service, and assisted in the training of new volunteers.
OTHER EXPERIENCE
Sarah Lawrence College, Bronxville, NY
- Research assistant for the March of Dimes Grant (April 2009 – May 2010)
Searching for and entering articles to a reference library in ENDNOTE.
- Audiovisual assistant for the Human Genetics Program (September 2008 – May 2010)
- Assistant in the Graduate Studies Office (2008 - 2009)
Technical research institute SINTEF, Oslo, Norway (2001 – 2004)
- Assistant at the Department of Applied Mathematics
PUBLISHING
Articles
Cambon-Thomsen, A., Thorisson, G. A., Mabile, L., Andrieu, S., Bertier, G., Boeckhout, M., et
al. (2011). The role of a Bioresource Research Impact Factor as an incentive to share human
bioresources. Nat Genet, 43(6), 503-504.
Leitsalu, L., Hercher, L., Metspalu A. (2011). Giving and Withholding of Information Following
Genomic Screening: Challenges Identified in a Study of Primary Care Physicians in Estonia.
J.Genet.Counsel.
Alavere H, Fischer K, Esko T, Leitsalu-moynihan L, Metspalu A. Tartu Ülikooli Eesti
geenivaramu on teadlaste käsutuses. Eesti Arst. 2012;91(4):190–8.
Leitsalu L, Alavere H, Allik A, Eesti TÜ. Eesti geenivaramu kavandab tagasiside andmist
geenidoonoritele. Eesti Arst. 2013;92(1):9–10.
Leitsalu L, Haller T, Esko T, Tammesoo M-L, Alavere H, Snieder H, et al. (2014) Cohort Profile:
Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol.
Milani L, Leitsalu L, Metspalu A. (2015) An epidemiological perspective of personalized
medicine: the Estonian experience. J Intern Med.
Leitsalu L, Alavere H, Tammesoo M, Leego E, Metspalu A. (2015) Linking a Population
Biobank with National Health Registries — The Estonian Experience. J Pers Med. 96–106.
Männik K, Mägi R, Macé A, Cole B, Guyatt AL, Shihab HA, et al. (2015) Copy Number
Variations and Cognitive Phenotypes in Unselected Populations. JAMA. 313(20):2044–54.
Meren ÜH, Metspalu A, Tammaru M, et al. Personaalse geneetilise riskiteabe mõju
hüpertensiooniravi järgimusele ja tulemuslikkusele Eesti patsientidel : juhuslikustatud uuringu
metoodika ülevaade. Eesti Arst 2016;94(13).
Books
Leitsalu L, Milani L, Esko T, Allik A, Lilienthal K, Tammesoo M-L, et al. The Estonian biobank
– the gateway for the stratified medicine. In: Engelbrecht J, Varlamova G, editors. RESEARCH
IN ESTONIA PRESENT AND FUTURE. ESTONIAN ACADEMY OF SCIENCES; 2011. p.
283–301.
AWARDS and STIPENDS
Recipient of a 2013 DoRa Activity 6 mobility stipend by European Social Fund’s Doctoral
Studies and Internationalisation Programme DoRa. Programme DoRa is carried out by
Archimedes Foundation.
Recipient of a 2011 Congress Travel Award named "ICHG Young Investigator Awards",
International Congress of Human Genetics scheduled to be held in Montreal, October 11-15,
2011.
References upon request
Maarja Lepamets
Telefon 737 4035
E-post
[email protected]
Töökohad ja ametid
01.02.2020– Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist
31.08.2020 (0,65)
01.09.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, spetsialist
31.08.2020 (0,50)
01.10.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist
31.01.2020 (0,30)
01.01.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist
30.09.2018 (0,50)
01.07.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, spetsialist
31.08.2016 (1,00)
04.01.2016– Tervisetehnoloogiate Arenduskeskus AS (endine
30.06.2016 Reproduktiivmeditsiini TAK AS) , Bioinformaatik (1,00)
14.09.2015– Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu
22.12.2015 Ülikooli Molekulaar- ja Rakubioloogia Instituut,
programmeerija (0,80)
01.01.2013– Center for Integrative Bioinformatics Vienna (CIBIV), assistent
31.12.2014 (0.25)
01.11.2012– Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu
13.09.2015 Ülikooli Molekulaar- ja Rakubioloogia Instituut,
programmeerija (0,50)
Haridustee
2016–... Tartu Ülikool, geenitehnoloogia, doktoriõpe
01.02.2017– Lausanne'i Ülikool, Integreeritud genoomika keskus, Prof
30.06.2017 Reymond' grupp, külalisdoktorant
01.02.2015– Oxfordi Ülikool, Wellcome Trusti Inimgeneetika keskus, prof
30.04.2015 Motti grupp, praktika
2013–2015 Tartu Ülikool, MSc Informaatika (cum laude)
01.07.2013– Center for Integrative Bioinformatics Vienna (CIBIV), Viini
31.08.2013 biokeskuse suvekool, praktika
2010–2013 Tartu Ülikool, BSc Matemaatiline statistika
2010–2014 Tartu Ülikool, BSc Geenitehnoloogia
2007–2010 Tallinna Reaalkool (lõpetanud kuldmedaliga)
Teaduskraadid
Maarja Lepamets, magistrikraad, 2015, (juh) Lauris Kaplinski, PCR-i praimerite
kvaliteedimudeli integreerimine Primer3-e disainimetoodikasse, Tartu Ülikool, Loodus-
ja täppisteaduste valdkond, arvutiteaduse instituut.
Maarja Lepamets, doktorant, (juh) Reedik Mägi; Andrew Paul Morris; Andres Salumets;
Andres Metspalu, Imputation and analysis of gene expression data using reproductive
health associated phenotypes (Reproduktiivtervisega seotud geenide ekspressiooni
analüüs ja geeniekspressiooni imputeerimine), Tartu Ülikool.
Teaduspreemiad ja tunnustused
2013 Skype'i ja IT akadeemia magistristipendium
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud
uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia,
molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatika; CERCS
KLASSIFIKAATOR: B110 Bioinformaatika, meditsiiniinformaatika, biomatemaatika,
biomeetrika
Jooksvad projektid
• SLTMR16142T (TK142) "Genoomika ja Siirdemeditsiini Tippkeskus (TK142)
(1.01.2016−1.03.2023)", Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti
Geenivaramu.
• IUT34-11 "Kiiremad ja usaldusväärsemad meetodid genoomijärjestuste
analüüsimiseks (1.01.2015−31.12.2020)", Maido Remm, Tartu Ülikool, Loodus- ja
täppisteaduste valdkond, molekulaar- ja rakubioloogia instituut.
• PRG687 "Suuremahuliste genoomika andmete kasutus ja metoodika arendus
geneetiliste haigusriskide hinnangute väljatöötamiseks (1.01.2020−31.12.2020)",
Reedik Mägi, Tartu Ülikool, Tartu Ülikooli genoomika instituut.
• PP1GI19935 "Koopiaarvu muutuste mõju komplekshaigustele
(7.08.2019−30.06.2020)", Reedik Mägi, Tartu Ülikool, Tartu Ülikooli genoomika
instituut.
Lõppenud projektid
• IUT20-60 "Oomiksi põhised meetodid terviseuuringutes: integreeritud lähenemine
haiguste tekkeprotsesside mõistmiseks ja prognoosimiseks (1.01.2014−31.12.2019)",
Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikool,
Tartu Ülikooli genoomika instituut.
Publikatsioonid
2019
Reisberg, Sulev; Krebs, Kristi; Lepamets, Maarja; Kals, Mart; Mägi, Reedik; Metsalu, Kristjan;
Lauschke, Volker M.; Vilo, Jaak; Milani, Lili; (2019). Translating genotype data of 44,000 biobank
participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in
medicine.10.1038/s41436-018-0337-5.
Läll, Kristi; Lepamets, Maarja; Palover, Marili; Esko, Tõnu; Metspalu, Andres; Tõnisson, Neeme;
Padrik, Peeter; Mägi, Reedik; Fischer, Krista (2019). Polygenic prediction of breast cancer:
comparison of genetic predictors and implications for risk stratification. Bmc Cancer, 19, ARTN
557.10.1186/s12885-019-5783-1.
Lee, Arthur S.; Rusch, Jannette; Lima, Ana C.; Usmani, Abul; Huang, Ni; Lepamets, Maarja; Vigh-
Conrad, Katinka A.; Worthington, Ronald E.; Magi, Reedik; Wu, Xiaobo; Aston, Kenneth, I;
Atkinson, John P.; Carrell, Douglas T.; Hess, Rex A.; O'Bryan, Moira K.; Conrad, Donald F. (2019).
Rare mutations in the complement regulatory gene CSMD1 are associated with male and female
infertility. Nature Communications, 10, ARTN 4626.10.1038/s41467-019-12522-w.
2018
Kõressaar, Triinu; Lepamets, Maarja; Kaplinski, Lauris; Raime, Kairi; Andreson, Reidar; Remm,
Maido (2018). Primer3_masker: integrating masking of template sequence with primer design
software. Bioinformatics, 34 (11), 1937−1938.10.1093/bioinformatics/bty036.
2017
Pajuste, Fanny-Dhelia; Kaplinski, Lauris; Möls, Märt; Puurand, Tarmo; Lepamets, Maarja; Remm,
Maido (2017). FastGT: an alignment-free method for calling common SNVs directly from raw
sequencing reads. Scientific Reports, 7 (1), 2537−2537.10.1038/s41598-017-02487-5.
Roosaare, Märt; Vaher, Mihkel; Kaplinski, Lauris; Möls, Märt; Andreson, Reidar; Lepamets, Maarja;
Kõressaar, Triinu; Naaber, Paul; Kõljalg, Siiri; Remm, Maido (2017). StrainSeeker: fast identification
of bacterial strains from raw sequencing reads using user-provided guide trees. PeerJ, 5, ARTN
e3353−e3353.10.7717/peerj.3353.
2015
Kaplinski, Lauris; Lepamets, Maarja; Remm, Maido (2015). GenomeTester4: a toolkit for performing
basic set operations - union, intersection and complement on k-mer lists. GigaScience, 4 (58),
1−8.10.1186/s13742-015-0097-y.
CURRICULUM VITAE
Contact and personal information
First and last name: Katrin Männik
Work address: Health2030 Genome Center
Campus Biotech - 9 Chemin des Mines,
1202 Geneva, Switzerland
Phone: + 41 58 201 02 34
Email:
[email protected]
Personal address: Rue Louis-Favre 20
2000 Neuchâtel, Switzerland
Nationality: Estonian (European Union); Swiss residence permit B
Languages: Estonian (mother tongue), English (fluent), French
(intermediate), Russian (elementary)
Education and degree information
Sept 2009 - Sept 2012 PhD, curriculum gene technology, Faculty of Science and
Technology, University of Tartu, Estonia
Aug 2011 - Aug 2012 PhD student in the Center for Integrative Genomics, University of
Lausanne, Switzerland
Sept 2001 - Aug 2004 MSc, curriculum molecular diagnostics, Faculty of Biology and
Geography, University of Tartu, Estonia
Sept 1996 - Aug 2001 BSc, curriculum biomedicine and biotechnology, Faculty of Biology
and Geography, University of Tartu, Estonia
Sept 1993 - Aug 1996 curriculum medicine, Faculty of Medicine, University of Tartu, Estonia
Professional experience
Nov 2019 - … Head of Data Strategy (Genomic Medicine), Health2030 Genome
Center, Geneva, Switzerland
Mar 2018 – Oct 2019 Research Associate (Chargé de recherche), Center for
Integrative Genomics, University of Lausanne, Switzerland
Sept 2014 – Oct 2019 Researcher, Estonian Genome Center, University of Tartu, Estonia
Jan 2019 Visiting Researcher, Center for Human Development and Disability,
University of Washington, Seattle, WA, USA
Sept 2016 - Mar 2018 Swiss National Science Foundation Senior Researcher, Center for
Integrative Genomics, University of Lausanne, Switzerland
Sept 2012 - Aug 2016 Post-doctoral researcher, Center for Integrative Genomics, University
of Lausanne, Switzerland
July 2008 - Aug 2014 Researcher, Institute of Molecular and Cell Biology, University of
Tartu, Estonia
Sept 2006 - June 2008 Extraordinary Researcher, Institute of Molecular and Cell Biology,
University of Tartu, Estonia
Aug 2004 - Aug 2006 Extraordinary Researcher, Estonian Biocenter, Tartu, Estonia
My education and professional path includes two periods of maternity leave (1999-2000 and
2005-2006).
Additional professional training
ELSI & Project management
⁃ Human Research Ethics; Training and Resources in Research Ethics Evaluation
(Programme de formation continue; awarded with Certificat de formation formally
acknowledged by Fédération des Médecins Suisses); February-March 2018
⁃ Ethical and Social Challenges of Genomic and Precision Medicine (awarded with ID-
verified certificate); University of California, San Francisco MOOC; December 2017 -
February 2018
⁃ Project Management; Koos&Effect/University of Lausanne; March 2016; Lausanne,
Switzerland
⁃ Biomedical Ethics (awarded with licence in bioethics); Faculty of Medicine, University
of Tartu; September – December 2010, Tartu, Estonia
Data analysis
⁃ Numerous training courses organized by the Swiss Institute of Bioinformatics in the
fields of big-data analysis, next-generation sequencing, gene expression, biological
networks and genomic medicine; 2012 - 2018, Lausanne, Bern, Basel, Switzerland
*Detailed information and certificates of attendance available upon request
⁃ Genome bioinformatics techniques; European Commission FP6 Marie Curie
Workshop; September 2008, Braga, Portugal
Human & Clinical genetics
⁃ Genetic Analysis of Mendelian and Complex Disorders; Wellcome Trust Genome
Campus; July 2019, Hinxton, United Kingdom
⁃ The Leena Peltonen School of Human Genomics; Wellcome Trust, University of
Cambridge; August 2012, Cambridge, United Kingdom
⁃ Fundamentals of Clinical Genetics; Wellcome Trust Conference Centre, Clinical
Genetics Society and Specialist Advisory Committee of the Royal College of
Physicians; January 2010, Hinxton, United Kingdom
⁃ Array techniques to identify copy number variations; European Commission FP6
Marie Curie Workshop; September 2007, Helsinki, Finland
⁃ 5th Course in Molecular Cytogenetics and DNA Arrays; European School of Genetic
Medicine; September 2003, Bertinoro, Italy
Neurology & Neurodevelopment
⁃ Mental Retardation: from clinic to gene and back; ICVS, University of Minho
postgraduate course; July 2011, Braga, Portugal
⁃ Paediatric Neurology; Faculty of Medicine, University of Tartu; February 2011, Tartu,
Estonia
⁃ Neuroscience; Faculty of Medicine, University of Tartu; November-December 2010,
Tartu, Estonia
Personal honours and Fellowships
The Jacobs Foundation, Early Career Research Fellowship (2017-2019)
Estonian Research Council, diploma in health sciences for PhD thesis (2012)
Swiss National Science Foundation, Sciex-NMSch research fellowship for PhD training (2011-
2012)
Jérôme Lejeune Foundation, fellowship for professional training (2011)
European Society of Human Genetics; national fellowship for young investigator (2009)
Scientific Committee of 13th International Workshop on Fragile X and X-linked Mental
Retardation; fellowship for young investigator (2007)
Estonian Academy of Sciences, first prize in student research for MSc thesis (2004)
Participation in international projects and organization of scientific events
GA4GH – Global Alliance for Genomics and Health, International policy-framing and technical
standards-setting organization in genomic medicine (2020 - …) (invited member of the Swiss
Personalized Health Network representation)
MINDDS - Maximising Impact of research in NeuroDevelopmental DisorderS, European
Commission COST Action CA16210 (2017-2021) (member of the Management Committee)
ECOS - Personalized health knowledge convergence space, The Leenards Foundation
funded Personalized Health & Society initiative; 2018-2019, Lausanne, Switzerland (invited
member of scientific college)
Workshop "Functional Annotation of Genome-Wide Variants"; March 2017, Lausanne,
Switzerland (organizer)
Workshop “Personalized Genomes – The Public Health Perspective” targeted to clinical
community in the frames of the 16th International Gene Forum; June 2016, Tartu, Estonia
(organizer)
The Forum for Genetic Research of the Swiss Academy of Sciences; April 2016, Lausanne,
Switzerland (invited participation in discussion session)
ePerMed - Rise of scientific excellence and collaboration for implementing personalised
medicine in Estonia, European Commission Horizon2020 692145 (2016-2018)
CHERISH - Improving Diagnoses of Mental Retardation in Children in Eastern Europe and
Central Asia through Genetic Characterisation and Bioinformatics/Statistics, European
Commission FP7 43230 (2009-2012)
Platform presentations at international conferences
13th Wellcome Trust Conference “Genomics of Rare Disease”; March 2019, Hinxton,
Cambridge, United Kingdom (invited talk)
The American Society Human Genetics Annual Meeting 2018; October 2018, San Diego, CA,
USA (selected talk)
The European Human Genetics Conference 2018; June 2018, Milan, Italy (selected talk)
The ACMG Annual Clinical Genetics Meeting 2017; March 2017, Phoenix, AZ, USA (selected
talk)
The European Human Genetics Conference 2016; May 2016, Barcelona, Spain (selected
talk)
11th Meeting on Genetics of Neurodevelopmental Disorders; April 2016, Troina, Italy (invited
talk)
The American Society Human Genetics Annual Meeting 2015; October 2015, Baltimore, MD,
USA (selected talk)
9th Wellcome Trust Conference “Genomics of Rare Disease: Beyond the Exome”; April 2015,
Hinxton, Cambridge, United Kingdom (selected talk)
8th Wellcome Trust Conference “Genomic Disorders 2014: The Genomics of Rare Diseases”;
March 2014, Cambridge, United Kingdom (selected talk)
Cold Spring Harbor Laboratory Meeting “Precision Medicine: Personal Genomes and
Pharmacogenomics”; November 2013, Cold Spring Harbor, NY, USA (selected talk)
The European Human Genetics Conference 2013; June 2013, Paris, France (selected talk)
2nd AnEUploidy Workshop; September 2010, Split, Croatia (selected talk)
4th International Meeting on Cryptic Chromosomal Rearrangements in Mental Retardation
and Autism; April 2008, Troina, Italy (selected talk)
Invited talks outside of home institute
11th World Conference of Science Journalists, pre-conference workshop "The science of
learning and science journalism"; July 2019, Lausanne, Switzerland
Lausanne University Hospital, Medical college of the ECOS project; April 2019, Lausanne,
Switzerland
University of Zürich, The Jacobs Center for Productive Youth Development; March 2017,
Zürich, Switzerland
Federal University of Sao Paulo, Workshop "Genome Structure and Expression"; October
2016, Sao Paulo, Brazil
University of Helsinki, Institute for Molecular Medicine Finland; April 2016, Helsinki, Finland
Association of Estonian Biomedical Laboratory Scientists; Tartu, Estonia, August 2010
Psychiatry Clinic, Tartu University Hospital; Tartu, Estonia, May 2010
Children`s Clinic, Tartu University Hospital; Tartu, Estonia, February 2010
Teaching and supervising experience
2017 Maarja Lepamets, PhD student in exchange (6 months), Center for
Integrative Genomics, University of Lausanne (supervisor)
2016 Sander Pajusalu, medical residency in exchange (1 month), Center for
Integrative Genomics, University of Lausanne (supervisor)
2016 Berit Kolk, MSc in biomedicine, Faculty of Science and Technology,
University of Tartu, Estonia (supervisor)
2013 Ilse van der Werf, MSc in molecular medicine, Department of Human
Genetics, Radboud University Nijmegen Medical Center, The Netherlands
(co-supervisor)
2012 Kristi-Liina Arusoo, BSc in biology, Faculty of Science and Technology,
University of Tartu, Estonia (supervisor)
2010 Margit Nõukas, MSc in biomedicine, Faculty of Medicine, University of Tartu,
Estonia (supervisor)
2008 Margit Nõukas, BSc in gene technology, Faculty of of Science and
Technology, University of Tartu, Estonia (co-supervisor)
2018 Practical course in Molecular Biology; Faculty of Biology and Medicine,
University of Lausanne
2012 – 2015 Practical course in Molecular Biology; Faculty of Biology and Medicine,
University of Lausanne
2012 – 2015 Seminars in Genetics and Genome Evolution; Faculty of Biology and
Medicine, University of Lausanne
2009 – 2011 Practical Course in Genetic Engineering; Institute of Molecular and Cell
Biology, Faculty of Science and Technology, University of Tartu
Other professional activities
Reviewer for peer-reviewed scientific journals (e.g. Journal of Medical Genetics, PLoS
Genetics, European Journal of Human Genetics, Human Genetics, Twin Research Human
Genetics, Applied Neuropsychology, International Journal of Obesity) and funding agencies
(Estonian Research Agency, The Jacobs Foundation)
Member of the European Society of Human Genetics, the American Society of Human
Genetics, the Nordic Society for Precision Medicine
Representative publications
Männik K*, Arbogast T*, Lepamets M*, Lepik K, Mikhaleva A, Ademi H, Kupchinsky ZA,
Ellegood J, Attanasio C, Messina A, Rotman S, Martin-Brevet S, Dubruc E, Chrast J, Lerch
JP, Qiu LR, Laisk-Podar T, The 16p11.2 European Consortium, The Simons VIP Consortium,
The eQTLGen Consortium, Henkelman RM, Herault Y, Lindgren CM, Peterson H, Stehle JC,
Katsanis N, Kutalik Z, Nef S, Draganski B, Davis E, Mägi R, Reymond A "Leveraging
biobank-scale rare and common variant analyses to identify ASPHD1 as the main driver of
reproductive traits in the 16p11.2 locus"; in review
*These authors contributed equally to this work
Pizzo L, Jensen M, Polyak A, Rosenfeld JA, Männik K, Krishnan A, McCready E, Pichon O,
Le Caignec C, Van Dijck A, Pope K, Voorhoeve E, Yoon J, Stankiewicz P, Cheung SW,
Pazuchanics D, Huber E, Kumar V, Kember R, Mari F, Curró A, Castiglia L, Galesi O, Avola
E, Mattina T, Fichera M, Mandarà L, Vincent M, Nizon M, Mercier S, Bénéteau C, Blesson S,
Martin-Coignard D, Mosca-Boidron A-L, Caberg JH, Bucan M, Zeesman S, Nowaczyk MJM,
Lefebvre M, Faivre L, Callier P, Skinner C, Keren B, Perrine C, Prontera P, Marle N, Renieri
A, Reymond A, Kooy RF, Isidor B, Schwartz C, Romano C, Sistermans E, Amor DJ, Andrieux
J, Girirajan S "Rare variants in the genetic background modulate the expressivity of
neurodevelopmental disorders"; Genet Med 2019 Apr;21(4):816-825
Leitsalu L, Alavere H, Jacquemont S, Kolk A, Maillard AM, Reigo A, Nõukas M, Reymond A,
Männik K, Ng PC, Metspalu A "Reporting incidental findings of genomic disorder-associated
CNVs to unselected biobank participants"; Per Med 2016; 13(4): 303-314
Männik K, Mägi R, Macé A, Cole B, Guyatt AL, Shihab HA, Maillard AM, Alavere H, Kolk A,
Reigo A, Mihailov E, Leitsalu L, Ferreira AM, Nõukas M, Teumer A, Salvi E, Cusi D, McGue
M, Iacono WG, Gaunt TR, Beckmann JS, Jacquemont S, Kutalik Z, Pankratz N, Timpson N,
Metspalu A, Reymond A. “Copy number variations and cognitive phenotypes in unselected
populations”; JAMA 2015 May 26;313(20):2044-54
Migliavacca E*, Golzio C*, Männik K*, Blumenthal I, Oh EC, Harewood L, Kosmicki J,
Loviglio MN, Giannuzzi G, Hippolyte L, Maillard AM, Alfaiz AA, 16p11.2 European
Consortium, van Haelst MM, Andrieux J, Gusella JF, Daly MJ, Beckmann JS, Jacquemont S,
Talkowski ME, Katsanis N, Reymond A “A potential contributory role for ciliary dysfunction in
the 16p11.2 600kb BP4-BP5 pathology”, Am J Hum Genet 2015 May 7;96(5):784-96
*These authors contributed equally to this work
Peer-reviewed publications
Munn-Chernoff MA, Johnson EC, Chou YL, Coleman JRI, Thornton LM, Walters RK, Yilmaz Z, Baker JH, Hübel C,
Gordon S, Medland SE, Watson HJ, Gaspar HA, Bryois J, Hinney A, Leppä VM, Mattheisen M, Ripke S, Yao S,
Giusti-Rodríguez P, Hanscombe KB, Adan RAH, Alfredsson L, Ando T, Andreassen OA, Berrettini WH, Boehm I,
Boni C, Boraska Perica V, Buehren K, Burghardt R, Cassina M, Cichon S, Clementi M, Cone RD, Courtet P, Crow S,
Crowley JJ, Danner UN, Davis OSP, de Zwaan M, Dedoussis G, Degortes D, DeSocio JE, Dick DM, Dikeos D, Dina
C, Dmitrzak-Weglarz M, Docampo E, Duncan LE, Egberts K, Ehrlich S, Escaramís G, Esko T, Estivill X, Farmer A,
Favaro A, Fernández-Aranda F, Fichter MM, Fischer K, Föcker M, Foretova L, Forstner AJ, Forzan M, Franklin CS,
Gallinger S, Giegling I, Giuranna J, Gonidakis F, Gorwood P, Gratacos Mayora M, Guillaume S, Guo Y, Hakonarson
H, Hatzikotoulas K, Hauser J, Hebebrand J, Helder SG, Herms S, Herpertz-Dahlmann B, Herzog W, Huckins LM,
Hudson JI, Imgart H, Inoko H, Janout V, Jiménez-Murcia S, Julià A, Kalsi G, Kaminská D, Karhunen L, Karwautz A,
Kas MJH, Kennedy JL, Keski-Rahkonen A, Kiezebrink K, Kim YR, Klump KL, Knudsen GPS, La Via MC, Le Hellard
S, Levitan RD, Li D, Lilenfeld L, Lin BD, Lissowska J, Luykx J, Magistretti PJ, Maj M, Mannik K, Marsal S, Marshall
CR, Mattingsdal M, McDevitt S, McGuffin P, Metspalu A, Meulenbelt I, Micali N, Mitchell K, Monteleone AM,
Monteleone P, Nacmias B, Navratilova M, Ntalla I, O'Toole JK, Ophoff RA, Padyukov L, Palotie A, Pantel J,
Papezova H, Pinto D, Rabionet R, Raevuori A, Ramoz N, Reichborn-Kjennerud T, Ricca V, Ripatti S, Ritschel F,
Roberts M, Rotondo A, Rujescu D, Rybakowski F, Santonastaso P, Scherag A, Scherer SW, Schmidt U, Schork NJ,
Schosser A, Seitz J, Slachtova L, Slagboom PE, Slof-Op't Landt MCT, Slopien A, Sorbi S, Świątkowska B,
Szatkiewicz JP, Tachmazidou I, Tenconi E, Tortorella A, Tozzi F, Treasure J, Tsitsika A, Tyszkiewicz-Nwafor M,
Tziouvas K, van Elburg AA, van Furth EF, Wagner G, Walton E, Widen E, Zeggini E, Zerwas S, Zipfel S, Bergen AW,
Boden JM, Brandt H, Crawford S, Halmi KA, Horwood LJ, Johnson C, Kaplan AS, Kaye WH, Mitchell J, Olsen CM,
Pearson JF, Pedersen NL, Strober M, Werge T, Whiteman DC, Woodside DB, Grove J, Henders AK, Larsen JT,
Parker R, Petersen LV, Jordan J, Kennedy MA, Birgegård A, Lichtenstein P, Norring C, Landén M, Mortensen PB,
Polimanti R, McClintick JN, Adkins AE, Aliev F, Bacanu SA, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen
LS, Clarke TK, Degenhardt F, Docherty AR, Edwards AC, Foo JC, Fox L, Frank J, Hack LM, Hartmann AM, Hartz
SM, Heilmann-Heimbach S, Hodgkinson C, Hoffmann P, Hottenga JJ, Konte B, Lahti J, Lahti-Pulkkinen M, Lai D,
Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Meyers JL, Milaneschi Y, Palviainen T,
Peterson RE, Ryu E, Saccone NL, Salvatore JE, Sanchez-Roige S, Schwandt M, Sherva R, Streit F, Strohmaier J,
Thomas N, Wang JC, Webb BT, Wedow R, Wetherill L, Wills AG, Zhou H, Boardman JD, Chen D, Choi DS,
Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L, Domingue BW, Frye MA, Gäbel W, Hayward C, Ising M,
Keyes M, Kiefer F, Koller G, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Männistö S, Müller-
Myhsok B, Murray AD, Nurnberger JI, Preuss U, Räikkönen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit
MA, Soyka M, Treutlein J, Witt SH, Wodarz N, Zill P, Adkins DE, Boomsma DI, Bierut LJ, Brown SA, Bucholz KK,
Costello EJ, de Wit H, Diazgranados N, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D,
Grucza RA, Hancock DB, Harris KM, Hesselbrock V, Hewitt JK, Hopfer CJ, Iacono WG, Johnson EO, Karpyak VM,
Kendler KS, Kranzler HR, Krauter K, Lind PA, McGue M, MacKillop J, Madden PAF, Maes HH, Magnusson PKE,
Nelson EC, Nöthen MM, Palmer AA, Penninx BWJH, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose RJ, Shen PH,
Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao H, Neale BM, Wade TD,
Heath AC, Montgomery GW, Martin NG, Sullivan PF, Kaprio J, Breen G, Gelernter J, Edenberg HJ, Bulik CM,
Agrawal A. “Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from
genome-wide association studies” Addict Biol. 2020 Feb 16
Giannuzzi G, Schmidt PJ, Porcu E, Willemin G, Munson KM, Nuttle X, Earl R, Chrast J, Hoekzema K, Risso D,
Männik K, De Nittis P, Baratz ED; 16p11.2 Consortium, Herault Y, Gao X, Philpott CC, Bernier RA, Kutalik Z,
Fleming MD, Eichler EE, Reymond “A The Human-Specific BOLA2 Duplication Modifies Iron Homeostasis and
Anemia Predisposition in Chromosome 16p11.2 Autism Individuals”; Am J Hum Genet. 2019 Nov 7;105(5):947-958
Watson HJ, Yilmaz Z, Thornton LM, Hübel C, Coleman JRI, Gaspar HA, Bryois J, Hinney A, Leppä VM, Mattheisen
M, Medland SE, Ripke S, Yao S, Giusti-Rodríguez P; Anorexia Nervosa Genetics Initiative, Hanscombe KB, Purves
KL; Eating Disorders Working Group of the Psychiatric Genomics Consortium, Adan RAH, Alfredsson L, Ando T,
Andreassen OA, Baker JH, Berrettini WH, Boehm I, Boni C, Perica VB, Buehren K, Burghardt R, Cassina M, Cichon
S, Clementi M, Cone RD, Courtet P, Crow S, Crowley JJ, Danner UN, Davis OSP, de Zwaan M, Dedoussis G,
Degortes D, DeSocio JE, Dick DM, Dikeos D, Dina C, Dmitrzak-Weglarz M, Docampo E, Duncan LE, Egberts K,
Ehrlich S, Escaramís G, Esko T, Estivill X, Farmer A, Favaro A, Fernández-Aranda F, Fichter MM, Fischer K, Föcker
M, Foretova L, Forstner AJ, Forzan M, Franklin CS, Gallinger S, Giegling I, Giuranna J, Gonidakis F, Gorwood P,
Mayora MG, Guillaume S, Guo Y, Hakonarson H, Hatzikotoulas K, Hauser J, Hebebrand J, Helder SG, Herms S,
Herpertz-Dahlmann B, Herzog W, Huckins LM, Hudson JI, Imgart H, Inoko H, Janout V, Jiménez-Murcia S, Julià A,
Kalsi G, Kaminská D, Kaprio J, Karhunen L, Karwautz A, Kas MJH, Kennedy JL, Keski-Rahkonen A, Kiezebrink K,
Kim YR, Klareskog L, Klump KL, Knudsen GPS, La Via MC, Le Hellard S, Levitan RD, Li D, Lilenfeld L, Lin BD,
Lissowska J, Luykx J, Magistretti PJ, Maj M, Mannik K, Marsal S, Marshall CR, Mattingsdal M, McDevitt S, McGuffin
P, Metspalu A, Meulenbelt I, Micali N, Mitchell K, Monteleone AM, Monteleone P, Munn-Chernoff MA, Nacmias B,
Navratilova M, Ntalla I, O'Toole JK, Ophoff RA, Padyukov L, Palotie A, Pantel J, Papezova H, Pinto D, Rabionet R,
Raevuori A, Ramoz N, Reichborn-Kjennerud T, Ricca V, Ripatti S, Ritschel F, Roberts M, Rotondo A, Rujescu D,
Rybakowski F, Santonastaso P, Scherag A, Scherer SW, Schmidt U, Schork NJ, Schosser A, Seitz J, Slachtova L,
Slagboom PE, Slof-Op 't Landt MCT, Slopien A, Sorbi S, Świątkowska B, Szatkiewicz JP, Tachmazidou I, Tenconi E,
Tortorella A, Tozzi F, Treasure J, Tsitsika A, Tyszkiewicz-Nwafor M, Tziouvas K, van Elburg AA, van Furth EF,
Wagner G, Walton E, Widen E, Zeggini E, Zerwas S, Zipfel S, Bergen AW, Boden JM, Brandt H, Crawford S, Halmi
KA, Horwood LJ, Johnson C, Kaplan AS, Kaye WH, Mitchell JE, Olsen CM, Pearson JF, Pedersen NL, Strober M,
Werge T, Whiteman DC, Woodside DB, Stuber GD, Gordon S, Grove J, Henders AK, Juréus A, Kirk KM, Larsen JT,
Parker R, Petersen L, Jordan J, Kennedy M, Montgomery GW, Wade TD, Birgegård A, Lichtenstein P, Norring C,
Landén M, Martin NG, Mortensen PB, Sullivan PF, Breen G, Bulik CM "Genome-wide association study identifies
eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa" Nat Genet 2019 Jul 15.
Yao S, Kuja-Halkola R, Martin J, Lu Y, Lichtenstein P, Norring C, Birgegård A, Yilmaz Z, Hübel C, Watson H, Baker
J, Almqvist C; Eating Disorders Working Group of the Psychiatric Genomics Consortium, Thornton LM,
Magnusson PK, Bulik CM, Larsson H "Associations Between Attention-Deficit/Hyperactivity Disorder and Various
Eating Disorders: A Swedish Nationwide Population Study Using Multiple Genetically Informative Approaches" Biol
Psychiatry 2019 pii: S0006-3223(19)31371-X
Pizzo L, Jensen M, Polyak A, Rosenfeld JA, Männik K, Krishnan A, McCready E, Pichon O, Le Caignec C, Van Dijck
A, Pope K, Voorhoeve E, Yoon J, Stankiewicz P, Cheung SW, Pazuchanics D, Huber E, Kumar V, Kember R, Mari
F, Curró A, Castiglia L, Galesi O, Avola E, Mattina T, Fichera M, Mandarà L, Vincent M, Nizon M, Mercier S,
Bénéteau C, Blesson S, Martin-Coignard D, Mosca-Boidron A-L, Caberg JH, Bucan M, Zeesman S, Nowaczyk MJM,
Lefebvre M, Faivre L, Callier P, Skinner C, Keren B, Perrine C, Prontera P, Marle N, Renieri A, Reymond A, Kooy
RF, Isidor B, Schwartz C, Romano C, Sistermans E, Amor DJ, Andrieux J, Girirajan S "Rare variants in the genetic
background modulate the expressivity of neurodevelopmental disorders" Genet Med 2019 21(4):816-825
Brainstorm Consortium "Analysis of shared heritability in common disorders of the brain", Science 2018
360(6395):pii:eaap8757
Huckins LM, Hatzikotoulas K, Southam L, Thornton LM, Steinberg J, Aguilera-McKay F, Treasure J, Schmidt U,
Gunasinghe C, Romero A, Curtis C, Rhodes D, Moens J, Kalsi G, Dempster D, Leung R, Keohane A, Burghardt R,
Ehrlich S, Hebebrand J, Hinney A, Ludolph A, Walton E, Deloukas P, Hofman A, Palotie A, Palta P, van Rooij FJA,
Stirrups K, Adan R, Boni C, Cone R, Dedoussis G, van Furth E, Gonidakis F, Gorwood P, Hudson J, Kaprio J, Kas
M, Keski-Rahonen A, Kiezebrink K, Knudsen GP, Slof-Op 't Landt MCT, Maj M, Monteleone AM, Monteleone P,
Raevuori AH, Reichborn-Kjennerud T, Tozzi F, Tsitsika A, van Elburg A; Eating Disorder Working Group of the
Psychiatric Genomics Consortium, Collier DA, Sullivan PF, Breen G, Bulik CM, Zeggini E "Investigation of
common, low-frequency and rare genome-wide variation in anorexia nervosa" Mol Psychiatry 2018, 23(5):1169-
1180
Macé A, Tuke M, Deelen P, Kristiansson K, Mattsson H, Nõukas M, Sapkota Y, Schick U, Porcu E, Rüeger S,
McDaid A, Porteous D, Winkler T, Salvi E, Shrine N, Liu X, Ang W, Zhang W, Feitosa M, Venturini C, van der Most
P, Rosengren A, Wood A, Beaumont R, Jones S, Ruth K, Yaghootkar H, Tyrrell J, Havulinna A, Boers H, Mägi R,
Kriebel J, Müller-Nurasyid M, Perola M, Nieminen M, Lokki ML, Kähönen M, Viikari J, Geller F, Lahti J, Palotie A,
Koponen P, Lundqvist A, Rissanen H, Bottinger E, Afaq S, Wojczynski M, Lenzini P, Nolte I, Sparsø T, Schupf N,
Christensen K, Perls T, Newman A, Werge T, Snieder H, Province M, Spector T, Kooner J, Chambers J, Koskinen S,
Melbye M, Raitakari O, Lehtimäki T, Tobin M, Wain L, Sinisalo J, Peters A, Meitinger T, Martin N, Wray N,
Montgomery G, Medland S, Swertz M, Vartiainen E, Borodulin K, Männistö S, Murray A, Bochud M, Jacquemont S,
Rivadeneira F, Hansen T, Oldehinkel A, Mangino M, Deloukas P, Freathy R, Pennell C, Feenstra B, Strachan D,
Lettre G, Hirschhorn J, Cusi D, Heid I, Hayward C, Männik K, Beckmann J, Loos R, Nyholt D, Metspalu A, Eriksson
J, Weedon M, Salomaa V, Franke L, Reymond A, Frayling T, Kutalik Z "CNV-association meta-analysis in 191,161
European adults reveals new loci associated with anthropometric traits" Nat Commun 2017 8(1):744
Li D, Chang X, Connolly JJ, Tian L, Liu Y, Bhoj EJ, Robinson N, Abrams D, Li YR, Bradfield JP, Kim CE, Li J, Wang
F, Snyder J, Lemma M, Hou C, Wei Z, Guo Y, Qiu H, Mentch FD, Thomas KA, Chiavacci RM, Cone R, Li B, Sleiman
PA, Hakonarson H; Eating Disorders Working Group of the Psychiatric Genomics Consortium; Price
Foundation Collaborative Group "A genome-wide association study of anorexia nervosa suggests a risk locus
implicated in dysregulated leptin signaling"
Sci Rep 2017 7(1):3847
Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, Bulik-Sullivan B, Ripke S; Eating Disorders
Working Group of the Psychiatric Genomics Consortium, Thornton L, Hinney A, Daly M, Sullivan PF, Zeggini E,
Breen G, Bulik CM "Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association
Study of Anorexia Nervosa", Am J Psychiatry 2017 174(9):850-858
Loviglio MN, Leleu M, Männik K, Passeggeri M, Giannuzzi G, van der Werf I, Waszak SM, Zazhytska M, Roberts-
Caldeira I, Gheldof N, Migliavacca E, Alfaiz AA, Hippolyte L, Maillard AM; 2p15 Consortium.; 16p11.2 Consortium.,
Van Dijck A, Kooy RF, Sanlaville D, Rosenfeld JA, Shaffer LG, Andrieux J, Marshall C, Scherer SW, Shen Y, Gusella
JF, Thorsteinsdottir U, Thorleifsson G, Dermitzakis ET, Deplancke B, Beckmann JS, Rougemont J, Jacquemont S,
Reymond A. "Chromosomal contacts connect loci associated with autism, BMI and head circumference phenotypes",
Mol Psychiatry 2017 22(6):836-849
Hinney A, Kesselmeier M, Jall S, Volckmar AL, Föcker M, Antel J; GCAN; WTCCC3., Heid IM, Winkler TW; GIANT.,
Grant SF; EGG., Guo Y, Bergen AW, Kaye W, Berrettini W, Hakonarson H; Price Foundation Collaborative Group.;
Children’s Hospital of Philadelphia/Price Foundation., Herpertz-Dahlmann B, de Zwaan M, Herzog W, Ehrlich S,
Zipfel S, Egberts KM, Adan R, Brandys M, van Elburg A, Boraska Perica V, Franklin CS, Tschöp MH, Zeggini E,
Bulik CM, Collier D, Scherag A, Müller TD, Hebebrand J. "Evidence for three genetic loci involved in both anorexia
nervosa risk and variation of body mass index", Mol Psychiatry 2017 22(2):192-201
Leitsalu L, Alavere H, Jacquemont S, Kolk A, Maillard AM, Reigo A, Nõukas M, Reymond A, Männik K, Ng PC,
Metspalu A "Reporting incidental findings of genomic disorder-associated CNVs to unselected biobank participants",
Per Med 2016; 13(4): 303-314
D'Angelo D, Lebon S, Chen Q, Martin-Brevet S, Snyder LG, Hippolyte L, Hanson E, Maillard AM, Faucett WA, Macé
A, Pain A, Bernier R, Chawner SJ, David A, Andrieux J, Aylward E, Baujat G, Caldeira I, Conus P, Ferrari C, Forzano
F, Gérard M, Goin-Kochel RP, Grant E, Hunter JV, Isidor B, Jacquette A, Jønch AE, Keren B, Lacombe D, Le
Caignec C, Martin CL, Männik K, Metspalu A, Mignot C, Mukherjee P, Owen MJ, Passeggeri M, Rooryck-Thambo C,
Rosenfeld JA, Spence SJ, Steinman KJ, Tjernagel J, Van Haelst M, Shen Y, Draganski B, Sherr EH, Ledbetter DH,
van den Bree MB, Beckmann JS, Spiro JE, Reymond A, Jacquemont S, Chung WK; Cardiff University Experiences
of Children With Copy Number Variants (ECHO) Study, the 16p11.2 European Consortium, and the Simons Variation
in Individuals Project (VIP) Consortium “Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and
Medical Comorbidities”, JAMA Psychiatry 2016 Jan 1;73(1):20-30
Hippolyte L, Maillard AM, Rodriguez-Herreros B, Pain A, Martin-Brevet S, Ferrari C, Conus P, Macé A, Hadjikhani N,
Metspalu A, Reigo A, Kolk A, Männik K, Barker M, Isidor B, Le Caignec C, Mignot C, Schneider L, Mottron L, Keren
B, David A, Doco-Fenzy M, Gérard M, Bernier R, Goin-Kochel RP, Hanson E, Green Snyder L; 16p11.2 European
Consortium, Simons Variation in Individuals Project Consortium, Ramus F, Beckmann JS, Draganski B, Reymond A,
Jacquemont S “The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and
Inhibition”, Biol Psychiatry 2015 Nov 10. pii: S0006-3223(15)00917-8
Maillard AM, Hippolyte L, Rodriguez-Herreros B, Chawner SJ, Dremmel D, Agüera Z, Fagundo AB, Pain A, Martin-
Brevet S, Hilbert A, Kurz S, Etienne R, Draganski B, Jimenez-Murcia S, Männik K, Metspalu A, Reigo A, Isidor B, Le
Caignec C, David A, Mignot C, Keren B; 16p11.2 European Consortium, van den Bree MB, Munsch S, Fernandez-
Aranda F, Beckmann JS, Reymond A, Jacquemont S “16p11.2 Locus modulates response to satiety before the onset
of obesity”, Int J Obes (Lond) 2015 Dec 1
Männik K, Mägi R, Macé A, Cole B, Guyatt AL, Shihab HA, Maillard AM, Alavere H, Kolk A, Reigo A, Mihailov E,
Leitsalu L, Ferreira AM, Nõukas M, Teumer A, Salvi E, Cusi D, McGue M, Iacono WG, Gaunt TR, Beckmann JS,
Jacquemont S, Kutalik Z, Pankratz N, Timpson N, Metspalu A, Reymond A. “Copy number variations and cognitive
phenotypes in unselected populations”, JAMA 2015 May 26;313(20):2044-54.
Migliavacca E*, Golzio C*, Männik K*, Blumenthal I, Oh EC, Harewood L, Kosmicki J, Loviglio MN, Giannuzzi G,
Hippolyte L, Maillard AM, Alfaiz AA, 16p11.2 European Consortium, van Haelst MM, Andrieux J, Gusella JF, Daly
MJ, Beckmann JS, Jacquemont S, Talkowski ME, Katsanis N, Reymond A “A potential contributory role for ciliary
dysfunction in the 16p11.2 600kb BP4-BP5 pathology”, Am J Hum Genet. 2015 May 7;96(5):784-96
*These authors contributed equally to this work
Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski S, Dukart J, Ferrari C, Conus P, Männik
K, Zazhytska M, Siffredi V, Maeder P, Kutalik Z, Kherif F, Hadjikhani N, Beckmann JS, Reymond A, Draganski B,
Jacquemont S; 16p11.2 European Consortium “The 16p11.2 locus modulates brain structures common to autism,
schizophrenia and obesity”, Mol Psychiatry 2015 Feb;20(1):140-7
Reinthaler EM, Lal D, Lebon S, Hildebrand MS, Dahl HH, Regan BM, Feucht M, Steinböck H, Neophytou B, Ronen
GM, Roche L, Gruber-Sedlmayr U, Geldner J, Haberlandt E, Hoffmann P, Herms S, Gieger C, Waldenberger M,
Franke A, Wittig M, Schoch S, Becker AJ, Hahn A, Männik K, Toliat MR, Winterer G; 16p11.2 European Consortium,
Lerche H, Nürnberg P, Mefford H, Scheffer IE, Berkovic SF, Beckmann JS; EPICURE Consortium; EuroEPINOMICS
Consortium, Sander T, Jacquemont S, Reymond A, Zimprich F, Neubauer BA “16p11.2 600 kb Duplications confer
risk for typical and atypical Rolandic epilepsy”, Hum Mol Genet 2014 Nov 15;23(22):6069-80
Vlckova M, Hancarova M, Drabova J, Slamova Z, Koudova M, Alanova R, Mannik K, Kurg A, Sedlacek Z
“Monozygotic twins with 17q21.31 microdeletion syndrome”, Twin Res Hum Genet 2014 Oct;17(5):405-10
Huckins LM, Boraska V, Franklin CS, Floyd JA, Southam L, GCAN, WTCCC3, Sullivan PF, Bulik CM, Collier DA,
Tyler-Smith C, Zeggini E, Tachmazidou I; GCAN; WTCCC3 “Using ancestry-informative markers to identify fine
structure across 15 populations of European origin”, Eur J Hum Genet 2014 Oct;22(10):1190-200
Boraska V, Franklin CS, Floyd JA, Thornton LM, Huckins LM, Southam L, Rayner NW, Tachmazidou I, Klump KL,
Treasure J, Lewis CM, Schmidt U, Tozzi F, Kiezebrink K, Hebebrand J, Gorwood P, Adan RA, Kas MJ, Favaro A,
Santonastaso P, Fernández-Aranda F, Gratacos M, Rybakowski F, Dmitrzak-Weglarz M, Kaprio J, Keski-Rahkonen
A, Raevuori A, Van Furth EF, Slof-Op 't Landt MC, Hudson JI, Reichborn-Kjennerud T, Knudsen GP, Monteleone P,
Kaplan AS, Karwautz A, Hakonarson H, Berrettini WH, Guo Y, Li D, Schork NJ, Komaki G, Ando T, Inoko H, Esko T,
Fischer K, Männik K, Metspalu A, Baker JH, Cone RD, Dackor J, DeSocio JE, Hilliard CE, O'Toole JK, Pantel J,
Szatkiewicz JP, Taico C, Zerwas S, Trace SE, Davis OS, Helder S, Bühren K, Burghardt R, de Zwaan M, Egberts K,
Ehrlich S, Herpertz-Dahlmann B, Herzog W, Imgart H, Scherag A, Scherag S, Zipfel S, Boni C, Ramoz N, Versini A,
Brandys MK, Danner UN, de Kovel C, Hendriks J, Koeleman BP, Ophoff RA, Strengman E, van Elburg AA, Bruson
A, Clementi M, Degortes D, Forzan M, Tenconi E, Docampo E, Escaramís G, Jiménez-Murcia S, Lissowska J,
Rajewski A, Szeszenia-Dabrowska N, Slopien A, Hauser J, Karhunen L, Meulenbelt I, Slagboom PE, Tortorella A,
Maj M, Dedoussis G, Dikeos D, Gonidakis F, Tziouvas K, Tsitsika A, Papezova H, Slachtova L, Martaskova D,
Kennedy JL, Levitan RD, Yilmaz Z, Huemer J, Koubek D, Merl E, Wagner G, Lichtenstein P, Breen G, Cohen-Woods
S, Farmer A, McGuffin P, Cichon S, Giegling I, Herms S, Rujescu D, Schreiber S, Wichmann HE, Dina C, Sladek R,
Gambaro G, Soranzo N, Julia A, Marsal S, Rabionet R, Gaborieau V, Dick DM, Palotie A, Ripatti S, Widén E,
Andreassen OA, Espeseth T, Lundervold A, Reinvang I, Steen VM, Le Hellard S, Mattingsdal M, Ntalla I, Bencko V,
Foretova L, Janout V, Navratilova M, Gallinger S, Pinto D, Scherer SW, Aschauer H, Carlberg L, Schosser A,
Alfredsson L, Ding B, Klareskog L, Padyukov L, Courtet P, Guillaume S, Jaussent I, Finan C, Kalsi G, Roberts M,
Logan DW, Peltonen L, Ritchie GR, Barrett JC; Wellcome Trust Case Control Consortium 3, Estivill X, Hinney A,
Sullivan PF, Collier DA, Zeggini E, Bulik CM “A genome-wide association study of anorexia nervosa”, Mol
Psychiatry 2014 Oct;19(10):1085-94
Vanmarsenille L, Giannandrea M, Fieremans N, Verbeeck J, Belet S, Raynaud M, Vogels A, Männik K, Õunap K,
Jacqueline V, Briault S, Van Esch H, D'Adamo P, Froyen G “Increased dosage of RAB39B affects neuronal
development and could explain the cognitive impairment in male patients with distal Xq28 copy number gains”, Hum
Mutat 2014 Mar;35(3):377-83
Walters RG, Coin LJM, Ruokonen A, de Smith AJ, El-Sayed Moustafa JS, Jacquemont S, Elliott P, Esko T,
Hartikainen AL, Laitinen J, Männik K, Martinet D, Meyre D, Nauck M, Schurmann C, Sladek R, Thorleifsson G,
Thorsteinsdóttir U, Valsesia A, Waeber G, Zufferey F, Balkau B, Pattou F, Metspalu A, Völzke H, Vollenweider P,
Stefansson K, Järvelin MR, Beckmann JS, Froguel P, Blakemore AIF “Rare genomic structural variants in complex
disease: lessons from the replication of associations with obesity", PLoS One 2013 8(3):e58048
Hancarova M, Simandlova M, Drabova J, Männik K, Kurg A, Sedlacek Z “A patient with de novo 0.45 Mb deletion of
2p16.1: The role of BCL11A, PAPOLG, REL, and FLJ16341 in the 2p15-p16.1 microdeletion syndrome” Am J Med
Genet. 2013 161(4), 865 - 870
Zufferey F, Sherr EH, Beckmann ND, Hanson E, Maillard AM, Hippolyte L, Macé A, Ferrari C, Kutalik Z,
Andrieux J, Aylward E, Barker M, Bernier R, Bouquillon S, Conus P, Delobel B, Faucett AW, Goin-Kochel RP, Grant
E, Harewood L, Hunter JV, Lebon S, Ledbetter DH, Martin CL, Mannik K, Martinet D, Mukherjee P, Ramocki MB,
Spence SJ, Steinman K, Tjernagel J, on behalf of the Simons VIP Consortium, on behalf of the 16p11.2 European
Consortium, Spiro JE, Reymond A, Beckmann JS, Chung WJ, Jacquemont S “A 600 kb deletion syndrome at
16p11.2 leads to energy imbalance and neuropsychiatric disorders“, J Med Genet. 2012 Oct;49(10):660-8
Preiksaitiene E, Männik K, Dirse V, Utkus A, Ciuladaite Z, Kasnauskiene J, Kurg A, Kucinskas V “A novel de novo
1.8 Mb microdeletion of 17q21.33 associated with intellectual disability and dysmorphic features” Eur J Med Genet,
2012 Nov;55(11):656-9
Žilina O, Reimand T, Zjabolovskaja P, Männik K, Männamaa M, Traat A, Puusepp-Benazzouz H, Kurg A, Õunap K
“Maternally and paternally inherited deletion of 7q31 involving the FOXP2 gene in two families”, Am J Med Genet.
2012 Jan;158A(1):254-6
Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z, Martinet D, Shen Y, Valsesia A,
Beckmann ND, Thorleifsson G, Belfiore M, Bouquillon S, Campion D, de Leeuw N, de Vries BB, Esko T, Fernandez
BA, Fernández-Aranda F, Fernández-Real JM, Gratacòs M, Guilmatre A, Hoyer J, Jarvelin MR, Kooy RF, Kurg A, Le
Caignec C, Männik K, Platt OS, Sanlaville D, Van Haelst MM, Villatoro Gomez S, Walha F, Wu BL, Yu Y, Aboura A,
Addor MC, Alembik Y, Antonarakis SE, Arveiler B, Barth M, Bednarek N, Béna F, Bergmann S, Beri M, Bernardini L,
Blaumeiser B, Bonneau D, Bottani A, Boute O, Brunner HG, Cailley D, Callier P, Chiesa J, Chrast J, Coin L, Coutton
C, Cuisset JM, Cuvellier JC, David A, de Freminville B, Delobel B, Delrue MA, Demeer B, Descamps D, Didelot G,
Dieterich K, Disciglio V, Doco-Fenzy M, Drunat S, Duban-Bedu B, Dubourg C, El-Sayed Moustafa JS, Elliott P, Faas
BH, Faivre L, Faudet A, Fellmann F, Ferrarini A, Fisher R, Flori E, Forer L, Gaillard D, Gerard M, Gieger C, Gimelli S,
Gimelli G, Grabe HJ, Guichet A, Guillin O, Hartikainen AL, Heron D, Hippolyte L, Holder M, Homuth G, Isidor B,
Jaillard S, Jaros Z, Jiménez-Murcia S, Helas GJ, Jonveaux P, Kaksonen S, Keren B, Kloss-Brandstätter A, Knoers
NV, Koolen DA, Kroisel PM, Kronenberg F, Labalme A, Landais E, Lapi E, Layet V, Legallic S, Leheup B, Leube B,
Lewis S, Lucas J, MacDermot KD, Magnusson P, Marshall C, Mathieu-Dramard M, McCarthy MI, Meitinger T,
Mencarelli MA, Merla G, Moerman A, Mooser V, Morice-Picard F, Mucciolo M, Nauck M, Ndiaye NC, Nordgren A,
Pasquier L, Petit F, Pfundt R, Plessis G, Rajcan-Separovic E, Ramelli GP, Rauch A, Ravazzolo R, Reis A, Renieri A,
Richart C, Ried JS, Rieubland C, Roberts W, Roetzer KM, Rooryck C, Rossi M, Saemundsen E, Satre V, Schurmann
C, Sigurdsson E, Stavropoulos DJ, Stefansson H, Tengström C, Thorsteinsdóttir U, Tinahones FJ, Touraine R,
Vallée L, van Binsbergen E, Van der Aa N, Vincent-Delorme C, Visvikis-Siest S, Vollenweider P, Völzke H, Vulto-van
Silfhout AT, Waeber G, Wallgren-Pettersson C, Witwicki RM, Zwolinksi S, Andrieux J, Estivill X, Gusella JF,
Gustafsson O, Metspalu A, Scherer SW, Stefansson K, Blakemore AI, Beckmann JS, Froguel P “Mirror extreme BMI
phenotypes associated with gene dosage at the chromosome 16p11.2 locus” Nature 2011 Aug 31;478(7367):97-102
Männik K, Parkel S, Palta P, Žilina O, Puusepp H, Esko T, Mägi R, Nõukas M, Veidenberg A, Nelis M, Metspalu A,
Remm M, Ounap K, Kurg A “A parallel SNP array study of genomic aberrations associated with mental retardation in
patients and the general population in Estonia” Eur J Med Genet 2011 Mar-Apr;54(2):136-43
Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J, Falchi M, Chen F, Andrieux J,
Lobbens S, Delobel B, Stutzmann F, El-Sayed Moustafa JS, Chèvre JC, Lecoeur C, Vatin V, Bouquillon S, Buxton
JL, Boute O, Holder-Espinasse M, Cuisset JM, Lemaitre MP, Ambresin AE, Brioschi A, Gaillard M, Giusti V,
Fellmann F, Ferrarini A, Hadjikhani N, Campion D, Guilmatre A, Goldenberg A, Calmels N, Mandel JL, Le Caignec
C, David A, Isidor B, Cordier MP, Dupuis-Girod S, Labalme A, Sanlaville D, Béri-Dexheimer M, Jonveaux P, Leheup
B, Ounap K, Bochukova EG, Henning E, Keogh J, Ellis RJ, Macdermot KD, van Haelst MM, Vincent-Delorme C,
Plessis G, Touraine R, Philippe A, Malan V, Mathieu-Dramard M, Chiesa J, Blaumeiser B, Kooy RF, Caiazzo R,
Pigeyre M, Balkau B, Sladek R, Bergmann S, Mooser V, Waterworth D, Reymond A, Vollenweider P, Waeber G,
Kurg A, Palta P, Esko T, Metspalu A, Nelis M, Elliott P, Hartikainen AL, McCarthy MI, Peltonen L, Carlsson L,
Jacobson P, Sjöström L, Huang N, Hurles ME, O'Rahilly S, Farooqi IS, Männik K, Jarvelin MR, Pattou F, Meyre D,
Walley AJ, Coin LJ, Blakemore AI, Froguel P, Beckmann JS. „A new highly penetrant form of obesity due to
deletions on chromosome 16p11.2“ Nature 2010 Feb 4;463(7281):671-5
Van der Aa N, Rooms L, Vandeweyer G, van den Ende J, Reyniers E, Fichera M, Romano C, Delle Chiaie B, Mortier
G, Menten B, Destrée A, Maystadt I, Männik K, Kurg A, Reimand T, McMullan D, Oley C, Brueton L, Bongers EM,
van Bon BW, Pfund R, Jacquemont S, Ferrarini A, Martinet D, Schrander-Stumpel C, Stegmann AP, Frints SG, de
Vries BB, Ceulemans B, Kooy RF “Fourteen new cases contribute to the characterization of the 7q11.23
microduplication syndrome” Eur J Med Genet 2009 Mar-Jun;52(2-3):94-100
Puusepp H, Zilina O, Teek R, Männik K, Parkel S, Kruustük K, Kuuse K, Kurg A, Ounap K “5.9 Mb microdeletion in
chromosome band 17q22-q23.2 associated with tracheo-esophageal fistula and conductive hearing loss” Eur J Med
Genet 2009 Jan-Feb;52(1):71-4
Kousoulidou L*, Männik K*, Sismani C, Žilina O, Parkel S, Puusepp H, Tõnisson N, Palta P, Remm M, Kurg A, Patsalis
PC "Array-MAPH: a methodology for the detection of locus copy-number changes in complex genomes." Nature
Protocols 2008;3(5):849-65
*These authors contributed equally to this work
Kousoulidou L, Männik K, Zilina O, Parkel S, Palta P, Remm M, Kurg A, and Patsalis PC “Application of two different
microarray-based copy-number detection methodologies – array-comparative genomic hybridization and array-
multiplex amplifiable probe hybridization – with identical amplifiable target sequences” Clin Chem Lab Med 2008
May; 46(5):722-4
Patsalis PC, Kousoulidou L, Mannik K, Sismani C, Zilina O, Parkel S, Puusepp H, Tonisson N, Palta P, Remm M,
Kurg A. “Detection of small genomic imbalances using microarray-based multiplex amplifiable probe hybridisation”
Eur J Hum Genet 2007 Feb;15(2):162-72
Patsalis PC, Kousoulidou L, Sismani C, Mannik K, Kurg A "MAPH: from gels to microarrays" Eur J Med Genet
2005 Jul-Sep;48(3):241-9
Olivier Menzel, PhD, MBA
Swiss, 26.07.1975
Married, 2 children
+41 76 378 17 77
[email protected]
I have almost 20 years of expertise in the life science, research and health sector. I
demonstrated expertise in health management and in conception, planning and realization
of projects in an international setting. I am a well-recognized strategic thinker, I have
developed a communicative, persuasive and visionary leadership style which promotes
human potential in accordance with the organizations’ values. I will describe myself as a
novelty seeker, cooperative, committed, open-minded and reliable person who adapts and
learns quickly with a deep sense of justice and ethics.
PROFESSIONAL EXPERIENCE
Head of Strategic Partnerships 2018 – present
Health 2030 Swiss Genome Center: The mission of the Health 2030 Genome Center is to act as a
hub and leading house for Swiss genomic medicine by supporting and facilitating research and clinical
activities nationally in the area of genetics and genomics.
Main activities: communicating and implementing the strategy, facilitate business growth,
partnering, strategic thinking development, marketing, public relations and promotion.
Managing director 2016 – 2018
Think Rare Sàrl: A company involved in commercial activities in relation to the healthcare and
medical sector, scientific research in the field of rare and orphan diseases, biotechnology, scientific
teaching and philanthropy.
Main activities: consultant, strategic thinking development, marketing, public relations and
promotion, healthcare management.
Director April 2014 – April 2016
Genolier Foundation: Philanthropic body of the private clinics Swiss Medical Network to support
patient in difficulty, medical humanitarian project, formation, learning and research.
Main activities: revitalization of the Foundation (existing since 1986), strategic development,
marketing, public relations and promotion. Projects management (corporate social responsibility,
humanitarian, medical and research).
Chief Strategy Officer March 2013 – February 2014
SICHH - Swiss Integrative Center for Human Health SA: center of academic competence open to
industries for R&D and innovation. (Fribourg – 25 employees).
Main activities: strategic planning, academic and industrial partnerships, creation and management
of events, health and research core facilities development.
1
Chairman and founder (voluntary & part time) 2009 – present
BLACKSWAN Foundation: Swiss Foundation for Research on Orphan Diseases which contribute to
the development of research on rare and orphan diseases worldwide.
Main activities: corporate brand and communication strategy, public relations, increase the
knowledge on orphan diseases and research. Initiator and organizer of the first International Congress
on Research of Rare and Orphan Diseases: RE(ACT) Congress with more than 1500 attendees,
fundraising.
Chief Executive Officer (part-time) 2011 – 2012
SanOrphan SA (now Dorphan SA): drug discovery and development company committed to the
development of innovative therapeutics for the treatment of rare and devastating lysosomal storage
diseases with high unmet medical need.
Main activities: company and strategy establishment, investors prospecting, academic partnerships.
Research Group Leader 2006 – 2012
University of Geneva Medical School and Pediatric Surgery Unit
Main activities: management of the gene therapy research laboratory for pediatric surgery (4
subordinates), supervise the research in the laboratory (3 projects), develop preclinical and clinical
studies (GLP and GMP), teaching to medical students (APP) and supervision of master works,
scientific presentation (national and international meetings), grants writing.
Assistant Coordinator 2001 – 2003
Orphanet Switzerland: A database of information on rare diseases and orphan drugs for all publics.
Its aim is to contribute to the improvement of the diagnosis, care and treatment of patients.
Main activities: implementation, extension and development of the Orphanet Web database
(www.orpha.net) in Switzerland, establishment and management of a scientific advisory board,
international partnerships.
SCIENTIFIC ADVISORY BOARDS AND BOARD OF DIRECTORS
- Member of the Chelonia Applied Science advisory board (since 2017).
- Member of the Swiss Personalized Health Network National Steering Board of the Swiss
Academy of Medical Science (patient representative, since 2017).
- Member of the radiz advisory board: Rare Disease Initiative Zurich, Clinical Research Priority
Program for Rare Diseases of the University of Zurich (since 2013).
- Member of the board of trustees ProRaris - Swiss alliance of patient organizations and individuals
active in the field of rare and orphan diseases (since 2010).
- AEMO - Scientific expert at the Association Enfance et Maladies Orphelines (since 2009).
EDUCATION
2013 Executive MBA in Healthcare Management at HEC Lausanne (IEMS)
2006 Ph.D. Thesis in Biology (Immunotherapy against cancer) at the Swiss Institute for Experimental
Cancer Research (ISREC - EPFL) under the supervision of Dr N. Rufer, in Lausanne.
2001 Master Work (M.Sc.) in Medical Genetics under the supervision of Prof. S.E. Antonarakis at the
Department of Genetic Medicine and Development, in Geneva.
2
AWARDS
SWISS SOCIETY OF PEDIATRIC SURGERY 2009: Prize for the best presentation and original
scientific work at the annual congress SSPS.
REGIO INSUBRICA 2002: Prize for the best post-university M.Sc. work from the Work Community
of the Regio Insubrica.
ASIRB-ROCHE 2001: Prize for the best M.Sc. work in the field of biomedical and biotechnologies
from the Swiss Italian Society for Biomedical Research in collaboration with ROCHE diagnostic.
LANGUAGES
Italian: native speaker
French: native speaker
English: fluent (C2)
German: good command (B1)
Spanish: basic (A2)
REFERENCES (on demand)
Professor at the University Children Hospital, Geneva
Professor at the University Medical School, Geneva
Former General Director of a Private Swiss Bank
Director, executive management healthcare sector
Human Resources specialist and Career manager
Vuarrens, March, 19
3
PUBLICATIONS: PEER-REVIEWED ARTICLES
O. Menzel. #RAREvolution - Stand up for Scientific Research on Rare Diseases. Mol Syndromol. 2018 Feb;9(2):115.
S.M. Gasser, J.R. Lupski, Y. Le Cam, O. Menzel. Leap year: Rare day to highlight rare diseases. Nature 2012 Jan 18;481(7381):265. IF
2016 40.137
A. Bosman, B.E. Wildhaber, J. Birraux, C. Jond, M. Jaconi, O. Menzel. Progress toward the clinical application of autologous induced
pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia (Meeting abstract). J Hepatol 2011 54:
S543-S544. IF 2016 12.486
J. Birraux, B.E. Wildhaber, C. Jond, D.C. Belli and O. Menzel. Ex vivo hepatocyte gene therapy: increased biosafety protocol for
transduction in Suspension with Lentiviral vectors and Immediate Transplantation (SLIT). Transplantation 2010 Jan 15;89(1):127-9.
Erratum in: Transplantation Feb 15;89(3):370. IF 2016 3.678
O. Menzel, J. Birraux, B.E. Wildhaber, C. Jond, F. Lasne, W. Habre, T. H. Nguyen and C. Chardot. Biosafety in ex vivo gene therapy
and conditional ablation of lentivirally-transduced hepatocytes in non-human primates. Mol Ther 2009 Oct;17(10):1754-60. IF 2016
6.688
O. Menzel, J. Birraux, J, B.E. Wildhaber, et al. Biosafety in ex vivo gene therapy and conditional ablation of lentivirally-transduced
hepatocytes in non-human primates (Meeting abstract). J Hepatol 2009 50: S17-S18. 2016 12.486
O. Menzel, J. Birraux, B.E. Wildhaber, C. Jond, C. Fux, T. H. Nguyen and C. Chardot. A step toward liver gene therapy: efficient
metabolic correction of hepatocytes isolated from a patient with Crigler-Najjar type 1 syndrome. Transplantation 2009 Apr 15;
87(7):1006-1012. IF 2016 3.678
J. Birraux, O. Menzel, B. Wildhaber, W. Habre, C. Jond, T.H.Nguyen, C. Chardot. Biosécurité et thérapie génique: le gene suicide
HSV-TK dans un modèlepré-humain (Meeting abstract). Archives de pédiatrie 2008 15(5): 890. IF 20106 0.372
L. Thadikkaran, O. Menzel, J.-D. Tissot, N. Rufer. Proteomic and transcriptomic analysis of. human CD8+ T lymphocytes over-
expressing telomerase. Proteomics-Clinical Applications 2007 Mar;1(3):299-311. IF 2016 3.814
O. Menzel, M. Migliaccio, D.R. Goldstein, S. Dahoun, M. Delorenzi and N. Rufer. Mechanisms regulating the proliferative potential
of human CD8+ T lymphocytes over-expressing hTERT. J Immunol 2006 177: 3657-3668. IF 2016 4.985
M. Migliaccio, K. Raj, O. Menzel and N. Rufer. Mechanisms that limit the in vitro proliferative potential of human CD8+ T
lymphocytes. J Immunol. 2005 Mar 15;174(6):3335-43. IF 2016 4.985
S.E. Antonarakis, O. Menzel, R.C. Bekkeheien, A. Reymond, N. Fukai, E. Boye, G. Kosztolanyi, S. Aftimos, S. Deutsch, H.S. Scott,
B.R. Olsen, M. Guipponi. A response to Suzuki et al. "How pathogenic is the p.D104N/endostatin polymorphic allele of COL18A1 in
Knobloch syndrome? "Hum Mutat. 2005 Feb 15;25(3):316. IF 2016 5.089
O. Menzel, T.Vellai, K.Tekacs-Vellai, A. Reymond, F.Mueller, S.E.Antonarakis, M.Guipponi. The Caenorhabditis elegans ortholog of
C21orf80, a potential new protein O-fucosyltransferase, is required for normal development. Genomics, 2004 Aug;84(2):320-30. . IF
2013 2.801
O. Menzel, R.C. Bekkeheien, A. Reymond, N. Fukai, E. Boye, G. Kosztolanyi, S. Aftimos, S. Deutsch, H.S. Scott, B.R. Olsen, S.E.
Antonarakis, M. Guipponi. Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity, and a functionally
impaired polymorphism in endostatin. Hum Mutat. 2004 Jan;23(1):77-84. IF 2016 5.089
O. Menzel, T.Vellai, K.Tekacs-Vellai, A. Reymond, F.Mueller, S.E.Antonarakis, M.Guipponi. DsRNAi and overexpression of the
C.elegans orthologue of MADSO1, a novel HC21 gene, suggest an important role in embryonic development and adult morphogenesis
(Meeting abstract). Am J Hum Genet. 2001 Oct; 69(4): 348-348. IF 2016 9.025
OTHER IMPORANT PUBLICATIONS
C. Ciriminna Swan and O. Menzel. The Patient Group Handbook: A Practical Guide for Research and Drug Development,
Edited by Anthony Hall and Nicolas Sireau. Chapter 10: Fund a cure: Crowdfunding for Rare Diseases. UK, April 2016,
CreateSpace Independent Publishing Platform, ISBN 978-1532938108.
O. Menzel and S. Panigone. Rare Diseases: Challenges and Opportunities for Social Entrepreneurs, Edited by Nicolas Sireau.
Chapter 10: The BLACKSWAN Foundation for Rare Diseases (p.193-201). UK, April 2013, Greenleaf Publishing, ISBN 978-1-
906093-52-5.
O.Menzel and C. DeLozier-Blanchet. “ORPHANET.CH” Base de données sur les maladies rares et les médicaments orphelins.
Bulletin d’information de la Société Suisse de Génétique Médicale. (No 44; Sep 2001)
4
Margit Nõukas
Date of birth 7.09.1985
E-mail
[email protected]
Institutions and positions
01.01.2018–... University of Tartu, Institute of Genomics, Specialist (1,00)
2012–... University of Tartu, Estonian Genome Center, Specialist (1,00)
01.07.2009– University of Tartu, Faculty of Science and Technology (old),
30.06.2011 Institute of Ecology and Earth Sciences, Tartu University,
Laboratory Assistant in Molecular Biology (0,50)
2008–2009 University of Tartu, Estonian Genome Center, laboratory
technician (0,50)
Education
2010–... Ph.D studies in Molecular and Cell Biology, Chair of
Biotechnology, Faculty of Science and Technology, University
of Tartu
2008–2010 M.Sc studies in Biomedicine (Faculty of Medicine), Chair of
Biotechnology, Faculty of Science and Technology, University
of Tartu
2005–2008 B.Sc studies in Gene Technology, Chair of Biotechnology,
Faculty of Science and Technology, University of Tartu
1997–2005
Academic degrees
Margit Nõukas, Master's Degree, 2010, (sup) Eve Õiglane-Šlik; Katrin Männik,
Uniparentaalse disoomia analüüs kogu-genoomi genotüpiseerimiskiipe kasutades
(Uniparental disomy analysis using whole-genome SNP genotyping arrays), University
of Tartu, Faculty of Medicine.
Margit Nõukas, Phd student, (sup) Ants Kurg, Copy-number variations in healthy
individuals and patients with developmental anomalies in Estonia, University of Tartu,
Faculty of Science and Technology (old), Institute of Molecular and Cell Biology,
University of Tartu, Chair of Biotechnology.
Honours & awards
2014 European Human Genetics Conference, fellowship
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.1. Biomedicine; CERCS CLASSIFICATION:
B726 Clinical biology
ETIS CLASSIFICATION: 3. Health; 3.11. Biochemistry, Genetics, Microbiology,
Biotechnology, Molecular Biology, Cell Biology, Biophysics and Bioinformatics
relating to Health Studies; CERCS CLASSIFICATION: B110 Bioinformatics, medical
informatics, biomathematics, biometrics
Additional information
13-16 May 2013. Course on Molecular Genetics of Consanguinity. Course consisted of
lectures, software installation and practical training. EuroMediterranean University
Center of Ronzano-Bologna (Italy) 22-27 June 2014 SystemsX.ch/SIB Joint Summer
School "Systems Medicine and its applications". Course consisted of lectures,
demonstration sessions, reading documents, software installation and included
presentations of participants` current projects. Swiss Institute of Bioinformatics;
SystemsX.ch, Switzerland
Projects in progress
• SLTMR16142T (TK142) "Centre of Excellence for Genomics and Translational
Medicine (TK142) (1.01.2016−1.03.2023)", Andres Metspalu, University of Tartu,
Estonian Genome Center .
• PRG555 "Evaluation of genetic variants potentially linked to actionable health risks
(1.01.2019−31.12.2022)", Neeme Tõnisson, University of Tartu, Institute of
Genomics.
• PRG687 "Development and application of genetic risk prediction algorithms for
personalised healthcare in the era of large-scale genomics (1.01.2020−31.12.2020)",
Reedik Mägi, University of Tartu, Institute of Genomics.
• PP1GI19935 "Copy-number variants in complex disease (7.08.2019−30.06.2020)",
Reedik Mägi, University of Tartu, Institute of Genomics.
Completed projects
• IUT20-60 "Omics for health: an integrated approach to understand and predict human
disease (1.01.2014−31.12.2019)", Andres Metspalu, University of Tartu, Estonian
Genome Center , University of Tartu, Institute of Genomics.
• ETF9205 "Identification of molecular genetic causes of intellectual disability and
developmental delay by next generation technologies (1.01.2012−31.12.2015)", Ants
Kurg, University of Tartu, Faculty of Science and Technology (old), Institute of
Molecular and Cell Biology, University of Tartu.
• SF0180027s10 (SF0180027s10) "DNA copy-number variations in healthy individuals
and patients with developmental anomalies in Estonia (1.01.2010−31.12.2015)", Ants
Kurg, University of Tartu, Faculty of Science and Technology (old), Institute of
Molecular and Cell Biology, University of Tartu.
• ETF7617 "DNA copy-number variations and human (X-linked) mental retardation
(1.01.2008−31.12.2011)", Ants Kurg, University of Tartu, Faculty of Biology and
Geography, University of Tartu, Faculty of Science and Technology (old), Institute of
Molecular and Cell Biology, University of Tartu, University of Tartu, Faculty of
Science and Technology (old).
Publications
2019
Reinson, Karit; Kovacs-Nagy, Reka; Õiglane-Shlik, Eve; Pajusalu, Sander; Nõukas, Margit; Wintjes,
Liesbeth T; van den Brandt, Frans C A; Brink, Maaike; Acker, Till; Ahting, Uwe; Hahn, Andreas;
Schänzer, Anne; Haack, Tobias B; Rodenburg, Richard J; Õunap, Katrin (2019). Diverse phenotype in
patients with complex I deficiency due to mutations in NDUFB11. European Journal of Medical
Genetics, 62 (11), 103572−103572.10.1016/j.ejmg.2018.11.006.
2017
Aurélien Macé; Marcus A. Tuke; Patrick Deelen; Kati Kristiansson; Hannele Mattsson; Margit
Nõukas; Yadav Sapkota; Ursula Schick; Eleonora Porcu; Sina Rüeger; Aaron F. McDaid; David
Porteous; Thomas W. Winkler; Erika Salvi; Nick Shrine; Xueping Liu; Wei Q. Ang; Weihua Zhang;
Mary F. Feitosa; Cristina Venturini ... Zoltán Kutalik (2017). CNV-association meta-analysis in
191,161 European adults reveals new loci associated with anthropometric traits. Nature
Communications, 8 (744).10.1038/s41467-017-00556-x.
Macé, Aurélien; Tuke, Marcus A; Deelen, Patrick; Kristiansson, Kati; Mattsson, Hannele; Nõukas,
Margit; Sapkota, Yadav; Schick, Ursula; Porcu, Eleonora; Rüeger, Sina; McDaid, Aaron F; Porteous,
David; Winkler, Thomas W; Salvi, Erika; Shrine, Nick; Liu, Xueping; Ang, Wei Q; Zhang, Weihua;
Feitosa, Mary F; Venturini, Cristina ... Kutalik, Zoltán (2017). CNV-association meta-analysis in
191,161 European adults reveals new loci associated with anthropometric traits. Nature
Communications, 8 (1), 744−744.10.1038/s41467-017-00556-x.
2016
Tšuiko, O.; Nõukas, M.; Žilina, O.; Hensen, K.; Tapanainen, J.; Mägi, R.; Kals, M.; Kivistik, PA.;
Haller-Kikkatalo, K.; Salumets, A.; Kurg, A. (2016). Copy number variation analysis detects novel
candidate genes involved in follicular growth and oocyte maturation in a cohort of premature ovarian
failure cases. Human Reproduction, 31 (8), 1913−1925.10.1093/humrep/dew142.
Pajusalu, S.; Talvik, I.; Noormets, K.; Talvik, T.; Põder, H.; Joost, K.; Puusepp, S.; Piirsoo, A.;
Stenzel, W.; Goebel, HH.; Nikopensius, T.; Annilo, T.; Nõukas, M.; Metspalu, A.; Õunap, K.;
Reimand, T. (2016). De novo exonic mutation in MYH7 gene leading to exon skipping in a patient
with early onset muscular weakness and fiber-type disproportion. Neuromuscular Disorders, 26 (3),
236−239.10.1016/j.nmd.2015.11.011.
Leitsalu, L.; Alavere, H.; Jacquemont, S.; Kolk, A.; Maillard, A.; Reigo, A.; Nõukas, M.; Reymond,
A.; Ng, PC.; Metspalu, A (2016). Reporting incidental findings of genomic disorder-associated copy
number variants to unselected biobank participants. Personalized Medicine, 13 (4),
303−314.10.2217/pme-2016-0009.
Tiirats, Airi; Viltrop, Triin; Noukas, Margit; Reimann, Ene; Salumets, Andres; Koks, Sulev (2016).
C14orf132 gene is possibly related to extremely low birth weight. BMC Genetics, 17, ARTN
132.10.1186/s12863-016-0439-5.
2015
Maasalu, K; Nikopensius, T; Kõks, S; Nõukas, M; Kals, M; Prans, E; Zhytnik, L; Metspalu, A;
Märtson, A. (2015). Whole-exome sequencing identifies de novo mutation in the COL1A1 gene to
underlie the severe osteogenesis imperfecta. Human Genomics, 9, 6.10.1186/s40246-015-0028-0.
Pajusalu, Sander; Žilina, Olga; Yakoreva, Maria; Tammur, Pille; Kuuse, Kati; Mölter-Väär, Triin;
Nõukas, Margit; Reimand, Tiia; Õunap, Katrin (2015). The Diagnostic Utility of Single Long
Contiguous Stretches of Homozygosity in Patients without Parental Consanguinity. Molecular
Syndromology, 6, 134−139.10.1159/000438776.
Graziano, C.; Wischmeijer, A.; Pippucci, T.; Fusco, C.; Diquigiovanni, C.; Nõukas, M.; Sauk, M.;
Kurg, A.; Rivieri, F.; Blau, N.; Hoffmann, G.; Chaubey, A.; Schwartz, C.F.; Romeo, G.; Bonora, E.;
Garavelli, L.; Seri, M. (2015). Syndromic intellectual disability: A new phenotype caused by an
aromatic amino acid decarboxylase gene (DDC) variant. Gene, 559 (2),
144−148.10.1016/j.gene.2015.01.026.
Männik, Katrin; Mägi, Reedik; Macé, Aurélien; Cole, Ben; Guyatt, Anna L; Shihab, Hashem A;
Maillard, Anne M; Alavere, Helene; Kolk, Anneli; Reigo, Anu; Mihailov, Evelin; Leitsalu, Liis;
Ferreira, Anne-Maud; Nõukas, Margit; Teumer, Alexander; Salvi, Erika; Cusi, Daniele; McGue, Matt;
Iacono, William G; Gaunt, Tom R ... Reymond, Alexandre (2015). Copy Number Variations and
Cognitive Phenotypes in Unselected Populations. JAMA : the journal of the American Medical
Association, 313 (20), 2044−2054.10.1001/jama.2015.4845.
Õunap, K.; Reinson, K.; Pajusalu, S.; Nõukas, M.; ÕiglaneShlik, E.; Rodenburg, R.; van den Heuvel,
L.P.; Reimand, T. (2015). The first male case with cardiomyopathy and isolated complex I deficiency
caused by hemizygous mutation in NDUFB11 gene. Journal of Inherited Metabolic Disease, 38:
Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Lyon, France, 1-
4.09.2015. Springer, S211−S212. (Suppl 1).
Talvik, I.; Steensbjerrer, R.; Vaher, U.; Vaher, M.; Noormets, K.; Lilles, L.; Nõukas, M.; Reimand, T.;
Kolk, A.; Metspalu, A.; Talvik, T. (2015). Epileptic encephalopathies – lessons learned. Eesti Arst:
2015 (Suppl 1): 13th International Conference of Baltic Child Neurology Association. 57.
Pajusalu, Sander; Žilina, Olga; Yakoreva, Maria; Tammur, Pille; Kuuse, Kati; Mölter-Väär, Triin;
Nõukas, Margit; Reimand, Tiia; Õunap, Katrin (2015). The diagnostic utility of single long contiguous
stretches of homozygosity in patients with suspected genetic disorder. 2nd International GENCODYS
Conference - Integrative Networks in Intellectual Disabilities, 27-29 April 2015, Chania, Crete,
Greece.
2014
Vals, M.-A.; Õiglane-Shlik, E.; Nõukas, M.; Shor, R.; Peet, A.; Kals, M.; Kivistik, P.A.; Metspalu, A.;
Õunap, K. (2014). Coffin-Siris syndrome with obesity, macrocephaly, hepatomegaly and
hyperinsulinism caused by a mutation in the ARID1B gene. European Journal of Human Genetics, 22
(11), 1327−1329.10.1038/ejhg.2014.25.
Vaher, Ulvi; Nõukas, Margit; Nikopensius, Tiit; Kals, Mart; Annilo, Tarmo; Nelis, Mari; Õunap,
Katrin; Reimand, Tiia; Talvik, Inga; Ilves, Pilvi; Piirsoo, Andres; Seppet, Enn; Metspalu, Andres;
Talvik, Tiina (2014). De Novo SCN8A Mutation Identified by Whole-Exome Sequencing in a Boy
With Neonatal Epileptic Encephalopathy, Multiple Congenital Anomalies, and Movement Disorders.
Journal of Child Neurology, 29 (12), 202−206.10.1177/0883073813511300.
Pajusalu, Sander; Nõukas, Margit; Rägo, Tiina; Metspalu, Andres; Õunap, Katrin. (2014). A case
report of a boy with unusual presentation of cleidocranial dysplasia - whole exome sequencing ends 10
years of diagnostic odyssey or does it really? Konverentsi kogumik: European School of Genetic
Medicine - 3rd Course in Next Generation Sequencing, Bertinoro, Italy, May 7-10, 2014.
2011
Männik, K; Parkel, S; Palta, P; Zilina, O; Puusepp, H; Esko, T; Mägi, R; Nõukas, M; Veidenberg, A;
Nelis, M; Metspalu, A; Remm, M; Ounap, K; Kurg, A. (2011). A parallel SNP array study of genomic
aberrations associated with mental retardation in patients and general population in Estonia. European
Journal of Medical Genetics, 54 (2), 136−143.
Curriculum Vitae
I. Personal particulars
Name: Marili Palover
Date of birth: 12.06.1991
Citizenship: Estonia
Aadress: Lemmatsi 26/1, Tartu 50413, Estonia
Telephone: +372 5124795
e-mail:
[email protected]
Education:
2019-2020 Department of Epidemiology and Preventive Medicine, School of Public Health and
Preventive Medicine, Monash University, Melbourne, Australia, visiting academic
2016-… University of Tartu, PhD in gene technology, title of thesis “Health-related feedback
studies of biobanks at the pilot phase of personalised medicine implementation”
2015 Summer practice, Thermo Fisher Scientific Baltics, Lithuania, Vilnius
2014–2016 University of Tartu, MSc in gene technology (cum laude)
2010–2013 University of Tartu, BSc in biology
2007–2010 Valga Gymnasium
Current position:
01.10.2017–… University of Tartu, Institute of Genomics, Biomedical Specialist (0,30)
Language skills:
Estonian – native language, very good in writing and in speech
English – highly proficient in spoken and written English
German – basic communication skills
Russian – basic communication skills
II. Research and development work
A list of publications and preprints
1.Alver M, Palover M, Saar A, et al. Recall by genotype and cascade screening for familial
hypercholesterolemia in a population-based biobank from Estonia. Genet Med. October 2018:1.
doi:10.1038/s41436-018-0311-2
2.Läll K, Lepamets M, Palover M, et al. Polygenic prediction of breast cancer: Comparison of genetic
predictors and implications for risk stratification. BMC Cancer. 2019;19(1). doi:10.1186/s12885-019-
5783-1
3.Palover, M; Leitsalu, L; Nikopensius, T; Sikka TT; Kals, M; Padrik, P; Esko, T; Metspalu, A;
Tõnisson, N. Genotype-first approach for detecting at risk individuals for familial breast and ovarian
cancer from the Estonian biobank (unpublished).
Honours and awards
2019, Marili Palover, Dora Plus, Scholarship for study Mobility of Doctoral Degree Students
2018, Marili Palover, Kristjan Jaak Scholarship for foreign visits
2017, Marili Palover, ESHG conference fellowship for European countries
Other administrative and professional activities
2016-… Estonian Society of Human Genetics, member
2014-… Bioscience Students’ Association, member
2011-… Academic Women’s Choir of the University of Tartu, member
III. Teaching work
2017-… instructor in the course “Practical Course in Genetic Engineering” (The Institute of Molecular
and Cell Biology, University of Tartu)
IV. Professional development
2019, CNV Technical Standards Web Series by ClinGen (ongoing)
2019, The 19th International Gene Forum 2019, Tartu, Estonia
2019, What is genetic counselling? 6-week web-based course, Wellcome Genome Campus advanced
courses
2018, Microbiome course, Tartu, Estonia
2018, The 18th International Gene Forum 2018, Tartu, Estonia
2018, ESHG conference, Milan, Italy
2018, Genomic Practice for Genetic Counsellors Course, Wellcome Genome Campus, Hinxton,UK
2017, ESHG conference, Amsterdam, Denmark
Curriculum vitae
Nimi : Esta Pintsaar
Sünniaeg: 18.07.1964
Elukoht: Mäelooga küla, Palupera vald, Valgamaa
Perekonnaseis: vabaabielus
Lapsi: 3 last
Telefon: 53455481
E-post:
[email protected]
Kutseala: velsker
Tervishoiutöötajate registris N10866-õde
Hariduskäik:
Kutseharidus: 1982-1985 Tartu Meditsiinikool-velsker
Keskharidus: 1979-1982 Räpina Keskkool
1971-1979 Kauksi 8-kl.Kool
Teenistuskäik:
01.09.2016- TÜ Eesti Geenivaramu andmekogumise spetsialist.
16.10.2007-02.11.2015 TÜ Eesti Geenivaramu-andmekoguja
(Terviseküsimustik,veeniveri,EKG,spirogramm,dünamomeetria,vererõhu
mõõtmine,ka monitoorimine).
01.09.2005-12.10.2007-Elva Gümnaasium –kooliõde (
Esmaabi, läbivaatused, vaktsineerimine, terviseedendus).
01.02.2005-11.10.2007-Elva Lasteaed ,,Murumuna”-tervishoiutöötaja
(Terviseedendus, esmaabi).
11.03.2003-01.10.2003-FIE perearst Taimi Laasik-pereõde
(Vastuvõtt koos arstiga ja iseseisvalt, protseduurid, koduvisiidid)
01.04.1985-22.05.2001-Hellenurme velskripunkt-juhataja
( ambultoorne vastuvõtt- diagnoosimine, ravi määramine, koduvisiidid,
vaktsineerimine, profülaktika).
Arvutioskused: tavakasutaja
Autosõiduoskused:B-kategooria
Eesti keel-emakeel
Vene keel -kesktase
Saksa keel-algtase
Inglise keel-algtase
Curriculum Vitae (February 2020)
Personal Information
Name: Eleonora Porcu
Date/Place of birth: 21/08/1984 Cagliari (Italy)
Nationality: Italian
Contact: Mobile: +41 79 3454841
Mail:
[email protected]
OrcID: 0000-0003-2878-7485
Education
20/02/2015 Phd Thesis “Sequencing-based GWAS using thousands
Sardinian genomes: an application to quantitative traits”.
University of Sassari (Italy), advisors: Prof Francesco Cucca
and Serena Sanna
29/09/2008 Master Thesis “Generalized additive models” (110/110 cum
laude). University of Cagliari (Italy), advisor: Monica Musio
28/07/2006 Bachelor Thesis “Bootstrap method in linear models”
(110/110 cum laude). University of Cagliari (Italy), advisor:
Prof. Maria Luisa Targhetta
Employment History
01/2016 - present Postdoc at Center for Integrative Genomics - University of
Lausanne (Switzerland) and Swiss Institute of Bioinformatics.
Supervisors: Prof. Alexandre Reymond and Prof. Zoltán
Kutalik
02/2015-11/2015 Postdoc at National Research Council (CNR) – Institute of
Genetics and Biomedical Research (IRGB) (Italy).
Supervisors: Prof. Francesco Cucca and Serena Sanna
01/2012-02/2015 PhD student at Department of Biomedical Sciences -
University of Sassari (Italy). Supervisors: Prof. Francesco
Cucca and Serena Sanna
06/2012-08/2014 Visiting Investigator at Center for Statistical Genetics –
University of Michigan (USA). Supervisor: Prof. Goncalo
Abecasis
11/2008-12/2011 Research Collaborator at National Research Council (CNR) –
Institute of Genetics and Biomedic Research (IRGB) (Italy).
Supervisors: Prof. Francesco Cucca and Serena Sanna
Teaching activity
Fall semester 2016 – Assistant for “Analyse de données en biologie” course at
present University of Lausanne (Switzerland)
Fall semester 2010 Teacher for “Mathematical Logic” course at Department of
Political Science, University of Cagliari (Italy)
Fall semester 2007 Assistant for “Geometry 3” course at Department of
Mathematics, University of Cagliari (Italy)
Memberships in Panels, Boards / Individual Scientific Reviewing
Activities
09/2017 Poster judge at Basel Computational Biology Conference
(BC2), Basel (Switzerland)
02/2017 Member of Scientific Programme Committee at Functional
annotation of genome-wide variants Workshop, Lausanne
2012 - present Reviewer for American Journal of Human Genetics, European
Journal of Human Genetics, PLoS One, Human Mutations,
Bioinformatics, Frontiers in Genetics, Ophthalmic Research
Conference/Meeting Organization
04/2019-04/2020 European Mathematical Genetics Meeting 2020, local
organizer
06/2019 European Society of Human Genetics Conference 2019,
session co-chair “Statistical and population genetics”
04/2018 European Mathematical Genetics Meeting 2018, session co-
chair “Statistical methods and modeling”
Active Memberships in Scientific Societies, Fellowships in Renowned
Academies
2016 - present Member of American Society of Human Genetics
2018 - present Member of European Society of Human Genetics
2012 - 2013 Member of American Society of Human Genetics
2011 Member of European Society of Human Genetics
Prizes, Awards, Fellowships
02/2020 Finalist of “PIs of tomorrow: The Future of Swiss Research”,
Life Sciences Switzerland (LS2) Annual Meeting, Zurich
09/2019 Swiss Institute of Bioinformatics (SIB) Early Career
Bioinformatician Award
06/2018 Lodewijk Sandkuijl Award for an outstanding talk in the field
of complex genetics and statistical genetics, European Society
of Human Genetics Conference, Milan (Italy)
03/2018 Fellowship of Excellence for Young Investigators, European
Society of Human Genetics
07/2008 “Medaglia D’Oro” Award for outstanding students graduated
in Mathematical Science at the University of Cagliari (Italy)
09/2006 Erasmus European Exchange Program Fellowship - Universitè
Louis Pasteur Strasbourg (France)
Invited Seminars
7. Department of Genetic Medicine and Development, University of Geneva, CH
6. Institute of Translational Genomics at the Helmholtz Centre, Munich, DE
5. Basel Computational Biology Conference (BC2), Basel, CH September 2019
4. 9th CompBio Meeting, University of Lausanne and EPFL, CH May 2019
3. Jacobs Center for Productive Youth Development, University of Zurich, CH May 2019
2. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FIN March 2017
1. Estonian Genome Center, University of Tartu, EE April 2017
Oral contributions to conferences (talk or poster)
17. American Society of Human Genetics 2019, Houston, USA 15-19 October 2019 (Talk)
16. European Society of Human Genetics 2019, Gothenburg, SE 15-18 June 2019 (Poster)
15. European Mathematical Genetics Meeting 2019, Dublin, IRL 8-9 April 2019 (Talk)
14. American Society of Human Genetics 2018, San Diego, USA 16-20 October 2018 (Talk)
13. Workshop Building Bridges 2018, Helsinki, FIN 16-19 September 2018 (Talk)
12. European Society of Human Genetics 2018, Milan, IT 16-19 June 2018 (Talk)
11. European Mathematical Genetics Meeting 2018, Cagliari, IT 18-20 April 2018 (Talk)
10. American Society of Human Genetics 2017, Orlando, USA 22-26 October 2017 (Poster)
9. Basel Computational Biology Conference 2017, Basel, CH 4-7 September 2017 (Talk)
8. European Mathematical Genetics Meeting 2017, Tartu, EE 4-7 April 2017 (Talk)
7. Workshop “Functional annotation of genome-wide variants”, Lausanne, CH 15 March 2017 (Talk)
6. American Society of Human Genetics 2016, Vancouver, CA 18-22 October 2016 (Poster)
5. SIB days 2016, Bienne, CH 18-22 June 2016 (Talk)
4. American Society of Human Genetics 2013, Boston, USA 22-26 October 2013 (Poster)
3. American Society of Human Genetics 2012, San Francisco, USA 6-10 November 2012 (Poster)
2. 1000 Genomes Community Meeting, Ann Arbor, USA 12-13 July 2012 (Poster)
1. European Society of Human Genetics 2011, Amsterdam, NL 28-31 May 2011 (Poster)
Publications in peer-reviewed scientific journals
H-INDEX: 33 – TOTAL NUMBER OF CITATIONS: 12103 (SOURCE: GOOGLE SCHOLAR)
(When the research project was conducted by a large international collaboration with more than 50
authors, the notation “et al." was used to shorten the list of authors)
44. Porcu E*, Sjaarda J*, Lepik K, Carmeli C, Darrous L, Sulc J, Mounier N, Kutalik Z, Causal
Inference Methods to Integrate Omics and Complex Traits. Invited review in Cold Spring Harbor
Perspectives (in press)
43. Giannuzzi G, Schmidt PJ, Porcu E, Willemin G, Munson KM, Nuttle X, Earl R, Chrast J,
Hoekzema K, Risso D, Männik K, De Nittis P, Baratz ED; 16p11.2 Consortium, Herault Y, Gao X,
Philpott CC, Bernier RA, Kutalik Z, Fleming MD, Eichler EE, Reymond A. The Human-Specific
BOLA2 Duplication Modifies Iron Homeostasis and Anemia Predisposition in Chromosome 16p11.2
Autism Individuals. Am J Hum Genet. 2019 Oct 21. doi: 10.1016/j.ajhg.2019.09.023.
PMID: 31668704
https://www.sciencedirect.com/science/article/pii/S0002929719303635?via=ihub
42. Porcu E, Rüeger S, Lepik K, eQTLGene Consortium, BIOS Consortium, Santoni FA, Reymond A,
Kutalik Z. Mendelian Randomization integrating GWAS and eQTL data reveals genetic determinants
of complex and clinical traits. Nat Commun. 2019 Jul 24;10(1):3300. doi: 10.1038/s41467-019-10936-
0. PubMed PMID: 31341166
https://www.nature.com/articles/s41467-019-10936-0
41. Teumer A et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid
hormone regulation. Nat Commun. 2018 Oct 26;9(1):4455. doi: 10.1038/s41467-018-06356-1.
https://www.nature.com/articles/s41467-018-06356-1
40. Macé A, Tuke MA, Deelen P, Kristiansson K, Mattsson H, Nõukas M, Sapkota Y, Schick U, Porcu
E, Rüeger S, McDaid AF, Porteous D, Winkler TW, Salvi E, Shrine N, Liu X, Ang WQ, Zhang W,
Feitosa MF, Venturini C, Van der Most PJ, Rosengren A, Wood AR, Beaumont RN, Jones SE, Ruth
KS, Yaghootkar H, Tyrrell J, Havulinna AS, Boers H, Mägi R, Kriebel J, Müller-Nurasyid M, Perola
M, Nieminen M, Lokki ML, Kähönen M, Viikari JS, Geller F, Lahti J, Palotie A, Koponen P,
Lundqvist A, Rissanen H, Bottinger EP, Afaq S, Wojczynski MK, Lenzini P, Nolte IM, Sparsø T,
Schupf N, Christensen K, Perls TT, Newman AB, Werge T, Snieder H, Spector TD, Chambers JC,
Koskinen S, Melbye M, Raitakari OT, Lehtimäki T, Tobin MD, Wain LV, Sinisalo J, Peters A,
Meitinger T, Martin NG, Wray NG, Montgomery GW, Medland SE, Swertz MA, Vartiainen E,
Borodulin K, Männistö S, Murray A, Bochud M, Jacquemont S, Rivadeneira F, Hansen TF, Oldehinkel
AJ, Mangino M, Province MA, Deloukas P. Kooner JS, Freathy RM, Pennell C, Feenstra B, Strachan
DP. Lettre G, Hischhorn J, Cusi D, Heid IM, Hayward C, Männik K, Beckmann JS, Loos RJF, Nyholt
DR, Metspalu A, Eriksson JG, Weedon MN, Salomaa V, Franke L, Reymond A, Frayling TM, Kutalik
Z. CNV-association meta-analysis in 191,161 European adults reveals new loci associated with
anthropometric traits. Nat Commun. 2017;8(1):744. doi: 10.1038/s41467-017-00556-x. PubMed
PMID: 28963451.
https://www.nature.com/articles/s41467-017-00556-x
39. McDaid AF, Joshi PK, Porcu E, Komljenovic A, Li H, Sorrentino V, Litovchenko M, Bevers RPJ,
Rüeger S, CHARGE Consortium, Reymond A, Bochud M, Deplancke B, Williams RW, Robinson-
Rechavi M, Paccaud F, Rousson V, Auwerx J, Wilson JF, Kutalik Z. Bayesian association scan
reveals novel loci associated with human lifespan and pinpoints causally implicated transcriptome
biomarkers. Nat Comun. 2017 Jul 27;8:15842. doi: 10.1038/ncomms15842. PubMed PMID:
28748955.
https://www.nature.com/articles/ncomms15842
38. Steri M et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med. 2017
Apr 27;376(17):1615-1626. doi: 10.1056/NEJMoa1610528. PubMed PMID: 28445677.
https://www.nejm.org/doi/full/10.1056/NEJMoa1610528
37. Day FR et al. Genomic analyses identify hundreds of variants associated with age at menarche and
support a role for puberty timing in cancer risk. Nat Genet. 2017 Jun;49(6):834-841.
doi:10.1038/ng.3841. Epub 2017 Apr 24. PubMed PMID: 28436984.
https://www.nature.com/articles/ng.3841
36. Barban N et al. Genome-wide analysis identifies 12 loci influencing human reproductive behavior.
Nat Genet. 2016 Dec;48(12):1462-1472. doi: 10.1038/ng.3698. Epub 2016 Oct 31. PubMed PMID:
27798627.
https://www.nature.com/articles/ng.3698
35. Andlauer TF et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.
Sci Adv. 2016 Jun 17;2(6):e1501678. doi:10.1126/sciadv.1501678. eCollection 2016 Jun. PubMed
PMID: 27386562; PubMed Central PMCID: PMC4928990.
http://advances.sciencemag.org/content/2/6/e1501678
34. Barizzone N, Zara I, Sorosina M, Lupoli S, Porcu E, Pitzalis M, Zoledziewska M, Esposito F,
Leone M, Mulas A, Cocco E, Ferrigno P, Guerini FR, Brambilla P, Farina G, Murru R, Deidda F,
Sanna S, Loi A, Barlassina C, Vecchio D, Zauli A, Clarelli F, Braga D, Poddie F, Cantello R,
Martinelli V, Comi G, Frau J, Lorefice L, Pugliatti M, Rosati G; PROGEMUS (PROgnostic GEnetic
factors in Multiple Sclerosis) Consortium PROGRESSO (Italian network of Primary Progressive
Multiple Sclerosis) Consortium., Melis M, Marrosu MG, Cusi D, Cucca F, Martinelli Boneschi F,
Sanna S, D'Alfonso S. The burden of multiple sclerosis variants in continental Italians and Sardinians.
Mult Scler. 2015 Oct;21(11):1385-95. doi:10.1177/1352458515596599. PubMed PMID: 26438306.
https://doi.org/10.1177/1352458515596599
33. Day FR et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling,
breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet. 2015 Nov;47(11):1294-303.
doi: 10.1038/ng.3412. Epub 2015 Sep 28. PubMed PMID:26414677.
https://www.nature.com/articles/ng.3412
32. Danjou F, Zoledziewska M, Sidore C, Steri M, Busonero F, Maschio A, Mulas A, Perseu L, Barella
S, Porcu E, Pistis G, Pitzalis M, Pala M, Menzel S, Metrustry S, Spector TD, Leoni L, Angius A, Uda
M, Moi P, Thein SL, Galanello R, Abecasis GR, Schlessinger D, Sanna S, Cucca F. Genome-wide
association analyses based on whole-genome sequencing in Sardinia provide insights into regulation
of hemoglobin levels. Nat Genet. 2015 Nov;47(11):1264-71. doi: 10.1038/ng.3307. Epub 2015 Sep 14.
https://www.nature.com/articles/ng.3307
31. Sidore C*, Busonero F*, Maschio A*, Porcu E*, Naitza S*, Zoledziewska M, Mulas A, Pistis G,
Steri M, Danjou F, Kwong A, Ortega del Vecchyo VD, Chiang CWK, Bragg-Gresham J, Pitzalis M,
Nagaraja R, Tarrier B, Brennan C, Uzzau S, Fuchsberger C, Atzeni R, Reinier F, Berutti R, Huang J,
Timpson NJ, Toniolo D, Gasparini P, Malerba G, Dedoussis G, Zeggini E, Soranzo N, Jones C, Lyons
R, Angius A, Kang HM, Novembre J, Sanna S, Schlessinger D, Cucca F, Abecasis GR. Genome
sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and
blood inflammatory markers. Nat Genet. 2015 Nov;47(11):1272-1281. doi: 10.1038/ng.3368
https://www.nature.com/articles/ng.3368
30. Lunetta KL et al. Rare coding variants and X-linked loci associated with age at menarche. Nat
Commun. 2015 Aug 4;6:7756. doi: 10.1038/ncomms8756.
https://www.nature.com/articles/ncomms8756
29. Palomba G*, Loi A*, Porcu E*, Cossu A*, Zara I, Budroni M, Dei M, Lai S, Mulas A, Olmeo N,
Ionta MT, Atzori F, Cuccuru G, Pitzalis M, Zoledziewska M, Olla N, Lovicu M, Pisano M, Abecasis
GR, Uda M, Tanda F, Michailidou K, Easton DF, Chanock SJ, Hoover RN, Hunter DJ, Schlessinger D,
Sanna S, Crisponi L, Palmieri G. Genome-wide association study of susceptibility loci for breast
cancer in Sardinian population. BMC Cancer. 2015 May 10;15(1):383. PubMed PMID: 25956309.
https://doi.org/10.1186/s12885-015-1392-9
28. Taylor PN*, Porcu E*, Chew S*, Campbell PJ*, Traglia M, Brown SJ, Mullin BH, Shihab HA,
Min J, Walter K, Memari Y, Huang J, Barnes MR, Beilby JP, Charoen P, Danecek P, Dudbridge F,
Forgetta V, Greenwood C, Grundberg E, Johnson AD, Hui J, Lim EM, McCarthy S, Muddyman D,
Panicker V, Perry JRB, Bell JT, Yuan W, Relton C, Gaunt T, Schlessinger D, Abecasis GR, Cucca F,
Surdulescu GL, Woltersdorf W, Zeggini E, Zheng H, Toniolo D, Dayan CM, Naitza S, Walsh JP,
Spector T, Smith GD, Durbin R, Richards JB, Sanna S, Soranzo N, Timpson NJ, Wilson SG and the
UK10K Consortium. Whole genome sequence based analysis of thyroid function. Nature
Comunications. 2015 Mar 6. doi: 10.1038/ncomms6681.
https://www.nature.com/articles/ncomms6681
27. Gottlieb DJ et al. Novel loci associated with usual sleep duration: the CHARGE Consortium
Genome-Wide Association Study. Mol Psychiatry. 2014 Nov 18. doi: 10.1038/mp.2014.133. PMID:
25349170.
https://www.nature.com/articles/mp2014133
26. Vrieze SI, Malone SM, Vaidyanathan U, Kwong A, Kang HM, Zhan X, Flickinger M, Irons D, Jun
G, Locke AE, Pistis G, Porcu E, Levy S, Myers RM, Oetting W, McGue M, Abecasis G, Iacono WG.
In search of rare variants: preliminary results from whole genome sequencing of 1,325 individuals
with psychophysiological endophenotypes. Psychophysiology. 2014 Dec;51(12):1309-20. doi:
10.1111/psyp.12350.
https://doi.org/10.1111/psyp.12350
25. Kuś A, Szymański K, Peeters RP, Miśkiewicz P, Porcu E, Pistis G, Sanna S, Naitza S, Płoski R,
Medici M, Bednarczuk T. The association of thyroid peroxidase antibody risk loci with susceptibility to
and phenotype of Graves' disease. Clin Endocrinol (Oxf). 2014 Oct 24. doi: 10.1111/cen.12640.
PMID: 25345847.
https://doi.org/10.1111/cen.12640
24. Pistis G*, Porcu E*, Vrieze SI, Sidore C, Steri M, Danjou F, Busonero F, Mulas A, Zoledziewska
M, Maschio A, Brennan C, Lai S, Miller MB, Marcelli M, Urru MF, Pitzalis M, Lyons RH, Kang HM,
Jones CM, Angius A, Iacono WG, Schlessinger D, McGue M, Cucca F, Abecasis GR, Sanna S. Rare
variant genotype imputation with thousands of study-specific whole-genome sequences: implications
for cost-effective study designs. Eur J Hum Genet. 2014 Oct 8. doi:10.1038/ejhg.2014.216. PubMed
PMID: 25293720.
https://www.nature.com/articles/ejhg2014216
23. Wood AR et al. Defining the role of common variation in the genomic and biological architecture
of adult human height. Nat Genet. 2014 Oct 5. doi: 10.1038/ng.3097. PubMed PMID: 25282103.
https://www.nature.com/articles/ng.3097
22. Perry JR et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at
menarche. Nature. 2014 Oct 2;514(7520):92-7. doi: 10.1038/nature13545. Epub 2014 Jul 23. PubMed
PMID: 25231870; PubMed Central PMCID: PMC4185210.
https://www.nature.com/articles/nature13545
21. Colonna V, Ayub Q, Chen Y, Pagani L, Luisi P, Pybus M, Garrison E, Xue Y, Tyler-Smith C; 1000
Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM,
Handsaker RE, Kang HM, Marth GT, McVean GA. Human genomic regions with exceptionally high
levels of population differentiation identified from 911 whole-genome sequences. Genome Biol. 2014
Jun 30;15(6):R88. doi:10.1186/gb-2014-15-6-r88. PubMed PMID: 24980144.
https://genomebiology.biomedcentral.com/articles/10.1186/gb-2014-15-6-r88
20. Medici M*, Porcu E*, Pistis G* et al. Identification of novel genetic Loci associated with thyroid
peroxidase antibodies and clinical thyroid disease. PLoS Genet. 2014 Feb 27;10(2):e1004123. doi:
10.1371/journal.pgen.1004123. eCollection 2014 Feb. PubMed PMID: 24586183; PubMed Central
PMCID: PMC3937134.
https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004123
19. Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, Sboner A, Lochovsky L, Chen J,
Harmanci A, Das J, Abyzov A, Balasubramanian S, Beal K, Chakravarty D, Challis D, Chen Y, Clarke
D, Clarke L, Cunningham F, Evani US, Flicek P, Fragoza R, Garrison E, Gibbs R, Gümüs ZH, Herrero
J, Kitabayashi N, Kong Y, Lage K, Liluashvili V, Lipkin SM, MacArthur DG, Marth G, Muzny D,
Pers TH, Ritchie GR, Rosenfeld JA, Sisu C, Wei X, Wilson M, Xue Y, Yu F; 1000 Genomes Project
Consortium, Dermitzakis ET, Yu H, Rubin MA, Tyler-Smith C, Gerstein M. Integrative annotation of
variants from 1092 humans: application to cancer genomics. Science. 2013 Oct 4;342(6154):1235587.
doi: 10.1126/science.1235587. PubMed PMID: 24092746; PubMed Central PMCID: PMC3947637.
http://science.sciencemag.org/content/342/6154/1235587.long
18. Orrù V, Steri M, Sole G, Sidore C, Virdis F, Dei M, Lai S, Zoledziewska M, Busonero F, Mulas A,
Floris M, Mentzen WI, Urru SA, Olla S, Marongiu M, Piras MG, Lobina M, Maschio A, Pitzalis M,
Urru MF, Marcelli M, Cusano R, Deidda F, Serra V, Oppo M, Pilu R, Reinier F, Berutti R, Pireddu L,
Zara I, Porcu E, Kwong A, Brennan C, Tarrier B, Lyons R, Kang HM, Uzzau S, Atzeni R, Valentini
M, Firinu D, Leoni L, Rotta G, Naitza S, Angius A, Congia M, Whalen MB, Jones CM, Schlessinger
D, Abecasis GR, Fiorillo E, Sanna S, Cucca F. Genetic variants regulating immune cell levels in health
and disease. Cell. 2013 Sep 26;155(1):242-56. doi:10.1016/j.cell.2013.08.041. PubMed PMID:
24074872.
https://doi.org/10.1016/j.cell.2013.08.041
17. Francalacci P, Morelli L, Angius A, Berutti R, Reinier F, Atzeni R, Pilu R, Busonero F, Maschio A,
Zara I, Sanna D, Useli A, Urru MF, Marcelli M, Cusano R, Oppo M, Zoledziewska M, Pitzalis M,
Deidda F, Porcu E, Poddie F, Kang HM, Lyons R, Tarrier B, Gresham JB, Li B, Tofanelli S, Alonso
S, Dei M, Lai S, Mulas A, Whalen MB, Uzzau S, Jones C, Schlessinger D, Abecasis GR, Sanna S,
Sidore C, Cucca F. Low-pass DNA sequencing of 1200 Sardinians reconstructs European Y-
chromosome phylogeny. Science 2013 Aug 2;341(6145):565-9. doi:10.1126/science.1237947. PubMed
PMID: 23908240.
http://science.sciencemag.org/content/341/6145/565.long
16. Porcu E, Sanna S, Fuchsberger C, Fritsche LG. Genotype imputation in genome-wide association
studies. Curr Protoc Hum Genet. 2013 Jul;Chapter 1:Unit 1.25. doi: 10.1002/0471142905.hg0125s78.
Review. PubMed PMID: 23853078.
https://doi.org/10.1002/0471142905.hg0125s78
15. Paul DS, Albers CA, Rendon A, Voss K, Stephens J; HaemGen Consortium, van der Harst P,
Chambers JC, Soranzo N, Ouwehand WH, Deloukas P. Maps of open chromatin highlight cell type-
restricted patterns of regulatory sequence variation at hematological trait loci. Genome Res. 2013
Jul;23(7):1130-41. doi:10.1101/gr.155127.113. Epub 2013 Apr 9. PubMed PMID: 23570689; PubMed
Central PMCID: PMC3698506.
https://genome.cshlp.org/content/23/7/1130.long
14. Fernández-Rhodes L et al. Association of adiposity genetic variants with menarche timing in
92,105 women of European descent. Am J Epidemiol. 2013 Aug 1;178(3):451-60. doi:
10.1093/aje/kws473. Epub 2013 Apr 4. PubMed PMID: 23558354; PubMed Central PMCID:
PMC3816344.
https://doi.org/10.1093/aje/kws473
13. Cousminer DL et al. Genome-wide association and longitudinal analyses reveal genetic loci
linking pubertal height growth, pubertal timing and childhood adiposity. Hum Mol Genet. 2013 Jul
1;22(13):2735-47. doi: 10.1093/hmg/ddt104. Epub 2013 Feb 27. PubMed PMID: 23449627; PubMed
Central PMCID: PMC3674797.
https://doi.org/10.1093/hmg/ddt104
12. Porcu E*, Medici M*, Pistis G* et al. A meta-analysis of thyroid-related traits reveals novel loci
and gender-specific differences in the regulation of thyroid function. PLoS Genet. 2013;9(2):e1003266.
doi: 10.1371/journal.pgen.1003266. Epub 2013 Feb 7. PubMed PMID: 23408906; PubMed Central
PMCID: PMC3567175.
https://doi.org/10.1371/journal.pgen.1003266
11. van der Harst P et al. Seventy-five genetic loci influencing the human red blood cell. Nature. 2012
Dec 20;492(7429):369-75. doi: 10.1038/nature11677. Epub 2012 Dec 5. PubMed PMID: 23222517;
PubMed Central PMCID: PMC3623669.
https://www.nature.com/articles/nature11677
10. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin
RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from
1,092 human genomes. Nature. 2012 Nov 1;491(7422):56-65. doi: 10.1038/nature11632. PubMed
PMID: 23128226; PubMed Central PMCID: PMC3498066.
https://www.nature.com/articles/nature11632
9. Nürnberg ST, Rendon A, Smethurst PA, Paul DS, Voss K, Thon JN, Lloyd-Jones H, Sambrook JG,
Tijssen MR; HaemGen Consortium, Italiano JE Jr, Deloukas P, Gottgens B, Soranzo N, Ouwehand
WH. A GWAS sequence variant for platelet volume marks an alternative DNM3 promoter in
megakaryocytes near a MEIS1 binding site. Blood. 2012 Dec 6;120(24):4859-68. doi: 10.1182/blood-
2012-01-401893. Epub 2012 Sep 12. PubMed PMID: 22972982; PubMed Central PMCID:
PMC3520622.
https://doi.org/10.1182/blood-2012-01-401893
8. He C, Chasman DI, Dreyfus J, Hwang SJ, Ruiter R, Sanna S, Buring JE, Fernández-Rhodes L,
Franceschini N, Hankinson SE, Hofman A, Lunetta KL, Palmieri G, Porcu E, Rivadeneira F, Rose
LM, Splansky GL, Stolk L, Uitterlinden AG, Chanock SJ, Crisponi L, Demerath EW, Murabito JM,
Ridker PM, Stricker BH, Hunter DJ. Reproductive aging-associated common genetic variants and the
risk of breast cancer. Breast Cancer Res. 2012 Mar 20;14(2):R54. PubMed PMID: 22433456; PubMed
Central PMCID: PMC3446388.
https://doi.org/10.1186/bcr3155
7. Naitza S, Porcu E, Steri M, Taub DD, Mulas A, Xiao X, Strait J, Dei M, Lai S, Busonero F,
Maschio A, Usala G, Zoledziewska M, Sidore C, Zara I, Pitzalis M, Loi A, Virdis F, Piras R, Deidda F,
Whalen MB, Crisponi L, Concas A, Podda C, Uzzau S, Scheet P, Longo DL, Lakatta E, Abecasis GR,
Cao A, Schlessinger D, Uda M, Sanna S, Cucca F. A genome-wide association scan on the levels of
markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS
Genet. 2012 Jan;8(1):e1002480. doi:10.1371/journal.pgen.1002480. Epub 2012 Jan 26. PubMed
PMID: 22291609; PubMed Central PMCID: PMC3266885
https://doi.org/10.1371/journal.pgen.1002480
6. Stolk L et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA
repair and immune pathways. Nat Genet. 2012 Jan 22;44(3):260-8. doi: 10.1038/ng.1051. PubMed
PMID: 22267201; PubMed Central PMCID: PMC3288642.
https://www.nature.com/articles/ng.1051
5. Gieger C*, Radhakrishnan A*, Cvejic A*, Tang W*, Porcu E*, Pistis G* et al. New gene functions
in megakaryopoiesis and platelet formation. Nature 2011 Nov 30;480(7376):201-8. doi:
10.1038/nature10659. PubMed PMID: 22139419; PubMed Central PMCID: PMC3335296.
https://www.nature.com/articles/nature10659
4. Pichler I, Minelli C, Sanna S, Tanaka T, Schwienbacher C, Naitza S, Porcu E, Pattaro C, Busonero
F, Zanon A, Maschio A, Melville SA, Grazia Piras M, Longo DL, Guralnik J, Hernandez D, Bandinelli
S, Aigner E, Murphy AT, Wroblewski V, Marroni F, Theurl I, Gnewuch C, Schadt E, Mitterer M,
Schlessinger D, Ferrucci L, Witcher DR, Hicks AA, Weiss G, Uda M, Pramstaller PP. Identification of
a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.
Hum Mol Genet. 2011 Mar 15;20(6):1232-40. doi: 10.1093/hmg/ddq552. Epub 2010 Dec 28. PubMed
PMID: 21208937; PubMed Central PMCID: PMC3043660.
https://doi.org/10.1093/hmg/ddq552
3. Elks CE et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide
association studies. Nat Genet. 2010 Dec;42(12):1077-85. doi:10.1038/ng.714. PubMed PMID:
21102462; PubMed Central PMCID: PMC3140055.
http://www.nature.com/articles/ng.714
2. Soranzo N et al. Common variants at 10 genomic loci influence hemoglobin A⁾(C) levels via
glycemic and nonglycemic pathways. Diabetes. 2010 Dec;59(12):3229-39. doi: 10.2337/db10-0502.
Epub 2010 Sep 21. Erratum in: Diabetes. 2011 Mar;60(3):1050-1. multiple author names added.
PubMed PMID: 20858683; PubMed Central PMCID: PMC2992787.
https://doi.org/10.2337/db10-0502
1. Sanna S, Pitzalis M, Zoledziewska M, Zara I, Sidore C, Murru R, Whalen MB, Busonero F, Maschio
A, Costa G, Melis MC, Deidda F, Poddie F, Morelli L, Farina G, Li Y, Dei M, Lai S, Mulas A,
Cuccuru G, Porcu E, Liang L, Zavattari P, Moi L, Deriu E, Urru MF, Bajorek M, Satta MA, Cocco E,
Ferrigno P, Sotgiu S, Pugliatti M, Traccis S, Angius A, Melis M, Rosati G, Abecasis GR, Uda M,
Marrosu MG, Schlessinger D, Cucca F. Variants within the immunoregulatory CBLB gene are
associated with multiple sclerosis. Nat Genet. 2010 Jun;42(6):495-7. doi:10.1038/ng.584. Epub 2010
May 9. PubMed PMID: 20453840; PubMed Central PMCID: PMC3786343.
https://www.nature.com/articles/ng.584
Curriculum vitae
Personal data
First Name Alexandre
Last Name Reymond
Date of Birth September 29, 1964
Place of Birth Vevey, Switzerland
Familial status married to Anne Simon,
father of Luc (Dec. 24, 1994) and Benjamin (Oct. 5, 1997)
Home address Chemin de Champ Paris 27, 1304 Cossonay-Ville
ph +41 21 861 0290
Work address Center for Integrative Genomics, Genopode building,
University of Lausanne, 1015 Lausanne, Switzerland
ph +41 21 692 3961 (personal assistant 3960)
fx +41 21 692 3965
em
[email protected]
ORCID 0000-0003-1030-8327
Degrees
1984 “Certificat de Maturité fédérale Type C, Baccalauréat ès
Sciences, Gymnase cantonal de Burier”, Vaud, Switzerland.
1989 “Licence ès Sciences” in Biology (M.Sc.), Faculty of
Sciences, University of Lausanne, Switzerland.
1993 Doctorat ès Sciences (Ph.D.) under the direction of Dr
Viesturs Simanis, Swiss Institute for Experimental Cancer
Research (ISREC), Epalinges, Switzerland and Faculty of
Sciences, University of Lausanne, Switzerland.
2005 Privat Docent, University of Geneva Medical School.
Professional experience
11.89-11.93 Graduate Student, Swiss Institute for Experimental Cancer
Research (ISREC; http://isrec.epfl.ch/), Epalinges,
Switzerland (laboratory of Viesturs Simanis).
12.93-07.94 Research Fellow, Swiss Institute for Experimental Cancer
Research (ISREC; http://isrec.epfl.ch/), Epalinges,
Switzerland (laboratory of Viesturs Simanis).
08.94-02.98 Research Fellow, Department of Molecular Biology,
Massachusetts General Hospital and Department of
Genetics, Harvard Medical School, Boston, MA, USA
(laboratory of Roger Brent).
1
03.98-09.00 Principal Investigator at the Telethon Institute of Genetics
and Medicine (TIGEM; www.tigem.it/; Director: Andrea
Ballabio), Milan, Italy.
10.00-09.04 “Maître-assistant”, Department of Genetic Medicine and
Development (laboratory of Stylianos E. Antonarakis)
(http://www.unige.ch/medecine/gede/fr/), University of
Geneva Medical School, Geneva, Switzerland.
10.04-01.09 Tenure-track Assistant Professor, Center for Integrative
Genomics (www.unil.ch/cig/), University of Lausanne,
Lausanne, Switzerland.
02.09-07.16 Associate Professor, Center for Integrative Genomics
(www.unil.ch/cig/), University of Lausanne, Lausanne,
Switzerland.
08.16-current Full Professor, Center for Integrative Genomics
(www.unil.ch/cig/), University of Lausanne, Lausanne,
Switzerland.
01.15-current Director, Center for Integrative Genomics (www.unil.ch/cig/),
University of Lausanne, Lausanne, Switzerland.
Fellowships and Honors
01.93-12.93 “Bourse de Chailly” Long Term Fellowship
05.94-06.94 “Ciba-Geigy-Jubilaüms-Stiftung” Short Term Fellowship
08.94-07.95 Swiss Cancer League Long Term Fellowship
08.95-01.97 Swiss National Science Foundation Long Term Fellowship
03.98-03.00 Telethon Italy Long Term Fellowship
06.06 Bizot Prize, University of Geneva Medical School, Geneva
03.10 Leenaards Foundation’s Prize (http://www.leenaards.ch/)
Scientific appointments
1. Ad hoc grant proposal reviewer for the European Research Council Starting,
Consolidator and Advanced Grant proposals, the Estonian Research Council (ETAg),
the British BBSRC, the Yorkshire Cancer Research Foundation, the Italian Telethon
2
Foundation, the Swiss National Science Foundation, the Dutch Cancer Society
(Nederlandse Kankerbestrijding), the Netherlands Organization for Health Research
and Development (ZonMw), the British Medical Research Council (MRC), the Hong
Kong Research Grant Council (RGC), the Excellence Initiative for Bourgogne
Franche-Comté (ISITE-BFC) and the French ANR (Agence Nationale de la
Recherche).
2. Ad hoc manuscript reviewer for American Journal of Human Genetics, BBA-
Molecular Basis of Disease, Biotechniques, Biological Psychiatry, BMC Genomics,
Cancer Research, Cell, Clinical Genetics, Current Genomics, Cytogenetic and
Genome Research, EMBO Molecular Medicine, European Journal of Human
Genetics, Expert Review of Molecular Diagnostics, FEBS Letters, G3: Genes,
Genomes, Genetics, Gene, Genes & Development, Genome Biology, Genome
Biology and Evolution, Genome Research, Genomics, Human Genetics, Human
Molecular Genetics, Human Mutation, International Journal of Obesity, Journal of
Investigative Dermatology, Journal of Medical Genetics, Nature, Nature
Biotechnology, Nature Genetics, Nature Medicine, Nature Methods, Nature Reviews
Genetics, New England Journal of Medicine, Nucleic Acids Research, Oncogene,
Orphanet Journal of Rare Diseases, Pathogenetics, Physiological Reviews, Prenatal
diagnosis, PLoS Biology, PLoS Genetics, PLoS One, Proceedings of the National
Academy of Sciences of the USA, Science, Science Translational Medicine.
3. 2004 and 2005, independent expert for the European Commission to evaluate,
monitor and review projects proposals submitted to the 6th Framework Program (http
//fp6.cordis.lu/fp6/home.cfm).
4. HUGO (HUman Genome Organization) Nomenclature Committee Specialist Advisor
for TRIM (TRIpartite Motif) protein (http
//www.gene.ucl.ac.uk/nomenclature/advisors.html).
5. Organizer of the “International Workshop on Human Chromosome 21 Annotation”,
Geneva, 17th-18th October 2003.
6. 12.2006 to 11.2010, leader of the training “Workpackage” of the European
Commission 6th Framework Program Integrated Project entitled “anEUploidy” (http
//www.aneuploidy.eu/).
7. Member of the scientific organizing committee of the “Genes, Genomes and
Evolution” lectures for the “IIIe cycle romand en sciences biologiques”, Villars-sur-
Ollon, Switzerland, 24th-27th June 2007.
8. Member of the scientific organizing committee of the “Expert Workshop on the
Biology of Chromosome 21 Genes: Towards Gene-phenotype Correlations in Down
Syndrome, Washington, DC, 28th September-1st October 2007.
9. 2007, 2008 and 2009, member of the review panel of the Academy of Finland,
Helsinki, Finland (www.aka.fi/eng).
10. Member of the scientific organizing committee of the annual USGEB meeting,
Lausanne, February 6-7, 2008 (Union of the Swiss Societies for Experimental
Biology; http //www.usgeb.ch/).
11. Organizer of the 1st anEUploidy workshop, Geneva, Switzerland, September 12-14,
2008 (http://www.aneuploidy.eu/).
12. March 2008, member of the review panel of the AERES (“L'Agence d'Evaluation de
la Recherche et de l'Enseignement Supérieur”; http //www.aeres-evaluation.fr/) to
3
evaluate the Jacques Monod Institute, Paris, France (http
//ijm2.ijm.jussieu.fr/ijm/institut/organigramme).
13. Organizer of the 2nd anEUploidy workshop, Split, Croatia, September 17-19, 2010
(http://www.aneuploidy.eu/).
14. August 09-current, member of the Genomics and Genetics Advisory Board for
Faculty of 1000 Biology Reports (http://www.f1000biology.com/).
15. 2009, member of the evaluators’ panel of the fellowship applications for the
INTERPOD interdisciplinary post-doctoral program of the Center for Genomic
Regulation (CRG, Barcelona, www.crg.es/) sponsored by the EC within FP7.
16. 2010, Chairman of the poster jury at the 42th Annual Meeting of the European
Society of Human Genetics, Gothenburg, Sweden.
17. 2010-current, co-organizer of the “Lausanne Genomic Days”
18. 2010-current, member of the Scientific Committee of the Blackswan Foundation
(http://www.blackswanfoundation.ch/).
19. 2011, Chairman of the poster jury at the 43rd Annual Meeting of the European
Society of Human Genetics, Amsterdam, The Netherlands.
20. 2011-2012, Section Editor for the area Molecular Genetics, Editorial Board of the
European Journal of Human Genetics (http://www.nature.com/ejhg/index.html).
21. July 2010-current, member of the Scientific Board of the Jérôme Lejeune Foundation
(http://www.fondationlejeune.org/).
22. 2012, Chairman of the poster jury at the 44th Annual Meeting of the European
Society of Human Genetics, Nuremberg, Germany.
23. 2013, Member of the Scientific Executive Board of SystemsX.ch, the Swiss Initiative
in Systems Biology (http://www.systemsx.ch/).
24. 2013, member of the working panel of the Wellcome Trust Rare Disease Workshop,
Gibbs Building, London, United Kingdom.
25. 2013, organizer of Prof Jacques S. Beckmann Farewell Symposium, Lausanne,
Switzerland.
26. 2013, organizer with Henrik Kaessmann of the CIG Symposium 2013 “genome,
diseases and evolution", Lausanne, Switzerland.
27. 2013, Chairman of the poster jury at the 45th Annual Meeting of the European
Society of Human Genetics, Paris, France.
28. 2014-2016, co-chair of the “data production” workstream of the new Swiss research
initiative about “Personalized Health”.
29. 2014, member of the review panel of the AERES (“L'Agence d'Evaluation de la
Recherche et de l'Enseignement Supérieur”; http //www.aeres-evaluation.fr/) to
evaluate the unit led by M.Claustres/M.Koenig in Montpellier, France.
30. 2014, member of the scientific organizing committee of the Symposium “From
Systems Medicine to Personalized Health, Bern, Switzerland
31. 2014, member of the scientific organizing committee of the HUGO Human Genome
Meeting 2014 “Genome Variation and Human Health”, Geneva, Switzerland.
32. 2014, Chairman of the poster jury at the 46th Annual Meeting of the European
Society of Human Genetics, Milan, Italy.
33. 2014, organizer with Laurent Keller of the “Evolution and Genomes” workshop for
graduate students of Western Switzerland, Villars-sur-Ollon, Switzerland.
34. 2014, member of the scientific organizing committee of the 2nd RING14 workshop.
35. 2015-current, member of the Swiss Institute of Bioinformatics Foundation Council.
4
36. 2015, member of the scientific organizing committee of 15th Congress of the
European Society for Evolutionary Biology, Lausanne, Switzerland.
37. 2015-2019, member of the European Society of Human Genetics annual meeting
Scientific Program Committee (https://www.eshg.org/spc.0.html).
38. 2015, member of the evaluation committee of “Epigenetics and Cancer” projects
submitted to the ITMO Cancer jointly proposed by the French National Alliance for
Life Sciences and Health (AVIESAN) and the National Cancer Institute under the
auspices of INSERM, Paris, France.
39. 2017, organizer of the ePerMed Workshop 2013 “Functional annotation of genome-
wide variants", Lausanne, Switzerland.
40. 2017, organizer of the symposium in honor of Prof. Stylianos E. Antonarakis, “50
years of human genetics”, Geneva, Switzerland.
41. 2017, chairman of the “Neurological disorders: Chromatin in the spotlight” session,
67th Annual Meeting of the American Society of Human Genetics, Orlando, FL.
42. 2017-current, member of the Board of the “Health 2030 Initiative” that regroups
Universities of Geneva (UNIGE), Lausanne (UNIL) and Bern (UNIBE), the University
Hospitals of Geneva (HUG), Lausanne (CHUV) and Bern (Inselspital) and the Swiss
Federal Institute of Technology of Lausanne (EPFL).
43. 2018, member of the Hcéres (Haut Conseil de l'évaluation de la recherche et de
l'enseignement supérieur) committee to evaluate the IMAGINE Institute (Institut des
Maladies Génétiques; http://www.institutimagine.org/en/), Paris, France.
44. 2018-current, member of the editorial board of the section “Human Genomics and
Genetic Diseases” of the journal “Genes”.
45. 2018, member of FCT (Fundação para a Ciência e a Tecnologia; Portuguese
national funding agency for science, research and technology) Biomedicine and
Molecular Biology panel to evaluate: Institute of Molecular Medicine (iMM, Lisbon),
Research Institute for Medicines (iMed, Lisbon), Health Sciences Research Centre
(CICS-UBI, Covilhã), Institute for Research and Innovation in Health (i3S, Porto),
ICVS/3B's (Barco-Guimarães), Research Center for Biosciences & Health
Technologies (CBIOS, Lisbon), Champalimaud Research Programme (CR, Lisbon),
Aveiro Institute of Biomedicine (iBiMED, Aveiro), Institute of Research and Advanced
Training in Health Sciences and Technologies (IINFACTS, Gandra), Center for
Innovative Biomedicine and Biotechnology (CIBB, Coimbra), Biosystems and
Integrative Sciences Institute (BioISI, Lisbon), Centre for Biomedical Research
(CBMR, Faro) and Instituto Gulbenkian de Ciência (IGC, Oeiras).
46. 2019, member of the Belgian FRFS (Fonds pour la Recherche Fondamentale
Stratégique)-WELBIO Scientific Committee.
47. 2019, member of the review panel of the Molecular Regulatory Networks of Life
(R’Life) research program of the Academy of Finland, Helsinki, Finland
(https://www.aka.fi/en).
5
Memberships to Academic Societies
Member of the Swiss Society of Medical Genetics (http://www.sgmg.ch/), the LS2 (Life
Science Switzerland) Section: Molecular and Cellular Biosciences
(https://www.ls2.ch/sections/mcb), the European Society of Human Genetics
(http://www.eshg.org/), the European Cytogeneticists Association
(http://www.biologia.uniba.it/eca/), the American Society of Human Genetics
(http://www.ashg.org/) and the International Society for Autism Research (http://autism-
insar.org/).
2008-2012, Member of the Board of the European Society of Human Genetics
(https://www.eshg.org/56.0.html).
2011-2013, Member of the Board of the Swiss Society of Medical Genetics
(http://www.sgmg.ch/).
6.2018-6.2019, President-elect of the European Society of Human Genetics
6.2019-6.2020, President of the European Society of Human Genetics
(https://www.eshg.org/index.php?id=56)
Consulting
2013-curr., member of the Scientific Advisory Board, Gene Predictis, Lausanne,
Switzerland.
2015-curr., member of the Scientific Advisory Board, Saphetor, Lausanne, Switzerland.
Invited Lectures (symposia, meetings and workshops)
1993, selected speaker at the Annual Meeting of the Union of the Swiss Societies for
Experimental Biology (USGEB), Lausanne, Switzerland.
1995, selected speaker at the Jacques Monod Conference “The Cell Division Cycle”,
Aussois, France.
1995, invited speaker at the 5th International Workshop on the “Identification of
transcribed Sequences”, Ile des Embiez, France.
1996, invited speaker at the Strategic Research Institute Meeting, “The Application of
Genomics to Drug Discovery”, Philadelphia, PA.
1997, invited speaker at the Boehringer Mannheim Italy Meeting, “New Technologies to
study the DNA”, Florence, Italy.
1999, selected speaker at the 4th Meeting of Molecular Oncology, Positano, Italy.
1999, invited speaker at the 3rd Italian Workshop on Genome Research, Baia delle
Zagare, Italy.
2000, selected speaker at the Juan March Foundation Meeting, “The Myc network:
regulation of cell proliferation, differentiation and death”, Madrid, Spain.
2001, selected speaker at the 51th Annual Meeting of the American Society of Human
Genetics, San Diego, CA.
6
2002, selected speaker at the 1st “Assises de Génétique Humaine et Médicale”,
Marseilles, France.
2002, selected speaker at the 34th Annual Meeting of the European Society of Human
Genetics, Strasbourg, France.
2002, invited speaker at the 10th International Meeting, “Molecular Biology of
Chromosome 21 and Down syndrome”, Sitges, Spain.
2002, invited speaker at the ACLF (Association des Cytogénéticiens de Langue
Française) Annual Meeting, Toulouse, France.
2003, invited speaker at the JIGO (Journées Internationales de Gynécologie et
Obstétrique) Meeting, Paris, France.
2003, invited speaker at the 2nd “Rencontres Européennes sur la trisomie 21” Meeting,
Orléans, France.
2003, invited speaker at the 26th Swiss Congress of General Medicine, La Chaux-de-
Fonds, Switzerland.
2004, invited speaker at the Annual Meeting of the Swiss Society of Pediatrician, Basel,
Switzerland.
2004, invited speaker at the 1st “Journées Internationales Jérôme Lejeune”, Paris,
France.
2004, invited speaker at the 6th Congress of the European Williams Syndrome
Foundation, Roma, Italy.
2004, selected speaker at the 54th Annual Meeting of the American Society of Human
Genetics, Toronto, Canada.
2005, invited speaker at the EGASP’05 meeting (The human ENCODE (ENCylopedia Of
DNA Elements) Genome Annotation Assessment Project), Hinxton, United
Kingdom.
2005, selected speaker at the 37th Annual Meeting of the European Society of Human
Genetics, Prague, Czech Republic.
2005, selected speaker at the 55th Annual Meeting of the American Society of Human
Genetics, Salt Lake City, UT.
2006, selected speaker at the 38th Annual Meeting of the European Society of Human
Genetics, Amsterdam, Netherlands.
2006, co-chairman of the “genetic disorders and genomics” session and invited speaker,
4th European meeting on Elastin, Lyon, France.
2006, selected speaker at the 11th International Congress of Human Genetics, Brisbane,
Queensland, Australia
2006, invited speaker at the British Society of Human Genetics (BSHG) annual meeting,
York, United Kingdom.
2006, invited speaker at the 56th Annual Meeting of the American Society of Human
Genetics, New Orleans, LA.
2006, invited speaker at the Swiss Society of Medical Genetics annual meeting,
Lausanne, Switzerland.
2006, invited speaker at the BIOSAPIENS Network of Excellence - ENCODE project
common workshop on alternatively spliced transcripts, Hinxton, United Kingdom.
2007, selected speaker at the 39th Annual Meeting of the European Society of Human
Genetics, Nice, France.
2007, invited speaker at the workshop “Importance of genome variations in pathology:
SNPs and CNVs”, Hôpital Necker Enfants Malades, Paris, France.
7
2007, invited speaker at 6th European Cytogenetics Conference, Istanbul, Turkey.
2007, co-organizer, invited speaker and session chair at the “Expert Workshop on the
Biology of Chromosome 21 Genes: Towards Gene-Phenotype Correlations in
Down Syndrome, Washington, DC.
2007, selected speaker at the 57th Annual Meeting of the American Society of Human
Genetics, San Diego, CA.
2008, invited speaker at the European Commission FP6 Integrated Project EURexpress
annual meeting.
2008, invited speaker at the International Conference on Williams Syndrome in Paris,
France.
2008, chairman of the “Molecular Cytogenetics” session at the 40th Annual Meeting of
the European Society of Human Genetics, Barcelona, Spain.
2008, invited speaker at the XIXth ACLF (Association des Cytogénéticiens de Langue
Française) Annual Meeting, Nantes, France.
2008, organizer, invited speaker and session chair at the “1st anEUploidy workshop“,
Geneva, Switzerland.
2008, plenary session selected speaker at the 58th Annual Meeting of the American
Society of Human Genetics, Philadelphia, PA.
2008, invited speaker at the “Down syndrome: a multidisciplinary perspective”
symposium, Barcelona, Spain.
2009, invited speaker at the Lausanne Life Sciences Festival “Genetics, Epigenetics and
Development”, Lausanne, Switzerland.
2009, invited speaker at the Gordon Conference “Epigenetics”, The Holderness School,
Holderness, NH.
2009, invited speaker at the 27th Annual Meeting of the Genetics and Environmental
Mutagenesis Society, The Friday Center, Chapel Hill, NC.
2009, invited speaker at the RGASP meeting (The RNAseq Genome Annotation
Assessment Project), Hinxton, United Kingdom.
2010, invited speaker at the 10th Genomics Days, Lausanne, Switzerland.
2010, invited speaker at the 4th Wellcome Trust Scientific Conference “Genomic
Disorders 2010, CNV in Mendelian and Complex traits”, Hinxton, UK.
2010, chairman of the “Next generation sequencing” session at the 42th Annual Meeting
of the European Society of Human Genetics, Gothenburg, Sweden.
2010, invited speaker at the “High-Definition Genomics” annual seminar from Roche
Diagnostics, Basel, Switzerland.
2010, organizer, invited speaker and session chair at the “2nd anEUploidy workshop“,
Split, Croatia.
2010, selected speaker at the 60th Annual Meeting of the American Society of Human
Genetics, Washington, DC.
2011, invited speaker at the Keystone Symposium “Functional Consequences of
Structural Variation in the Genome”, Steamboat Springs, CO.
2011, invited speaker at the 2nd “Journées Internationales Jérôme Lejeune”, Paris,
France.
2011, invited speaker at the 5th Wellcome Trust Scientific Conference “Genomic
Disorders 2011, The Genomics of Rare Diseases”, Hinxton, United Kingdom.
2011, chairman of the “Molecular Cytogenetics” session at the 43rd Annual Meeting of
the European Society of Human Genetics, Amsterdam, Netherlands.
8
2011, invited speaker, Swiss Institute of Bioinformatics RNA-seq minisymposium,
Lausanne, Switzerland.
2011, invited speaker at the 8th European Cytogenetics Conference, Porto, Portugal.
2011, organizer and chairman of the invited session entitled “the nucleus, a transcription
factory” featuring Peter Fraser, Wendy Bickmore, John Stamatoyannopoulos and
Emmanouil Dermitzakis at the 12th International Congress of Human Genetics,
Montreal, Canada.
2012, debate moderator, “Genomic testing: Individual choice or at the discretion of
doctors? Controversial direct to consumer testing”, Swiss Society of Medical
Genetics Annual Meeting, Basel, Switzerland
2012, invited speaker at the Simons Foundation Autism Research Initiative (SFARI)
16p11.2 workshop, New York, NY
2012, invited speaker at the 12th Annual International GeneForum, Tartu, Estonia.
2012, chairman of the “Intellectual Disability: From Gene to Function” session at the 44th
Annual Meeting of the European Society of Human Genetics, Nuremberg,
Germany.
2012, invited speaker and chairman of the “Exobiology of Origin of life” session at the
16th Evolutionary Biology Meeting, Marseilles, France.
2013, invited speaker at the 27th meeting of the “Atualizações em Oncologia” 2013
(Advances in Oncology) and 2nd Congress of CIMAGO (Centro de Investigação
em Meio Ambiente, Genética e Oncobiologia), Coimbra, Portugal.
2013, invited speaker at the 45th Annual Meeting of the European Society of Human
Genetics, Paris, France.
2013, chairman of the “Basic mechanisms in cytogenetics and molecular genetics”
session at the 45th Annual Meeting of the European Society of Human Genetics,
Paris, France.
2013, chairman of session V of the 11th [BC]2 Basel Computational Biology Conference
“Genetic Variation + Human Health”, Basel, Switzerland.
2013, invited speaker at the Genomic Medicine in the Mediterranean (GM2) Conference,
Hersonissos, Crete, Greece.
2014, invited speaker at the RE(ACT) Congress 2014 - The 2nd International Congress
on Research of Rare and Orphan Diseases, Basel, Switzerland.
2014, invited speaker at the 9th International Meeting on Genetics of
Neurodevelopmental Disorders, Troina, Sicily, Italy.
2014, invited speaker at the HUGO Human Genome Meeting 2014 “Genome Variation
and Human Health”, Geneva, Switzerland.
2014, selected speaker at the 46th Annual Meeting of the European Society of Human
Genetics, Milan, Italy.
2014, invited speaker at the Simons Foundation Autism Research Initiative (SFARI)
workshop, New York, NY.
2014, keynote speaker at the XXIIth ACLF (Association des Cytogénéticiens de Langue
Française) Annual Meeting, Lyon, France.
2014, invited speaker at the 2nd RING14 chromosome workshop, Franciacorta. Italy.
2014, invited speaker at the ALLBIO and COST “next generation sequencing method for
identification of mutations and large structural variants”, Lausanne, Switzerland.
2014, invited speaker at the 2nd Annual Molecular Psychiatry Meeting, San Francisco,
CA.
9
2014, invited speaker at the Lyon Genomics Day (New genomics tools to study human
pathologies), Lyon, France.
2015, tutor at the 3rd European Society for Pediatric Dermatology (ESPD) Summer
School, Lausanne, Switzerland.
2015, tutor at the 8th Leena Peltonen School of Human Genomics, Hinxton, United
Kingdom.
2015, invited speaker at the Simons Foundation Autism Research Initiative (SFARI)
workshop, New York, NY.
2015, selected speaker at the 65th Annual Meeting of the American Society of Human
Genetics, Baltimore, MD.
2015, invited speaker at the 18th Congress of the Italian Society of Human Genetics
(SIGU), Rimini, Italy.
2016, invited speaker at the EPFL symposium "Personalized Health in Digital Age”,
Campus Biotech, Geneva, Switzerland.
2016, invited speaker at the « Genome Structure and Expression Workshop »,
Universidade Federal de São Paulo, São Paulo, Brazil.
2016, invited speaker at the 20th Congress of the Portuguese Society of Human
Genetics (SPGH), Coimbra, Portugal.
2016, invited speaker at the « NGS (New Generation Sequencing) Benelux
Conference », Vrije Universiteit Brussels, Belgium.
2017, selected speaker at the 70th Annual Meeting of the European Society of Human
Genetics, Copenhagen, Denmark.
2017, invited speaker at the Dutch Society of Human Genetics (NVHG) annual meeting,
Veldhoven, The Netherlands.
2018, invited speaker at the annual meeting of the Swiss Society for Neuroscience,
Zurich, Switzerland.
2018, invited speaker at the 13th International Meeting on Genetics of
Neurodevelopmental Disorders, Troina, Sicily, Italy.
2018, invited speaker at the 18th annual conference “BioInformatics in Torun – BIT18”,
Torun, Poland.
2018, invited speaker at the 7th “Building Bridges Symposium: Large scale Sequencing
Initiatives and Precision Medicine in Clinical and Translational Research”,
Helsinki, Finland.
2018, tutor at the 11th Leena Peltonen School of Human Genomics, Les Diablerets,
Switzerland.
2019, invited speaker at the « Multiomics » 3rd Thursdays of Necker-Enfants malades,
Institut Imagine, Paris, France.
2019, invited speaker at the 3rd biennial International Convention of Psychological
Science (ICPS), Paris, France.
2019, invited speaker at the International Society for Autism Research (INSAR) Annual
Meeting, Montreal, Canada.
2019, invited speaker at the Iranian-Swiss Workshop on Mental Health Diseases,
Winterthur, Switzerland.
2019, invited speaker at the 12th European Cytogenetics Conference, Salzburg, Austria.
2019, tutor at the 12th Leena Peltonen School of Human Genomics, Les Diablerets,
Switzerland.
10
2019, selected speaker at the 19th International Workshop on Fragile X and other
Neurodevelopmental Disorders, Sorrento, Italy.
2019, invited speaker at the 33rd congress of the International Mammalian Genome
Society (IGMS), Strasbourg, France.
2019, invited speaker at the Swiss Genomics Forum, Geneva, Switzerland.
2019, invited speaker at the 3rd IGEE (Integrative analyses of Gene Expression and the
Epigenome) Symposium: Human Genetics and Neurodevelopment, Strasbourg,
France.
2019, invited speaker at the Alumni Meeting to celebrate the 25th Anniversary of the
Telethon Institute of Medicine (TIGEM), Pozzuoli, Naples, Italy.
2020, selected speaker at the 10th « Assises de Génétique humaine et médicale »,
Tours, France.
2020, invited speaker at the joint 4th IRDiRC Conference (International Rare Diseases
Research Consortium Conference) and 6th RE(ACT) Congress (International
Congress on Research of Rare and Orphan Diseases), Berlin, Germany.
2020, invited speaker, Séminaires Pierre Royer, Paris, France.
Invited Lectures (departmental seminars)
1993, Fred Hutchinson Cancer Research Center, Seattle, WA
1993, The Scripps Research Institute, San Diego, CA
1993, Department of Genetics and Development, Columbia University College of
Physicians and Surgeons, New York, NY
1993, Department of Embryology, Carnegie Institution of Washington, Baltimore, MD
1993, Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
1993, Department of Biochemistry, University of Wisconsin-Madison, Madison, WI
1995, Department of Genetics, Harvard Medical School, Boston, MA
1997, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges,
Switzerland
1997, Friedrich Miescher Institute, Basel, Switzerland
1997, Institute of Biochemistry, University of Fribourg, Fribourg, Switzerland.
1997, Ares-Serono, Plan-Les-Ouates, Switzerland
1997, Institut de Biologie Animale, Université de Lausanne, Lausanne, Switzerland
1999, Ecole Normale Supérieure, Lyon, France
1999, Stazione Zoologica A. Dohrn, Naples, Italy
2000, Division of Medical Genetics, University of Geneva Medical School, Geneva,
Switzerland
2000, Institute of Biochemistry and Molecular Biology, University of Berne, Berne,
Switzerland
2000, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges,
Switzerland
2000, Institut de Biologie Animale, Université de Lausanne, Lausanne, Switzerland
2002, Genetic Department, INSERM U533, Faculté de Médecine, Université de Nantes,
France
2003, Department of Genetics, INSERM U393, Hôpital Necker Enfants Malades, Paris,
France
11
2003, Section de Biologie, Faculté des Sciences, Université de Lausanne, Lausanne,
Switzerland
2003, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges,
Switzerland
2003, Molecular Science Institute, Berkeley, California
2003, Cedars-Sinai Medical Center, UCLA, Los Angeles, California
2004, Department of Biomedical Sciences and Biotechnologies, School of Medicine,
University of Brescia, Italy
2004, Faculty of Medicine Laennec, Claude Bernard University, Lyon, France
2004, Universität-Kinderspital beider Basel (UKBB), Basel University, Basel, Switzerland
2005, Zoological Institute, University of Bern, Bern, Switzerland
2006, Faculty of Psychology and Education Sciences, University of Geneva, Geneva,
Switzerland
2006, Department of Genetic Medicine and Development, University of Geneva Medical
School, Geneva, Switzerland
2007, Department of Medical Genetics, University of Lausanne, Switzerland
2007, TIGEM (Telethon Institute of Genetics and Medicine), Naples, Italy
2007, Medical Genetics Service, IRCCS "Casa Sollievo della Sofferenza", San Giovanni
Rotondo, Italy
2007, Institute of Medical Genetics, University of Zurich, Schwerzenbach, Switzerland
2007, webinar, Affymetrix Inc., Santa Clara, California
2007, Department of Pathology, University of Lausanne, Lausanne, Switzerland
2008, Department of Molecular Biology, University of Siena, Siena, Italy
2008, Laboratoire de Biométrie et Biologie Evolutive (UMR 5558), CNRS, Université
Lyon 1, Villeurbanne, France.
2008, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg,
Switzerland.
2009, Babraham Institute, Cambridge, United Kingdom.
2009, Center for Comparative Genomics and Bioinformatics, Penn State University,
University Park, PA.
2009, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford,
United Kingdom
2009, National Institute of Environmental Health Sciences (NIEHS), Research Triangle
Park, NC.
2010, John P. Hussman Institute for Human Genomics, University of Miami Miller School
of Medicine, Miami, FL.
2011, Department of Genetic Medicine and Development, University of Geneva Medical
School, Geneva, Switzerland
2011, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2011, Swiss Institute of Bioinformatics, Lausanne, Switzerland
2011, CHU Sainte-Justine Research Center, Montreal, Canada
2011, Faculty of Medicine, University of Coimbra, Portugal
2012, Department of Dermatology, University of Lausanne
2012, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France
2013, Lithuanian Academy of Sciences, Vilnius, Lithuania
2013, Human Brain Seminars, LREN (Laboratoire de recherche en neuroimagerie),
University of Lausanne
12
2015, Life Science Symposium Series, EPFL, Lausanne, Switzerland
2015, Utrecht University Medical Centre, Utrecht, The Netherlands.
2015, “Institut universitaire de médecine sociale et préventive (IUMPS)”, Lausanne,
Switzerland.
2016, Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
2016, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United
Kingdom.
2016, Fred Hutchinson Cancer Research Center, Seattle, WA.
2016, Department of Medical Genetics, University of Antwerp, Antwerp, Belgium.
2017, Department of Genetic Medicine, University of Geneva, Switzerland.
2017, Academisch Medisch Centrum (AMC), Amsterdam, The Netherlands.
2017, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.
2017, Smurfit Institute of Genetics, Trinity College, Dublin, Ireland.
2017, Mount Sinai Hospital, New York, NY.
2017, Estonian Genome Center, University of Tartu, Tartu, Estonia.
2017, The European Bioinformatics Institute (EBI), Hinxton, Cambridge, UK.
2018, TIGEM (Telethon Institute of Genetics and Medicine), Naples, Italy.
2018, CEINGE - Biotecnologie Avanzate, Naples, Italy.
2018, Institute of Genetics and Biophysics "Adriano Buzzati-Traverso", National
Research Council (CNR), Naples, Italy.
2019, Center for Human Disease Modeling, Duke University, Durham, NC.
2019, Department of Genetic Medicine and Development, University of Geneva Medical
School, Geneva, Switzerland.
2019, Academisch Medisch Centrum (AMC), Amsterdam, The Netherlands.
2019, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical
School, Boston, MA.
2019, Department of Molecular and Human Genetics, Baylor College of Medicine,
Houston, TX.
2019, Department of Psychiatry, University of Geneva Medical School, Geneva,
Switzerland.
2019, Institute of Genomics, University of Tartu, Estonia.
2019, Génétique des Anomalies du Développement, CHU Dijon, Dijon, France
2019, Department of Genetics, Hôpital Femme Mère Enfant, Lyon Bron, France
2020, Department of Human Genetics, Radboud University Medical Center, Nijmegen,
the Netherlands.
Teaching Experience
2000 Member, “DEA/DGI course”, entitled “Analysis and Manipulation of protein
interactions”, Ecole Normale Supérieure de Lyon, Lyon, France.
1998-2000 Member, Human Genetics Course for TIGEM (Telethon Institute of
Genetics and Medicine) graduate students.
2000-2004 Member, course to 2nd year University of Geneva Medical School students
on Human Reproduction and Genetics (Problem-based learning)
2000-2002 Member, Human Genetics course for University of Geneva 3rd year biology
students, University of Geneva Medical School
13
2003-2004 Organizer, Human Genetics course for University of Geneva 3rd year
biology students, University of Geneva Medical School
2005-2007 Member, Human Genetics course for University of Geneva 3rd year biology
students, University of Geneva Medical School
2005-2009 Member, Genome to Phenome course for University of Lausanne 3rd year
B.Sc. biology students.
2005-curr. Organizer, Evolutionary and Comparative Genomics course for University
of Lausanne M.Sc. biology students.
2005-curr. Chair of the Genetics/Genomics teaching track of the University of
Lausanne biology students.
2006-2010 Member, Statistics for Biologists course for University of Lausanne 2th year
B.Sc. biology students.
2006-curr. Member, SIB-CIG (Swiss Institute of Bioinformatics – Center for Integrative
Genomics) Workshops for University of Lausanne and Swiss Institute of
Technology graduate students.
2006-2011 Member, Functional Genomics course for Swiss Institute of Technology
graduate students.
2010-curr. Organizer and/or Member, Genetics and Genome Evolution module for
University of Lausanne 3rd year B.Sc. biology students.
2010-curr. Member, “Genetics today: societal and scientific challenges” optional
course for University of Lausanne Humanities and Social Sciences
students.
2011 Member, Doctoral Program in Health Sciences, University of Coimbra,
Portugal.
2012-curr. Member, Swiss postgraduate training program in medical genetics
(FMH/FAMH medical genetics specialty).
14
Alumni
Emilie Aït-Yahya Graison2, Ali Alfaiz1, Thomas Arbogast2, Catia Attanasio2, Chiara
Auwerx1, Sissy Bassani1, Adriana Di Battista1, Bastien Braillard3, Anna Moreno Bernat4,
Stefano Cairo2, Evelyne Chaignat1, Nicolas Chatron1, Jacqueline Chrast5, Gérard
Didelot2, Seda Ekizoglu3, Véronique Falciola3, Anne-Maud Ferreira1, Marc Friedli4, Nele
Gheldof2, Giuliana Giannuzzi2, Andreas Gschwind1, Lucie Gueneau2, Louise Amanda
Jane Harewood2, Charlotte Neergaard Hor Henrichsen1,4, Isabel Herr3, Cédric
Howald1,4, Sébastien Jacquemont8, Berit Kolk4, Christine Lamon4, Maria Nicla Loviglio1,
Katrin Männik2, Francesca Mattioli2, Véronique Menoni4, Olivier Menzel4,2, Giuseppe
Merla2, Eugenia Migliavacca7, Anna Mikhaleva1, Pasquelena De Nittis1, Mariana
Moysés-Oliveira1, Leila Parand3, Konstantin Popadin2, Eleonora Porcu2, Ali Rashidi-
Nezhad1, Guénola Ricard2, Ludivine Rielle3, Léonore Rougemont4, Marie Sadler4,
Domingo Sánchez Ruiz3, Namrata Sarkar1, Evelina Siavrienė1, Léonard Studer7,
Fabrizia Urbinati4, Catherine Ucla5, Kristina Ushakova3, Norine Voisin1, Faida Walha4,
Robert Witwicki1, Carine Wyss5, Nathalie Walters6, Ilse van der Werf4, Florence
Winteler4, Helen Whitley4, Michaël Wiederkehr5, Binnaz Yalcin2, Marianna Zazhytska1
1
Graduate students, 2Postdoctoral fellows, 3Students on laboratory rotations,
4
Undergraduate students, 5Technician, 6Technician in training, 7Data analyst, 8MD-
PhD graduate student
Selected Lectures of Alumni / Awards and Fellowships received by Alumni
2006-08, Gérard Didelot, FRM (Fondation pour la Recherche Médicale) fellow
2007-10, Robert Witwicki, UNIL PhD FBM fellow.
2007, Louise Harewood, selected speaker at the 57th Annual Meeting of the American
Society of Human Genetics, San Diego, CA.
2008, Guénola Ricard, selected speaker at the 58th Annual Meeting of the American
Society of Human Genetics, Philadelphia, PA.
2008, Louise Harewood, selected speaker at the “1st anEUploidy workshop“, Geneva,
Switzerland.
2009-2010, Nele Gheldof, Swiss National Science Foundation, Marie Heim-Vögtlin
fellow.
2009, Charlotte Henrichsen, selected speaker at the 3rd Wellcome Trust Scientific
Conference “Genomic Disorders 2009, Genomic Variation in Health and Disease”,
Hinxton, UK.
2009, Louise Harewood, selected speaker at the Lausanne Life Sciences Festival
“Genetics, Epigenetics and Development”, Lausanne, Switzerland.
2009, Evelyne Chaignat, selected speaker at the 42nd Annual Meeting of the European
Society of Human Genetics, Vienna, Austria.
2009, Louise Harewood, selected speaker and recipient of the ESHG Young Investigator
award at the 42nd Annual Meeting of the European Society of Human Genetics,
Vienna, Austria.
2009, Louise Harewood, selected speaker and recipient of an ASHG Travel award at the
59th Annual Meeting of the American Society of Human Genetics, Honolulu, HI.
2009, Charlotte Henrichsen was awarded the "Prix d'Excellence du jeune chercheur" by
the Dean of the Faculty of Biology and Medicine, University of Lausanne.
15
2009, Charlotte Henrichsen was granted a Swiss National Science Foundation young
research fellowship for her postdoctoral studies.
2010-12, Emilie Aït-Yahya Graison, Marie Curie fellow
2010-12, Binnaz Yalcin, EMBO long-term fellow.
2010, Louise Harewood, selected speaker for the plenary session and recipient of the
ESHG Young Investigator award at the 43rd Annual Meeting of the European
Society of Human Genetics, Gothenburg, Sweden.
2010, Nele Gheldof, selected speaker at the 43rd Annual Meeting of the European
Society of Human Genetics, Gothenburg, Sweden.
2010, Guénola Ricard, selected speaker at the EMBO/EMBL Symposium, Human
Variation: Cause and Consequence, Heidelberg, Germany.
2010, Charlotte Henrichsen, selected speaker at the 2nd anEUploidy workshop, Split,
Croatia.
2010, Louise Harewood, selected speaker at the 2nd anEUploidy workshop, Split,
Croatia.
2010, Emilie Aït-Yahya Graison, selected speaker at the Wellcome Trust Scientific
Conference “Genome Informatics”, Hinxton, UK.
2010, Guénola Ricard, selected speaker and recipient of an ASHG Travel award at the
60th Annual Meeting of the American Society of Human Genetics, Washington, DC.
2011-12, Katrin Männik, Sciex (Swiss exchange Program) fellow.
2011-12, Nele Gheldof, University of Lausanne Faculty of Biology and Medicine, Pro-
Women scientist fellow.
2011-14, Ali Alfaiz, Saudi Arabian National Guard Health Affairs fellow
2011, Robert Witwicki, selected speaker at the 44th Annual Meeting of the European
Society of Human Genetics, Amsterdam, Netherlands.
2011, Nele Gheldof, selected speaker at the 12th International Congress of Human
Genetics, Montreal, Canada.
2012-15, Binnaz Yalcin, Swiss National Science Foundation, Ambizione fellow.
2012, Cédric Howald, selected speaker at the 2012 ENCODE/modENCODE meeting,
Boston, MA.
2012, Cédric Howald, selected speaker and recipient of the ESHG Young Investigator
award at the 44th Annual Meeting of the European Society of Human Genetics,
Nuremberg, Germany.
2012, Katrin Männik, selected to participate in and speaker at the Leena Peltonen
School of Human Genomics, Cambridge, United Kingdom.
2012, Eugenia Migliavacca, selected speaker at the 62th Annual Meeting of the
American Society of Human Genetics, San Francisco, CA.
2013-2016, Marianna Zazhytska, UNIL PhD FBM fellow.
2013, Katrin Männik, selected speaker at the 46th Annual Meeting of the European
Society of Human Genetics, Paris, France.
2013, Andreas Gschwind, selected speaker at the 46th Annual Meeting of the European
Society of Human Genetics, Paris, France.
2013, Emilie Aït-Yahya Graison, selected speaker at the 63rd Annual Meeting of the
American Society of Human Genetics, Boston, MA.
2013, Emilie Aït-Yahya Graison, ASHG/Charles J. Epstein Trainee Award for Excellence
in Human Genetics Research – Semifinalist.
16
2013, Maria Nicla Loviglio, selected speaker and recipient of an ESHG travel award at
the Genomic Medicine in the Mediterranean (GM2) Conference, Hersonissos,
Crete, Greece.
2013, Maria Nicla Loviglio, plenary session selected speaker at the 63rd Annual Meeting
of the American Society of Human Genetics, Boston, MA.
2013, Maria Nicla Loviglio, ASHG/Charles J. Epstein Trainee Award for Excellence in
Human Genetics Research – Finalist.
2013, Katrin Männik, selected speaker at the CSHL Meeting - Precision Medicine:
Personal Genomes & Pharmacogenomics, Cold Spring Harbor, NY.
2013, Cédric Howald was awarded the "Prix de Faculté” by the Dean of the Faculty of
Biology and Medicine, University of Lausanne.
2013, Cédric Howald was granted a Swiss National Science Foundation young research
fellowship for his postdoctoral studies.
2013, Katrin Männik, selected speaker at the 8th Wellcome Trust Scientific Conference
“Genomic Disorders 2014, The Genomic of Rare Diseases”, Cambridge, UK.
2014, Maria Nicla Loviglio, selected speaker at the 47th Annual Meeting of the European
Society of Human Genetics, Milan, Italy.
2014, Binnaz Yalcin, selected speaker at the 6th meeting of the international society of
hydrocephalus and CSF disorders, Bristol, UK.
2014, Binnaz Yalcin, selected speaker at the 28th International Mammalian Genome
Conference (IMGC), Bar Harbor, ME.
2014, Anna Mikhaleva, selected speaker at the CSHL Meeting - Personal Genomes:
Discovery, Treatment & Outcomes, Cold Spring Harbor, NY.
2015, Binnaz Yalcin, selected speaker at the 2nd International Gencodys Conference,
“Integrative Networks in Intellectual Disabilities”, Chania, Crete, Greece.
2015, Katrin Männik, selected speaker at the 9th Wellcome Trust Scientific Conference
Genomics of Rare Disease: Beyond the Exome, Hinxton, United Kingdom.
2015, Norine Voisin, selected speaker at the 10th International Meeting on Genetics of
Neurodevelopmental Disorders, Troina, Sicily, Italy.
2015, Maria Nicla Loviglio, selected speaker at the 48th Annual Meeting of the European
Society of Human Genetics, Glasgow, United Kingdom.
2015, Giuliana Giannuzzi, selected speaker at the 48th Annual Meeting of the European
Society of Human Genetics, Glasgow, United Kingdom.
2015, Anna Mikhaleva, selected speaker at the 48th Annual Meeting of the European
Society of Human Genetics, Glasgow, United Kingdom.
2015, Andreas Gschwind, travel grant to attend the Practical Summer Course “Modeling
for Systems Biology”, CRG, Barcelona.
2015-17, Giuliana Giannuzzi, University of Lausanne Faculty of Biology and Medicine,
Pro-Women scientist fellow.
2015, Maria Nicla Loviglio, recipient of an EMBO short-term fellowship award to visit the
laboratories of Christelle Golzio and Nico Katsanis, Duke University, NC.
2015, Binnaz Yalcin, selected speaker at the 65th Annual Meeting of the American
Society of Human Genetics, Baltimore, MA.
2015, Katrin Männik, selected speaker at the 65th Annual Meeting of the American
Society of Human Genetics, Baltimore, MA.
2015, Maria Nicla Loviglio, selected speaker at the 65th Annual Meeting of the American
Society of Human Genetics, Baltimore, MA.
17
2015, Elena De Nittis, selected speaker at the 18th Congress of the Italian Society of
Human Genetics (SIGU), Rimini, Italy.
2015, Andreas Gschwind, selected speaker at the Wellcome Trust Scientific Conference
“Functional Genomics and Systems Biology: From Model Organisms to Human
Health”, Cambridge, UK.
2016, Katrin Männik, invited speaker at the 11th International Meeting on Genetics of
Neurodevelopmental Disorders, Troina, Sicily, Italy..
2016, Binnaz Yalcin, invited speaker at the 11th International Meeting on Genetics of
Neurodevelopmental Disorders, Troina, Sicily, Italy.
2016, Konstantin Popadin, selected speaker at 13th International Congress of Human
Genetics (ICHG2016), Kyoto, Japan.
2016-2017, Catia Attanasio, Swiss National Science Foundation, Marie Heim-Vögtlin
fellow.
2016, Maria Nicla Loviglio, selected speaker at the 49th Annual Meeting of the European
Society of Human Genetics, Barcelona, Spain.
2016, Giuliana Giannuzzi, selected speaker at the 49th Annual Meeting of the European
Society of Human Genetics, Barcelona, Spain.
2016, Konstantin Popadin, selected speaker at the 49th Annual Meeting of the European
Society of Human Genetics, Barcelona, Spain.
2016, Anne-Maud Ferreira, selected speaker at the 49th Annual Meeting of the
European Society of Human Genetics, Barcelona, Spain.
2016, Katrin Männik, selected speaker at the 49th Annual Meeting of the European
Society of Human Genetics, Barcelona, Spain.
2016, Maria Nicla Loviglio, recipient of the Isabelle Oberlé award at the 49th Annual
Meeting of the European Society of Human Genetics, Barcelona, Spain.
2016, Anna Mikhaleva, selected speaker at the 10th Anniversary of the Joint Master in
Neuroscience, 29-30th of September, Strasbourg
2016, Elena De Nittis, selected speaker at the 66th Annual Meeting of the American
Society of Human Genetics, Vancouver, Canada.
2016, Maria Nicla Loviglio, selected speaker at the 66th Annual Meeting of the American
Society of Human Genetics, Vancouver, Canada.
2016, Norine Voisin, selected speaker at the 66th Annual Meeting of the American
Society of Human Genetics, Vancouver, Canada.
2016, Norine Voisin, ASHG/Charles J. Epstein Trainee Award for Excellence in Human
Genetics Research – Semifinalist.
2016, Elena De Nittis, ASHG/Charles J. Epstein Trainee Award for Excellence in Human
Genetics Research – Semifinalist.
2016, Elena De Nittis, selected speaker at the 19th Congress of the Italian Society of
Human Genetics (SIGU), Turin, Italy.
2016, Maria Nicla Loviglio was granted a Swiss National Science Foundation young
research fellowship for her postdoctoral studies.
2016, Andreas Gschwind was granted a Swiss National Science Foundation young
research fellowship for his postdoctoral studies.
2016, Elena De Nittis, received the "Leopoldo Zelante award for genetic research" for
her presentation at the 19th Congress of the Italian Society of Human Genetics
(SIGU), Turin, Italy.
2017-2019, Katrin Männik, Jacobs Foundation Research fellow.
18
2017, Katrin Männik, selected speaker at the 2017 annual clinical genetics meeting of
the ACMG (American College of Medical Genetics and Genomics), Phoenix, AZ.
2017, Elena De Nittis, selected speaker at the ePerMed workshop, Lausanne,
Switzerland.
2017, Giuliana Giannuzzi, selected speaker at the ePerMed workshop, Lausanne,
Switzerland.
2017, Eleonora Porcu, selected speaker at the ePerMed workshop, Lausanne,
Switzerland.
2017, Eleonora Porcu, selected speaker at the European Mathematical Genetics
Meeting 2017, Tartu, Estonia.
2017, Norine Voisin, selected speaker at the 50th Annual Meeting of the European
Society of Human Genetics, Copenhagen, Denmark.
2017, Lucie Gueneau, selected speaker at the 50th Annual Meeting of the European
Society of Human Genetics, Copenhagen, Denmark.
2017, Mariana Moysés-Oliveira, selected speaker at the 11th European Cytogenetics
Conference, Florence, Italy.
2017, Norine Voisin, recipient of one of the four ESHG Young Investigator Awards at the
50th Annual Meeting of the European Society of Human Genetics, Copenhagen,
Denmark.
2017, Eleonora Porcu, selected speaker at the [BC]2 Basel Computational Biology
Conference, Basel, Switzerland.
2017, Konstantin Popadin, selected speaker at the 67th Annual Meeting of the American
Society of Human Genetics, Orlando, FL.
2017, Maria Nicla Loviglio was awarded the "Prix de Faculté” by the Dean of the Faculty
of Biology and Medicine, University of Lausanne.
2018, Konstantin Popadin, selected speaker at the 51th Annual Meeting of the European
Society of Human Genetics, Milan, Italy.
2018, Katrin Männik, selected speaker at the 51th Annual Meeting of the European
Society of Human Genetics, Milan, Italy.
2018, Eleonora Porcu, selected speaker at the 51th Annual Meeting of the European
Society of Human Genetics and recipient of one of the fellowship of Excellence for
Young Investigators, Milan, Italy.
2018, Eleonora Porcu, recipient of the Lodewijk Sandkuijl award for best presentation in
statistical genetics at the 51th Annual Meeting of the European Society of Human
Genetics, Milan, Italy.
2018, Eleonora Porcu, selected speaker at the European Mathematical Genetics
Meeting, Cagliari, Italy.
2018, Maria Nicla Loviglio was granted the Guenin Award 2018 for best thesis defended
at the Center for Integrative Genomics, University of Lausanne in 2016-2017.
2018, Katrin Männik, selected speaker at the 68th Annual Meeting of the American
Society of Human Genetics, San Diego, CA.
2018, Eleonora Porcu, selected speaker at the 68th Annual Meeting of the American
Society of Human Genetics, San Diego, CA.
2019, Katrin Männik, invited speaker at the Genomics of Rare Disease meeting,
Welcome Genome Campus, Hinxton, UK.
2019, Elena De Nittis, selected speaker at the Swiss Society of Medical Genetics annual
meeting.
19
2019, Eleonora Porcu, selected speaker at the 47th European Mathematical Genetics
Meeting, Dublin, Ireland.
2019, Thomas Arbogast, selected speaker at the SwissZebra meeting, Leukerbad,
Switzerland.
2019, Olivier Delaneau, selected speaker for the plenary session of the 52nd Annual
Meeting of the European Society of Human Genetics, Gothenburg, Sweden.
2019, Elena De Nittis, selected speaker at the 52nd Annual Meeting of the European
Society of Human Genetics, Gothenburg, Sweden.
2019, Adriana Di Battista, selected speaker at the 12th European Cytogenetics
Conference, Salzburg, Austria.
2019, Elena De Nittis, selected to participate in and speaker at the Leena Peltonen
School of Human Genomics, Les Diablerets, Switzerland.
2019, Eleonora Porcu recipient of the Swiss Institute of Bioinformatics Early Career
Bioinformatician Award.
2019, Eleonora Porcu, selected speaker at the 69th Annual Meeting of the American
Society of Human Genetics, Houston, TX.
2019, Elena De Nittis, selected speaker at the MedLem19 (Medical Research in the
Lemanic region) Meeting, Lausanne, Switzerland.
2019, Giuliana Giannuzzi, selected speaker at the 22nd Congress of the Italian Society of
Human Genetics (SIGU), Rome, Italy.
2019, Giuliana Giannuzzi received the "Franca Dagna Bricarelli award” for best
presentation in cytogenetics at the 22nd Congress of the Italian Society of Human
Genetics (SIGU), Rome, Italy.
2019, Giuliana Giannuzzi was awarded a "Germaine de Staël" France-Switzerland
collaboration award.
2020, Eleonora Porcu, invited speaker at the Genomics of Brain Disorders, Wellcome
Genome Campus Advanced Courses, Hinxton, UK.
2020, Eleonora Porcu, selected speaker for the “PIs of tomorrow” session at the LS2
(Life Sciences Switzerland) meeting, Zurich, Switzerland.
20
List of Publications
H-factor of 56 and 68 according to web of science and Googlescholar, respectively.
Original research manuscripts (peer-reviewed)
1. Marks, J., Fankhauser, C., Reymond, A. & Simanis, V., Cytoskeletal and DNA
structure abnormalities result from bypass of requirement for the cdc10 start gene in
fission yeast Schizosaccharomyces pombe, J Cell Sci 101, 1992, 517-528.
2. Reymond, A., Schmidt, S. & Simanis, V., Mutations in the cdc10 start gene of
Schizosaccharomyces pombe implicate the homologous region of cdc10 and SWI6
as important for p85cdc10 function, Mol Gen Genet 234, 1992, 449-456.
3. Fankhauser, C., Marks, J., Reymond, A. & Simanis, V., The S. pombe cdc16 gene is
required both for maintenance of p34cdc2 kinase activity and regulation of septum
formation: a link between mitosis and cytokinesis?, EMBO J 12, 1993, 2697-2704.
4. Reymond, A., Marks, J. & Simanis, V., The activity of the S. pombe DSC1-like factor
is cell cycle regulated and dependent upon the activity of p34cdc2, EMBO J 12, 1993,
4325-4334.
5. Reymond, A. & Simanis, V., Domains of p85cdc10 required for function of the fission
yeast DSC1-like factor, Nucleic Acids Res 21, 1993, 3615-3621.
6. Reymond, A. & Zuchuat, O. Axial migration routes in Cormorants Phalacrocorax
carbo passing through or wintering in Switzerland, Ardea 83, 1995, 275-280.
7. Reymond, A. & Zuchuat, O., Perch Fidelity of cormorants Phalacrocorax carbo
outside the breeding season, Ardea 83, 1995, 281-284.
8. Fankhauser, C., Reymond, A., Cerutti, L., Utzig, S., Hofmann, K. & Simanis, V., The
S. pombe cdc15 gene is a key element in the reorganization of F-actin at mitosis,
Cell 82, 1995, 435-444.
9. Reymond, A. & Brent, R., p16 proteins from melanoma-prone families are deficient
in binding to cdk4, Oncogene 11, 1995, 1173-1178.
10. Meroni*, G., Reymond*, A., Alcalay, M., Borsani., G., Tanigami, A., Tonlorenzi, R.,
Lo Nigro, C., Messali, S., Zollo, M., Ledbetter, D.H., Brent, R., Ballabio, A. &
Carrozzo, R., Rox, a novel bHLHZip protein expressed in quiescent cells that
heterodimerizes with Max, binds non-canonical E box and acts as a transcriptional
repressor, EMBO J 16, 1997, 2892-2906.*The two first authors contributed
equally to this work
11. Lo Nigro, C., Venesio, T., Reymond, A., Meroni, G., Alberici, P., Cainarca, S.,
Enrico, F., Stack, M., Ledbetter, D.H., Liscia, D.S., Ballabio, A. & Carrozzo, R., The
21
Human Rox Gene: Genomic structure and Mutation Analysis in Human Breast
Tumors, Genomics 49, 1998, 275-282.
12. Fusco, C., Reymond, A. & Zervos, A.S., Molecular cloning and characterization of a
novel Retinoblastoma-binding protein, Genomics 51, 1998, 351-358.
13. Reymond, A., Volorio, S., Merla, G., Al-Maghtheh, M., Zuffardi, O., Bulfone, A.,
Ballabio, A. & Zollo, M., Evidence for interaction between human PRUNE and nm23-
H1 proteins: implications for the progression of neuroblastoma, Oncogene 18, 1999,
7244-252
14. Meroni, G, Cairo, S., Merla, G., Messali, S., Brent, R., Ballabio, A. & Reymond, A.,
Mlx, a new Max-like bHLHZip family member: the center stage of a novel
transcription factors regulatory pathway?, Oncogene 19, 2000, 3266-3277.
15. Cairo, S., Merla, G., Urbinati, F., Ballabio, A. & Reymond, A., WBSCR14, a gene
mapping to the Williams-Beuren syndrome deleted region, is a new member of the
Mlx transcription factor network, Hum Mol Genet 10, 2001, 617-627.
16. Reymond*, A., Meroni*, G., Merla, G., Fantozzi, A., Cairo, S., Riganelli, D., Zanaria,
E., Messali, S., Luzi L., Guffanti, A., Cainarca, S., Minucci, S., Pelicci, P.G. &
Ballabio, A., The TRIM Motif family identifies cell compartments, EMBO J 20 (9),
2001, 2140-2151.
*The two first authors contributed equally to this work
17. Forus A., D'Angelo, A., Henriksen, J., Merla, G., Gunhild M. Maelandsmo, G.M.,
Flørenes, V.A., Olivieri, S., Bjerkehagen, B., Meza-Zepeda, L.A., Del Vecchio Blanco,
F., Sanvito, F., Kononem, J., Nesland, J.M., Fodstad, Ø., Reymond, A., Kallioniemi,
O.P., Arrigoni, G., Ballabio, A., Myklebos, O. & Zollo., M., Amplification and
overexpression of PRUNE in human sarcomas and breast carcinomas – a possible
mechanism for altering the nm23-H1 activity, Oncogene 20, 2001, 6881-6890.
18. Guipponi, M,, Tapparel, C., Jousson, O., Scamuffa, N., Mas, C., Rossier, C., Hutter,
P., Meda, P., Lyle, R., Reymond, A. & Stylianos E. Antonarakis, The murine
orthologue of the Golgi localized TPTE protein provides clues to the evolutionary
history of human TPTE gene family, Hum Genet 109, 2001, 569-575.
19. Reymond, A., M. Friedli, M., Henrichsen, C.N., Chapot, F., Deutsch, S., Ucla, C.,
Rossier, C., Lyle, R., Guipponi, M., Antonarakis, S.E., From PREDs and Open
Reading Frames to cDNA Isolation: Revisiting the Human Chromosome 21,
Transcription Map, Genomics 78, 2001, 46-54.
20. Merla, G., Ucla, C., Guipponi, M. & Reymond, A., Identification of additional
transcripts in the Williams-Beuren syndrome critical region, Hum Genet 110, 2002,
429-438.
22
21. Reymond*, A., Camargo*, A.A, Deutsch*, S., Stevenson*, B.J., Parmigiani R.B.,
Ucla, C., Bettoni, F., Rossier, C., Lyle, R., Guipponi, M., de Souza, S., Iseli, C,
Jongeneel C.V., Bucher, P., Simpson A.J.G. & Antonarakis, S.E., Nineteen additional
unpredicted transcripts from the human chromosome 21, Genomics 79, 2002, 824-
32.
*These authors contributed equally to this work
22. Berti, C., Messali, S., Ballabio, A., Reymond, A. & Meroni, G. TRIM9 is specifically
expressed in the central nervous system during mouse development, Mech Dev 113,
2002, 159-162.
23. Guipponi, M., Vuagniaux, G., Wattenhofer, M., Shibuya, K., Vazquez, M., Dougherty,
L., Scamuffa, N., Guida, E., Okui, M., Kudoh, J., Rossier, C., Hancock M., Buchet, K.,
Reymond, A., Hummler, E., Marzella, P.L., Shimizu, N., Scott, H.S., Antonarakis,
S.E. and Rossier, B.C., The transmembrane serine protease (TMPRSS3) mutated in
deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro, Hum
Mol Genet 11, 2002, 2829-2836.
24. Reymond*, A., Marigo*, V., Yaylaoglu*, M.B., Leoni, A., Ucla, C., Scamuffa, N.,
Caccioppoli, C., Dermitzakis, E.T., Lyle, R., Banfi, S., Eichele, G., Antonarakis, S.E.
& Ballabio, A., Human chromosome 21 gene expression atlas in the mouse, Nature
420, 2002, 582-586.
*These authors contributed equally to this work
25. Dermitzakis, E.T., Reymond, A., Lyle, R., Scamuffa, N., Ucla, C., Deutsch, S.,
Stevenson, B.J., Flegel, V., Bucher, P., Jongeneel C.V. & Antonarakis, S.E.,
Numerous potentially functional but non-genic conserved sequences on human
chromosome 21, Nature 420, 2002, 578-582.
26. Waterston R.H. & 225 authors including Reymond, A., Initial sequencing and
comparative analysis of the mouse genome, Nature 420, 2002, 520-562.
27. Guigo, R., Dermitzakis, E.T., Agarwal, P., Ponting, C.P., Parra, G., Reymond, A.,
Abril, J.F., Keibler, E., Lyle, R., Ucla, C., Antonarakis, S.E. & Brent, M.R.,
Comparison of mouse and human genomes followed by experimental verification
yields an estimated 1,019 additional genes, Proc Natl Acad Sci USA 100, 2003,
1140-1145.
28. Friedli, M., Guipponi, M., Bertrand, S., Bertrand, D., Neerman-Arbez, M.,
Antonarakis, S.E. & Reymond, A., Identification of CLIC6, a novel member of the
CLIC family, Gene 320, 2003, 31-40.
29. Frederiksen, M., Bregnballe, T. & Reymond, A., Estimating turnover at a staging
site: how many Great Cormorants Phalacrocorax carbo sinensis used the Lake
Geneva roost in autumn 1987?, Vogelwelt 124(suppl.), 2003, 123-125.
23
30. Dermitzakis*, E.T., Reymond*, A., Scamuffa, N., Ucla, C., Rossier, C. &
Antonarakis, S.E., Evolutionary Discrimination of Mammalian Conserved Non-Genic
Sequences (CNGs), Science 302, 2003, 1033-1035
*These authors contributed equally to this work
31. Tapparel, C., Reymond, A., Girardet, C., Guillou, L., Lyle, R., Hutter, P. &
Antonarakis, S.E., The TPTE gene family: cellular expression, subcellular localization
and alternative splicing, Gene 323, 2003, 189-199.
32. Menzel*, O., Bekkeheien*, R., Reymond*, A., Fukai, N., Kosztolanyi, G., Aftimos, S.,
Deutsch, S., Scott, H.S., Olsen, B.J., Antonarakis, S.E. & Guipponi, M., Knobloch
syndrome: novel mutations in COL18A1 and evidence for genetic heterogeneity,
Hum Mutat 23, 2004, 77-84.
*These authors contributed equally to this work
33. Dermitzakis, E.T., Kirkness, E., Schwarz, S., Blanco, E., Birney, E, Reymond, A. &
Antonarakis, S.E., Selective constraint of Conserved Non-Genic (CNG) sequences
on human chromosome 21 is independent of the genic environment. Genome Res
14, 2004, 852-859.
34. Menzel, O., Vellai, T., Takacs-Vellai, K., Reymond, A., Mueller, F., Antonarakis, S.E.
& Guipponi, M., The Caenorhabditis elegans ortholog of C21orf80, a potential new
protein O-fucosyltransferase, is required for normal development, Genomics 84,
2004, 320-330.
35. Merla, G., Howald, C., Antonarakis, S.E., & Reymond, A., The subcellular
localization of the ChoRE binding protein, encoded by the Williams-Beuren
Syndrome Critical Region gene 14, is regulated by 14-3-3, Hum Mol Genet 13, 2004,
1505-1514.
36. The ENCODE Project Consortium including Reymond, A., The ENCODE
(ENCyclopedia Of DNA Elements) Project, Science 22, 2004, 636-40.
37. International Chicken Genome Sequencing Consortium (ICGSC) including
Reymond, A., Sequence and comparative analysis of the chicken genome provide
unique perspectives on vertebrate evolution, Nature 432, 2004, 695-716.
38. Eyras, E., Reymond, A., Castelo, R., Bye, J.M., Camara, F., Flicek, P., Elizabeth J.
Huckle, E.J, Parra, G., Shteynberg, D.D., Wyss, C., Rogers, J., Antonarakis, S.E.,
Birney, E., Guigo, R. & Brent, M.R., Gene finding in the chicken genome, BMC
Bioinformatics 6, 2005, 131.
39. Wattenhofer, M., Reymond, A., Falciola, V., Charollais, A., Caille, D., Borel, C., Lyle,
R., Estivill, X., Petersen, M.B., Meda, P. & Antonarakis, S.E., Different mechanisms
preclude mutant CLDN14 proteins to form tight junctions in vitro, Hum Mutat 25,
2005, 543-549.
24
40. Castelo, R., Reymond, A., Wyss, C., Camara, F., Parra, G., Antonarakis, S.E.,
Guigó, R. & Eyras, E., Comparative gene finding in chicken indicates that we are
closing in on the human gene set, Nucleic Acids Res 33, 2005, 1935-39.
41. Wattenhofer, M., Sahin-Calapoglu, N., Andreasen, D., Kalay, E, Caylan, R., Braillard,
B., Fowler-Jaeger, N., Reymond, A., Rossier, B.C., Karaguzel, A. & Antonarakis,
S.E., A novel TMPRSS3 missense mutation in a DFNB8/10 family prevents
proteolytic activation of the protein, Hum Genet 117(6), 2005, 528-35.
42. Bonafé, L., Dermitzakis, E.T., Unger, S., Greenberg, C., Xavier, B., Zankl, A., Ucla,
C., Antonarakis, S.E., Superti-Furga, A. & Reymond, A., Evolutionary comparisons
provide evidence for pathogenicity of RMRP mutations in Cartilage-Hair-Hypoplasia,
PLoS Genet 1(4), 2005, e47.
43. Mehenni, H., Lin-Marq, N., Buchet-Poyau, K., Reymond, A., Collart, M.A., Picard, D.
& Antonarakis, S.E., LKB1 interacts with and phosphorylates PTEN- a functional link
between two proteins involved in cancer predisposing syndromes, Hum Mol Genet
14, 2005, 2209-19.
44. Marques, A.C, Dupanloup, I., Vinckenbosch, N., Reymond, A. & Kaessmann, H.,
Emergence of Young Human Genes after a Burst of Retroposition in Primates, PLoS
Biol 3(11), 2005, e357.
45. Parra, G., Reymond, A., Dabbouseh, N., Dermitzakis, E.T., Antonarakis, S.E.,
Thomson, T.M. & Guigó, R., Tandem chimerism as a mean to increase protein
complexity in the human genome, Genome Res 16(1), 2006, 37-44.
46. Howald, C., Merla, G., Digilio, M.C., Amenta, S., Lyle, R., Deutsch, S., Choudhury, U,
Bottani, A., Antonarakis, S.E., Fryssira, H., Dallapiccola, B. & Reymond, A., Two
high-throughput technologies to detect segmental aneuploidies identify new Williams-
Beuren Syndrome patients with atypical deletions, J Med Genet, 43(3), 2006, 266-
73.
47. Drake, J.A., Bird, C., Nemesh, J., Thomas, D., Newton-Cheh, C., Reymond, A.,
Excoffier, L., Attar, H., Antonarakis, S.E., Dermitzakis, E.T. & Hirschhorn, J.N.,
Conserved non-coding sequences are selectively constrained and not mutation cold
spots, Nat Genet 38(2), 2006, 223-227.
48. Harrow*, J., Denoeud*, F., Frankish*, A., Reymond*, A., Chen C.K., Chrast, J.,
Lagarde, J., Gilbert, J.G.R, Storey, R., Swarbreck., D., Ucla, C., Hubbard, T.,
Antonarakis, S.E. & Guigó, R., GENCODE: Producing a reference annotation for
ENCODE, Genome Biol 7 Suppl 1, 2006, S4.
*These authors contributed equally to this work
49. Guigó, R., Flicek, P., Abril, J.F., Reymond, A., Lagarde, J., Denoeud, F.,
Antonarakis, S.E., Ashburner, M., Bajic, V.B., Birney, E., Castelo, R., Eyras, E.,
Gingeras, T.R., Good, P., Harrow, J., Lewis, S., Hubbard, T. & Reese, M.G., EGASP:
25
the human ENCODE Genome Annotation Assessment Project, Genome Biol, 7
Suppl 1, 2006, S2.
50. Merla, G., Howald, C., Henrichsen, C.N., Lyle, R., Wyss, C., Zabot, M.T.,
Antonarakis, S.E., & Reymond, A., Submicroscopic Deletion in Patients with
Williams-Beuren Syndrome Influences Expression Levels of the Nonhemizygous
Flanking Genes, Am J Hum Genet 79, 2006, 332-341.
51. The ENCODE Project Consortium including Reymond, A., The ENCODE pilot
project: identification and analysis of functional elements in 1% of the human
genome, Nature 447, 2007, 799-816.
52. Zheng, D., Frankish, A., Baertsch, R., Siew Woh Choo, S., Denoeud, F., Kapranov,
P., Lu, Y., Reymond, A., Chia-Lin Wei, C.L., Gingeras, T.R., Guigo, R., Harrow, J.,
Haussler D & Gerstein, M.B., Pseudogenes in the ENCODE regions: Consensus
annotation, analysis of transcription and evolution, Genome Res 17, 2007, 839-851.
53. Washietl, S., Pedersen, J.S., Korbel, J.O., Gruber, A., Hackermüller, J., Hertel, J.,
Lindemeyer, M., Reiche, K., Stocsits, C., Tanzer, A., Ucla, C., Wyss, C., Antonarakis,
S.E., Denoeud, F., Lagarde, J., Drenkow, J., Kapranov, P., Gingeras, T.R., Snyder,
M., Gerstein, M.B., Reymond, A., Hofacker, I.L. & Stadler, P.F., Structured RNAs in
the ENCODE Selected Regions of the Human Genome, Genome Res 17, 2007, 852-
864.
54. Denoeud, F., Kapranov, P., Ucla, C., Frankish, A., Castelo, R., Drenkow, J., Lagarde,
J., Alioto, T., Manzano, C., Chrast, J., Dike, S., Wyss, C., Henrichsen, C.N., Holroyd,
J., Dickson, M.C., Taylor, R., Hance, Z., Foissac, S., Myers, R.M., Rogers, J.,
Hubbard, T., Harrow, J., Guigó, R., Gingeras, T.R., Antonarakis, S.E. & Reymond,
A., Prominent use of distal 5’ transcription start sites and discovery of a large number
of additional exons in ENCODE regions, Genome Res 17, 2007, 746-759.
55. Tress, M.L., Martelli, P.L., Frankish, A., Reeves, G.A., Wesselink, J.J., Yeats, C.,
Olason, P.I., Albrecht, M., Hegyi, H., Giorgetti, A., Raimondo, D., Lagarde, J.,
Laskowski, R.A., Lopez, G., Sadowski, M.I., Watson, J.D., Fariselli, P., Rossi, I.,
Nagy, A., Kai, W., Storling, Z., Orsini, M., Assenov, Y., Blankenburg, H.,
Huthmacher, C., Ramirez, F., Schlicker, A., Denoeud, F., Jones, P., Kerrien, S.,
Orchard, S., Antonarakis, S.E., Reymond, A., Birney, E., Brunak, S., Casadio, R.,
Guigo, R., Harrow, J., Hermjakob, H., Jones, D.T., Lengauer, T., Orengo, C.A.,
Patthy, L., Thornton, J.M., Tramontano, A., Valencia, A., The implications of
alternative splicing in the ENCODE protein complement, Proc Natl Acad Sci USA
104(13), 2007, 5495-5500.
56. Lyle, R., Prandini, P., Osoegawa, K., ten Hallers, B., Humphray, S., Zhu, B., Eyras,
E., Castelo, R., Bird, C., Gagos, S., Scott, C., Cox, A., Deutsch, S., Ucla, C., Cruts,
M., Dahoun, S., She, X., Bena, F., Wang, S.Y, Van Broeckhoven, C., Eichler, E.E.,
Guigo, R., Rogers, J., de Jong, P., Reymond, A. & Antonarakis, S.E., Islands of
euchromatin-like sequence and expressed sequences within heterochromatic
26
regions of the human genome: initial sequence analysis of 21p, Genome Res 17,
2007, 1690-1696.
57. Micale, L., Fusco, C., Augello, B., Napolitano, L.M.R., Dermitzakis, E.T., Meroni, G.,
Merla, G., & Reymond, A., Williams-Beuren Syndrome TRIM50 encodes an E3-
Ubiquitin Ligase, Eur J Hum Genet 16(9), 2008, 1038-49.
58. Molina, J., Carmona Mora, P., Chrast, J., Krall, P., Canales, C.P., Lupski, J.R.,
Reymond, A. & Walz, K., Abnormal social behaviors and altered gene expression
rates in a mouse model for Potocki-Lupski Syndrome, Hum Mol Genet 17(16), 2008,
2486-95.
59. Djebali*, S., Kapranov*, P., Foissac*, S., Lagarde*, J., Reymond*, A., Ucla, C.,
Wyss, C., Drenkow, J., Dumais, E., Murray, R.R., Lin, C., Szeto, D., Denoeud, F.,
Vidal, M., Calvo, M., Salehi-Ashtiani, K., Antonarakis, S.E., Gingeras, T.R., & Guigo,
R., Efficient targeted transcript discovery via array-based normalization of RACE
libraries, Nat Methods 5(7), 2008, 629-35.
*These authors contributed equally to this work
60. Marshall, C., Young, E.J., Pani, A.M., Freckmann, M.L., Lacassie, Y., Howald, C.,
Fitzgerald, K.K., Peippo, M., Morris, C.A., Shane, K., Priolo, M., Morimoto, M.,
Kondo, I., Manguoglu, E., Berker-Karauzum, S., Edery, P., Hobart, H.H., Mervis,
C.B., Zuffardi, O., Reymond, A., Kaplan, P., Tassabehji, M., Gregg, R.G., Scherer,
S.W., & Osborne, L.R., Infantile spasms associated with deletion of the MAGI2 gene
on chromosome 7q11.23-7q21.11, Am J Hum Genet 83(1), 2008, 106-111.
61. Attanasio, C., Reymond, A., Humbert, R., Lyle, R., Kuehn M.S., Neph, S., Sabo,
P.J., Goldy. J., Weaver. M., Lee, K., Haydock, A., Dermitzakis, E.T., Dorschner,
M.O., Antonarakis, S.E. & Stamatoyannopoulos, J.A., Assaying the regulatory
potential of mammalian conserved non-coding sequences in human cells, Genome
Biol 9(12), 2008, R168.
62. Henrichsen*, C.N., Vinckenbosch*, N., Zollner*, S., Chaignat, E., Pradervand, S.,
Schütz, F., Ruedi, M., Kaessmann, H. & Reymond, A., Segmental copy number
variation shapes tissue transcriptome, Nat Genet 41, 2009, 424-429.
*These authors contributed equally to this work
63. Bovine Genome Sequencing and Analysis Consortium including Reymond, A.
(leader of the exon skipping analysis group; member of the analysis group
organization; member of the gene prediction and consensus gene set group;
member of the experimental validation of gene set group), The Genome Sequence of
Taurine Cattle: a window to ruminant biology and evolution, Science 324, 2009, 522-
528.
64. Makrythanasis, P., Kapranov, P., Bartoloni, L., Reymond, A., Deutsch, S., Guigó, R.
Denoeud, F., Drenkow, J., Rossier, C., Ariani, F., Capra, V., Excoffier, L., Renieri, A.,
Gingeras, T.R. & Antonarakis, S.E., Variation in novel exons (RACEfrags) of the
27
MECP2 gene in Rett syndrome patients and controls, Hum Mutat 30(9), 2009, E866-
79.
65. Ferrero*, G.B., Howald*, C., Micale, L., Biamino, E., Augello, B., Fusco, C., Turturo,
M.G., Reymond, A. & and Merla, G., An atypical 7q11 deletion in a normal IQ
Williams-Beuren syndrome patient, Eur J Hum Genet 18(1), 2010, 33-38.
*These authors contributed equally to this work
66. Walters, R.G., Jacquemont, S. and 92 other authors including Reymond, A., A novel
highly-penetrant form of obesity due to microdeletions on chromosome 16p11.2,
Nature 463, 2010, 671-675.
67. Gimelli, S., Chrast, J., Baban, A., Henrichsen, C.N., Leroni, M., Zuffardi, O., Gimelli,
G. & Reymond, A., A t(7;12) balanced translocation with breakpoints overlapping
those of the Williams-Beuren syndrome and the 12q14 microdeletion syndrome, Am
J Med Genet Part A 152A(5), 2010, 1285-94.
68. Harewood, L., Schütz, F., Boyle, S., Perry, P., Delorenzi, M., Bickmore, W.A. &
Reymond, A., The Effect of Translocation-Induced Nuclear Re-organization on Gene
Expression, Genome Res 20(5), 2010, 554-564.
69. Ricard, G., Molina, J., Chrast, J., Gu, W., Gheldof, N., Pradervand, S., Schütz, F.,
Lupski, J.R., Reymond*, A. & Walz*, K., Long-range expression consequences of
copy number variation: insights from Smith-Magenis and Potocki-Lupski syndrome
mouse models, PLoS Biol 8(11), 2010, e1000543, doi:10.1371/journal.pbio.1000543.
*These laboratories contributed equally to this work
70. The EURexpress consortium including Reymond, A., A high-resolution anatomical
atlas of the transcriptome in the mouse embryo, PLoS Biol 9(1), 2011, e1000582,
doi:10.1371/journal.pbio.1000582.
71. Henrichsen, C.N., Csárdi, G., Zabot, M.T., Fusco, C., Bergmann, S., Merla, G. &
Reymond, A., Using transcription modules to identify expression clusters perturbed
in Williams-Beuren syndrome, PLoS Comp Biol 7(1), 2011, e1001054.
72. Chaignat, E., Aït-Yahya Graison, E., Henrichsen, C.N., Chrast, J., Schütz, F.,
Pradervand, S., & Reymond, A., Copy Number Variation modifies expression time-
courses, Genome Res 21(1), 2011, 106-113.
73. The ENCODE Project Consortium including Reymond, A., A Users Guide to the
Encyclopedia of DNA Elements (ENCODE) Functional Genomic Data, PLoS Biol
9(4), 2011, e1001046. doi:10.1371/journal.pbio.1001046.
74. Micale, L., Augello, B., Fusco, C., Selicorni, A., Loviglio, M.N., Cirillo Silengo, M.,
Reymond, A., Gumiero, B., Zucchetti, F., D’Addetta, E.V., Belligni, E., Calcagni, A.,
Digilio, M.C., Dallapiccola, B., Faravelli, F., Forzano, F., Accadia, M., Bonfante, A.,
Clementi, M., Douzgou, S., Ferrari, P., Fischetto, R., Livia, G., Lapi, E., Mattina, T.,
28
Melis, D., Patricelli, M.G., Priolo, M., Prontera, P., Renieri, A, Scarano, G., Toschi, B.,
Turolla, L., Vancini, A., Zatterale, A., Zelante, L., & Merla, G., Mutation Spectrum of
MLL2 in a cohort of Kabuki syndrome patients, Orphanet J Rare Dis 6(1), 2011, 38,
doi:10.1186/1750-1172-6-38
75. Mudge, J.M., Frankish, A., Fernandez-Banet, J., Alioto, T., Derrien, T., Howald, C.,
Reymond, A., Guigo, R., Hubbard, T., & Harrow, J., The origins, evolution and
functional potential of alternative splicing in vertebrates, Mol Biol Evol 28(10), 2011,
2949-2959, doi: 10.1093/molbev/msr127.
76. Jacquemont*, S., Reymond*, A. and 176 other authors, Mirror extreme BMI
phenotypes associated with gene dosage at the 16p11.2 locus, Nature 478, 2011,
97-102, doi: 10.1038/nature10406.
*These authors contributed equally to this work
77. Djebali, S. and 37 other authors including Reymond, A., Evidence for transcript
networks composed of chimeric RNAs in human cells, PLoS One 7(1), 2012,
e28213.
78. Rashidi-Nezhad, A., Parvaneh, N., Farzanfar, F., Azimi, C., Akrami, S.M., Harewood,
L. & Reymond, A., 2q34-qter duplication and 4q34.2-qter deletion in a patient with
developmental delay, Eur J Med Genet 55(3), 2012, 203-210.
79. Golzio, C., Willer, J., Talkowski, M.E., Oh, E.C., Taniguchi, Y., Jacquemont, S.,
Reymond, A., Sun, M., Sawa, A., Gusella, J.F., Kamiya, A., Beckmann, J.S., &
Katsanis, N., KCTD13 is a major driver of mirrored neuroanatomical phenotypes of
the 16p11.2 copy number variant, Nature 485, 2012, 363-367.
80. Hu, B., Castillo, E., Harewood, L., Reymond, A., Dummer, R., Raffoul, W.,
Hötzenecker, W., Günther F. L. Hofbauer, G.F.L. & Dotto, G.P., Loss of
mesenchymal Notch/CSL signaling leads to field cancerization and epithelial tumor
development, Cell 149(6), 2012, 1207-20.
81. Howald, C., Tanzer, A., Chrast, J., Kokocinski, F., Derrien, T., Walters, N., Gonzalez,
J.M., Frankish, A., Aken, B.L., Hourlier, T., Vogel, J.H., White, S., Harrow, J.,
Hubbard, T., Guigo, R., & Reymond, A., Combining RT-PCR-seq and RNA-seq to
catalog all genic elements encoded in the human genome, Genome Res 22(9), 2012,
1698-1710.
82. Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F.,
Aken, B., Barrell D., Searle, S., Mike Kay, M., Mukherjee, G., Bignell, A., Hunt, T.,
Boychenko, V., Saunders, G., Despacio-Reyes, G., Harte R., Lin, M., Howald, C.,
Tanzer, A., Chrast, J., Walters, N., Bala, S., Pei, B., Tress, M., Rodriguez, J.M.,
Ezkurdia, I, Brent, M., Haussler, D., Kellis, M., Valencia, A., Reymond, A., Gerstein,
M., Guigo, R. & Hubbard, T.J., GENCODE: The reference human genome
annotation for the ENCODE project, Genome Res 22(9), 2012, 1760-1764.
29
83. The ENCODE Project Consortium including Reymond, A., An Integrated
Encyclopedia of DNA Elements in the Human Genome, Nature 489, 2012, 57-74.
84. The ENCODE Project Transcriptome Consortium including Reymond, A.,
Landscape of transcription in human cells, Nature 489, 2012, 101-108.
85. Pei, B., Sisu, C., Frankish, A., Howald, C., Habegger, L. Mu, X.J., Harte, R.,
Balasubramanian, S., Tanzer, A., Diekhans, M., Zheng, D., Reymond, A., Hubbard,
T., Harrow, J. & Gerstein, M., The GENCODE Pseudogene Resource, Genome Biol
13(9), 2012, R51.
86. Fusco, C., Micale, L., Egorov, M., Monti, M., D’Addetta, E.V., Augello, B., Cozzolino,
F., Calcagnì, A., Fontana, A., Polishchuk, R.S., Didelot, G., Reymond, A., Pucci, P.,
& Merla, G., The E3-Ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and
promotes the sequestration and clearance of ubiquitinated proteins into the
aggresome, PLoS One 7(7), 2012, e40440.
87. Micale, L., Loviglio, M.N., Manzoni, M., Fusco, C., Augello, B., Migliavacca, E.,
Cotugno, G., Monti, E., Borsani, G., Reymond*, A. & Merla*, G., A fish–specific
transposable element shapes the repertoire of p53 target genes in zebrafish, PLoS
One 7(10), 2012, e46642.
*These laboratories contributed equally to this work
88. Zufferey, F., Sherr. E.H., Beckmann, N.D., Hanson, E., Maillard, A.M., Hippolyte, L.,
Macé, A., Ferrari, C., Kutalik, Z., Andrieux, J., Aylward, E., Barker, M., Bernier, R.,
Bouquillon, S., Conus, P., Delobel, B., Faucett, W.A., Goin-Kochel, R.B., Grant, E.,
Harewood, L., Hunter, J.V., Lebon, S., Ledbetter, D.H., Martin, C.L., Männik, K.,
Martinet, D., Mukherjee, P., Ramocki, M.B., Spence, S.J., Steinman, K., Tjernagel,
J., Simons VIP Consortium, 16p11.2 European Consortium, Spiro, J.E., Reymond*,
A., Beckmann*, J.S., Chung*, W.K. & Jacquemont*, S., A 600 kb deletion syndrome
at 16p11.2 leads to energy imbalance and neuropsychiatric disorders, J Med Genet
49(10), 2012, 660-668.
*These laboratories contributed equally to this work
89. Makrythanasis, P. and 56 other authors including Reymond, A., MLL2 mutation
detection in 86 patients with Kabuki syndrome: a genotype-phenotype study, Clin
Genet 84(6), 2013, 744-747.
90. RGASP Consortium including Reymond, A., Assessment of transcript reconstruction
methods for RNA-seq, Nat Methods 10(12), 2013, 1177-84.
91. Gheldof, N., Witwicki, R.M., Migliavacca, E., Leleu, M., Didelot, G., Harewood, L.,
Rougemont, J. & Reymond, A., Structural variation-induced expression changes are
paralleled by chromatin architecture modifications, PLoS One 8(11), 2013, e79973.
30
92. Kilpinen, H., Waszak, S.M., Gschwind, A., Raghav, S.K., Witwicki, R.M., Orioli, A.,
Migliavacca, E., Wiederkehr, M., Gutierrez-Arcelus, M., Panousis, N., Yurovsky, A.,
Lappalainen, T., Romano-Palumbo, L., Planchon, A, Bielser, D., Bryois, J.,
Padioleau, I., Udin, G., Thurnheer, S., Hacker, D., Core, L.J., Lis, J.T., Hernandez*,
N., Reymond*, A., Deplancke*, B. & Dermitzakis*, E.T., Coordinated effects of
sequence variation on DNA binding, chromatin structure, and transcription, Science
342(6159), 2013, 744-747.
*These laboratories contributed equally to this work
93. Waszak, S.M., Kilpinen, H., Gschwind, A.R., Orioli, A,, Raghav, S.K., Witwicki, R.M.,
Migliavacca, E., Yurovsky, A., Lappalainen, T., Hernandez, N., Reymond, A.,
Dermitzakis, E.T. & Deplancke, B., Identification and removal of low-complexity sites
in allele-specific analysis of ChIP-seq data, Bioinformatics 30(2), 2014,165-71.
94. Alfaiz, A.A., Micale, L., Mandriani, B., Augello, B., Pellico, M.T., Chrast, J., Xenarios,
I., Zelante, L., Merla, G. & Reymond, A., TBC1D7 mutations are associated with
intellectual disability, macrocrania, patellar dislocation, and celiac disease, Hum
Mutat 35(4), 2014, 447-51.
95. Mark Gerstein, Joel Rozowsky, Koon-Kiu Yan, Daifeng Wang, Chao Cheng, James
Brown, Carrie Davis, LaDeana Hillier, Cristina Sisu, Jingyi Li, Baikang Pei, Arif
Harmanci, Michael Duff, Sarah Djebali, Roger Alexander, Burak Alver, Raymond
Auerbach, Kimberly Bell, Peter Bickel, Max Boech, Nathan Boley, Benjamin Booth,
Lucy Cherbas, Peter Cherbas, Chao Di, Alex Dobin, Jorg Drenkow, Brent Ewing,
Gang Fang, Meagan Fastuca, Elise Feingold, Adam Frankish, Guanjun Gao, Peter
Good, Phil Green, Roderic Guigo, Ann Hammonds, Jennifer Harrow, Roger Hoskins,
Cédric Howald, Long Hu, Haiyan Huang, Tim Hubbard, Chau Huynh, Sonali Jha,
Dionna Kasper, Masaomi Kato, Thomas Kaufman, Robert Kitchen, Erik Ladewig,
Julien Lagarde, Eric Lai, Jing Leng, Zhi Lu, Michael MacCoss, Gemma May,
Rebecca McWhirter, Gennifer Merrihew, David Miller III, Ali Mortazavi, Rabi Murad,
Brian Oliver, Sara Olson, Peter Park, Michael Pazin, Norbert Perrimon, Dmitri
Pervouchine, Valerie Reinke, Alexandre Reymond, Garrett Robinson, Anastasia
Samsonova, Gary Saunders, Felix Schlesinger, Anurag Sethi, Frank Slack, William
Spencer, Marcus Stoiber, Pnina Strasbourger, Andrea Tanzer, Owen Thompson,
Kenneth Wan, Guilin Wang, Huaien Wang, Kathie Watkins, Jiayu Wen, Kejia Wen,
Chenghai Xue, Li Yang, Kevin Yip, Christopher Zaleski, Yan Zhang, Henry Zheng,
Steven Brenner, Brenton Graveley, Susan Celniker, Thomas Gingeras & Robert
Waterston, Comparative Analysis of the Transcriptome across Distant Species,
Nature 512(7515), 2014, 445-48.
96. Reinthaler, E.M. Lal, D., Lebon, S., Hildebrand, M.S., Dahl, H.H.M., Regan, B.M.,
Feucht, M., Steinböck, H., Neophythou, B., Ronen, G.M., Roche, L., Gruber-
Sedlmayer, U., Geldner, J., Haberlandt, E., Hoffmann, P., Herms, S., Gieger, C.,
Waldenberger, M., Franke, A., Wittig, M., Schoch McGovern, S., Becker, A.J., Hahn,
A., Männik, K., Toliat, M.R., 16p11.2 European Consortium, Lerche, H., Nürnberg,
P., Mefford, H., Scheffer, I.E., Berkovic, S.F., Beckmann, J.S., EPICURE
Consortium, EuroEPINOMICS Consortium, Sander, T., Jacquemont, S., Reymond,
31
A., Zimprich, F. & Neubauer, B.A., 16p11.2 600 kb duplications confer risk for typical
and atypical Rolandic epilepsy, Hum Mol Genet 23(22), 2014, 6069-80.
97. Giannuzzi, G., Migliavacca, E. & Reymond, A., Novel H3K4me3 marks are enriched
at human- and chimpanzee-specific cytogenetic structures, Genome Res 24(9) 2014,
1455-68.
98. Rashidi-Nezhad, A., Talebi, S., Saebnouri, H., Akrami, S.M., & Reymond, A., The
effect of homozygous deletion of the BBOX1 and Fibin genes on carnitine level and
acyl carnitine profile, BMC Med Gen 15(1), 2014, 75.
99. Maillard, A.M., Ruef, A., Pizzagalli, F., Migliavacca, E., Hippolyte, L., Adaszewski, S.,
Dukart, J., Ferrari, C., Conus, P., Männik, K., Zazhytska, M., Siffredi, V., Maeder, P.,
Kutalik, Z., Kherif, F., Hadjikhani, N., Beckmann, J.S., Reymond*, A., Draganski*, B.,
Jacquemont*, S., The 16p11.2 locus modulates brain structures involved in autism,
schizophrenia and obesity, Mol Psychiatry 20(1), 2015, 140-147.
*These laboratories contributed equally to this work
100. Borck, G., Hög, F., Dentici, M.L., Tan, P.L., Sowada, N., Medeira, A., Gueneau,
L., Thiele, H., Kousi, M., Lepri, F., Wenzeck, L., Blumenthal, I., Radicioni, A.,
Schwarzenberg, T.L., Mandriani, B., Fischetto, R., Morris-Rosendahl, D.J., Altmüller,
J., Reymond, A., Nürnberg, P., Merla, G., Dallapiccola, B., Katsanis, N., Cramer, P.,
& Kubisch, C., BRF1 mutations alter RNA polymerase III-dependent transcription and
cause neurodevelopmental anomalies, Genome Res 25(2), 2015, 155-166.
101. Migliavacca, E., Golzio, C., Männik, K., Blumenthal, I., Oh, E.C., Harewood, L.,
Kosmicki, J., Loviglio, M.N., Hippolyte, L., Maillard, A.M., the 16p11.2 European
Consortium, van Haelst, M.M., Andrieux, J., Gusella, J.F., Daly, M.J., Beckmann,
J.S., Jacquemont, S., Talkowski, M.E., Katsanis, N. & Reymond, A., A potential
contributory role for ciliary dysfunction in the 16p11.2 600kb BP4-BP5 pathology, Am
J Hum Genet 96(5), 2015, 784-96.
102. Dikoglu, E., Alfaiz, A.A., Gorna, M., Bertola, D., Chae, J.H., Cho, T.J., Derbent,
M., Alanay, Y., Guran, T., Kim, O.H., Llerena Jr, J.C., Yamamoto, G., Superti-Furga,
G., Reymond, A., Xenarios, I., Stevenson, B., Campos-Xavier, B., Bonafé, L.,
Superti-Furga, A., Unger, S., Mutations in LONP1, a mitochondrial matrix protease,
cause CODAS syndrome, Am J Med Genet Part A 167(7), 2015, 1501-9.
103. Männik, K., Mägi, R., Macé, A., Cole B., Guyatt A.L., Shihab H.A., Maillard, A.M.,
Alavere, H., Kolk, A., Reigo, A., Mihailov E., Leitsalu, L., Ferreira, A.M., Nõukas, M.,
Teumer A., Salvi E., Cusi D., McGue M., Iacono W.G., Gaunt T.R., Beckmann, J.S.,
Jacquemont, S., Kutalik, Z., Pankratz N., Timpson N., Metspalu, A. & Reymond, A.,
Copy number variations and cognitive phenotypes in unselected populations, JAMA
313(20), 2015, 2044-2054.
104. Waszak, S.M., Delaneau, O., Gschwind, A.R., Kilpinen, H., Raghav, S.K.,
Witwicki, R.M., Orioli, A., Wiederkehr, M., Panousis, N.I., Yurovsky, A., Romano-
32
Palumbo, L., Planchon, A., Bielser, D., Padioleau, I., Udin, G., Thurnheer, S.,
Hacker, D., Hernandez, N., Reymond*, A., Deplancke*, B. & Dermitzakis*, E.T.,
Variation and genetic control of chromatin architecture in humans, Cell 162(5), 2015,
1039-50
*These laboratories contributed equally to this work
105. Alfaiz, A.A., Müller, V., Boutry-Kryza, N., Ville, D., Guex, N., de Bellescize, J.,
Rivier, C., Labalme, A., des Portes. V., Edery. P., Till, M., Xenarios, I., Herrmann, J.,
Sanlaville, D., Lesca, G. & Reymond, A., West syndrome caused by homozygous
mutation in the evolutionary conserved gene encoding the mitochondrial elongation
factor GUF1, Eur J Hum Genet 24(7), 2015, 1001-8.
106. D'Angelo, D., Lebon, S., Chen, Q., Martin-Brevet, S., Green Snyder L.A.,
Hippolyte, L., Hanson, E., Maillard, A.M., Faucett, W.A., Macé, A., Pain, A., Bernier,
R., Chawner, S., Albert, D., Andrieux, J., Aylward, E., Baujat, G., Caldeira, I., Conus,
P., Ferrari, C., Forzano, F., Gérard, M., Goin-Kochel, R.P., Grant, E., Hunter, J.V.,
Isidor, B., Jacquette, A., Jonch, A., Keren, B., Lacombe, D., Le Caignec, C., Martin,
C.L., Männik, K., Metspalu, A., Mignot, C., Mukherjee, P., Owen, M., Passeggeri, M.,
Rooryck Thambo, C., Spence, S.J., Steinman, K.J., Tjernagel, J., Van Haelst, M.,
Yiping, S., the ECHO study, the 16p11.2 European Consortium, the Simons VIP
Consortium, Sherr, E.H., Ledbetter, D.H., Van Den Bree, M., Beckmann, J.S., Spiro,
J.E., Reymond, A., Jacquemont, S. & Chung, W.K., Defining the effect of the
16p11.2 duplication on cognition, behavior, and medical comorbidities, JAMA
Psychiatry 73(1), 2016, 20-30.
107. Hippolyte, L., Maillard, A.M., Rodriguez-Herreros, B., Pain, A., Martin-Brevet, S.,
Ferrari, C., Conus, P., Macé, A., Hadjikhani, N., Metspalu, A., Reigo, A., Kolk, A.,
Männik, K., Isidor, B., Le Caignec, C., Mignot, C., Kutalik, Z., Schneider, L., Mottron,
L., Keren, B., Albert, D., Doco-Fenzy, M., Gérard, M., 16p11.2 European Consortium,
Ramus, F., Beckmann, J.S., Draganski, B., Reymond, A. & Jacquemont, S., Gene
dosage at the 16p11.2 locus modulates language, verbal memory and inhibition, Biol
Psychiatry 2016, pii: S0006-3223(15)00917-8, doi: 10.1016/j.biopsych.2015.10.021.
108. Arbogast, T., Ouagazzal, A.M., Chevalier, C., Kopanitsa, M., Afinowi, N.O.,
Migliavacca, E., Birling, M.C., Champy, M.F., Reymond, A. & Herault, Y., Opposite
phenotypes and genetic dosage effects in mouse models of 16p11.2 600kb deletion
and duplication syndromes, PLoS Genet 12(2), 2016, e1005709.
109. Maillard, A., Hippolyte, L., Rodriguez-Herreros, B., Chawner, S., Dremmel, D.,
Agüera, Z., Fagundo, A.B., Pain, A., Martin-Brevet, S., Hilbert, A., Kurz, S., Etienne,
R., Draganski, B., Jiménez-Murcia, S., Männik, K., Metspalu, K., Reigo, A., Isidor, B.,
LeCaignec, C., David, A., Mignot, C., Keren, B., 16p11.2 European Consortium, Van
den Bree, M., Munsch, S., Fernandez-Aranda, F., Beckmann, J., Reymond, A. &
Jacquemont, S., 16p11.2 locus modulates response to satiety before the onset of
obesity, Int J Obes 40(5), 2016, 870-6.
33
110. Leitsalu, L., Alavere, H., Jacquemont, S., Kolk, A., Maillard, A.M., Reigo, A.,
Nõukas, M., Reymond, A., Männik, K., Ng, P.C., & Metspalu, A., Reporting
incidental findings of genomic disorder-associated CNVs to unselected biobank
participants, Personalized Medicine 2016, doi: 10.2217/pme-2016-0009.
111. Loviglio, M.N., Leleu, M., Männik, K., Passeggeri, M. van der Werf, I. Giannuzzi,
G., Waszak, S.M., Zazhytska, Z., Roberts-Caldeira, I., Gheldof, N., Migliavacca, E.,
Alfaiz, A.A., Hippolyte, L., Maillard, A.M., 16p11.2 Consortium, 2p15 Consortium,
Van Dijck, A., Kooy, R.F., Sanlaville, D., Rosenfeld, J.A. Shaffer, L.G., Andrieux, J.
Marshall, C., Scherer, S.W., Shen, Y., Gusella, J.F., Thorsteinsdottir, U.,
Thorleifsson, G., Dermitzakis, E.T., Deplancke, B., Beckmann, J.S., Rougemont, J.,
Jacquemont, S. & Reymond, A., Chromosomal contacts connect loci associated
with autism, BMI and head circumference phenotypes, Mol Psychiatry 22(6), 2016,
836-849.
112. Terrone, G., Voisin, N., Alfaiz, A.A., Cappuccio, G., Guex, N., D’Amico, A.,
Barkovich, J.A., Brunetti-Pierri, N., Del Giudice*, E., & Reymond*, A., De novo
PIK3R2 variant causes PMG, corpus callosum hyperplasia and focal cortical
dysplasia, Eur J Hum Genet 24(9), 2016, 1359-62.
*These laboratories contributed equally to this work
113. Nuttle, X., Giannuzzi, G., Duyzend, M.H., Schraiber, J.G., Narvaiza, I., Sudmant,
P.H., Penn, O., Chiatante, G., Malig, M., Huddleston, J., Benner, C., Denman, L.,
Harshman, L., Baker, C., Raja, A., Penewit, K., Antonacci, F., Akey, J.M., Gage, F.H,
Reymond*, A., and Eichler*, E.E., Homo sapiens-specific gene family expansion and
the evolution of autism risk at chromosome 16p11.2, Nature 536(7615), 2016, 205-
209.
*These laboratories contributed equally to this work
114. Lagarde, J., Uszczynska-Ratajczak, B., Santoyo-Lopez, J., Gonzalez, J.,
Tapanari, E., Mudge, J., Steward, C., Wilming, L., Tanzer, A., Howald, C., Chrast, J.,
Vela-Boza, A., Rueda, A., Lopez-Domingo, F.J., Dopazo, J., Reymond, A., Guigo,
R, & Harrow, J., Extension of human lncRNA transcripts by RACE coupled with long
read high-throughput sequencing (RACE-Seq), Nat Commun 7, 2016, 12339.
115. Macé, A., Marcus, T., Beckmann, J.S., Lin, L., Jacquemont, S., Frayling, T.,
Reymond, A. & Kutalik, Z., Bioinformatics 32(21), 2016, 3298-3305.
116. Loviglio, M.N., Beck, C.R., White, J.J., Leleu, M., Harel, T., Guex, N., Niknejad,
A., Bi, W., Chen, E.S., Crespo, I., Yan, J., Charng, W.L., Gu, S., Fang, P., Coban-
Akdemir, Z., Shaw, C.A., Jhangiani, S.N., Muzny, D.M., Gibbs, R.A., Rougemont, J.,
Xenarios, I., Lupski, J.R. & Reymond, A., Identification of a RAI1-associated disease
network through integration of exome sequencing, transcriptomics and 3D genomics,
Genome Med 8(1), 2016, 105.
117. Lodder, E.M., De Nittis, P., Koopman, C.D., Wiszniewski, W.K., Fishinger, C.,
Lahrouchi, N., Guex, N., Napolioni, V., Tessadori, F., de Boer, T., Beekman, L.,
34
Nannenberg, E.A., Wilde, A.A.M., Boualla, L., Sefiani, A., de Graaff, W., Kamermans,
M., Cocciadiferro, D., Malerba, N., Mandriani, B., Coban-Akdemir, Z., Fish, R.,
Kayss, M., Eldomery, I., Ratbi, I., Simonds, W.F., Neerman-Arbez, M., Sutton, V.R.
Kok, F., Lupski, J.R., Reymond*, A., Bezzina*, C.R. Bakkers*, J., Merla*, G., GNB5
mutations cause a multisystem syndrome associated with cardiovascular defect and
cognition disability, Am J Hum Genet 99(3), 2016, 704-710.
*These laboratories contributed equally to this work
118. Tumienė, B., Voisin, N., Preikšaitienė, E., Petroška, D., Grikinienė, J.,
Samaitienė, R., Utkus, A., Reymond, A. & Kučinskas, V., Inflammatory Myopathy in
a Patient with Aicardi-Goutières Syndrome, Eur J Med Genet 60(3), 2017, 154-158.
119. Fusco, C., De Nittis, P., Alfaiz, A.A., Pellico, M.T., Augello, B., Malerba, N.,
Zelante, L., Reymond, A. & Merla, G., A New Split Hand/Foot Malformation with
Long Bone Deficiency Familial Case, J Pediatr Genet 6(2), 2017, 98-102.
120. Gschwind, A.R., Singh, A., Certa, U., Reymond*, A. & Heckel*, T., Diversity and
regulatory impact of copy number variation in the primate Macaca fascicularis, BMC
Genomics 18(1), 2017, 144.
*These laboratories contributed equally to this work
121. McDaid, A.F., Joshi, P.K. Porcu, E., Komljenovic, A., Li, H., Sorrentino, V.,
Litovchenko, M., Bevers, R.P.J., Rüeger, S., CHARGE Consortium, Reymond, A.
Bochud, M., Deplancke, B., Williams, R.W., Robinson-Rechavi, M., Paccaud, F.,
Rousson, V., Auwerx, J., Wilson, J.F. & Kutalik, Z., Bayesian association scan
reveals loci associated with human lifespan and linked biomarkers, Nat Commun 8,
2017, 15842.
122. Macé A, Tuke MA, Deelen P, Kristiansson K, Mattsson H, Nõukas M, Sapkota Y,
Schick U, Porcu E, Rüeger S, McDaid AF, Porteous D, Winkler TW, Salvi E, Shrine
N, Liu X, Ang WQ, Zhang W, Feitosa MF, Venturini C, van der Most PJ, Rosengren
A, Wood AR, Beaumont RN, Jones SE, Ruth KS, Yaghootkar H, Tyrrell J, Havulinna
AS, Boers H, Mägi R, Kriebel J, Müller-Nurasyid M, Perola M, Nieminen M, Lokki ML,
Kähönen M, Viikari JS, Geller F, Lahti J, Palotie A, Koponen P, Lundqvist A,
Rissanen H, Bottinger EP, Afaq S, Wojczynski MK, Lenzini P, Nolte IM, Sparsø T,
Schupf N, Christensen K, Perls TT, Newman AB, Werge T, Snieder H, Spector TD,
Chambers JC, Koskinen S, Melbye M, Raitakari OT, Lehtimäki T, Tobin MD, Wain
LV, Sinisalo J, Peters A, Meitinger T, Martin NG, Wray NR, Montgomery GW,
Medland SE, Swertz MA, Vartiainen E, Borodulin K, Männistö S, Murray A, Bochud
M, Jacquemont S, Rivadeneira F, Hansen TF, Oldehinkel AJ, Mangino M, Province
MA, Deloukas P, Kooner JS, Freathy RM, Pennell C, Feenstra B, Strachan DP,
Lettre G, Hirschhorn J, Cusi D, Heid IM, Hayward C, Männik K, Beckmann JS, Loos
RJF, Nyholt DR, Metspalu A, Eriksson JG, Weedon MN, Salomaa V, Franke L,
Reymond A, Frayling TM & Kutalik Z., CNV-association meta-analysis in 191,161
European adults reveals new loci associated with anthropometric traits, Nat Commun
8(1), 2017, 744.
35
123. Loviglio, M.N., Arbogast, T., Jønch, A.E., Collins, S.C, Popadin, K., Bonnet, C.,
Giannuzzi, G., Maillard, A.M., Jacquemont, S., 16p11.2 Consortium, Yalcin, B.,
Katsanis*, N., Golzio*, C. & Reymond*, A., The linker for activation of T-cells (LAT)
contributes to the neuroanatomical phenotype of 16p11.2 BP2-BP3 CNVs, Am J
Hum Genet 101(4), 2017, 564-577.
*These laboratories contributed equally to this work
124. Schmid-Siegert, E., Sarkar, N., Iseli, C., Calderon, S., Gouhier-Darimont, C.,
Chrast, J., Cattaneo, P., Schütz, F., Farinelli, L., Pagni, M., Schneider, M., Voumard,
J., Jaboyedoff, M., Fankhauser, C., Hardtke, C.S., Keller, L., Pannell, J.R.,
Reymond*, A., Robinson-Rechavi*, M., Xenarios*, I., & Reymond*, P., Low number
of fixed somatic mutations in a long-lived oak tree, Nat Plant 3(12), 2017, 926-929.
*These laboratories contributed equally to this work
125. Gueneau, L., Fish, R., Shamseddin, H.E., Voisin, N., Tran Mau-Them, F.,
Preiksaitiene, E., Monroe, G.R., Lai, A., Putoux, A., Allias, F., Ambosaidi, Q.,
Ambrozaityte, L., Cimbalistienė, L., Delafontaine, J., Guex, N., Hashem, M.A., Kurdi,
W., Jamuar, S.S., Ying, L.J., Bonnard, C., Pippucci, T., Pradervand, S., Roechert, B.,
Van Hasselt, P.M., Wiederkehr, M., Wright, C.F., DDD Study, Xenarios, I., van
Haaften, G., Shaw-Smith, C., Schindewolf, E.M., Neerman-Arbez, M., Sanlaville, D.,
Lesca, G., Guibaud, L., Reversade, B., Chelly, J., Kučinskas, V., Alkuraya*, F.S. &
Reymond*, A., KIAA1109 variants are associated with a severe disorder of brain
development and arthrogryposis, Am J Hum Genet 102(1), 2018, 116-132.
*These laboratories contributed equally to this work
126. Popadin, K., Peischl, S., Garieri, M., Sailani, M.R., Letourneau, A., Santoni, F.,
Lukowski, S.W., Bazykin, G., Nikolaev, S., Meyer, D., Excoffier, L., Reymond*, A., &
Antonarakis*, S.E., Slightly deleterious genomic variants and transcriptome
perturbations as main targets of Down syndrome embryonic selection, Genome Res
28(1), 2018, 1-10.
*These laboratories contributed equally to this work
127. Moysés-Oliveira, M., Giannuzzi, G., Fish, R.J., Rosenfeld, J.A., Petit, F., de
Fatima Soares, M., Kulikowski, L.D., Di Battista, A., Zamariolli, M., Xia, F., Liehr, T.,
Kosyakova, N., Carvalheira, G., Parker, M., Seaby, E.G., Gilbert, R.D., Hagelstrom,
R.T., Cremona, M.L., Li, W.L., Malhotra, A., Chandrasekhar, A., Perry, D.L., Taft,
R.J., McCarrier, J., Basel, D.G., Andrieux, J., Stumpp, T., Antunes, F., Pereira, G.J.,
Neerman-Arbez, M., Meloni, V.A., Drummond-Borg, M., Melaragno, M.I. &
Reymond, A., Inactivation of AMMECR1 is associated with growth, bone and heart
alterations, Hum Mutat 39(2), 2018, 281-291.
128. Martin-Brevet, S., Rodriguez-Herreros, B., Nielsen, J. A., Moreau, C., Modenato,
C., Maillard, A.M., Pain, A., Richetin, S., Jønch, A.E., Qureshi, A.Y., Zürcher, N. R.,
European Consortium, Simons Variation in Individuals Project (VIP) Consortium,
Chung, W. K., Sherr, E.H., Spiro, J.E., Beckmann, J.S., Hadjikhani, N., Reymond,
A., Buckner, R. L., Draganski, B. & Jacquemont, S., Quantifying the effects of
36
16p11.2 copy number variants on brain structure: A multi-site 'genetic-first' study,
Biol Psychiatry 84(4), 2018, 253-264.
129. Tripathy, R., Leca, I., van Dijk, T., van Bon, B., Gstrein, T., Breuss, M., Bahi-
Buisson, N., Paciorkowski, A.R., Pagnamenta, A., Taylor, J., Terrone, G., Vitiello, G.,
D’Amico, A., Del Giudice, E., Brunetti-Pierri, N., Reymond, A., Voisin, N., Bernstein,
J.A., Farrelly, E., Pierson, T., Kini, U., Leonard, T., Armstrong, L., Hiatt, S., Cooper,
G., Mirzaa, G., Pierson, T., Baas, F., Chelly, J., Cowan, N.J., Keays, D.A., Mutations
in MAST1 cause mega-corpus-callosum syndrome with cerebellar hypoplasia and
cortical malformations, Neuron 100(6), 2018, 1354-1368.
130. Pizzo, L., Jensen, M., Polyak, A., Rosenfeld, J.A., Männik, K., Krishnan, A.,
McCready, E., Pichon, O., Le Caignec, C., Van Dijck, A., Pope, K., Voorhoeve, E.,
Yoon, J., Stankiewicz, P., Cheung, S.W., Pazuchanics, D., Huber, E., Kumar, V.,
Kember, R., Mari, F., Curró, A., Castiglia, L., Galesi, O., Avola, E., Mattina, T.,
Fichera, M., Mandarà, L., Vincent, M., Nizon, M., Mercier, S., Bénéteau, C., Blesson,
S., Martin-Coignard D., Mosca-Boidron, A-L., Caberg, J-H., Bucan, M., Zeesman, S.,
Nowaczyk, M.J.M., Lefebvre, M., Faivre, L., Callier, P., Skinner, C., Keren, B.,
Perrine, C., Prontera, P., Marle, N., Renieri, A., Reymond, A., Kooy, R.F., Isidor, B.,
Schwartz, C., Romano, C., Sistermans, E., Amor, D.J., Andrieux, J. & Girirajan, S.,
Rare variants in the genetic background modulate cognitive and developmental
phenotypes in individuals carrying disease-associated variants, Genet Med 2018,
doi: 10.1038/s41436-018-0266-3.
131. Frankish, A., Diekhans, M., Ferreira, A.M., Johnson, R., Jungreis, I., Loveland, J.,
Mudge, J.M., Sisu, C., Wright, J., Armstrong, J., Barnes, I., Berry, A., Bignell, A.,
Carbonell Sala, S., Chrast, J., Cunningham, F., Di Domenico, T., Donaldson, S.,
Fiddes, I.T., García Girón, C., Gonzalez, J.M., Grego, T., Hardy, M., Hourlier, T.,
Hunt, T., Izuogu, O.G., Lagarde, J., Martin, F.J., Martínez, L., Mohanan, S., Muir, P.,
Navarro, F.C.P., Parker, A., Pei, B., Pozo, F., Ruffier, M., Schmitt, B.M., Stapleton,
E., Suner, M.M., Sycheva, I., Uszczynska-Ratajczak, B., Xu, J., Yates, A., Zerbino,
D., Zhang, Y., Aken, B., Choudhary, J.S., Gerstein, M., Guigó, R., Hubbard, T.J.P.,
Kellis, M., Paten, B., Reymond, A., Tress, M.L., Flicek, P., GENCODE reference
annotation for the human and mouse genomes, Nucleic Acids Res 47(D1), 2019,
D766-D773.
132. The ENIGMA-CNV working group including Reymond, A., Dose response of
the 16p11.2 distal copy number variant on intracranial volume and basal ganglia, Mol
Psychiatry 2018, doi: 10.1038/s41380-018-0118-1.
133. Moysés-Oliveira, M., Di-Battista, A., Zamariolli, M., Meloni, V.A., Bragagnolo, S.,
Christofolini, D., Steiner, C.E., Kosyakova, N., Liehr, T., Reymond, A., & Melaragno,
M.I., Breakpoint mapping at nucleotide resolution in X-autosome balanced
translocations associated with clinical phenotypes, Eur J Hum Genet 27(5), 2019,
760-771.
37
134. Delaneau, O., Zazhytska, M., Giannuzzi, G., Rey, G., Borel, C., Howald, C.,
Kumar, S., Ongen, H., Popadin, K., Marbach, D., Ambrosini, G., Bielser, D., Hacker,
D., Romano-Palumbo, L., Ribaux, P., Wiederkehr, M., Falconnet, E., Bucher, P.,
Bergmann, S., Antonarakis, S. E., Reymond*, A., & Dermitzakis*, E. T., Chromatin
interactions mediate genetic effects on regulatory networks, Science 364(6439),
2019, pii: eaat8266. doi: 10.1126/science.aat8266.
*These laboratories contributed equally to this work
135. Porcu, E., Rueger, S., eQTLGen Consortium, Santoni, F.A., Reymond*, A.,
Kutalik*, Z., Mendelian randomization integrating GWAS and eQTL data reveals
genetic determinants of complex and clinical traits, Nat Commun 10(1), 2019, 3300.
*These laboratories contributed equally to this work
136. Collins, S.C., Mikhaleva, A., Vrcelj, K., Vancollie, V.E., Demeure, N., Wagner, C.,
Kannan, M., Whitley, H., Balz, R., Anthony, L.F.E., Edwards, A., Sanger Mouse
Genetics Project, Moine, H., White, J.K., Adams, D.J., Reymond, A., Lelliott, C.J.,
Webber, C., & Yalcin, B., Large-scale neuroanatomical screen uncovers 198 gene
associations in mouse brain morphogenesis, Nat Commun 10(1), 2019, 3465.
137. Pranckėnienė, L., Preikšaitienė, E., Gueneau, L., Reymond, A. & Kučinskas, V.,
De Novo Duplication in the CHD7 Gene Associated With Severe CHARGE
Syndrome, Genomics Insights 12:11786310198390102019, 2020.
138. Cárdenas-de-la-Parra, A., Martin-Brevet, S., Moreau, C., Rodriguez-Herreros, B.,
Fonov, V.S., Maillard, A.M., Zürcher, N.R., 16p11.2 European Consortium,
Hadjikhani, N., Beckmann, J.S., Reymond, A., Draganski, B., Jacquemont, S.,
Collins, D.L., Developmental trajectories of neuroanatomical alterations associated
with the 16p11.2 Copy Number Variations, NeuroImage 2020, doi:
10.1016/j.neuroimage.2019.116155.
139. Giannuzzi, G., Schmidt, P.J., Porcu, E., Willemin, G., Munson, K.M., Nuttle, X.,
Earl, R., Chrast, J., Hoekzema, K., Risso, D., De Nittis, P., Männik, K., 16p11.2
Consortium, Herault, Y., Gao, X., Philpott, C.C., Bernier, R.A., Kutalik, Z., Fleming,
M.D., Eichler, E.E. & Reymond, A., The human-specific BOLA2 duplication modifies
iron homeostasis and anemia predisposition in chromosome 16p11.2 autism
patients, Am J Hum Genet 105(5), 2019, 947-958.
140. Pranckėnienė, L., Siavrienė, E., Gueneau, L., Preikšaitienė, E., Mikštienė, V.,
Reymond, A., Kučinskas, V., De novo splice site variant of ARID1B associated with
pathogenesis of Coffin-Siris syndrome, Mol Genet Genomic Med 2019, e1006, doi:
10.1002/mgg3.1006.
141. Preikšaitienė, E., Voisin, N., Gueneau, L., Blažytė, E.M., Benušienė, E.,
Krasovskaja, N., Ambrozaitytė, L., Reymond, A. & Kučinskas, V., Pathogenic
homozygous variant in POMK gene is the cause of prenatally detected severe
ventriculomegaly in two Lithuanian families, Am J Med Genet Part A 2019, doi:
10.1002/ajmg.a.61453.
38
142. Cabet, S., Putoux, A., Buenerd, A., Gueneau, L., Reymond, A., Thia, E.W.H.,
Lai, A.H.M., Schindewolf, E.M., Sanlaville, D., Lesca, G. & Guibaud, L., Prenatal
cerebral imaging features of a new syndromic entity related to KIAA1109 pathogenic
variants mimicking tubulinopathy, Prenatal Diagnosis 2019, Nov 17. doi:
10.1002/pd.5589.
143. Voisin, N., Schnur, R.E., Douzgou, S., Hiatt, S.M., Rustad, C.F., Brown, N., Earl,
D.L., Keren, B., Levchenko, O., Geuer, S., Amor, D., Brusco, A., Bebin, E.M.,
Cappucio, G., Charrow, J., Chatron, N., Cooper, G.M., Dadali, E., Delafontaine, J.,
Del Giudice, E., Douglas, G., Funari, T., Giannuzzi, G., Guex, N., Heron, D., Holla,
Ø.L., Hurst, A.C.E., Juusola, J., Kronn, D., Lavrov, A., Lee, C., Merckoll, E.,
Mikhaleva, A., Norman, J., Pradervand, S., Sanders, V., Sirchia, F., Takenouchi, T.,
Tanaka, A.J., Taska-Tench, H., Tønne, E., Tveten, K., Vitiello, G., Uehara, T., Nava,
C., Yalcin, B., Kosaki, K., Donnai, D., Mundlos, S., Brunetti-Pierri, N., Chung, W.K. &
Reymond, A., Variants in the degron of AFF3 cause a multi-system disorder with
mesomelic dysplasia, horseshoe kidney and developmental and epileptic
encephalopathy, 2020, submitted, preprint in biorxiv:
https://www.biorxiv.org/content/10.1101/693937v1
144. Männik, K., Arbogast, T., Lepamets, M., Lepik, K., Pellaz, A., Ademi, H.,
Kupchinsky, Z.A., Ellegood, J., Attanasio, C., Messina, A., Rotman, S., Martin-
Brevet, S., Dubruc, E., Chrast, J., Lerch, J.P., Qiu, L.R., Laisk, T., The 16p11.2
European Consortium, The Simons VIP Consortium, The eQTLGen Consortium,
Henkelman, R.M., Jacquemont, S., Herault, Y., Lindgren, C.M., Peterson, H., Stehle,
J.C., Katsanis, N., Kutalik, Z., Nef, S., Draganski, B., Davis, E.E., Mägi, R. &
Reymond, A., Leveraging biobank-scale rare and common variant analyses to
identify ASPHD1 as the main driver of reproductive traits in the 16p11.2 locus, 2019,
submitted; preprint in biorxiv: https://www.biorxiv.org/content/10.1101/716415v1
145. Siavrienė, E., Preikšaitienė, E., Maldžienė, Ž., Ambrozaitytėa, L., Gueneau, L.,
Reymond, A., Kučinskas, V., A de novo 13q31.3 microduplication encompassing the
miR-17~92 cluster results in features mirroring those associated with Feingold
syndrome 2, 2020, submitted.
146. The ENCODE Project Consortium including Reymond, A., Expanded
Encyclopedias of DNA Elements in the Human and Mouse Genomes, 2020, Nature
in press.
147. De Nittis, P., Sarre, A., Efthymiou, S., Putoux, A., Guex, N., Chrast, J., Maroofian,
R., SYNAPS Study Group, Lesca, G., Chatron, N., Sultana, T., Raza Alvi, J., ur
Rahman, Z., Zafar, F., Rana, N., Rahman, F., Anwar, N., Maqbool, S., Salpietro, V.,
Christoforou, M., Houlden, H., Simonds, W.F., Pedrazzini, T., and Reymond, A.,
Inhibition of G-protein signaling in cardiac dysfunction of Intellectual Developmental
Disorder with Cardiac Arrhythmia (IDDCA) syndrome, 2020, submitted.
39
Original review manuscripts (peer-reviewed)
148. Antonarakis, S.E., Lyle, R., Deutsch, S. & Reymond, A., Chromosome 21: a
small land of fascinating disorders with unknown pathophysiology, Int J Dev Biol 46,
2002, 89-96.
149. Antonarakis, S.E., Reymond, A., Lyle, R., Deutsch, S. & Dermitzakis, E.T.,
Chromosome 21 and Down syndrome; the post genome sequence era, Cold Spring
Harb Symp Quant Biol 68, 2004, 425-430.
150. Antonarakis, S.E., Lyle, R., Dermitzakis, E.T., Reymond, A. & Deutsch, S.,
Chromosome 21 and Down syndrome; current model and future developments, Nat
Rev Genet 5, 2004, 725-738.
151. Dermitzakis, E.T., Reymond, A. & Antonarakis, S.E., Conserved non-genic
sequences - an unexpected feature of mammalian genomes, Nat Rev Genet, 6,
2005, 151-157.
152. Reymond, A., Henrichsen, C.N., Harewood, L. & Merla, G., Side effects of
genome structural changes, Curr Opin Genet Dev, 17, 2007, 381-386.
153. Henrichsen, C.N., Chaignat, E. & Reymond, A., Copy number variants, diseases
and gene expression, Hum Mol Genet 18(R1), 2009, R1-R8.
154. Harrow, J., Nagy, A., Reymond, A., Alioto, T., Patthy, L., Antonarakis, S.E., &
Guigo, R., Identifying Protein-Coding Genes in Genomic Sequences, Genome Biol
10, 2009, 201.
155. Keane, T.M., Wong, K., Adams, D.J., Flint, J., Reymond, A. & Yalcin, B.,
Identification of structural variation in mouse genomes, Front Genet 5:192, 2014, doi:
10.3389/fgene.2014.00192.
Letter to the editor
156. Antonarakis, S.E. Reymond, A., Menzel, O., Bekkeheien, R., Fukai, N.,
Kosztolanyi, G., Aftimos, S., Deutsch, S., Scott, H.S., Olsen, B.J., & Guipponi, M., A
response to Suzuki et al. "How pathogenic is the p.D104N/endostatin polymorphic
allele of COL18A1 in Knobloch syndrome?", Hum Mutat 25, 2005, 316.
157. Deutsch, S. & Reymond, A., Meeting report: The future is genome-wide,
Genome Biol 7, 2006, 324.
40
158. Vernon, H., Cohen, J., De Nittis, P., Fatemi, A., McClellan, R., Goldstein, A.,
Malerba, N., Guex, N., Reymond, A. & Merla, G., IDDCA syndrome in a child with
compound heterozygous GNB5 variants, Clin Genet 93(6), 2018, 1254-1256.
Book chapters
159. Reymond, A., & Arlettaz, R., Barbastella barbastellus (Schreber, 1774), pp 190-
193, in “Säugetiere der Schweiz: Verbreitung, Biologie, Ökologie”, edited by J.
Hausser, 1995 Basel, Boston, Berlin, Birkhäuser Verlag.
160. Deutsch, S., Antonarakis, S.E. & Reymond, A., Disorders of Chromosome 21, in
Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine, edited
by Ganten, D. & Ruckpaul, K., Springer Verlag, 2006.
161. Dermitzakis, E.T. & Reymond, A., Chapter 12, DNA sequence evolution and
phylogenetic footprinting, in Mammalian Genomics, edited by Ruvinsky, A. &
Marshall Graves, J.A., CAB International, 2004.
162. Micale, L., Reymond, A. & Merla, G., Molecular approaches to study genotype-
phenotype in contiguous gene disorders, the example of Williams Beuren Syndrome,
in Human Molecular Genetics Research Trends, edited by Columbus, F., Nova
Publishers, 2007.
163. Micale, L., Chaignat, E., Reymond, A. & Merla, G., The TRIpartite Motif:
Structure and function, in TRIM/RBCC Proteins, edited by G. Meroni, Landes
Bioscience, 2011, http://www.landesbioscience.com/curie/chapter/4478/
164. Gheldof, N., Leleu, M., Noordermeer, D., Rougemont, J. & Reymond, A.,
Detecting Long-Range Chromatin Interactions Using the Chromosome Conformation
Capture Sequencing (4C-seq) Method, Methods Mol Biol 786, 2012, 211-25, doi:
10.1007/978-1-61779-292-2_13
165. Harewood, L., Chaignat, E. & Reymond, A., Structural variation and its effect on
expression, Methods Mol Biol 838, 2012, 173-186, DOI: 10.1007/978-1-61779-507-
7_8
Ph.D. Thesis
166. Reymond, A., The Schizosaccharomyces pombe DSC-1 complex: cell cycle
regulation and functional domains of p85cdc10, University of Lausanne, 1993
41
Funding (since joining CIG, UNIL)
period Agency/Foundation (AR role) amount for UNIL
2003-2005 Telethon Action Suisse Foundation (PI) CHF 98’100.-
2003-2007 Swiss National Science Foundation (PI) CHF 202’938.-
2004-2007 Désirée and Niels Yde Foundation (PI) CHF 41’900.-
2005-2007 Jérôme Lejeune Foundation (PI) € 40’000.-
2006-2007 Novartis Foundation (PI) CHF 49’950.-
2006-2010 European Commission
FP6 Integrated Project “anEUploidy” (co-PI) € 730’000.-
2007-2010 Swiss National Science Foundation (PI) CHF 296’000.-
2007-2011 NIH-NHGRI-ENCODE project (co-PI) US$ 760’339.-
2007-2011 NIH-NHGRI-ENCODE project (co-PI) US$ 1’255’681.-
2007-2010 FBM UNIL PhD Fellowship (PI) CHF 144’693.-
2008 Roche Foundation (PI) CHF 55’000.-
2008-2009 Jérôme Lejeune Foundation (PI) € 30’000.-
2008-2009 Telethon Action Suisse Foundation (PI) CHF 60’000.-
2009-2011 Interdisciplinary research project FBM UNIL CHF 200’000.-
2010-2014 Swiss National Science Foundation (PI) CHF 415’000.-
2010-2013 Sinergia Collaborative project, Swiss National
Science Foundation (co-PI) CHF 400’000.-
2010 Prix Fondation Leenaards CHF 477’000.-
2011-2014 Sinergia Collaborative project, Swiss National
Science Foundation (PI) CHF 1’500’000
2011 R’Equip grant, Swiss National Science
Foundation (co-PI) CHF 341’000.-
2012-2014 ProDoc Population Genomics, SNF (PI) CHF 219’139.-
2011 Hewlett-Packard (material)(co-PI) CHF 250’000.-
2012-2013 NIH-NHGRI-ENCODE U54 project (co-PI) US$ 159’790.-
2013-2017 NIH-NHGRI-GENCODE U41 project (co-PI) US$ 1’952’940.-
2013-2018 SystemsX.ch project (co-PI) CHF 1’060’000.-
2013-2016 Simons Foundation Autism Research Initiative (PI) US$ 300’000.-
2013-2016 FBM UNIL PhD Fellowship (PI) CHF 150’000.-
2013-2015 SNSF AGORA project (PI) CHF 200’000.-
2013-2014 Foundation Herbette (PI) CHF 25’000.-
2013-2017 Lithuanian-Swiss Cooperation Program (PI) LTL 1’048’000.-
2015-2018 Swiss National Science Foundation (PI) CHF 803’000.-
2016 Brazilian-Swiss Joint Research Programme (PI) CHF 9’600.-
2016-2018 Horizon 2020, Twinning program (co-PI) € 281,375.-
2018-2022 Swiss National Science Foundation (PI) CHF 1,224,000.-
2019-2021 Jérôme Lejeune Foundation (PI) € 40’000.-
42
Curriculum Vitae
Isiklik informatsioon
Ees- ja perekonnanimi Triinu Temberg
Sünniaeg 10.03.1975
Kodakondsus Eesti
Elukoht Veski 15-3, Tartu 51005
Telefon 55 44 524
E-mail
[email protected]
Hariduskäik
2006-2009 Tartu Ülikool, arstiteaduskond, biomeditsiini magistriõpe
(MA 002458)
2003-2006 Tartu Tervishoiu Kõrgkool, bioanalüütiku õppekava,
tasemeõpe (EL002478)
1993-1996 Tartu Meditsiinikool, laboratoorse diagnostika eriala
(reg. nr. 6877)
1989-1993 Tõrva Keskkool
1981-1989 Vastseliina Keskkool
Täiendkoolitus
30.08.2019 - 31.08.2019 Geenifoorum 2019
29.04.2019 - 30.04.2019 Esmaabi baaskoolitus
22.11.2018 – 23.11.2018 Eesti Inimesegeneetika aastakonverents
13.02.2017 – 28.04.2017 Eesti keele õigekirja e-kursus
10.02.2011 – 11.02.2011 Labqualiti-päivät, Helsingi
04.08.2010 – 05.08.2010 Keskastmejuhi roll info liikumise juhtimisel (sh kriisi
juhtimine) 16t, Tartu Ülikool, Avatud Ülikooli Keskus
03.08.2009 – 04.08.2009 Mõjus suhtlemine organistasioonis 16t, Tartu Ülikool,
Avatud Ülikooli Keskus
10.08.2009 – 11.08.2009 Konfliktide juhtimine ja tundetarkus 14t, Tartu Ülikool,
Avatud Ülikooli Keskus
21.04.2009 Töötervishoiu-ja tööohutusealane täiendõpe 8t, Juunika
Koolitus, Tartu
27.08.2009 – 29.09.2009 Laborimeditsiini Ühingu XII suvekool, Otepää
17.06.2009 Juhtimine ja turundus, Projektijuhtimine - , Eesti
Majandusjuhtide Ettevõtluskool EMI EWT, Tartu
01.04.2009 – 02.04.2009 Meeskonna juhtimine 16t, Klienditeeninduskeskus, Tartu
26.10.2007 – 27.10.2007 Ülevaade geneetikast ja lähivaade neurogeneetikale, Eesti
Inimesegeneetika Ühing, Pärnu
23.08.2007 – 25.08.2007 Eesti Laborimeditsiini Ühingu X suvekool, Kuressaare
22.01.2007 – 08.02.2007 Katseloomateadus B-kategooria kursus, Tartu Ülikool
08.03.2007 Meeskonnatöö kui edu võti 5t, SA TÜK Kliinilise Eetika
komitee ja SA TÜK juhatus, Tartu
16.02.2007 Arst-õde-haige suhted ja neid mõjutavad faktorid 5t,
SA TÜK Kliinilise Eetika Komitee ja SA TÜK juhatus
09.02.2007 – 11.02.2007 Molekulaarbioloogia Talvekool 2007, TÜ molekulaar-ja
rakubiolooia Instituut, Jäneda
26.01.2007 – 27.01.2007 Immuunsus, geenid ja elukeskkond, Eesti Inimesegeneetika
Ühing, Jäneda
25.11.2005 – 06.12.2005 Töökeskkonnavolinike ja töökeskkonnanõukogu liikmete
väljaõppekursus 24t, Tartu Haritlaste Liit
21.09.2005 – 30.11.2005 Raamatupidamise algkursus 80t, Tartu Haritlaste Liit
Töökogemus
01.01.2017 - Tartu Ülikooli Geenivaramu – mikrobioomika spetsialist
100K ja 50K projekti geenidoonorite kogumise koordinaator.
04.05.2008 – 31.12.2016 Asper Biotech AS – laborijuhataja
Tööjuhendite ja analüüsimetoodikate väljatöötamine.
Laboriprotokollide koostamine. Kvaliteedikäsiraamatu
dokumentide kaasajastamine. Kvaliteedikäsiraamatus
olevate nõuete täitmise kontroll laboris. Labori aparatuuri
kasutamise juhendite koostamine, hooldus.
Isadustestide ja tromboositestide analüüsimine, tulemuste
interpreteerimine vastuste allkirjastamine.
Saabunud proovide analüüsi teostamine (PCR,
restriktsioonanalüüs, MLPA, RT-PCR, NGS, APEX)
Töökohustuste hulka kuulus igapäevase töö korraldamine ja
planeerimine laboris, vajalike töövahendite, vajaliku
aparatuuri hankimine/hinnapakkumused erinevatelt
tarnijatelt. Iganädalased labori töö ja analüüside
kokkuvõtted ning nende esitlemine juhtkonna koosolekutel.
01.04.1996 – 04.06.2008 Sihtasutus TÜK Ühendlabor, Molekulaardiagnostika Keskus
- vanemlaborant
Tööülesannete hulka kuulus DNA eraldamine, DNA testide
teostamine, esmane tulemuste interpretatsioon.
Vanemlaborandi ametikohustuste hulka kuulus
laboriseadmete hankimine, reagentide tellimine,
kvaliteedikäsiraamatu dokumentide kaasajastamine.
Igakuised analüüside kokkuvõtted, arvete esitamine
raamatupidamisse. 2006. aastal omistati
kõrgem kvalifikatsioonikategooria. Olen osalenud
Kliinikumis Ühendlabori osakondade siseauditeerimisel.
01.07.1995 – 30.06.1996 Tartu Ülikooli Närvikliinik, neurokirurgia osakond -
hooldusõde.
Keelteoskus
Eesti keel Emakeel
Vene keel Kõnes keskmine, kirjas keskmine
Inglise keel Kõnes keskmine, kirjas keskmine
Soome keel 2006. aastal läbinud algkursuse
Arvutioskus
MS Word, Excel, Power Point, CRM Kasutan tööülesannete täitmisel sagedasti
Täiendav info
Isikuomadused Korrektne, täpne, aus, õppimisvõimeline, uuendusmeelne
Sõidukijuhtimine B-kategooria autojuhiload
Huvialad Lugemine, jalutamine
Kuulun Tähtvere Seltsi juhatusse ja olen aktiivne Tähtvere linnaosapäevade korraldaja.
Olen Eesti Inimesegeneetika Ühingu liige ning Laborimeditsiini Ühingu liige.
Neeme Tõnisson
Date of birth 17.02.1971
E-mail
[email protected]
Google scholar Citations 2125
h-index 17
Institutions and positions
01.09.2015–... University of Tartu, Institute of Genomics, Senior Researcher
01.01.2015–... Tartu University Hospital, United Laboratories of Tartu University
Hospital, Dept. of Genetics; Clinical Geneticist
15.10.2013– University of Tartu, Faculty of Science and Technology (old), Institute
28.02.2015 of Molecular and Cell Biology, University of Tartu, Senior Researcher
01.01.2007– Tartu University Hospital, United Laboratories of Tartu University
31.12.2012 Hospital, Dept. of Genetics; Med Lab Specialist, Head of Molecular
Diagnostics Lab 2008-2012
01.01.2004– Visiting Scientist, Deutsches Krebsforschngszentrum (DKFZ),
31.12.2006 Heidelberg, Germany
01.01.2004– Scientist, Institute of Molecular and Cell Biology, University of Tartu
31.12.2004
01.01.2001– Senior Researcher, Asper Biotech, Ltd. Head of Genotyping
31.12.2007 Applications, 2001-2002
Education
2012–2015 Resident Physician in clinical genetics, University of Tartu /Tartu
University Hospital
2008–2012 Resident Physician in laboratory medicine, University of Tartu /Tartu
University Hospital
2003 Ph.D in molecular diagnostics, University of Tartu
1995 Medical Faculty, University of Tartu
R&D related managerial and administrative work
2018−... Member of Nordic Society of Precision Medicine
2017−... Member of European Society of Human Genetics
2014−... Member of the Estonian Society of Medical Genetics
2009−... Member of the Estonian Medical Association, Member of EMA
Management Board since 2016
2007−... Member of the Estonian Society of Laboratory Medicine
2000−... Member of the Estonian Society of Human Genetics. Member of the
Management Board since 2017
2006−2011 Estonian Science Foundation, member of Expert Board
Honours & awards
2007 Return scholarship from Alexander von Humboldti Foundation / Hertie Foundation
2004 Roman Herzog Research Fellowship, Alexander von Humboldt Foundation / Hertie
Foundation
Projects in progress
• SLTMR16142T (TK142) "Centre of Excellence for Genomics and Translational Medicine
(TK142) (1.01.2016−1.03.2023)", Andres Metspalu, University of Tartu, Estonian Genome
Center .
• PRG555 "Evaluation of genetic variants potentially linked to actionable health risks
(1.01.2019−31.12.2022)", Neeme Tõnisson, University of Tartu, Institute of Genomics.
• SP1GV16037T ( EU48684 / 4.1) "Technologies for Information Extraction, data integration
and management (1.12.2015−30.06.2022)", Tõnu Esko, University of Tartu, Estonian
Genome Center .
• (RITA1/01-42-01) "Clinical pilot projects of personalised medicine in the precise prevention
of breast cancer and cardiovascular diseases (1.01.2018−31.12.2020)", Peeter Padrik, Tartu
University Hospital.
• LP1GI18069 (RITA1/01-42-03) "Clinical pilot projects of personalised medicine in the
precise prevention of breast cancer and cardiovascular diseases (1.01.2018−31.12.2020)",
Andres Metspalu, University of Tartu, Institute of Genomics.
• LP1GI18069 (RITA1/01-42-03) "Clinical pilot projects of personalised medicine in the
precise prevention of breast cancer and cardiovascular diseases (1.01.2018−31.12.2020)",
Andres Metspalu, University of Tartu, Institute of Genomics.
• SP1GI18534 "Extended phenotype studies in carriers and potentially affected individuals of
selected lysosomal storage diseases among the participants of Estonian Biobank, Step II
analysis (1.01.2019−30.06.2020)", Neeme Tõnisson, University of Tartu, Institute of
Genomics.
Supervised dissertations
• Kaie Lokk, Doctor's Degree, 2017, (sup) Neeme Tõnisson; Lili Azin Milani, Comparative
genome-wide DNA methylation studies of healthy human tissues and non-small cell lung
cancer tissue, University of Tartu, Faculty of Science and Technology, Institute of Molecular
and Cell Biology.
• Karmen Vaiküll, Master's Degree, 2018, (sup) Tiit Nikopensius; Neeme Tõnisson, Sekkumist
võimaldavad geenivariandid TÜ Eesti Geenivaramu valimis - haigusseoselisuse tuvastamine
ja võimalik kasutamine geneetilises tagasisides (Actionable gene variants in Estonian
Genome Center sample - identification of disease-associated variants and their possible use in
genetic feedback), University of Tartu, Faculty of Science and Technology, Institute of
Molecular and Cell Biology.
• Margot Saare, Master's Degree, 2017, (sup) Neeme Tõnisson; Kaie Lokk; Madli Tamm,
Tsirkuleeriva rakuvaba DNA metülatsioonitaseme muutused kopsuvähi biomarkerina
(Altered methylation of circulating cell-free DNA as a biomarker of lung cancer), University
of Tartu, Estonian Genome Center.
• Madli Tamm, Master's Degree, 2016, (sup) Neeme Tõnisson; Paula Ann Kivistik; Mart Kals,
Kasvajaseoseliste mutatsioonide määramine kopsuvähiga uuritavate rakuvabast DNA-st
(Detecting cancer related mutations in cell-free DNA of lung cancer patients), University of
Tartu, Faculty of Science and Technology (old), Institute of Molecular and Cell Biology,
University of Tartu.
Publications
2019
Alver, Maris; Palover, Marili; Saar, Aet; Läll, Kristi; Zekavat, Seyedeh Maryam; Tõnisson,
Neeme; Leitsalu, Liis; Reigo, Anu; Nikopensius, Tiit; Ainla, Tiia; Kals, Mart; Mägi, Reedik;
Gabriel, Stacey B; Eha, Jaan; Lander, Eric S; Irs, Alar; Philippakis, Anthony; Marandi, Toomas;
Natarajan, Pradeep; Metspalu, Andres ... Esko, Tõnu (2019). Recall by genotype and cascade
screening for familial hypercholesterolemia in a population-based biobank from Estonia.
Genetics in medicine, 21 (5), 1−8.10.1038/s41436-018-0311-2.
Läll, Kristi; Lepamets, Maarja; Palover, Marili; Esko, Tõnu; Metspalu, Andres; Tõnisson,
Neeme; Padrik, Peeter; Mägi, Reedik; Fischer, Krista (2019). Polygenic prediction of breast
cancer: comparison of genetic predictors and implications for risk stratification. Bmc Cancer, 19,
ARTN 557.10.1186/s12885-019-5783-1.
Tšuiko, Olga; Dmitrijeva, Tuuli; Kask, Katrin; Tammur, Pille; Tõnisson, Neeme; Salumets,
Andres; Jatsenko, Tatjana (2019). Detection of a balanced translocation carrier through
trophectoderm biopsy analysis: a case report. Molecular Cytogenetics, 12, ARTN
28.10.1186/s13039-019-0444-2.
2018
Tanskanen, Tomas; van den Berg, Linda; Välimäki, Niko; Aavikko, Mervi; Ness-Jensen, Eivind;
Hveem, Kristian; Wettergren, Yvonne; Bexe Lindskog, Elinor; Tõnisson, Neeme; Metspalu,
Andres; Silander, Kaisa; Orlando, Giulia; Law, Philip J; Tuupanen, Sari; Gylfe, Alexandra E;
Hänninen, Ulrika A; Cajuso, Tatiana; Kondelin, Johanna; Sarin, Antti-Pekka; Pukkala, Eero ...
Aaltonen, Lauri A (2018). Genome-wide association study and meta-analysis in Northern
European populations replicate multiple colorectal cancer risk loci. International journal of
cancer, 142 (3), 540−546.10.1002/ijc.31076.
2017
Grigorova, Marina; Punab, Margus; Kahre, Tiina; Ivandi, Mare; Tõnisson, Neeme; Poolamets,
Olev; Vihljajev, Vladimir; Žilaitienė, Birutė; Erenpreiss, Juris; Matulevičius, Valentinas; Laan,
Maris (2017). The number of CAG and GGN triplet repeats in the Androgen Receptor gene exert
combinatorial effect on hormonal and sperm parameters in young men. Andrology, 5 (3),
495−504.10.1111/andr.12344.
Klaeger, Susan; Heinzlmeir, Stephanie; Wilhelm, Mathias; Polzer, Harald; Vick, Binje; Koenig,
Paul-Albert; Reinecke, Maria; Ruprecht, Benjamin; Petzoldt, Svenja; Meng, Chen; Zecha, Jana;
Reiter, Katrin; Qiao, Huichao; Helm, Dominic; Koch, Heiner; Schoof, Melanie; Canevari,
Giulia; Casale, Elena; Depaolini, Stefania Re; Feuchtinger, Annette ... Kuster, Bernhard (2017).
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 358 (6367),
eaan4368.10.1126/science.aan4368.
2015
Žilina, Olga; Koltšina, Marina; Raid, Raivo; Kurg, Ants; Tõnisson, Neeme; Salumets, Andres
(2015). Somatic mosaicism for copy-neutral loss of heterozygosity and DNA copy number
variations in the human genome. BMC Genomics, 16 (703), 1−10.10.1186/s12864-015-1916-3.
2014
Lokk, Kaie; Modhukur, Vijayachitra; Rajashekar, Balaji; Märtens, Kaspar; Mägi, Reedik; Kolde,
Raivo; Koltšina, Marina; Nilsson, Torbjörn K.; Vilo, Jaak; Salumets, Andres; Tõnisson, Neeme
(2014). DNA methylome profiling of human tissues identifies global and tissue-specific
methylation patterns. Genome Biology, 15 (4), R54.10.1186/gb-2014-15-4-r54.
2012
Lokk, Kaie; Vooder, Tõnu; Kolde, Raivo; Välk, Kristjan; Võsa, Urmo; Roosipuu, Retlav;
Milani, Lili; Fischer, Krista; Koltšina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres;
Tõnisson, Neeme (2012). Methylation Markers of Early-Stage Non-Small Cell Lung Cancer.
PLOS ONE, 7 (6), e39813− .10.1371/journal.pone.0039813.
Industrial property
International patent application: Method for optimising the sequences of synthetic nucleic
acids; Owners: Asper Biotech AS; Authors: Neeme Tõnisson, Pavel, H.; Tõnisson, N.; Zernant,
J.; Priority number: PCT/EE00/00003; Priority date: 24.11.2000.
Utility model: Praimerekstensioonil põhinev geenianalüüsi meetod; Owners: Asper Biotech;
Authors: Andres Metspalu, Ants Kurg, Hendrik Pavel, Jana Zernant, Neeme Tõnisson; Priority
number: U200100038; Priority date: 8.11.2001.
Professor IOANNIS XENARIOS Ph.D.
Health2030 Genome Center
Center for Integrative Genomics
Departement Formation et Recherche
CHUV
University of Lausanne
Quartier Sorge- Bâtiment Génopode
CH-1015 LAUSANNE
Tel: +41 78 826 05 70 / Email :
[email protected]
http://orcid.org/0000-0002-3413-6841
Current position
Professor CHUV /DFR Computational Biology and Bioinformatics
Professor, University of Lausanne
Professor, University of Geneva
Education
Ph.D. 1999 University of Lausanne, Institute of Biochemistry, Switzerland
Thesis: Role of virus specific B cells in mouse mammary tumor
virus infection.
Master 1995 Diploma work on recombination mechanism of superantigens
from Mouse Mammary Tumor Virus
BSC 1993 Certificate Study on Sequence Profile Analysis method
1989-1993 Biological Sciences and specialization in Zoology, Molecular
Biology, and Biochemistry
Professional and academic experiences
Head of DAIP 2019- Head of the Data Analysis for Health2030 Genome Center
Professor 2018- CHUV / DFR Computational Biology and Bioinformatics
Professor 2014- University of Geneva / Biochemistry/Chemistry Department
Professor 2010- University of Lausanne / Center for Integrative Genomics
Director of Swiss-Prot 2009-2018 SIB Swiss Institute of Bioinformatics, Geneva
Director of Vital-IT 2007-2018 SIB Swiss Institute of Bioinformatics, Lausanne
Manage a high performance computing center dedicated to life
sciences
Head of Translational
Bioinformatics 2005-2007 Serono Pharmaceutical Research Institute (Merck-Serono)
Support research function in area of genomics/proteomics/genetics
Head of Bioinformatics 2003-2005 Serono Pharmaceutical Research Institute
Head translational bioinformatics and bioanalysis groups
Head of Bioanalysis 2002-2003 Serono Pharmaceutical Research Institute, Plan-les-Ouates
Responsible for the bioanalysis genomic target team
Postdoctoral Fellow 1999-2002 University of California, Los Angeles
Development and implementation of the database of interacting
Proteins. Supervised by Prof. David Eisenberg
Research output list: 2013-2018
Peer reviewed publications 159: H-index 55 (November 2018)
159) Genome-Wide Identification of microRNAs Regulating the Human Prion Protein. Pease D,
Scheckel C, Schaper E, Eckhardt V, Emmenegger M, Xenarios I, Aguzzi A. Brain Pathol. 2018 Nov 19.
doi: 10.1111/bpa.12679.
158) UniProt: a worldwide hub of protein knowledge. UniProt Consortium . Nucleic Acids Res. 2018 Nov
5. doi: 10.1093/nar/gky1049.
157) Updates in Rhea: SPARQLing biochemical reaction data. Lombardot T, Morgat A, Axelsen KB,
Aimo L, Hyka-Nouspikel N, Niknejad A, Ignatchenko A, Xenarios I, Coudert E, Redaschi N, Bridge A.
Nucleic Acids Res. 2018 Oct 1. doi: 10.1093/nar/gky876. [Epub ahead of print]
156) Cycles of gene expression and genome response during mammalian tissue regeneration. Rib L,
Villeneuve D, Minocha S, Praz V, Hernandez N, Guex N, Herr W; CycliX Consortium. Epigenetics
Chromatin. 2018 Sep 12;11(1):52. doi: 10.1186/s13072-018-0222-0.
155) Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome. Mylonas R,
Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M. Mol
Cell Proteomics. 2018 Aug 31. pii: mcp.RA118.000877. doi: 10.1074/mcp.RA118.000877.
154) Scaling up data curation using deep learning: An application to literature triage in genomic
variation resources. Lee K, Famiglietti ML, McMahon A, Wei CH, MacArthur JAL, Poux S, Breuza L,
Bridge A, Cunningham F, Xenarios I, Lu Z. PLoS Comput Biol. 2018 Aug 13;14(8):e1006390. doi:
10.1371/journal.pcbi.1006390. eCollection 2018 Aug.
153) A systems genetics resource and analysis of sleep regulation in the mouse. Diessler S, Jan M,
Emmenegger Y, Guex N, Middleton B, Skene DJ, Ibberson M, Burdet F, Götz L, Pagni M, Sankar M,
Liechti R, Hor CN, Xenarios I, Franken P. PLoS Biol. 2018 Aug 9;16(8):e2005750. doi:
10.1371/journal.pbio.2005750.
152) Expert curation for building network-based dynamical models: a case study on atherosclerotic
plaque formation. Bekkar A, Estreicher A, Niknejad A, Casals-Casas C, Bridge A, Xenarios I, Dorier J,
Crespo I. Database (Oxford). 2018 Jan 1;2018. doi: 10.1093/database/bay031.
151) Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C,
Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA,
Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V,
Harari A, Coukos G, Kandalaft LE. Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi:
10.1126/scitranslmed.aao5931.
150) Deciphering the Dynamic Transcriptional and Post-transcriptional Networks of Macrophages in the
Healthy Heart and after Myocardial Injury. Walter W, Alonso-Herranz L, Trappetti V, Crespo I, Ibberson
M, Cedenilla M, Karaszewska A, Núñez V, Xenarios I, Arroyo AG, Sánchez-Cabo F, Ricote M. Cell
Rep. 2018 Apr 10;23(2):622-636. doi: 10.1016/j.celrep.2018.03.029.
149) Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in
immunotherapy-naive ovarian cancer. Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson
BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L,
Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.
Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.
148) KIAA1109 Variants Are Associated with a Severe Disorder of Brain Development and
Arthrogryposis. Gueneau L, Fish RJ, Shamseldin HE, Voisin N, Tran Mau-Them F, Preiksaitiene E,
Monroe GR, Lai A, Putoux A, Allias F, Ambusaidi Q, Ambrozaityte L, Cimbalistienė L, Delafontaine J,
Guex N, Hashem M, Kurdi W, Jamuar SS, Ying LJ, Bonnard C, Pippucci T, Pradervand S, Roechert B,
van Hasselt PM, Wiederkehr M, Wright CF; DDD Study, Xenarios I, van Haaften G, Shaw-Smith C,
Schindewolf EM, Neerman-Arbez M, Sanlaville D, Lesca G, Guibaud L, Reversade B, Chelly J,
Kučinskas V, Alkuraya FS, Reymond A. Am J Hum Genet. 2018 Jan 4;102(1):116-132. doi:
10.1016/j.ajhg.2017.12.002.
147)Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung
Cancer. Faget J, Groeneveld S, Boivin G, Sankar M, Zangger N, Garcia M, Guex N, Zlobec I, Steiner L,
Piersigilli A, Xenarios I, Meylan E. Cell Rep. 2017 Dec 12;21(11):3190-3204. doi:
10.1016/j.celrep.2017.11.052.
146) Low number of fixed somatic mutations in a long-lived oak tree. Schmid-Siegert E, Sarkar N, Iseli
C, Calderon S, Gouhier-Darimont C, Chrast J, Cattaneo P, Schütz F, Farinelli L, Pagni M, Schneider M,
Voumard J, Jaboyedoff M, Fankhauser C, Hardtke CS, Keller L, Pannell JR, Reymond A, Robinson-
Rechavi M, Xenarios I, Reymond P. Nat Plants. 2017 Dec;3(12):926-929. doi: 10.1038/s41477-017-
0066-9.
145) Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines
a novel transcriptomic signature of islets from individuals with type 2 diabetes. Solimena M, Schulte AM,
Marselli L, Ehehalt F, Richter D, Kleeberg M, Mziaut H, Knoch KP, Parnis J, Bugliani M, Siddiq A, Jörns
A, Burdet F, Liechti R, Suleiman M, Margerie D, Syed F, Distler M, Grützmann R, Petretto E, Moreno-
Moral A, Wegbrod C, Sönmez A, Pfriem K, Friedrich A, Meinel J, Wollheim CB, Baretton GB,
Scharfmann R, Nogoceke E, Bonifacio E, Sturm D, Meyer-Puttlitz B, Boggi U, Saeger HD, Filipponi F,
Lesche M, Meda P, Dahl A, Wigger L, Xenarios I, Falchi M, Thorens B, Weitz J, Bokvist K, Lenzen S,
Rutter GA, Froguel P, von Bülow M, Ibberson M, Marchetti P. Diabetologia. 2018 Mar;61(3):641-657.
doi: 10.1007/s00125-017-4500-3.
144) SourceData: a semantic platform for curating and searching figures. Liechti R, George N, Götz L,
El-Gebali S, Chasapi A, Crespo I, Xenarios I, Lemberger T. Nat Methods. 2017 Oct 31;14(11):1021-
1022. doi: 10.1038/nmeth.4471.
143) Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven
iterative survival analysis. Crespo I, Götz L, Liechti R, Coukos G, Doucey MA, Xenarios I. NPJ Syst
Biol Appl. 2016 Dec 22;2:16037. doi: 10.1038/npjsba.2016.37. eCollection 2016.
142) A Clb/Cdk1-mediated regulation of Fkh2 synchronizes CLB expression in the budding yeast cell
cycle.Linke C, Chasapi A, González-Novo A, Al Sawad I, Tognetti S, Klipp E, Loog M, Krobitsch S,
Posas F, Xenarios I, Barberis M. NPJ Syst Biol Appl. 2017 Mar 6;3:7. doi: 10.1038/s41540-017-0008-1.
eCollection 2017.
141) MsViz, a graphical software tool for in-depth manual validation and quantitation of post-translational
modifications. Martin Campos T, Mylonas R, Masselot A, Waridel P, Petricevic T, Xenarios I, Quadroni
M. J Proteome Res. 2017 Jun 21. doi: 10.1021/acs.jproteome.7b00194. [Epub ahead of print]
140) Bacterial Virus Ontology; Coordinating across Databases. Hulo C, Masson P, Toussaint A, Osumi-
Sutherland D, de Castro E, Auchincloss AH, Poux S, Bougueleret L, Xenarios I, Le Mercier P. Viruses.
2017 May 23;9(6). pii: E126. doi: 10.3390/v9060126.
139) TIE-2 expressing monocytes in human cancers. Turrini R, Pabois A, Xenarios I, Coukos G, Delaloye
JF, Doucey MA. Oncoimmunology. 2017 Mar 16;6(4):e1303585. doi: 10.1080/2162402X.2017.1303585.
eCollection 2017.
138) Enhanced metabolite annotation via dynamic retention time prediction: Steroidogenesis alterations
as a case study. Randazzo GM, Tonoli D, Strajhar P, Xenarios I, Odermatt A, Boccard J, Rudaz S. J
Chromatogr B Analyt Technol Biomed Life Sci. 2017 Apr 23. pii: S1570-0232(17)30716-X. doi:
10.1016/j.jchromb.2017.04.032. [Epub ahead of print]
137) Molecular phenotyping of multiple mouse strains under metabolic challenge uncovers a role for
Elovl2 in glucose-induced insulin secretion. Cruciani-Guglielmacci C, Bellini L, Denom J, Oshima M,
Fernandez N, Normandie-Levi P, Berney XP, Kassis N, Rouch C, Dairou J, Gorman T, Smith DM, Marley
A, Liechti R, Kuznetsov D, Wigger L, Burdet F, Lefèvre AL, Wehrle I, Uphues I, Hildebrandt T, Rust W,
Bernard C, Ktorza A, Rutter GA, Scharfmann R, Xenarios I, Le Stunff H, Thorens B, Magnan C, Ibberson
M. Mol Metab. 2017 Jan 26;6(4):340-351. doi: 10.1016/j.molmet.2017.01.009. eCollection 2017 Apr.
136) Diurnal regulation of RNA polymerase III transcription is under the control of both the feeding-fasting
response and the circadian clock. Mange F, Praz V, Migliavacca E, Willis IM, Schütz F, Hernandez N;
CycliX Consortium. Genome Res. 2017 Jun;27(6):973-984. doi: 10.1101/gr.217521.116. Epub 2017
Mar 24.
CycliX Consortium: Hernandez N, Delorenzi M, Deplancke B, Desvergne B, Guex N, Herr W, Naef F,
Rougemont J, Schibler U, Andersin T, Cousin P, Gilardi F, Lammers F, Mange F, Villeneuve D, David F,
Fabbretti R, Jacquet P, Krier I, Kuznetsov D, Leleu M, Liechti R, Martin O, Migliavacca E, Naldi A, Praz
V, Rib L, Sobel J, Vlegel V, Xenarios I.
135) Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans.
Wigger L, Cruciani-Guglielmacci C, Nicolas A, Denom J, Fernandez N, Fumeron F, Marques-Vidal P,
Ktorza A, Kramer W, Schulte A, Le Stunff H, Liechti R, Xenarios I, Vollenweider P, Waeber G, Uphues I,
Roussel R, Magnan C, Ibberson M, Thorens B. Cell Rep. 2017 Feb 28;18(9):2269-2279. doi:
10.1016/j.celrep.2017.02.019.
134) The ins and outs of eukaryotic viruses: Knowledge base and ontology of a viral infection. Hulo C,
Masson P, de Castro E, Auchincloss AH, Foulger R, Poux S, Lomax J, Bougueleret L, Xenarios I, Le
Mercier P. PLoS One. 2017 Feb 16;12(2):e0171746. doi: 10.1371/journal.pone.0171746. eCollection
2017.
133) Pressing needs of biomedical text mining in biocuration and beyond: opportunities and challenges.
Singhal A, Leaman R, Catlett N, Lemberger T, McEntyre J, Polson S, Xenarios I, Arighi C, Lu Z. Database
(Oxford). 2016 Dec 26; 2016. pii: baw161. doi: 10.1093/database/baw161. Print 2016.
132) Updates in Rhea - an expert curated resource of biochemical reactions. Morgat A, Lombardot T,
Axelsen KB, Aimo L, Niknejad A, Hyka-Nouspikel N, Coudert E, Pozzato M, Pagni M, Moretti S, Rosanoff
S, Onwubiko J, Bougueleret L, Xenarios I, Redaschi N, Bridge A. Nucleic Acids Res. 2017 Apr
20;45(7):4279. doi: 10.1093/nar/gkw1299. No abstract available.
131) Neighbor Detection Induces Organ-Specific Transcriptomes, Revealing Patterns Underlying
Hypocotyl-Specific Growth. Kohnen MV, Schmid-Siegert E, Trevisan M, Petrolati LA, Sénéchal F, Müller-
Moulé P, Maloof J, Xenarios I, Fankhauser C. Plant Cell. 2016 Dec;28(12):2889-2904. doi:
10.1105/tpc.16.00463. Epub 2016 Dec 6.
130) InterPro in 2017-beyond protein family and domain annotations. Finn RD, Attwood TK, Babbitt PC,
Bateman A, Bork P, Bridge AJ, Chang HY, Dosztányi Z, El-Gebali S, Fraser M, Gough J, Haft D, Holliday
GL, Huang H, Huang X, Letunic I, Lopez R, Lu S, Marchler-Bauer A, Mi H, Mistry J, Natale DA, Necci M,
Nuka G, Orengo CA, Park Y, Pesseat S, Piovesan D, Potter SC, Rawlings ND, Redaschi N, Richardson
L, Rivoire C, Sangrador-Vegas A, Sigrist C, Sillitoe I, Smithers B, Squizzato S, Sutton G, Thanki N,
Thomas PD, Tosatto SC, Wu CH, Xenarios I, Yeh LS, Young SY, Mitchell AL. Nucleic Acids Res. 2017
Jan 4;45(D1):D190-D199. doi: 10.1093/nar/gkw1107. Epub 2016 Nov 29.
129) Global mapping of highly pathogenic avian influenza H5N1 and H5Nx clade 2.3.4.4 viruses with
spatial cross-validation. Dinghra MS, Artois J, Robinson TP, Linard C, Chaiban C, Xenarios I, Engler R,
Liechti R, Kuznetsov D, Xiao X, Dobschuetz SV, Claes F, Newman SH, Dauphin G, Gilbert M. Elife. 2016
Nov 25;5. pii: e19571. doi: 10.7554/eLife.19571.
128) Identification of a RAI1-associated disease network through integration of exome sequencing,
transcriptomics, and 3D genomics. Loviglio MN, Beck CR, White JJ, Leleu M, Harel T, Guex N, Niknejad
A, Bi W, Chen ES, Crespo I, Yan J, Charng WL, Gu S, Fang P, Coban-Akdemir Z, Shaw CA, Jhangiani
SN, Muzny DM, Gibbs RA, Rougemont J, Xenarios I, Lupski JR, Reymond A. Genome Med. 2016 Nov
1;8(1):105.
127) Updates in Rhea - an expert curated resource of biochemical reactions. Morgat A, Lombardot T,
Axelsen KB, Aimo L, Niknejad A, Hyka-Nouspikel N, Coudert E, Pozzato M, Pagni M, Moretti S, Rosanoff
S, Onwubiko J, Bougueleret L, Xenarios I, Redaschi N, Bridge A. Nucleic Acids Res. 2017 Jan
4;45(D1):D415-D418. doi: 10.1093/nar/gkw990. Epub 2016 Oct 26. Erratum in: Nucleic Acids Res. 2016
Dec 15.
126) MAR-Mediated transgene integration into permissive chromatin and increased expression by
recombination pathway engineering. Kostyrko K, Neuenschwander S, Junier T, Regamey A, Iseli C,
Schmid-Siegert E, Bosshard S, Majocchi S, Le Fourn V, Girod PA, Xenarios I, Mermod N. Biotechnol
Bioeng. 2017 Feb;114(2):384-396. doi: 10.1002/bit.26086. Epub 2016 Oct 3.
125) Boolean regulatory network reconstruction using literature based knowledge with a genetic algorithm
optimization method. 126) Dorier J, Crespo I, Niknejad A, Liechti R, Ebeling M, Xenarios I. BMC
Bioinformatics. 2016 Oct 6;17(1):410.
124) Clade-level Spatial Modelling of HPAI H5N1 Dynamics in the Mekong Region Reveals New Patterns
and Associations with Agro-Ecological Factors. Artois J, Newman SH, Dhingra MS, Chaiban C, Linard C,
Cattoli G, Monne I, Fusaro A, Xenarios I, Engler R, Liechti R, Kuznetsov D, Pham TL, Nguyen T, Pham
VD, Castellan D, Von Dobschuetz S, Claes F, Dauphin G, Inui K, Gilbert M. Sci Rep. 2016 Jul 25;6:30316.
doi: 10.1038/srep30316.
123) Cell-free DNA testing of an extended range of chromosomal anomalies: clinical experience with
6,388 consecutive cases. Pescia G, Guex N, Iseli C, Brennan L, Osteras M, Xenarios I, Farinelli L,
Conrad B. Genet Med. 2017 Feb;19(2):169-175. doi: 10.1038/gim.2016.72. Epub 2016 Jun 30.
122) Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation. Degueurce G,
D'Errico I, Pich C, Ibberson M, Schütz F, Montagner A, Sgandurra M, Mury L, Jafari P, Boda A, Meunier
J, Rezzonico R, Brembilla NC, Hohl D, Kolios A, Hofbauer G, Xenarios I, Michalik L. EMBO Mol Med.
2016 Aug 1;8(8):919-36. doi: 10.15252/emmm.201505384. Print 2016 Aug.
121) Analysis of the dynamic co-expression network of heart regeneration in the zebrafish. Rodius S,
Androsova G, Götz L, Liechti R, Crespo I, Merz S, Nazarov PV, de Klein N, Jeanty C, González-Rosa
JM, Muller A, Bernardin F, Niclou SP, Vallar L, Mercader N, Ibberson M, Xenarios I, Azuaje F. Sci Rep.
2016 May 31;6:26822. doi: 10.1038/srep26822.
120) Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource. Druce M,
Hulo C, Masson P, Sommer P, Xenarios I, Le Mercier P, De Oliveira T. Database (Oxford). 2016 Apr
17;2016. pii: baw045. doi: 10.1093/database/baw045. Print 2016.
119) TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of
human breast cancer. Bron S, Henry L, Faes-Van't Hull E, Turrini R, Vanhecke D, Guex N, Ifticene-
Treboux A, Marina Iancu E, Semilietof A, Rufer N, Lehr HA, Xenarios I, Coukos G, Delaloye JF, Doucey
MA. Oncoimmunology. 2015 Aug 20;5(2):e1073882. eCollection 2016 Feb.
118) Standardized benchmarking in the quest for orthologs. Altenhoff AM, Boeckmann B, Capella-
Gutierrez S, Dalquen DA, DeLuca T, Forslund K, Huerta-Cepas J, Linard B, Pereira C, Pryszcz LP,
Schreiber F, da Silva AS, Szklarczyk D, Train CM, Bork P, Lecompte O, von Mering C, Xenarios I,
Sjölander K, Jensen LJ, Martin MJ, Muffato M; Quest for Orthologs consortium, Gabaldón T, Lewis SE,
Thomas PD, Sonnhammer E, Dessimoz C. Nat Methods. 2016 May;13(5):425-30. doi:
10.1038/nmeth.3830. Epub 2016 Apr 4.
117) Social networks help to infer causality in the tumor microenvironment. Crespo I, Doucey MA,
Xenarios I. BMC Res Notes. 2016 Mar 15;9:168. doi: 10.1186/s13104-016-1976-8.
116) New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a
network-based approach. Zufferey A, Ibberson M, Reny JL, Nolli S, Schvartz D, Docquier M, Xenarios I,
Sanchez JC, Fontana P. Hum Genet. 2016 Apr;135(4):403-14. doi: 10.1007/s00439-016-1642-1. Epub
2016 Feb 16.
115) Comparative transcriptome profiling of the injured zebrafish and mouse hearts identifies miRNA-
dependent repair pathways. Crippa S, Nemir M, Ounzain S, Ibberson M, Berthonneche C, Sarre A,
Boisset G, Maison D, Harshman K, Xenarios I, Diviani D, Schorderet D, Pedrazzini T. Cardiovasc Res.
2016 May 1;110(1):73-84. doi: 10.1093/cvr/cvw031. Epub 2016 Feb 7.
114) The SIB Swiss Institute of Bioinformatics' resources: focus on curated databases. SIB Swiss
Institute of Bioinformatics Members. Nucleic Acids Res. 2016 Jan 4;44(D1):D27-37. doi:
10.1093/nar/gkv1310. Epub 2015 Nov 28.
SIB Swiss Institute of Bioinformatics Members: Bultet LA, Aguilar-Rodríguez J, Ahrens CH, Ahrné
EL, Ai N, Aimo L, Akalin A, Aleksiev T, Alocci D, Altenhoff A, Alves I, Ambrosini G, Pedone PA, Angelino
P, Anisimova M, Appel R, Argoud-Puy G, Arnold K, Arpat B, Artimo P, Ascencao K, Auchincloss A,
Axelsen K, Gerritsen VB, Bairoch A, Bansal P, Baratin D, Barbato A, Barbié V, Barras D, Barreiro M,
Barret S, Bastian F, Neto TM, Baudis M, Beaudoing E, Beckmann JS, Bekkar AK, Cammoun LB,
Benmohammed S, Bernard M, Bertelli C, Bertoni M, Bienert S, Bignucolo O, Bilbao A, Bilican A, Blank
D, Blatter MC, Blum L, Bocquet J, Boeckmann B, Bolleman JT, Bordoli L, Bosshard L, Bouchet G,
Bougueleret L, Boutet E, Bovigny C, Bratulic S, Breuza L, Bridge AJ, Britan A, Brito F, Frazão JB,
Bruggmann R, Bucher P, Burdet F, Burger L, Cabello EM, Gomez RM, Calderon S, Cannarozzi G, Carl
S, Casas CC, Catherinet S, Périer RC, Charpilloz C, Chaskar PD, Chen W, Pepe AC, Chopard B, Chu
HY, Civic N, Claassen M, Clottu S, Colombo M, Cosandier I, Coudert E, Crespo I, Creus M, Cuche B,
Cuendet MA, Cusin I, Daga N, Daina A, Dauvillier J, David F, Davydov I, Manadelo Ferreira Mde S, de
Beer T, de Castro E, de Santana C, Delafontaine J, Delorenzi M, Delucinge-Vivier C, Demirel Ö, Derham
R, Dermitzakis EM, Dib L, Diene S, Dilek N, Dilmi J, Domagalski MJ, Dorier J, Dornevil D, Dousse A,
Dreos R, Duchen P, Roggli PD, Duperret ID, Durinx C, Duvaud S, Engler R, Erkek S, López PE,
Estreicher A, Excoffier L, Fabbretti R, Falcone JL, Falquet L, Famiglietti ML, Ferreira AM, Feuermann M,
Filliettaz M, Flegel V, Foucal A, Franceschini A, Fucile G, Gaidatzis D, Garcia V, Gasteiger E, Gateau A,
Gatti L, Gaudet P, Gaudinat A, Gehant S, Gfeller D, Gharib WH, Ghraichy M, Gidoin C, Gil M, Gleizes A,
Gobeill J, Gonnet G, Gos A, Gotz L, Gouy A, Grbic D, Groux R, Gruaz-Gumowski N, Grun D, Gschwind
A, Guex N, Gupta S, Gétaz M, Haake D, Haas J, Hatzimanikatis V, Heckel G, Gardiol DF, Hinard V, Hinz
U, Homicsko K, Horlacher O, Hosseini SR, Hotz HR, Hulo C, Hundsrucker C, Ibberson M, Ilmjärv S,
Ioannidis V, Ioannidis P, Iseli C, Ivanek R, Iwaszkiewicz J, Jacquet P, Jacquot M, Jagannathan V, Jan M,
Jensen J, Johansson MU, Johner N, Jungo F, Junier T, Kahraman A, Katsantoni M, Keller G, Kerhornou
A, Khalid F, Klingbiel D, Komljenovic A, Kriventseva E, Kryuchkova N, Kumar S, Kutalik Z, Kuznetsov D,
Kuzyakiv R, Lane L, Lara V, Ledesma L, Leleu M, Lemercier P, Lew D, Lieberherr D, Liechti R, Lisacek
F, Lischer H, Litsios G, Liu J, Lombardot T, Macé A, Maffioletti S, Mahi MA, Maiolo M, Majjigapu SR,
Malmström L, Mangold V, Marek D, Mariethoz J, Marin R, Martin O, Martin X, Martín-Campos T, Mary C,
Masclaux F, Masson P, Meier C, Messina A, Lenoir MM, Meyer X, Michel PA, Michielin O, Milanese A,
Missiaglia E, Perez JM, Caria VM, Moret P, Moretti S, Morgat A, Mottaz A, Mottin L, Mouscaz Y, Mueller
M, Murri R, Mylonas R, Neuenschwander S, Nikitin F, Niknejad A, Nouspikel N, Nso LN, Okoniewski M,
Omasits U, Paccaud B, Pachkov M, Paesano SG, Pagni M, Palagi PM, Pasche E, Payne JL, Pedruzzi I,
Peischl S, Peitsch M, Perlini S, Pilbout S, Podvinec M, Pohlmann R, Polizzi D, Potter D, Poux S, Pozzato
M, Pradervand S, Praz V, Pruess M, Pujadas E, Racle J, Raschi M, Ratib O, Rausell A, de Laval VR,
Redaschi N, Rempfer C, Ren G, Vahdati RA, Rib L, Grognuz OR, Altimiras ER, Rivoire C, Robin T,
Robinson-Rechavi M, Rodrigues J, Roechert B, Roelli P, Romano V, Rossier G, Roth A, Rougemont J,
Roux J, Royo H, Ruch P, Ruinelli M, Abdul Sater MR, Röhrig UF, Rüeger S, Salamin N, Sankar M, Sarkar
N, Saxenhofer M, Schaeffer M, Schaerli Y, Schaper E, Schmid A, Schmid E, Schmid C, Schmid M,
Schmidt S, Schmocker D, Schneider M, Schuepbach T, Schwede T, Schütz F, Sengstag T, Serrano M,
Sethi A, Shahmirzadi O, Sigrist C, Silvestro D, Neto FA, Simillion C, Simonovic M, Skunca N, Sluzek K,
Soneson C, Sprouffske K, Stadler M, Staehli S, Stevenson B, Stockinger H, Straszewski J, Stricker T,
Studer G, Stutz A, Suffiotti M, Sundaram S, Szklarczyk D, Szövenyi P, Tegenfeldt F, Teixeira D,
Tellenbach S, Smith AA, Tognolli M, Topolsky I, Van Du Tran T, Tsantoulis P, Tzika AC, Agote AU, van
Nimwegen E, von Mering C, Varadarajan A, Veranneman M, Verbregue L, Veuthey AL, Vishnyakova D,
Vyas R, Wagner A, Walther D, Wan HW, Wang M, Waterhouse R, Waterhouse A, Wicki A, Wigger L,
Wirapati P, Witschi U, Wyder S, Wyler K, Wüthrich D, Xenarios I, Yamada K, Yan Z, Yasrebi H, Zahn M,
Zangger N, Zdobnov E, Zerzion D, Zoete V, Zoller S, Abriata L, Aebischer T, Akhmedov M, Meireles Filho
AA, Andreozzi S, Appel N, Armand F, Arribas A, Asgari S, Ataman M, Audagnotto M, Aydin D, Bady P,
Bank C, Barac D, Bargeton B, Barido-Sottani J, Barillari C, Bartha I, Bean A, Becker J, Beerenwinkel N,
Bellement G, Benedetti F, Bergmann S, Berneche S, Bevers R, Biasse D, Bichsel M, Bieler J, Piccini AP,
Boareto do Amaral M, Bolliger C, Boskova V, Brown A, Bryois J, Buil A, Cannavo R, Cardner M, Carelli
FN, Carmona S, Cascione L, Chakrabarti A, Chaturvedi N, Choobdar S, Clivaz C, Constantinescu S,
Corre T, Quezada DC, Croce R, Cuendet A, Cui J, Dainese R, Peraro MD, Dallavilla T, De Oliveira L,
Delaleu N, Delaneau O, Deplancke B, Dharmarajan L, Diekmann M, Dimitrakopoulos C, Dimitriades-
Schmutz B, Dimitrova YA, Dirmeier S, Dobay MP, Dougoud M, Duc J, Dumont G, du Plessis L, Dörr D,
Elfstroem K, Elmer FJ, Ewing GB, Fanaswala I, Fellay J, Feller C, Fengos G, Ferrer A, Fiaux S, Field C,
Finci I, Fofonjka A, Fonti G, Fried P, Frochaux M, Fuentes J, Galbusera L, Galimberti M, Garcia-Albornoz
M, Garcia-Escudero R, Garieri M, Georgieva L, Ghiurcuta CG, Ghosh S, Gnann A, Gnuegge R,
Golumbeanu M, Gomez H, Goudet J, Gruber AJ, Gruhl F, Guethe S, Guillot E, Guimarães J, Gumienny
RW, Gunawan R, Gustafson K, Gypas F, Hadadi N, Hameri T, Hammer C, Heer F, Heller DM, Hersch M,
Hofmann AL, Howald C, Hutter S, Iber D, Irwin K, Jahn K, Jedlinski D, Jethava V, Jorjani H, Julou T,
Kaessmann H, Kalantzi A, Kanitz A, Kapopoulou A, Karamasioti E, Karimaddini Z, Keller I, Kiparissides
A, Kohler M, Kousathanas A, Kuipers J, Kupczyk P, Kwee I, Kühnert D, Lakshmanan LN, Lamparter D,
Lang B, Laurent S, Laurent S, Leigh D, Lin Y, Lindsay H, Link V, Linnik J, Liphardt T, Liu Y, Loetscher A,
Luomi AO, Lykov K, Machlab D, Magnus C, Maillard-Wermelinger A, Malafeev A, Malaspinas AS, Parera
RM, Manesso E, Manukyan L, Mapelli SN, Marbach D, Lopez MJ, Wynn MM, Martin G, Martins AF,
Matthes K, Mazza C, McDaid A, Mermet J, Michos O, Milinkovitch MC, Misios A, Miskovic L, Mitov V,
Mitra A, Mittal N, Montazeri H, Moret B, Naef F, Nair N, Nicolas DL, Nicolet S, Noh H, Nowicka M, Oeyaas
O, Omidi S, Ongen H, Ormond L, Ottoz D, Panousis N, Gao NP, Modarres HP, Pečerska J, Vieira JP,
Pivkin I, Planet E, Céspedes SP, Pradhan R, Prados J, Racko D, Radigois MF, Rasmussen D, Riba A,
Rinn B, Rivoal M, Robinson M, Rossi S, Rudolf F, Rueedi R, Ruscheweyh HJ, Rybinski M, Rzepiela AJ,
Sakoparnig T, San Román Rincón MM, Savoglidis G, Scepanovic P, Schaad O, Schleiss R, Schmich F,
Schmid E, Schmidt R, Schulthess S, Schwalie PC, Seifert D, Seijo M, Shao M, Shim H, Singer J, Sobel
J, Soh KC, Flitman RS, Soto S, Sousa V, Stadler T, Stasiak A, Stefani A, Steger Y, Stelling J, Stopka A,
Stévant I, Sunnaker M, Syed AP, Tamo G, Tanaka S, Theiler G, Thorball CA, Thurnherr T, Ccenhua MR,
Tidin O, Tokic M, Riera MT, Tomasini M, Tymoshenko S, Ud-Dean M, Urchueguia A, Quintero NV,
Vinckenbosch L, Viñuela A, Vollmer J, Voordijk S, Wang J, Wang Z, Warnefors M, Weber LM, Wegmann
D, Whitehead E, Wicky A, Widmer L, Ye M, Yerly F, Yeung J, Yordanov P, Zavolan M, Zehnder T, Zhang
C, Zhou X, Zisaki A, Zoller B, Zollinger A.
113) UniProtKB/Swiss-Prot, the Manually Annotated Section of the UniProt KnowledgeBase: How to Use
the Entry View. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bansal P, Bridge AJ, Poux S,
Bougueleret L, Xenarios I. Methods Mol Biol. 2016;1374:23-54. doi: 10.1007/978-1-4939-3167-5_2.
112) West syndrome caused by homozygous variant in the evolutionary conserved gene encoding the
mitochondrial elongation factor GUF1. Alfaiz AA, Müller V, Boutry-Kryza N, Ville D, Guex N, de Bellescize
J, Rivier C, Labalme A, des Portes V, Edery P, Till M, Xenarios I, Sanlaville D, Herrmann JM, Lesca G,
Reymond A. Eur J Hum Genet. 2016 Jul;24(7):1001-8. doi: 10.1038/ejhg.2015.227. Epub 2015 Oct 21.
111) Toward a rational design of combination therapy in cancer. Doucey MA, Xenarios I.
Oncoimmunology. 2015 Jul 7;4(11):e1046674. eCollection 2015 Nov.
110) An Extended, Boolean Model of the Septation Initiation Network in S.Pombe Provides Insights into
Its Regulation. Chasapi A, Wachowicz P, Niknejad A, Collin P, Krapp A, Cano E, Simanis V, Xenarios I.
PLoS One. 2015 Aug 5;10(8):e0134214. doi: 10.1371/journal.pone.0134214. eCollection 2015.
109) Quest for Orthologs Entails Quest for Tree of Life: In Search of the Gene Stream. Boeckmann B,
Marcet-Houben M, Rees JA, Forslund K, Huerta-Cepas J, Muffato M, Yilmaz P, Xenarios I, Bork P, Lewis
SE, Gabaldón T; Quest for Orthologs Species Tree Working Group. Genome Biol Evol. 2015 Jul
1;7(7):1988-99. doi: 10.1093/gbe/evv121.
108) TRAL: tandem repeat annotation library. Schaper E, Korsunsky A, Pečerska J, Messina A, Murri R,
Stockinger H, Zoller S, Xenarios I, Anisimova M. Bioinformatics. 2015 Sep 15;31(18):3051-3. doi:
10.1093/bioinformatics/btv306. Epub 2015 May 18.
107) MorphoGraphX: A platform for quantifying morphogenesis in 4D. Barbier de Reuille P, Routier-
Kierzkowska AL, Kierzkowski D, Bassel GW, Schüpbach T, Tauriello G, Bajpai N, Strauss S, Weber A,
Kiss A, Burian A, Hofhuis H, Sapala A, Lipowczan M, Heimlicher MB, Robinson S, Bayer EM, Basler K,
Koumoutsakos P, Roeder AH, Aegerter-Wilmsen T, Nakayama N, Tsiantis M, Hay A, Kwiatkowska D,
Xenarios I, Kuhlemeier C, Smith RS. Elife. 2015 May 6;4:05864. doi: 10.7554/eLife.05864.
106) The SwissLipids knowledgebase for lipid biology. Aimo L, Liechti R, Hyka-Nouspikel N, Niknejad A,
Gleizes A, Götz L, Kuznetsov D, David FP, van der Goot FG, Riezman H, Bougueleret L, Xenarios I,
Bridge A. Bioinformatics. 2015 Sep 1;31(17):2860-6. doi: 10.1093/bioinformatics/btv285. Epub 2015 May
5.
105) Mutations in LONP1, a mitochondrial matrix protease, cause CODAS syndrome. Dikoglu E, Alfaiz
A, Gorna M, Bertola D, Chae JH, Cho TJ, Derbent M, Alanay Y, Guran T, Kim OH, Llerenar JC Jr,
Yamamoto G, Superti-Furga G, Reymond A, Xenarios I, Stevenson B, Campos-Xavier B, Bonafé L,
Superti-Furga A, Unger S. Am J Med Genet A. 2015 Jul;167(7):1501-9. doi: 10.1002/ajmg.a.37029. Epub
2015 Mar 21.
104) Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems
modeling and experimental approaches. Guex N, Crespo I, Bron S, Ifticene-Treboux A, Faes-Van't Hull
E, Kharoubi S, Liechti R, Werffeli P, Ibberson M, Majo F, Nicolas M, Laurent J, Garg A, Zaman K, Lehr
HA, Stevenson BJ, Rüegg C, Coukos G, Delaloye JF, Xenarios I, Doucey MA. PLoS Comput Biol. 2015
Mar 13;11(3):e1004050. doi: 10.1371/journal.pcbi.1004050. eCollection 2015 Mar.
103) Cooperative development of logical modelling standards and tools with CoLoMoTo. Naldi A,
Monteiro PT, Müssel C; Consortium for Logical Models and Tools, Kestler HA, Thieffry D, Xenarios I,
Saez-Rodriguez J, Helikar T, Chaouiya C. Bioinformatics. 2015 Apr 1;31(7):1154-9. doi:
10.1093/bioinformatics/btv013. Epub 2015 Jan 25.
102) Analysis of S. pombe SIN protein association to the SPB reveals two genetically separable states
of the SIN. Wachowicz P, Chasapi A, Krapp A, Cano Del Rosario E, Schmitter D, Sage D, Unser M,
Xenarios I, Rougemont J, Simanis V. J Cell Sci. 2015 Feb 15;128(4):741-54. doi: 10.1242/jcs.160150.
Epub 2014 Dec 12.
101) The InterPro protein families database: the classification resource after 15 years. Mitchell A, Chang
HY, Daugherty L, Fraser M, Hunter S, Lopez R, McAnulla C, McMenamin C, Nuka G, Pesseat S,
Sangrador-Vegas A, Scheremetjew M, Rato C, Yong SY, Bateman A, Punta M, Attwood TK, Sigrist CJ,
Redaschi N, Rivoire C, Xenarios I, Kahn D, Guyot D, Bork P, Letunic I, Gough J, Oates M, Haft D, Huang
H, Natale DA, Wu CH, Orengo C, Sillitoe I, Mi H, Thomas PD, Finn RD. Nucleic Acids Res. 2015
Jan;43(Database issue):D213-21. doi: 10.1093/nar/gku1243. Epub 2014 Nov 26.
100) UniProt: a hub for protein information. UniProt Consortium. Nucleic Acids Res. 2015
Jan;43(Database issue):D204-12. doi: 10.1093/nar/gku989. Epub 2014 Oct 27.
UniProt Consortium: Bateman A, Martin MJ, O'Donovan C, Magrane M, Apweiler R, Alpi E, Antunes R,
Arganiska J, Bely B, Bingley M, Bonilla C, Britto R, Bursteinas B, Chavali G, Cibrian-Uhalte E, Silva AD,
De Giorgi M, Dogan T, Fazzini F, Gane P, Castro LG, Garmiri P, Hatton-Ellis E, Hieta R, Huntley R, Legge
D, Liu W, Luo J, MacDougall A, Mutowo P, Nightingale A, Orchard S, Pichler K, Poggioli D, Pundir S,
Pureza L, Qi G, Rosanoff S, Saidi R, Sawford T, Shypitsyna A, Turner E, Volynkin V, Wardell T, Watkins
X, Zellner H, Cowley A, Figueira L, Li W, McWilliam H, Lopez R, Xenarios I, Bougueleret L, Bridge A,
Poux S, Redaschi N, Aimo L, Argoud-Puy G, Auchincloss A, Axelsen K, Bansal P, Baratin D, Blatter MC,
Boeckmann B, Bolleman J, Boutet E, Breuza L, Casal-Casas C, de Castro E, Coudert E, Cuche B, Doche
M, Dornevil D, Duvaud S, Estreicher A, Famiglietti L, Feuermann M, Gasteiger E, Gehant S, Gerritsen V,
Gos A, Gruaz-Gumowski N, Hinz U, Hulo C, Jungo F, Keller G, Lara V, Lemercier P, Lieberherr D,
Lombardot T, Martin X, Masson P, Morgat A, Neto T, Nouspikel N, Paesano S, Pedruzzi I, Pilbout S,
Pozzato M, Pruess M, Rivoire C, Roechert B, Schneider M, Sigrist C, Sonesson K, Staehli S, Stutz A,
Sundaram S, Tognolli M, Verbregue L, Veuthey AL, Wu CH, Arighi CN, Arminski L, Chen C, Chen Y,
Garavelli JS, Huang H, Laiho K, McGarvey P, Natale DA, Suzek BE, Vinayaka C, Wang Q, Wang Y, Yeh
LS, Yerramalla MS, Zhang J.
99) HAMAP in 2015: updates to the protein family classification and annotation system. Pedruzzi I, Rivoire
C, Auchincloss AH, Coudert E, Keller G, de Castro E, Baratin D, Cuche BA, Bougueleret L, Poux S,
Redaschi N, Xenarios I, Bridge A. Nucleic Acids Res. 2015 Jan;43(Database issue):D1064-70. doi:
10.1093/nar/gku1002. Epub 2014 Oct 27.
98) Updates in Rhea--a manually curated resource of biochemical reactions. Morgat A, Axelsen KB,
Lombardot T, Alcántara R, Aimo L, Zerara M, Niknejad A, Belda E, Hyka-Nouspikel N, Coudert E,
Redaschi N, Bougueleret L, Steinbeck C, Xenarios I, Bridge A. Nucleic Acids Res. 2015 Jan;43(Database
issue):D459-64. doi: 10.1093/nar/gku961. Epub 2014 Oct 20.
97) Differentially phased leaf growth and movements in Arabidopsis depend on coordinated circadian and
light regulation. Dornbusch T, Michaud O, Xenarios I, Fankhauser C. Plant Cell. 2014 Oct;26(10):3911-
21. doi: 10.1105/tpc.114.129031. Epub 2014 Oct 3.
96) Transcriptional response to cardiac injury in the zebrafish: systematic identification of genes with
highly concordant activity across in vivo models. Rodius S, Nazarov PV, Nepomuceno-Chamorro IA,
Jeanty C, González-Rosa JM, Ibberson M, da Costa RM, Xenarios I, Mercader N, Azuaje F. BMC
Genomics. 2014 Oct 3;15:852. doi: 10.1186/1471-2164-15-852.
95) An integrated ontology resource to explore and study host-virus relationships. Masson P, Hulo C, de
Castro E, Foulger R, Poux S, Bridge A, Lomax J, Bougueleret L, Xenarios I, Le Mercier P. PLoS One.
2014 Sep 18;9(9):e108075. doi: 10.1371/journal.pone.0108075. eCollection 2014.
94) Extensive remodeling of DC function by rapid maturation-induced transcriptional silencing.Seguín-
Estévez Q, Dunand-Sauthier I, Lemeille S, Iseli C, Ibberson M, Ioannidis V, Schmid CD, Rousseau P,
Barras E, Geinoz A, Xenarios I, Acha-Orbea H, Reith W. Nucleic Acids Res. 2014 Sep;42(15):9641-55.
doi: 10.1093/nar/gku674. Epub 2014 Aug 7.
93) Big data and other challenges in the quest for orthologs. Sonnhammer EL, Gabaldón T, Sousa da
Silva AW, Martin M, Robinson-Rechavi M, Boeckmann B, Thomas PD, Dessimoz C; Quest for
Orthologs consortium. Bioinformatics. 2014 Nov 1;30(21):2993-8. doi: 10.1093/bioinformatics/btu492.
Epub 2014 Jul 26.
Quest for Orthologs consortium: Altenhoff A, Blake J, Boeckmann B, Cherry M, Chiba H, Daubin V,
DeLuca T, Dessimoz C, Dufayard JF, Durand D, Ebersberger I, Breis JT, Forslund K, Gabaldon T, Gil M,
Grbić Đ, Herrero J, Keseler I, Kriventseva E, Lasalle G, Lewis S, Li LM, Linard B, Löytynoja A, Lyne R,
Martin M, Mazumder R, Miele V, Moretti S, Muffato M, Mungall C, Patricio M, Penel S, Pereira C, Petersen
M, Planel R, Robinson-Rechavi M, Roos D, Schmitt T, Schreiber F, Sjölander K, Škunca N, Sonnhammer
E, Sousa da Silva AW, Szklarczyk R, Thomas P, Uchiyama I, Ullate A, Van Bel M, Vandepoele K,
Waterhouse R, Wilbrandt J, Xenarios I, Yates A, Zdobnov E.
92) Analysis of stop-gain and frameshift variants in human innate immunity genes. Rausell A, Mohammadi
P, McLaren PJ, Bartha I, Xenarios I, Fellay J, Telenti A. PLoS Comput Biol. 2014 Jul 24;10(7):e1003757.
doi: 10.1371/journal.pcbi.1003757. eCollection 2014 Jul.
91) The mzTab data exchange format: communicating mass-spectrometry-based proteomics and
metabolomics experimental results to a wider audience. Griss J, Jones AR, Sachsenberg T, Walzer M,
Gatto L, Hartler J, Thallinger GG, Salek RM, Steinbeck C, Neuhauser N, Cox J, Neumann S, Fan J,
Reisinger F, Xu QW, Del Toro N, Pérez-Riverol Y, Ghali F, Bandeira N, Xenarios I, Kohlbacher O,
Vizcaíno JA, Hermjakob H. Mol Cell Proteomics. 2014 Oct;13(10):2765-75. doi:
10.1074/mcp.O113.036681. Epub 2014 Jun 30.
90) Functional and Evolutionary Analysis of the CASPARIAN STRIP MEMBRANE DOMAIN PROTEIN
Family. Roppolo D, Boeckmann B, Pfister A, Boutet E, Rubio MC, Dénervaud-Tendon V, Vermeer JE,
Gheyselinck J, Xenarios I, Geldner N. Plant Physiol. 2014 Aug;165(4):1709-1722. Epub 2014 Jun 11.
89) Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.
Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S,
Oxenius A. Immunity. 2014 Jun 19;40(6):961-73. doi: 10.1016/j.immuni.2014.05.003. Epub 2014 Jun 5.
88) Genetic variations and diseases in UniProtKB/Swiss-Prot: the ins and outs of expert manual curation.
Famiglietti ML, Estreicher A, Gos A, Bolleman J, Géhant S, Breuza L, Bridge A, Poux S, Redaschi N,
Bougueleret L, Xenarios I; UniProt Consortium. Hum Mutat. 2014 Aug;35(8):927-35. doi:
10.1002/humu.22594. Epub 2014 Jun 24. Review.
87) Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Stockinger H, Altenhoff AM, Arnold K, Bairoch A, Bastian F, Bergmann S, Bougueleret L, Bucher P,
Delorenzi M, Lane L, Le Mercier P, Lisacek F, Michielin O, Palagi PM, Rougemont J, Schwede T, von
Mering C, van Nimwegen E, Walther D, Xenarios I, Zavolan M, Zdobnov EM, Zoete V, Appel RD. Nucleic
Acids Res. 2014 Jul;42(Web Server issue):W436-41. doi: 10.1093/nar/gku380. Epub 2014 May 3.
86) Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-
specific long non-coding RNAs. Ounzain S, Micheletti R, Beckmann T, Schroen B, Alexanian M, Pezzuto
I, Crippa S, Nemir M, Sarre A, Johnson R, Dauvillier J, Burdet F, Ibberson M, Guigó R, Xenarios I,
Heymans S, Pedrazzini T. Eur Heart J. 2015 Feb 7;36(6):353-68a. doi: 10.1093/eurheartj/ehu180. Epub
2014 Apr 30.
85) ProteomeXchange provides globally coordinated proteomics data submission and dissemination.
Vizcaíno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Ríos D, Dianes JA, Sun Z, Farrah T,
Bandeira N, Binz PA, Xenarios I, Eisenacher M, Mayer G, Gatto L, Campos A, Chalkley RJ, Kraus HJ,
Albar JP, Martinez-Bartolomé S, Apweiler R, Omenn GS, Martens L, Jones AR, Hermjakob H. Nat
Biotechnol. 2014 Mar;32(3):223-6. doi: 10.1038/nbt.2839. No abstract available.
84) Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample
normalization. Bonhoure N, Bounova G, Bernasconi D, Praz V, Lammers F, Canella D, Willis IM, Herr W,
Hernandez N, Delorenzi M; CycliX Consortium. Genome Res. 2014 Jul;24(7):1157-68. doi:
10.1101/gr.168260.113. Epub 2014 Apr 7.
CycliX Consortium: Hernandez N, Delorenzi M, Deplancke B, Desvergne B, Guex N, Herr W, Naef F,
Rougemont J, Schibler U, Andersin T, Cousin P, Gilardi F, Gos P, Lammers F, Raghav S, Villeneuve D,
Fabbretti R, Vlegel V, Xenarios I, Migliavacca E, Praz V, David F, Jarosz Y, Kuznetsov D, Liechti R,
Martin O, Delafontaine J, Cajan J, Gustafson K, Krier I, Leleu M, Molina N, Naldi A, Rib L, Symul L,
Bounova G.
83) Integrative knowledge management to enhance pharmaceutical R&D. Marti-Solano M, Birney E, Bril
A, Della Pasqua O, Kitano H, Mons B, Xenarios I, Sanz F. Nat Rev Drug Discov. 2014 Apr;13(4):239-40.
doi: 10.1038/nrd4290.
82) Expert curation in UniProtKB: a case study on dealing with conflicting and erroneous data. Poux S,
Magrane M, Arighi CN, Bridge A, O'Donovan C, Laiho K; UniProt Consortium. Database (Oxford). 2014
Mar 12;2014:bau016. doi: 10.1093/database/bau016. Print 2014.
UniProt Consortium: Apweiler R, Bateman A, Martin MJ, Alam-Faruque Y, Alpi E, Antunes R, Arganiska
J, Casanova EB, Bely B, Bingley M, Bonilla C, Britto R, Bursteinas B, Chan WM, Chavali G, Cibrian-
Uhalte E, Da Silva A, De Giorgi M, Fazzini F, Gane P, Castro LG, Garmiri P, Hatton-Ellis E, Hieta R,
Huntley R, Legge D, Liu W, Luo J, MacDougall A, Mutowo P, Nightingale A, Orchard S, Pichler K, Poggioli
D, Pundir S, Pureza L, Qi G, Rosanoff S, Sawford T, Shypitsyna A, Turner E, Volynkin V, Wardell T,
Watkins X, Zellner H, Corbett M, Donnelly M, van Rensburg P, Goujon M, McWilliam H, Lopez R,
Xenarios I, Bougueleret L, Redaschi N, Aimo L, Auchincloss A, Axelsen K, Bansal P, Baratin D, Binz PA,
Blatter MC, Boeckmann B, Bolleman J, Boutet E, Breuza L, Casal-Casas C, de Castro E, Cerutti L,
Coudert E, Cuche B, Doche M, Dornevil D, Duvaud S, Estreicher A, Famiglietti L, Feuermann M,
Gasteiger E, Gehant S, Gerritsen V, Gos A, Gruaz-Gumowski N, Hinz U, Hulo C, James J, Jungo F,
Keller G, Lara V, Lemercier P, Lew J, Lieberherr D, Lombardot T, Martin X, Masson P, Morgat A, Neto T,
Paesano S, Pedruzzi I, Pilbout S, Pozzato M, Pruess M, Rivoire C, Roechert B, Schneider M, Sigrist C,
Sonesson K, Staehli S, Stutz A, Sundaram S, Tognolli M, Verbregue L, Veuthey AL, Wu CH, Arminski L,
Chen C, Chen Y, Garavelli JS, Huang H, McGarvey P, Natale DA, Suzek BE, Vinayaka C, Wang Q, Wang
Y, Yeh LS, Yerramalla MS, Zhang J.
81) The EMPRES-i genetic module: a novel tool linking epidemiological outbreak information and genetic
characteristics of influenza viruses. Claes F, Kuznetsov D, Liechti R, Von Dobschuetz S, Truong BD,
Gleizes A, Conversa D, Colonna A, Demaio E, Ramazzotto S, Larfaoui F, Pinto J, Le Mercier P, Xenarios
I, Dauphin G. Database (Oxford). 2014 Mar 6;2014:bau008. doi: 10.1093/database/bau008. Print 2014.
80) Genome-wide analysis of SREBP1 activity around the clock reveals its combined dependency on
nutrient and circadian signals. Gilardi F, Migliavacca E, Naldi A, Baruchet M, Canella D, Le Martelot G,
Guex N, Desvergne B; CycliX Consortium. PLoS Genet. 2014 Mar 6;10(3):e1004155. doi:
10.1371/journal.pgen.1004155. eCollection 2014 Mar.
CycliX Consortium: Hernandez N, Delorenzi M, Deplancke B, Desvergne B, Guex N, Herr W, Naef F,
Rougemont J, Schibler U, Deplancke B, Guex N, Herr W, Guex N, Andersin T, Cousin P, Gilardi F, Gos
P, Martelot G, Lammers F, Canella D, Gilardi F, Raghav S, Fabbretti R, Fortier A, Long L, Vlegel V,
Xenarios I, Migliavacca E, Praz V, Guex N, Naef F, Rougemont J, David F, Jarosz Y, Kuznetsov D,
Liechti R, Martin O, Delafontaine J, Sinclair L, Cajan J, Krier I, Leleu M, Migliavacca E, Molina N, Naldi
A, Rey G, Symul L, Guex N, Naef F, Rougemont J, Bernasconi D, Delorenzi M, Andersin T, Canella D,
Gilardi F, Martelot G, Lammers F, Baruchet M, Raghav S.
79) Automated quantitative histology reveals vascular morphodynamics during Arabidopsis hypocotyl
secondary growth. Sankar M, Nieminen K, Ragni L, Xenarios I, Hardtke CS. Elife. 2014 Feb 11;3:e01567.
doi: 10.7554/eLife.01567.
78) TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and
celiac disease. Alfaiz AA, Micale L, Mandriani B, Augello B, Pellico MT, Chrast J, Xenarios I, Zelante L,
Merla G, Reymond A. Hum Mutat. 2014 Apr;35(4):447-51. doi: 10.1002/humu.22529.
77) Efficient computation of minimal perturbation sets in gene regulatory networks. Garg A, Mohanram
K, Di7Cara A, Degueurce G, Ibberson M, Dorier J, Xenarios I. Front Physiol. 2013 Dec 17;4:361. doi:
10.3389/fphys.2013.00361. eCollection 2013.
76) Plant species distributions along environmental gradients: do belowground interactions with fungi
matter? Pellissier L, Pinto-Figueroa E, Niculita-Hirzel H, Moora M, Villard L, Goudet J, Guex N, Pagni M,
Xenarios I, Sanders I, Guisan A. Front Plant Sci. 2013 Dec 10;4:500. doi: 10.3389/fpls.2013.00500.
eCollection 2013.
75) SBML qualitative models: a model representation format and infrastructure to foster interactions
between qualitative modelling formalisms and tools. Chaouiya C, Bérenguier D, Keating SM, Naldi A, van
Iersel MP, Rodriguez N, Dräger A, Büchel F, Cokelaer T, Kowal B, Wicks B, Gonçalves E, Dorier J, Page
M, Monteiro PT, von Kamp A, Xenarios I, de Jong H, Hucka M, Klamt S, Thieffry D, Le Novère N, Saez-
Rodriguez J, Helikar T. BMC Syst Biol. 2013 Dec 10;7:135. doi: 10.1186/1752-0509-7-135.
74) Activities at the Universal Protein Resource (UniProt). UniProt Consortium. Nucleic Acids Res. 2014
Jan;42 (Database issue):D191-8. doi: 10.1093/nar/gkt1140. Epub 2013 Nov 18.
UniProt Consortium: Apweiler R, Bateman A, Martin MJ, O'Donovan C, Magrane M, Alam-Faruque Y,
Alpi E, Antunes R, Arganiska J, Barrera Casanova E, Bely B, Bingley M, Bonilla C, Britto R, Bursteinas
B, Mun Chan W, Chavali G, Cibrian-Uhalte E, Da Silva A, De Giorgi M, Fazzini F, Gane P, Castro LG,
Garmiri P, Hatton-Ellis E, Hieta R, Huntley R, Legge D, Liu W, Luo J, MacDougall A, Mutowo P,
Nightingale A, Orchard S, Pichler K, Poggioli D, Pundir S, Pureza L, Qi G, Rosanoff S, Sawford T,
Shypitsyna A, Turner E, Volynkin V, Wardell T, Watkins X, Zellner H, Corbett M, Donnelly M, van
Rensburg P, Goujon M, McWilliam H, Lopez R, Xenarios I, Bougueleret L, Bridge A, Poux S, Redaschi
N, Aimo L, Auchincloss A, Axelsen K, Bansal P, Baratin D, Binz PA, Blatter MC, Boeckmann B, Bolleman
J, Boutet E, Breuza L, Casal-Casas C, de Castro E, Cerutti L, Coudert E, Cuche B, Doche M, Dornevil
D, Duvaud S, Estreicher A, Famiglietti L, Feuermann M, Gasteiger E, Gehant S, Gerritsen V, Gos A,
Gruaz-Gumowski N, Hinz U, Hulo C, James J, Jungo F, Keller G, Lara V, Lemercier P, Lew J, Lieberherr
D, Lombardot T, Martin X, Masson P, Morgat A, Neto T, Paesano S, Pedruzzi I, Pilbout S, Pozzato M,
Pruess M, Rivoire C, Roechert B, Schneider M, Sigrist C, Sonesson K, Staehli S, Stutz A, Sundaram S,
Tognolli M, Verbregue L, Veuthey AL, Wu CH, Arighi CN, Arminski L, Chen C, Chen Y, Garavelli JS,
Huang H, Laiho K, McGarvey P, Natale DA, Suzek BE, Vinayaka C, Wang Q, Wang Y, Yeh LS,
Yerramalla MS, Zhang J.
73) Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human
pluripotent stem cells. Peterson H, Abu Dawud R, Garg A, Wang Y, Vilo J, Xenarios I, Adjaye J. Front
Physiol. 2013 Oct 28;4:303. doi: 10.3389/fphys.2013.00303. eCollection 2013.
72) Hard-wired heterogeneity in blood stem cells revealed using a dynamic regulatory network model.
Bonzanni N, Garg A, Feenstra KA, Schütte J, Kinston S, Miranda-Saavedra D, Heringa J, Xenarios I,
Göttgens B. Bioinformatics. 2013 Jul 1;29(13):i80-8. doi: 10.1093/bioinformatics/btt243.
71) TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes
in human breast tumors. Ibberson M, Bron S, Guex N, Faes-van't Hull E, Ifticene-Treboux A, Henry L,
Lehr HA, Delaloye JF, Coukos G, Xenarios I, Doucey MA. Clin Cancer Res. 2013 Jul 1;19(13):3439-49.
doi: 10.1158/1078-0432.CCR-12-3181. Epub 2013 May 6.
70) A 2D/3D image analysis system to track fluorescently labeled structures in rod-shaped cells:
application to measure spindle pole asymmetry during mitosis. Schmitter D, Wachowicz P, Sage D,
Chasapi A, Xenarios I, Simanis, Unser M. Cell Div. 2013 Apr 27;8:6. doi: 10.1186/1747-1028-8-6.
eCollection 2013.
69) Density-based hierarchical clustering of pyro-sequences on a large scale--the case of fungal ITS1.
Pagni M, Niculita-Hirzel H, Pellissier L, Dubuis A, Xenarios I, Guisan A, Sanders IR, Goudet J, Guex N.
Bioinformatics. 2013 May 15;29(10):1268-74. doi: 10.1093/bioinformatics/btt149. Epub 2013 Mar 28.
68) Application of text-mining for updating protein post-translational modification annotation in UniProtKB.
Veuthey AL, Bridge A, Gobeill J, Ruch P, McEntyre JR, Bougueleret L, Xenarios I. BMC Bioinformatics.
2013 Mar 22;14:104. doi: 10.1186/1471-2105-14-104.
67) Evolution of the ferric reductase domain (FRD) superfamily: modularity, functional diversification, and
signature motifs. Zhang X, Krause KH, Xenarios I, Soldati T, Boeckmann B.PLoS One. 2013;
8(3):e58126. doi: 10.1371/journal.pone.0058126. Epub 2013 Mar 7.
66) pfsearchV3: a code acceleration and heuristic to search PROSITE profiles. Schuepbach T, Pagni M,
Bridge A, Bougueleret L, Xenarios I, Cerutti L. Bioinformatics. 2013 May 1;29(9):1215-7. doi:
10.1093/bioinformatics/btt129. Epub 2013 Mar 16.
65) Database resources for the tuberculosis community. Lew JM, Mao C, Shukla M, Warren A, Will R,
Kuznetsov D, Xenarios I, Robertson BD, Gordon SV, Schnappinger D, Cole ST, Sobral B. Tuberculosis
(Edinb). 2013 Jan;93(1):12-7. doi: 10.1016/j.tube.2012.11.003. Epub 2013 Jan 17. Review.
64) Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the
ubiquitin-proteasome system in pancreatic beta cell dysfunction. Bugliani M, Liechti R, Cheon H,
Suleiman M, Marselli L, Kirkpatrick C, Filipponi F, Boggi U, Xenarios I, Syed F, Ladriere L, Wollheim C,
Lee MS, Marchetti P. Mol Cell Endocrinol. 2013 Mar 10;367(1-2):1-10. doi: 10.1016/j.mce.2012.12.001.
Epub 2012 Dec 12.
63) Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and
associated epigenetic changes during diurnal cycles. Le Martelot G, Canella D, Symul L, Migliavacca E,
Gilardi F, Liechti R, Martin O, Harshman K, Delorenzi M, Desvergne B, Herr W, Deplancke B, Schibler U,
Rougemont J, Guex N, Hernandez N, Naef F; CycliX Consortium. PLoS Biol. 2012;10(11):e1001442.
doi: 10.1371/journal.pbio.1001442. Epub 2012 Nov 27.
CycliX Consortium: Hernandez N, Delorenzi M, Deplancke B, Desvergne B, Guex N, Herr W, Naef F,
Rougemont J, Schibler U, Deplancke B, Guex N, Herr W, Guex N, Andersin T, Cousin P, Gilardi F, Gos
P, Le Martelot G, Lammers F, Canella D, Gilardi F, Raghav S, Fabbretti R, Fortier A, Long L, Vlegel V,
Xenarios I, Migliavacca E, Praz V, Guex N, Naef F, Rougemont J, David F, Jarosz Y, Kuznetsov D,
Liechti R, Martin O, Delafontaine J, Sinclair L, Cajan J, Krier I, Leleu M, Migliavacca E, Molina N, Naldi
A, Rey G, Symul L, Guex N, Naef F, Rougemont J, Bernasconi D, Delorenzi M.
62) ViralZone: recent updates to the virus knowledge resource. Masson P, Hulo C, De Castro E, Bitter H,
Gruenbaum L, Essioux L, Bougueleret L, Xenarios I, Le Mercier P. Nucleic Acids Res. 2013
Jan;41(Database issue):D579-83. doi: 10.1093/nar/gks1220. Epub 2012 Nov 28.
61) HAMAP in 2013, new developments in the protein family classification and annotation system.
Pedruzzi I, Rivoire C, Auchincloss AH, Coudert E, Keller G, de Castro E, Baratin D, Cuche BA,
Bougueleret L, Poux S, Redaschi N, Xenarios I, Bridge A; UniProt Consortium. Nucleic Acids Res. 2013
Jan;41(Database issue):D584-9. doi: 10.1093/nar/gks1157. Epub 2012 Nov 27.
60) Reconciliation of metabolites and biochemical reactions for metabolic networks. Bernard T, Bridge A,
Morgat A, Moretti S, Xenarios I, Pagni M. Brief Bioinform. 2014 Jan;15(1):123-35. doi:
10.1093/bib/bbs058. Epub 2012 Nov 19. Review.
59) New and continuing developments at PROSITE. Sigrist CJ, de Castro E, Cerutti L, Cuche BA, Hulo
N, Bridge A, Bougueleret L, Xenarios I. Nucleic Acids Res. 2013 Jan;41(Database issue):D344-7. doi:
10.1093/nar/gks1067
CURRICULUM VITAE of
Anu Reigo
Date and place of birth: July 26, 1963, Estonia
Citizenship: Estonian
Family status: married, four children
Home address: Sahkri weski, Veski village, Kanepi parish, Põlva County 63511, Estonia
Contact:
[email protected]
Education:
1981 - 1987 - Medical Faculty of Tartu University, graduated in June 1987 cum laude as M.D.
1987 - 1989 - postgraduate specialization in anaesthesiology and intensive care medicine in Tartu
University Maarjamõisa Hospital
1997 - 2007 - Ph.D. studies in molecular biomedicine in Department of Biotechnology of Tartu
University Institute of Molecular and Cell Biology.
Field of study: Human chromosomal region 9p22.3-23: expression mapping, functional
genomics and scan for candidate disease genes.
Advisor: Prof. Andres Metspalu.
Professional refresher courses:
A. In anaesthesiology and intensive care medicine:
During 1989 - 1994, 18 short-time professional refresher courses (in Tartu, Tallinn, St.Petersbourg, Moscow,
Uppsala, Stockholm, the Hague and Paris with total duration of 28 weeks) and two longer professional visits to
Leiden University Cancer Centre, the Netherlands, in 1992 and to Örebro District Hospital, Sweden, in 1993 (6
months altogether).
B. In molecular biology and biomedicine:
March 1998 - 11th course (Introduction to Genetic Analysis, Genetics of Complex Traits, Disease
Gene Identification, Genome Projects and Model Organisms, Clinical Genetics,
Human Diversity and Genetic Disease, Emerging Biochip Technologies) of European
School of Medical Genetics at Sestri Levante, Genoa, Italy
August 1998 - visiting Institute of Cell Biology and Institute of Genetics at Erasmus University of
Rotterdam (TEMPUS student mobility program), the Netherlands
December 1998 - refresher course and practical training (Chromosome and Gene Alterations in Cancer
and Their clinical Significance) at Haartman Institute, University of Helsinki, Finland
May 1999 – HUGO workshop on DNA microarray technologies and their applications, Tartu,
Estonia;
July 1999 - 22nd advanced course of functional genomics of Wellcome Trust Summer Schools at
Hinxton, Cambridge, UK
October 1999 - participation and poster presentation at ASHG’1999 meeting in San Francisco, USA
May 2000 - participation and poster presentation at ESHG’2000 meeting in Amsterdam, the
Netherlands
May 2001 - participation and poster presentation at ICHG’2001 meeting in Vienna, Austria
June 2002 - participation and poster presentation at ESHG’2002 meeting in Strasbourg, France
June-July 2002 - visiting scientist at Institute of Human Genetics, Medical Faculty of Ernst Moritz Arndt
University of Greifswald, Germany. Participation in a collaboration project: Application
of molecular genetics advances to the understanding of Emery-Dreifuss muscular
dystrophies and associated skeletal and cardiac phenotypes (Acronym: EUROMEN
/EUROpean Muscle Envelope Nucleopathies) 1999-2003. Supervisor in Greifswald:
Prof. Dr. Manfred Wehnert
September 2002 - International course APEX on DNA microarrays, Tartu, Estonia
May 2003 - participation and poster presentation at ESF Conference “Functional Genomics and
Disease” in Prague, Czech Republic
June 2007 - participation at 39th European Human Genetics Conference /ESHG, Nice, France
August 2014 - International course Logical Reasoning in Human Genetics (Helsinki Biomedical
Graduate Program, THL&FIMM, BBMRI-LPC) in Helsinki, Finland
July 2015 - refresher course by Estonian Headache Society and International Headache Society
on chronic headache syndromes, in Tartu, Estonia
August 2015 - 3rd BBMRI-LPC workshop “Biobanks, data and access” in Tartu, Estonia
Professional History:
1989 - 1998 - anaesthesiologist in Department of Anaesthesiology and Intensive Care of Tartu
University Lung Hospital. 2nd qualification degree in anaesthesiology and intensive
care medicine from 1994
1992 - 1994 - part-time lecturer and supervisor of practical training for medical doctors in Faculty of
Postgraduate Education of Tartu University
1993 - 1995 - anaesthesiologist and project manager in Pain Clinic at Tartu University Lung Hospital.
1997 - 2007 - PhD student at Department of Biotechnology, Institute of Molecular and Cell Biology,
University of Tartu
2007 - 2015 - biomedical database specialist and medical data collector at Estonian Genome Center,
University of Tartu
From 2015 – present lead specialist of medical genomics, Estonian Biobank, Institute of Genomics,
University of Tartu
Fields of research:
1. Molecular biomedicine
2. Genetics (gene expression, biotechnology)
3. Population genetics
4. Biomedical databases
5. Medical genomics (precision medicine)
Students and thesis co-supervised:
1. Kristi Kallassalu, pre-diploma studies “Analysis of a cDNA clone similar to RASAL1” (RASAL1 sarnase
cDNA klooni analüüs),1999.
2. Evelin Mihailov, pre-diploma studies “Analysis of a cDNA clone corresponding to human
calcium/calmodulin-dependent protein kinase II mRNA” (Inimese kaltsium/kalmoduliin-sõltuva
proteiinkinaas II gamma A mRNA-le vastava cDNA klooni analüüs), 2000.
3. Margus Lukk, pre-diploma studies “Extended physical map of human chromosomal region 9p22 between
RPS6 and MLLT3/AF9 genes: in silico analysis” (Inimese kromosoomiregiooni 9p22 täiendatud füüsiline
kaart RPS6 ja MLLT3/AF9 geenide vahelisel alal: in silico analüüs), 2000.
4. Margus Lukk, BSc studies “A novel gene froom human chromosomal region 5p13: intron-exon structure
and primary characteristics of the predicted protein” (Uus geen inimese kromosoomialas 5p13:
intronekson struktuur ja oletatava valgu esialgne iseloomustus), 2000.
5. Rainer Kahre, BSc studies “Analysis of a cDNA clone corresponding to human nuclear rim protein, nurim”
(Inimese tuumaümbrise valgule nurim vastava cDNA klooni analüüs), 2000.
6. Kristi Kallassalu, BSc studies “A novel gene in human chromosomal region 5p13: structure and
expression” (Uus geen inimese kromosoomialas 5p13: struktuur ja ekspressioon), 2001.
7. Evelin Mihailov, BSc studies “Gamma A and gamma A/E isoforms of human
calcium/calmodulindependent protein kinase II: coding transcripts and expression” (Inimese
kaltsium/kalmoduliin-sõltuva proteiinkinaas II isovormid gamma A ja gamma A/E: kodeerivad transkriptid
ja ekspressioon), 2001.
8. Kristi Kallassalu, MSc studies “A novel gene in human chromosomal region 5p13: structure, expression
and comparative phylogenetic analysis” (Uus geen inimese kromosoomialas 5p13.2: struktuur,
ekspressioon ja võrdlev fülogeneetiline analüüs), 2003.
9. Evelin Mihailov, MSc degree “Lymphocyclin, a novel mouse gene: structure and expression pattern”
(Hiire lümfotsükliini geen: struktuur ja ekspressioon varajases embrüonaalses arengus), 2003.
10. Egon Urgard, pre-diploma studies “Disco silencing by RNAi” (RNAi disco vaigistamiseks), 2004.
11. Egon Urgard, MSc degree (BSc to MSc studies) “Disco: evolutionary origin and silencing by RNAi” (Disco
evolutsiooniline päritolu ja selle vaigistamine RNAi abil), 2006.
12. Egon Urgard, PhD studies (accepted for defence in June 2020) “ Potential therapeutic approaches for
modulation of inflammatory response pathways”, 2020.
Supervised practical courses in molecular biotechnology (BGMR.01.018) for biotechnology students at Institute
of Molecular and Cell Biology, University of Tartu, 1999-2002:
1. Molecular cloning
2. DNA sequencing
3. Basic introduction to bioinformatics
Lectures at Institute of Molecular and Cell Biology, University of Tartu, 1999-2002:
1. Lecture series in “Molecular biotechnology” (BGMR.01.001) - Molecular cloning II (big DNA fragments).
Vector systems. Experimental analysis of big DNA fragments. Biomolecular databases.
2. Lecture series in “Genome structure and function” (BGMR.01.003) - Genome as a topological space.
Genetic maps (types, levels, methods). Genome as a semiosphere. Functional genomics.
Miscellaneous:
1989 - 1995 member of Estonian Society of Anaesthesiologists.
1991 - 1995 establishing member of Estonian Pain Society (secretary during 1991 - 1995)
1992 - 1995 member of International Association for the Study of Pain
1994 - 1995 member of European Society of Regional Anaesthesia
1999 establishing member of Estonian Genome Foundation
1999 - present - establishing member of Estonian Society of Human Genetics
2010 - present - member of Estonian Heavy Draught Breeders’ Society (board member from 2014 -
present)
Results of practical and scientific work:
A. Organization and start-up of the first outpatient pain service in Estonia, 1993.
B. Publications:
1. Reigo A; Nikolajev G; Vahtramäe J. Prolonged epidural analgesia in thoracic and upper
abdominal surgery: clinical results and postoperative outcome. In Proceedings of the 10th World
Congress of Anaesthesiologists, 1992, p.216.
2. Hansdottir V; Bake B; Reigo A; Nordberg G. Pharmacodynamic aspects of epidural Sufentanil
and Bupivacaine infusion after thoracotomy. In Scandinavian ESRA Congress, 1994, p.44.
3. Reigo A; Lushnikova T; Laanpere I; Ilisson R; Metspalu A. Refined mapping of human
chromosomal region 9p22 distal to the interferon gene cluster and construction of a transcript
map of 1.2 Mb surrounding RP S6 gene. Am J Hum Genet. 1999 Vol.65 No.4 Suppl. p. A418.
4. Reigo A; Lind I; Ilisson R; Lushnikova T; Metspalu, A. Two novel transcripts from human
chromosome 9p22: primary characterization and position in 4.5 Mb refined physical map of the
surrounding region. Eur J Hum Genet. 2000 Vol.8 Suppl.1 p.131.
5. Reigo A; Metspalu A. Human genes for K+-dependent Na/Ca-exchangers, NCKX1, NCKX2 and
NCKX3: genomic structure, comparative analysis of promoter regions and expression patterns.
Eur J Hum Genet. 2001 Vol.9 Suppl.1 p.247.
6. Reigo A; Metspalu A. Zinc fingers on short arm of chromosome 9 pointing to lymphocytes. Eur
J Hum Genet. 2002 Vol.10 Suppl.1 p.167.
7. Reigo A; Metspalu A. More zinc fingers on short arm of human chromosome 9: the lymphocyclin
gene. In Proceedings of the ESF conference Functional genomics and disease, Prague, Czech
Republic, May 14-17, 2003.
8. Kallassalu K; Haller T; Mihailov E; Reigo A; Metspalu A. A novel gene in human chromosomal
region 5p13.2; structure, expression pattern and comparative phylogenetic analysis. Eur J Hum
Genet. 2004 Vol.12 Suppl.1 p.329.
9. Mihailov E; Reigo A; Kallassalu K; Metspalu A. Genomic organisation and expression analysis
of the murine basonuclin gene. In European Human Genetics Conference2005 /Prague, Czech
Republic, May 7-10, 2005/, p.371.
10. Kallassalu K; Haller T; Mihailov E; Reigo A; Metspalu A. Molecular characterisation of the
human Hubert gene located on chromosome 5p13.2. In European Human Genetics Conference
2005 /Prague, Czech Republic, May 7-10, 2005/, p.371.
11. Männik K; Mägi R; Macé A; Cole B; Guyatt AL; Shihab HA; Maillard AM; Alavere H; Kolk A;
Reigo A; Mihailov E; Leitsalu L; Ferreira A-M; Nõukas M; Teumer A; Salvi E; Cusi D; McGue
M; Iacono WG; Gaunt TR; Beckmann JS; Jacquemont S; Kutalik Z; Pankratz N; Timpson N;
Metspalu A; Reymond A. (2015). Copy Number Variations and Cognitive Phenotypes in
Unselected Populations. JAMA : the journal of the American Medical Association, 2015;
313(20), 2044 - 2054.
12. Maillard AM; Hippolyte L; Rodriguez-Herreros B; Chawner SJ; Dremmel D; Agüera Z; Fagundo
AB; Pain A; Martin-Brevet S; Hilbert A; Kurz S; Etienne R; Draganski B; Jimenez-Murcia S;
Männik K; Metspalu A; Reigo A; Isidor B; Le Caignec C; David A; Mignot C; Keren B; 16p11.2
European Consortium; van den Bree MB; Munsch S; Fernandez-Aranda F; Beckmann JS;
Reymond A; Jacquemont S. 16p11.2 locus modulates response to satiety before the onset of
obesity. Int J Obes (Lond). 2015 Dec 1. PMID:26620891.
13. Hippolyte L; Maillard AM; Rodriguez-Herreros B; Pain A; Martin-Brevet S; Ferrari C; Conus P;
Macé A; Hadjikhani N; Metspalu A; Reigo A; Kolk A; Männik K; Barker M; Isidor B; Le Caignec
C; Mignot C; Schneider L; Mottron L; Keren B; David A; Doco-Fenzy M; Gérard M; Bernier R;
Goin-Kochel RP; Hanson E; Green Snyder L; 16p11.2 European Consortium; Simons Variation
in Individuals Project Consortium; Ramus F; Beckmann JS; Draganski B; Reymond A;
Jacquemont S. The number of genomic copies at the 16p11.2 locus modulates language, verbal
memory, and inhibition. Biol Psychiatry. 2015 Nov 10. PMID:26742926.
14. D'Angelo D, Lebon S, Chen Q, Martin-Brevet S, Snyder LG, Hippolyte L, Hanson E, Maillard
AM, Faucett WA, Macé A, Pain A, Bernier R, Chawner SJ, David A, Andrieux J, Aylward E,
Baujat G, Caldeira I, Conus P, Ferrari C, Forzano F, Gérard M, Goin-Kochel RP, Grant E, Hunter
JV, Isidor B, Jacquette A, Jønch AE, Keren B, Lacombe D, Le Caignec C, Martin CL, Männik
K, Metspalu A, Mignot C, Mukherjee P, Owen MJ, Passeggeri M, Rooryck-Thambo C,
Rosenfeld JA, Spence SJ, Steinman KJ, Tjernagel J, Van Haelst M, Shen Y, Draganski B, Sherr
EH, Ledbetter DH, van den Bree MB, Beckmann JS, Spiro JE, Reymond A, Jacquemont S,
Chung WK; Cardiff University Experiences of Children With Copy Number Variants (ECHO)
Study; 16p11.2 European Consortium (…, Reigo A, …); Simons Variation in Individuals Project
(VIP) Consortium. Defining the effect of the 16p11.2 duplication on cognition, behavior, and
medical comorbidities. JAMA Psychiatry. 2016 Jan;73(1):20-30. PMID:26629640.
15. Mihailov E, Nikopensius T, Reigo A, Nikkolo C, Kals M, Aruaas K, Milani L, Seepter H, Metspalu
A. Whole-exome sequencing identifies a potential TTN mutation in a multiplex family with
inguinal hernia. Hernia. 2016 Apr 26. PMID:27115767.
16. Urgard E, Reigo A, Reinmaa E, Rebane A, Metspalu A. Human basonuclin 2 up-regulates a
cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer
model. Cancer Cell International. 2017;17:18. PMCID: PMC5294813.
17. Alver M, Palover M, Saar A, Läll K, Zekavat SM, Tõnisson N, Leitsalu L, Reigo A, Nikopensius
T, Ainla T, Kals M, Mägi R, Gabriel SB, Eha J, Lander ES, Irs A, Philippakis A, Marandi T,
Natarajan P, Metspalu A, Kathiresan S, Esko T. Recall by genotype and cascade screening for
familial hypercholesterolemia in a population-based biobank from Estonia.Genet Med.
2019;21(5):1173–1180. PMCID: PMC6443485.
Additional skills:
driving license
graphics techniques: different modes of engraving - etching, dry point, mezzotinto, aquatinta.
languages:
▪ fluent in South-Estonian dialect (native), Estonian, English, Russian;
▪ medium conversation level in French and Italian
Hobbies:
• gardening
• poetry
• breeding of an endangered horse breed, the Estonian heavy draught (Estonian ardennes)
Additional publications:
a. Anu Reigo. Päritolu /poems of 1973-1996. Illustrations by author. Tartu 1996.
b. Silvia Kaugia, Aita Maasik. Mõttekäände / aphorisms and maxims. Illustrations by Anu Reigo.
Tartu 1997.
c. Silvia Kaugia, Aita Maasik. Otsene olevik / aphorisms and maxims. Illustrations by Anu Reigo.
Tartu 2000.
February 18, 2020
EESTI BIOEETIKA JA INIMUURINGUTE NÕUKOGU OTSUS 1 4 . aprill 20 20 nr 1.1-12/ 6 49 Nõukogu koosseisus: Esimees: Liina Vahter Tallinna Ülikool Aseesimees: Aime Keis Tartu Ülikooli inimuuringute eetika komitee Teadussekretär: Aive Pevkur Tallinna Tehnikaülikool Liikmed: Kristi Rüütel Tervise Arengu Instituudi inimuuringute eetikakomitee Irja Lutsar Tartu Ülikool Kärt Salumaa-Lepik Tallinna Tehnikaülikool Meego Remmel Eesti Kirikute Nõukogu Agne Velthut-Meikas Tallinna Tehnikaülikool Merike Sisask Tallinna Ülikool Ingeri Luik-Tamme TGS Baltic Advokaadibüroo Pärt Peterson Tartu Ülikool Kristjan Kask Tallinna Ülikool Arutas 7 . aprillil 20 20 .a Tartu Ülikooli genoomika instituut projekti “Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus” („ The impact of clinically relevant CNVs in the general population – the health consequences and personalized management of undiagnosed adult CNV carriers " ) . Uuringu viib läbi Tartu Ülikool ja Health2030 Genome Center , Campus Biotech . Uuringu taotluse menetlusest taandas ennast Maarja Kirss, Andmekaitse Inspektsioonist. Uuringu taotluse menetluses ei osalenud Priit Ennet, MTÜ Eesti Teadusajakirjanike Selts. Läbivi idava uuringu üldine eesmärk on uurida geenivaramu geenidoonoreid , kellel on leitud kliiniliselt oluline struktuurne geenivariant ehk DNA koopia-arvu variatsioon (CNV). Uuringu eesmärgiks on rakendada nö. 2 genotüübil põhinevat terviseandmete kogumist, et uurida CNV- dega inimeste tervise tulemeid täiskasvanud üldpopulatsioonis . Lisaks soovivad uuringu läbiviijad anda CNV kandjatele personaalse kokkuvõtte ja tagada geneetiline nõustamine nende seni tuvastamata geneetilise leiu kohta. Kogutud andmete alusel on kavas välja töötada tõendus-põhine protokoll geneetilise tagasiside andmiseks kõrge komplekshaiguste riskiga geenidoonoritele. Uuringus töödeldakse järgmise andmekategooriaid ja –koosseis on toodud Eesti bioeetika ja inimuuringute nõukogule esitatud taotluse punktis 8 . Valimi moodustab kuni 215 0 00 geenidoonorit . Depseudonüümitakse kuni 400 geenidoonori andmed. Andmeandja te ks on geenivaramu . Otsus: anda luba uuringu läbiviimiseks. Otsuse lahutamatu lisad on Tartu Ülikooli Genoomika I nstituu di ja Health2030 Genome Center , Campus Biotech „ Kliiniliselt oluliste struktuursete geenivariantide mõju üldpopulatsioonis – diagnoosimata täiskasvanud struktuursete geenivariantide kandjate tervise tulemid ja personaliseeritud käsitlus” („ The impact of clinically relevant CNVs in the general population – the health consequences and personalized management of undiagnosed adult CNV carriers " ) uuringutaotlus koos lisadega . /allkirjastatud digitaalselt/ Liina Vahter Eesti bioeetika ja inimuuringute nõukogu esimees